<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies - Storebø, OJ - 2018 | Cochrane Library</title> <meta content="Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies - Storebø, OJ - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012069.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies - Storebø, OJ - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012069.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012069.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies" name="citation_title"/> <meta content="Ole Jakob Storebø" name="citation_author"/> <meta content="ojst@regionsjaelland.dk" name="citation_author_email"/> <meta content="Nadia Pedersen" name="citation_author"/> <meta content="Region Zealand Psychiatry" name="citation_author_institution"/> <meta content="Erica Ramstad" name="citation_author"/> <meta content="Maja Lærke Kielsholm" name="citation_author"/> <meta content="Region Zealand Psychiatry" name="citation_author_institution"/> <meta content="Signe Sofie Nielsen" name="citation_author"/> <meta content="Region Zealand Psychiatry" name="citation_author_institution"/> <meta content="Helle B Krogh" name="citation_author"/> <meta content="Carlos R Moreira‐Maia" name="citation_author"/> <meta content="Federal University of Rio Grande do Sul" name="citation_author_institution"/> <meta content="Frederik L Magnusson" name="citation_author"/> <meta content="Region Zealand Psychiatry" name="citation_author_institution"/> <meta content="Mathilde Holmskov" name="citation_author"/> <meta content="Region Zealand Psychiatry" name="citation_author_institution"/> <meta content="Trine Gerner" name="citation_author"/> <meta content="Region Zealand Psychiatry" name="citation_author_institution"/> <meta content="Maria Skoog" name="citation_author"/> <meta content="Clinical Studies Sweden ‐ Forum South" name="citation_author_institution"/> <meta content="Susanne Rosendal" name="citation_author"/> <meta content="Psychiatric Centre North Zealand" name="citation_author_institution"/> <meta content="Camilla Groth" name="citation_author"/> <meta content="Herlev University Hospital" name="citation_author_institution"/> <meta content="Donna Gillies" name="citation_author"/> <meta content="Kirsten Buch Rasmussen" name="citation_author"/> <meta content="Region Zealand Psychiatry" name="citation_author_institution"/> <meta content="Dorothy Gauci" name="citation_author"/> <meta content="Department of Health" name="citation_author_institution"/> <meta content="Morris Zwi" name="citation_author"/> <meta content="Whittington Health" name="citation_author_institution"/> <meta content="Richard Kirubakaran" name="citation_author"/> <meta content="Christian Medical College" name="citation_author_institution"/> <meta content="Sasja J Håkonsen" name="citation_author"/> <meta content="Aalborg University" name="citation_author_institution"/> <meta content="Lise Aagaard" name="citation_author"/> <meta content="Havemann Law Firm" name="citation_author_institution"/> <meta content="Erik Simonsen" name="citation_author"/> <meta content="Region Zealand Psychiatry" name="citation_author_institution"/> <meta content="Christian Gluud" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD012069.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/05/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012069.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012069.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012069.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Attention Deficit Disorder with Hyperactivity [*drug therapy]; Central Nervous System Stimulants [*adverse effects, therapeutic use]; Methylphenidate [*adverse effects, therapeutic use]; Non‐Randomized Controlled Trials as Topic; Patient Dropouts [statistics &amp; numerical data]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012069.pub2&amp;doi=10.1002/14651858.CD012069.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="loVWuZlx";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012069\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012069\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012069\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012069\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","fa","es","de","zh_HANS","ms","ja"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012069.pub2",title:"Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents \\u2013 assessment of adverse events in non\\u2010randomised studies",firstPublishedDate:"May 10, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Developmental, Psychosocial and Learning Problems Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012069.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012069.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012069.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012069.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012069.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012069.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012069.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012069.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012069.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012069.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>22949 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012069.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-sec-0228"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-sec-0028"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-sec-0029"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-sec-0062"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-sec-0221"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/appendices#CD012069-sec-0233"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/table_n/CD012069StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/table_n/CD012069StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non‐randomised studies </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Ole Jakob Storebø</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0003">Nadia Pedersen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0004">Erica Ramstad</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0005">Maja Lærke Kielsholm</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0006">Signe Sofie Nielsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0007">Helle B Krogh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0008">Carlos R Moreira‐Maia</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0009">Frederik L Magnusson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0010">Mathilde Holmskov</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0011">Trine Gerner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0012">Maria Skoog</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0013">Susanne Rosendal</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0014">Camilla Groth</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0015">Donna Gillies</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0016">Kirsten Buch Rasmussen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0017">Dorothy Gauci</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0018">Morris Zwi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0019">Richard Kirubakaran</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0020">Sasja J Håkonsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0021">Lise Aagaard</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0022">Erik Simonsen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information#CD012069-cr-0023">Christian Gluud</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information/en#CD012069-sec-0271">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 May 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012069.pub2">https://doi.org/10.1002/14651858.CD012069.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012069-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012069-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012069-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012069-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012069-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012069-abs-0001" lang="en"> <section id="CD012069-sec-0001"> <h3 class="title" id="CD012069-sec-0001">Background</h3> <p>Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable effects on ADHD symptoms, but the true magnitude of the effect is unknown. Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non‐serious adverse events. </p> </section> <section id="CD012069-sec-0002"> <h3 class="title" id="CD012069-sec-0002">Objectives</h3> <p>To assess the adverse events associated with methylphenidate treatment for children and adolescents with ADHD in non‐randomised studies. </p> </section> <section id="CD012069-sec-0003"> <h3 class="title" id="CD012069-sec-0003">Search methods</h3> <p>In January 2016, we searched CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, 12 other databases and two trials registers. We also checked reference lists and contacted authors and pharmaceutical companies to identify additional studies. </p> </section> <section id="CD012069-sec-0004"> <h3 class="title" id="CD012069-sec-0004">Selection criteria</h3> <p>We included non‐randomised study designs. These comprised comparative and non‐comparative cohort studies, patient‐control studies, patient reports/series and cross‐sectional studies of methylphenidate administered at any dosage or formulation. We also included methylphenidate groups from RCTs assessing methylphenidate versus other interventions for ADHD as well as data from follow‐up periods in RCTs. Participants had to have an ADHD diagnosis (from the 3rd to the 5th edition of the <i>Diagnostic and Statistical Manual of Mental Disorders</i> or the 9th or 10th edition of the<i>International Classification of Diseases</i>, with or without comorbid diagnoses. We required that at least 75% of participants had a normal intellectual capacity (intelligence quotient of more than 70 points) and were aged below 20 years. We excluded studies that used another ADHD drug as a co‐intervention. </p> </section> <section id="CD012069-sec-0005"> <h3 class="title" id="CD012069-sec-0005">Data collection and analysis</h3> <p>Fourteen review authors selected studies independently. Two review authors assessed risk of bias independently using the ROBINS‐I tool for assessing <b>r</b> isk <b>o</b> f <b>b</b> ias <b>i</b> n <b>n</b> on‐randomised <b>s</b> tudies of <b>i</b>nterventions. All review authors extracted data. We defined serious adverse events according to the International Committee of Harmonization as any lethal, life‐threatening or life‐changing event. We considered all other adverse events to be non‐serious adverse events and conducted meta‐analyses of data from comparative studies. We calculated meta‐analytic estimates of prevalence from non‐comparative cohorts studies and synthesised data from patient reports/series qualitatively. We investigated heterogeneity by conducting subgroup analyses, and we also conducted sensitivity analyses. </p> </section> <section id="CD012069-sec-0006"> <h3 class="title" id="CD012069-sec-0006">Main results</h3> <p>We included a total of 260 studies: 7 comparative cohort studies, 6 of which compared 968 patients who were exposed to methylphenidate to 166 controls, and 1 which assessed 1224 patients that were exposed or not exposed to methylphenidate during different time periods; 4 patient‐control studies (53,192 exposed to methylphenidate and 19,906 controls); 177 non‐comparative cohort studies (2,207,751 participants); 2 cross‐sectional studies (96 participants) and 70 patient reports/series (206 participants). Participants' ages ranged from 3 years to 20 years. Risk of bias in the included comparative studies ranged from moderate to critical, with most studies showing critical risk of bias. We evaluated all non‐comparative studies at critical risk of bias. The GRADE quality rating of the evidence was very low. </p> <p><b>Primary outcomes</b> </p> <p>In the comparative studies, methylphenidate increased the risk ratio (RR) of serious adverse events (RR 1.36, 95% confidence interval (CI) 1.17 to 1.57; 2 studies, 72,005 participants); any psychotic disorder (RR 1.36, 95% CI 1.17 to 1.57; 1 study, 71,771 participants); and arrhythmia (RR 1.61, 95% CI 1.48 to 1.74; 1 study, 1224 participants) compared to no intervention. </p> <p>In the non‐comparative cohort studies, the proportion of participants on methylphenidate experiencing any serious adverse event was 1.20% (95% CI 0.70% to 2.00%; 50 studies, 162,422 participants). Withdrawal from methylphenidate due to any serious adverse events occurred in 1.20% (95% CI 0.60% to 2.30%; 7 studies, 1173 participants) and adverse events of unknown severity led to withdrawal in 7.30% of participants (95% CI 5.30% to 10.0%; 22 studies, 3708 participants). </p> <p><b>Secondary outcomes</b> </p> <p>In the comparative studies, methylphenidate, compared to no intervention, increased the RR of insomnia and sleep problems (RR 2.58, 95% CI 1.24 to 5.34; 3 studies, 425 participants) and decreased appetite (RR 15.06, 95% CI 2.12 to 106.83; 1 study, 335 participants). </p> <p>With non‐comparative cohort studies, the proportion of participants on methylphenidate with any non‐serious adverse events was 51.2% (95% CI 41.2% to 61.1%; 49 studies, 13,978 participants). These included difficulty falling asleep, 17.9% (95% CI 14.7% to 21.6%; 82 studies, 11,507 participants); headache, 14.4% (95% CI 11.3% to 18.3%; 90 studies, 13,469 participants); abdominal pain, 10.7% (95% CI 8.60% to 13.3%; 79 studies, 11,750 participants); and decreased appetite, 31.1% (95% CI 26.5% to 36.2%; 84 studies, 11,594 participants). Withdrawal of methylphenidate due to non‐serious adverse events occurred in 6.20% (95% CI 4.80% to 7.90%; 37 studies, 7142 participants), and 16.2% were withdrawn for unknown reasons (95% CI 13.0% to 19.9%; 57 studies, 8340 participants). </p> </section> <section id="CD012069-sec-0007"> <h3 class="title" id="CD012069-sec-0007">Authors' conclusions</h3> <p>Our findings suggest that methylphenidate may be associated with a number of serious adverse events as well as a large number of non‐serious adverse events in children and adolescents, which often lead to withdrawal of methylphenidate. Our certainty in the evidence is very low, and accordingly, it is not possible to accurately estimate the actual risk of adverse events. It might be higher than reported here. </p> <p>Given the possible association between methylphenidate and the adverse events identified, it may be important to identify people who are most susceptible to adverse events. To do this we must undertake large‐scale, high‐quality RCTs, along with studies aimed at identifying responders and non‐responders. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012069-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012069-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012069-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012069-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012069-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012069-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012069-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012069-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012069-abs-0004" lang="en"> <h3>Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents ‐ assessment of harmful effects </h3> <p><b>Review question</b> </p> <p>Is methylphenidate administration associated with harmful effects in children and adolescents with attention deficit hyperactivity disorder (ADHD)? </p> <p><b>Background</b> </p> <p>ADHD is one of the most common neurodevelopmental disorders in childhood and is associated with impaired functioning and negative outcomes for development. Individuals diagnosed with ADHD are often hyperactive and impulsive. Methylphenidate, a psychostimulant, is the drug most often prescribed for children and adolescents with ADHD. </p> <p><b>Study characteristics</b> </p> <p>We searched for available research up to January 2016 and found 260 studies with different designs. We included a number of non‐randomised designs (where investigators did not assign participants to a certain treatment): </p> <p>– 7 comparative cohort studies (a group of people followed over time; six studies compared 968 patients who were taking methylphenidate to 166 controls who were not taking methylphenidate; and 1 study included 1224 patients that were taking or not taking methylphenidate during different time periods);<br/> – 4 patient‐control studies (comparing two groups of people: 53,192 were taking methylphenidate, and 19,906 were not);<br/> – 177 non‐comparative cohort studies (2,207,751 participants) with no control group (i.e. who were not taking methylphenidate);<br/> – 2 cross‐sectional studies (96 participants were taking methylphenidate at a single time point); and<br/> – 70 patient reports/series (206 participants were taking methylphenidate). </p> <p>We also included methylphenidate groups from randomised clinical trials (RCTs; experiments in which participants are randomly put into independent groups that compare different treatments). All RCTs assessed methylphenidate versus other interventions for ADHD and follow‐up periods from RCTs. We only used the data from the intervention arm with methylphenidate. In all the included non‐comparative cohort studies, 2,207,751 participants were taking methylphenidate. Participants' ages ranged from 3 years to 20 years. </p> <p><b>Key results</b> </p> <p>The findings suggest that methylphenidate administration might lead to serious adverse (harmful) events, including death, cardiac problems, and psychotic disorders. About 1 in 100 patients treated with methylphenidate seemed to suffer a serious adverse event. Withdrawal from methylphenidate due to serious adverse events occurred in about 1.2 out of 100 patients treated with methylphenidate. Withdrawal from methylphenidate due to any adverse events occurred in about 7.3 out of 100 patients treated with methylphenidate. We also noted a large proportion of non‐serious adverse events. More than half the patients exposed to methylphenidate seemed to suffer one or more adverse events. Withdrawal from methylphenidate due to non‐serious adverse events occurred in about 6.2 out of 100 patients exposed to methylphenidate. Withdrawal of methylphenidate for unknown reasons was 16.2 out of 100 patients exposed to methylphenidate. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of the evidence and hence the certainty or reliability of the evidence for the comparative studies is very low. The reliability of the evidence for the non‐comparative studies is low due to weaknesses in study design. Accordingly, it is not possible to accurately estimate the risks of adverse events in children and adolescents prescribed methylphenidate. </p> <p><b>Conclusions</b> </p> <p>Methyphenidiate might be associated with a number of serious adverse events. Methylphenidate produces a large number of other non‐serious harmful effects in children and adolescents with ADHD. We suggest that clinicians and parents are alert to the importance of monitoring adverse events in a systematic, meticulous manner. If methylphenidate is to continue to have a place in ADHD treatment in the future, we need to identify subgroups of patients in whom the benefits of methylphenidate outweigh the harms. Just as we need to be able to identify who is likely to benefit from treatment, we also need to be able to identify those who are most at risk of experiencing adverse events. In order to do this, we need to undertake large‐scale, high‐quality RCTs along with other studies aimed at identifying those who respond and those who do not respond to treatment. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012069-sec-0228" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012069-sec-0228"></div> <h3 class="title" id="CD012069-sec-0229">Implications for practice</h3> <section id="CD012069-sec-0229"> <p>Our findings suggest that methylphenidate may be associated with a number of serious adverse events. In addition, a large number of non‐serious adverse events are reported in children and adolescents, often leading to withdrawal of treatment. Although our results suggest adverse events may be more common than previously reported, included studies were of very low quality. Therefore, we cannot be confident that the size of the effects are significantly higher compared with other treatments. Given the high rates of reported adverse events, clinicians need to carefully balance the potential risks to the potential benefits for each individual patient when considering methylphenidate for the treatment of ADHD. </p> <p>In view of the possible relationship between adverse events and discontinuation of treatment, it may be necessary to record the presence or absence of sleep difficulties, appetite suppression, cardiovascular problems, psychosis and tics prior to commencement of medication, with active monitoring after medication has been prescribed. Recording family history of neuro‐developmental disorders and other physical health problems may also help to inform decisions to commence and persist with treatment. </p> <p>Adverse events reported in observational studies do not seem to depend on dose or duration of methylphenidate treatment, comorbidity, age of participants, or use of cointerventions. It remains unclear how medications used just prior to methylphenidate intervention may influence the development of adverse events. </p> <p>Studies funded by pharmaceutical companies reported a much lower proportion of both serious and non‐serious adverse events, confirming previous studies and systematic reviews on industry bias. </p> </section> <h3 class="title" id="CD012069-sec-0230">Implications for research</h3> <section id="CD012069-sec-0230"> <p>Methyphenidiate may be associated with a number of serious adverse events as well as a large number of other adverse events in children and adolescents with ADHD. The increasing use of methylphenidate in childhood and adolescence, often continuing into adulthood, also supports the need for more certainty about the true amount of serious adverse events (<a href="./references#CD012069-bbs2-0421" title="BachmannCJ , WiljlaarsLP , KalverdijkLJ , BurcuM , GlaeskeG , Schuiling‐VeningaCCM , et al. Trends in ADHD medication use in children and adolescents in five western countries, 2005‐2012. European Neuropsychopharmacology2017;27(5):484‐93. [DOI: 10.1016/j.euroneuro.2017.03.002; PUBMED: 28336088] ">Bachmann 2017</a>). In order to investigate this, we need to undertake large‐scale, high‐quality RCTs along with studies aimed at identifying responders and non‐responders. </p> <p>Better designed non‐randomised studies are needed to assess possible rare and unexpected adverse events occurring from methylphenidate use in the paediatric population. </p> <p>Future observational studies must include a comparator group of untreated participants more often; otherwise it will not be possible to distinguish between harms related to the drug studied and harms related to the patients' disease. </p> <p>The study duration ranged from 1 day to 11 years, yet most included studies were less than six months. Therefore, we need to conduct large, long‐term observational studies to be able to detect adverse events across paediatric populations and differences in prescribing practice and patterns. The ICH Guideline (E17) on the general principles for planning and design of multi‐regional clinical trials should be consulted when planning new studies in this field. </p> <p>Future studies should publish depersonalised, individual participant data and report all outcomes, including adverse events (<a href="./references#CD012069-bbs2-0641" title="SkoogM , SaarimäkiJM , GluudC , SheininM , ErlendssonK , AamdalS , et al. Transparency and registration in clinical research in the Nordic countries. NordicTrial Alliance, NordForsk2015:1‐108. ">Skoog 2015</a>). This will enable researchers conducting systematic reviews to assess differences between intervention effects according to sex, age, type of AHDH, presence of comorbidities, and use of comedications (especially antipsychotics and antidepressants). Future studies should also screen for potential adverse events. Such screening has been recently shown to increase the reporting of adverse events in adolescents on antipsychotic medication from about 50% to 100% (<a href="./references#CD012069-bbs2-0595" title="PagsbergAK , JeppesenP , KlauberDG , JensenKG , RudåD , Stentebjerg‐OlesenM , et al. Quetiapine extended release versus aripiprazole in children and adolescents with first‐episode psychosis: the multicentre, double‐blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. Lancet Psychiatry2017;4(8):605‐8. ">Pagsberg 2017</a>). </p> <p>Adverse events should be monitored through the use of structured tools in order to ensure consistency of practice amongst clinicians. </p> <p>Systematic analyses of adverse events reported to national databases are also necessary, as these databases constitute an underestimated source of important data, particularly information about serious and unexpected reactions from medicine use (<a href="./references#CD012069-bbs2-0396" title="AagaardL , HansenEH . Adverse drug reactions reported for systemic antibacterials in Danish children over a decade. British Journal of Clinical Pharmacology2010;70(5):765‐8. [DOI: 10.1111/j.1365‐2125.2010.03732.x; PMC2997318] ">Aagaard 2010a</a>; <a href="./references#CD012069-bbs2-0397" title="AagaardL , ChristensenA , HansenEH . Information about adverse drug reactions reported in children: a qualitative review of empirical studies. British Journal of Clinical Pharmacology2010;70(4):481‐91. [DOI: 10.1111/j.1365‐2125.2010.03682.x; PMC2950983] ">Aagaard 2010b</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012069-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012069-sec-0022"></div> <div class="table" id="CD012069-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methylphenidate for children and adolescents aged 18 years and under with attention deficit hyperactivity disorder (ADHD): adverse events</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Methylphenidate for children and adolescents aged 18 and under with attention deficit hyperactivity disorder (ADHD): adverse events</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b>: children and adolescents aged 18 years and under diagnosed with ADHD </p> <p><b>Settings</b>: outpatient clinic, inpatient hospital ward and register data </p> <p><b>Intervention</b>: methylphenidate </p> <p><b>Comparision</b>: control or no control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies) at follow‐up</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control or no control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with Methylphenidate</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b><i>Comparative studies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Measured by: proportion of serious adverse events (total)</p> <p>Average study duration (range): not stated</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 more per 1000</p> <p>(2 more to 7 more)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.36</b><br/> (1.17 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72,005 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b><i>Non‐comparative studies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Measured by: proportion of any serious adverse events</p> <p>Average study duration (range): 4.7 months (14 days to 21 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1.20% (0.70% to 2.00%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162,422 (51 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal of methylphenidate due to serious adverse events (non‐comparative cohort studies)</b> </p> <p>Measured by: proportion of participants withdrawn from treatment</p> <p>Average study duration (range): 7.9 months (1 month to 37 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1.20% (0.60% to 2.30%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1173 (7 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal of methylphenidate due to adverse events of unknown severity</b> </p> <p>Measured by: proportion of participants withdrawn from treatment</p> <p>Average study duration (range): 4.6 months (21 days to 36 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>7.30% (5.30% to 10.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3708 (22 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐serious adverse events</b> </p> <p>Measured by: proportion of any non‐serious adverse events</p> <p>Average study duration (range): 5.99 months (1 day to 41 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>51.2% (41.2% to 61.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,978 (49 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal of methylphenidate due to non‐serious adverse events</b> </p> <p>Measured by: proportion of participants withdrawn from treatment</p> <p>Average study duration (range): 5.60 months (0.6 months to 41 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>6.20% (4.80% to 7.90%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7142 (37 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal of methylphenidate for unknown reasons</b> </p> <p>Measure by: proportion of participants withdrawn from treatment</p> <p>Average study duration (range): 6.13 months (1 day to 36 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>16.2% (13.0% to 19.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8340 (57 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>ROBINS‐I:</b> Risk Of Bias In Non‐randomised Studies ‐ of Interventions; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality</b> : our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Outcome assessed at critical risk of bias using the ROBINS‐I. Consequently, we downgraded the quality of the evidence by 3 levels due to study limitations. <br/> <sup>b</sup>Outcome not critically assessed with ROBINS‐I due to lack of control group. However, due to the nature of the studies and the risk of confounding, we considered the studies to be at critical risk of bias. Consequently, we downgraded the quality of the evidence by 3 levels due to study limitations. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012069-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012069-sec-0023"></div> <section id="CD012069-sec-0024"> <h3 class="title" id="CD012069-sec-0024">Description of the condition</h3> <p>Attention deficit hyperactivity disorder (ADHD) is one of the most commonly diagnosed and treated childhood neurodevelopmental disorders (<a href="./references#CD012069-bbs2-0624" title="ScahillL , Schwab‐StoneM . Epidemiology of ADHD in school‐age children. Child and Adolescent Psychiatric Clinics of North America2000;9(3):541‐55. [PUBMED: 10944656] ">Scahill 2000</a>). The estimated prevalence in children and adolescents is between 3% to 8% (<a href="./references#CD012069-bbs2-0607" title="PolanczykG , RohdeLA . Epidemiology of attention‐deficit/hyperactivity disorder across the lifespan. Current Opinion in Psychiatry2007;20(4):386‐92. [PUBMED: 17551354] ">Polanczyk 2007a</a>; <a href="./references#CD012069-bbs2-0657" title="ThomasR , SandersS , DoustJ , BellerE , GlasziouP . Prevalence of attention‐deficit/hyperactivity disorder: a systematic review and meta‐analysis. Pediatrics2015;135(4):e994‐e1001. [DOI: 10.1542/peds.2014‐3482] ">Thomas 2015</a>; <a href="./references#CD012069-bbs2-0676" title="WillcuttEG . The prevalence of DSM‐IV attention‐deficit/hyperactivity disorder: a meta‐analytic review. Neurotherapeutics2012;9(3):490‐9. [DOI: 10.1007/s13311‐012‐0135‐8] ">Willcut 2012</a>), depending on the classification system used, with boys two to four times more likely to be diagnosed than girls (<a href="./references#CD012069-bbs2-0626" title="SchmidtS , PetermannF . Developmental psychopathology: attention deficit hyperactivity disorder (ADHD). BMC Psychiatry2009;9:58. [DOI: 10.1186/1471‐244X‐9‐58] ">Schmidt 2009</a>). Prevalences have remained stable over the past 30 years and do not appear to vary between countries (<a href="./references#CD012069-bbs2-0608" title="PolanczykGV , WillcuttEG , SalumGA , KielingC , RohdeLA . ADHD prevalence estimates across three decades: an updated systematic review and meta‐regression analysis. International Journal of Epidemiology2014;43(2):434‐42. [PUBMED: 24464188] ">Polanczyk 2014</a>). Individuals with ADHD may show difficulties in attention and cognitive functions like problem‐solving, planning, orienting, flexibility, response inhibition and working memory, as well as impulsivity and hyperactivity (<a href="./references#CD012069-bbs2-0599" title="PasiniA , PalosciaC , AlessandrelliR , PorfirioMC , CuratoloP . Attention and executive functions profile in drug naive ADHD subtypes. Brain and Development2007;29(7):400‐8. [PUBMED: 17207595] ">Pasini 2007</a>; <a href="./references#CD012069-bbs2-0634" title="SergeantJA , GeurtsH , HuijbregtsS , ScheresA , OosterlaanJ . The top and the bottom of ADHD: a neuropsychological perspective. Neuroscience and Biobehavioural Reviews2003;27(7):583‐92. [PUBMED: 14624803] ">Sergeant 2003</a>). Furthermore, children and adolescents have difficulties handling affective components such as motivational delay and mood dysregulation (<a href="./references#CD012069-bbs2-0439" title="CastellanosFX , Sonuga‐BarkeEJS , MilhamMP , TannockR . Characterizing cognition in ADHD: beyond executive dysfunction. Trends in Cognitive Sciences2006;10(3):117‐23. [DOI: 10.1016/j.tics.2006.01.011] ">Castellanos 2006</a>; <a href="./references#CD012069-bbs2-0592" title="NiggJT , CaseyBJ . An integrative theory of attention‐deficit/hyperactivity disorder based on the cognitive and affective neurosciences. Development and Psychopathology2005;17(3):785‐806. [DOI: 10.1017/S0954579405050376] ">Nigg 2005</a>; <a href="./references#CD012069-bbs2-0626" title="SchmidtS , PetermannF . Developmental psychopathology: attention deficit hyperactivity disorder (ADHD). BMC Psychiatry2009;9:58. [DOI: 10.1186/1471‐244X‐9‐58] ">Schmidt 2009</a>). The aetiology of ADHD involves genetic, environmental and social factors but is not yet completely understood. Family and twin studies have shown a high heritability of around 70% to 80% and with a substantial overlap between the two dimensions of hyperactivity/impulsivity and inattention and with no sex differences of heritability (<a href="./references#CD012069-bbs2-0486" title="FrankeB , FaraoneSV , AshersonP , BuitelaarJ , BauCHD , Ramos‐QuirogaJA , et al. International Multicentre persistent ADHD CollaboraTion. The genetics of attention deficit/hyperactivity disorder in adults, a review. Molecular Psychiatry2012;17(10):960‐87. ">Franke 2012</a>; <a href="./references#CD012069-bbs2-0587" title="NealeBM , MedlandSE , RipkeS , AshersonP , FrankeB , LeschKP , et al. Meta‐analysis of genome‐wide association studies of attention‐deficit/hyperactivity disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2010;49(9):884‐97. ">Neale 2010</a>). Furthermore, genetic factors may be involved in determining the persistence of ADHD into adulthood (<a href="./references#CD012069-bbs2-0479" title="FaraoneSV , BiedermanJ , SpencerT , WilensT , SeidmanLJ , MickE , et al. Attention‐deficit/hyperactivity disorder in adults: an overview. Biological Psychiatry2000;48(1):9‐20. [PUBMED: 10913503] ">Faraone 2000</a>; <a href="./references#CD012069-bbs2-0486" title="FrankeB , FaraoneSV , AshersonP , BuitelaarJ , BauCHD , Ramos‐QuirogaJA , et al. International Multicentre persistent ADHD CollaboraTion. The genetics of attention deficit/hyperactivity disorder in adults, a review. Molecular Psychiatry2012;17(10):960‐87. ">Franke 2012</a>). Although family studies have shown high heritability, and there are many candidate genes that may be involved in the disorder (<a href="./references#CD012069-bbs2-0587" title="NealeBM , MedlandSE , RipkeS , AshersonP , FrankeB , LeschKP , et al. Meta‐analysis of genome‐wide association studies of attention‐deficit/hyperactivity disorder. Journal of the American Academy of Child &amp; Adolescent Psychiatry2010;49(9):884‐97. ">Neale 2010</a>), genome‐wide studies have yet to find any clear associations. </p> <p>Several studies have examined environmental risk factors for ADHD; however, researchers have not found any specific predictor for elevated risk. At the population level, poverty (families living under the poverty level) is more likely to be a feature among American children and adolescents diagnosed with ADHD (<a href="./references#CD012069-bbs2-0441" title="Centers for Disease Control and Prevention (CDC). QuickStats: percentage of children aged 5‐17 years with diagnosed attention deficit/hyperactivity disorder (ADHD), by poverty status and sex – National Health Interview Survey, 2011–2014. Morbidity and Mortality Weekly Report2015; Vol. 64, issue 40:1156. [PUBMED: 26469562] ">CDC 2015</a>). In a Swedish cohort of 811,803 individuals, low family income in early childhood was highly associated with ADHD (<a href="./references#CD012069-bbs2-0560" title="LarssonH , SariaslanA , LångströmN , D'OnofrioB , LichtensteinP . Family income in early childhood and subsequent attention deficit/hyperactivity disorder: a quasi‐experimental study. Journal of Child Psychology and Psychiatry and Allied Disciplines2014;55(5):428‐35. [PUBMED: 24111650] ">Larsson 2014</a>). Other potential risk factors for ADHD development include low birthweight (<a href="./references#CD012069-bbs2-0541" title="IndredavikMS , VikT , HeyerdahlS , KulsengS , FayersP , BrubakkAM . Psychiatric symptoms and disorders in adolescents with low birth weight. Archives of Disease in Childhood. Fetal and Neonatal Edition2004;89(5):F445‐50. [DOI: 10.1136/adc.2003.038943] ">Indredavik 2004</a>; <a href="./references#CD012069-bbs2-0668" title="VanLieshoutRJ , BoyleMH , SaigalS , MorrisonK , SchmidtLA . Mental health of extremely low birth weight survivors in their 30s. Pediatrics2015;135(3):452‐9. [PUBMED: 25667243] ">Van Lieshout 2015</a>), prematurity (<a href="./references#CD012069-bbs2-0428" title="BhuttaAT , ClevesMA , CaseyPH , CradockMM , AnandKJ . Cognitive and behavioral outcomes of school‐aged children who were born preterm: a meta‐analysis. Journal of the American Medical Association2002;288(6):728‐37. [PUBMED: 12169077] ">Bhutta 2002</a>; <a href="./references#CD012069-bbs2-0435" title="BurnettA , DaveyCG , WoodSJ , Wilson‐ChingM , MolloyC , CheongJLY , et al. Extremely preterm birth and adolescent mental health in a geographical cohort born in the 1990s. Psychological Medicine2014;44(7):1533‐44. [DOI: 10.1017/S0033291713002158] ">Burnett 2014</a>; <a href="./references#CD012069-bbs2-0474" title="ElgenSK , SommerfeltK , LeversenKT , MarkestadT . Minor neurodevelopmental impairments are associated with increased occurrence of ADHD symptoms in children born extremely preterm. European Child and Adolescent Psychiatry2015;24(4):463‐70. [DOI: 1007/s00787‐014‐0597‐9] ">Elgen 2015</a>), maternal exposure to tobacco (<a href="./references#CD012069-bbs2-0556" title="KovessV , KeyesKM , HamiltonA , PezO , BitfoiA , KoçC , et al. Maternal smoking and offspring inattention and hyperactivity: results from a cross‐national European survey. European Child and Adolescent Psychiatry2015;24(8):919‐29. [DOI: 10.1007/s00787‐014‐0641‐9] ">Kovess 2015</a>; <a href="./references#CD012069-bbs2-0593" title="ObelC , ZhuJL , OlsenJ , BreiningS , LiJ , GrønborgTK , et al. The risk of attention deficit hyperactivity disorder in children exposed to maternal smoking during pregnancy ‐ a reexamination using a sibling design. Journal of Child Psychology and Psychiatry2016; Vol. 57, issue 4:532‐7. [DOI: 10.1111/jcpp.12478; PUBMED: 26511313] ">Obel 2016</a>), and exposure to chemical components like manganese and lead (<a href="./references#CD012069-bbs2-0533" title="HongSB , KimJW , ChoiBS , HongYC , ParkEJ , ShinMS , et al. Blood manganese levels in relation to comorbid behavioral and emotional problems in children with attention‐deficit/hyperactivity disorder. Psychiatry Research2014;220(1‐2):418‐25. [PUBMED: 25064383] ">Hong 2014</a>; <a href="./references#CD012069-bbs2-0534" title="HongSB , ImMH , KimJW , ParkEJ , ShinMS , KimBN , et al. Environmental lead exposure and attention deficit/hyperactivity disorder symptom domains in a community sample of South Korean school‐age children. Environmental Health Perspectives2015;123(3):271‐6. [PUBMED: 25280233] ">Hong 2015</a>). </p> <p>The diagnosis of ADHD is purely clinical, requiring recognition of excessive inattention, hyperactivity and impulsivity that interfere with or reduce the quality of social, academic, or occupational functioning (<a href="./references#CD012069-bbs2-0413" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐5). 5th Edition. Washington (DC): American Psychiatric Association, 2013. ">APA 2013</a>; <a href="./references#CD012069-bbs2-0675" title="World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992. ">WHO 1992</a>). There are 18 core symptoms of ADHD according to the principal diagnostic classification systems: <i>International Classification of Diseases ‐ 10th Revision</i> (ICD‐10; <a href="./references#CD012069-bbs2-0675" title="World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992. ">WHO 1992</a>) and the <i>Diagnostic and Statistical Manual of Mental Disorders</i> (DSM) ‐ <i>4th Edition</i> (DSM‐IV; <a href="./references#CD012069-bbs2-0411" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV). 4th Edition. Washington (DC): American Psychiatric Association, 1994. ">APA 1994</a>), ‐ <i>4th Edition ‐ Text Revision</i> (DSM‐IV‐TR; <a href="./references#CD012069-bbs2-0412" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: Text revision (DSM‐IV‐TR). 4th Edition. Washington (DC): American Psychiatric Association, 2000. ">APA 2000</a>), and<i>‐ 5th Edition</i> (DSM‐5; <a href="./references#CD012069-bbs2-0413" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐5). 5th Edition. Washington (DC): American Psychiatric Association, 2013. ">APA 2013</a>). </p> <p>Both the DSM‐5 and ICD‐10 criteria require excessive inattention, hyperactivity, and impulsivity to be inconsistent with the developmental level and to be pervasive. The symptoms must be present in two or more settings and appear before the age of 6 years according to the ICD‐10 (<a href="./references#CD012069-bbs2-0675" title="World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992. ">WHO 1992</a>), or 12 years according to the DSM‐5 (<a href="./references#CD012069-bbs2-0413" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐5). 5th Edition. Washington (DC): American Psychiatric Association, 2013. ">APA 2013</a>), and they should also persist for at least six months. The DSM‐5 modified the criteria for adolescents and adults older than 17 years of age, requiring fewer perceived symptoms and providing further descriptions to better identify typical ADHD symptoms in adolescents. Earlier versions of the DSM and the ICD‐10 required that there be clear evidence of clinically significant impairment in social, academic, and occupational functioning (<a href="./references#CD012069-bbs2-0411" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV). 4th Edition. Washington (DC): American Psychiatric Association, 1994. ">APA 1994</a>; <a href="./references#CD012069-bbs2-0412" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: Text revision (DSM‐IV‐TR). 4th Edition. Washington (DC): American Psychiatric Association, 2000. ">APA 2000</a>; <a href="./references#CD012069-bbs2-0413" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐5). 5th Edition. Washington (DC): American Psychiatric Association, 2013. ">APA 2013</a>; <a href="./references#CD012069-bbs2-0675" title="World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992. ">WHO 1992</a>), but the DSM‐5 only requires that symptoms interfere with or reduce the quality of these domains (<a href="./references#CD012069-bbs2-0413" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐5). 5th Edition. Washington (DC): American Psychiatric Association, 2013. ">APA 2013</a>). Furthermore the ICD‐10 and the DSM‐IV differ from the newer DSM‐5 in excluding people with autism spectrum disorder; DSM‐5 only excludes people during the course of schizophrenia or another psychotic or mental disorder. </p> <p>The diagnostic criteria describe three different subtypes or 'presentations' in the DSM‐5, according to the predominant symptoms: 'predominantly inattentive type', 'predominantly hyperactive‐impulsive type', and 'combined type' – a combination of both hyperactive‐impulsive and inattentive symptoms. The DSM‐5 acknowledges the absence of validity for these subtypes by renaming them predominantly inattentive, predominantly hyperactive‐impulsive, and combined presentations (<a href="./references#CD012069-bbs2-0413" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐5). 5th Edition. Washington (DC): American Psychiatric Association, 2013. ">APA 2013</a>; <a href="./references#CD012069-bbs2-0676" title="WillcuttEG . The prevalence of DSM‐IV attention‐deficit/hyperactivity disorder: a meta‐analytic review. Neurotherapeutics2012;9(3):490‐9. [DOI: 10.1007/s13311‐012‐0135‐8] ">Willcut 2012</a>). </p> <p>Children, adolescents, and adults with ADHD are at increased risk of a broad spectrum of co‐occurring conditions, which frequently result in negative outcomes later in life (<a href="./references#CD012069-bbs2-0588" title="NewcornJH . Co‐morbidity in adults with ADHD. CNS Spectrums2008;13(Suppl 12):12‐5. [DOI: 10.1017/S1092852900003199] ">Newcorn 2008</a>; <a href="./references#CD012069-bbs2-0626" title="SchmidtS , PetermannF . Developmental psychopathology: attention deficit hyperactivity disorder (ADHD). BMC Psychiatry2009;9:58. [DOI: 10.1186/1471‐244X‐9‐58] ">Schmidt 2009</a>). The Multimodal Treatment of Attention Deficit Hyperactivity Disorder (MTA) trial identified one or more comorbid disorders in almost 40% of the participants (<a href="./references#CD012069-bbs2-0579" title="MTA Cooperation Group. A 14‐month randomized clinical trial of treatment strategies for attention‐deficit/hyperactivity disorder. The MTA Cooperative Group. Archives of General Psychiatry1999;56(12):1073‐86. [DOI: 10.1001/archpsyc.56.12.1073] ">MTA 1999</a>). These included oppositional defiant disorder, conduct disorder, depression, anxiety, tics, learning disorders, and verbal and cognitive difficulties (<a href="./references#CD012069-bbs2-0546" title="JensenPS , HinshawSP , KraemerHC , LenoraN , NewcornJH , AbikoffHB , et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):147‐58. [DOI: 10.1097/00004583‐200102000‐00009] ">Jensen 2001</a>; <a href="./references#CD012069-bbs2-0548" title="KadesjöB , GillbergC . The comorbidity of ADHD in the general population of Swedish school‐age children. Journal of Child Psychology and Psychiatry and Allied Disciplines2001;42(4):487‐92. [DOI: 10.1111/1469‐7610.00742] ">Kadesjö 2001</a>). ADHD has also been shown to co‐occur with bipolar disorder (<a href="./references#CD012069-bbs2-0604" title="PerroudN , CorderaP , ZimmermannJ , MichalopoulosG , BancilaV , DayerA , et al. Comorbidity between attention deficit hyperactivity disorder (ADHD) and bipolar disorder in a specialized mood disorders outpatient clinic. Journal of Affective Disorders2014;168:161‐6. [DOI: 10.1016/j.jad.2014.06.053] ">Perroud 2014</a>). More recently, studies have confirmed such comorbidity (<a href="./references#CD012069-bbs2-0464" title="CzamaraD , TieslerCM , KohlböckG , BerdelD , HoffmannB , BauerCP , et al. Children with ADHD symptoms have a higher risk for reading, spelling and math difficulties in the GINIplus and LISAplus cohort studies. PLOS ONE2013;8(5):e63859. [DOI: 10.1371/journal.pone.0063859] ">Czamara 2013</a>; <a href="./references#CD012069-bbs2-0684" title="YoshimasuK , BarbaresiWJ , ColliganRC , VoigtRG , KillianJM , WeaverAL , et al. Childhood ADHD is strongly associated with a broad range of psychiatric disorders: a population‐based birth cohort study. Journal of Child Psychology and Psychiatry and Allied Disciplines2012;53(10):1036‐43. [PUBMED: 22647074] ">Yoshimasu 2012</a>), with some authors noting that excess weight and obesity are found in children with ADHD (<a href="./references#CD012069-bbs2-0456" title="CorteseS , Moreira‐MaiaCR , St. FleurD , Morcillo‐PeñalverC , RohdeLA , FaraoneSV . Association between ADHD and obesity: a systematic review and meta‐analysis. American Journal of Psychiatry2016;173(1):34‐43. [DOI: 10.1176/appi.ajp.2015.15020266] ">Cortese 2016</a>). In a study with 1480 twin pairs from Sweden, researchers found that persistent hyperactivity or impulsivity symptoms of ADHD are associated with both early‐onset tobacco and alcohol use (<a href="./references#CD012069-bbs2-0442" title="ChangZ , LichtensteinP , LarssonH . The effects of childhood ADHD symptoms on early‐onset substance use: a Swedish twin study. Journal of Abnormal Child Psychology2012;40(3):425‐35. [DOI: 10.1007/s10802‐011‐9575‐6; PUBMED: 21947618] ">Chang 2012</a>). Similarly, ADHD comorbidity with conduct disorder can lead to adverse outcomes in academic achievement, failure to complete high school, criminality, substance use disorder, and unemployment (<a href="./references#CD012069-bbs2-0477" title="ErskineHE , NormanRE , FerrariAJ , ChanGC , CopelandWE , WhitefordHA , et al. Long‐term outcomes of attention‐deficit/hyperactivity disorder and conduct disorder: a systematic review and meta‐analysis. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(10):841–50. [doi: 10.1016/j.jaac.2016.06.016; PUBMED: 27663939] ">Erskine 2016</a>). </p> <p>In addition, ADHD is associated with several harmful consequences. A cohort of participants with ADHD who were followed up to the age of 40 years demonstrated that these individuals have an elevated risk of criminality and a high risk of death before 40 years of age (<a href="./references#CD012069-bbs2-0554" title="KoisaariT , MichelssonK , HolopainenJM , MaksimainenR , PäivänsaloJ , RantalaK , et al. Traffic and criminal behavior of adults with attention deficit‐hyperactivity with a prospective follow‐up from birth to the age of 40 years. Traffic Injury Prevention2015;16(8):824‐30. [DOI: 10.1080/15389588.2015.1029068; PUBMED: 25837647] ">Koisaari 2015</a>). Similarly, studies from health insurance plans demonstrated not only elevated risk of injury, but also higher indirect costs of those with an ADHD diagnosis compared to diagnosis of depression (<a href="./references#CD012069-bbs2-0530" title="HodgkinsP , MontejanoL , SasanéR , HuseD . Risk of injury associated with attention‐deficit/hyperactivity disorder in adults enrolled in employer‐sponsored health plans: a retrospective analysis. Primary Care Companion for CNS Disorders2011;13(2):PCC.10m01031. [DOI: 10.4088/PCC.10m01031; PMC3184594; PUBMED: 21977357] ">Hodgkins 2011</a>). Recently, ADHD has been linked to increased premature mortality higher than 50%, compared to non‐ADHD patients, in a 24.9 million person‐years Danish cohort study (<a href="./references#CD012069-bbs2-0467" title="DalsgaardS , ØstergaardSD , LeckmanJF , MortensenPB , PedersenMG . Mortality in children, adolescents, and adults with attention deficit hyperactivity disorder: a nationwide cohort study. Lancet2015;385(9983):2190‐6. [DOI: 10.1016/S0140‐6736(14)61684‐6] ">Dalsgaard 2015b</a>). </p> <p>To ensure high standards in assessment, diagnosis and therapeutic practice, professional and national bodies have developed guidelines (<a href="./references#CD012069-bbs2-0399" title="Subcommittee on Attention‐Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, WolraichM , BrownL , BrownRT , DuPaulG , EarlsM , FeldmanHM , et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and the treatment of attention‐deficit/hyperactivity disorder in children and adolescents. Pediatrics2011;128(5):1077‐22. [DOI: 10.1542/peds.2011‐2654; PMC4500647; PUBMED: 2200306] ">AAP 2011</a>; <a href="./references#CD012069-bbs2-0437" title="Canadian Attention Deficit Hyperactivity Disorder Resource Alliance(CADDRA) . Canadian ADHD Practice Guidelines. Vol. 3rd Edition, Toronto (ON): CADDRA, 2011. ">CADDRA 2011</a>; <a href="./references#CD012069-bbs2-0586" title="National Collaborating Centre for Mental Health (NCCMH) commissioned by the National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. www.nccmh.org.uk/downloads/ADHD/CG72FullGuideline.pdf (accessed 11 December 2015). ">NCCMH 2009</a>; <a href="./references#CD012069-bbs2-0606" title="PliszkaS , The AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention‐deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):894‐921. [DOI: 10.1097/chi.0b013e318054e724; PUBMED: 17581453] ">Pliszka 2007a</a>; <a href="./references#CD012069-bbs2-0633" title="Scottish Intercollegiate Guidelines Network (SIGN). Management of attention deficit and hyperkinetic disorders in children and young people. A national clinical guideline. www.sign.ac.uk/pdf/sign112.pdf (accessed prior to 15 May 2017). ">Scottish Intercollegiate Guidelines Network (SIGN)</a>). Psychosocial interventions are recommended initially for younger children and for mild to moderate symptoms (<a href="./references#CD012069-bbs2-0399" title="Subcommittee on Attention‐Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, WolraichM , BrownL , BrownRT , DuPaulG , EarlsM , FeldmanHM , et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and the treatment of attention‐deficit/hyperactivity disorder in children and adolescents. Pediatrics2011;128(5):1077‐22. [DOI: 10.1542/peds.2011‐2654; PMC4500647; PUBMED: 2200306] ">AAP 2011</a>; <a href="./references#CD012069-bbs2-0586" title="National Collaborating Centre for Mental Health (NCCMH) commissioned by the National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. www.nccmh.org.uk/downloads/ADHD/CG72FullGuideline.pdf (accessed 11 December 2015). ">NCCMH 2009</a>; <a href="./references#CD012069-bbs2-0606" title="PliszkaS , The AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention‐deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):894‐921. [DOI: 10.1097/chi.0b013e318054e724; PUBMED: 17581453] ">Pliszka 2007a</a>). For more severe ADHD symptoms, stimulants, either alone or in combination with psychosocial interventions, may be necessary (<a href="./references#CD012069-bbs2-0399" title="Subcommittee on Attention‐Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, WolraichM , BrownL , BrownRT , DuPaulG , EarlsM , FeldmanHM , et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and the treatment of attention‐deficit/hyperactivity disorder in children and adolescents. Pediatrics2011;128(5):1077‐22. [DOI: 10.1542/peds.2011‐2654; PMC4500647; PUBMED: 2200306] ">AAP 2011</a>; <a href="./references#CD012069-bbs2-0437" title="Canadian Attention Deficit Hyperactivity Disorder Resource Alliance(CADDRA) . Canadian ADHD Practice Guidelines. Vol. 3rd Edition, Toronto (ON): CADDRA, 2011. ">CADDRA 2011</a>; <a href="./references#CD012069-bbs2-0586" title="National Collaborating Centre for Mental Health (NCCMH) commissioned by the National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. www.nccmh.org.uk/downloads/ADHD/CG72FullGuideline.pdf (accessed 11 December 2015). ">NCCMH 2009</a>). </p> </section> <section id="CD012069-sec-0025"> <h3 class="title" id="CD012069-sec-0025">Description of the intervention</h3> <p>Stimulant medication, notably methylphenidate and dexamphetamine (or dextroamphetamine), together with the non‐stimulants atomoxetine (a non‐stimulant selective noradrenaline reuptake inhibitor) and guanfacine (an alpha 2A agonist), are considered the treatments of choice along with psychosocial treatments for children and adolescents with ADHD (<a href="./references#CD012069-bbs2-0505" title="GreenhillL , KollinsS , AbikoffH , McCrackenJ , RiddleM , SwansonJ , et al. Efficacy and safety of immediate‐release methylphenidate treatment for preschoolers with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(11):1284‐93. [DOI: 10.1097/01.chi.0000235077.32661.61] ">Greenhill 2006</a>; <a href="./references#CD012069-bbs2-0589" title="National Collaborating Centre for Mental Health (NCCMH) commissioned by the National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. www.nice.org.uk/guidance/cg72/resources/attention‐deficit‐hyperactivity‐disorder‐diagnosis‐and‐management‐975625063621 (accessed prior to 15 May 2017). ">NICE 2008</a>; <a href="./references#CD012069-bbs2-0606" title="PliszkaS , The AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention‐deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):894‐921. [DOI: 10.1097/chi.0b013e318054e724; PUBMED: 17581453] ">Pliszka 2007a</a>)<i>.</i> Globally, methylphenidate is the most commonly used drug prescribed for ADHD; it has been used in practice for more than 50 years (<a href="./references#CD012069-bbs2-0549" title="KadesjöB . [ADHD hos barn och vuxna]. ADHD in Children and Adults. Stockholm: Socialstyrelsen, 2002. ">Kadesjö 2002</a>; <a href="./references#CD012069-bbs2-0586" title="National Collaborating Centre for Mental Health (NCCMH) commissioned by the National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. www.nccmh.org.uk/downloads/ADHD/CG72FullGuideline.pdf (accessed 11 December 2015). ">NCCMH 2009</a>)<i>.</i> Methylphenidate is used because it appears to have a favourable effect on reducing the core symptoms of excessive hyperactivity, impulsivity, and inattention in children and adolescents with ADHD. It is licensed for use in children aged six years and older. Rates of prescription of methylphenidate are high and increasing, standing at approximately 8% of children and adolescents under 15 years of age in the USA (<a href="./references#CD012069-bbs2-0404" title="AkinbamiLJ , LiuX , PastorPN , ReubenCA . Attention deficit hyperactivity disorder among children aged 5‐17 years in the United States, 1998–2009. NCHS Data Brief2011; Vol. 70:1‐8. [PUBMED: 22142479] ">Akinbami 2011</a>), and around 3% to 5% in Europe (<a href="./references#CD012069-bbs2-0421" title="BachmannCJ , WiljlaarsLP , KalverdijkLJ , BurcuM , GlaeskeG , Schuiling‐VeningaCCM , et al. Trends in ADHD medication use in children and adolescents in five western countries, 2005‐2012. European Neuropsychopharmacology2017;27(5):484‐93. [DOI: 10.1016/j.euroneuro.2017.03.002; PUBMED: 28336088] ">Bachmann 2017</a>; <a href="./references#CD012069-bbs2-0531" title="HodgkinsP , SetyawanJ , MitraD , DavisK , QuinteraJ , FridmanM , et al. Management of ADHD in children across Europe: patient demographics, physician characteristics and treatment patterns. European Journal of Pediatrics2013;172(7):895‐906. [DOI: 10.1007/s00431‐013‐1969‐8; PMC3701791; PUBMED: 23440479] ">Hodgkins 2013</a>; <a href="./references#CD012069-bbs2-0628" title="SchubertI , KösterI , LehmkuhlG . The changing prevalence of attention‐deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German state of Hesse, 2000–2007. Deutsches Ärzteblatt International2010;107(36):615‐21. [DOI: 10.3238/arztebl.2010.0615; PMC2947846; PUBMED: 20948775] ">Schubert 2010</a>; <a href="./references#CD012069-bbs2-0661" title="TreceñoC , Martín AriasLH , SáinzM , SaladoI , García OrtegaP , VelascoV , et al. Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate. Pharmacoepidemiology and Drug Safety2012;21(4):435–41. [DOI: 10.1002/pds.2348; PUBMED: 22253017] ">Trecenõ 2012</a>; <a href="./references#CD012069-bbs2-0687" title="ZoëgaH , FuruM , HalldórssonM , ThomsenPH , SouranderA , MartikainenJE . Use of ADHD drugs in the Nordic countries: a population‐based comparison study. Acta Psychiatrica ScandinavicaMay 2011;123(5):360‐7. [DOI: 10.1111/j.1600‐0447.2010.01607.x; PUBMED: 20860726] ">Zoëga 2016</a>). ADHD medication appears to be discontinued in 13% to 64% of patients from all age groups (<a href="./references#CD012069-bbs2-0401" title="AdlerLD , NierenbergAA . Review of medication adherence in children and adults with ADHD. Postgraduate Medicine2010;122(1):184‐91. [DOI: 10.3810/pgm.2010.01.2112] ">Adler 2010</a>)<i>,</i> but information of the continuity of these treatments from childhood or adolescence into adulthood is still lacking. Dexamphetamine is licensed for use in children aged three years and older. It is also available for use as mixed‐amphetamine salts (levoamphetamine plus dextroamphetamine) and as a pro‐drug of dexamphetamine, lisdexamphetamine. These have a longer duration of action than dextroamphetamine. Clinical choice of preparation by clinicians and families is based on a range of factors, including the presence of co‐occurring conditions, adverse events associated with the drug, issues regarding compliance, and the preference of the child and parents. </p> <p>Methylphenidate dose varies from patient to patient. The dose needs to be titrated individually in order to maximise benefits and minimise potential adverse events (<a href="./references#CD012069-bbs2-0648" title="StevensonRD , WolraichML . Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. Pediatric Clinics of North America1989;36(5):1183‐97. [PUBMED: 2677938] ">Stevenson 1989</a>)<i>.</i> The daily therapeutic range of methylphenidate dosages varies from 5 mg to 60 mg, administered one to three times daily, depending on the release system (immediate, sustained, or extended release) and mode of administration (oral or transdermal) (<a href="./references#CD012069-bbs2-0606" title="PliszkaS , The AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention‐deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(7):894‐921. [DOI: 10.1097/chi.0b013e318054e724; PUBMED: 17581453] ">Pliszka 2007a</a>; <a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>)<i>.</i> The British National Formulary suggests that initial doses in children aged four to six years should be 2.5 mg twice daily. Where necessary, it should be increased at weekly intervals by 2.5 mg daily, to a maximum of 1.4 mg/kg daily (divided into two to three doses per day) (<a href="./references#CD012069-bbs2-0431" title="BNF . Methylphenidate hydrochloride: indications and dose. British National Formulary (accessed 9 February 2017). [DOI: 10.18578/BNF.995526496; www.medicinescomplete.com/mc/bnfc/2011/PHP2479‐methylphenidate‐hydrochloride.htm] ">BNF 2018</a>). In children aged 6 years to 18 years, the initial dose may be 5 mg once or twice daily, increased, where necessary, at weekly intervals by 5 mg to 10 mg daily in two to three divided doses. Although methylphenidate is licensed to a maximum dose of 60 mg daily, it may be increased by 2.1 mg/kg daily in two to three divided doses (maximum 90 mg daily) under specialist supervision. The bioavailability of oral methylphenidate is 11% to 52%, with an approximate duration of action of 2 to 4 hours for immediate‐release methylphenidate, 3 to 8 hours for sustained‐release methylphenidate, and 8 to 12 hours for extended‐release methylphenidate (<a href="./references#CD012069-bbs2-0551" title="KimkoHC , CrossJT , AbernethyDR . Pharmacokinetics and clinical effectiveness of methylphenidate. Clinical Pharmacokinetics1999;37(6):457–70. [PUBMED: 10628897] ">Kimko 1999</a>)<i>.</i> </p> </section> <section id="CD012069-sec-0026"> <h3 class="title" id="CD012069-sec-0026">How the intervention might work</h3> <p>The pharmacodynamics of methylphenidate are still not entirely clear. Methylphenidate has both dopamine and noradrenaline transporter‐binding affinity and binds to and blocks both transporters, leading to increased availability of noradrenaline and dopamine within the synaptic cleft (<a href="./references#CD012069-bbs2-0525" title="HealDJ , PierceDM . Methylphenidate and its isomers: their role in the treatment of attention‐deficit hyperactivity disorder using a transdermal delivery system. CNS Drugs2006;20(9):713‐38. [PUBMED: 16953648] ">Heal 2006</a>; <a href="http://Volkow%201998" target="_blank">Volkow 1998</a>; <a href="http://Volkow%202004" target="_blank">Volkow 2004</a>; <a href="./references#CD012069-bbs2-0671" title="VolkowND , WangGJ , TomasiD , KollinsSH , WigalTL , NewcornJH , et al. Methylphenidate‐elicited dopamine increases in ventral striatum are associated with long‐term symptom improvement in adults with attention deficit hyperactivity disorder. Journal of Neuroscience2012;32(3):841‐9. [PUBMED: 22262882] ">Volkow 2012</a>). This is thought to increase the general firing rate via increased neurotransmission of dopamine and noradrenaline, which, in turn, has an effect on the prefrontal cortex – responsible for executive function – and is linked to sub‐performance of dopamine and noradrenaline functions associated with ADHD (<a href="./references#CD012069-bbs2-0417" title="ArnstenAF , DudleyAG . Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in Attention Deficit Hyperactivity Disorder. Behavioral and Brain Functions2005;1(1):2. [DOI: doi:10.1186/1744‐9081‐1‐2; PMC1143775; PUBMED: 15916700] ">Arnsten 2005</a>). As a result, patients can improve function (through symptom control) and experience several benefits such as improved attention and reduced hyperactivity‐impulsivity (<a href="./references#CD012069-bbs2-0424" title="BarkleyRA . A review of stimulant drug research with hyperactive children. Journal of Child Psychology and Psychiatry1977;18(2):137‐65. [DOI: 10.1111/j.1469‐7610.1977.tb00425.x] ">Barkley 1977</a>; <a href="http://Barkley%201981" target="_blank">Barkley 1981</a>; <a href="http://Barkley%201989" target="_blank">Barkley 1989</a>; <a href="http://Connor%202002" target="_blank">Connor 2002</a>; <a href="./references#CD012069-bbs2-0476" title="EngertV , PruessnerJC . Dopaminergic and noradrenergic contributions to functionality in ADHD: the role of methylphenidate. Current Neuropharmacology2008;6(4):322‐8. [DOI: 10.2174/157015908787386069] ">Engert 2008</a>; <a href="./references#CD012069-bbs2-0630" title="SchulzKP , FanJ , BédardAC , ClerkinSM , IvanovI , TangCY , et al. Common and unique therapeutic mechanisms of stimulant and nonstimulant treatments for attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2012;69(9):952‐61. [DOI: 10.1001/archgenpsychiatry.2011.2053; PUBMED: 22945622] ">Schulz 2012</a>; <a href="./references#CD012069-bbs2-0637" title="ShawM , HodgkinsP , CaciH , YoungS , KahleJ , WoodsAG , et al. A systematic review and analysis of long‐term outcomes in attention deficit hyperactivity disorder: effects of treatment and non‐treatment. BMC Medicine2012;10:99. [DOI: 10.1186/1741‐7015‐10‐99] ">Shaw 2012</a>; <a href="./references#CD012069-bbs2-0644" title="SolantoMV . Neuropsychopharmacological mechanisms of stimulant drug action in attention‐deficit hyperactivity disorder: a review and integration. Behavioural Brain Research1998;94(1):127‐52. [DOI: 10.1016/S0166‐4328(97)00175‐7] ">Solanto 1998</a>), which may improve classroom functioning and academic learning (<a href="./references#CD012069-bbs2-0429" title="BiedermanJ . Pharmacotherapy for attention‐deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow‐up of youths with and without ADHD. Journal of Clinical Psychiatry2003;64(Suppl 11):3‐8. [PUBMED: 14529323] ">Biederman 2003</a>; <a href="./references#CD012069-bbs2-0457" title="CoxDJ , MerkelRL , PenberthyJK , KovatchevB , HankinCS . Impact of methylphenidate delivery profiles on driving performance of adolescents with attention‐deficit/hyperactivity disorder: a pilot study. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(3):269‐75. [PUBMED: 15076259] ">Cox 2004</a>; <a href="./references#CD012069-bbs2-0478" title="EvansSW , PelhamWE , SmithBH , BuksteinO , GnagyEM , GreinerAR , et al. Dose‐response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Experimental and Clinical Psychopharmacology2001;9(2):163‐75. [PUBMED: 11518092] ">Evans 2001</a>; <a href="./references#CD012069-bbs2-0654" title="SwansonJM , WigalSB , WigalT , Sonuga‐BarkeE , GreenhillLL , BiedermanJ , et al. A comparison of once‐daily extended‐release methylphenidate formulations in children with attention‐deficit/hyperactivity disorder in the laboratory school (the Comacs study). Pediatrics2004;113(3 Pt 1):e206‐16. [PUBMED: 14993578] ">Swanson 2004</a>). </p> <p>Methylphenidate has also been correlated with a reduction of several harmful outcomes. In an extensive cohort of 710,120 individuals, including 4557 individuals diagnosed with ADHD before age 10 years, the use of methylphenidate was found to reduce emergency department visits by 46% and injuries by 44% (<a href="./references#CD012069-bbs2-0466" title="DalsgaardS , LeckmanJF , MortensenPB , NielsenHS , SimonsenM . Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry2015;2(8):702‐9. [DOI: 10.1016/S2215‐0366(15)00271‐0] ">Dalsgaard 2015a</a>). However, given the lack of sufficiently powered, well‐conducted randomised clinical trials (RCTs), it is not clear if these are genuine benefits or statistical artefacts (<a href="./references#CD012069-bbs2-0491" title="GarattiniS , JakobsenJC , WetterslevJ , BerteléV , BanziR , RathA , et al. Evidence‐based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13‐21. [DOI: 10.1016/j.ejim.2016.03.020; PUBMED: 27160381] ">Garattini 2016</a>; <a href="http://Storeb%C3%B8%202015" target="_blank">Storebø 2015</a>). In a Swedish national register composed of 25,656 participants, <a href="./references#CD012069-bbs2-0566" title="LichtensteinP , HallderL , ZetterqvistJ , SjölanderA , SerlachiusE , FazelS , et al. Medication for attention deficit‐hyperactivity disorder and criminality. Engl J Med2012;367(21):2006‐14. [DOI: 10.1056/NEJMoa1203241] ">Lichteinstein 2012</a> demonstrated a 32% and 41% reduction in criminality among men and woman respectively, when treated with medications for ADHD. In another study, the researchers found that medication was associated with a 58% risk reduction in serious transport accidents, and estimated that 41% to 49% of the accidents could have been avoided if ADHD male patients were in drug treatment (<a href="./references#CD012069-bbs2-0443" title="ChangZ , LichtensteinP , D'OnofrioBM , SjölanderA , LarssonH . Serious transport accidents in adults with ADHD, and the effect of medication: a population based study. JAMA Psychiatry2014;71(3):319‐25. [DOI: 10.1001/jamapsychiatry.2013.4174] ">Chang 2014a</a>). There have also been more recent reports of reductions in motor vehicle crashes in patients on methylphenidate (<a href="./references#CD012069-bbs2-0445" title="ChangZ , QuinnPD , HurK , GibbonsRD , SjölanderA , LarssonH , D'OnofrioBM . Associations between medication use for attention‐deficit/hyperactivity disorder and risk of motor vehicle crashes. JAMA Psychiatry2017;74(6):597‐603. [DOI: 10.1001/jamapsychiatry.2017.0659] ">Chang 2017</a>). Similarly, ADHD drugs decreased injuries among 5‐ to 10‐year‐old children from 32% to 44%, when compared to ADHD children without treatment (<a href="./references#CD012069-bbs2-0466" title="DalsgaardS , LeckmanJF , MortensenPB , NielsenHS , SimonsenM . Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry2015;2(8):702‐9. [DOI: 10.1016/S2215‐0366(15)00271‐0] ">Dalsgaard 2015a</a>). It is also a general concern that ADHD medication treatment can lead to substance abuse. Contrary to this, the prescription of ADHD stimulants was associated with a 31% decrease in substance abuse (<a href="./references#CD012069-bbs2-0444" title="ChangZ , LichtensteinP , HallderL , D'OnofrioB , SerlachiusE , FazelS , LångströmN , LarssonH . Stimulant ADHD medication and risk for substance abuse. Journal of Child Psychology and Psychiatry2014;55(8):878‐85. [DOI: 10.1111/jcpp.12164] ">Chang 2014b</a>). A similar concern was the association of ADHD treatment and suicide, but again, the treatment was correlated with a protective effect (<a href="./references#CD012069-bbs2-0447" title="ChenQi , SjölanderA , RunesonB , D'OnofrioBM , LichtensteinP , LarssonH . Drug treatment for attention‐deficit/hyperactivity disorder and suicidal behaviour: register based study. BMJ2014;348:g3769. ">Chen 2014</a>). </p> </section> <section id="CD012069-sec-0027"> <h3 class="title" id="CD012069-sec-0027">Why it is important to do this review</h3> <p>The most commonly reported adverse events associated with methylphenidate are headache, sleep problems, fatigue, and decreased appetite. Studies have indicated that methylphenidate also impairs both children's height and increases in weight (<a href="./references#CD012069-bbs2-0625" title="SchacharRJ , TannockR , CunninghamC , CorkumPV . Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(6):754‐63. [DOI: 10.1097/00004583‐199706000‐00011; PUBMED: 9183129] ">Schachar 1997</a>; <a href="./references#CD012069-bbs2-0654" title="SwansonJM , WigalSB , WigalT , Sonuga‐BarkeE , GreenhillLL , BiedermanJ , et al. A comparison of once‐daily extended‐release methylphenidate formulations in children with attention‐deficit/hyperactivity disorder in the laboratory school (the Comacs study). Pediatrics2004;113(3 Pt 1):e206‐16. [PUBMED: 14993578] ">Swanson 2004</a>; <a href="./references#CD012069-bbs2-0655" title="SwansonJ . The MTA follow‐up into adolescence: implications for personalized treatment. International Society for Research in Child and Adolescent Psychopathology (ISRCAP); 2009 June 19, Seattle. 2009. ">Swanson 2009</a>). </p> <p>Serious adverse events, such as psychosis and mood disorders, are reported to affect approximately 3% of children treated with methylphenidate (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009885.pub2/full#CD009885-bbs2-0303" target="_blank">Block 1998</a>; <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009885.pub2/full#CD009885-bbs2-0317" target="_blank">Cherland 1999</a>; <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009885.pub2/full#CD009885-bbs2-0435" target="_blank">MTA 1999</a>; <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009885.pub2/full#CD009885-bbs2-0439" target="_blank">NICE 2009</a>; <a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009885.pub2/full#CD009885-bbs2-0447" target="_blank">Pliszka 1998</a>). An observational study supports an association between the use of stimulants and sudden unexplained death among children and adolescents (<a href="./references#CD012069-bbs2-0292" title="GouldMS , WalshBT , MunfakhJL , KleinmanM , DuanNH , OlfsonM , et al. Sudden death and use of stimulant medications in youths. American Journal of Psychiatry2009;166(9):992‐1001. [DOI: 10.1176/appi.ajp.2009.09040472; PUBMED: 19528194] GouldMS , WalshBT , MunfakhJL , et al. Study finds link between stimulants and sudden unexplained death in young people. Brown University Psychopharmacology Update2009;20(12):1,1‐5,6. [DOI: 10.1002/pu.20105] KuehnBM . Stimulant use linked to sudden death in children without heart problems. JAMA: Journal of the American Medical Association2009;302(6):613‐4. [DOI: 10.1001/jama.2009.1115; PUBMED: 19671894] UhlD . Stimulant therapy: sudden death cases under methylphenidate [Plötzliche Todesfälle unter Methylphenidat]. Deutsche Apotheker Zeitung2009;26:46‐8. ">Gould 2009</a>). The study showed an odds ratio (OR) of 7.4 (95% confidence interval (CI) 1.4 to 74.9) for use of stimulants, specifically methylphenidate, in children and adolescents with sudden death compared to aged‐matched, motor vehicle accident deaths (<a href="./references#CD012069-bbs2-0292" title="GouldMS , WalshBT , MunfakhJL , KleinmanM , DuanNH , OlfsonM , et al. Sudden death and use of stimulant medications in youths. American Journal of Psychiatry2009;166(9):992‐1001. [DOI: 10.1176/appi.ajp.2009.09040472; PUBMED: 19528194] GouldMS , WalshBT , MunfakhJL , et al. Study finds link between stimulants and sudden unexplained death in young people. Brown University Psychopharmacology Update2009;20(12):1,1‐5,6. [DOI: 10.1002/pu.20105] KuehnBM . Stimulant use linked to sudden death in children without heart problems. JAMA: Journal of the American Medical Association2009;302(6):613‐4. [DOI: 10.1001/jama.2009.1115; PUBMED: 19671894] UhlD . Stimulant therapy: sudden death cases under methylphenidate [Plötzliche Todesfälle unter Methylphenidat]. Deutsche Apotheker Zeitung2009;26:46‐8. ">Gould 2009</a>). Further research is needed to determine whether these deaths are related to methylphenidate (<a href="./references#CD012069-bbs2-0664" title="USFood , Drug Administration(FDA) . Communication about an ongoing safety review of stimulant medications used in children with attention‐deficit/hyperactivity disorder (ADHD). 1.usa.gov/1M5AYoq (accessed 6 May 2011). ">US FDA 2011</a>). </p> <p>Reports of sudden death in adults taking methylphenidate are also a concern (<a href="./references#CD012069-bbs2-0545" title="JacksonJW . The cardiovascular safety of methylphenidate. BMJ2016;353:i2874. [DOI: 10.1136/bmj.i2874; PMC4887615; PUBMED: 27245078] ">Jackson 2016</a>). In an update (<a href="./references#CD012069-bbs2-0664" title="USFood , Drug Administration(FDA) . Communication about an ongoing safety review of stimulant medications used in children with attention‐deficit/hyperactivity disorder (ADHD). 1.usa.gov/1M5AYoq (accessed 6 May 2011). ">US FDA 2011</a>), the FDA found no evidence for increased risk of serious cardiovascular events in adults treated with ADHD medications, based on two epidemiological studies (<a href="./references#CD012069-bbs2-0278" title="CooperWO . E‐mail regarding your study 'ADHD drugs and serious cardiovascular events in children and young adults'. Email to: M Holmskov 10 September 2014. CooperWO , HabelLA , SoxCM , ChanKA , ArbogastPG , CheethamTC , et al. ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine2011;365(20):1896‐904. [DOI: 10.1056/NEJMoa1110212] ">Cooper 2011</a>; <a href="./references#CD012069-bbs2-0519" title="HabelLA , CooperWO , SoxCM . ADHD medications and risk of serious cardiovascular events in young and middle‐aged adults. JAMA2011;306(224):2673‐83. ">Habel 2011</a>). </p> <p>Recent reviews of methylphenidate treatment have focused on its benefits only, as opposed to its harmful effects (<a href="./references#CD012069-bbs2-0446" title="CharachA , CarsonP , FoxS , AliMU , BeckettJ , LimCG . Interventions for preschool children at high risk for ADHD: a comparative effectiveness review. Pediatrics2013;131(5):e1584–604. [DOI: 10.1542/peds.2012‐0974; PUBMED: 23545375] ">Charach 2013</a>; <a href="./references#CD012069-bbs2-0480" title="FaraoneSV , BiedermanJ , RoeC . Comparative efficacy of Adderall and methylphenidate in attention‐deficit/hyperactivity disorder: a meta‐analysis.. Journal of Clinical Psychopharmacology2002;22(5):468–73. ">Faraone 2002</a>; <a href="./references#CD012069-bbs2-0481" title="FaraoneS V , BiedermanJ , SpencerTJ , AleardiM . Comparing the efficacy of medications for A DHD using meta‐analysis. Medscape General Medicine2006;8(4):4. ">Faraone 2006</a>; <a href="./references#CD012069-bbs2-0482" title="FaraoneSV , GlattSJ . A comparison of the efficacy of medications for adult attention‐deficit/hyperactivity disorder using meta‐analysis of effect sizes. Journal of Clinical Psychiatry2010;71(6):754‐63. ">Faraone 2010</a>; <a href="./references#CD012069-bbs2-0523" title="HanwellaR , SenanayakeMi , DeSilvaV . Comparative efficacy and acceptability of methylphenidate andatomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta‐analysis. BMC Psychiatry2011;11(1):176. ">Hanwella 2011</a>; <a href="./references#CD012069-bbs2-0571" title="MaiaCR , CorteseS , CayeA , DeakinTK , PolanczykGV , PolanczykGV , et al. Long‐term efficacy of methylphenidate immediate‐release for the treatment of childhood ADHD. Journal of Attention Disorders2017; Vol. 21, issue 1:3‐13. [DOI: 10.1177/1087054714559643; PUBMED: 25501355] ">Maia 2017</a>). </p> <p>Relatively few randomised clinical trials included in our Cochrane Review assessing methylphenidate versus placebo or no intervention reported adverse events (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). Given the worldwide increase in methylphenidate prescriptions to children and adolescents, the need for an evidence‐based risk profile for serious and non‐serious adverse events remains (<a href="./references#CD012069-bbs2-0436" title="BusheCJ , SavillNC . Suicide related events and attention deficit hyperactivity disorder treatments in children and adolescents: a meta‐analysis of atomoxetine and methylphenidate comparator clinical trials. Child and Adolescent Psychiatry and Mental Health2013;7(1):19. [DOI: 10.1186/1753‐2000‐7‐19; PMC3691607] ">Bushe 2013</a>; <a href="./references#CD012069-bbs2-0438" title="CairnsR , DanielsB , WoodDA , BrettJ . ADHD medication overdose and misuse: the NSW Poisons Information Centre experience, 2004‐2014. Medical Journal of Australia2016;204(4):154. [PUBMED: 26937669] ">Cairns 2014</a>). </p> <p>To expand our understanding of adverse events, particularly where these are rare or take time to become apparent, it is necessary to bolster the limited data from RCTs by including data from non‐randomised studies (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). </p> <p>Non‐randomised studies have a number of advantages; they are often larger (allowing for detection of rare events), have a broader range of participants (reflecting 'real‐life'), longer follow‐up times, and lower costs than RCTs (<a href="./references#CD012069-bbs2-0426" title="BensonK , HartzAJ . A comparison of observational studies and randomized, controlled trials. New England Journal of Medicine2000;342(25):1878‐86. [DOI: 10.1056/NEJM200006223422506] ">Benson 2000</a>; <a href="./references#CD012069-bbs2-0522" title="HannanEL . Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovascular Interventions2008;1(3):211‐7. [DOI: 10.1016/j.jcin.2008.01.008] ">Hannan 2008</a>; <a href="./references#CD012069-bbs2-0639" title="SilvermanSL . From randomized controlled trials to observational studies. American Journal of Medicine2009;122(2):114‐20. [DOI: 10.1016/j.amjmed.2008.09.030; PUBMED: 19185083] ">Silverman 2009</a>). Non‐randomised studies may detect adverse events due to long‐term drug exposure, which would not be detected in relatively short RCTs (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). Some adverse events may be too uncommon to be detected in RCTs (<a href="./references#CD012069-bbs2-0567" title="LokeYK , PriceD , HerxheimerA . Chapter 14: Adverse effects. In Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbok.cochrane.org. ">Loke 2011</a>), and as a result, cohort studies, patient‐control studies, and even patient reports/series may be of value (<a href="./references#CD012069-bbs2-0615" title="ReevesBC , DeeksJJ , HigginsJPT , WellsGA . Chapter 14: Including non‐randomized studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Reeves 2011</a>). In fact, non‐randomised studies can estimate the adverse events of treatment as well as, and maybe even more comprehensively than, RCTs (<a href="./references#CD012069-bbs2-0669" title="VandenbrouckeJP . What is the best evidence for determining harms of medical treatment?. Canadian Medical Association Journal2006;174(5):645‐6. [DOI: 10.1503/cmaj.051484; PMC1389828; PUBMED: 16505461] ">Vandenbroucke 2006</a>). </p> <p>RCTs and non‐randomised studies investigating adverse events rarely find differences in risk estimates (<a href="./references#CD012069-bbs2-0497" title="GolderS , LokeYK , BlandM . Meta‐analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLOS Medicine2011;8(5):e1001026. [DOI: 10.1371/journal.pmed.1001026] ">Golder 2011</a>). In their review, <a href="./references#CD012069-bbs2-0605" title="PitrouI , BoutronI , AhmadN , RavaudP . Reporting of safety results in published reports of randomized controlled trials. Archives of Internal Medicine2009;169(19):1756‐61. [DOI: 10.1001/archinternmed.2009.306; PUBMED: 19858432] ">Pitrou 2009</a> found that some RCTs provided no information on adverse events, and severity was often poorly defined. Only 13% of studies noted the reasons for patient withdrawal due to adverse events. Another study reported that only 18% of all paediatric RCTs published between 2006 and 2009 documented harms adequately according to CONSORT guidelines (<a href="./references#CD012069-bbs2-0470" title="DeVriesTW , vanRoonEN . Low quality of reporting adverse drug reactions in paediatric randomised controlled trials. Archives of Disease in Childhood2010;95(12):1023‐6. [DOI: 10.1136/adc.2009.175562; PUBMED: 20551194] ">De Vries 2010</a>). Our findings were similar (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>), with only 17/185 RCTs (9.20%) reporting serious adverse events and approximately 60/185 RCTs (32.0%) reporting non‐serious adverse events. </p> <p>The main disadvantage, however, is that causality cannot be established in observational studies because the observed adverse event may be related to other factors. Nonetheless, in view of the poor reporting of adverse events in RCTs, non‐randomised studies may provide important data that would otherwise remain undetected (<a href="./references#CD012069-bbs2-0567" title="LokeYK , PriceD , HerxheimerA . Chapter 14: Adverse effects. In Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbok.cochrane.org. ">Loke 2011</a>; <a href="./references#CD012069-bbs2-0669" title="VandenbrouckeJP . What is the best evidence for determining harms of medical treatment?. Canadian Medical Association Journal2006;174(5):645‐6. [DOI: 10.1503/cmaj.051484; PMC1389828; PUBMED: 16505461] ">Vandenbroucke 2006</a>). Such data from non‐randomised studies may help children, adolescents, families, clinicians, and policymakers understand the relative risks and benefits, leading to better informed choices regarding methylphenidate treatment. When we deal with serious adverse events, troublesome non‐serious adverse events, and/or prevalent non‐serious adverse events, we should remember the recommendations from regulatory authorities stating that P values are of very limited value as substantial differences (expressed as relative risk or risk differences) require careful assessment and will, in addition, raise concern, depending on seriousness, severity or outcome, irrespective of the P value observed (<a href="./references#CD012069-bbs2-0475" title="European Medicines Agency. Guideline on multiplicity issues in clinical trials. Committee for Human Medicinal products (CHMP)2017. ">EMA 2017</a>). A non‐significant difference between treatments will not allow for a conclusion on the absence of a difference in safety. In other words, in line with general principles, a non‐significant test result should not be confused with the demonstration of equivalence (<a href="./references#CD012069-bbs2-0475" title="European Medicines Agency. Guideline on multiplicity issues in clinical trials. Committee for Human Medicinal products (CHMP)2017. ">EMA 2017</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012069-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012069-sec-0028"></div> <p>To assess the adverse events associated with methylphenidate treatment for children and adolescents with ADHD in non‐randomised studies. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012069-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012069-sec-0029"></div> <section id="CD012069-sec-0030"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012069-sec-0031"> <h4 class="title">Types of studies</h4> <p>We only included the following non‐randomised study designs (<a href="./references#CD012069-bbs2-0529" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p> <ol id="CD012069-list-0001"> <li> <p>Comparative cohort studies. Here, the experimental group was children or adolescents with ADHD exposed to methylphenidate and the control group was comparable patients not exposed to methylphenidate. </p> </li> <li> <p>Patient‐control studies. Here, the patient ('case') group was children or adolescents with ADHD exposed to methylphenidate, and the control group was comparable patients not exposed to methylphenidate. </p> </li> <li> <p>Non‐comparative cohort studies. In this study type, children or adolescents with ADHD were exposed to methylphenidate with no control group. We also included the methylphenidate‐treated group from randomised clinical trials (RCTs) comparing methylphenidate versus other interventions for ADHD, as these trials were not included in our previous review of RCTs assessing methylphenidate versus placebo or no intervention (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). In this way, we were able to expand our evidence base on adverse events during methylphenidate administration (as such groups are comparable to classic cohort studies), without double‐counting from RCTs assessing methylphenidate versus placebo or no intervention (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). For assessment of adverse events in RCTs assessing methylphenidate versus placebo or no intervention, the reader is referred to our systematic review on that topic (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). </p> </li> <li> <p>Patient reports/series. This study type was formerly known and also described in our protocol as 'case‐studies' (<a href="./references#CD012069-bbs2-0688" title="StorebøOJ , PedersenN , RamstadE , KroghHB , Moreira‐MaiaCR , MagnussonFL , et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents ‐ assessment of harmful effects in non‐randomised studies. Cochrane Database of Systematic Reviews2016, Issue 2. [DOI: 10.1002/14651858.CD012069] ">Storebø 2016</a>). </p> </li> <li> <p>Cross‐sectional studies.</p> </li> </ol> </p> <p>For a description of cohort, cross‐sectional, and patient‐control studies, see <a href="#CD012069-tbl-0002">Table 1</a>. </p> <div class="table" id="CD012069-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study design</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study design</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An observational study in which a defined group with ≥ 1 samples of people (the cohort) is followed over time. The outcomes of people in subsets of this cohort might be compared, to examine people who were exposed or not exposed (or exposed at different levels) to a particular intervention or other factor of interest. A prospective cohort study assembles participants and follows them into the future. A retrospective (or historical) cohort study identifies participants from past records and follows them from the time of those records to the present. Because participants are not allocated by the investigator to different interventions or other exposures, adjusted analysis is usually required to minimise the influence of other factors (confounders). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient‐control study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A study that compares people with a specific disease or outcome of interest (cases) to people from the same population without that disease or outcome (controls), and which seeks to find associations between the outcome and prior exposure to particular risk factors. This design is particularly useful when the outcome is rare and when past exposure can be reliably measured. Patient‐control studies are usually but not always retrospective. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐sectional study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Studies in which the presence or absence of disease or other health‐related variables are determined for each member of the study population or in a representative sample at one particular time. This contrasts with cohort studies, which are followed over a period of time. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>Taken from the <a href="http://community.cochrane.org/glossary" target="_blank">Cochrane Glossary</a>. </p> </div> </div> <p>See <a href="#CD012069-sec-0275">Differences between protocol and review</a>. </p> </section> <section id="CD012069-sec-0032"> <h4 class="title">Types of participants</h4> <p>Children and adolescents with ADHD, with or without comorbid conditions. At least 75% of study participants were required to be aged 18 years or younger, and the mean age of the trial population had to be 18 years of age or younger. We also required that at least 75% of participants had a normal intellectual quotient (IQ &gt; 70 points). See <a href="#CD012069-sec-0275">Differences between protocol and review</a>. </p> <p>We accepted the following diagnoses of ADHD.</p> <p> <ol id="CD012069-list-0002"> <li> <p>A diagnosis of ADHD made according to the <i>Diagnostic and Statistical Manual of Mental Disorders</i> (DSM) <i>‐ 3rd Edition</i> (DSM‐III; <a href="./references#CD012069-bbs2-0409" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐III). 3rd Edition. Washington (DC): American Psychiatric Association, 1980. ">APA 1980</a>); <i>3rd Edition ‐ Revised</i> (DSM‐III‐R; <a href="./references#CD012069-bbs2-0410" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM III‐R). 3rd Edition. Washington (DC): American Psychiatric Association, 1987. ">APA 1987</a>); <i>4th Edition</i> (DSM‐IV; <a href="./references#CD012069-bbs2-0411" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐IV). 4th Edition. Washington (DC): American Psychiatric Association, 1994. ">APA 1994</a>); <i>4th Edition ‐ Text Revision</i> (DSM‐IV‐TR; <a href="./references#CD012069-bbs2-0412" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: Text revision (DSM‐IV‐TR). 4th Edition. Washington (DC): American Psychiatric Association, 2000. ">APA 2000</a>), or<i>5th Edition</i> (DSM‐5; <a href="./references#CD012069-bbs2-0413" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM‐5). 5th Edition. Washington (DC): American Psychiatric Association, 2013. ">APA 2013</a>). </p> </li> <li> <p>A diagnosis of hyperkinetic disorders made in accordance with the <i>International Classification of Diseases ‐ 9th Revision</i> (ICD‐9; <a href="./references#CD012069-bbs2-0674" title="World Health Organization. International Classification of Diseases, Ninth Revision. Vol. 1, Geneva: World Health Organization, 1977. ">WHO 1977</a>) and<i>‐10th Revision</i> (ICD‐10; <a href="./references#CD012069-bbs2-0675" title="World Health Organization. The ICD‐10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization, 1992. ">WHO 1992</a>). </p> </li> </ol> </p> </section> <section id="CD012069-sec-0033"> <h4 class="title">Types of interventions</h4> <p>Methylphenidate administered at any dosage or formulation as part of any medical treatment regimen. </p> <p>In the comparative cohort studies and patient‐control studies, we included studies that compared cointerventions as long as the compared intervention groups received the same cointerventions. </p> <p>In the non‐comparative cohort studies, we allowed some types of comedication but not cointervention with another type of ADHD medication. </p> <p>See <a href="#CD012069-sec-0275">Differences between protocol and review</a>. </p> </section> <section id="CD012069-sec-0034"> <h4 class="title">Types of outcome measures</h4> <p>We defined the term 'adverse events' as any harm, adverse effect, or adverse drug reaction associated with methylphenidate. We defined 'withdrawals' as any participants withdrawn from methylphenidate medication. </p> <section id="CD012069-sec-0035"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD012069-list-0003"> <li> <p>Serious adverse events. A serious adverse event is defined as any event that is fatal; life‐threatening; requires inpatient hospitalisation or prolongation of existing hospitalisation; or results in persistent or significant disability, or any event that requires intervention to prevent any of these outcomes in accordance with the <i>Guideline for Good Clinical Practice E6(R1)</i> (<a href="./references#CD012069-bbs2-0539" title="International Council for Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice E6(R1) 1996. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (accessed 6 May 2011). ">ICH 1996</a>). </p> </li> <li> <p>Withdrawal of methylphenidate due to serious adverse events.</p> </li> <li> <p>Withdrawal of methylphenidate due to adverse events of unknown severity.</p> </li> </ol> </p> </section> <section id="CD012069-sec-0036"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD012069-list-0004"> <li> <p>Non‐serious adverse events. All other adverse events, including but not confined to, the following common types of adverse events: cardiovascular, neurological, gastrointestinal, difficulty with sleep, and growth retardation in accordance with the <i>Guideline for Good Clinical Practice E6(R1)</i> (<a href="./references#CD012069-bbs2-0539" title="International Council for Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice E6(R1) 1996. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (accessed 6 May 2011). ">ICH 1996</a>)<i>.</i> </p> </li> <li> <p>Withdrawal of methylphenidate due to non‐serious adverse events.</p> </li> <li> <p>Withdrawal of methylphenidate for unknown reasons.</p> </li> </ol> </p> <p>Adverse events were measured during treatment, at the end of treatment and at the longest follow‐up, using rating scales, spontaneous reports recorded by the investigators at regular interviews or visits, and physical examinations or para‐clinical examinations. </p> <p>We reported the primary and the secondary outcomes in <a href="./full#CD012069-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>See <a href="#CD012069-sec-0275">Differences between protocol and review</a>. </p> </section> </section> </section> <section id="CD012069-sec-0037"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012069-sec-0038"> <h4 class="title">Electronic searches</h4> <p>In February 2015, we simultaneously conducted the literature searches for this and another review by including a separate search strategy of adverse events, as described in the previous review (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). We predicted that reports on efficacy as well as adverse events would both describe the adverse events of methylphenidate, which is why it made good sense to combine the two search strategies and thus maximise the retrieval of relevant publications. In order to overcome poor indexing and abstracting, we listed individual brand names in the search strategies. The search strategies, as executed in both reviews, are shown in <a href="./appendices#CD012069-sec-0234">Appendix 1</a>. </p> <p>On 8 January 2016, we ran an updated version of the adverse events search strategy that included new brand names and study designs. We also searched a number of additional sources to identify grey literature. </p> <p>We searched the electronic databases and trial registers listed below, in order to identify relevant studies. </p> <p> <ol id="CD012069-list-0005"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 1), in the Cochrane Library, which includes the Cochrane Developmental, Psychosocial and Learning Problems Specialised Register (searched 8 January 2016). </p> </li> <li> <p>MEDLINE Ovid (1948 to January week 3 2016).</p> </li> <li> <p>Embase Ovid (1980 to January week 3 2016).</p> </li> <li> <p>PsycINFO Ovid (1806 to January week 3 2016).</p> </li> <li> <p>CINAHL EBSCOhost (Cumulative Index to Nursing &amp; Allied Health Literature; 1980 to 8 January 2016). </p> </li> <li> <p>Conference Proceedings Citation Index ‐ Science Web of Science (CPCI‐S; 1990 to 14 November 2017). </p> </li> <li> <p>Conference Proceedings Citation Index ‐ Social Science &amp; Humanities Web of Science (CPCI‐SS&amp;H; 1990 to 14 November 2017). </p> </li> <li> <p>NDLTD Theses Resources (<a href="http://www.ndltd.org/resources" target="_blank">ndltd.org/resources</a>; all available years; searched 11 January 2016). </p> </li> <li> <p>Trove ‐ National Library of Australia (<a href="http://trove.nla.gov.au/" target="_blank">trove.nla.gov.au</a>; all available years; searched 11 January 2016). </p> </li> <li> <p>British Library E‐Theses Online Service (EThOS; <a href="http://ethos.bl.uk/" target="_blank">ethos.bl.uk</a>; all available years; searched 11 January 2016). </p> </li> <li> <p>Deutsche Nationalbibliothek Dissertations (<a href="http://www.dnb.de/EN/Home/home_node.html" target="_blank">www.dnb.de/EN/Home/home_node.html</a>; all available years; searched 11 January 2016). </p> </li> <li> <p>Open Access Theses and Dissertations (OATD; <a href="https://oatd.org/" target="_blank">oatd.org</a>; all available years; searched 11 January 2016). </p> </li> <li> <p>Theses Collection Wales ‐ The National Library of Wales (<a href="https://www.llgc.org.uk/en/discover/nlw-resources/theses-collection-wales/" target="_blank">www.llgc.org.uk/en/discover/nlw‐resources/theses‐collection‐wales</a>; all available years; searched 11 January 2016). </p> </li> <li> <p>DART‐Europe E‐Theses Portal (<a href="http://www.dart-europe.eu/basic-search.php" target="_blank">www.dart‐europe.eu/basic‐search.php</a>; all available years; searched 11 January 2016). </p> </li> <li> <p>Bielefeld Academic Search Engine (BASE; <a href="https://www.base-search.net/about/en/" target="_blank">www.base‐search.net/about/en</a>; all available years; searched 11 January 2016). </p> </li> <li> <p>Theses France (<a href="https://www.theses.fr/en/" target="_blank">www.theses.fr/en</a>; all available years; searched 11 January 2016). </p> </li> <li> <p>ProQuest Open Access Dissertations (PQDT; <a href="http://pqdtopen.proquest.com/search.html" target="_blank">pqdtopen.proquest.com/search.html</a>; all available years; searched 11 January 2016). </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>; all available years; searched 11 January 2016). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP; <a href="http://who.int/ictrp/en/" target="_blank">who.int/ictrp/en</a>; all available years; searched 11 January 2016). </p> </li> </ol> </p> <p>We did not limit the searches by language, year of publication, or type of publication. We translated relevant sections of non‐English language reports when needed. </p> <p>See <a href="#CD012069-sec-0275">Differences between protocol and review</a>. </p> </section> <section id="CD012069-sec-0039"> <h4 class="title">Searching other resources</h4> <p>In order to find additional relevant studies not identified by the electronic searches listed above, we scrutinised the bibliographic references of identified review articles and meta‐analyses. Furthermore, we sent requests for published as well as unpublished data to pharmaceutical companies manufacturing methylphenidate, including Shire (<a href="https://www.shire.com/" target="_blank">www.shire.com</a>), Medice (represented in Denmark by HB Pharma: <a href="http://www.hbpharma.dk/" target="_blank">www.hbpharma.dk</a>), Janssen‐Cilag (<a href="http://www.janssen.com/)" target="_blank">www.janssen.com</a>), and Novartis (<a href="https://www.novartis.com/" target="_blank">www.novartis.com</a>) (<a href="https://zenodo.org/record/1165119#.WnWDKmeWyxA" target="_blank">see supplementary file Letter to pharmaceutical companies</a>). We also requested unpublished studies from several hundred authors (<a href="#CD012069-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD012069-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD012069-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> <p>In addition, we searched the websites of the US Food and Drug Administration (FDA; <a href="https://www.fda.gov/" target="_blank">www.fda.gov</a>) and the European Medicines Agency (EMA; <a href="http://www.ema.europa.eu/ema/" target="_blank">www.ema.europa.eu/ema</a>). </p> </section> </section> <section id="CD012069-sec-0040"> <h3 class="title" id="CD012069-sec-0040">Data collection and analysis</h3> <p>We conducted the review in accordance with guidance in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012069-bbs2-0529" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), the PRISMA guidelines (<a href="./references#CD012069-bbs2-0565" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ2009;339:b2700. [DOI: 10.1136/bmj.b2700] ">Liberati 2009</a>; <a href="./references#CD012069-bbs2-0577" title="MoherD , ShamseerL , ClarkeM , GhersiD , LiberatiA , PetticrewM , et al. Preferred reporting items for systematic review and meta‐analysis protocols (PRISMA‐P) 2015 statement. Systematic Reviews2015;4(1):1‐9. [DOI: 10.1186/2046‐4053‐4‐1] ">Moher 2015</a>), and the Cochrane ROBINS‐I tool for for assessing <b>r</b> isk <b>o</b> f <b>b</b> ias <b>i</b> n <b>n</b> on‐randomised <b>s</b> tudies of <b>i</b>nterventions (formerly named ACROBAT) (<a href="./references#CD012069-bbs2-0646" title="SterneJAC , HigginsJPT , ReevesBC , on behalf of the development group for ACROBAT‐NRSI. A Cochrane Risk Of Bias Assessment Tool: for Non‐Randomised Studies of Interventions (ACROBAT‐NRSI), Version 1.0.0, 24 September 2014. www.riskofbias.info (accessed 25 May 2015). ">Sterne 2014</a>; <a href="./references#CD012069-bbs2-0647" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ2016; Vol. 355, issue i4919. [DOI: 10.1136/bmj.i4919; PMC5062054; PUBMED: 27733354] ">Sterne 2016</a>). </p> <p>We performed the analysis using Cochrane's software, Review Manager 5 (RevMan 5) (<a href="./references#CD012069-bbs2-0616" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> <section id="CD012069-sec-0041"> <h4 class="title">Selection of studies</h4> <p>Fourteen review authors (CRMM, ER, FLM, HBK, KBR, LA, MH, MS, NP, OJS, SJH, SR, TB, and TG) worked together in groups of two and independently screened the titles and abstracts of all records retrieved by the searches; we resolved uncertainty or disagreement by consensus. We obtained the full texts of all potentially relevant reports and assessed each one against our inclusion criteria (<a href="#CD012069-sec-0030">Criteria for considering studies for this review</a>). We discussed disagreements and consulted OJS and CG when agreement could not be reached. We have listed relevant non‐randomised studies that do not fulfil the inclusion criteria with reasons for exclusion in the <a href="./references#CD012069-sec-0278" title="">Characteristics of excluded studies</a> table. We recorded our selection process in a study flow diagram (<a href="./references#CD012069-bbs2-0576" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. PLoS Medicine2009;6(7):e1000097. [DOI: 10.1371/journal.pmed.1000097; PMC2707599; PUBMED: 19621072] ">Moher 2009</a>). </p> <p>See <a href="#CD012069-sec-0275">Differences between protocol and review</a>. </p> </section> <section id="CD012069-sec-0042"> <h4 class="title">Data extraction and management</h4> <p>We developed data extraction forms to facilitate standardisation of this process. We extracted data on participants, study design and methods, interventions, adverse events, and relevant data for 'Risk of bias' assessments. </p> <p>All review authors extracted data. The authors worked together in groups of two, and each pair completed the data collection form independently to ensure accuracy. We resolved disagreements by discussion or used an arbiter if required. Six review authors (CRMM, FLM, HBK, MH, NP, and OJS) entered data into RevMan 5 (<a href="./references#CD012069-bbs2-0616" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). In cases of insufficient data, or where data in the published study reports were unclear, we contacted the study authors requesting them to clarify the missing information (see <a href="#CD012069-sec-0055">Dealing with missing data</a>). </p> <p>See <a href="#CD012069-sec-0275">Differences between protocol and review</a>. </p> </section> <section id="CD012069-sec-0043"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For each included study, two review authors (LA, SJH) used the ROBINS‐I tool and independently assessed the risk of bias of comparative cohort studies and patient‐control studies across the following seven domains (<a href="./references#CD012069-bbs2-0646" title="SterneJAC , HigginsJPT , ReevesBC , on behalf of the development group for ACROBAT‐NRSI. A Cochrane Risk Of Bias Assessment Tool: for Non‐Randomised Studies of Interventions (ACROBAT‐NRSI), Version 1.0.0, 24 September 2014. www.riskofbias.info (accessed 25 May 2015). ">Sterne 2014</a>; <a href="./references#CD012069-bbs2-0647" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ2016; Vol. 355, issue i4919. [DOI: 10.1136/bmj.i4919; PMC5062054; PUBMED: 27733354] ">Sterne 2016</a>). </p> <section id="CD012069-sec-0044"> <h5 class="title">1. Possible bias due to confounding factors</h5> <p>We assessed risk of bias due to:</p> <p> <ul id="CD012069-list-0006"> <li> <p>comorbidity;</p> </li> <li> <p>age;</p> </li> <li> <p>sex;</p> </li> <li> <p>subtypes of ADHD;</p> </li> <li> <p>socioeconomic factors;</p> </li> <li> <p>switch between ADHD medications;</p> </li> <li> <p>adjustment of medication; and</p> </li> <li> <p>any other confounding factor in the study.</p> </li> </ul> </p> </section> <section id="CD012069-sec-0045"> <h5 class="title">2. Possible bias due to selection of participants</h5> <p>We assessed risk of bias due to:</p> <p> <ul id="CD012069-list-0007"> <li> <p>inclusion of patients;</p> </li> <li> <p>time from diagnosis to inclusion in study; and</p> </li> <li> <p>naïve to previous methylphenidate exposure compared to non‐naïve patients.</p> </li> </ul> </p> <p>For patient‐control studies, we assessed risk of bias due to selection of controls.</p> </section> <section id="CD012069-sec-0046"> <h5 class="title">3. Possible bias due to measurement of interventions</h5> <p>We assessed risk of bias due to:</p> <p> <ul id="CD012069-list-0008"> <li> <p>measurement of intervention status at start of follow‐up; and</p> </li> <li> <p>self‐reporting of intervention status.</p> </li> </ul> </p> </section> <section id="CD012069-sec-0047"> <h5 class="title">4. Possible bias due to departures from intended interventions</h5> <p>We assessed risk of bias due to:</p> <p> <ul id="CD012069-list-0009"> <li> <p>compliance with assigned medication;</p> </li> <li> <p>practitioner administration;</p> </li> <li> <p>characteristics of the healthcare setting, for instance, public outpatient compared to hospital outpatient; </p> </li> <li> <p>adverse events; and</p> </li> <li> <p>lack of efficacy of treatment.</p> </li> </ul> </p> </section> <section id="CD012069-sec-0048"> <h5 class="title">5. Possible bias due to missing data</h5> <p>We assessed risk of bias due to loss to follow‐up.</p> <p>For patient‐control studies, we assessed risk of bias due to differences in follow‐up between exposed and non‐exposed patients. </p> </section> <section id="CD012069-sec-0049"> <h5 class="title">6. Possible bias in measurement of outcomes</h5> <p>We assessed risk of bias due to:</p> <p> <ul id="CD012069-list-0010"> <li> <p>self‐reporting of adverse events; and</p> </li> <li> <p>error in instruments measuring adverse events.</p> </li> </ul> </p> </section> <section id="CD012069-sec-0050"> <h5 class="title">7. Possible bias in selection of reported results</h5> <p>We assessed risk of bias due to:</p> <p> <ul id="CD012069-list-0011"> <li> <p>type of analysis; and</p> </li> <li> <p>selection of results.</p> </li> </ul> </p> <p>Review authors judged each domain to be at low risk of bias, moderate risk of bias, serious risk of bias, critical risk of bias, or no information, as follows. </p> <p> <ol id="CD012069-list-0012"> <li> <p>Low risk of bias: the study is comparable to a well‐performed RCT with regards to this domain. </p> </li> <li> <p>Moderate risk of bias: the study is sound for a non‐randomised study with regards to this domain but cannot be considered comparable to a well‐performed RCT. </p> </li> <li> <p>Serious risk of bias: the study has some important problems in this domain.</p> </li> <li> <p>Critical risk of bias: the study is too problematic in this domain to provide any useful evidence on the effects of the intervention. </p> </li> <li> <p>No information: there is no information on which to base a judgment about risk of bias for this domain. </p> </li> </ol> </p> <p>We assigned studies an overall rating of low risk of bias when we judged them to be at low risk of bias in all domains; moderate risk of bias when we judged them to be at moderate risk of bias in at least one domain, but not at serious or critical risk of bias in any domain; serious risk of bias when we judged them to be at serious risk of bias in at least one domain, but not at critical risk of bias in any domains; critical risk of bias when we judged them to be at critical risk of bias in at least one domain; and no information when there was no clear indication that the study is at serious or critical risk of bias and there was a lack of information in one or more key domains of bias. </p> <p>We resolved any disagreements by discussion. It was not possible to assess non‐comparative studies for risk of bias using ROBINS‐I because it is a prerequisite in this tool that there is a comparative study. The non‐comparative studies are at critical risk of bias mostly due to confounding factors, so we considered all these studies to be at critical risk of bias as described in the ROBINS‐I manual: "a study is too problematic to provide any useful evidence on the effects of intervention" (<a href="./references#CD012069-bbs2-0646" title="SterneJAC , HigginsJPT , ReevesBC , on behalf of the development group for ACROBAT‐NRSI. A Cochrane Risk Of Bias Assessment Tool: for Non‐Randomised Studies of Interventions (ACROBAT‐NRSI), Version 1.0.0, 24 September 2014. www.riskofbias.info (accessed 25 May 2015). ">Sterne 2014</a>; <a href="./references#CD012069-bbs2-0647" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ2016; Vol. 355, issue i4919. [DOI: 10.1136/bmj.i4919; PMC5062054; PUBMED: 27733354] ">Sterne 2016</a>). </p> <p>There is reason to believe that other factors result in an under‐reporting of adverse events, such as a general reluctance to report them (<a href="./references#CD012069-bbs2-0542" title="IoannidisJP , Contopoulos‐IoannidisDG . Reporting of safety data from randomised trials. Lancet1998;352(9142):1752‐3. [DOI: 10.1016/S0140‐6736(05)79825‐1; PUBMED: 9848355] ">Ioannidis 1998</a>; <a href="./references#CD012069-bbs2-0543" title="IoannidisJP . Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Archives of Internal Medicine2009;169(19):1737‐9. [DOI: 10.1001/archinternmed.2009.313; PUBMED: 19858427] ">Ioannidis 2009</a>), inadequate monitoring (<a href="./references#CD012069-bbs2-0567" title="LokeYK , PriceD , HerxheimerA . Chapter 14: Adverse effects. In Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbok.cochrane.org. ">Loke 2011</a>), and exclusion of patients with risk factors for adverse events (<a href="./references#CD012069-bbs2-0595" title="PagsbergAK , JeppesenP , KlauberDG , JensenKG , RudåD , Stentebjerg‐OlesenM , et al. Quetiapine extended release versus aripiprazole in children and adolescents with first‐episode psychosis: the multicentre, double‐blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. Lancet Psychiatry2017;4(8):605‐8. ">Pagsberg 2017</a>). </p> </section> </section> <section id="CD012069-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <section id="CD012069-sec-0052"> <h5 class="title">Dichotomous data</h5> <p>We summarised dichotomous data as risk ratios (RR) with 95% confidence intervals (CI). We present pooled proportion data from non‐comparative studies using the Comprehensive Meta‐Analysis Software (CMA; <a href="./references#CD012069-bbs2-0453" title="BioStat . Comprehensive Meta Analysis. www.meta‐analysis.com (accessed 9 February 2018). ">Comprehensive Meta Analysis</a>). See <a href="#CD012069-sec-0275">Differences between protocol and review</a>. For numbers below 10, we gave two decimals. For numbers at 10 or above, we gave one decimal. </p> </section> <section id="CD012069-sec-0053"> <h5 class="title">Continuous data</h5> <p>For continuous data, we calculated the mean difference (MD) between the two groups and present it with 95% CI. We used the overall MD, where possible, to compare outcome measures from studies. We estimated the standardised MD (SMD) where studies used different measures to assess the same outcome. If studies did not report means and standard deviations (SD) but reported other values, such as t‐tests and P values, we calculated the SD using the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012069-bbs2-0529" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). For numbers below 10, we gave two decimals. For numbers at 10 or above, we gave one decimal. </p> </section> </section> <section id="CD012069-sec-0054"> <h4 class="title">Unit of analysis issues</h4> <p>We included in this review a number of cross‐over trials that met our inclusion criteria (<a href="#CD012069-sec-0030">Criteria for considering studies for this review</a>). Cross‐over trials are more prone to bias from carry‐over effects, period effects, and unit‐of analysis issues (<a href="./references#CD012069-bbs2-0463" title="CurtinF , ElbourneD , AltmanDG . Meta‐analysis combining parallel and cross‐over clinical trials. III: The issue of carry over. Statistics in Medicine2002;21(15):2161‐73. ">Curtin 2002</a>). However, as we only used the data from the methylphenidate groups from the first period of these trials, we believe that these biases do not influence the proportions reported. </p> </section> <section id="CD012069-sec-0055"> <h4 class="title">Dealing with missing data</h4> <p>We tried to obtain missing data by contacting the authors of the studies. We wrote letters to 174 authors twice and received replies from 108. Many authors supplied us with missing sociodemographic data and missing information about methodology, and some supplied us with missing statistics. If data remained unavailable, we tried to estimate the missing data using the available information (e.g. if the SD was missing, we estimated it from the standard error, if reported). </p> </section> <section id="CD012069-sec-0056"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed the following types of heterogeneity: clinical (variability in participants, interventions, or settings); methodological (variation in study designs); and statistical heterogeneity (variation in intervention effects). We assessed heterogeneity between studies by visual inspection of the forest plot for overlapping CIs; using the Chi<sup>2</sup> test for homogeneity with a significance level of α (alpha) = 0.10, and the I<sup>2</sup> statistic for quantifying inconsistency (estimating the percentage of variation in effect estimates due to heterogeneity rather than sampling error). We judged I<sup>2</sup> values of 0% to 40% to indicate little heterogeneity; 30% to 60%, moderate heterogeneity; 50% to 90%, substantial heterogeneity; and 75% to 100%, considerable heterogeneity (<a href="./references#CD012069-bbs2-0529" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We abstained from conducting a meta‐analysis if there was a very high level of heterogeneity and the studies seemed to address different questions; Section 9.5.3.2 in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> recommends that if "there is considerable variation in results, and particularly if there is inconsistency in the direction of effect, it may be misleading to quote an average value for the intervention effect" (<a href="./references#CD012069-bbs2-0529" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Where it was not possible to undertake a meta‐analysis, we provided a narrative description of the prevalence estimate. </p> <p>Not all studies used the same outcome measures. For example, for height, some studies used centimetres while other studies provided age and sex‐adjusted scores, and we could not analyse these studies. </p> <p>Study characteristics that may have been important to assess included the following.</p> <p> <ol id="CD012069-list-0013"> <li> <p>Number of confounders included in the models.</p> </li> <li> <p>Analysis technique used.</p> </li> </ol> </p> </section> <section id="CD012069-sec-0057"> <h4 class="title">Assessment of reporting biases</h4> <p>Reporting bias and missing studies are more complex issues for non‐randomised studies than for RCTs. Registration and publication of protocols for non‐randomised studies are not as common as for RCTs (<a href="./references#CD012069-bbs2-0641" title="SkoogM , SaarimäkiJM , GluudC , SheininM , ErlendssonK , AamdalS , et al. Transparency and registration in clinical research in the Nordic countries. NordicTrial Alliance, NordForsk2015:1‐108. ">Skoog 2015</a>). We aimed to include a wide range of studies by using a broad search strategy, and we handled different forms of reporting bias, especially publication bias and outcome reporting bias, according to the recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012069-bbs2-0529" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>)<i>.</i> We did not draw funnel plots (estimated differences in treatment effects against their standard error) due to too few studies, nor did we perform Egger's statistical test for small‐study effects (<a href="./references#CD012069-bbs2-0473" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. [DOI: 10.1136/bmj.315.7109.629; PUBMED: 9310563] ">Egger 1997</a>). Asymmetry could be due to publication bias but also to genuine heterogeneity between small and large trials (<a href="./references#CD012069-bbs2-0529" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>)<i>.</i> </p> <p>See <a href="#CD012069-sec-0275">Differences between protocol and review</a>. </p> </section> <section id="CD012069-sec-0058"> <h4 class="title">Data synthesis</h4> <p>We analysed and presented the pooled estimates of the different adverse events according to the following study designs: </p> <p> <ol id="CD012069-list-0014"> <li> <p>comparative studies (cohort studies and patient‐control studies);</p> </li> <li> <p>non‐comparative studies (cohort studies without a control group, including the methylphenidate‐treated group from randomised clinical trials (RCTs) comparing methylphenidate versus other interventions for ADHD excluded from our previous review (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>), and cross sectional studies); and </p> </li> <li> <p>patient reports/series, which we used to identify less common (rare) adverse events, defined according to the brand leader's Summary of Product Characteristics (SPC; <a href="./references#CD012069-bbs2-0395" title="AagaardL , HansenEH . Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs. BMC Clinical Pharmacology2009;9:4. [DOI: 10.1186/1472‐6904‐9‐4] ">Aagaard 2009</a>). </p> </li> </ol> </p> <p>As prespecified in our protocol (<a href="./references#CD012069-bbs2-0688" title="StorebøOJ , PedersenN , RamstadE , KroghHB , Moreira‐MaiaCR , MagnussonFL , et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents ‐ assessment of harmful effects in non‐randomised studies. Cochrane Database of Systematic Reviews2016, Issue 2. [DOI: 10.1002/14651858.CD012069] ">Storebø 2016</a>), we tried to be as pragmatic as possible by further grouping the reported adverse events according to the main body systems affected, namely: central nervous system; cardiovascular and respiratory systems; gastrointestinal system; musculoskeletal system; immune system; urinogenital system; and other body systems. We then conducted meta‐analyses of the proportion of different adverse events under each system. </p> <p>If there were adequate data, we pooled the data from comparative studies and conducted a meta‐analysis of the estimates. If there were inadequate data, we reported the results qualitatively. </p> <p>We synthesised data qualitatively across some cohort studies, cross sectional studies and patient report/series when data could not be used in meta‐analyses. </p> <p>Some studies have combined designs (for example, non‐comparative cohort and patient‐control study design). In those cases we synthesised the comparative and non‐comparative data separately. </p> <p>Our analyses and conclusions of the results differ between comparative and non‐comparative studies. We use data from comparative cohort studies and patient‐control studies to evaluate the RR of harms. For the comparative studies, we performed a meta‐analysis according to recommendations in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012069-bbs2-0529" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>If clinical heterogeneity was not excessive (for example, there was not too much variability in participants' characteristics), we performed a meta‐analysis of the results using the inverse‐variance method. This method gives more weight to larger studies, reducing imprecision in the pooled estimate of effect. We used the random‐effects model in all meta‐analyses and the fixed‐effect model in sensitivity analyses (see <a href="#CD012069-sec-0060">Sensitivity analysis</a>). The random‐effects model is best suited to our data due to the relatively high heterogeneity. In most analyses there were no significant differences between the two statistical models. In cases where there was a statistical difference, the fixed‐effect model mostly showed a higher proportion of adverse events. The decision to report the random‐effects model was therefore a conservative one. </p> </section> <section id="CD012069-sec-0059"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Because of high levels of clinical and statistical heterogeneity, we conducted subgroup analyses to identify whether there was an increased risk associated with children who: had received concurrent medication; had a comorbid condition; had received methylphenidate for longer periods; were younger; or had received a higher dose of methylphenidate. Study characteristics that may have been associated with differences in risk included higher quality and independent funding. </p> <p>We conducted the following subgroup analyses.</p> <p> <ol id="CD012069-list-0015"> <li> <p>Studies with concurrent medication versus studies without any concurrent medication (children and adolescents may be more susceptible to adverse events if they are also receiving other medications). </p> </li> <li> <p>Studies with ADHD as the only disease versus studies with ADHD and comorbidity (children and adolescents may be more susceptible to adverse events if they have other behavioural, neurological or psychological comorbidities). </p> </li> <li> <p>Studies with a treatment duration shorter than six months versus studies with a treatment duration of six months or longer (there may be cumulative effects of methylphenidate over time). </p> </li> <li> <p>Studies with participants with a mean age younger than 10 years versus studies with participants with a mean age of 10 years or older (younger children are more susceptible to the adverse events of methylphenidate because of their smaller size and differences in metabolism). </p> </li> <li> <p>Studies with a low dosage of methylphenidate (below 20 mg/day) versus studies with a high dosage of methylphenidate (20 mg/day and above) (adverse events are more likely with high‐dose methylphenidate). </p> </li> <li> <p>Cohort studies on methylphenidate originating from RCTs comparing methylphenidate to other ADHD interventions versus studies with a classic cohort design (there may be differences in estimates in higher‐quality studies (RCTs) relative to lower‐quality studies (cohorts and other observational designs)) (<a href="./references#CD012069-bbs2-0491" title="GarattiniS , JakobsenJC , WetterslevJ , BerteléV , BanziR , RathA , et al. Evidence‐based clinical practice: overview of threats to the validity of evidence and how to minimise them. European Journal of Internal Medicine2016;32:13‐21. [DOI: 10.1016/j.ejim.2016.03.020; PUBMED: 27160381] ">Garattini 2016</a>). </p> </li> <li> <p>Studies funded by industry versus studies not funded by industry (studies sponsored by drug companies have been shown to be less likely to report risks) (<a href="./references#CD012069-bbs2-0569" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>). </p> </li> </ol> </p> <p>See <a href="#CD012069-sec-0275">Differences between protocol and review</a>. </p> </section> <section id="CD012069-sec-0060"> <h4 class="title">Sensitivity analysis</h4> <p>As we used a random‐effects model for all analyses, we conducted a sensitivity analysis to test the robustness of our findings when using the alternative, fixed‐effect model for the outcomes of non‐serious adverse events (there were inadequate data available to test this for serious adverse events). In addition, we tested the robustness of findings when lower‐quality patient‐control studies were removed from the analysis. </p> <p>See <a href="#CD012069-sec-0275">Differences between protocol and review</a>. </p> <section id="CD012069-sec-0061"> <h5 class="title">'Summary of findings' table</h5> <p>We constructed a 'Summary of findings' table for all outcomes, using <a href="./references#CD012069-bbs2-0500" title="McMaster University (developed by Evidence Prime, Inc.).. GRADEpro GDT. Version accessed prior to 12 March 2018. Hamilton (ON): McMaster University (developed by Evidence Prime, Inc.)., 2015. ">GRADEpro GDT 2015</a> software. We assessed the quality of the body of evidence for each outcome using the GRADE approach based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. Considerations are due to: within‐study risk of bias; the directness of the evidence; heterogeneity of the data; precision of effect estimates; and risk of publication bias (<a href="./references#CD012069-bbs2-0407" title="AndrewsJ , GuyattG , OxmanAD , AldersonP , DahmP , Falck‐YtterY , et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. Journal of Clinical Epidemiology2013;66(7):719‐25. [DOI: 10.1016/j.jclinepi.2012.03.013] ">Andrews 2013a</a>; <a href="./references#CD012069-bbs2-0408" title="AndrewsJC , SchünemannHJ , OxmanAD , PottieK , MeerpohlJJ , CoelloPA , et al. GRADE guidelines: 15. Going from evidence to recommendation ‐ determinants of a recommendation's direction and strength. Journal of Clinical Epidemiology2013;66(7):726‐35. [DOI: 10.1016/j.jclinepi.2013.02.003] ">Andrews 2013b</a>; <a href="./references#CD012069-bbs2-0422" title="BalshemH , HelfandM , SchünemannHJ , OxmanAD , KunzR , BrozekJ , et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology2011;64(4):401‐6. [DOI: 10.1016/j.jclinepi.2010.07.015] ">Balshem 2011</a>; <a href="./references#CD012069-bbs2-0432" title="BrunettiM , ShemiltI , PregnoS , ValeL , OxmanAD , LordJ , et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. Journal of Clinical Epidemiology2013;66(2):140‐50. [DOI: 10.1016/j.jclinepi.2012.04.012] ">Brunetti 2013</a>; <a href="./references#CD012069-bbs2-0509" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383–94. [DOI: 10.1016/j.jclinepi.2010.04.026] ">Guyatt 2011a</a>; <a href="./references#CD012069-bbs2-0510" title="GuyattGH , OxmanAD , KunzR , AtkinsD , BrozekJ , VistG , et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. Journal of Clinical Epidemiology2011;64(4):395–400. ">Guyatt 2011b</a>; <a href="./references#CD012069-bbs2-0511" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso‐CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence‐ study limitations (risk of bias). Journal of Clinical Epidemiology2011;64(4):407–15. [DOI: 10.1016/j.jclinepi.2010.07.017] ">Guyatt 2011c</a>; <a href="./references#CD012069-bbs2-0512" title="GuyattGH , OxmanAD , KunzR , BrozekJ , Alonso‐CoelloP , RindD , et al. GRADE guidelines 6. Rating the quality of evidence ‐ imprecision. Journal of Clinical Epidemiology2011;64(12):1283–93. [DOI: 10.1016/j.jclinepi.2011.01.012] ">Guyatt 2011d</a>; <a href="./references#CD012069-bbs2-0513" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence ‐ inconsistency. Journal of Clinical Epidemiology2011;64(12):1294–302. [DOI: 10.1016/j.jclinepi.2011.03.017] ">Guyatt 2011e</a>; <a href="./references#CD012069-bbs2-0514" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence ‐ indirectness. Journal of Clinical Epidemiology2011;64(12):1303–10. [DOI: 10.1016/j.jclinepi.2011.04.014] ">Guyatt 2011f</a>; <a href="./references#CD012069-bbs2-0515" title="GuyattGH , OxmanAD , SultanS , GlasziouP , AklEA , Alonso‐CoelloP , et al. GRADE guidelines: 9. Rating up the quality of evidence. Journal of Clinical Epidemiology2011;64(12):1311–6. [DOI: 10.1016/j.jclinepi.2011.06.004] ">Guyatt 2011g</a>; <a href="./references#CD012069-bbs2-0516" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso‐CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66(2):151–7. [DOI: 10.1016/j.jclinepi.2012.01.006] ">Guyatt 2013a</a>; <a href="./references#CD012069-bbs2-0517" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables ‐ binary outcomes. Journal of Clinical Epidemiology2013;66(2):158–72. [DOI: 10.1016/j.jclinepi.2012.01.012] ">Guyatt 2013b</a>; <a href="./references#CD012069-bbs2-0518" title="GuyattGH , ThorlundK , OxmanAD , WalterSD , PatrickD , FurukawaTA , et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles ‐ continuous outcomes. Journal of Clinical Epidemiology2013;66(2):173–83. [DOI: 10.1016/j.jclinepi.2012.08.001] ">Guyatt 2013c</a>; <a href="./references#CD012069-bbs2-0583" title="MustafaRA , SantessoN , BrozekJ , AklEA , WalterSD , NormanG , et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. Journal of Clinical Epidemiology2013;66(7):736‐42.e5. [DOI: 10.1016/j.jclinepi.2013.02.004] ">Mustafa 2013</a>). We reported all three primary (serious adverse events, withdrawal of methylphenidate due to serious adverse events, withdrawal of methylphenidate due to adverse events of unknown severity) and secondary outcomes (non‐serious adverse events, withdrawal of methylphenidate due to non‐serious adverse events, withdrawal of methylphenidate due to unknown reasons) in <a href="./full#CD012069-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012069-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012069-sec-0062"></div> <section id="CD012069-sec-0063"> <h3 class="title">Description of studies</h3> <p>For more information, please see <a href="./references#CD012069-sec-0277" title="">Characteristics of included studies</a>, <a href="./references#CD012069-sec-0278" title="">Characteristics of excluded studies</a>, <a href="./references#CD012069-sec-0279" title="">Characteristics of studies awaiting classification</a>, and <a href="./references#CD012069-sec-0280" title="">Characteristics of ongoing studies</a>. </p> <section id="CD012069-sec-0064"> <h4 class="title">Results of the search</h4> <p>We carried out the first set of electronic searches in November 2012 (11,329 records), and ran top‐up searches in March 2014 (1274 records), February 2015 (1460 records) and January 2016 (1102 records). Conference Proceedings Citation Indexes were not available to us in 2016, but we were able to complete our searches of these two databases in November 2017 (20 records). We included additional sources to the January 2016 search in order to identify new theses but did not find any. Our electronic searches yielded a total of 15,185 records. We also identified an additional 817 publications by reading the reference lists of included articles and reviews, and from correspondence with authors and with pharmaceutical companies and other sources. We contacted the authors of 174 studies and received replies from 109. </p> <p>After eliminating duplicate records, we screened 12,916 records and excluded 10,598 clearly irrelevant reports on the basis of title and abstract. We retrieved the full texts of the remaining 2318 reports, which we assessed for eligibility. We excluded 691 full‐text reports from our systematic review on RCTs assessing methylphenidate versus placebo or no intervention (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). We excluded a further 715 ineligible reports; see <a href="./references#CD012069-bbs1-0002" title="">Excluded studies</a> and <a href="./references#CD012069-sec-0278" title="">Characteristics of excluded studies</a> tables. We identified 15 studies (from 21 reports) as awaiting classification (see <a href="./references#CD012069-sec-0279" title="">Characteristics of studies awaiting classification</a>) and 8 ongoing studies (from 11 reports, see <a href="./references#CD012069-sec-0280" title="">Characteristics of ongoing studies</a>). </p> <p>We included 880 reports, of which 449 described 185 RCTs and 431 reports described 260 non‐randomised studies (of which 49 originated from 49 head‐to head RCTs comparing methylphenidate versus other interventions aimed at treating ADHD). The data from the 185 RCTs in which methylphenidate was compared with placebo or no intervention are published in <a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>. The present review focuses on non‐randomised studies only and thus includes 260 studies (Figure 1), which includes methylphenidate groups from the 49 RCTs comparing methylphenidate versus another medication aimed at treating ADHD, excluded in the <a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a> review. Accordingly, we assessed a total of 260 non‐randomised studies described in 431 publications. For more information of these studies, please see <a href="./references#CD012069-sec-0277" title="">Characteristics of included studies</a>. </p> </section> <section id="CD012069-sec-0065"> <h4 class="title">Included studies</h4> <section id="CD012069-sec-0066"> <h5 class="title">Comparative studies</h5> <p>We included 11 comparative studies in this review: seven cohort studies (<a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>; <a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>; <a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>; <a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>; <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>; <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>; <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>), plus four patient‐control studies (<a href="./references#CD012069-bbs2-0021" title="AyazM , AyazAB , SoyluN , YükselS . Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598] ">Ayaz 2014</a>; <a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>). One study had both comparative and non‐comparative cohort data (<a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>). </p> <section id="CD012069-sec-0067"> <h6 class="title">Study duration</h6> <p>We were unable to find any information about study duration in two studies (<a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>; <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>). The other studies ranged in duration from one day in <a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a> up to 11 years in <a href="./references#CD012069-bbs2-0021" title="AyazM , AyazAB , SoyluN , YükselS . Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598] ">Ayaz 2014</a>, <a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>, <a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>, <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>, <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>, <a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>, <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>, and <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>. </p> </section> <section id="CD012069-sec-0068"> <h6 class="title">Location</h6> <p>Two studies took place in Canada (<a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>; <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>), two in China (<a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>), two in Israel, (<a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>; <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>), and one each in South Africa (<a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>), South Korea (<a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>), Taiwan (<a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>), Turkey (<a href="./references#CD012069-bbs2-0021" title="AyazM , AyazAB , SoyluN , YükselS . Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598] ">Ayaz 2014</a>), and the USA (<a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>). </p> </section> <section id="CD012069-sec-0069"> <h6 class="title">Settings</h6> <p>All were outpatient studies (<a href="./references#CD012069-bbs2-0021" title="AyazM , AyazAB , SoyluN , YükselS . Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598] ">Ayaz 2014</a>; <a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>; <a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>; <a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>; <a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>; <a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>; <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>; <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>; <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>), two of which were based on register data (<a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>). </p> </section> <section id="CD012069-sec-0070"> <h6 class="title">Participants</h6> <p>There was considerable heterogeneity amongst the studies in terms of diagnostic criteria used, presence of comorbidity, numbers exposed to methylphenidate and simultaneous exposure to other medication. The mean age of children varied from 7.4 years in <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a> to 13.0 years in <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>, with an age range of 3 years to 20 years. All studies involved predominantly male participants ranging from 69% in <a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a> to 100% in both <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a> and <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>. </p> <p>Six comparative cohort studies involved 1134 participants, 968 of whom received methylphenidate and 166 of whom did not (<a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>; <a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>; <a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>; <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>; <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>; <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>). A seventh study, <a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>, involved 1224 participants, all of whom were exposed to methylphenidate for a specific treatment period. This study only included patients with an adverse cardiovascular event. The four patient‐control studies comprised 73,098 participants: 53,192 cases who received methylphenidate and 19,906 controls who did not. All participants were aged 6 years to 19 years. The male‐to‐female ratio was approximately 80:20. </p> <p>Three studies made DSM‐IV diagnoses (<a href="./references#CD012069-bbs2-0021" title="AyazM , AyazAB , SoyluN , YükselS . Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598] ">Ayaz 2014</a>; <a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010)</a>; and two made ICD‐9 and ICD‐10 diagnoses (<a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>). <a href="./references#CD012069-bbs2-0021" title="AyazM , AyazAB , SoyluN , YükselS . Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598] ">Ayaz 2014</a> required that ADHD medication be administered to patients at least 12 months prior to the study. <a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a> only included patients with an adverse cardiovascular event. </p> </section> <section id="CD012069-sec-0071"> <h6 class="title">Interventions</h6> <p>There was considerable variation in dosage and methylphenidate preparation used as well as mean duration of exposure. The control groups not exposed to methylphenidate received atomoxetine in two studies (<a href="./references#CD012069-bbs2-0021" title="AyazM , AyazAB , SoyluN , YükselS . Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598] ">Ayaz 2014</a>; <a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>), while in eight studies the control was no treatment (<a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>; <a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>; <a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>; <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>; <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>; <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>). Participants in <a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a> received methylphenidate or no treatment at different times. </p> </section> </section> <section id="CD012069-sec-0072"> <h5 class="title">Non‐comparative studies</h5> <p>In the following section, we describe non‐comparative studies according to the design of the individual study, namely cohort studies, cross‐sectional studies, and patient reports/series. </p> <section id="CD012069-sec-0073"> <h6 class="title">Cohort studies</h6> <p>We included 177 cohort studies, reported in 341 publications. Of these, 49 cohorts were the methylphenidate group of the RCTs assessing this drug versus other medications for ADHD. Many of the cohort studies included in this review originally had a control group of healthy participants, but these groups did not fulfil our inclusion criteria (<a href="#CD012069-sec-0030">Criteria for considering studies for this review</a>); we only included groups with participants diagnosed with ADHD (e.g. <a href="./references#CD012069-bbs2-0187" title="SahinS , YuceM , AlacamH , KarabekirogluK , SayGN , SalisO . Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain‐derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder. International Journal of Psychiatry in Clinical Practice2014;18(4):280‐7. [DOI: 10.3109/13651501.2014.940054; PUBMED: 24994482] ">Sahin 2014</a>). One study had both comparative and non‐comparative cohort data (<a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>). </p> <section id="CD012069-sec-0074"> <p><b>Study duration</b></p> <p>The cohort studies lasted from one day in <a href="./references#CD012069-bbs2-0022" title="BalázsJ , DallosG , KeresztényA , CzoborP , GádorosJ . Methylphenidate treatment and dyskinesia in children with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2011;21(2):133‐8. [DOI: 10.1089/cap.2010.0030; PUBMED: 21486166] ">Balázs 2011</a>, <a href="./references#CD012069-bbs2-0042" title="CongologluMA , TurkbayT , CiyiltepeM , DurukanI , DogangunB , YuceM . Immediate effects of methylphenidate on vocal acoustic parameters in children with attention deficit hyperactivity disorder. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2009;19(4):365‐72. ">Congologlu 2009</a>, <a href="./references#CD012069-bbs2-0051" title="DelignieresA , QuerneL , Bourel‐PonchelE , ArdointA , BerquinP . Attention‐deficit disorders and epilepsy in childhood: use methylphenidate treatment?. European Journal of Paediatric Neurology. 9th Congress of the European Paediatric Neurology Society (EPNS); May 11‐14 2011; Cavtat (Croatia). 2011; Vol. 15:S127‐8. ">Delignieres 2011</a>, <a href="./references#CD012069-bbs2-0110" title="IlgenliTF , CongologluA , OzturkC , TurkbayT , AkpinarO , KilicaslanF . Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder. Advances in Therapy2007;24(1):182‐8. [PUBMED: 17526476] ">Ilgenli 2007</a>, and <a href="./references#CD012069-bbs2-0145" title="Dexmethylphenidate in youth with ADHD and Tourette's. Brown University Child and Adolescent Psychopharmacology Update2010;12(11):4‐5. [DOI: 10.1002/cpu.20127] LyonGJ , CoffeyB , CastellanosXF , WoodsD . Improving TIC‐related response inhibition: comparing the effects of dexmethylphenidate to placebo in children and adolescents with ADHD and chronic TIC disorders. International Journal of Neuropsychopharmacology2008;11(Suppl 1):292. LyonGJ , CoffeyB , WoodsD , SamarS , ConeleaC , BauerCC , et al. Improving tic‐related response inhibition: comparing the effects of dexmethylphenidate to no medication in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) and chronic tic disorders. Journal of Child and Adolescent Psychopharmacology2010;20(6):537‐8. [DOI: 10.1089/cap.2010.2064] LyonGJ , SamarSM , ConeleaC , TrujilloMR , LipinskiCM , BauerCC , et al. Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention‐deficit/hyperactivity disorder and Tourette's disorder. Journal of Child and Adolescent Psychopharmacology2010;20(4):283‐9. [DOI: 10.1089/cap.2010.0032] ">Lyon 2010</a> to 9.70 years in <a href="./references#CD012069-bbs2-0102" title="HauboldKH . Attention Deficit Hyperactivity Disorder ADHD ‐ A Retrospective Population‐based Analysis Concerning the Treatment of Children and Adolescents with Stimulant Medication in a Child and Adolescent Psychiatry Practice [PhD thesis]. Tübingen: Eberhard Karls Universität Tübingen, 2009. ">Haubold 2010</a>. Nine studies lasted 28 days or less (<a href="./references#CD012069-bbs2-0052" title="DirksenSJ , D'ImperioJM , BirdsallD , HatchSJ . A postmarketing clinical experience study of Metadate CD. Current Medical Research and Opinion2002;18(7):371‐80. [PUBMED: 12487502] ">Dirksen 2002</a>; <a href="./references#CD012069-bbs2-0056" title="DöpfnerM , OseC , FischerR , AmmerR , ScheragA . Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention‐deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet® retard and Concerta® ‐ a randomized, controlled, double‐blind multicenter clinical crossover trial. Journal of Child &amp; Adolescent Psychopharmacology2011;21(5):445‐54. [DOI: 10.1089/cap.2010.0082; PMC3205792; PUBMED: 21790298] DöpfnerM , OseC , FischerR , AmmerR , ScheragA . The CoMeCo‐trial: comparison of the efficacy of two methylphenidate preparations for children and adolescents with ADHD in a natural setting. European Child and Adolescent Psychiatry.14th International Congress of ESCAP European Society for Child and Adolescent Psychiatry (ESCAP); June 11‐15, 2011; Helsinki (Finland)2011;20:S116. ">Döpfner 2011b</a>; <a href="./references#CD012069-bbs2-0073" title="GallandBC , TrippEG , GrayA , TaylorBJ . Apnea‐hypopnea indices and snoring in children diagnosed with ADHD: a matched case‐control study. Sleep and Breathing2011;15(3):455‐62. [DOI: 10.1007/s11325‐010‐0357‐0; PUBMED: 20440568] GallandBC , TrippEG , TaylorBJ . Methylphenidate effects on sleep in children. Brown University Child and Adolescent Psychopharmacology Update2010;12(3):5‐6. [DOI: 10.1002/cpu.20111] GallandBC , TrippEG , TaylorBJ . The sleep of children with attention deficit hyperactivity disorder on and off methylphenidate: a matched case‐control study. Journal of Sleep Research2010;19(2):366‐73. [DOI: 10.1111/j.1365‐2869.2009.00795.x; PUBMED: 20050995] ">Galland 2010</a>; <a href="./references#CD012069-bbs2-0076" title="GauSS , ChenSJ , ChouWJ , ChengH , TangCS , ChangHL , et al. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention‐deficit/hyperactivity disorder in Taiwan. Journal of Clinical Psychiatry2008;69(1):131‐40. [PUBMED: 18312048] ">Gau 2008</a>; <a href="./references#CD012069-bbs2-0121" title="KemnerJE , StarrHL , BowenDL , CicconePL , LynchJM . Greater symptom improvement and response rates with OROS® MPH vs. atomoxetine in children with ADHD. International Journal of Neuropsychopharmacology2004;7:S273‐4. [DOI: 10.1017/S1461145704004547] KemnerJE , StarrHL , CicconePE , Hooper‐WoodCG , CrockettRS . Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Advances in Therapy2005;22(5):498‐512. [PUBMED: 16418159] KemnerJE , StarrHL , Hooper‐WoodCG , CicconePE . Greater improvement and response rates with OROS (R) methylphenidate compared with atomoxetine in children with attention‐deficit/hyperactivity disorder. Pharmacotherapy2004;24(10):1462‐3. [DOI: 10.1592/phco.24.14.1419.43157] StarrHL , KemnerJ . Multicenter, randomized, open‐label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African‐American children with ADHD. Journal of the National Medical Association2005;97(10 Suppl):11S‐6S. [PMC2640623; PUBMED: 16350601] ">Kemner 2005 (FOCUS)</a>; <a href="./references#CD012069-bbs2-0139" title="LeeSI , HongSD , KimS . Efficacy and tolerability of OROS methylphenidate in Korean children with AD/HD ‐ Reply. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2007; Vol. 31, issue 5:1151‐2. [DOI: 10.1016/j.pnpbp.2007.03.019] LeeSI , HongSD , KimSY , KimEJ , KimJH , KimJH , et al. Efficacy and tolerability of OROS methylphenidate in Korean children with attention‐deficit/hyperactivity disorder. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2007;31(1):210‐6. [DOI: 10.1016/j.pnpbp.2006.09.002; PUBMED: 17046131] PaeCU . Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention‐deficit/hyperactivity disorder. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2007;31(5):1151‐2. [DOI: 10.1016/j.pnpbp.2007.03.018] ">Lee 2007</a>; <a href="./references#CD012069-bbs2-0172" title="ParkS , KimBN , KimJW , ShinMS , ChoSC , KimJH , et al. Neurotrophin 3 genotype and emotional adverse effects of osmotic‐release oral system methylphenidate (OROS‐MPH) in children with attention‐deficit/hyperactivity disorder. Journal of Psychopharmacology2014;28(3):220‐6. [DOI: 10.1177/0269881113480989; PUBMED: 23471121] ">Park 2013</a>; <a href="./references#CD012069-bbs2-0193" title="SchulzE , FleischhakerC , HennighausenK , HeiserP , HaesslerF , LinderM , et al. A randomized, rater‐blinded, crossover study comparing the clinical efficacy of Ritalin(®) LA (methylphenidate) treatment in children with attention‐deficit hyperactivity disorder under different breakfast conditions over 2 weeks. Attention Deficit and Hyperactivity Disorders2010;2(3):133‐8. [DOI: 10.1007/s12402‐010‐0031‐1; PUBMED: 21432599] ">Schulz 2010</a>; <a href="./references#CD012069-bbs2-0208" title="SudarmadjiSS , MelialaL , AzizA . Improvement of cognitive function in attention deficit hyperactivity disorder (ADHD) treatment by methylphenidate (MPH) of elementary school students at Bantul District, Yogyakarta Special Regency. Journal of the Neurological Sciences2009;285(Suppl 1):S236. [DOI: 10.1016/S0022‐510X(09)70898‐6] ">Sudarmadji 2009</a>). Twenty‐five studies were performed over 42 days, and 15 studies over 28 days (<a href="./references#CD012069-bbs2-0007" title="AkhondzadehS , TavakolianR , Davari‐AshtianiR , ArabgolF , AminiH . Selegiline in the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial. Progress in Neuro Psychopharmacology and Biological Psychiatry2003;27(5):841‐5. [DOI: 10.1016/S0278‐5846(03)00117‐9; PUBMED: 12921918] ">Akhondzadeh 2003</a>; <a href="./references#CD012069-bbs2-0016" title="ArnoldLE , BozzoloDR , HodgkinsP , McKayM , Beckett‐ThurmanL , GreenbaumM , et al. Switching from oral extended‐release methylphenidate to the methylphenidate transdermal system: continued attention‐deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Current Medical Research and Opinion2010;26(1):129‐37. [DOI: 10.1185/03007990903437412; PMC3875401; PUBMED: 19916704] BuksteinOG , ArnoldLE , LandgrafJM , HodgkinsP . Does switching from oral extended‐release methylphenidate to the methylphenidate transdermal system affect health‐related quality‐of‐life and medication satisfaction for children with attention‐deficit/hyperactivity disorder?. Child and Adolescent Psychiatry and Mental Health2009;3(1):39. [DOI: 10.1186/1753‐2000‐3‐39; PMC2796990; PUBMED: 20003260] ">Arnold 2010</a>; <a href="./references#CD012069-bbs2-0019" title="AshkenasiA . Effect of transdermal methylphenidate wear times on sleep in children with ADHD. Journal of Neurology2012;259(Suppl 1):S33‐4. [DOI: 10.1007/s00415‐012‐6524‐4] AshkenasiA . Effect of transdermal methylphenidate wear times on sleep in children with attention deficit hyperactivity disorder. Pediatric Neurology2011;45(6):381‐6. [DOI: 10.1016/j.pediatrneurol.2011.09.003; PUBMED: 22115000] ">Ashkenasi 2011</a>; <a href="./references#CD012069-bbs2-0061" title="EfronD . Methylphenidate versus dextroamphetamine in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry1999;38(5):500. [PUBMED: 10230180] EfronD , JarmanFC , BarkerMJ . Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder. Journal of Paediatrics and Child Health1998;34(3):288‐92. [DOI: 10.1046/j.1440‐1754.1998.00224.x] EfronD , JarmanFC , BarkerMJ . Medium‐term outcomes are comparable with short‐term outcomes in children with attention deficit hyperactivity disorder treated with stimulant medication. Journal of Paediatrics and Child Health2000;36(5):457‐61. [PUBMED: 11036801] EfronD , JarmanFC , BarkerMJ . Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial. Pediatrics1997;100(6):E6. [PUBMED: 9382907] EfronD , JarmanFC , BarkerMJ . Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial. Pediatrics1997;100(4):662‐6. [PUBMED: 9310521] ">Efron 1997</a>; <a href="./references#CD012069-bbs2-0075" title="GauSS , ShenHY , SoongWT , GauCS . An open‐label, randomized, active‐controlled equivalent trial of osmotic release oral system methylphenidate in children with attention‐deficit/hyperactivity disorder in Taiwan. Journal of Child and Adolescent Psychopharmacology2006;16(4):441‐55. [DOI: 10.1089/cap.2006.16.441; PUBMED: 16958569] ">Gau 2006</a>; <a href="./references#CD012069-bbs2-0109" title="HulvershornL . Methylphenidate treatment of chronic irritability: symptom improvement and underlying neural mechanisms. Biological Psychiatry2015;77(1S):444S. HulvershornLA , HummerT , WangY , LothA , AnandA . The impact of methylphenidate on corticolimbic functional connectivity in children with ADHD and chronic irritability. Biological Psychiatry2012;71(8):193S. ">Hulvershorn 2012</a>; <a href="./references#CD012069-bbs2-0116" title="JungC , ChoiS , JeongS , SongCJ , SeoW , ChungUS , et al. Multicenter, open‐label study to evaluate the effects of methylphenidate‐OROS (Concerta®) on cognitive functions in children with attention deficit hyperactivity disorder. Clinical Psychopharmacology and Neuroscience2007;5(1):31‐7. LeeJH , JungCH , SongCJ , ChoiSY , JeongSH , ChungUS , et al. Multi‐center study for evaluation of efficacy and safety of methylphenidate‐OROS in children with ADHD. European Neuropsychopharmacology2007;17(Suppl 4):S571‐2. [DOI: 10.1016/S0924‐977X(07)70890‐8] ">Jung 2007</a>; <a href="./references#CD012069-bbs2-0125" title="KimBN , KimYN , CheongUS , KimJW , HwangJW , ShinMS , et al. Switching from Methylphenidate‐Immediate Release (MPH‐IR) to Methylphenidate‐OROS (OROS‐MPH): a multi‐center, open‐label study in Korea. Clinical Psychopharmacology and Neuroscience2011;9(1):29‐35. [DOI: 10.9758/cpn.2011.9.1.29; PMC3568652; PUBMED: 23430964] ">Kim 2011</a>; <a href="./references#CD012069-bbs2-0136" title="LambertiM , ItalianoD , GuerrieroL , D'AmicoG , SiracusanoR , IngrassiaM , et al. Evaluation of acute cardiovascular effects of immediate‐release methylphenidate in children and adolescents with attention‐deficit hyperactivity disorder. Neuropsychiatric Disease and Treatment2015;11:1169‐74. [DOI: 10.2147/NDT.S79866; PMC4431494; PUBMED: 26056451] ">Lamberti 2015</a>; <a href="./references#CD012069-bbs2-0141" title="LeeSH , SeoWS , SungHM , ChoiTY , KimSY , ChoiSJ , et al. Effect of methylphenidate on sleep parameters in children with ADHD. Psychiatry Investigation2012;9(4):384‐90. [DOI: 10.4306/pi.2012.9.4.384; PMC3521116] ">Lee 2012</a>; <a href="./references#CD012069-bbs2-0146" title="Methylphenidate for preschool ADHD. Brown University Child and Adolescent Psychopharmacology Update2009;11(7):4‐4. [DOI: 10.1002/cpu.20095] MaayanL , PaykinaN , FriedJ , StraussT , GuggaSS , GreenhillL . The open‐label treatment of attention‐deficit/hyperactivity disorder in 4‐ and 5‐year‐old children with beaded methylphenidate. Journal of Child and Adolescent Psychopharmacology2009;19(2):147‐53. [PMC2935832; PUBMED: 19374023] ">Maayan 2009</a>; <a href="./references#CD012069-bbs2-0153" title="LooSK , BilderR , ChoAL , SturmA , CowenJ , WelkerPW , et al. Effects of d‐Methylphenidate, Guanfacine, and their combination on electroencephalogram resting state spectral power in Attention‐Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):674‐82.e1. [DOI: 10.1016/j.jaac.2016.04.020; PMC5003618; PUBMED: 27453081] McCrackenJT , McGoughJJ , LooSK , LevittJ , Del'HommeM , CowenJ , et al. Combined stimulant and Guanfacine administration in Attention‐Deficit/Hyperactivity Disorder: a controlled, comparative study. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):657‐66.e1. [DOI: 10.1016/j.jaac.2016.05.015; PMC4976782; PUBMED: 27453079] ">McCracken 2016</a>; <a href="./references#CD012069-bbs2-0175" title="PierceD , KaticA , BuckwalterM , WebsterK . Single‐ and multiple‐dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic‐release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. Journal of Clinical Psychopharmacology2010;30(5):554‐64. [DOI: 10.1097/JCP.0b013e3181f0c2f6; PUBMED: 20814325] ">Pierce 2010</a>; <a href="./references#CD012069-bbs2-0237" title="Oral system methylphenidate for teen ADHD. Brown University Child and Adolescent Psychopharmacology Update2006;8(3):4‐5. [DOI: 10.1002/cpu.20015] BiedermanJ . Effectiveness and safety of the once‐daily OROS formulation of methylphenidate in adolescents with attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2003;13(Suppl 4):S448. GreenhillLL . Safety and efficacy of OROS MPH in adolescents with ADHD. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco (CA). 2003. McGoughJJ , McBurnettK , BuksteinO , WilensTE , GreenhillL , LernerM , et al. Once‐daily OROS methylphenidate is safe and well tolerated in adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2006;16(3):351‐6. [DOI: 10.1089/cap.2006.16.351; PUBMED: 16768642] NewcornJH , SteinMA , CooperKM . Dose‐response characteristics in adolescents with attention‐deficit/hyperactivity disorder treated with OROS methylphenidate in a 4‐week, open‐label, dose‐titration study. Journal of Child and Adolescent Psychopharmacology2010;20(3):187‐96. [DOI: 10.1089/cap.2009.0102; PUBMED: 20578931] WilensTE , McBurnettK , BuksteinO , McGoughJ , GreenhillL , LernerM , et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention‐deficit/hyperactivity disorder. Archives of Pediatrics and Adolescent Medicine2006;160(1):82‐90. [DOI: 10.1001/archpedi.160.1.82; PUBMED: 16389216] ">Wilens 2006</a>; <a href="./references#CD012069-bbs2-0239" title="WilliamsLM , HermensDF , PalmerD , KohnM , ClarkeS , KeageH , et al. Misinterpreting emotional expressions in attention‐deficit/hyperactivity disorder: evidence for a neural marker and stimulant effects. Biological Psychiatry2008;63(10):917‐26. [DOI: 10.1016/j.biopsych.2007.11.022; PUBMED: 18272140] ">Williams 2008</a>). Sixty‐six studies lasted 42 to 180 days. Forty‐four studies lasted 180 days or more. Twelve studies did not report any study duration. </p> </section> <section id="CD012069-sec-0075"> <p><b>Location</b></p> <p>Forty‐eight studies were carried out in the USA; 18 studies each in Iran, South Korea, and in Germany; 17 studies in Turkey; 7 studies in Taiwan (<a href="./references#CD012069-bbs2-0036" title="ChouWJ , ChenSJ , ChenYS , LiangHY , LinCC , TangCS , et al. Remission in children and adolescents diagnosed with attention‐deficit/ hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate. Journal of Child and Adolescent Psychopharmacology2012;22(3):215‐25. [DOI: 10.1089/cap.2011.0006; PMC3373222; PUBMED: 22537358] ">Chou 2012a</a>; <a href="./references#CD012069-bbs2-0037" title="WJChou , LJWang . The family impact in children and adolescent with ADHD after the switch of treatment from immediate‐release MPH to OROS‐MPH. Neuropsychiatrie de l'Enfance et de l'Adolescence2012;60(5S):S262. [DOI: 10.1016/j.neurenf.2012.04.683] ">Chou 2012b</a>; <a href="./references#CD012069-bbs2-0075" title="GauSS , ShenHY , SoongWT , GauCS . An open‐label, randomized, active‐controlled equivalent trial of osmotic release oral system methylphenidate in children with attention‐deficit/hyperactivity disorder in Taiwan. Journal of Child and Adolescent Psychopharmacology2006;16(4):441‐55. [DOI: 10.1089/cap.2006.16.441; PUBMED: 16958569] ">Gau 2006</a>; <a href="./references#CD012069-bbs2-0076" title="GauSS , ChenSJ , ChouWJ , ChengH , TangCS , ChangHL , et al. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention‐deficit/hyperactivity disorder in Taiwan. Journal of Clinical Psychiatry2008;69(1):131‐40. [PUBMED: 18312048] ">Gau 2008</a>; <a href="./references#CD012069-bbs2-0195" title="ShangCY , PanYL , LinHY , HuangLW , GauSS . An open‐label, randomized trial of methylphenidate and atomoxetine treatment in children with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2015;25(7):566‐73. [DOI: 10.1089/cap.2015.0035; PUBMED: 26222447] ">Shang 2015</a>; <a href="./references#CD012069-bbs2-0228" title="WangLJ , HsiaoCC , HuangYS , ChiangYL , ReeSC , ChenYC , et al. Association of salivary dehydroepiandrosterone levels and symptoms in patients with attention deficit hyperactivity disorder during six months of treatment with methylphenidate. Psychoneuroendocrinology2011;36(8):1209‐16. [DOI: 10.1016/j.psyneuen.2011.02.014; PUBMED: 21411231] WangLJ , HuangYS , ChiangYL , HsiaoCC , ShangZY , ChenCK . Clinical symptoms and performance on the Continuous Performance Test in children with attention deficit hyperactivity disorder between subtypes: a natural follow‐up study for 6 months. BMC Psychiatry2011;11:65. [DOI: 10.1186/1471‐244X‐11‐65; PMC3111344; PUBMED: 21504587] WangLJ , HuangYS , HsiaoCC , ChiangYL , WuCC , ShangZY , et al. Salivary dehydroepiandrosterone, but not cortisol, is associated with attention deficit hyperactivity disorder. World Journal of Biological Psychiatry2011;12(2):99‐109. [DOI: 10.3109/15622975.2010.512090; PUBMED: 20822373] WangLJ , WuCC , LeeSY , TsaiYF . Salivary neurosteroid levels and behavioural profiles of children with attention‐deficit/hyperactivity disorder during six months of methylphenidate treatment. Journal of Child and Adolescent Psychopharmacology2014;24(6):336‐40. [DOI: 10.1089/cap.2013.0122; PUBMED: 24956271] ">Wang 2011</a>; <a href="./references#CD012069-bbs2-0247" title="YangP , ChungLC , ChenCS , ChenCC . Rapid improvement in academic grades following methylphenidate treatment in attention‐deficit hyperactivity disorder. Psychiatry and Clinical Neurosciences2004;58(1):37‐41. [PUBMED: 14678455] ">Yang 2004</a>); 6 studies each in Australia (<a href="./references#CD012069-bbs2-0059" title="DupuyFE , ClarkeAR , BarryRJ , McCarthyR , SelikowitzM . EEG coherence in girls with attention‐deficit/hyperactivity disorder: stimulant effects in good responders. International Journal of Psychophysiology2008;70(3):151‐7. [DOI: 10.1016/j.ijpsycho.2008.07.012; PUBMED: 18708101] ">Dupuy 2008</a>; <a href="./references#CD012069-bbs2-0061" title="EfronD . Methylphenidate versus dextroamphetamine in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry1999;38(5):500. [PUBMED: 10230180] EfronD , JarmanFC , BarkerMJ . Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder. Journal of Paediatrics and Child Health1998;34(3):288‐92. [DOI: 10.1046/j.1440‐1754.1998.00224.x] EfronD , JarmanFC , BarkerMJ . Medium‐term outcomes are comparable with short‐term outcomes in children with attention deficit hyperactivity disorder treated with stimulant medication. Journal of Paediatrics and Child Health2000;36(5):457‐61. [PUBMED: 11036801] EfronD , JarmanFC , BarkerMJ . Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial. Pediatrics1997;100(6):E6. [PUBMED: 9382907] EfronD , JarmanFC , BarkerMJ . Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial. Pediatrics1997;100(4):662‐6. [PUBMED: 9310521] ">Efron 1997</a>; <a href="./references#CD012069-bbs2-0103" title="HazellPL , StuartJE . A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(8):886‐94. [DOI: 10.1097/01.CHI.0000046908.27264.00] ">Hazell 2003</a>; <a href="./references#CD012069-bbs2-0178" title="PoultonA , CowellCT . Slowing of growth in height and weight on stimulants: a characteristic pattern. Journal of Paediatrics and Child Health2003;39(3):180‐5. [PUBMED: 12654140] ">Poulton 2003</a>; <a href="./references#CD012069-bbs2-0179" title="PoultonA , BriodyJ , McCorquodaleT , MelzerE , HerrmannM , BaurLA , et al. Weight loss on stimulant medication: how does it affect body composition and bone metabolism? ‐ A prospective longitudinal study. International Journal of Pediatric Endocrinology2012;2012(1):30. [DOI: 10.1186/1687‐9856‐2012‐30; PMC3549744; PUBMED: 23216890] PoultonA , EvansR , MelzerE , BuiQ . Stimulant medication affects growth but not bone age. Archives of Disease in Childhood2014;99(Suppl 1):A4.A5. [DOI: 10.1136/archdischild‐2014‐306237.10] PoultonA , NananR . Differential effects of dexamphetamine and methylphenidate on symptoms of inattention‐overactivity, oppositional‐defiant and weight. Archives of Disease in Childhood2014;99(Suppl 1):A70. [DOI: 10.1136/archdischild‐2014‐306237.167] ">Poulton 2012</a>; <a href="./references#CD012069-bbs2-0239" title="WilliamsLM , HermensDF , PalmerD , KohnM , ClarkeS , KeageH , et al. Misinterpreting emotional expressions in attention‐deficit/hyperactivity disorder: evidence for a neural marker and stimulant effects. Biological Psychiatry2008;63(10):917‐26. [DOI: 10.1016/j.biopsych.2007.11.022; PUBMED: 18272140] ">Williams 2008</a>) and Spain (<a href="./references#CD012069-bbs2-0060" title="Durá‐TravéT , Yoldi‐PetriME , Gallinas‐VictorianoF , Zardoya‐SantosP . Effects of osmotic‐release methylphenidate on height and weight in children with attention‐deficit hyperactivity disorder (ADHD) following up to four years of treatment. Journal of Child Neurology2012; Vol. 27, issue 5:604‐9. [DOI: 10.1177/0883073811422752; PUBMED: 22190507] Durá‐TravéT , Yoldi‐PetriME , Zardoya‐SantosP . Nutrition and attention deficit hyperactivity disorder: developmental follow‐up of the anthropometric variables of a group of patients receiving treatment with osmotic controlled‐release methylphenidate [Nutrición y trastorno por déficit de atención/hiperactividad: seguimiento evolutivo de las variables antropométricas de un grupo de pacientes en tratamiento con metilfenidato de liberación osmótica]. Revista de Neurologia2011;53(5):257‐64. [PUBMED: 21796603] ">Durá‐Travé 2012</a>; <a href="./references#CD012069-bbs2-0138" title="Larrañaga‐FragosoP , NovalS , RiveroJC , Boto‐de‐los‐BueisA . The effects of methylphenidate on refraction and anterior segment parameters in children with attention deficit hyperactivity disorder. Journal of AAPOS2015;19(4):322‐6. [DOI: 10.1016/j.jaapos.2015.04.005; PUBMED: 26235791] ">Larrañaga‐Fragoso 2015</a>; <a href="./references#CD012069-bbs2-0163" title="Montañés RadaF , Martínez GraneroMA , Vidal FormosoM , Sanchez RomeroS , Andrés PradoMJ . Extended release methylphenidate (medikinet®) twice a day, a prospective open trial [Metilfenidato de liberación prolongada 50/50 (medikinet®) dos veces al día, estudio abierto prospectivo]. Revista de Psiquiatria Infanto‐Juvenil2012;29(1):50‐8. ">Montañés‐Rada 2012</a>; <a href="./references#CD012069-bbs2-0213" title="Tomás VilaM , Izquierdo QuevedoFJ , Cerdán VeraMT , FernándezA , Artás FigueresM , Revert GomasM . Visual hallucinations caused by methylphenidate. Anales de Pediatria2010;72(3):229‐30. [DOI: 10.1016/j.anpedi.2009.10.013; PUBMED: 20097145] ">Tomás Vila 2010a</a>; <a href="./references#CD012069-bbs2-0218" title="Valdizan UsonJR . Diagnostic and therapeutic electroclinical correlation with immediate action methylphenidate in ADHD [Correlación electrónica diagnóstica y terapéutica con metilfeniato de acción inmediata en TDAH]. Revista Espanola de Pediatria2004;60(3):181‐7. ">Valdizán Usón 2004</a>; <a href="./references#CD012069-bbs2-0219" title="Valdizán UsonJR . Methylphenidate in children and adolescents with attention‐deficit/ hyperactivity disorder: The DIHANA Study. Acta Pediatrica Espanola2013;71(3):67‐76. Valdizán UsonJR , Cánovas‐MartínezA , DeLucas‐TaracenaMT , Díaz‐AtienzaF , Eddy‐IvesLS , Fernandez‐JaenA , et al. Response to methylphenidate by adult and pediatric patients with attention‐deficit/hyperactivity disorder: the Spanish multicenter DIHANA study. Neuropsychiatric Disease and Treatment2013;9:211‐8. [DOI: 10.2147/NDT.S35836; PMC3573811] ">Valdizán Usón 2013</a>); 5 studies each in Brazil (<a href="./references#CD012069-bbs2-0033" title="BruxelEM , Salatino‐OliveiraA , GenroJP , ZeniCP , PolanczykGV , ChazanR , et al. Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention‐deficit/hyperactivity disorder treated with methylphenidate. Pharmacogenomics Journal2013;13(5):476‐80. [DOI: 10.1038/tpj.2012.25; PUBMED: 22688218] ChazanR , BorowskiC , PiancaT , LudwigH , RohdeLA , PolanczykG . Do phenotypic characteristics, parental psychopathology, family functioning, and environmental stressors have a role in the response to methylphenidate in children with attention‐deficit/hyperactivity disorder? A naturalistic study from a developing count. Journal of Clinical Psychopharmacology2011;31(3):309‐17. [DOI: 10.1097/JCP.0b013e318217b4df; PUBMED: 21508864] Salatino‐OliveiraA , GenroJP , ZeniC , PolanczykGV , ChazanR , GuimarãesAP , et al. Catechol‐O‐methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention‐deficit/hyperactivity disorder. Biological Psychiatry2011;70(3):216‐21. [DOI: 10.1016/j.biopsych.2011.03.025; PUBMED: 21550019] ">Chazan 2011</a>; <a href="./references#CD012069-bbs2-0097" title="GuerreiroMM , MontenegroMA , PivaRT , Moura‐RibeiroMV . Attention deficit disorder: treatment with methylphenidate [Distúrbio do déficit de atenção: tratamento com metilfenidato]. Arquivos de Neuro‐Psiquiatria1996;54(1):25‐9. [DOI: 10.1590/S0004‐282X1996000100004] ">Guerreiro 1996</a>; <a href="./references#CD012069-bbs2-0149" title="MaiaCR . Evalution of the Exchange of Immediate Release Methylphenidate for Prolonged Release Methylphenidate in Attention Deficit/Hyperactivity Disorder [Availação da troca do metilfenidato de liberação imediata para o metilfenidato de liberação prolongada no transtorno de déficit de atenção/hiperatividade] [Masters thesis]. Rio Grande (BZ): The Federal University of Rio Grande, 2009. MaiaCR , MatteBC , LudwigHT , RohdeLA . Switching from methylphenidate immediate release to MPH‐SODAS in attention‐deficit/hyperactivity disorder. European Child and Adolescent Psychiatry2008;17(3):133‐42. [DOI: 10.1007/s00787‐007‐0647‐7; PUBMED: 17846812] ">Maia 2008</a>; <a href="./references#CD012069-bbs2-0176" title="PolanczykG , ZeniC , GenroJP , GuimarãesAP , RomanT , HutzMH , et al. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2007;64(2):218‐24. [DOI: 10.1001/archpsyc.64.2.218; PUBMED: 17283289] ">Polanczyk 2007</a>; <a href="./references#CD012069-bbs2-0256" title="ZeniCP , GuimarãesAP , PolanczykGV , GenroJP , RomanT , HutzMH , et al. No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention‐deficit/hyperactivity disorder. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics2007;144B(3):391‐4. [DOI: 10.1002/ajmg.b.30474; PUBMED: 17171656] ">Zeni 2007</a>) and China (<a href="./references#CD012069-bbs2-0144" title="LiJJ , LiZW , WangSZ , QiFH , ZhaoL , LvH , et al. Ningdong granule: a complementary and alternative therapy in the treatment of attention deficit/hyperactivity disorder. Psychopharmacology2011; Vol. 216, issue 4:501‐9. [DOI: 10.1007/s00213‐011‐2238‐z; PUBMED: 21416235] ">Li 2011</a>; <a href="./references#CD012069-bbs2-0207" title="SuY , LiH , ChenY , FangF , XuT , LuH , et al. Remission rate and functional outcomes during a 6‐month treatment with Osmotic‐Release Oral‐System methylphenidate in children with attention‐deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology2015;35(5):525‐34. [DOI: 10.1097/JCP.0000000000000389; PUBMED: 26267421] ">Su 2015</a>; <a href="./references#CD012069-bbs2-0248" title="YangL , CaoQ , ShuaiL , LiH , ChanRC , WangY . Comparative study of OROS‐MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial. International Journal of Neuropsychopharmacology2012; Vol. 15, issue 1:15‐26. [DOI: 10.1017/S1461145711001490; PUBMED: 22017969] ">Yang 2012</a>; <a href="./references#CD012069-bbs2-0258" title="ZhengY , WangYF , QinJ , WangLW , ZouLP , JinXM , et al. Prospective, naturalistic study of open‐label OROS methylphenidate treatment in Chinese school‐aged children with attention‐deficit/hyperactivity disorder. Chinese Medical Journal2011;124(20):3269‐74. [PUBMED: 22088519] ">Zheng 2011</a>; <a href="./references#CD012069-bbs2-0259" title="ZhengY , LiangJM , GaoHY , YangZW , JiaFJ , LiangYZ , et al. An open‐label, self‐control, prospective study on cognitive function, academic performance, and tolerability of osmotic‐release oral system methylphenidate in children with attention‐deficit hyperactivity disorder. Chinese Medical Journal2015;128(22):2988‐97. [DOI: 10.4103/0366‐6999.168948; PMC4795269; PUBMED: 26608976] ">Zheng 2015</a>); 4 studies each in Israel (<a href="./references#CD012069-bbs2-0088" title="GolubchikP , GolubchikL , SeverJM , WeizmanA . The beneficial effect of methylphenidate in ADHD with comorbid separation anxiety. International Clinical Psychopharmacology2014;29(5):274‐8. [DOI: 10.1097/YIC.0000000000000034; PUBMED: 24743562] GolubchikP , KodeshA , WeizmanA . Attention‐deficit/hyperactivity disorder and comorbid subsyndromal depression: what is the impact of methylphenidate on mood?. Clinical Neuropharmacology2013;36(5):141‐5. [DOI: 10.1097/WNF.0b013e31829eb204; PUBMED: 24045603] GolubchikP , SeverJ , WeizmanA . Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia. International Clinical Psychopharmacology2014;29(4):212‐5. [DOI: 10.1097/YIC.0000000000000029; PMC4047304; PUBMED: 24448460] GolubchikP , SeverJ , WeizmanA , ZalsmanG . Methylphenidate treatment in pediatric patients with attention‐deficit/hyperactivity disorder and comorbid trichotillomania: a preliminary report. Clinical Neuropharmacology2011;34(3):108‐10. [DOI: 10.1097/WNF.0b013e31821f4da9; PUBMED: 21586916] ">Golubchik 2011</a>; <a href="./references#CD012069-bbs2-0091" title="GreenT , WeinbergerR , DiamondA , BerantM , HirschfeldL , FrischA , et al. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. Journal of Child and Adolescent Psychopharmacology2011;21(6):589‐95. [DOI: 10.1089/cap.2011.0042; PUBMED: 22149470] GreenT , WeinbergerR , WeizmanA , KotlerM , GothelfD . Effect of methylphenidate on neurocognitive functioning in velocardiofacial syndrome: a randomized placebo‐controlled trial. Biological Psychiatry2009;65(Suppl 8):147 S. ">Green 2011</a>; <a href="./references#CD012069-bbs2-0134" title="LahatE , WeissM , Ben‐ShlomoA , EvansS , BistritzerT . Bone mineral density and turnover in children with attention‐deficit hyperactivity disorder receiving methylphenidate. Journal of Child Neurology2000;15(7):436‐9. [DOI: 10.1177/088307380001500702; PUBMED: 10921512] ">Lahat 2000</a>; <a href="./references#CD012069-bbs2-0255" title="ZelnikN , Terkel‐DawerR . The clinical profile of children with ADHD that require OROS‐methylphenidate combined with shorter‐acting formulations. ADHD Attention Deficit and Hyperactivity Disorders2015;7(4):313‐8. [DOI: 10.1007/s12402‐015‐0168‐z; PUBMED: 25838111] ">Zelnik 2015</a>) and Italy (<a href="./references#CD012069-bbs2-0020" title="AtzoriP , AncillettaB , UsalaT , DanjouF , ZuddasA . Predictive parameters for methylphenidate use and compliance in children with attention deficit hyperactivity disorder. European Neuropsychopharmacology2006;16(Suppl 1):S73‐4. [DOI: 10.1016/S0924‐977X(06)80087‐8] AtzoriP , UsalaT , CarucciS , DanjouF , ZuddasA . Predictive factors for persistent use and compliance of immediate‐release methylphenidate: a 36‐month naturalistic study. Journal of Child and Adolescent Psychopharmacology2009;19(6):673‐81. [DOI: 10.1089/cap.2008.0146; PUBMED: 20035585] ">Atzori 2009</a>; <a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a>; <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a>; <a href="./references#CD012069-bbs2-0136" title="LambertiM , ItalianoD , GuerrieroL , D'AmicoG , SiracusanoR , IngrassiaM , et al. Evaluation of acute cardiovascular effects of immediate‐release methylphenidate in children and adolescents with attention‐deficit hyperactivity disorder. Neuropsychiatric Disease and Treatment2015;11:1169‐74. [DOI: 10.2147/NDT.S79866; PMC4431494; PUBMED: 26056451] ">Lamberti 2015</a>); 3 studies each in Canada (<a href="./references#CD012069-bbs2-0034" title="CherlandE , FitzpatrickR . Psychotic side effects of psychostimulants: a 5‐year review. Canadian Journal of Psychiatry1999;44(8):811‐3. [DOI: 10.1177/070674379904400810; PUBMED: 10566114] ">Cherland 1999</a>; <a href="./references#CD012069-bbs2-0203" title="HechtmanL . Effects of treatment on the overall functioning of children with ADHD. Journal of the Canadian Academy of Child and Adolescent Psychiatry2009;14(Suppl 1):10‐5. [PMC2547092] SteeleM , RiccardelliR , BinderC . The effectiveness of OROS® methylphenidate (Concerta®) vs. usual treatment with immediate‐release methylphenidate (IR MPH) in children aged 6‐12 years with attention deficit hyperactivity disorder (ADHD). International Journal of Neuropsychopharmacology2004;7(Suppl 2):S442. [DOI: 10.1017/S1461145704004547] SteeleM , WeissM , SwansonJ , WangJ , PrinzoRS , BinderCE . A randomized, controlled effectiveness trial of OROS‐methylphenidate compared to usual care with immediate‐release methylphenidate in ADHD. Canadian Journal of Clinical Pharmacology2006;13(1):e50‐62. [PUBMED: 16456216] SteeleMM , PrinzoR , BinderC . Effectiveness of Concerta versus twice or thrice daily IR‐MPH in children with ADHD. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta (GA). 2005. SteeleMM , PrinzoR , BinderC . Long‐term effectiveness and safety of Concerta in children with ADHD: a six‐month study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta (GA). 2005. ">Steele 2006</a>; <a href="./references#CD012069-bbs2-0231" title="WeissM , HechtmanL , TurgayA , JainU , QuinnD , AhmedTS , et al. Once‐daily multilayer‐release methylphenidate in a double‐blind, crossover comparison to immediate‐release methylphenidate in children with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2007;17(5):675‐88. [DOI: 10.1089/cap.2006.0101; PUBMED: 17979587] ">Weiss 2007</a>) and the UK (<a href="./references#CD012069-bbs2-0002" title="AbbasE , DesoysaR . Use of methylphenidate for attention‐deficit‐hyperactivity disorder in childhood. Developmental Medicine and Child Neurology2006;48(Suppl 107):23. [DOI: 10.1111/j.1469‐8749.2006.tb12600.x] ">Abbas 2006</a>; <a href="./references#CD012069-bbs2-0152" title="McCarthyS , CranswickN , PottsL , TaylorE , WongIC . Mortality associated with attention‐deficit hyperactivity disorder: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Safety2009;32(11):1089‐96. [DOI: 10.2165/11317630‐000000000‐00000; PUBMED: 19810780] ">McCarthy 2009</a>; <a href="./references#CD012069-bbs2-0190" title="SantoshPJ , BairdG , PityaratstianN , TavareE , GringrasP . Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child: Care, Health and Development2006;32(5):575‐83. [DOI: 10.1111/j.1365‐2214.2006.00631.x; PUBMED: 16919137] ">Santosh 2006</a>); 2 studies each in Egypt (<a href="./references#CD012069-bbs2-0062" title="El‐FikyMR , El‐NahasGM , El‐ShahawyHH , Abdel AzizMF , AliDH , KhalifaNM . Study the gender differences in ADHD children: is the response to CNS stimulants a case of one fits both?. Indian Streams Research Journal2014;4(5):1‐10. ">El‐Fiky 2014</a>; <a href="./references#CD012069-bbs2-0248" title="YangL , CaoQ , ShuaiL , LiH , ChanRC , WangY . Comparative study of OROS‐MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial. International Journal of Neuropsychopharmacology2012; Vol. 15, issue 1:15‐26. [DOI: 10.1017/S1461145711001490; PUBMED: 22017969] ">Yang 2012</a>), France (<a href="./references#CD012069-bbs2-0051" title="DelignieresA , QuerneL , Bourel‐PonchelE , ArdointA , BerquinP . Attention‐deficit disorders and epilepsy in childhood: use methylphenidate treatment?. European Journal of Paediatric Neurology. 9th Congress of the European Paediatric Neurology Society (EPNS); May 11‐14 2011; Cavtat (Croatia). 2011; Vol. 15:S127‐8. ">Delignieres 2011</a>; <a href="./references#CD012069-bbs2-0174" title="PeyreH , SperanzaM , CorteseS , WohlM , Purper‐OuakilD . Do ADHD children with and without child behavior checklist‐dysregulation profile have different clinical characteristics, cognitive features, and treatment outcomes?. Journal of Attention Disorders2012;19(1):63‐71. [DOI: 10.1177/1087054712452135; PUBMED: 22837549] ">Peyre 2012a</a>), and Indonesia (<a href="./references#CD012069-bbs2-0208" title="SudarmadjiSS , MelialaL , AzizA . Improvement of cognitive function in attention deficit hyperactivity disorder (ADHD) treatment by methylphenidate (MPH) of elementary school students at Bantul District, Yogyakarta Special Regency. Journal of the Neurological Sciences2009;285(Suppl 1):S236. [DOI: 10.1016/S0022‐510X(09)70898‐6] ">Sudarmadji 2009</a>; <a href="./references#CD012069-bbs2-0235" title="WigunaT , GuerreroAP , WibisonoS , SastroasmoroS . Effect of 12‐week administration of 20‐mg long‐acting methylphenidate on Glu/Cr, NAA/Cr, Cho/Cr, and mI/Cr ratios in the prefrontal cortices of school‐age children in Indonesia: a study using 1H Magnetic Resonance Spectroscopy (MRS). Clinical Neuropharmacology. T. Wiguna, Child and Adolescent Psychiatry Division, Department of Psychiatry, University of Indonesia, Jl. Salemba Raya 4, Jakarta 10430, Indonesia. E‐mail: twiga00@yahoo.com: Lippincott Williams and Wilkins (530 Walnut Street,P O Box 327, Philadelphia PA 19106‐3621, United States), 2012; Vol. 35, issue 2:81‐5. [DOI: 10.1097/WNF.0b013e3182452572; PUBMED: 22318191] ">Wiguna 2012</a>); 1 study each in India (<a href="./references#CD012069-bbs2-0074" title="GargJ , ArunP , ChavanBS . Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. International Journal of Applied and Basic Medical Research2015;5(2):114‐8. [DOI: 10.4103/2229‐516X.157162; PMC4456885] GargJ , ArunP , ChavanBS . Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder. Indian Pediatrics2014;51(7):550‐4. [PUBMED: 25031133] ">Garg 2014</a>), Ireland (<a href="./references#CD012069-bbs2-0115" title="JohnsonKA , BarryE , LambertD , FitzgeraldM , McNicholasF , KirleyA , et al. Methylphenidate side effect profile is influenced by genetic variation in the attention‐deficit/hyperactivity disorder‐associated CES1 gene. Journal of Child and Adolescent Psychopharmacology2013;23(10):655‐64. [DOI: 10.1089/cap.2013.0032; PUBMED: 24350812] ">Johnson 2013</a>), Japan (<a href="./references#CD012069-bbs2-0249" title="YatsugaC , ToyohisaD , FujisawaTX , NishitaniS , ShinoharaK , MatsuuraN , et al. No association between catechol‐O‐methyltransferase (COMT) genotype and attention deficit hyperactivity disorder (ADHD) in Japanese children. Brain and Development2014;36(7):620‐5. [DOI: 10.1016/j.braindev.2013.08.006; PUBMED: 24035255] ">Yatsuga 2014</a>), New Zealand (<a href="./references#CD012069-bbs2-0073" title="GallandBC , TrippEG , GrayA , TaylorBJ . Apnea‐hypopnea indices and snoring in children diagnosed with ADHD: a matched case‐control study. Sleep and Breathing2011;15(3):455‐62. [DOI: 10.1007/s11325‐010‐0357‐0; PUBMED: 20440568] GallandBC , TrippEG , TaylorBJ . Methylphenidate effects on sleep in children. Brown University Child and Adolescent Psychopharmacology Update2010;12(3):5‐6. [DOI: 10.1002/cpu.20111] GallandBC , TrippEG , TaylorBJ . The sleep of children with attention deficit hyperactivity disorder on and off methylphenidate: a matched case‐control study. Journal of Sleep Research2010;19(2):366‐73. [DOI: 10.1111/j.1365‐2869.2009.00795.x; PUBMED: 20050995] ">Galland 2010</a>), Serbia (<a href="./references#CD012069-bbs2-0135" title="LakicA , KesicA , DronjakD . Tics in children with attention‐deficit/hyperactivity disorder under treatment with the sustained‐release form of methylphenidate. European Neuropsychopharmacology2012; Vol. 22, issue Suppl 2:S420. [DOI: 10.1016/S0924‐977X(12)70658‐2] ">Lakic 2012</a>), Sri Lanka (<a href="./references#CD012069-bbs2-0173" title="PereraH , JeewandaraKC , SeneviratneS , GurugeC . Assessment of outcome of an ADHD treatment program using parent feedback. Sri Lanka Journal of Psychiatry2010;1(2):51‐5. [DOI: 10.4038/sljpsyc.v1i2.2575] ">Perera 2010</a>), Thailand (<a href="./references#CD012069-bbs2-0165" title="MoungnoiP , MaipangP . Long‐term effects of short‐acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health. Journal of the Medical Association of Thailand2011;94(Suppl 3):S158‐63. [PUBMED: 22043770] ">Moungnoi 2011</a>), the Netherlands (<a href="./references#CD012069-bbs2-0220" title="Van derOordS , PrinsPJ , OosterlaanJ , EmmelkampPM . Does brief, clinically based, intensive multimodal behavior therapy enhance the effects of methylphenidate in children with ADHD?. European Child and Adolescent Psychiatry2007;16(1):48‐57. [DOI: 10.1007/s00787‐006‐0574‐z; PUBMED: 16972117] ">Van der Oord 2007</a>), and Venezuela (<a href="./references#CD012069-bbs2-0164" title="Montiel‐NavaC , PeñaJA , Espina‐MariñesG , Ferrer‐HernandezME , López‐RubioA , Puertas‐SánchezS , et al. A pilot study of methylphenidate and parent training in the treatment of children with attention deficit hyperactivity disorder [Estudio piloto de metilfenidato y entrenamiento a padres en el tratamiento de niños con trastorno por déficit de atención‐hiperactividad]. Revista de Neurologia2002;35(3):201‐5. [PUBMED: 12235578] ">Montiel‐Nava 2002</a>). </p> <p>Seven studies (3.9%) were multicentre studies, carried out in more than one country: <a href="./references#CD012069-bbs2-0010" title="AltinM , El‐ShafeiAA , YuM , DesaiahD , TreuerT , ZavadenkoN , et al. Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non‐Western countries. Drugs in Context2013;2013:212260. [DOI: 10.7573/dic.212260; PMC3884848] HongJ , NovickD , TreuerT , MontgomeryW , HaynesVS , WuS , et al. Predictors and consequences of adherence to the treatment of pediatric patients with attention‐deficit/hyperactivity disorder in Central Europe and East Asia. Patient Preference and Adherence2013;30(7):987‐95. [DOI: 10.2147/PPA.S50628; PMC3794850; PUBMED: 24124351] TruerT , FengQ , DesaiahD , AltinM , WuS , El‐ShafeiA , et al. Predictors of pharmacological treatment outcomes with atomoxetine or methylphenidate in patients with attention‐deficit/hyperactivity disorder from China, Egypt, Lebanon, Russian Federation, Taiwan, and United Arab Emirates. International Journal of Clinical Practice2014;68(9):1152‐62. [DOI: 10.1111/ijcp.12437; PUBMED: 24703228] ">Altin 2013</a> (China, Egypt, Lebanon, Russia, Taiwan, and the United Arab Emirates); <a href="./references#CD012069-bbs2-0086" title="GoezHR , ScottO , NevoN , Bennett‐BackO , ZelnikN . Using the test of variables of attention to determine the effectiveness of modafinil in children with attention‐deficit hyperactivity disorder (ADHD): a prospective methylphenidate‐controlled trial. Journal of Child Neurology2012;27(12):1547‐52. [DOI: 10.1177/0883073812439101; PUBMED: 22447850] ZelnikN , NevoN , GoezH , Bennett‐BackO . Modafinil vs. methylphenidate for children and adolescents with ADHD. European Journal of Paediatric Neurology2011;15(Suppl 1):S126‐7. [DOI: 10.1016/S1090‐3798(11)70442‐1] ">Goez 2012</a> (Canada and Israel); <a href="./references#CD012069-bbs2-0184" title="HoareP , RemschmidtH , MedoriR , EttrichC , RothenbergerA , SantoshP , et al. 12‐month efficacy and safety of OROS MPH in children and adolescents with attention‐deficit/hyperactivity disorder switched from MPH. European Child and Adolescent Psychiatry2005;14(6):305‐9. [DOI: 10.1007/s00787‐005‐0486‐3; PUBMED: 16220214] RemschmidtH , HoareP , EttrichC , RothenbergerA , SantoshP , SchmidtM , et al. Symptom control in children and adolescents with attention‐deficit/hyperactivity disorder on switching from immediate‐release MPH to OROS® MPH. European Child and Adolescent Psychiatry2005;14(6):297‐304. [DOI: 10.1007/s00787‐005‐0467‐6] ">Remschmidt 2005</a> (Germany and the UK); <a href="./references#CD012069-bbs2-0227" title="WangY , ZhengY , DuY , SongDH , ShinYJ , ChoSC , et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double‐blind comparison trial. Australian and New Zealand Journal of Psychiatry2007;41(3):222‐30. [DOI: 10.1080/00048670601057767; PUBMED: 17464703] ">Wang 2007</a> (China, Korea, and Mexico); and <a href="./references#CD012069-bbs2-0114" title="AbikoffH . Tailored psychosocial treatments for ADHD: the search for a good fit. Journal of Clinical Child Psychology2001; Vol. 30, issue 1:122‐5. [DOI: 10.1207/S15374424JCCP3001_14; PUBMED: 11294070] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottG , GreenhillLL , et al. National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choices. Archives of General Psychiatry1997;54(9):865‐70. [PUBMED: 9294378] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottGR , GreenhillLL , et al. NIMH collaborative multimodal treatment study of children with ADHD (MTA): design, methodology, and protocol evolution. Journal of Attention Disorders1997;2(3):141‐58. [DOI: 10.1177/108705479700200301] ArnoldLE , ChuangS , DaviesM , AbikoffHB , ConnersCK , ElliottGR , et al. Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures. Journal of Abnormal Child Psychology2004;32(1):39‐51. [PUBMED: 14998110] ArnoldLE , ElliottM , SachsL , BirdH , KraemerHC , WellsKC , et al. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14‐month outcome in ADHD. Journal of Consulting and Clinical Psychology2003;71(4):713‐27. [PUBMED: 12924677] CareyWB . What the multimodal treatment study of children with attention deficit/hyperactivity disorder did and did not say about the use of methylphenidate for attention deficits. Pediatrics2000;105(4):863‐4. [PUBMED: 10742336] ConnersCK , EpsteinJN , MarchJS , AngoldA , WellsKC , KlaricJ , et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):159‐67. [DOI: 10.1097/00004583‐200102000‐00010; PUBMED: 11211364] GalanterCA , CarlsonGA , JensenPS , GreenhillLL , DaviesM , LiW , et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. Journal of Child and Adolescent Psychopharmacology2003;13(2):123‐36. [DOI: 10.1089/104454603322163844; PUBMED: 12880507] GreeneRW , AblonJS . What does the MTA study tell us about effective psychosocial treatment for ADHD?. Journal of Clinical Child Psychology2001;30(1):114‐21. [DOI: 10.1207/S15374424JCCP3001_13; PUBMED: 11294069] GreenhillLL , AbikoffHB , ArnoldLE , CantwellDP , ConnersCK , ElliottG , et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. Journal of the American Academy of Child and Adolescent Psychiatry1996;35(10):1304‐13. [DOI: 10.1097/00004583‐199610000‐00017; PUBMED: 8885584] GreenhillLL , SwansonJM , VitielloB , DaviesM , ClevengerW , WuM , et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):180‐7. [DOI: 10.1097/00004583‐200102000‐00012; PUBMED: 11211366] HansenL , ThomsenPH . How to treat ADHD/DAMP? Is there a conclusive answer? A critical survey of the MTA trial?. Ugeskr Laeger2005;167(48):4555‐9. [PUBMED: 16324436] HinshawSP . Moderators and mediators of treatment response for children with attention‐deficit/hyperactivity disorder: the Multimodal Treatment Study of children with attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1088‐96. [PUBMED: 10591284] HinshawSP , MarchJS , AbikoffH , ArnoldLE , CantwellDP , ConnersCK , et al. Comprehensive assessment of childhood Attention‐Deficit Hyperactivity Disorder in the context of a multisite, multimodal clinical trial. Journal of Attention Disorders1997;1(4):217‐34. [DOI: 10.1177/108705479700100403] JensenPS , ArnoldLE , SwansonJM , VitielloB , AbikoffHB , GreenhillLL , et al. 3‐year follow‐up of the NIMH MTA study. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):989‐1002. [DOI: 10.1097/CHI.0b013e3180686d48; PUBMED: 17667478] JensenPS , HinshawSP , KraemerHC , LeonoraN , NewcornJH , AbikoffHB , et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. Journal of the American Academy of Child and Adolescent Psychiatry2001; Vol. 40, issue 2:147‐58. [DOI: 10.1097/00004583‐200102000‐00009; PUBMED: 11211363] JensenPS , HinshawSP , SwansonJM , GreenhillLL , ConnersCK , ArnoldLE , et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. Journal of Developmental and Behavioral Pediatrics2001;22(1):60‐73. [PUBMED: 11265923] MTA Cooperative Group. A 14‐month randomized clinical trial of treatment strategies for attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1073‐86. [DOI: 10.1001/archpsyc.56.12.1073; PUBMED: 10591283] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: 24‐month outcomes of treatment strategies for attention‐deficit/hyperactivity disorder. Pediatrics2004;113(4):754‐61. [PUBMED: 15060224] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: changes in effectiveness and growth after the end of treatment. Pediatrics2004;113(4):762‐9. [PUBMED: 15060225] MarchJS , SwansonJM , ArnoldLE , HozaB , ConnersCK , HinshawSP , et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). Journal of Abnormal Child Psychology2000;28(6):527‐41. [PUBMED: 11104315] MolinaBS , FloryK , HinshawSP , GreinerAR , ArnoldLE , SwansonJM , et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1028‐40. [DOI: 10.1097/chi.0b013e3180686d96; PUBMED: 17667481] MolinaBS , HinshawSP , EugeneAL , SwansonJM , PelhamWE , HechtmanL , et al. Adolescent substance use in the multimodal treatment study of attention‐deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. Journal of the American Academy of Child and Adolescent Psychiatry2013;52(3):250‐63. [DOI: 10.1016/j.jaac.2012.12.014; PMC3589108; PUBMED: 23452682] MolinaBS , HinshawSP , SwansonJM , ArnoldLE , VitielloB , JensenPS , et al. The MTA at 8 years: prospective follow‐up of children treated for combined‐type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(5):484‐500. [DOI: 10.1097/CHI.0b013e31819c23d0; PMC3063150] NiewegEH . Does ADHD medication stop working after 2‐3 years? On the surprising, but little known follow‐up of the MTA study [Is adhd‐medicatie na 2‐3 jaar uitgewerkt? Over de verrassende, maar weinig bekendefollow‐up van het mta‐onderzoek]. Tijdschrift voor Psychiatrie2010;52(4):245‐54. [PUBMED: 20503165] OwensEB , HinshawSP , KraemerHC , ArnoldLE , AbikoffHB , CantwellDP , et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. Journal of Consulting and Clinical Psychology2003;71(3):540‐52. [PUBMED: 12795577] PelhamWEJr . The NIMH multimodal treatment study for attention‐deficit hyperactivity disorder: just say yes to drugs alone?. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie1999;44(10):981‐90. [DOI: 10.1177/070674379904401004; PUBMED: 10637677] PelhamWE , GnagyEM , GreinerAR , HozaB , HinshawSP , SwansonJM , et al. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. Journal of Abnormal Child Psychology2000;28(6):507‐25. [PUBMED: 11104314] RichtersJE , ArnoldLE , JensenPS , AbikoffH , ConnersCK , GreenhillLL , et al. NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale. Journal of the American Academy of Child and Adolescent Psychiatry1995;34(8):987‐1000. [DOI: 10.1097/00004583‐199508000‐00008; PUBMED: 7665456] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. Journal of Attention Disorders2008;12(1):15‐43. [DOI: 10.1177/1087054708319525; PUBMED: 18573924] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. Journal of Attention Disorders2008;12(1):4‐14. [DOI: 10.1177/1087054708319345; PUBMED: 18573923] SwansonJM , ElliottGR , GreenhillLL , WigalT , ArnoldLE , VitielloB , et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow‐up. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1015‐27. [DOI: 10.1097/chi.0b013e3180686d7e; PUBMED: 17667480] SwansonJM , HinshawSP , ArnoldLE , GibbonsRD , MarcusS , HurK , et al. Secondary evaluations of MTA 36‐month outcomes: propensity score and growth mixture model analyses. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1003‐14. [DOI: 10.1097/CHI.0b013e3180686d63; PUBMED: 17667479] SwansonJM , KraemerHC , HinshawSP , ArnoldLE , ConnersCK , AbikoffHB , et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):168‐79. [DOI: 10.1097/00004583‐200102000‐00011; PUBMED: 1121136] VitielloB , ElliottGR , SwansonJM , ArnoldLE , HechtmanL , AbikoffH , et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. American Journal of Psychiatry2012; Vol. 169, issue 2:167‐77. [DOI: 10.1176/appi.ajp.2011.10111705; PMC4132884; PUBMED: 21890793] VitielloB , SevereJB , GreenhillLL , ArnoldLE , AbikoffHB , BuksteinOG , et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):188‐96. [DOI: 10.1097/00004583‐200102000‐00013; PUBMED: 11211367] ">Jensen 1999 (MTA)</a>, <a href="./references#CD012069-bbs2-0130" title="HechtmanL , AbikoffH , KleinRG , WeissG , RespitzC , KouriJ , et al. Academic achievement and emotional status of children with ADHD treated with long‐term methylphenidate and multimodal psychosocial treatment. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(7):812‐9. [DOI: 10.1097/01.chi.0000128796.84202.eb; PUBMED: 15213582] KleinRG , AbikoffH , HechtmanL , WeissG . Design and rationale of controlled study of long‐term methylphenidate and multimodal psychosocial treatment in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(7):792‐801. [DOI: 10.1097/01.chi.0000128798.91601.fe; PUBMED: 15213580] ">Klein 2004</a> and <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a> (Canada and the USA). </p> <p>The distribution of studies among continents is: 72 studies (40.7%) in Asia, 51 studies (28.8%) in North America, 6 studies (3.40%) in South America (<a href="./references#CD012069-bbs2-0033" title="BruxelEM , Salatino‐OliveiraA , GenroJP , ZeniCP , PolanczykGV , ChazanR , et al. Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention‐deficit/hyperactivity disorder treated with methylphenidate. Pharmacogenomics Journal2013;13(5):476‐80. [DOI: 10.1038/tpj.2012.25; PUBMED: 22688218] ChazanR , BorowskiC , PiancaT , LudwigH , RohdeLA , PolanczykG . Do phenotypic characteristics, parental psychopathology, family functioning, and environmental stressors have a role in the response to methylphenidate in children with attention‐deficit/hyperactivity disorder? A naturalistic study from a developing count. Journal of Clinical Psychopharmacology2011;31(3):309‐17. [DOI: 10.1097/JCP.0b013e318217b4df; PUBMED: 21508864] Salatino‐OliveiraA , GenroJP , ZeniC , PolanczykGV , ChazanR , GuimarãesAP , et al. Catechol‐O‐methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention‐deficit/hyperactivity disorder. Biological Psychiatry2011;70(3):216‐21. [DOI: 10.1016/j.biopsych.2011.03.025; PUBMED: 21550019] ">Chazan 2011</a>; <a href="./references#CD012069-bbs2-0097" title="GuerreiroMM , MontenegroMA , PivaRT , Moura‐RibeiroMV . Attention deficit disorder: treatment with methylphenidate [Distúrbio do déficit de atenção: tratamento com metilfenidato]. Arquivos de Neuro‐Psiquiatria1996;54(1):25‐9. [DOI: 10.1590/S0004‐282X1996000100004] ">Guerreiro 1996</a>; <a href="./references#CD012069-bbs2-0149" title="MaiaCR . Evalution of the Exchange of Immediate Release Methylphenidate for Prolonged Release Methylphenidate in Attention Deficit/Hyperactivity Disorder [Availação da troca do metilfenidato de liberação imediata para o metilfenidato de liberação prolongada no transtorno de déficit de atenção/hiperatividade] [Masters thesis]. Rio Grande (BZ): The Federal University of Rio Grande, 2009. MaiaCR , MatteBC , LudwigHT , RohdeLA . Switching from methylphenidate immediate release to MPH‐SODAS in attention‐deficit/hyperactivity disorder. European Child and Adolescent Psychiatry2008;17(3):133‐42. [DOI: 10.1007/s00787‐007‐0647‐7; PUBMED: 17846812] ">Maia 2008</a>; <a href="./references#CD012069-bbs2-0176" title="PolanczykG , ZeniC , GenroJP , GuimarãesAP , RomanT , HutzMH , et al. Association of the adrenergic alpha2A receptor gene with methylphenidate improvement of inattentive symptoms in children and adolescents with attention‐deficit/hyperactivity disorder. Archives of General Psychiatry2007;64(2):218‐24. [DOI: 10.1001/archpsyc.64.2.218; PUBMED: 17283289] ">Polanczyk 2007</a>; <a href="./references#CD012069-bbs2-0256" title="ZeniCP , GuimarãesAP , PolanczykGV , GenroJP , RomanT , HutzMH , et al. No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention‐deficit/hyperactivity disorder. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics2007;144B(3):391‐4. [DOI: 10.1002/ajmg.b.30474; PUBMED: 17171656] ">Zeni 2007</a>; <a href="./references#CD012069-bbs2-0164" title="Montiel‐NavaC , PeñaJA , Espina‐MariñesG , Ferrer‐HernandezME , López‐RubioA , Puertas‐SánchezS , et al. A pilot study of methylphenidate and parent training in the treatment of children with attention deficit hyperactivity disorder [Estudio piloto de metilfenidato y entrenamiento a padres en el tratamiento de niños con trastorno por déficit de atención‐hiperactividad]. Revista de Neurologia2002;35(3):201‐5. [PUBMED: 12235578] ">Montiel‐Nava 2002</a>), 38 studies (21.5%) in Europe, 8 studies (4.50%) in Oceania (<a href="./references#CD012069-bbs2-0059" title="DupuyFE , ClarkeAR , BarryRJ , McCarthyR , SelikowitzM . EEG coherence in girls with attention‐deficit/hyperactivity disorder: stimulant effects in good responders. International Journal of Psychophysiology2008;70(3):151‐7. [DOI: 10.1016/j.ijpsycho.2008.07.012; PUBMED: 18708101] ">Dupuy 2008</a>; <a href="./references#CD012069-bbs2-0061" title="EfronD . Methylphenidate versus dextroamphetamine in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry1999;38(5):500. [PUBMED: 10230180] EfronD , JarmanFC , BarkerMJ . Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder. Journal of Paediatrics and Child Health1998;34(3):288‐92. [DOI: 10.1046/j.1440‐1754.1998.00224.x] EfronD , JarmanFC , BarkerMJ . Medium‐term outcomes are comparable with short‐term outcomes in children with attention deficit hyperactivity disorder treated with stimulant medication. Journal of Paediatrics and Child Health2000;36(5):457‐61. [PUBMED: 11036801] EfronD , JarmanFC , BarkerMJ . Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial. Pediatrics1997;100(6):E6. [PUBMED: 9382907] EfronD , JarmanFC , BarkerMJ . Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial. Pediatrics1997;100(4):662‐6. [PUBMED: 9310521] ">Efron 1997</a>; <a href="./references#CD012069-bbs2-0073" title="GallandBC , TrippEG , GrayA , TaylorBJ . Apnea‐hypopnea indices and snoring in children diagnosed with ADHD: a matched case‐control study. Sleep and Breathing2011;15(3):455‐62. [DOI: 10.1007/s11325‐010‐0357‐0; PUBMED: 20440568] GallandBC , TrippEG , TaylorBJ . Methylphenidate effects on sleep in children. Brown University Child and Adolescent Psychopharmacology Update2010;12(3):5‐6. [DOI: 10.1002/cpu.20111] GallandBC , TrippEG , TaylorBJ . The sleep of children with attention deficit hyperactivity disorder on and off methylphenidate: a matched case‐control study. Journal of Sleep Research2010;19(2):366‐73. [DOI: 10.1111/j.1365‐2869.2009.00795.x; PUBMED: 20050995] ">Galland 2010</a>; <a href="./references#CD012069-bbs2-0103" title="HazellPL , StuartJE . A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(8):886‐94. [DOI: 10.1097/01.CHI.0000046908.27264.00] ">Hazell 2003</a>; <a href="./references#CD012069-bbs2-0178" title="PoultonA , CowellCT . Slowing of growth in height and weight on stimulants: a characteristic pattern. Journal of Paediatrics and Child Health2003;39(3):180‐5. [PUBMED: 12654140] ">Poulton 2003</a>; <a href="./references#CD012069-bbs2-0179" title="PoultonA , BriodyJ , McCorquodaleT , MelzerE , HerrmannM , BaurLA , et al. Weight loss on stimulant medication: how does it affect body composition and bone metabolism? ‐ A prospective longitudinal study. International Journal of Pediatric Endocrinology2012;2012(1):30. [DOI: 10.1186/1687‐9856‐2012‐30; PMC3549744; PUBMED: 23216890] PoultonA , EvansR , MelzerE , BuiQ . Stimulant medication affects growth but not bone age. Archives of Disease in Childhood2014;99(Suppl 1):A4.A5. [DOI: 10.1136/archdischild‐2014‐306237.10] PoultonA , NananR . Differential effects of dexamphetamine and methylphenidate on symptoms of inattention‐overactivity, oppositional‐defiant and weight. Archives of Disease in Childhood2014;99(Suppl 1):A70. [DOI: 10.1136/archdischild‐2014‐306237.167] ">Poulton 2012</a>; <a href="./references#CD012069-bbs2-0239" title="WilliamsLM , HermensDF , PalmerD , KohnM , ClarkeS , KeageH , et al. Misinterpreting emotional expressions in attention‐deficit/hyperactivity disorder: evidence for a neural marker and stimulant effects. Biological Psychiatry2008;63(10):917‐26. [DOI: 10.1016/j.biopsych.2007.11.022; PUBMED: 18272140] ">Williams 2008</a>; <a href="./references#CD012069-bbs2-0164" title="Montiel‐NavaC , PeñaJA , Espina‐MariñesG , Ferrer‐HernandezME , López‐RubioA , Puertas‐SánchezS , et al. A pilot study of methylphenidate and parent training in the treatment of children with attention deficit hyperactivity disorder [Estudio piloto de metilfenidato y entrenamiento a padres en el tratamiento de niños con trastorno por déficit de atención‐hiperactividad]. Revista de Neurologia2002;35(3):201‐5. [PUBMED: 12235578] ">Montiel‐Nava 2002</a>), and 2 studies (1.1%) in Africa (<a href="./references#CD012069-bbs2-0062" title="El‐FikyMR , El‐NahasGM , El‐ShahawyHH , Abdel AzizMF , AliDH , KhalifaNM . Study the gender differences in ADHD children: is the response to CNS stimulants a case of one fits both?. Indian Streams Research Journal2014;4(5):1‐10. ">El‐Fiky 2014</a>; <a href="./references#CD012069-bbs2-0248" title="YangL , CaoQ , ShuaiL , LiH , ChanRC , WangY . Comparative study of OROS‐MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial. International Journal of Neuropsychopharmacology2012; Vol. 15, issue 1:15‐26. [DOI: 10.1017/S1461145711001490; PUBMED: 22017969] ">Yang 2012</a>). </p> </section> <section id="CD012069-sec-0076"> <p><b>Setting</b></p> <p>Most studies took place in outpatient settings, with very few in‐hospital settings (<a href="./references#CD012069-bbs2-0013" title="ArdicUA , ErcanES , ErcanE , YuceD , BasayBK . Osmotic release oral system methylphenidate is more effective than immediate release methylphenidate: a retrospective chart review in Turkish children with attention deficit hyperactivity disorder. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(4):342‐9. [DOI: 10.5455/bcp.20141009112739] ErcanES , Akyol‐ArdicU , ErcanE , YuceD , Kabukcu‐BasayB . OROS‐MPH is more effective than IR‐MPH in Turkish children: a retrospective chart review. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(1):306‐7. [DOI: 10.5455/bcp.20141009112739] ">Ardic 2014</a>; <a href="./references#CD012069-bbs2-0124" title="ChungI , HanCH , KimHW , ChoSC . The effect of prolonged‐release methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorders. European Neuropsychopharmacology2010;20(Suppl 3):S624‐5. KimHW , YoonIY , ChoSC , KimBN , ChungS , LeeH , et al. The effect of OROS methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorder. International Clinical Psychopharmacology2010;25(2):107‐15. [DOI: 10.1097/YIC.0b013e3283364411; PUBMED: 20093941] ">Kim 2010</a>; <a href="./references#CD012069-bbs2-0138" title="Larrañaga‐FragosoP , NovalS , RiveroJC , Boto‐de‐los‐BueisA . The effects of methylphenidate on refraction and anterior segment parameters in children with attention deficit hyperactivity disorder. Journal of AAPOS2015;19(4):322‐6. [DOI: 10.1016/j.jaapos.2015.04.005; PUBMED: 26235791] ">Larrañaga‐Fragoso 2015</a>; <a href="./references#CD012069-bbs2-0246" title="YalcinO , IseriE , BukanN , ErcinU . Effects of long acting methylphenidate on ghrelin levels in male children with attention deficit hyperactivity disorder: an open label trial. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(2):146‐57. [DOI: 10.5455/bcp.20130708042604] ">Yalcin 2014</a>). </p> </section> <section id="CD012069-sec-0077"> <p><b>Participants</b></p> <p>The 177 cohort studies included 2,207,751 participants. Not all studies provided information on age and sex. The mean age was 9.71 years; 34,753 participants were male, and 9537 were female. One large study with 2,150,362 participants did not provide information on sex (<a href="./references#CD012069-bbs2-0133" title="KrautAA , LangnerI , LindemannC , BanaschewskiT , PetermannU , PetermannF , et al. Comorbidities in ADHD children treated with methylphenidate: a database study. BMC Psychiatry2013;13:11. [DOI: 10.1186/1471‐244X‐13‐11; PMC3544568; PUBMED: 23294623] ">Kraut 2013</a>). </p> <p>Fifty‐two studies (29.4%) included methylphenidate‐naïve participants, 29 (16.4%) included no methylphenidate‐naïve participants, and 26 (14.9%) included a combination of naïve and non‐naïve participants. The remaining 70 studies (39.5%) did not report any information regarding drug naïvety. </p> <p>Thirty studies (16.9%) included participants with ADHD diagnoses alone, while 81 studies (45.8%) included patients with one or more comorbid psychiatric conditions. In 66 studies (37.3%), it was not possible to retrieve information regarding comorbidity. Twenty‐one studies (11.9%) included participants using concurrent medications, whereas 57 studies (32.2%) excluded participants using non‐methylphenidate medication during follow‐up. Reported concurrent medication included other ADHD medications, antidepressants, antipsychotics, pain relievers, antiepileptics, anticonvulsants, antiasthmatic drugs, allergy medications, and anxiolytics. Ninety‐nine studies (55.9%) did not provide data regarding concurrent use of medication. </p> </section> <section id="CD012069-sec-0078"> <p><b>Interventions</b></p> <p>The 177 studies used a range of formulations of methylphenidate. Sixty‐three (35.6%) studies did not specify the type of methylphenidate. </p> <p>Fifty‐two studies (29.4%) used extended‐release methylphenidate only: 4, dexmethylphenidate (<a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0145" title="Dexmethylphenidate in youth with ADHD and Tourette's. Brown University Child and Adolescent Psychopharmacology Update2010;12(11):4‐5. [DOI: 10.1002/cpu.20127] LyonGJ , CoffeyB , CastellanosXF , WoodsD . Improving TIC‐related response inhibition: comparing the effects of dexmethylphenidate to placebo in children and adolescents with ADHD and chronic TIC disorders. International Journal of Neuropsychopharmacology2008;11(Suppl 1):292. LyonGJ , CoffeyB , WoodsD , SamarS , ConeleaC , BauerCC , et al. Improving tic‐related response inhibition: comparing the effects of dexmethylphenidate to no medication in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) and chronic tic disorders. Journal of Child and Adolescent Psychopharmacology2010;20(6):537‐8. [DOI: 10.1089/cap.2010.2064] LyonGJ , SamarSM , ConeleaC , TrujilloMR , LipinskiCM , BauerCC , et al. Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention‐deficit/hyperactivity disorder and Tourette's disorder. Journal of Child and Adolescent Psychopharmacology2010;20(4):283‐9. [DOI: 10.1089/cap.2010.0032] ">Lyon 2010</a>; <a href="./references#CD012069-bbs2-0153" title="LooSK , BilderR , ChoAL , SturmA , CowenJ , WelkerPW , et al. Effects of d‐Methylphenidate, Guanfacine, and their combination on electroencephalogram resting state spectral power in Attention‐Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):674‐82.e1. [DOI: 10.1016/j.jaac.2016.04.020; PMC5003618; PUBMED: 27453081] McCrackenJT , McGoughJJ , LooSK , LevittJ , Del'HommeM , CowenJ , et al. Combined stimulant and Guanfacine administration in Attention‐Deficit/Hyperactivity Disorder: a controlled, comparative study. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):657‐66.e1. [DOI: 10.1016/j.jaac.2016.05.015; PMC4976782; PUBMED: 27453079] ">McCracken 2016</a>; <a href="./references#CD012069-bbs2-0199" title="SilvaR , TilkerHA , CecilJT , KowalikS , KhetaniV , FaleckH , et al. Open‐label study of dexmethylphenidate hydrochloride in children and adolescents with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004;14(4):555‐63. [DOI: 10.1089/cap.2004.14.555; PUBMED: 15662147] TilkerH , SilvaR , CecilJ , KowalikS , FaleckH , RobinsonW , et al. Open label, pilot study of dexmethylphenidate in children with ADHD. Journal of Child and Adolescent Psychopharmacology2002;12(4):295. [DOI: 10.1089/104454602762599835] ">Silva 2004</a>); 7, methylphenidate‐spheroidal oral drug absorption system (<a href="./references#CD012069-bbs2-0098" title="HaertlingF , MuellerB , Bilke‐HentschO . Effectiveness and safety of a long‐acting, once‐daily, two‐phase release formulation of methylphenidate (Ritalin® LA) in school children under daily practice conditions. Attention Deficit and Hyperactivity Disorders2015;7(2):157‐64. [DOI: 10.1007/s12402‐014‐0154‐x; PMC4449385; PUBMED: 25346231] ">Haertling 2015</a>; <a href="./references#CD012069-bbs2-0146" title="Methylphenidate for preschool ADHD. Brown University Child and Adolescent Psychopharmacology Update2009;11(7):4‐4. [DOI: 10.1002/cpu.20095] MaayanL , PaykinaN , FriedJ , StraussT , GuggaSS , GreenhillL . The open‐label treatment of attention‐deficit/hyperactivity disorder in 4‐ and 5‐year‐old children with beaded methylphenidate. Journal of Child and Adolescent Psychopharmacology2009;19(2):147‐53. [PMC2935832; PUBMED: 19374023] ">Maayan 2009</a>; <a href="./references#CD012069-bbs2-0149" title="MaiaCR . Evalution of the Exchange of Immediate Release Methylphenidate for Prolonged Release Methylphenidate in Attention Deficit/Hyperactivity Disorder [Availação da troca do metilfenidato de liberação imediata para o metilfenidato de liberação prolongada no transtorno de déficit de atenção/hiperatividade] [Masters thesis]. Rio Grande (BZ): The Federal University of Rio Grande, 2009. MaiaCR , MatteBC , LudwigHT , RohdeLA . Switching from methylphenidate immediate release to MPH‐SODAS in attention‐deficit/hyperactivity disorder. European Child and Adolescent Psychiatry2008;17(3):133‐42. [DOI: 10.1007/s00787‐007‐0647‐7; PUBMED: 17846812] ">Maia 2008</a>; <a href="./references#CD012069-bbs2-0174" title="PeyreH , SperanzaM , CorteseS , WohlM , Purper‐OuakilD . Do ADHD children with and without child behavior checklist‐dysregulation profile have different clinical characteristics, cognitive features, and treatment outcomes?. Journal of Attention Disorders2012;19(1):63‐71. [DOI: 10.1177/1087054712452135; PUBMED: 22837549] ">Peyre 2012a</a>; <a href="./references#CD012069-bbs2-0193" title="SchulzE , FleischhakerC , HennighausenK , HeiserP , HaesslerF , LinderM , et al. A randomized, rater‐blinded, crossover study comparing the clinical efficacy of Ritalin(®) LA (methylphenidate) treatment in children with attention‐deficit hyperactivity disorder under different breakfast conditions over 2 weeks. Attention Deficit and Hyperactivity Disorders2010;2(3):133‐8. [DOI: 10.1007/s12402‐010‐0031‐1; PUBMED: 21432599] ">Schulz 2010</a>; <a href="./references#CD012069-bbs2-0235" title="WigunaT , GuerreroAP , WibisonoS , SastroasmoroS . Effect of 12‐week administration of 20‐mg long‐acting methylphenidate on Glu/Cr, NAA/Cr, Cho/Cr, and mI/Cr ratios in the prefrontal cortices of school‐age children in Indonesia: a study using 1H Magnetic Resonance Spectroscopy (MRS). Clinical Neuropharmacology. T. Wiguna, Child and Adolescent Psychiatry Division, Department of Psychiatry, University of Indonesia, Jl. Salemba Raya 4, Jakarta 10430, Indonesia. E‐mail: twiga00@yahoo.com: Lippincott Williams and Wilkins (530 Walnut Street,P O Box 327, Philadelphia PA 19106‐3621, United States), 2012; Vol. 35, issue 2:81‐5. [DOI: 10.1097/WNF.0b013e3182452572; PUBMED: 22318191] ">Wiguna 2012</a>; <a href="./references#CD012069-bbs2-0243" title="WittKL , ShelbyMD , ItchonRN , FairclothM , KisslingGE , ChrismanAK , et al. Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry2008;47(12):1375‐83. [DOI: 10.1097/CHI.0b013e3181893620; PMC2807376; PUBMED: 18978633] ">Witt 2008</a>); 7, methylphenidate‐transdermal patch (<a href="./references#CD012069-bbs2-0016" title="ArnoldLE , BozzoloDR , HodgkinsP , McKayM , Beckett‐ThurmanL , GreenbaumM , et al. Switching from oral extended‐release methylphenidate to the methylphenidate transdermal system: continued attention‐deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Current Medical Research and Opinion2010;26(1):129‐37. [DOI: 10.1185/03007990903437412; PMC3875401; PUBMED: 19916704] BuksteinOG , ArnoldLE , LandgrafJM , HodgkinsP . Does switching from oral extended‐release methylphenidate to the methylphenidate transdermal system affect health‐related quality‐of‐life and medication satisfaction for children with attention‐deficit/hyperactivity disorder?. Child and Adolescent Psychiatry and Mental Health2009;3(1):39. [DOI: 10.1186/1753‐2000‐3‐39; PMC2796990; PUBMED: 20003260] ">Arnold 2010</a>; <a href="./references#CD012069-bbs2-0019" title="AshkenasiA . Effect of transdermal methylphenidate wear times on sleep in children with ADHD. Journal of Neurology2012;259(Suppl 1):S33‐4. [DOI: 10.1007/s00415‐012‐6524‐4] AshkenasiA . Effect of transdermal methylphenidate wear times on sleep in children with attention deficit hyperactivity disorder. Pediatric Neurology2011;45(6):381‐6. [DOI: 10.1016/j.pediatrneurol.2011.09.003; PUBMED: 22115000] ">Ashkenasi 2011</a>; <a href="./references#CD012069-bbs2-0065" title="FaraoneSV , GieferEE . Long‐term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(9):1138‐47. [DOI: 10.1097/chi.0b013e31806ad1d7; PUBMED: 17712237] ">Faraone 2007a</a>; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0071" title="FindlingRL , KaticA , RubinR , MoonE , CivilR , LiY . A 6‐month, open‐label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2010;20(5):366‐75. [DOI: 10.1089/cap.2009.0122; PUBMED: 20973707] FindlingRL , TurnbowJ , BurnsideJ , MelmedR , CivilR , LiY . A randomized, double‐blind, multicenter, parallel‐group, placebo‐controlled, dose‐optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents. CNS Spectrums2010;15(7):419‐30. [PUBMED: 20625364] KeatingGM . Methylphenidate transdermal system in attention‐deficit hyperactivity disorder in adolescents: profile report. Drugs in R&amp;D. G.M. Keating, Adis, Private Bag 65901, 41 Centorian Drive, Mairangi Bay, North Shore 0754, Auckland, New Zealand. E‐mail: demail@springer.com, 2012; Vol. 12, issue 3:171‐3. [DOI: 10.2165/11207490‐000000000‐00000; PMC3585903; PUBMED: 22934753] ">Findling 2010</a>; <a href="./references#CD012069-bbs2-0229" title="WarshawEM , SquiresL , LiY , CivilR , PallerAS . Methylphenidate transdermal system: a multisite, open‐label study of dermal reactions in pediatric patients diagnosed with ADHD. Primary Care Companion to the Journal of Clinical Psychiatry2010;12(6):e1‐e9. [DOI: 10.4088/PCC.10m00996pur; NCT00434213; PMC3067997; PUBMED: 21494336] ">Warshaw 2010</a>; <a href="./references#CD012069-bbs2-0238" title="LópezFA , LandgrafJM , WilensTE . Quality of life and parent satisfaction with the methylphenidate transdermal system. European Neuropsychopharmacology2008;18(Suppl 4):S562. [DOI: 10.1016/S0924‐977X(08)70856‐3] LópezFA , WilensTE , WigalSB , TurnbowJM . Effects of variable wear times on transdermal methylphenidate in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(Suppl 4):S561‐2. [DOI: 10.1016/S0924‐977X(08)70855‐1] ManosM , FrazierTW , LandgrafJM , WeissM , HodgkinsP . HRQL and medication satisfaction in children with ADHD treated with the methylphenidate transdermal system. Current Medical Research and Opinion2009;25(12):3001‐10. [DOI: 19849639; PUBMED: 10.1185/03007990903388797] WilensTE , BoellnerSW , LópezFA , TurnbowJM , WigalSB , ChildressAC , et al. Varying the wear time of the methylphenidate transdermal system in children with attention‐deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry2008;47(6):700‐8. [DOI: 10.1097/CHI.0b013e31816bffdf; PUBMED: 18434918] ">Wilens 2008</a>); and 34, methylphenidate‐osmotic‐release oral system. Thirteen studies did not specify which type of extended‐release methylphenidate was used in the study (<a href="./references#CD012069-bbs2-0029" title="BuchmannJ , GierowW , WeberS , HoeppnerJ , KlauerT , BeneckeR , et al. Restoration of disturbed intracortical motor inhibition and facilitation in attention deficit hyperactivity disorder children by methylphenidate. Biological Psychiatry2007;62(9):963‐9. [DOI: 10.1016/j.biopsych.2007.05.010; PUBMED: 17719015] BuchmannJ , GierowW , WeberS , HoeppnerJ , KlauerT , WittsockM , et al. Modulation of transcallosally mediated motor inhibition in children with attention deficit hyperactivity disorder (ADHD) by medication with methylphenidate (MPH). Neuroscience Letters2006;405(1‐2):14‐8. [DOI: 10.1016/j.neulet.2006.06.026; PUBMED: 16815631] BuchmannJ , WoltersA , HaesslerF , BohneS , NordbeckR , KuneschE . Disturbed transcallosally mediated motor inhibition in children with attention deficit hyperactivity disorder (ADHD). Clinical Neurophysiology2003;114(11):2036‐42. [PUBMED: 14580601] ">Buchmann 2007</a>; <a href="./references#CD012069-bbs2-0033" title="BruxelEM , Salatino‐OliveiraA , GenroJP , ZeniCP , PolanczykGV , ChazanR , et al. Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention‐deficit/hyperactivity disorder treated with methylphenidate. Pharmacogenomics Journal2013;13(5):476‐80. [DOI: 10.1038/tpj.2012.25; PUBMED: 22688218] ChazanR , BorowskiC , PiancaT , LudwigH , RohdeLA , PolanczykG . Do phenotypic characteristics, parental psychopathology, family functioning, and environmental stressors have a role in the response to methylphenidate in children with attention‐deficit/hyperactivity disorder? A naturalistic study from a developing count. Journal of Clinical Psychopharmacology2011;31(3):309‐17. [DOI: 10.1097/JCP.0b013e318217b4df; PUBMED: 21508864] Salatino‐OliveiraA , GenroJP , ZeniC , PolanczykGV , ChazanR , GuimarãesAP , et al. Catechol‐O‐methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention‐deficit/hyperactivity disorder. Biological Psychiatry2011;70(3):216‐21. [DOI: 10.1016/j.biopsych.2011.03.025; PUBMED: 21550019] ">Chazan 2011</a>; <a href="./references#CD012069-bbs2-0052" title="DirksenSJ , D'ImperioJM , BirdsallD , HatchSJ . A postmarketing clinical experience study of Metadate CD. Current Medical Research and Opinion2002;18(7):371‐80. [PUBMED: 12487502] ">Dirksen 2002</a>; <a href="./references#CD012069-bbs2-0055" title="BeckerA , RoessnerV , BreuerD , DöpfnerM , RothenbergerA . Relationship between quality of life and psychopathological profile: data from an observational study in children with ADHD. European Child and Adolescent Psychiatry2011;20(Suppl 2):S267‐75. [DOI: 10.1007/s00787‐011‐0204‐2; PMC3180591; PUBMED: 21901415] BreuerD , Görtz‐DortenA , RothenbergerA , DöpfnerM . Assessment of daily profiles of ADHD and ODD symptoms, and symptomatology related to ADHD medication, by parent and teacher ratings. European Child and Adolescent Psychiatry2011;20(Suppl 2):S289‐96. [DOI: 10.1007/s00787‐011‐0206‐0; PMC3180560; PUBMED: 21901413] DöpfnerM , BreuerD , WalterD , RothenbergerA . An observational study of once‐daily modified‐release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality‐of‐life outcomes. European Child and Adolescent Psychiatry2011;20(Suppl 2):S277‐88. [DOI: 10.1007/s00787‐011‐0205‐1; PMC3098980; PUBMED: 21901414] DöpfnerM , Görtz‐DortenA , BreuerD , RothenbergerA . An observational study of once‐daily modified‐release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety. European Child and Adolescent Psychiatry2011;20(Suppl 2):S243‐55. [DOI: 10.1007/s00787‐011‐0202‐4; PMC3180616; PUBMED: 21901417] DöpfnerM , RothenbergerA , OseC . Assessment of Equasym XL under routine conditions by physicians, parents, teachers, and children. International Journal of Neuropsychopharmacology2008;11(Suppl 1):290. [DOI: 10.1017/S1461145708009462] Görtz‐DortenA , BreuerD , HautmannC , RothenbergerA , DöpfnerM . What contributes to patient and parent satisfaction with medication in the treatment of children with ADHD? A report on the development of a new rating scale. European Child and Adolescent Psychiatry2011; Vol. 20, issue Suppl 2:S297‐307. [DOI: 10.1007/s00787‐011‐0207‐z; PMC3180627] RothenbergerA , BeckerA , BreuerD , DöpfnerM . An observational study of once‐daily modified‐release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence. European Child and Adolescent Psychiatry2011;20(Suppl 2):257‐65. [DOI: 10.1007/s00787‐011‐0203‐3; PMC3180635] ">Döpfner 2011a, OBSEER</a>; <a href="./references#CD012069-bbs2-0057" title="DöpfnerM , BreuerD , OseC , FischerR . Methylphenidate with modified release in routine treatment [Methylphenidat mit modifizierter Freisetzung in der Routineversorgung]. Monatsschrift Kinderheilkunde2011;159(11):1119‐25. [DOI: 10.1007/s00112‐011‐2413‐7] ">Döpfner 2011c</a>; <a href="./references#CD012069-bbs2-0102" title="HauboldKH . Attention Deficit Hyperactivity Disorder ADHD ‐ A Retrospective Population‐based Analysis Concerning the Treatment of Children and Adolescents with Stimulant Medication in a Child and Adolescent Psychiatry Practice [PhD thesis]. Tübingen: Eberhard Karls Universität Tübingen, 2009. ">Haubold 2010</a>; <a href="./references#CD012069-bbs2-0108" title="HongSB , KimJW , ChoSC , ShinMS , KimBN , YooHJ . Dopaminergic and noradrenergic gene polymorphisms and response to methylphenidate in Korean children with attention‐deficit/Hyperactivity disorder: is there an interaction?. Journal of Child and Adolescent Psychopharmacology2012; Vol. 22, issue 5:343‐52. [DOI: 10.1089/cap.2011.0076; PUBMED: 23083021] ">Hong 2012</a>; <a href="./references#CD012069-bbs2-0128" title="KimHJ , YangJ , LeeMS . Changes of heart rate variability during methylphenidate treatment in attention‐deficit hyperactivity disorder children: a 12‐week prospective study. Yonsei Medical Journal2015;56(5):1365‐71. [DOI: 10.3349/ymj.2015.56.5.1365; PMC4541668] ">Kim 2015a</a>; <a href="./references#CD012069-bbs2-0159" title="MohammadiMR , AkhondzadehS , MehrNK , MohammadiM , MahintorabiS . Comparison of Stimdate with Ritalin in children and adolescents with attention deficit hyperactivity disorder. Iranian Journal of Psychiatry2009;4(1):31‐4. ">Mohammadi 2009</a>; <a href="./references#CD012069-bbs2-0163" title="Montañés RadaF , Martínez GraneroMA , Vidal FormosoM , Sanchez RomeroS , Andrés PradoMJ . Extended release methylphenidate (medikinet®) twice a day, a prospective open trial [Metilfenidato de liberación prolongada 50/50 (medikinet®) dos veces al día, estudio abierto prospectivo]. Revista de Psiquiatria Infanto‐Juvenil2012;29(1):50‐8. ">Montañés‐Rada 2012</a>; <a href="./references#CD012069-bbs2-0214" title="Tomás VilaM , Aleu Pérez‐GramuntM , Beseler SotoB , Benac PrefasiM , Pantoja MartínezJ , Pitarch CastellanoI . Methylphenidate and sleep: results of a multicentre study on a population of children with attention deficit hyperactivity disorder. Anales de Pediatria2010;73(2):78‐83. [DOI: 10.1016/j.anpedi.2010.05.013; PUBMED: 20605120] ">Tomás Vila 2010b</a>; <a href="./references#CD012069-bbs2-0231" title="WeissM , HechtmanL , TurgayA , JainU , QuinnD , AhmedTS , et al. Once‐daily multilayer‐release methylphenidate in a double‐blind, crossover comparison to immediate‐release methylphenidate in children with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2007;17(5):675‐88. [DOI: 10.1089/cap.2006.0101; PUBMED: 17979587] ">Weiss 2007</a>; <a href="./references#CD012069-bbs2-0234" title="WigalSB , NordbrockE , AdjeiAL , ChildressA , KupperRJ , GreenhillL . Efficacy of methylphenidate hydrochloride extended‐release capsules (Aptensio XRTM) in children and adolescents with attention‐deficit/hyperactivity disorder: a phase III, randomized, double‐blind study. CNS Drugs2015;29(4):331‐40. ">Wigal 2015</a>). </p> <p>Twenty‐nine studies (16.4%) used immediate‐release methylphenidate only. Twenty‐two studies (12.4%) used combinations of methylphenidate‐immediate release and methylphenidate‐extended release, or combinations with placebo (<a href="./references#CD012069-bbs2-0003" title="AbbasiSH , HeidariS , MohammadiMR , TabriziM , GhaleihaA , AkhondzadehS . Acetyl‐L‐carnitine as an adjunctive therapy in the treatment of attention‐deficit/hyperactivity disorder in children and adolescents: a placebo‐controlled trial. Child Psychiatry and Human Development2011;42(3):367‐75. [DOI: 10.1007/s10578‐011‐0220‐y; PUBMED: 21336630] ">Abbasi 2011</a>; <a href="./references#CD012069-bbs2-0084" title="GhanizadehA , SayyariZ , MohammadiMR . Effect of methylphenidate and folic acid on ADHD symptoms and quality of life and aggression: a randomized double blind placebo controlled clinical trial. Iranian Journal of Psychiatry2013;8(3):108‐12. [PMC3887226; PUBMED: 24454418] ">Ghanizadeh 2013</a>). Fifteen studies (8.50%) did not specify dosage. </p> <p>Sixty‐three studies (35.6%) reported methylphenidate dosage in mg/kg/day, ranging from 0.30 mg/kg/day in <a href="./references#CD012069-bbs2-0061" title="EfronD . Methylphenidate versus dextroamphetamine in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry1999;38(5):500. [PUBMED: 10230180] EfronD , JarmanFC , BarkerMJ . Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder. Journal of Paediatrics and Child Health1998;34(3):288‐92. [DOI: 10.1046/j.1440‐1754.1998.00224.x] EfronD , JarmanFC , BarkerMJ . Medium‐term outcomes are comparable with short‐term outcomes in children with attention deficit hyperactivity disorder treated with stimulant medication. Journal of Paediatrics and Child Health2000;36(5):457‐61. [PUBMED: 11036801] EfronD , JarmanFC , BarkerMJ . Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial. Pediatrics1997;100(6):E6. [PUBMED: 9382907] EfronD , JarmanFC , BarkerMJ . Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial. Pediatrics1997;100(4):662‐6. [PUBMED: 9310521] ">Efron 1997</a> to 1.52 mg/kg/day in <a href="./references#CD012069-bbs2-0236" title="BiedermanJ . Evaluation of once‐daily OROS methylphenidate in children with attention‐deficit/hyperactivity disorder: effects on sleep, appetite, and tics. European Neuropsychopharmacology2003;13(Suppl 4):S447‐8. BiedermanJ . Treatment of attention‐deficit/hyperactivity disorder with the once‐daily OROS formulation of methylphenidate: effect on growth in children. European Neuropsychopharmacology2003;13(Suppl 4):S448‐9. FaraoneSV , BiedermanJ , ZimmermanB . An analysis of patient adherence to treatment during a 1‐year, open‐label study of OROS methylphenidate in children with ADHD. Journal of Attention Disorders2007;11(2):157‐66. [DOI: 10.1177/1087054706295663; PUBMED: 17494833] LernerMA , SpencerT . Analysis of growth in children with ADHD during long‐term therapy with once‐daily OROS® methylphenidate. Pediatric Academic Societies' Annual Meeting; 2004 May 1‐4; San Francisco (CA). 2004; Vol. 55. PalumboDR , StarrHL . Once‐daily OROS methylphenidate: Impact on tics in children with attention deficit hyperactivity disorder. Annals of Neurology2003;54(Suppl 7):S27. [DOI: 10.1002/ana.5049/epdf] SpencerTJ , FaraoneSV , BiedermanJ , LernerM , CooperKM , ZimmermanB , Concerta Study Group. Does prolonged therapy with a long‐acting stimulant suppress growth in children with ADHD?. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(5):527‐37. [DOI: 10.1097/01.chi.0000205710.01690.d4; PUBMED: 16670649] SpencerTJ , FaraoneSV , LernerM , CooperKM , ZimmermanB . Effect of long‐term treatment with stimulant medication on growth? Drs. Spencer et al. Reply. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(3):306. [DOI: 10.1097/chi.0b013e31802ed960] WigalSB , WilensTE , WolraichM , LernerM . Hematologic and blood biochemistry monitoring during methylphenidate treatment in children with attention‐deficit/hyperactivity disorder: 2‐year, open‐label study results. Pediatrics2007;120(1):e120‐8. [DOI: 10.1542/peds.2006‐1402] WilensT , BiedermanJ , LernerM , Concerta Study Group. Effects of once‐daily osmotic‐release methylphenidate on blood pressure and heart rate in children with attention‐deficit/hyperactivity disorder: results from a one‐year follow‐up study. Journal of Clinical Psychopharmacology2004;24(1):36‐41. [DOI: 10.1097/01.jcp.0000106223.36344.df; PUBMED: 14709945] WilensT , McBurnettK , SteinM , LernerM , SpencerT , WolraichM . ADHD treatment with once‐daily OROS methylphenidate: final results from a long‐term open‐label study. Journal of the American Academy of Child and Adolescent Psychiatry2005;44(10):1015‐23. [DOI: 10.1097/01.chi.0000173291.28688.e7; PUBMED: 16175106] WilensT , McBurnettK , SteinM , LernerM , SpencerT , WolraichM . ADHD treatment with once‐daily OROS methylphenidate: final results from a long‐term open‐label study: erratum. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(5):632. [DOI: 10.1097/00004583‐200605000‐00020] WilensT , PelhamW , SteinM , ConnersCK , AbikoffH , AtkinsM , et al. ADHD treatment with once‐daily OROS methylphenidate: interim 12‐month results from a long‐term open‐label study. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(4):424‐33. [DOI: 10.1097/01.CHI.0000046814.95464.7D; PUBMED: 12649629] ">Wilens 2005</a>. Twelve studies (6.80% of the total sample) used a dosage of 0.60 mg/kg/day or less (<a href="./references#CD012069-bbs2-0014" title="ArmanAR , YilmazS , CarkaxhiuG , SoysalD , AkalinF . Risk assessment using heart rate variability due to methylphenidate treatment in children with attention deficit hyperactivity disorder. European Child and Adolescent Psychiatry. 15th International Congress of European Society for Child and Adolescent Psychiatry (ESCAP); 2013 Jul 1; Dublin (Ireland). New York: Springer, 2013; Vol. 22:S302‐S303. ">Arman 2013</a>; <a href="./references#CD012069-bbs2-0020" title="AtzoriP , AncillettaB , UsalaT , DanjouF , ZuddasA . Predictive parameters for methylphenidate use and compliance in children with attention deficit hyperactivity disorder. European Neuropsychopharmacology2006;16(Suppl 1):S73‐4. [DOI: 10.1016/S0924‐977X(06)80087‐8] AtzoriP , UsalaT , CarucciS , DanjouF , ZuddasA . Predictive factors for persistent use and compliance of immediate‐release methylphenidate: a 36‐month naturalistic study. Journal of Child and Adolescent Psychopharmacology2009;19(6):673‐81. [DOI: 10.1089/cap.2008.0146; PUBMED: 20035585] ">Atzori 2009</a>; <a href="./references#CD012069-bbs2-0033" title="BruxelEM , Salatino‐OliveiraA , GenroJP , ZeniCP , PolanczykGV , ChazanR , et al. Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention‐deficit/hyperactivity disorder treated with methylphenidate. Pharmacogenomics Journal2013;13(5):476‐80. [DOI: 10.1038/tpj.2012.25; PUBMED: 22688218] ChazanR , BorowskiC , PiancaT , LudwigH , RohdeLA , PolanczykG . Do phenotypic characteristics, parental psychopathology, family functioning, and environmental stressors have a role in the response to methylphenidate in children with attention‐deficit/hyperactivity disorder? A naturalistic study from a developing count. Journal of Clinical Psychopharmacology2011;31(3):309‐17. [DOI: 10.1097/JCP.0b013e318217b4df; PUBMED: 21508864] Salatino‐OliveiraA , GenroJP , ZeniC , PolanczykGV , ChazanR , GuimarãesAP , et al. Catechol‐O‐methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention‐deficit/hyperactivity disorder. Biological Psychiatry2011;70(3):216‐21. [DOI: 10.1016/j.biopsych.2011.03.025; PUBMED: 21550019] ">Chazan 2011</a>; <a href="./references#CD012069-bbs2-0042" title="CongologluMA , TurkbayT , CiyiltepeM , DurukanI , DogangunB , YuceM . Immediate effects of methylphenidate on vocal acoustic parameters in children with attention deficit hyperactivity disorder. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2009;19(4):365‐72. ">Congologlu 2009</a>; <a href="./references#CD012069-bbs2-0053" title="DittmannRW , BanaschewskiT , SchachtA , WehmeierPM . Findings from the observational COMPLY study in children and adolescents with ADHD: core symptoms, ADHD‐related difficulties, and patients' emotional expression during psychostimulant or nonstimulant ADHD treatment. Attention Deficit and Hyperactivity Disorders2014;6(2014):291‐302. [DOI: 10.1007/s12402‐014‐0136‐z; PUBMED: 24705867] ">Dittmann 2014</a>; <a href="./references#CD012069-bbs2-0061" title="EfronD . Methylphenidate versus dextroamphetamine in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry1999;38(5):500. [PUBMED: 10230180] EfronD , JarmanFC , BarkerMJ . Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder. Journal of Paediatrics and Child Health1998;34(3):288‐92. [DOI: 10.1046/j.1440‐1754.1998.00224.x] EfronD , JarmanFC , BarkerMJ . Medium‐term outcomes are comparable with short‐term outcomes in children with attention deficit hyperactivity disorder treated with stimulant medication. Journal of Paediatrics and Child Health2000;36(5):457‐61. [PUBMED: 11036801] EfronD , JarmanFC , BarkerMJ . Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial. Pediatrics1997;100(6):E6. [PUBMED: 9382907] EfronD , JarmanFC , BarkerMJ . Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial. Pediatrics1997;100(4):662‐6. [PUBMED: 9310521] ">Efron 1997</a>; <a href="./references#CD012069-bbs2-0074" title="GargJ , ArunP , ChavanBS . Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. International Journal of Applied and Basic Medical Research2015;5(2):114‐8. [DOI: 10.4103/2229‐516X.157162; PMC4456885] GargJ , ArunP , ChavanBS . Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder. Indian Pediatrics2014;51(7):550‐4. [PUBMED: 25031133] ">Garg 2014</a>; <a href="./references#CD012069-bbs2-0092" title="GreenbergLM . An objective measure of methylphenidate response: clinical use of the MCA. Psychopharmacology Bulletin1987;23(2):279‐82. [PUBMED: 3615775] ">Greenberg 1987</a>; <a href="./references#CD012069-bbs2-0115" title="JohnsonKA , BarryE , LambertD , FitzgeraldM , McNicholasF , KirleyA , et al. Methylphenidate side effect profile is influenced by genetic variation in the attention‐deficit/hyperactivity disorder‐associated CES1 gene. Journal of Child and Adolescent Psychopharmacology2013;23(10):655‐64. [DOI: 10.1089/cap.2013.0032; PUBMED: 24350812] ">Johnson 2013</a>; <a href="./references#CD012069-bbs2-0165" title="MoungnoiP , MaipangP . Long‐term effects of short‐acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health. Journal of the Medical Association of Thailand2011;94(Suppl 3):S158‐63. [PUBMED: 22043770] ">Moungnoi 2011</a>; <a href="./references#CD012069-bbs2-0227" title="WangY , ZhengY , DuY , SongDH , ShinYJ , ChoSC , et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double‐blind comparison trial. Australian and New Zealand Journal of Psychiatry2007;41(3):222‐30. [DOI: 10.1080/00048670601057767; PUBMED: 17464703] ">Wang 2007</a>; <a href="./references#CD012069-bbs2-0256" title="ZeniCP , GuimarãesAP , PolanczykGV , GenroJP , RomanT , HutzMH , et al. No significant association between response to methylphenidate and genes of the dopaminergic and serotonergic systems in a sample of Brazilian children with attention‐deficit/hyperactivity disorder. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics2007;144B(3):391‐4. [DOI: 10.1002/ajmg.b.30474; PUBMED: 17171656] ">Zeni 2007</a>). </p> <p>One hundred and six (59.9%) studies reported methylphenidate dosage in mg/day, 64 studies (36.2%) reported dosage as a range, from 2.50 mg/day in <a href="./references#CD012069-bbs2-0151" title="MayesSD , CritesDL , BixlerEO , HumphreyFJ2nd , MattisonRE . Methylphenidate and ADHD: influence of age, IQ and neurodevelopmental status. Developmental Medicine and Child Neurology1994;36(12):1099‐107. [PUBMED: 7525394] ">Mayes 1994</a> and <a href="./references#CD012069-bbs2-0173" title="PereraH , JeewandaraKC , SeneviratneS , GurugeC . Assessment of outcome of an ADHD treatment program using parent feedback. Sri Lanka Journal of Psychiatry2010;1(2):51‐5. [DOI: 10.4038/sljpsyc.v1i2.2575] ">Perera 2010</a> to 120 mg/day in <a href="./references#CD012069-bbs2-0055" title="BeckerA , RoessnerV , BreuerD , DöpfnerM , RothenbergerA . Relationship between quality of life and psychopathological profile: data from an observational study in children with ADHD. European Child and Adolescent Psychiatry2011;20(Suppl 2):S267‐75. [DOI: 10.1007/s00787‐011‐0204‐2; PMC3180591; PUBMED: 21901415] BreuerD , Görtz‐DortenA , RothenbergerA , DöpfnerM . Assessment of daily profiles of ADHD and ODD symptoms, and symptomatology related to ADHD medication, by parent and teacher ratings. European Child and Adolescent Psychiatry2011;20(Suppl 2):S289‐96. [DOI: 10.1007/s00787‐011‐0206‐0; PMC3180560; PUBMED: 21901413] DöpfnerM , BreuerD , WalterD , RothenbergerA . An observational study of once‐daily modified‐release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality‐of‐life outcomes. European Child and Adolescent Psychiatry2011;20(Suppl 2):S277‐88. [DOI: 10.1007/s00787‐011‐0205‐1; PMC3098980; PUBMED: 21901414] DöpfnerM , Görtz‐DortenA , BreuerD , RothenbergerA . An observational study of once‐daily modified‐release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety. European Child and Adolescent Psychiatry2011;20(Suppl 2):S243‐55. [DOI: 10.1007/s00787‐011‐0202‐4; PMC3180616; PUBMED: 21901417] DöpfnerM , RothenbergerA , OseC . Assessment of Equasym XL under routine conditions by physicians, parents, teachers, and children. International Journal of Neuropsychopharmacology2008;11(Suppl 1):290. [DOI: 10.1017/S1461145708009462] Görtz‐DortenA , BreuerD , HautmannC , RothenbergerA , DöpfnerM . What contributes to patient and parent satisfaction with medication in the treatment of children with ADHD? A report on the development of a new rating scale. European Child and Adolescent Psychiatry2011; Vol. 20, issue Suppl 2:S297‐307. [DOI: 10.1007/s00787‐011‐0207‐z; PMC3180627] RothenbergerA , BeckerA , BreuerD , DöpfnerM . An observational study of once‐daily modified‐release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence. European Child and Adolescent Psychiatry2011;20(Suppl 2):257‐65. [DOI: 10.1007/s00787‐011‐0203‐3; PMC3180635] ">Döpfner 2011a, OBSEER</a>. </p> <p>Ninety‐seven studies (54.8%) reported mean dosage. The mean daily dose of methylphenidate‐immediate release was 0.67 mg/kg/day (13 studies) and 24.7 mg/day (19 studies). Mean daily dose ranged from 0.42 mg/kg/day in <a href="./references#CD012069-bbs2-0020" title="AtzoriP , AncillettaB , UsalaT , DanjouF , ZuddasA . Predictive parameters for methylphenidate use and compliance in children with attention deficit hyperactivity disorder. European Neuropsychopharmacology2006;16(Suppl 1):S73‐4. [DOI: 10.1016/S0924‐977X(06)80087‐8] AtzoriP , UsalaT , CarucciS , DanjouF , ZuddasA . Predictive factors for persistent use and compliance of immediate‐release methylphenidate: a 36‐month naturalistic study. Journal of Child and Adolescent Psychopharmacology2009;19(6):673‐81. [DOI: 10.1089/cap.2008.0146; PUBMED: 20035585] ">Atzori 2009</a> to 1 mg/kg/day in <a href="./references#CD012069-bbs2-0191" title="SchertzM , AdesmanAR , AlfieriNE , BienkowskiRS . Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication. Pediatrics1996;98(4 Pt 1):763‐9. [PUBMED: 8885958] ">Schertz 1996</a> and <a href="./references#CD012069-bbs2-0202" title="SpencerT , BiedermanJ , WrightV , DanonM . Growth deficits in children treated with desipramine: a controlled study. Journal of the American Academy of Child &amp; Adolescent Psychiatry1992;31(2):235‐43. [DOI: 10.1097/00004583‐199203000‐00009; PUBMED: 1564024] ">Spencer 1992</a>), and from 10 mg/day in <a href="./references#CD012069-bbs2-0134" title="LahatE , WeissM , Ben‐ShlomoA , EvansS , BistritzerT . Bone mineral density and turnover in children with attention‐deficit hyperactivity disorder receiving methylphenidate. Journal of Child Neurology2000;15(7):436‐9. [DOI: 10.1177/088307380001500702; PUBMED: 10921512] ">Lahat 2000</a> to 36.9 mg/day in <a href="./references#CD012069-bbs2-0130" title="HechtmanL , AbikoffH , KleinRG , WeissG , RespitzC , KouriJ , et al. Academic achievement and emotional status of children with ADHD treated with long‐term methylphenidate and multimodal psychosocial treatment. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(7):812‐9. [DOI: 10.1097/01.chi.0000128796.84202.eb; PUBMED: 15213582] KleinRG , AbikoffH , HechtmanL , WeissG . Design and rationale of controlled study of long‐term methylphenidate and multimodal psychosocial treatment in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry2004;43(7):792‐801. [DOI: 10.1097/01.chi.0000128798.91601.fe; PUBMED: 15213580] ">Klein 2004</a>. For methylphenidate‐extended release, the daily dose was, on average, 0.95 mg/kg/day (18 studies) and 26.8 mg/day (26 studies), ranging from 0.48 mg/kg/day (<a href="./references#CD012069-bbs2-0033" title="BruxelEM , Salatino‐OliveiraA , GenroJP , ZeniCP , PolanczykGV , ChazanR , et al. Association of a carboxylesterase 1 polymorphism with appetite reduction in children and adolescents with attention‐deficit/hyperactivity disorder treated with methylphenidate. Pharmacogenomics Journal2013;13(5):476‐80. [DOI: 10.1038/tpj.2012.25; PUBMED: 22688218] ChazanR , BorowskiC , PiancaT , LudwigH , RohdeLA , PolanczykG . Do phenotypic characteristics, parental psychopathology, family functioning, and environmental stressors have a role in the response to methylphenidate in children with attention‐deficit/hyperactivity disorder? A naturalistic study from a developing count. Journal of Clinical Psychopharmacology2011;31(3):309‐17. [DOI: 10.1097/JCP.0b013e318217b4df; PUBMED: 21508864] Salatino‐OliveiraA , GenroJP , ZeniC , PolanczykGV , ChazanR , GuimarãesAP , et al. Catechol‐O‐methyltransferase valine158methionine polymorphism moderates methylphenidate effects on oppositional symptoms in boys with attention‐deficit/hyperactivity disorder. Biological Psychiatry2011;70(3):216‐21. [DOI: 10.1016/j.biopsych.2011.03.025; PUBMED: 21550019] ">Chazan 2011</a>) to 1.18 mg/kg/day (<a href="./references#CD012069-bbs2-0036" title="ChouWJ , ChenSJ , ChenYS , LiangHY , LinCC , TangCS , et al. Remission in children and adolescents diagnosed with attention‐deficit/ hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate. Journal of Child and Adolescent Psychopharmacology2012;22(3):215‐25. [DOI: 10.1089/cap.2011.0006; PMC3373222; PUBMED: 22537358] ">Chou 2012a</a>), and from 7.50 mg/day (<a href="./references#CD012069-bbs2-0145" title="Dexmethylphenidate in youth with ADHD and Tourette's. Brown University Child and Adolescent Psychopharmacology Update2010;12(11):4‐5. [DOI: 10.1002/cpu.20127] LyonGJ , CoffeyB , CastellanosXF , WoodsD . Improving TIC‐related response inhibition: comparing the effects of dexmethylphenidate to placebo in children and adolescents with ADHD and chronic TIC disorders. International Journal of Neuropsychopharmacology2008;11(Suppl 1):292. LyonGJ , CoffeyB , WoodsD , SamarS , ConeleaC , BauerCC , et al. Improving tic‐related response inhibition: comparing the effects of dexmethylphenidate to no medication in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) and chronic tic disorders. Journal of Child and Adolescent Psychopharmacology2010;20(6):537‐8. [DOI: 10.1089/cap.2010.2064] LyonGJ , SamarSM , ConeleaC , TrujilloMR , LipinskiCM , BauerCC , et al. Testing tic suppression: comparing the effects of dexmethylphenidate to no medication in children and adolescents with attention‐deficit/hyperactivity disorder and Tourette's disorder. Journal of Child and Adolescent Psychopharmacology2010;20(4):283‐9. [DOI: 10.1089/cap.2010.0032] ">Lyon 2010</a>) to 60 mg/day (<a href="./references#CD012069-bbs2-0055" title="BeckerA , RoessnerV , BreuerD , DöpfnerM , RothenbergerA . Relationship between quality of life and psychopathological profile: data from an observational study in children with ADHD. European Child and Adolescent Psychiatry2011;20(Suppl 2):S267‐75. [DOI: 10.1007/s00787‐011‐0204‐2; PMC3180591; PUBMED: 21901415] BreuerD , Görtz‐DortenA , RothenbergerA , DöpfnerM . Assessment of daily profiles of ADHD and ODD symptoms, and symptomatology related to ADHD medication, by parent and teacher ratings. European Child and Adolescent Psychiatry2011;20(Suppl 2):S289‐96. [DOI: 10.1007/s00787‐011‐0206‐0; PMC3180560; PUBMED: 21901413] DöpfnerM , BreuerD , WalterD , RothenbergerA . An observational study of once‐daily modified‐release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality‐of‐life outcomes. European Child and Adolescent Psychiatry2011;20(Suppl 2):S277‐88. [DOI: 10.1007/s00787‐011‐0205‐1; PMC3098980; PUBMED: 21901414] DöpfnerM , Görtz‐DortenA , BreuerD , RothenbergerA . An observational study of once‐daily modified‐release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety. European Child and Adolescent Psychiatry2011;20(Suppl 2):S243‐55. [DOI: 10.1007/s00787‐011‐0202‐4; PMC3180616; PUBMED: 21901417] DöpfnerM , RothenbergerA , OseC . Assessment of Equasym XL under routine conditions by physicians, parents, teachers, and children. International Journal of Neuropsychopharmacology2008;11(Suppl 1):290. [DOI: 10.1017/S1461145708009462] Görtz‐DortenA , BreuerD , HautmannC , RothenbergerA , DöpfnerM . What contributes to patient and parent satisfaction with medication in the treatment of children with ADHD? A report on the development of a new rating scale. European Child and Adolescent Psychiatry2011; Vol. 20, issue Suppl 2:S297‐307. [DOI: 10.1007/s00787‐011‐0207‐z; PMC3180627] RothenbergerA , BeckerA , BreuerD , DöpfnerM . An observational study of once‐daily modified‐release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence. European Child and Adolescent Psychiatry2011;20(Suppl 2):257‐65. [DOI: 10.1007/s00787‐011‐0203‐3; PMC3180635] ">Döpfner 2011a, OBSEER</a>). </p> </section> </section> <section id="CD012069-sec-0079"> <h6 class="title">Cross‐sectional studies</h6> <p>We included two cross‐sectional studies described in two publications (<a href="./references#CD012069-bbs2-0205" title="StevensJR , GeorgeRA , FusilloS , SternTA , WilensTE . Plasma methylphenidate concentration in youths treated with high‐dose osmotic release oral system formulation. Journal of Child and Adolescent Psychopharmacology2010;20(1):49‐54. [DOI: 10.1089/cap.2008.0128; PUBMED: 20166796] ">Stevens 2010</a>; <a href="./references#CD012069-bbs2-0212" title="ThorellLB , DahlströmK . Children's self‐reports on perceived effects on taking stimulant medication for ADHD. Journal of Attention Disorders2009;12(5):460‐8. [DOI: 10.1177/1087054708320430; PUBMED: 18685139] ">Thorell 2009</a>). </p> <section id="CD012069-sec-0080"> <p><b>Location</b></p> <p><a href="./references#CD012069-bbs2-0212" title="ThorellLB , DahlströmK . Children's self‐reports on perceived effects on taking stimulant medication for ADHD. Journal of Attention Disorders2009;12(5):460‐8. [DOI: 10.1177/1087054708320430; PUBMED: 18685139] ">Thorell 2009</a> took place in Sweden and <a href="./references#CD012069-bbs2-0205" title="StevensJR , GeorgeRA , FusilloS , SternTA , WilensTE . Plasma methylphenidate concentration in youths treated with high‐dose osmotic release oral system formulation. Journal of Child and Adolescent Psychopharmacology2010;20(1):49‐54. [DOI: 10.1089/cap.2008.0128; PUBMED: 20166796] ">Stevens 2010</a> in the USA. </p> </section> <section id="CD012069-sec-0081"> <p><b>Setting</b></p> <p><a href="./references#CD012069-bbs2-0205" title="StevensJR , GeorgeRA , FusilloS , SternTA , WilensTE . Plasma methylphenidate concentration in youths treated with high‐dose osmotic release oral system formulation. Journal of Child and Adolescent Psychopharmacology2010;20(1):49‐54. [DOI: 10.1089/cap.2008.0128; PUBMED: 20166796] ">Stevens 2010</a> was carried out in both inpatient and outpatient clinics, whereas <a href="./references#CD012069-bbs2-0212" title="ThorellLB , DahlströmK . Children's self‐reports on perceived effects on taking stimulant medication for ADHD. Journal of Attention Disorders2009;12(5):460‐8. [DOI: 10.1177/1087054708320430; PUBMED: 18685139] ">Thorell 2009</a> was an outpatient study. </p> </section> <section id="CD012069-sec-0082"> <p><b>Participants</b></p> <p>The two cross‐sectional studies included a total of 96 participants, all of whom were aged between 9 and 20 years. In one study, participants were eligible for inclusion if diagnosed with ADHD and treated with higher than FDA‐approved doses of methylphenidate (&gt; 72 mg/d) between December 2006 and August 2007 (<a href="./references#CD012069-bbs2-0205" title="StevensJR , GeorgeRA , FusilloS , SternTA , WilensTE . Plasma methylphenidate concentration in youths treated with high‐dose osmotic release oral system formulation. Journal of Child and Adolescent Psychopharmacology2010;20(1):49‐54. [DOI: 10.1089/cap.2008.0128; PUBMED: 20166796] ">Stevens 2010</a>). Seventeen participants were included in the analysis. The most common comorbid disorder with ADHD was mood disorders followed by pervasive development disorders and oppositional disorders. The other study included 79 children between the ages of 9 and 17 years receiving stimulant medication (<a href="./references#CD012069-bbs2-0212" title="ThorellLB , DahlströmK . Children's self‐reports on perceived effects on taking stimulant medication for ADHD. Journal of Attention Disorders2009;12(5):460‐8. [DOI: 10.1177/1087054708320430; PUBMED: 18685139] ">Thorell 2009</a>). The included participants had the following comorbid diagnoses: Asperger's syndrome (n = 6), Tourette syndrome (n = 11), obsessive‐compulsive disorder (n = 2), mild mental retardation (n = 2), and oppositional defiant disorder or conduct disorder (n = 2). </p> </section> <section id="CD012069-sec-0083"> <p><b>Interventions</b></p> <p>In <a href="./references#CD012069-bbs2-0205" title="StevensJR , GeorgeRA , FusilloS , SternTA , WilensTE . Plasma methylphenidate concentration in youths treated with high‐dose osmotic release oral system formulation. Journal of Child and Adolescent Psychopharmacology2010;20(1):49‐54. [DOI: 10.1089/cap.2008.0128; PUBMED: 20166796] ">Stevens 2010</a>, all participants were treated with osmotic‐release oral‐system (OROS) methylphenidate. The mean total daily dose was 169 mg/day (SD 31 mg/day; range 126 mg/day to 270 mg/day) or 2.97 mg/day (SD 0.76 mg/kg/day; range 1.13 mg/kg/day to 4.21 mg/kg/day). All patients received concomitant psychotropic medication during the evaluation period. Bupropion, selective serotonin re‐uptake inhibitors, and lithium were the most commonly medications coadministered with OROS methylphenidate. </p> <p>Nearly all (96.0%) the children in <a href="./references#CD012069-bbs2-0212" title="ThorellLB , DahlströmK . Children's self‐reports on perceived effects on taking stimulant medication for ADHD. Journal of Attention Disorders2009;12(5):460‐8. [DOI: 10.1177/1087054708320430; PUBMED: 18685139] ">Thorell 2009</a> took methylphenidate, whereas 4.0% took amphetamine. The authors did not report methylphenidate type or dosage. </p> </section> </section> <section id="CD012069-sec-0084"> <h6 class="title">Patient reports/series</h6> <p>We included 70 patient reports/series described in 75 publications (<a href="http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007470.pub3/full#CD007470-fig-0001" target="_blank">Figure 1</a>). Nineteen reports were from the USA; 16 from Turkey; five each from Israel (<a href="./references#CD012069-bbs2-0017" title="ArtulS , ArtoulF , HabibG , NseirW , BisharatB , NijimY . Severe recurrent pancreatitis in a child with ADHD after starting treatment with methylphenidate (Ritalin). Case Reports in Gastrointestinal Medicine2014;2014:319162. [DOI: 10.1155/2014/319162; PMC3965929; PUBMED: 24711932; PUBMED: 24711932] ">Artul 2014</a>; <a href="./references#CD012069-bbs2-0039" title="CohenHA , AshkenaziA , NussinovitchM , GrossS , FrydmanM . Fixed drug eruption of the scrotum due to methylphenidate. Annals of Pharmacotherapy1992;26(11):1378‐9. [DOI: 10.1177/106002809202601107; PUBMED: 1477441] ">Cohen 1992</a>; <a href="./references#CD012069-bbs2-0041" title="Confino‐CohenR , GoldbergA . Successful desensitization of methylphenidate‐induced rash. Journal of Child and Adolescent Psychopharmacology2005;15(4):703‐5. [DOI: 10.1089/cap.2005.15.703; PUBMED: 16190802] ">Confino‐Cohen 2005</a>; <a href="./references#CD012069-bbs2-0095" title="Gross‐TsurV , JosephA , ShalevRS . Hallucinations during methylphenidate therapy. Neurology2004;63(4):753‐4. [PUBMED: 15326264] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] ">Gross‐Tsur 2004</a>; <a href="./references#CD012069-bbs2-0099" title="HalevyA , ShuperA . Methylphenidate induction of complex visual hallucinations. Journal of Child Neurology2009;24(8):1005‐7. [DOI: 10.1177/0883073808331357; PUBMED: 19502578] ">Halevy 2009</a>) and the UK (<a href="./references#CD012069-bbs2-0004" title="AdrianN . Explosive outbursts associated with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(6):618‐9. [DOI: 10.1097/00004583‐200106000‐00002; PUBMED: 11392335] ">Adrian 2001</a>; <a href="./references#CD012069-bbs2-0043" title="CorrigallR , FordT . Methylphenidate euphoria. Journal of the American Academy of Child and Adolescent Psychiatry1996;35(11):1421. [DOI: 10.1097/00004583‐199611000‐00005; PUBMED: 8936903] ">Corrigall 1996</a>; <a href="./references#CD012069-bbs2-0106" title="HollisCP , ThompsonA . Acute dyskinesia on starting methylphenidate after risperidone withdrawal. Pediatric Neurology2007;37(4):287‐8. [DOI: 10.1016/j.pediatrneurol.2007.05.017; PUBMED: 17903675] ">Hollis 2007</a>; <a href="./references#CD012069-bbs2-0196" title="ShibibS , ChalhoubN . Stimulant induced psychosis. Child and Adolescent Mental Health2009;14(1):20‐3. [DOI: 10.1111/j.1475‐3588.2008.00490.x] ">Shibib 2009</a>; <a href="./references#CD012069-bbs2-0244" title="WoolleyJB , HeymanI . Dexamphetamine for obsessive‐compulsive disorder. American Journal of Psychiatry2003;160(1):183. ">Woolley 2003</a>); four each from Iran (<a href="./references#CD012069-bbs2-0079" title="GhanizadehA . Insomnia, night terror, and depression related to clonidine in attention‐deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology2008;28(6):725‐6. [DOI: 10.1097/JCP.0b013e31818ce741; PUBMED: 19011458] ">Ghanizadeh 2008a</a>; <a href="./references#CD012069-bbs2-0080" title="GhanizadehA . Methylphenidate‐associated enuresis in attention deficit hyperactivity disorder. Journal of Pediatric Urology2008;4(4):306‐7. [DOI: 10.1016/j.jpurol.2007.10.001; PUBMED: 18644535] ">Ghanizadeh 2008b</a>; <a href="./references#CD012069-bbs2-0081" title="GhanizadehA . Questions regarding 'Insomnia, night terror, and depression related to clonidine in attention‐deficit/hyperactivity disorder' [personal communication]. Email to: EL Ramstad 4 July 2013. GhanizadehA , AghakhaniK . Photophobia and methylphenidate. Psychopharmacology Bulletin2008;41(1):171‐3. [PUBMED: 18362880] ">Ghanizadeh 2008c</a>; <a href="./references#CD012069-bbs2-0082" title="GhanizadehA . Excessive talking triggered by methylphenidate in a boy with ADHD. Pharmacopsychiatry2009;42(1):35‐6. [DOI: 10.1055/s‐0028‐1083821; PUBMED: 19153945] ">Ghanizadeh 2009</a>) and Spain (<a href="./references#CD012069-bbs2-0006" title="Aguilera‐AlbesaS , Yoldi‐PetriME , Molins‐CastiellaT , Durá‐TravéT . Hallucinations caused by the introduction of methylphenidate at low doses. Revista de Neurologia2010;51(4):254‐5. [PUBMED: 20648469] ">Aguilera‐Albesa 2010</a>; <a href="./references#CD012069-bbs2-0067" title="Fernández‐FernándezMA , Rufo‐CamposM , Mateos‐ChecaR , Muñoz‐CabelloB , Madruga‐GarridoM , Blanco‐MartínezB . Cardiovascular side effects secondary to treatment with methylphenidate [Reacciones adversas cardiovasculares secundarias al tratamiento con metilfenidato]. Revista de Neurologia2010;50(9):573‐4. [PUBMED: 20443179] ">Fernández‐Fernández 2010</a>; <a href="./references#CD012069-bbs2-0068" title="Fernández‐FernándezMA , Rufo‐CamposM , Mateos‐ChecaR , Muñoz‐CabelloB , Madruga‐GarridoM , Blanco‐MartínezB . Infantile psychosis secondary to methylphenidate. Revista de Neurologia2011;52(7):446‐7. [PUBMED: 21425116] ">Fernández‐Fernández 2011</a>; <a href="./references#CD012069-bbs2-0213" title="Tomás VilaM , Izquierdo QuevedoFJ , Cerdán VeraMT , FernándezA , Artás FigueresM , Revert GomasM . Visual hallucinations caused by methylphenidate. Anales de Pediatria2010;72(3):229‐30. [DOI: 10.1016/j.anpedi.2009.10.013; PUBMED: 20097145] ">Tomás Vila 2010a</a>); three from Italy (<a href="./references#CD012069-bbs2-0168" title="NiederhoferH . Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?. Psychiatria Danubina2009;21(3):330. [PUBMED: 19794351] NiederhoferH . Questions regarding your study 'Combining carbamazepine, neuroleptics and acetylcholinesterase inhibitors with methylphenidate only reduces adverse side effects, but is less effective than a combination with atomoxetine' [personal communication]. Email to: HB Krogh 31 July 2013. ">Niederhofer 2009</a>; <a href="./references#CD012069-bbs2-0169" title="NiederhoferH . Combining carbamazepine, neuroleptics and acetylcholinesterase inhibitors with methylphenidate only reduces adverse side effects, but is less effective than a combination with atomoxetine. Medical Hypotheses2011;76(5):764‐5. [DOI: 10.1016/j.mehy.2011.02.011; PUBMED: 21397406] ">Niederhofer 2011</a>; <a href="./references#CD012069-bbs2-0177" title="PorfirioMC , GianaG , GiovinazzoS , CuratoloP . Methylphenidate‐induced visual hallucinations. Neuropediatrics2011;42(1):30‐1. [DOI: 10.1055/s‐0031‐1275738; PUBMED: 21500140] ">Porfirio 2011</a>); two each from Germany (<a href="./references#CD012069-bbs2-0027" title="BernhardMK , HugleB , MerkenschlagerA . Elevated liver enzymes under therapy with methylphenidate in a boy with T‐cell leukemia. Journal of Pediatric Neurology2009; Vol. 7, issue 3:297‐9. [DOI: 10.3233/JPN‐2009‐0303] ">Bernhard 2009</a>; <a href="./references#CD012069-bbs2-0107" title="HoltkampK , Peters‐WallrafB , WullerS , PfäaffleR , Herpertz‐DahlmannB . Methylphenidate‐related growth impairment. Journal of Child and Adolescent Psychopharmacology2002;12(1):55‐61. [DOI: 10.1089/10445460252943579; PUBMED: 12014596] ">Holtkamp 2002</a>), India (<a href="./references#CD012069-bbs2-0005" title="AgarwalV , SitholeyP . Combination of atomoxetine and methylphenidate in attention deficit/hyperactivity disorder: a case report. Journal of the Canadian Academy of Child and Adolescent Psychiatry2008;17(3):160. [PMC2527769] ">Agarwal 2008</a>; <a href="./references#CD012069-bbs2-0018" title="ArunP , SahniS . Methylphenidate and suicidal ideation: report of two cases. Indian Journal of Psychiatry2014;56(1):79‐81. [DOI: 10.4103/0019‐5545.124721; PMC3927251] ">Arun 2014</a>), and Norway (<a href="./references#CD012069-bbs2-0170" title='GhanizadehA . A commentary on "A young man with acute dilated cardiomyopathy associated with methylphenidate". Vascular Health and Risk Management2009;5(2):525‐6. [DOI: 10.2147/VHRM.S5108] NymarkTB , HovlandA , BjørnstadH , NielsenEW . A young man with acute dilated cardiomyopathy associated with methylphenidate. Vascular Health and Risk Management2008;4(2):477‐9. [PMC2496981; PUBMED: 18561524] '>Nymark 2008</a>; <a href="./references#CD012069-bbs2-0217" title="TølløfsrudC , HoelT . A young man with acute dilated cardiomyopathy. Tidsskrift for Den Norske Laegeforening2006;126(10):1338‐9. [PUBMED: 16715575] ">Tølløfsrud 2006</a>); and one each from Canada (<a href="./references#CD012069-bbs2-0104" title="HechtmanL . Treatment of ADHD in patients unresponsive to methylphenidate. Journal of Psychiatry and Neuroscience2011;36(3):216. [DOI: 10.1503/jpn.110020; PMC3080516] ">Hechtman 2011</a>), Chile (<a href="./references#CD012069-bbs2-0188" title="SaiehAC . Methylphenidate: arterial hypertension, a side effect to take into account [Metilfenidato: hipertensión arterial, un efecto a tener en cuenta]. Revista Chilena de Pediatria2004;75(1):80‐1. [DOI: 10.4067/S0370‐41062004000100014] ">Saieh 2004</a>), the Czech Republic (<a href="./references#CD012069-bbs2-0085" title="GoetzM , PrihodovaI , HrdlickaM . Long lasting complex nocturnal hallucinations during Osmotic Release Oral System (OROS) methylphenidate treatment in a 7‐year old girl. Neuro Endocrinology Letters2011;32(5):619‐22. [PUBMED: 22167138] ">Goetz 2011</a>), Denmark (<a href="./references#CD012069-bbs2-0166" title="MunkK , GormsenL , KimWY , AndersenNH . Cardiac arrest following a myocardial infarction in a child treated with methylphenidate. Case Reports in Pediatrics2015;2015:905097. [DOI: 10.1155/2015/905097] ">Munk 2015</a>), France (<a href="./references#CD012069-bbs2-0040" title="CoignouxY , EstingoyP , BastardA . From hyperactivity to schizophrenia? Clinical, neurobiological and therapeutic discussion of a case [De l'hyperactivité à la schizophrénie? Discussion clinique, neurobiologique et thérapeutique, à propos d'un cas]. Annales Médico‐psychologiques, Revue Psychatrique2009;167(1):57‐65. [DOI: 10.1016/j.amp.2008.11.006] ">Coignoux 2009</a>), Japan (<a href="./references#CD012069-bbs2-0156" title="MinoY , AokiS . Methylphenidate‐induced psychosis in an adolescent with hyperkinetic disorder. Kawasaki Medical Journal1999;25(2):81‐5. [DOI: 10.11482/KMJ25(2)81‐85.1999.pdf] MinoY , OharaH , NagamatsuI , NagamatsuK . Methylphenidate psychosis in an adolescent with attention deficit disorder. Japanese Journal of Child and Adolescent Psychiatry1986; Vol. 27, issue 3:178‐87. ">Mino 1999</a>), Sweden (<a href="./references#CD012069-bbs2-0206" title="StrandellJ , StarrK . Reports of suicide related behaviour with methylphenidate and atomoxetine in children and adolescents. Drug Safety2007;30(10):919‐90. [DOI: 10.2165/00002018‐200730100‐00105] ">Strandell 2007</a>), and Taiwan (<a href="./references#CD012069-bbs2-0209" title="TangCS , ChouWJ , ChengAT . Osmotic release oral system (OROS) methylphenidate‐induced double incontinence: a case report. Primary Care Companion to the Journal of Clinical Psychiatry2010;12(3):PCC.09l00870. [DOI: 10.4088/PCC.09l00870pur; PMC2947529] ">Tang 2010</a>). The 70 patient reports/series included a total of 206 participants. A single report from a pharmacovigilance programme accounted for 116 of these (<a href="./references#CD012069-bbs2-0206" title="StrandellJ , StarrK . Reports of suicide related behaviour with methylphenidate and atomoxetine in children and adolescents. Drug Safety2007;30(10):919‐90. [DOI: 10.2165/00002018‐200730100‐00105] ">Strandell 2007</a>). </p> <p>All participants were aged between 4 and 20 years, with a mean age of 10 years. Seventy participants were male, 20 were female, and the sex for the remaining 116 patients was not stated. The participants were treated with both immediate‐release and extended‐release formulations of methylphenidate, and the doses ranged from 10 mg/day to 108 mg/day. The duration of treatment ranged from one day in <a href="./references#CD012069-bbs2-0148" title="MachadoA , CerqueiraJ , RodriguesM , Soares‐FernandesJ . Is methylphenidate‐induced chorea responsive to chlorpromazine?. Journal of Neuropsychiatry and Clinical Neurosciences2010;22(3):352.e20. [DOI: 10.1176/jnp.2010.22.3.352.e20; PUBMED: 20686158] ">Machado 2010</a> to 17 years in <a href="./references#CD012069-bbs2-0180" title="RamasamyR , DadhichP , DhingraA , LipshultzL . Case report: testicular failure possibly associated with chronic use of methylphenidate. F1000Research2014;3:207. [DOI: 10.12688/f1000research.5163.1; PMC4215747; PUBMED: 25383187] ">Ramasamy 2014</a>. </p> </section> </section> <section id="CD012069-sec-0085"> <h5 class="title">Outcome measures: serious and non‐serious adverse events</h5> <p>Adverse events were measured by rating scales, including questionnaires and checklists, by spontaneous reports and/or were recorded by investigators at regular interviews or visits. </p> <p>Some studies included specific measurements such as physical examinations, para‐clinical examinations, or both, including blood testing, electrocardiogram (ECG), blood pressure reading, measurement of heart rate and assessment of weight and height. </p> <p>Serious adverse events were recorded in accordance with the International Conference of Harmonization (ICH) classification (<a href="./references#CD012069-bbs2-0539" title="International Council for Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice E6(R1) 1996. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (accessed 6 May 2011). ">ICH 1996</a>). </p> <p>Some studies combined some or all of the above modes of measurement; others used a single measure such as spontaneous reports or rating scales. </p> <p>Investigators used the Barkley Side Effects Rating Scale most frequently (<a href="./references#CD012069-bbs2-0425" title="BarkleyRA , McMurrayMB , EdelbrockCS , RobbinsK . Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo‐controlled evaluation. Pediatrics1990;86(2):184‐192. [PUBMED: 2196520] ">Barkley 1990</a>). Other scales used included the Safety Monitoring Uniform Report Form (<a href="./references#CD012069-bbs2-0504" title="GreenhillLL , VitielloB , FisherP , LevineJ , DaviesM , AbikoffH , et al. Comparison of increasingly detailed elicitation methods for the assessment of adverse events in pediatric psychopharmacology. Journal of the American Academy of Child and Adolescent Psychiatry2004; Vol. 43, issue 12:1488‐96. [DOI: 10.1097/01.chi.0000142668.29191.13; PUBMED: 15564818] ">Greenhill 2004</a>), the Pittsburgh Side Effects Rating Scale (<a href="./references#CD012069-bbs2-0600" title="PelhamWEJr . Pharmacotherapy for children with attention‐deficit hyperactivity disorder. School Psychology Review1993;22(2):199‐227. ">Pelham 1993</a>; <a href="./references#CD012069-bbs2-0602" title="PelhamWE , Burrows‐MacLeanL , GnagyEM , FabianoGA , ColesEK , TrescoKE , et al. Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Experimental and Clinical Psychopharmacology2005;13(2):111‐26. [DOI: 10.1037/1064‐1297.13.2.111; PUBMED: 15943544] ">Pelham 2005</a>), and the Clinical Assessment of Side Effects. </p> <p>For measuring specific adverse events, some studies used rating scales such as the Children's Depression inventory (<a href="./references#CD012069-bbs2-0555" title="KovacsM . Children's Depression Inventory. North Tonawanda (NY): Multi‐Health Systems, Inc, 1992. ">Kovacs 1992</a>), the Children's Yale‐Brown Obsessive‐Compulsive Scale (<a href="./references#CD012069-bbs2-0623" title="ScahillL , RiddleMA , McSwiggin‐HardinM , OrtSI , KingRA , GoodmanWK , et al. Children's Yale‐Brown Obsessive Compulsive Scale: reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(6):844‐52. [DOI: 10.1097/00004583‐199706000‐00023; PUBMED: 9183141] ">Scahill 1997</a>), the Revised Children's Manifest Anxiety Scale (<a href="./references#CD012069-bbs2-0617" title="ReynoldsCR , RichmondBO . Revised Children's Manifest Anxiety Scale. RCMAS Manual. Los Angeles (CA): Western Psychological Services, 1985. ">Reynolds 1985</a>), the Yale Global Tic Severity Scale (<a href="./references#CD012069-bbs2-0561" title="LeckmanJF , RiddleMA , HardinMT , OrtSI , SwartzKL , StevensonJ , et al. The Yale Global Tic Severity Scale: initial testing of a clinician‐rated scale of tic severity. Journal of the American Academy of Child and Adolescent Psychiatry1989;28(4):566‐73. ">Leckman 1989</a>), the Sleep Disturbances Scale for Children (<a href="./references#CD012069-bbs2-0433" title="BruniO , OttavianoS , GuidettiV , RomoliM , InnocenziM , CortesiF , et al. The Sleep Disturbance Scale for Children (SDSC). Construction and validation of an instrument to evaluate sleep disturbances in childhood and adolescence. Journal of Sleep Research1996;5(4):251‐61. [PUBMED: 9065877] ">Bruni 1996</a>), the Children's Sleep Habits Questionnaire (<a href="./references#CD012069-bbs2-0594" title="OwensJA , SpiritoA , McGuinnM . The Children's Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school‐aged children. Sleep2000;23(8):1043‐51. ">Owens 2000</a>), and the Paediatric Sleep Questionnaire (<a href="./references#CD012069-bbs2-0448" title="ChervinRD , HedgerK , DillonJE , PituchKJ . Pediatric Sleep Questionnaire (PSQ): validity and reliability of scales for sleep‐disordered breathing, snoring, sleepiness, and behavioral problems. Sleep Medicine2000;1(1):21‐32. [PUBMED: 10733617] ">Chervin 2000</a>). </p> <section id="CD012069-sec-0086"> <h6 class="title">Comparative cohort studies</h6> <p>In the seven comparative studies that we included, four studies employed a rating scale (<a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>; <a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>; <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>; <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>), two used a specific measurement (<a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>; <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>), and one used diagnostic assessment (<a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>). <a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a> also used a subjective pictorial scale designed specifically for the study. </p> </section> <section id="CD012069-sec-0087"> <h6 class="title">Patient‐control studies</h6> <p>In the four included patient‐control studies, two used spontaneous reporting (<a href="./references#CD012069-bbs2-0021" title="AyazM , AyazAB , SoyluN , YükselS . Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598] ">Ayaz 2014</a>; <a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>), two used a specific measurement (<a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>), and one used diagnostic assessment (<a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>). Accordingly, one study used both spontaneous reporting and a specific measurement (<a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>). </p> </section> <section id="CD012069-sec-0088"> <h6 class="title">Cohort studies</h6> <p>Of the 177 included cohort studies, 84 employed a checklist, questionnaire, or rating scale. Sixty‐nine studies used a specific physiological measurement, such as heart rate or blood pressure, 26 used spontaneous reporting, and 44 used some other method to assess adverse events. Several studies used more than one mode of measurement. </p> </section> <section id="CD012069-sec-0089"> <h6 class="title">Cross‐sectional studies</h6> <p>Of the two included cross‐sectional studies, <a href="./references#CD012069-bbs2-0205" title="StevensJR , GeorgeRA , FusilloS , SternTA , WilensTE . Plasma methylphenidate concentration in youths treated with high‐dose osmotic release oral system formulation. Journal of Child and Adolescent Psychopharmacology2010;20(1):49‐54. [DOI: 10.1089/cap.2008.0128; PUBMED: 20166796] ">Stevens 2010</a> used spontaneous reports, and <a href="./references#CD012069-bbs2-0212" title="ThorellLB , DahlströmK . Children's self‐reports on perceived effects on taking stimulant medication for ADHD. Journal of Attention Disorders2009;12(5):460‐8. [DOI: 10.1177/1087054708320430; PUBMED: 18685139] ">Thorell 2009</a> used a questionnaire to measure adverse events. </p> </section> <section id="CD012069-sec-0090"> <h6 class="title">Patient reports/series</h6> <p>Of the 70 included patient reports/series, 68 had spontaneous reporting of adverse events. One study used both spontaneous reporting and a rating scale (<a href="./references#CD012069-bbs2-0049" title="CoşkunM . Methylphenidate induced obsessive‐compulsive symptoms treated with sertraline. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2011;21(3):274. [DOI: 10.5455/bcp.20110904061403] ">Coşkun 2011</a>), one study used only a rating scale (<a href="./references#CD012069-bbs2-0182" title="RapportMD , LooS , IsaacsP , GoyaS , DenneyC , ScanlanS . Methylphenidate and attentional training. Comparative effects on behavior and neurocognitive performance in twin girls with attention‐deficit/hyperactivity disorder. Behavior Modification1996;20(4):428‐50. [DOI: 10.1177/01454455960204004; PUBMED: 8875814] ">Rapport 1996</a>), and one study used ophthalmic examination (<a href="./references#CD012069-bbs2-0143" title="LewisH , LewisJ . Safe and effective methylphenidate therapy in a pediatric patient with glaucoma. ADHD Attention Deficit and Hyperactivity Disorders2012; Vol. 4, issue 1:37‐9. [DOI: 10.1007/s12402‐012‐0071‐9; PUBMED: 22311620] ">Lewis 2012</a>). </p> </section> </section> <section id="CD012069-sec-0091"> <h5 class="title">Funding</h5> <p>Pharmaceutical companies funded 53 out of the 177 non‐comparative cohort studies, and 11 out of the 177 had authors with connections to pharmaceutical advisory boards. Forty‐five out of the 177 did not report a source of funding, and 68 out of 177 were not funded by or affiliated with pharmaceutical industries. </p> <p>We performed two subgroup analyses investigating the differences in the proportion of adverse events in studies funded by industry and studies not funded by industry, and we found large differences, with many more adverse events (both serious and non‐serious) in the studies not funded by industry (see Subgroup analyses, under <a href="#CD012069-sec-0106">Effects of interventions</a>). </p> </section> </section> <section id="CD012069-sec-0092"> <h4 class="title">Excluded studies</h4> <p>We took an inclusive approach by assessing 2318 full‐text reports for eligibility against our inclusion criteria (<a href="#CD012069-sec-0030">Criteria for considering studies for this review</a>). We subsequently excluded 1285 reports as ineligible: 691 reported on RCTs (those containing new data will be included in an update of our systematic review; <a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>), and 594 others either did not report data on adverse events; had ineligible study designs; involved polypharmacy; lacked an ADHD diagnosis; had ineligible interventions; had no data; focused on adults, patients with intellectual disability, or other ineligible patient populations; or otherwise failed to meet the inclusion criteria. </p> <p>In addition, we formally excluded 112 studies (from 121 reports) because they did not report anything about the presence or absence of adverse events. Furthermore, most of these studies had outcomes outside of the focus of this review such as visual attention, reaction time, memory skills, and functional abnormalities. Please see the <a href="./references#CD012069-sec-0278" title="">Characteristics of excluded studies</a> tables. See <a href="#CD012069-sec-0275">Differences between protocol and review</a>. </p> <section id="CD012069-sec-0093"> <h5 class="title">Studies awaiting classification</h5> <p>We included 15 studies awaiting classification (<a href="./references#CD012069-bbs2-0372" title="Arnold‐von SaherRA , BoerF , BurggraafJ . The clinical use of a double‐blind placebo‐controlled trial with methylphenidate: advantages and limitations [Pleidooi voor een dubbelblinde proefbehandeling met methylfenidaat in de dagelijkse klinische praktijk van ADHD bij kinderen]. Tijdschrift voor Psychiatrie2000;42(11):837‐44. ">Arnold‐Von 2000</a>; <a href="./references#CD012069-bbs2-0373" title="DalsgaardS , KvistAP , LeckmanJF , NielsenHS , SimonsenM . Cardiovascular safety of stimulants in children with attention‐deficit/hyperactivity disorder: a nationwide prospective cohort study. Journal of Child and Adolescent Psychopharmacology2014;24(6):1‐9. [DOI: 10.1089/cap.2014.0020; PMC4137345; PUBMED: 24956171] DalsgaardS , LeckmanJF , MortensenPB , NielsenHS , SimonsenM . Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry2015;2(8):702‐9. [DOI: 10.1016/S2215‐0366(15)00271‐0; PUBMED: 26249301] DalsgaardS , NielsenHS , SimonsenM . Long‐term cardiac adverse effects of ADHD medication in children and adolescents: a nationwide register based follow‐up study. European Child and Adolescent Psychiatry2011;20(Suppl 1):S107. [DOI: 10.1007/s00787‐011‐0181‐5] ">Dalsgaard 2011</a>; <a href="./references#CD012069-bbs2-0374" title="FlapperBC , KoopmanHM , HeltzelA . Methylphenidate a stimulant in treatment of children with minimal brain dysfunction. Tijdschrift voor Kindergeneeskunde1989;57(1):14‐20. ">Flapper 1989</a>; <a href="./references#CD012069-bbs2-0375" title="HusárM , ZerhauP . Priapism in childhood ‐ case report of 14‐year‐old boy [Priapismus v dĕtsékm veku ‐ kazuistika 14 letého chlapce]. Rozhledy V Chirurgii2006;85(7):329‐30. [PUBMED: 17044274] ">Husár 2006</a>; <a href="./references#CD012069-bbs2-0376" title="InceE , AlgedikP , DemirdogenES , EmulM , DemirT . The relationship between acute dyskinesia with a single dose of methylphenidate and recent risperidone discontinuation in a child with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2015;25(4):378‐9. [DOI: 10.1089/cap.2014.0148; PUBMED: 25920038] ">Ince 2015</a>; <a href="./references#CD012069-bbs2-0377" title="IshizakiA , SugamaM . Methylphenidate therapy in 141 patients with hyperkinetic disorder or with pervasive developmental disorder and hyperkinesia. No To Hattatsu2001;33(4):323‐8. [PUBMED: 11494575] ">Ishizaki 2001</a>; <a href="./references#CD012069-bbs2-0378" title="LaezerKL . Effectiveness of psychoanalytic psychotherapy and behavioral therapy treatment in children with attention deficit hyperactivity disorder and oppositional defiant disorder. Journal of Infant, Child, and Adolescent Psychotherapy 2015, 2015;14(2):111‐28. [DOI: 10.1080/15289168.2015.1014991] ">Laezer 2015</a>; <a href="./references#CD012069-bbs2-0379" title="MulasF , RocaP , Ros‐CerveraG , Gandía‐BenetóR , Ortiz‐SánchezP . Pharmacological management of attention deficit hyperactivity disorder with methylphenidate and atomoxetine within a context of epilepsy [Manejo farmacológico del trastorno por déficit de atención/hiperactividad con metilfenidato y atomoxetina en un contexto de epilepsia]. Revista de Neurologia2014;58(Suppl 1):S34‐9. [PUBMED: 25252667] ">Mulas 2014</a>; <a href="./references#CD012069-bbs2-0380" title="PtáčekR , KuželováH , PacltI , ŽukovI . Effect of medication on anthropometric characteristic of ADHD children [Vliv medikace na antropometrické charakteristiky dětí s ADHD]. Ceska a Slovenska Psychiatrie2008;104(8):415‐9. PtáčekR , KuželováH , PacltI , ŽukovI , FischerS . Developmental changes in children with ADHD and effecto [sic] of medication on growth [Vyvojove zmeny u deti s ADHD a vliv medikace na rust]. Psychiatrie2009;13(Suppl):104‐5. ">Ptáček 2008</a>; <a href="./references#CD012069-bbs2-0381" title="RadziukAL , KielingRR , SantosK , RotertR , BastosF , PalminiAL . Methylphenidate improves the quality of life of children and adolescents with ADHD and difficult‐to‐treat epilepsies. Epilepsy and Behavior2015;46:215‐20. [DOI: 10.1016/j.yebeh.2015.02.019; PUBMED: 25940104] ">Radziuk 2015</a>; <a href="./references#CD012069-bbs2-0382" title="SocanskiD , AurlienD , HerigstadA , ThomsenPH , LarsenTK . Attention deficit/hyperactivity disorder and interictal epileptiform discharges: it is safe to use methylphenidate?. Seizure2015; Vol. 25:80‐3. [DOI: 10.1016/j.seizure.2015.01.002; PUBMED: 25645642] ">Socanski 2015</a>; <a href="./references#CD012069-bbs2-0383" title="SugamaM , IshizakiA . Clinical assessment of the effect of switch from immediate‐release to extended‐release methylphenidate in 181 patients with isolated attention deficit/hyperactivity disorder (AD/HD) or AD/HD associated with pervasive developmental disorder. No to Hattatsu2009;41(6):436‐41. [PUBMED: 19928542] ">Sugama 2009</a>; <a href="./references#CD012069-bbs2-0384" title="Polypharmacy in treating severe childhood aggression. Brown University Child and Adolescent Psychopharmacology Update2012;14(1):1‐4. [DOI: 10.1002/cpu.20155] AmanMG , BuksteinOG , GadowKD , ArnoldLE , MolinaBS , McNamaraNK , et al. What does risperidone add to parent training and stimulant for severe aggression in child attention‐deficit/hyperactivity disorder?. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(1):47‐60. [DOI: 10.1016/j.jaac.2013.09.022; PMC3984501; PUBMED: 24342385] FarmerCA , ArnoldLE , BuksteinOG , FindlingRL , GadowKD , LiXi , et al. The treatment of severe child aggression (TOSCA) study: design challenges. Child and Adolescent Psychiatry and Mental Health2011;5(1):36. [DOI: 10.1186/1753‐2000‐5‐36; PMC3231878; PUBMED: 22074813] ">TOSCA 2011</a>; <a href="./references#CD012069-bbs2-0385" title="GendronM , RusakB , RajdaM , CorkumPV . Assessing the impact of methylphenidate on sleep in children with ADHD using polysomnography and actigraphy. Sleep2012;35:A374. WaldonJ , BegumE , GendronM , RusakB , AndreouP , RajdaM , et al. Concordance of actigraphy with polysomnography in children with and without attention‐deficit/hyperactivity disorder. Journal of Sleep Research2016;25(5):524‐33. [PUBMED: 27140929] ">Waldon 2016</a>; <a href="./references#CD012069-bbs2-0386" title="YusufogluC , SonkayaAR , TaymurI . Henoch‐Schönlein Purpura with attention deficit hyperactivity disorder. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(Suppl 1):S158‐S159. ">Yusufoglu 2014</a>). Among these are five patient studies (<a href="./references#CD012069-bbs2-0372" title="Arnold‐von SaherRA , BoerF , BurggraafJ . The clinical use of a double‐blind placebo‐controlled trial with methylphenidate: advantages and limitations [Pleidooi voor een dubbelblinde proefbehandeling met methylfenidaat in de dagelijkse klinische praktijk van ADHD bij kinderen]. Tijdschrift voor Psychiatrie2000;42(11):837‐44. ">Arnold‐Von 2000</a>; <a href="./references#CD012069-bbs2-0374" title="FlapperBC , KoopmanHM , HeltzelA . Methylphenidate a stimulant in treatment of children with minimal brain dysfunction. Tijdschrift voor Kindergeneeskunde1989;57(1):14‐20. ">Flapper 1989</a>; <a href="./references#CD012069-bbs2-0375" title="HusárM , ZerhauP . Priapism in childhood ‐ case report of 14‐year‐old boy [Priapismus v dĕtsékm veku ‐ kazuistika 14 letého chlapce]. Rozhledy V Chirurgii2006;85(7):329‐30. [PUBMED: 17044274] ">Husár 2006</a>; <a href="./references#CD012069-bbs2-0383" title="SugamaM , IshizakiA . Clinical assessment of the effect of switch from immediate‐release to extended‐release methylphenidate in 181 patients with isolated attention deficit/hyperactivity disorder (AD/HD) or AD/HD associated with pervasive developmental disorder. No to Hattatsu2009;41(6):436‐41. [PUBMED: 19928542] ">Sugama 2009</a>; <a href="./references#CD012069-bbs2-0386" title="YusufogluC , SonkayaAR , TaymurI . Henoch‐Schönlein Purpura with attention deficit hyperactivity disorder. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(Suppl 1):S158‐S159. ">Yusufoglu 2014</a>), one parallel‐group RCT (<a href="./references#CD012069-bbs2-0384" title="Polypharmacy in treating severe childhood aggression. Brown University Child and Adolescent Psychopharmacology Update2012;14(1):1‐4. [DOI: 10.1002/cpu.20155] AmanMG , BuksteinOG , GadowKD , ArnoldLE , MolinaBS , McNamaraNK , et al. What does risperidone add to parent training and stimulant for severe aggression in child attention‐deficit/hyperactivity disorder?. Journal of the American Academy of Child and Adolescent Psychiatry2014;53(1):47‐60. [DOI: 10.1016/j.jaac.2013.09.022; PMC3984501; PUBMED: 24342385] FarmerCA , ArnoldLE , BuksteinOG , FindlingRL , GadowKD , LiXi , et al. The treatment of severe child aggression (TOSCA) study: design challenges. Child and Adolescent Psychiatry and Mental Health2011;5(1):36. [DOI: 10.1186/1753‐2000‐5‐36; PMC3231878; PUBMED: 22074813] ">TOSCA 2011</a>), one open‐label non‐controlled trial (<a href="./references#CD012069-bbs2-0381" title="RadziukAL , KielingRR , SantosK , RotertR , BastosF , PalminiAL . Methylphenidate improves the quality of life of children and adolescents with ADHD and difficult‐to‐treat epilepsies. Epilepsy and Behavior2015;46:215‐20. [DOI: 10.1016/j.yebeh.2015.02.019; PUBMED: 25940104] ">Radziuk 2015</a>), one review of parents reports (<a href="./references#CD012069-bbs2-0379" title="MulasF , RocaP , Ros‐CerveraG , Gandía‐BenetóR , Ortiz‐SánchezP . Pharmacological management of attention deficit hyperactivity disorder with methylphenidate and atomoxetine within a context of epilepsy [Manejo farmacológico del trastorno por déficit de atención/hiperactividad con metilfenidato y atomoxetina en un contexto de epilepsia]. Revista de Neurologia2014;58(Suppl 1):S34‐9. [PUBMED: 25252667] ">Mulas 2014</a>), one observational study (<a href="./references#CD012069-bbs2-0377" title="IshizakiA , SugamaM . Methylphenidate therapy in 141 patients with hyperkinetic disorder or with pervasive developmental disorder and hyperkinesia. No To Hattatsu2001;33(4):323‐8. [PUBMED: 11494575] ">Ishizaki 2001</a>), one patient‐control study (<a href="./references#CD012069-bbs2-0380" title="PtáčekR , KuželováH , PacltI , ŽukovI . Effect of medication on anthropometric characteristic of ADHD children [Vliv medikace na antropometrické charakteristiky dětí s ADHD]. Ceska a Slovenska Psychiatrie2008;104(8):415‐9. PtáčekR , KuželováH , PacltI , ŽukovI , FischerS . Developmental changes in children with ADHD and effecto [sic] of medication on growth [Vyvojove zmeny u deti s ADHD a vliv medikace na rust]. Psychiatrie2009;13(Suppl):104‐5. ">Ptáček 2008</a>), and two non‐comparative cohort studies (<a href="./references#CD012069-bbs2-0373" title="DalsgaardS , KvistAP , LeckmanJF , NielsenHS , SimonsenM . Cardiovascular safety of stimulants in children with attention‐deficit/hyperactivity disorder: a nationwide prospective cohort study. Journal of Child and Adolescent Psychopharmacology2014;24(6):1‐9. [DOI: 10.1089/cap.2014.0020; PMC4137345; PUBMED: 24956171] DalsgaardS , LeckmanJF , MortensenPB , NielsenHS , SimonsenM . Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry2015;2(8):702‐9. [DOI: 10.1016/S2215‐0366(15)00271‐0; PUBMED: 26249301] DalsgaardS , NielsenHS , SimonsenM . Long‐term cardiac adverse effects of ADHD medication in children and adolescents: a nationwide register based follow‐up study. European Child and Adolescent Psychiatry2011;20(Suppl 1):S107. [DOI: 10.1007/s00787‐011‐0181‐5] ">Dalsgaard 2011</a>; <a href="./references#CD012069-bbs2-0382" title="SocanskiD , AurlienD , HerigstadA , ThomsenPH , LarsenTK . Attention deficit/hyperactivity disorder and interictal epileptiform discharges: it is safe to use methylphenidate?. Seizure2015; Vol. 25:80‐3. [DOI: 10.1016/j.seizure.2015.01.002; PUBMED: 25645642] ">Socanski 2015</a>). The designs used in <a href="./references#CD012069-bbs2-0376" title="InceE , AlgedikP , DemirdogenES , EmulM , DemirT . The relationship between acute dyskinesia with a single dose of methylphenidate and recent risperidone discontinuation in a child with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2015;25(4):378‐9. [DOI: 10.1089/cap.2014.0148; PUBMED: 25920038] ">Ince 2015</a> and <a href="./references#CD012069-bbs2-0385" title="GendronM , RusakB , RajdaM , CorkumPV . Assessing the impact of methylphenidate on sleep in children with ADHD using polysomnography and actigraphy. Sleep2012;35:A374. WaldonJ , BegumE , GendronM , RusakB , AndreouP , RajdaM , et al. Concordance of actigraphy with polysomnography in children with and without attention‐deficit/hyperactivity disorder. Journal of Sleep Research2016;25(5):524‐33. [PUBMED: 27140929] ">Waldon 2016</a> were unclear, and we could not retrieve <a href="./references#CD012069-bbs2-0378" title="LaezerKL . Effectiveness of psychoanalytic psychotherapy and behavioral therapy treatment in children with attention deficit hyperactivity disorder and oppositional defiant disorder. Journal of Infant, Child, and Adolescent Psychotherapy 2015, 2015;14(2):111‐28. [DOI: 10.1080/15289168.2015.1014991] ">Laezer 2015</a>. </p> </section> <section id="CD012069-sec-0094"> <h5 class="title">Ongoing studies</h5> <p>We included eight ongoing studies (<a href="./references#CD012069-bbs2-0387" title="BeauR , DouglasI , SmeethL , EvansSJ . Spontaneous report safety signals profile and comparative Bayesian analysis of ADHD medication in children in the UK. Pharmacoepidemiology and Drug Safety2009;18(S1):S208‐9. [DOI: 10.1002/pds.1806] ">Beau 2009</a>; <a href="./references#CD012069-bbs2-0388" title="BottelierMA , SchouwML , KlompA , TammingaHG , SchranteeAG , BouzianeC , et al. The effects of Psychotropic drugs On Developing brain (ePOD) study: methods and design. BMC Psychiatry2014;14(48):2‐12. [DOI: 10.1186/1471‐244X‐14‐48] ">Bottelier 2014</a>; <a href="./references#CD012069-bbs2-0389" title="DahlgrenJ , WentzE . Overweight and obese children with diagnosed attention deficit hyperactivity disorder have a favourable weight loss with methylphenidate ‐ one year data. Obesity Facts2012; Vol. 5, issue Suppl 1:208. ">Dahlgren 2012</a>; <a href="./references#CD012069-bbs2-0390" title="DeCastro‐ManglanoP , Vallejo‐ValdivielsoM , Díez‐SuárezA , Figueroa‐QuintanaA . Factors that may predict a good response to pharmacological treatment. European Child and Adolescent Psychiatry2015;24(Suppl 1):S74‐5. [DOI: 10.1007/s00787‐015‐0714‐4] Díez‐SuárezA , Vallejo‐ValdivielsoM , MendezJ , DeCastro‐ManglanoP . Long term effects of medication for ADHD in weight and height in children and adolescents. European Child and Adolescent Psychiatry2015;24(Suppl 1):S74. [DOI: 10.1007/s00787‐015‐0714‐4] Díez‐SuárezA , Vallejo‐ValdiviesoM , Marín‐MéndezJ , DeCastro‐ManglanoP , SoutulloC . Weight, height and body mass index in patients with adhd treated with methylphenidate. European Child and Adolescent Psychiatry2015;24(Suppl 1):S175. [DOI: 10.1007/s00787‐015‐0714‐4] Vallejo‐ValdivielsoM , DeCastro‐ManglanoP , Díez‐SuárezA , Marín‐MéndezJ , Figueroa‐QuintanaA . Clinical and neurocognitive predictive factors for good response to methylphenidate treatment in a ADHD sample in Spain: a naturalistic follow‐up study. European Child and Adolescent Psychiatry2015;24(Suppl 1):S137. [DOI: 10.1007/s00787‐015‐0714‐4] ">Díez‐Suárez 2015</a>; <a href="./references#CD012069-bbs2-0391" title="Djurkovic‐LazicJ , LazicB , MilojevicN , DjuricD . School children with ADHD ‐ effects of once‐daily OROS methylphenidate treatment ADHD symptoms included improvement academic functioning. European Psychiatry2009;24(Suppl 1):S396. [DOI: 10.1016/S0924‐9338(09)70629‐7] ">Djurkovic‐Lazic 2009</a>; <a href="./references#CD012069-bbs2-0392" title="GauCS , ChenCF , GauSS . The influence of using methylphenidate on the coming up of psychiatric disorders in children with ADHD. Pharmacoepidemiology and Drug Safety2010;19(Suppl 1):S152‐3. [DOI: 10.1002/pds.2019] ">Gau 2010</a>; <a href="./references#CD012069-bbs2-0393" title="HoumannT , SkovgaardAM , RasmussenHB . Individualised methylphenidate therapy based on pharmacogenomics: focus on carboxylesterase1 (CES1). European Child and Adolescent Psychiatry2011;20(Suppl 1):S120. [DOI: 10.1007/s00787‐011‐0181‐5] ">Houmann 2011</a>; <a href="./references#CD012069-bbs2-0394" title="YookKH , KimYW , SuhHS . Obesity is associated with non‐response to prolonged‐release methylphenidate treatment in ADHD. European Neuropsychopharmacology2012;22(Suppl 2):S415‐6. [DOI: 10.1016/S0924‐977X(12)70651‐X] ">Yook 2012</a>). </p> <p>Among these are one study that examines safety signal profiles in the UK Yellow Card database (<a href="./references#CD012069-bbs2-0387" title="BeauR , DouglasI , SmeethL , EvansSJ . Spontaneous report safety signals profile and comparative Bayesian analysis of ADHD medication in children in the UK. Pharmacoepidemiology and Drug Safety2009;18(S1):S208‐9. [DOI: 10.1002/pds.1806] ">Beau 2009</a>), one placebo‐controlled trial (<a href="./references#CD012069-bbs2-0388" title="BottelierMA , SchouwML , KlompA , TammingaHG , SchranteeAG , BouzianeC , et al. The effects of Psychotropic drugs On Developing brain (ePOD) study: methods and design. BMC Psychiatry2014;14(48):2‐12. [DOI: 10.1186/1471‐244X‐14‐48] ">Bottelier 2014</a>), one study that retrospectively investigated records of children (<a href="./references#CD012069-bbs2-0389" title="DahlgrenJ , WentzE . Overweight and obese children with diagnosed attention deficit hyperactivity disorder have a favourable weight loss with methylphenidate ‐ one year data. Obesity Facts2012; Vol. 5, issue Suppl 1:208. ">Dahlgren 2012</a>), one cohort study (<a href="./references#CD012069-bbs2-0391" title="Djurkovic‐LazicJ , LazicB , MilojevicN , DjuricD . School children with ADHD ‐ effects of once‐daily OROS methylphenidate treatment ADHD symptoms included improvement academic functioning. European Psychiatry2009;24(Suppl 1):S396. [DOI: 10.1016/S0924‐9338(09)70629‐7] ">Djurkovic‐Lazic 2009</a>), one longitudinal naturalistic follow‐up study (<a href="./references#CD012069-bbs2-0390" title="DeCastro‐ManglanoP , Vallejo‐ValdivielsoM , Díez‐SuárezA , Figueroa‐QuintanaA . Factors that may predict a good response to pharmacological treatment. European Child and Adolescent Psychiatry2015;24(Suppl 1):S74‐5. [DOI: 10.1007/s00787‐015‐0714‐4] Díez‐SuárezA , Vallejo‐ValdivielsoM , MendezJ , DeCastro‐ManglanoP . Long term effects of medication for ADHD in weight and height in children and adolescents. European Child and Adolescent Psychiatry2015;24(Suppl 1):S74. [DOI: 10.1007/s00787‐015‐0714‐4] Díez‐SuárezA , Vallejo‐ValdiviesoM , Marín‐MéndezJ , DeCastro‐ManglanoP , SoutulloC . Weight, height and body mass index in patients with adhd treated with methylphenidate. European Child and Adolescent Psychiatry2015;24(Suppl 1):S175. [DOI: 10.1007/s00787‐015‐0714‐4] Vallejo‐ValdivielsoM , DeCastro‐ManglanoP , Díez‐SuárezA , Marín‐MéndezJ , Figueroa‐QuintanaA . Clinical and neurocognitive predictive factors for good response to methylphenidate treatment in a ADHD sample in Spain: a naturalistic follow‐up study. European Child and Adolescent Psychiatry2015;24(Suppl 1):S137. [DOI: 10.1007/s00787‐015‐0714‐4] ">Díez‐Suárez 2015</a>), one database study (<a href="./references#CD012069-bbs2-0392" title="GauCS , ChenCF , GauSS . The influence of using methylphenidate on the coming up of psychiatric disorders in children with ADHD. Pharmacoepidemiology and Drug Safety2010;19(Suppl 1):S152‐3. [DOI: 10.1002/pds.2019] ">Gau 2010</a>), a multicenter study on CES1 genotype response in ADHD children (<a href="./references#CD012069-bbs2-0393" title="HoumannT , SkovgaardAM , RasmussenHB . Individualised methylphenidate therapy based on pharmacogenomics: focus on carboxylesterase1 (CES1). European Child and Adolescent Psychiatry2011;20(Suppl 1):S120. [DOI: 10.1007/s00787‐011‐0181‐5] ">Houmann 2011</a>), and one open‐label trial (<a href="./references#CD012069-bbs2-0394" title="YookKH , KimYW , SuhHS . Obesity is associated with non‐response to prolonged‐release methylphenidate treatment in ADHD. European Neuropsychopharmacology2012;22(Suppl 2):S415‐6. [DOI: 10.1016/S0924‐977X(12)70651‐X] ">Yook 2012</a>). </p> </section> </section> </section> <section id="CD012069-sec-0095"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD012069-sec-0096"> <h4 class="title">Risk of bias in comparative studies</h4> <section id="CD012069-sec-0097"> <h5 class="title">Possible bias due to confounding factors</h5> <p>We judged the risk of bias on this domain as moderate in two studies (<a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>), serious in four studies (<a href="./references#CD012069-bbs2-0021" title="AyazM , AyazAB , SoyluN , YükselS . Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598] ">Ayaz 2014</a>; <a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>; <a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>; <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>), and critical in five studies (<a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>; <a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>; <a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>; <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>). </p> </section> <section id="CD012069-sec-0098"> <h5 class="title">Possible bias due to selection of participants</h5> <p>We judged the risk of bias on this domain as moderate in five studies (<a href="./references#CD012069-bbs2-0021" title="AyazM , AyazAB , SoyluN , YükselS . Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598] ">Ayaz 2014</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>; <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>; <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>), serious in five studies (<a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>; <a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>; <a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>; <a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>; <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>), and critical in one study (<a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>). </p> </section> <section id="CD012069-sec-0099"> <h5 class="title">Possible bias due to measurement of interventions</h5> <p>We judged the risk of bias on this domain as moderate in eight studies (<a href="./references#CD012069-bbs2-0021" title="AyazM , AyazAB , SoyluN , YükselS . Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598] ">Ayaz 2014</a>; <a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>; <a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>; <a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>; <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>; <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>), and serious in three studies (<a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>; <a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>; <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>). </p> </section> <section id="CD012069-sec-0100"> <h5 class="title">Possible bias due to departures from intended interventions</h5> <p>We judged the risk of bias on this domain as moderate in five studies (<a href="./references#CD012069-bbs2-0021" title="AyazM , AyazAB , SoyluN , YükselS . Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598] ">Ayaz 2014</a>; <a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>; <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>; <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>), serious in three studies (<a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>; <a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>; <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>), and critical in three studies (<a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>; <a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>). </p> </section> <section id="CD012069-sec-0101"> <h5 class="title">Possible bias due to missing data</h5> <p>We judged the risk of bias on this domain as moderate in eight studies (<a href="./references#CD012069-bbs2-0021" title="AyazM , AyazAB , SoyluN , YükselS . Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598] ">Ayaz 2014</a>; <a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>; <a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>; <a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>; <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>; <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>; <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>), serious in one study (<a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>), and critical in two studies (<a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>; <a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>). </p> </section> <section id="CD012069-sec-0102"> <h5 class="title">Possible bias in measurement of outcomes</h5> <p>We judged the risk of bias on this domain as low in one study (<a href="./references#CD012069-bbs2-0021" title="AyazM , AyazAB , SoyluN , YükselS . Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598] ">Ayaz 2014</a>), moderate in five studies (<a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>; <a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>; <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>; <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>; <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>), and serious in five studies (<a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>; <a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>; <a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>). </p> </section> <section id="CD012069-sec-0103"> <h5 class="title">Possible bias in selection of reported results</h5> <p>We judged the risk of bias on this domain as moderate in seven studies (<a href="./references#CD012069-bbs2-0021" title="AyazM , AyazAB , SoyluN , YükselS . Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598] ">Ayaz 2014</a>; <a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>; <a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>; <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>; <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>; <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>), and critical in one study (<a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>). For three studies, no information was available regarding this domain (<a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>; <a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>). </p> </section> <section id="CD012069-sec-0104"> <h5 class="title">Overall risk of bias</h5> <p>Overall, we found five studies to be at serious risk of bias (<a href="./references#CD012069-bbs2-0021" title="AyazM , AyazAB , SoyluN , YükselS . Medication persistence in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2014;24(8):442‐7. [DOI: 10.1089/cap.2014.0002; PUBMED: 25010598] ">Ayaz 2014</a>; <a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>; <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>; <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>), and six studies to be at critical risk of bias (<a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>; <a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>; <a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>; <a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>; <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>). </p> <p>A table depicting the results of our 'Risk of bias' assessment for all individual studies can be seen at at <a href="https://zenodo.org/" target="_blank">zenodo.org</a>. See <a href="https://zenodo.org/record/1165115#.WnV8QWeWyxA" target="_blank">supplementary file ROBINS‐I Risk of Bias Table</a>. </p> </section> </section> <section id="CD012069-sec-0105"> <h4 class="title">Risk of bias in non‐comparative studies</h4> <p>In our protocol, <a href="./references#CD012069-bbs2-0688" title="StorebøOJ , PedersenN , RamstadE , KroghHB , Moreira‐MaiaCR , MagnussonFL , et al. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents ‐ assessment of harmful effects in non‐randomised studies. Cochrane Database of Systematic Reviews2016, Issue 2. [DOI: 10.1002/14651858.CD012069] ">Storebø 2016</a>, we decided to use the ROBINS‐I tool to rate the risk of bias in the included non‐randomised studies (<a href="./references#CD012069-bbs2-0646" title="SterneJAC , HigginsJPT , ReevesBC , on behalf of the development group for ACROBAT‐NRSI. A Cochrane Risk Of Bias Assessment Tool: for Non‐Randomised Studies of Interventions (ACROBAT‐NRSI), Version 1.0.0, 24 September 2014. www.riskofbias.info (accessed 25 May 2015). ">Sterne 2014</a>; <a href="./references#CD012069-bbs2-0647" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ2016; Vol. 355, issue i4919. [DOI: 10.1136/bmj.i4919; PMC5062054; PUBMED: 27733354] ">Sterne 2016</a>). For studies without a control group, we initially set out to use baseline data as control information, comparing them as before‐after exposure to methylphenidate. However, a number of time‐dependent biases, such as time‐lag bias, may limit the validity of this approach (<a href="./references#CD012069-bbs2-0646" title="SterneJAC , HigginsJPT , ReevesBC , on behalf of the development group for ACROBAT‐NRSI. A Cochrane Risk Of Bias Assessment Tool: for Non‐Randomised Studies of Interventions (ACROBAT‐NRSI), Version 1.0.0, 24 September 2014. www.riskofbias.info (accessed 25 May 2015). ">Sterne 2014</a>; <a href="./references#CD012069-bbs2-0647" title="SterneJA , HernánMA , ReevesBC , SavovićJ , BerkmanND , ViswanathanM , et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ2016; Vol. 355, issue i4919. [DOI: 10.1136/bmj.i4919; PMC5062054; PUBMED: 27733354] ">Sterne 2016</a>). Therefore, we avoided baseline control information. Realising that the ROBINS‐I tool is designed for studies with control groups, we chose not to assess risk of bias for studies without a valid control group. Some of the included non‐randomised studies had control groups with healthy participants, but designs with healthy participants were not eligible for inclusion (see <a href="#CD012069-sec-0030">Criteria for considering studies for this review</a>). Cochrane does not recommend any tools other than ROBINS‐I for rating risk of bias in non‐randomised studies. Thus, we deemed all studies without valid or eligible control groups to be at critical risk of bias due to many factors, with the most important being potential confounding factors. </p> </section> </section> <section id="CD012069-sec-0106"> <h3 class="title" id="CD012069-sec-0106">Effects of interventions</h3> <p>See: <a href="./full#CD012069-tbl-0001"><b>Summary of findings for the main comparison</b> Methylphenidate for children and adolescents aged 18 years and under with attention deficit hyperactivity disorder (ADHD): adverse events</a> </p> <p>Below, we present our findings for our primary (serious adverse events) and secondary (non‐serious adverse events) outcomes, organised by comparative studies, non‐comparative studies, and patient reports/series. </p> <p>A summary of the findings can be found in <a href="./full#CD012069-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>Forest plots for all meta‐analyses are available as supplementary files at <a href="https://zenodo.org/" target="_blank">zenodo.org</a> </p> <section id="CD012069-sec-0107"> <h4 class="title">1. Comparative studies</h4> <section id="CD012069-sec-0108"> <h5 class="title">1.1 Primary outcomes: serious adverse events</h5> <section id="CD012069-sec-0109"> <h6 class="title">1.1.1 Frequency of any serious adverse events</h6> <p>See <a href="./references#CD012069-fig-0008" title="">Analysis 1.1</a>. Of the 11 comparative studies, only three provided data on serious adverse events. We included two studies of these studies in a meta‐analysis (<a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>); we excluded the third because it did not report on total serious adverse events (<a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>). Compared to no intervention, methylphenidate increased the number of patients with any serious adverse event (RR 1.36, 95% CI 1.17 to 1.57; 72,005 participants). A meta‐analysis that included the double‐zero event studies did not change this result. </p> <p>The results of a sensitivity analysis, with the patient‐control study removed (<a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>), gives an RR of 1.36 (95% CI 1.17 to 1.57) and is thus comparable. </p> </section> <section id="CD012069-sec-0110"> <h6 class="title">1.1.2 Central nervous system</h6> <p>See <a href="./references#CD012069-fig-0009" title="">Analysis 1.2</a>. Two studies reported on different adverse events of the central nervous system (<a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>). Compared to no intervention, methylphenidate did not increase the number of patients with seizures (RR 1.31, 95% CI 0.07 to 23.74; 1 study, 234 participants; <a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a>), but it did increase the number of patients with psychotic disorder (RR 1.36, 95% CI 1.17 to 1.57; 1 study, 71,771 participants; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>). </p> </section> <section id="CD012069-sec-0111"> <h6 class="title">1.1.3 Cardiovascular and respiratory system</h6> <p>See <a href="./references#CD012069-fig-0010" title="">Analysis 1.3</a>. One study with 1224 participants, <a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a>, reported on cardiovascular and respiratory adverse events. Compared to no intervention, methylphenidate increased the number of patients with arrhythmias (RR 1.61, 95% CI 1.48 to 1.74), but it did not change the number of patients with: </p> <p> <ol id="CD012069-list-0016"> <li> <p>hypertension (RR 1.07, 95% CI 0.94 to 1.22);</p> </li> <li> <p>myocardial infarction (RR 1.33, 95% CI 0.90 to 1.98); or</p> </li> <li> <p>ischaemic stroke (RR 0.70, 95% CI 0.49 to 1.01).</p> </li> </ol> </p> <p>Methylphenidate also decreased the number of patients with heart failure (RR 0.54, 95% CI 0.30 to 0.96). </p> <p>No respiratory outcomes were reported.</p> <p>No comparative studies reported adverse events related to the gastrointestinal, musculoskeletal, immune, urogenital or other body systems, and no comparative studies reported withdrawal of treatment due to serious adverse events or adverse events of unknown severity. </p> </section> </section> <section id="CD012069-sec-0112"> <h5 class="title">1.2 Secondary outcomes: non‐serious adverse events</h5> <p>Seven studies reported data on this outcome. We included five of these studies in meta‐analyses (<a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>; <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>; <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>; <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>). We could not use data from two further studies in our meta‐analyses because the authors reported other types of outcomes on adverse events with single study results (<a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>; <a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>). </p> <section id="CD012069-sec-0113"> <h6 class="title">1.2.1 Frequency of any non‐serious adverse events</h6> <p>None of the seven studies reported data on the frequency of any non‐serious adverse events. </p> </section> <section id="CD012069-sec-0114"> <h6 class="title">1.2.2 Central nervous system</h6> <section id="CD012069-sec-0115"> <p><b>Sleep‐related adverse events</b></p> <p>See <a href="./references#CD012069-fig-0011" title="">Analysis 2.1</a>. Three studies with 425 participants reported data on sleep disturbance (<a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>; <a href="./references#CD012069-bbs2-0204" title="SteinD , Pat‐HorenczykR , BlankS , DaganY , BarakY , GumpelTP . Sleep disturbances in adolescents with symptoms of attention‐deficit/hyperactivity disorder. Journal of Learning Disabilities2002;35(3):268‐75. [DOI: 10.1177/002221940203500308; PUBMED: 15493323] ">Stein 2002</a>; <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>). We conducted a meta‐analysis and found that, compared to no intervention, methylphenidate increased the number of patients with insomnia and sleep problems (RR 2.58, 95% CI 1.24 to 5.34; 3 studies, 425 participants). </p> <p>One study with 23 participants, <a href="./references#CD012069-bbs2-0038" title="CockcroftK , AshwalJ , BentleyA . Sleep and daytime sleepiness in methylphenidate medicated and un‐medicated children with attention‐deficit/hyperactivity disorder (ADHD). African Journal of Psychiatry2009;12(4):275‐9. [PUBMED: 20033109] ">Cockcroft 2009</a>, compared methylphenidate to no intervention and found that methylphenidate did not increase the number of patients with: </p> <p> <ul class="plain" id="CD012069-list-0017"> <li> <ol id="CD012069-list-0018"> <li> <p>nightmares (RR 1.15, 95% CI 0.41 to 3.21);</p> </li> <li> <p>snoring (RR 4.62, 95% CI 0.25 to 86.7);</p> </li> <li> <p>non‐breathing or gasping while sleeping (RR 2.77, 95% CI 0.12 to 61.7);</p> </li> <li> <p>sleepwalking (RR 2.75, 95% CI 0.33 to 22.7);</p> </li> <li> <p>various sleep positions (RR 2.77, 95% CI 0.12 to 61.7);</p> </li> <li> <p>enuresis (RR 4.62, 95% CI 0.25 to 86.7); or</p> </li> <li> <p>talking in sleep (RR 0.46, 95% CI 0.05 to 4.38).</p> </li> </ol> </li> </ul> </p> </section> <section id="CD012069-sec-0116"> <p><b>Other specific sleep‐related adverse effects</b></p> <p>See <a href="./references#CD012069-fig-0012" title="">Analysis 2.2</a>. <a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a> (10 participants) compared methylphenidate to no intervention and found that methylphenidate did not decrease: </p> <p> <ol id="CD012069-list-0019"> <li> <p>the number of hours of sleep (MD −0.65 hours, 95% CI −1.32 to 0.02);</p> </li> <li> <p>the number of nocturnal movements (MD −27.84 movements, 95% CI −57.9 to 2.22); or</p> </li> <li> <p>sleep quality (MD −0.20, 95% CI −0.74 to 0.34), as measured on a five‐point sleep quality scale (ranging from −2 = very poor to 2 = very good) from “The Morpheus Network Wake and Sleep Calendar.” </p> </li> </ol> </p> </section> <section id="CD012069-sec-0117"> <p><b>Other specific adverse events</b></p> <p>See <a href="./references#CD012069-fig-0013" title="">Analysis 2.3</a>. One study with, <a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>, reported on different adverse events of the central nervous system. Compared to no intervention, methylphenidate did not increase the number of patients with: </p> <p> <ol id="CD012069-list-0020"> <li> <p>headache (RR 8.13, 95% CI 0.48 to 137.8; 235 participants); or</p> </li> <li> <p>dizziness (RR 4.00, 95% CI 0.23 to 69.3; 335 participants).</p> </li> </ol> </p> </section> </section> <section id="CD012069-sec-0118"> <h6 class="title">1.2.3 Cardiovascular and respiratory system</h6> <p>See analysis <a href="./references#CD012069-fig-0014" title="">Analysis 2.4</a> </p> <section id="CD012069-sec-0119"> <p><b>Systolic blood pressure</b></p> <p>Only one study with 43 participants reported data on this outcome (<a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>). Compared to no intervention, methylphenidate did not affect systolic blood pressure (MD 0.10 mmHg, 95% CI −6.27 to 6.47). </p> </section> <section id="CD012069-sec-0120"> <p><b>Diastolic blood pressure</b></p> <p>Only one study with 43 participants reported data on this outcome (<a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>). Compared to no intervention, methylphenidate did not affect diastolic blood pressure (MD 3.50 mmHg, 95% CI −1.42 to 8.42). </p> </section> <section id="CD012069-sec-0121"> <p><b>Pulse rate</b></p> <p>Only one study with 43 participants reported data on this outcome (<a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>). Compared to no intervention, methylphenidate did not seem to affect pulse rate (MD 0.60 beats per minute, 95% CI −7.95 to 9.15). </p> </section> </section> <section id="CD012069-sec-0122"> <h6 class="title">1.2.4 Gastrointestinal system</h6> <p>See <a href="./references#CD012069-fig-0015" title="">Analysis 2.5</a>. One study with 335 participants reported on gastrointestinal adverse events (<a href="./references#CD012069-bbs2-0216" title="TzangRF , WangYC , YehCB , HsuCD , LiangHY , YangPC , et al. Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit‐hyperactivity disorder. Psychiatry and Clinical Neurosciences2012; Vol. 66, issue 1:53‐63. [DOI: 10.1111/j.1440‐1819.2011.02289.x; PUBMED: 22250610] ">Tzang 2012</a>). Compared to no intervention, methylphenidate did not increase the number of patients with: </p> <p> <ol id="CD012069-list-0021"> <li> <p>nausea (RR 2.64, 95% CI 0.34 to 20.3); or</p> </li> <li> <p>abdominal pain (RR 0.79, 95% CI 0.16 to 3.84).</p> </li> </ol> </p> <p>However, methylphenidate did increase the number with decreased appetite (RR 15.06, 95% CI 2.12 to 106.8). </p> </section> <section id="CD012069-sec-0123"> <h6 class="title">1.2.5 Musculoskeletal system</h6> <p>See <a href="./references#CD012069-fig-0016" title="">Analysis 2.6</a>. </p> <section id="CD012069-sec-0124"> <p><b>Height</b></p> <p>Two studies reported data on height (<a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>). We pooled data from both studies (93 participants) in a meta‐analysis and found that, compared to no intervention, methylphenidate did not increase the number of patients with reduced height (SMD −0.93, 95% CI −2.61 to 0.75). </p> </section> <section id="CD012069-sec-0125"> <p><b>Weight</b></p> <p>Four studies reported data on weight (<a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>; <a href="./references#CD012069-bbs2-0114" title="AbikoffH . Tailored psychosocial treatments for ADHD: the search for a good fit. Journal of Clinical Child Psychology2001; Vol. 30, issue 1:122‐5. [DOI: 10.1207/S15374424JCCP3001_14; PUBMED: 11294070] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottG , GreenhillLL , et al. National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choices. Archives of General Psychiatry1997;54(9):865‐70. [PUBMED: 9294378] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottGR , GreenhillLL , et al. NIMH collaborative multimodal treatment study of children with ADHD (MTA): design, methodology, and protocol evolution. Journal of Attention Disorders1997;2(3):141‐58. [DOI: 10.1177/108705479700200301] ArnoldLE , ChuangS , DaviesM , AbikoffHB , ConnersCK , ElliottGR , et al. Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures. Journal of Abnormal Child Psychology2004;32(1):39‐51. [PUBMED: 14998110] ArnoldLE , ElliottM , SachsL , BirdH , KraemerHC , WellsKC , et al. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14‐month outcome in ADHD. Journal of Consulting and Clinical Psychology2003;71(4):713‐27. [PUBMED: 12924677] CareyWB . What the multimodal treatment study of children with attention deficit/hyperactivity disorder did and did not say about the use of methylphenidate for attention deficits. Pediatrics2000;105(4):863‐4. [PUBMED: 10742336] ConnersCK , EpsteinJN , MarchJS , AngoldA , WellsKC , KlaricJ , et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):159‐67. [DOI: 10.1097/00004583‐200102000‐00010; PUBMED: 11211364] GalanterCA , CarlsonGA , JensenPS , GreenhillLL , DaviesM , LiW , et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. Journal of Child and Adolescent Psychopharmacology2003;13(2):123‐36. [DOI: 10.1089/104454603322163844; PUBMED: 12880507] GreeneRW , AblonJS . What does the MTA study tell us about effective psychosocial treatment for ADHD?. Journal of Clinical Child Psychology2001;30(1):114‐21. [DOI: 10.1207/S15374424JCCP3001_13; PUBMED: 11294069] GreenhillLL , AbikoffHB , ArnoldLE , CantwellDP , ConnersCK , ElliottG , et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. Journal of the American Academy of Child and Adolescent Psychiatry1996;35(10):1304‐13. [DOI: 10.1097/00004583‐199610000‐00017; PUBMED: 8885584] GreenhillLL , SwansonJM , VitielloB , DaviesM , ClevengerW , WuM , et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):180‐7. [DOI: 10.1097/00004583‐200102000‐00012; PUBMED: 11211366] HansenL , ThomsenPH . How to treat ADHD/DAMP? Is there a conclusive answer? A critical survey of the MTA trial?. Ugeskr Laeger2005;167(48):4555‐9. [PUBMED: 16324436] HinshawSP . Moderators and mediators of treatment response for children with attention‐deficit/hyperactivity disorder: the Multimodal Treatment Study of children with attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1088‐96. [PUBMED: 10591284] HinshawSP , MarchJS , AbikoffH , ArnoldLE , CantwellDP , ConnersCK , et al. Comprehensive assessment of childhood Attention‐Deficit Hyperactivity Disorder in the context of a multisite, multimodal clinical trial. Journal of Attention Disorders1997;1(4):217‐34. [DOI: 10.1177/108705479700100403] JensenPS , ArnoldLE , SwansonJM , VitielloB , AbikoffHB , GreenhillLL , et al. 3‐year follow‐up of the NIMH MTA study. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):989‐1002. [DOI: 10.1097/CHI.0b013e3180686d48; PUBMED: 17667478] JensenPS , HinshawSP , KraemerHC , LeonoraN , NewcornJH , AbikoffHB , et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. Journal of the American Academy of Child and Adolescent Psychiatry2001; Vol. 40, issue 2:147‐58. [DOI: 10.1097/00004583‐200102000‐00009; PUBMED: 11211363] JensenPS , HinshawSP , SwansonJM , GreenhillLL , ConnersCK , ArnoldLE , et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. Journal of Developmental and Behavioral Pediatrics2001;22(1):60‐73. [PUBMED: 11265923] MTA Cooperative Group. A 14‐month randomized clinical trial of treatment strategies for attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1073‐86. [DOI: 10.1001/archpsyc.56.12.1073; PUBMED: 10591283] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: 24‐month outcomes of treatment strategies for attention‐deficit/hyperactivity disorder. Pediatrics2004;113(4):754‐61. [PUBMED: 15060224] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: changes in effectiveness and growth after the end of treatment. Pediatrics2004;113(4):762‐9. [PUBMED: 15060225] MarchJS , SwansonJM , ArnoldLE , HozaB , ConnersCK , HinshawSP , et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). Journal of Abnormal Child Psychology2000;28(6):527‐41. [PUBMED: 11104315] MolinaBS , FloryK , HinshawSP , GreinerAR , ArnoldLE , SwansonJM , et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1028‐40. [DOI: 10.1097/chi.0b013e3180686d96; PUBMED: 17667481] MolinaBS , HinshawSP , EugeneAL , SwansonJM , PelhamWE , HechtmanL , et al. Adolescent substance use in the multimodal treatment study of attention‐deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. Journal of the American Academy of Child and Adolescent Psychiatry2013;52(3):250‐63. [DOI: 10.1016/j.jaac.2012.12.014; PMC3589108; PUBMED: 23452682] MolinaBS , HinshawSP , SwansonJM , ArnoldLE , VitielloB , JensenPS , et al. The MTA at 8 years: prospective follow‐up of children treated for combined‐type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(5):484‐500. [DOI: 10.1097/CHI.0b013e31819c23d0; PMC3063150] NiewegEH . Does ADHD medication stop working after 2‐3 years? On the surprising, but little known follow‐up of the MTA study [Is adhd‐medicatie na 2‐3 jaar uitgewerkt? Over de verrassende, maar weinig bekendefollow‐up van het mta‐onderzoek]. Tijdschrift voor Psychiatrie2010;52(4):245‐54. [PUBMED: 20503165] OwensEB , HinshawSP , KraemerHC , ArnoldLE , AbikoffHB , CantwellDP , et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. Journal of Consulting and Clinical Psychology2003;71(3):540‐52. [PUBMED: 12795577] PelhamWEJr . The NIMH multimodal treatment study for attention‐deficit hyperactivity disorder: just say yes to drugs alone?. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie1999;44(10):981‐90. [DOI: 10.1177/070674379904401004; PUBMED: 10637677] PelhamWE , GnagyEM , GreinerAR , HozaB , HinshawSP , SwansonJM , et al. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. Journal of Abnormal Child Psychology2000;28(6):507‐25. [PUBMED: 11104314] RichtersJE , ArnoldLE , JensenPS , AbikoffH , ConnersCK , GreenhillLL , et al. NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale. Journal of the American Academy of Child and Adolescent Psychiatry1995;34(8):987‐1000. [DOI: 10.1097/00004583‐199508000‐00008; PUBMED: 7665456] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. Journal of Attention Disorders2008;12(1):15‐43. [DOI: 10.1177/1087054708319525; PUBMED: 18573924] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. Journal of Attention Disorders2008;12(1):4‐14. [DOI: 10.1177/1087054708319345; PUBMED: 18573923] SwansonJM , ElliottGR , GreenhillLL , WigalT , ArnoldLE , VitielloB , et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow‐up. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1015‐27. [DOI: 10.1097/chi.0b013e3180686d7e; PUBMED: 17667480] SwansonJM , HinshawSP , ArnoldLE , GibbonsRD , MarcusS , HurK , et al. Secondary evaluations of MTA 36‐month outcomes: propensity score and growth mixture model analyses. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1003‐14. [DOI: 10.1097/CHI.0b013e3180686d63; PUBMED: 17667479] SwansonJM , KraemerHC , HinshawSP , ArnoldLE , ConnersCK , AbikoffHB , et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):168‐79. [DOI: 10.1097/00004583‐200102000‐00011; PUBMED: 1121136] VitielloB , ElliottGR , SwansonJM , ArnoldLE , HechtmanL , AbikoffH , et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. American Journal of Psychiatry2012; Vol. 169, issue 2:167‐77. [DOI: 10.1176/appi.ajp.2011.10111705; PMC4132884; PUBMED: 21890793] VitielloB , SevereJB , GreenhillLL , ArnoldLE , AbikoffHB , BuksteinOG , et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):188‐96. [DOI: 10.1097/00004583‐200102000‐00013; PUBMED: 11211367] ">Jensen 1999 (MTA)</a>; <a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>). We pooled data from two studies (93 participants) in a meta‐analysis (<a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>; <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>). Compared to no intervention, methylphenidate did not decrease weight (SMD −0.27, 95% CI −1.16 to 0.62). </p> </section> <section id="CD012069-sec-0126"> <p><b>Body mass index (BMI)</b></p> <p>See <a href="./references#CD012069-fig-0017" title="">Analysis 2.7</a>. Compared to no intervention, methylphenidate decreased BMI (MD −1.60 kg/m<sup>2</sup>, 95% CI −2.96 to −0.24) in one study with 43 participants (<a href="./references#CD012069-bbs2-0223" title="VerretC , GardinerP , BéliveauL . Fitness level and gross motor performance of children with attention‐deficit hyperactivity disorder. Adapted Physical Activity Quarterly2010;27(4):337‐51. [PUBMED: 20956839] ">Verret 2010</a>). </p> </section> <section id="CD012069-sec-0127"> <p><b>Z scores</b></p> <p>See <a href="./references#CD012069-fig-0018" title="">Analysis 2.8</a>. </p> <p> <ul id="CD012069-list-0022"> <li> <p>Height</p> </li> </ul> </p> <p>Compared to no intervention, methylphenidate did not decrease the height z score (MD −0.19, 95% CI −0.43 to 0.05) in one study with 275 participants (<a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>). </p> <p> <ul id="CD012069-list-0023"> <li> <p>Weight</p> </li> </ul> </p> <p>Compared to no intervention, methylphenidate did not decrease the weight z score (MD −0.07, 95% CI −0.30 to 0.16) in one study with 275 participants (<a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>). </p> <p><a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a> also observed no change in weight related to methylphenidate (P = 0.05) when comparing participants receiving methylphenidate (39.7 (SD 17.70) kg; n = 135) to untreated participants (35.30 (SD 13.40) kg; n = 140). </p> <p>In <a href="./references#CD012069-bbs2-0114" title="AbikoffH . Tailored psychosocial treatments for ADHD: the search for a good fit. Journal of Clinical Child Psychology2001; Vol. 30, issue 1:122‐5. [DOI: 10.1207/S15374424JCCP3001_14; PUBMED: 11294070] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottG , GreenhillLL , et al. National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choices. Archives of General Psychiatry1997;54(9):865‐70. [PUBMED: 9294378] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottGR , GreenhillLL , et al. NIMH collaborative multimodal treatment study of children with ADHD (MTA): design, methodology, and protocol evolution. Journal of Attention Disorders1997;2(3):141‐58. [DOI: 10.1177/108705479700200301] ArnoldLE , ChuangS , DaviesM , AbikoffHB , ConnersCK , ElliottGR , et al. Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures. Journal of Abnormal Child Psychology2004;32(1):39‐51. [PUBMED: 14998110] ArnoldLE , ElliottM , SachsL , BirdH , KraemerHC , WellsKC , et al. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14‐month outcome in ADHD. Journal of Consulting and Clinical Psychology2003;71(4):713‐27. [PUBMED: 12924677] CareyWB . What the multimodal treatment study of children with attention deficit/hyperactivity disorder did and did not say about the use of methylphenidate for attention deficits. Pediatrics2000;105(4):863‐4. [PUBMED: 10742336] ConnersCK , EpsteinJN , MarchJS , AngoldA , WellsKC , KlaricJ , et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):159‐67. [DOI: 10.1097/00004583‐200102000‐00010; PUBMED: 11211364] GalanterCA , CarlsonGA , JensenPS , GreenhillLL , DaviesM , LiW , et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. Journal of Child and Adolescent Psychopharmacology2003;13(2):123‐36. [DOI: 10.1089/104454603322163844; PUBMED: 12880507] GreeneRW , AblonJS . What does the MTA study tell us about effective psychosocial treatment for ADHD?. Journal of Clinical Child Psychology2001;30(1):114‐21. [DOI: 10.1207/S15374424JCCP3001_13; PUBMED: 11294069] GreenhillLL , AbikoffHB , ArnoldLE , CantwellDP , ConnersCK , ElliottG , et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. Journal of the American Academy of Child and Adolescent Psychiatry1996;35(10):1304‐13. [DOI: 10.1097/00004583‐199610000‐00017; PUBMED: 8885584] GreenhillLL , SwansonJM , VitielloB , DaviesM , ClevengerW , WuM , et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):180‐7. [DOI: 10.1097/00004583‐200102000‐00012; PUBMED: 11211366] HansenL , ThomsenPH . How to treat ADHD/DAMP? Is there a conclusive answer? A critical survey of the MTA trial?. Ugeskr Laeger2005;167(48):4555‐9. [PUBMED: 16324436] HinshawSP . Moderators and mediators of treatment response for children with attention‐deficit/hyperactivity disorder: the Multimodal Treatment Study of children with attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1088‐96. [PUBMED: 10591284] HinshawSP , MarchJS , AbikoffH , ArnoldLE , CantwellDP , ConnersCK , et al. Comprehensive assessment of childhood Attention‐Deficit Hyperactivity Disorder in the context of a multisite, multimodal clinical trial. Journal of Attention Disorders1997;1(4):217‐34. [DOI: 10.1177/108705479700100403] JensenPS , ArnoldLE , SwansonJM , VitielloB , AbikoffHB , GreenhillLL , et al. 3‐year follow‐up of the NIMH MTA study. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):989‐1002. [DOI: 10.1097/CHI.0b013e3180686d48; PUBMED: 17667478] JensenPS , HinshawSP , KraemerHC , LeonoraN , NewcornJH , AbikoffHB , et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. Journal of the American Academy of Child and Adolescent Psychiatry2001; Vol. 40, issue 2:147‐58. [DOI: 10.1097/00004583‐200102000‐00009; PUBMED: 11211363] JensenPS , HinshawSP , SwansonJM , GreenhillLL , ConnersCK , ArnoldLE , et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. Journal of Developmental and Behavioral Pediatrics2001;22(1):60‐73. [PUBMED: 11265923] MTA Cooperative Group. A 14‐month randomized clinical trial of treatment strategies for attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1073‐86. [DOI: 10.1001/archpsyc.56.12.1073; PUBMED: 10591283] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: 24‐month outcomes of treatment strategies for attention‐deficit/hyperactivity disorder. Pediatrics2004;113(4):754‐61. [PUBMED: 15060224] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: changes in effectiveness and growth after the end of treatment. Pediatrics2004;113(4):762‐9. [PUBMED: 15060225] MarchJS , SwansonJM , ArnoldLE , HozaB , ConnersCK , HinshawSP , et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). Journal of Abnormal Child Psychology2000;28(6):527‐41. [PUBMED: 11104315] MolinaBS , FloryK , HinshawSP , GreinerAR , ArnoldLE , SwansonJM , et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1028‐40. [DOI: 10.1097/chi.0b013e3180686d96; PUBMED: 17667481] MolinaBS , HinshawSP , EugeneAL , SwansonJM , PelhamWE , HechtmanL , et al. Adolescent substance use in the multimodal treatment study of attention‐deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. Journal of the American Academy of Child and Adolescent Psychiatry2013;52(3):250‐63. [DOI: 10.1016/j.jaac.2012.12.014; PMC3589108; PUBMED: 23452682] MolinaBS , HinshawSP , SwansonJM , ArnoldLE , VitielloB , JensenPS , et al. The MTA at 8 years: prospective follow‐up of children treated for combined‐type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(5):484‐500. [DOI: 10.1097/CHI.0b013e31819c23d0; PMC3063150] NiewegEH . Does ADHD medication stop working after 2‐3 years? On the surprising, but little known follow‐up of the MTA study [Is adhd‐medicatie na 2‐3 jaar uitgewerkt? Over de verrassende, maar weinig bekendefollow‐up van het mta‐onderzoek]. Tijdschrift voor Psychiatrie2010;52(4):245‐54. [PUBMED: 20503165] OwensEB , HinshawSP , KraemerHC , ArnoldLE , AbikoffHB , CantwellDP , et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. Journal of Consulting and Clinical Psychology2003;71(3):540‐52. [PUBMED: 12795577] PelhamWEJr . The NIMH multimodal treatment study for attention‐deficit hyperactivity disorder: just say yes to drugs alone?. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie1999;44(10):981‐90. [DOI: 10.1177/070674379904401004; PUBMED: 10637677] PelhamWE , GnagyEM , GreinerAR , HozaB , HinshawSP , SwansonJM , et al. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. Journal of Abnormal Child Psychology2000;28(6):507‐25. [PUBMED: 11104314] RichtersJE , ArnoldLE , JensenPS , AbikoffH , ConnersCK , GreenhillLL , et al. NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale. Journal of the American Academy of Child and Adolescent Psychiatry1995;34(8):987‐1000. [DOI: 10.1097/00004583‐199508000‐00008; PUBMED: 7665456] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. Journal of Attention Disorders2008;12(1):15‐43. [DOI: 10.1177/1087054708319525; PUBMED: 18573924] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. Journal of Attention Disorders2008;12(1):4‐14. [DOI: 10.1177/1087054708319345; PUBMED: 18573923] SwansonJM , ElliottGR , GreenhillLL , WigalT , ArnoldLE , VitielloB , et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow‐up. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1015‐27. [DOI: 10.1097/chi.0b013e3180686d7e; PUBMED: 17667480] SwansonJM , HinshawSP , ArnoldLE , GibbonsRD , MarcusS , HurK , et al. Secondary evaluations of MTA 36‐month outcomes: propensity score and growth mixture model analyses. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1003‐14. [DOI: 10.1097/CHI.0b013e3180686d63; PUBMED: 17667479] SwansonJM , KraemerHC , HinshawSP , ArnoldLE , ConnersCK , AbikoffHB , et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):168‐79. [DOI: 10.1097/00004583‐200102000‐00011; PUBMED: 1121136] VitielloB , ElliottGR , SwansonJM , ArnoldLE , HechtmanL , AbikoffH , et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. American Journal of Psychiatry2012; Vol. 169, issue 2:167‐77. [DOI: 10.1176/appi.ajp.2011.10111705; PMC4132884; PUBMED: 21890793] VitielloB , SevereJB , GreenhillLL , ArnoldLE , AbikoffHB , BuksteinOG , et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):188‐96. [DOI: 10.1097/00004583‐200102000‐00013; PUBMED: 11211367] ">Jensen 1999 (MTA)</a>, weight gain was apparently lower in the methylphenidate group (n = 222) at 14 months (2.36 (SD 3.00) kg) and at 24 months (3.81 (SD 2.84) kg), compared to the untreated group (14 months: 5.14 (SD 3.53) kg; 24 months: 4.83 (SD 3.10) kg; n = 106). </p> <p> <ul id="CD012069-list-0024"> <li> <p>BMI</p> </li> </ul> </p> <p>One study with 275 participants, <a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a>, found no difference between those in the methylphenidate group and those in the no intervention group for BMI z score (MD 0.01, 95% CI −0.22 to 0.24). </p> <p>No comparative studies reported non‐serious adverse events related to the immune, urogenital, or other body systems. </p> </section> </section> <section id="CD012069-sec-0128"> <h6 class="title">1.2.6 Withdrawal of treatment</h6> <section id="CD012069-sec-0129"> <p><b>Due to non‐serious adverse events</b></p> <p>No comparative studies reported withdrawal of treatment due to non‐serious adverse events. </p> </section> <section id="CD012069-sec-0130"> <p><b>For unknown reasons</b></p> <p>See <a href="./references#CD012069-fig-0019" title="">Analysis 3.1</a>. One study with 146 participants, <a href="./references#CD012069-bbs2-0257" title="ZhangH , DuM , ZhuangS . Impact of long‐term treatment of methylphenidate on height and weight of school age children with ADHD. Neuropediatrics2010;41(2):55‐9. [DOI: 10.1055/s‐0030‐1261893; PUBMED: 20799150] ">Zhang 2010</a>, compared methylphenidate to no intervention, finding that it increased the proportion of participants withdrawn from methylphenidate for unknown reasons (RR 0.72 95% CI 0.62 to 0.84). </p> </section> </section> </section> </section> <section id="CD012069-sec-0131"> <h4 class="title">2. Non‐comparative studies</h4> <section id="CD012069-sec-0132"> <h5 class="title">2.1 Primary outcomes: serious adverse events</h5> <p>We included a total of 54 studies in meta‐analyses on this outcome.</p> <section id="CD012069-sec-0133"> <h6 class="title">2.1.1. Frequency of any serious adverse events</h6> <p>See <a href="./references#CD012069-fig-0020" title="">Analysis 4.1</a>. We included 50 studies (162,422 participants) that reported data on this outcome in a meta‐analysis. The proportion of participants on methylphenidate experiencing one or more serious adverse events was 1.20% (95% CI 0.70% to 2.00%; <a href="#CD012069-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD012069-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Proportion of participants on methylphenidate with any serious adverse events" data-id="CD012069-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Proportion of participants on methylphenidate with any serious adverse events</p> </div> </div> </div> </section> <section id="CD012069-sec-0134"> <h6 class="title">2.1.2 Central nervous system</h6> <p>See <a href="./references#CD012069-fig-0021" title="">Analysis 4.2</a>. Twenty‐two studies reported data on serious central nervous system adverse events (<a href="./references#CD012069-bbs2-0012" title="ArabgolF , PanaghiL , NikzadV . Risperidone versus methylphenidate in treatment of preschool children with attention‐deficit hyperactivity disorder. Iranian Journal of Pediatrics2015;25(1):1‐6. [DOI: 10.5812/ijp.265; PMC4505976] ">Arabgol 2015</a>; <a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0016" title="ArnoldLE , BozzoloDR , HodgkinsP , McKayM , Beckett‐ThurmanL , GreenbaumM , et al. Switching from oral extended‐release methylphenidate to the methylphenidate transdermal system: continued attention‐deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Current Medical Research and Opinion2010;26(1):129‐37. [DOI: 10.1185/03007990903437412; PMC3875401; PUBMED: 19916704] BuksteinOG , ArnoldLE , LandgrafJM , HodgkinsP . Does switching from oral extended‐release methylphenidate to the methylphenidate transdermal system affect health‐related quality‐of‐life and medication satisfaction for children with attention‐deficit/hyperactivity disorder?. Child and Adolescent Psychiatry and Mental Health2009;3(1):39. [DOI: 10.1186/1753‐2000‐3‐39; PMC2796990; PUBMED: 20003260] ">Arnold 2010</a>; <a href="./references#CD012069-bbs2-0034" title="CherlandE , FitzpatrickR . Psychotic side effects of psychostimulants: a 5‐year review. Canadian Journal of Psychiatry1999;44(8):811‐3. [DOI: 10.1177/070674379904400810; PUBMED: 10566114] ">Cherland 1999</a>; <a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a>; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a>; <a href="./references#CD012069-bbs2-0078" title="GerweM , StollhoffK , MossakowskiJ , KuehleHJ , GoertzU , SchaeferC , et al. Tolerability and effects of OROS® MPH (Concerta®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non‐interventional trial. Attention Deficit and Hyperactivity Disorders2009;1(2):175‐86. [DOI: 10.1007/s12402‐009‐0010‐6; PUBMED: 21432582] ">Gerwe 2009</a>; <a href="./references#CD012069-bbs2-0091" title="GreenT , WeinbergerR , DiamondA , BerantM , HirschfeldL , FrischA , et al. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. Journal of Child and Adolescent Psychopharmacology2011;21(6):589‐95. [DOI: 10.1089/cap.2011.0042; PUBMED: 22149470] GreenT , WeinbergerR , WeizmanA , KotlerM , GothelfD . Effect of methylphenidate on neurocognitive functioning in velocardiofacial syndrome: a randomized placebo‐controlled trial. Biological Psychiatry2009;65(Suppl 8):147 S. ">Green 2011</a>; <a href="./references#CD012069-bbs2-0114" title="AbikoffH . Tailored psychosocial treatments for ADHD: the search for a good fit. Journal of Clinical Child Psychology2001; Vol. 30, issue 1:122‐5. [DOI: 10.1207/S15374424JCCP3001_14; PUBMED: 11294070] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottG , GreenhillLL , et al. National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choices. Archives of General Psychiatry1997;54(9):865‐70. [PUBMED: 9294378] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottGR , GreenhillLL , et al. NIMH collaborative multimodal treatment study of children with ADHD (MTA): design, methodology, and protocol evolution. Journal of Attention Disorders1997;2(3):141‐58. [DOI: 10.1177/108705479700200301] ArnoldLE , ChuangS , DaviesM , AbikoffHB , ConnersCK , ElliottGR , et al. Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures. Journal of Abnormal Child Psychology2004;32(1):39‐51. [PUBMED: 14998110] ArnoldLE , ElliottM , SachsL , BirdH , KraemerHC , WellsKC , et al. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14‐month outcome in ADHD. Journal of Consulting and Clinical Psychology2003;71(4):713‐27. [PUBMED: 12924677] CareyWB . What the multimodal treatment study of children with attention deficit/hyperactivity disorder did and did not say about the use of methylphenidate for attention deficits. Pediatrics2000;105(4):863‐4. [PUBMED: 10742336] ConnersCK , EpsteinJN , MarchJS , AngoldA , WellsKC , KlaricJ , et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):159‐67. [DOI: 10.1097/00004583‐200102000‐00010; PUBMED: 11211364] GalanterCA , CarlsonGA , JensenPS , GreenhillLL , DaviesM , LiW , et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. Journal of Child and Adolescent Psychopharmacology2003;13(2):123‐36. [DOI: 10.1089/104454603322163844; PUBMED: 12880507] GreeneRW , AblonJS . What does the MTA study tell us about effective psychosocial treatment for ADHD?. Journal of Clinical Child Psychology2001;30(1):114‐21. [DOI: 10.1207/S15374424JCCP3001_13; PUBMED: 11294069] GreenhillLL , AbikoffHB , ArnoldLE , CantwellDP , ConnersCK , ElliottG , et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. Journal of the American Academy of Child and Adolescent Psychiatry1996;35(10):1304‐13. [DOI: 10.1097/00004583‐199610000‐00017; PUBMED: 8885584] GreenhillLL , SwansonJM , VitielloB , DaviesM , ClevengerW , WuM , et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):180‐7. [DOI: 10.1097/00004583‐200102000‐00012; PUBMED: 11211366] HansenL , ThomsenPH . How to treat ADHD/DAMP? Is there a conclusive answer? A critical survey of the MTA trial?. Ugeskr Laeger2005;167(48):4555‐9. [PUBMED: 16324436] HinshawSP . Moderators and mediators of treatment response for children with attention‐deficit/hyperactivity disorder: the Multimodal Treatment Study of children with attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1088‐96. [PUBMED: 10591284] HinshawSP , MarchJS , AbikoffH , ArnoldLE , CantwellDP , ConnersCK , et al. Comprehensive assessment of childhood Attention‐Deficit Hyperactivity Disorder in the context of a multisite, multimodal clinical trial. Journal of Attention Disorders1997;1(4):217‐34. [DOI: 10.1177/108705479700100403] JensenPS , ArnoldLE , SwansonJM , VitielloB , AbikoffHB , GreenhillLL , et al. 3‐year follow‐up of the NIMH MTA study. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):989‐1002. [DOI: 10.1097/CHI.0b013e3180686d48; PUBMED: 17667478] JensenPS , HinshawSP , KraemerHC , LeonoraN , NewcornJH , AbikoffHB , et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. Journal of the American Academy of Child and Adolescent Psychiatry2001; Vol. 40, issue 2:147‐58. [DOI: 10.1097/00004583‐200102000‐00009; PUBMED: 11211363] JensenPS , HinshawSP , SwansonJM , GreenhillLL , ConnersCK , ArnoldLE , et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. Journal of Developmental and Behavioral Pediatrics2001;22(1):60‐73. [PUBMED: 11265923] MTA Cooperative Group. A 14‐month randomized clinical trial of treatment strategies for attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1073‐86. [DOI: 10.1001/archpsyc.56.12.1073; PUBMED: 10591283] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: 24‐month outcomes of treatment strategies for attention‐deficit/hyperactivity disorder. Pediatrics2004;113(4):754‐61. [PUBMED: 15060224] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: changes in effectiveness and growth after the end of treatment. Pediatrics2004;113(4):762‐9. [PUBMED: 15060225] MarchJS , SwansonJM , ArnoldLE , HozaB , ConnersCK , HinshawSP , et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). Journal of Abnormal Child Psychology2000;28(6):527‐41. [PUBMED: 11104315] MolinaBS , FloryK , HinshawSP , GreinerAR , ArnoldLE , SwansonJM , et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1028‐40. [DOI: 10.1097/chi.0b013e3180686d96; PUBMED: 17667481] MolinaBS , HinshawSP , EugeneAL , SwansonJM , PelhamWE , HechtmanL , et al. Adolescent substance use in the multimodal treatment study of attention‐deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. Journal of the American Academy of Child and Adolescent Psychiatry2013;52(3):250‐63. [DOI: 10.1016/j.jaac.2012.12.014; PMC3589108; PUBMED: 23452682] MolinaBS , HinshawSP , SwansonJM , ArnoldLE , VitielloB , JensenPS , et al. The MTA at 8 years: prospective follow‐up of children treated for combined‐type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(5):484‐500. [DOI: 10.1097/CHI.0b013e31819c23d0; PMC3063150] NiewegEH . Does ADHD medication stop working after 2‐3 years? On the surprising, but little known follow‐up of the MTA study [Is adhd‐medicatie na 2‐3 jaar uitgewerkt? Over de verrassende, maar weinig bekendefollow‐up van het mta‐onderzoek]. Tijdschrift voor Psychiatrie2010;52(4):245‐54. [PUBMED: 20503165] OwensEB , HinshawSP , KraemerHC , ArnoldLE , AbikoffHB , CantwellDP , et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. Journal of Consulting and Clinical Psychology2003;71(3):540‐52. [PUBMED: 12795577] PelhamWEJr . The NIMH multimodal treatment study for attention‐deficit hyperactivity disorder: just say yes to drugs alone?. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie1999;44(10):981‐90. [DOI: 10.1177/070674379904401004; PUBMED: 10637677] PelhamWE , GnagyEM , GreinerAR , HozaB , HinshawSP , SwansonJM , et al. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. Journal of Abnormal Child Psychology2000;28(6):507‐25. [PUBMED: 11104314] RichtersJE , ArnoldLE , JensenPS , AbikoffH , ConnersCK , GreenhillLL , et al. NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale. Journal of the American Academy of Child and Adolescent Psychiatry1995;34(8):987‐1000. [DOI: 10.1097/00004583‐199508000‐00008; PUBMED: 7665456] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. Journal of Attention Disorders2008;12(1):15‐43. [DOI: 10.1177/1087054708319525; PUBMED: 18573924] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. Journal of Attention Disorders2008;12(1):4‐14. [DOI: 10.1177/1087054708319345; PUBMED: 18573923] SwansonJM , ElliottGR , GreenhillLL , WigalT , ArnoldLE , VitielloB , et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow‐up. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1015‐27. [DOI: 10.1097/chi.0b013e3180686d7e; PUBMED: 17667480] SwansonJM , HinshawSP , ArnoldLE , GibbonsRD , MarcusS , HurK , et al. Secondary evaluations of MTA 36‐month outcomes: propensity score and growth mixture model analyses. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1003‐14. [DOI: 10.1097/CHI.0b013e3180686d63; PUBMED: 17667479] SwansonJM , KraemerHC , HinshawSP , ArnoldLE , ConnersCK , AbikoffHB , et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):168‐79. [DOI: 10.1097/00004583‐200102000‐00011; PUBMED: 1121136] VitielloB , ElliottGR , SwansonJM , ArnoldLE , HechtmanL , AbikoffH , et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. American Journal of Psychiatry2012; Vol. 169, issue 2:167‐77. [DOI: 10.1176/appi.ajp.2011.10111705; PMC4132884; PUBMED: 21890793] VitielloB , SevereJB , GreenhillLL , ArnoldLE , AbikoffHB , BuksteinOG , et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):188‐96. [DOI: 10.1097/00004583‐200102000‐00013; PUBMED: 11211367] ">Jensen 1999 (MTA)</a>; <a href="./references#CD012069-bbs2-0121" title="KemnerJE , StarrHL , BowenDL , CicconePL , LynchJM . Greater symptom improvement and response rates with OROS® MPH vs. atomoxetine in children with ADHD. International Journal of Neuropsychopharmacology2004;7:S273‐4. [DOI: 10.1017/S1461145704004547] KemnerJE , StarrHL , CicconePE , Hooper‐WoodCG , CrockettRS . Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Advances in Therapy2005;22(5):498‐512. [PUBMED: 16418159] KemnerJE , StarrHL , Hooper‐WoodCG , CicconePE . Greater improvement and response rates with OROS (R) methylphenidate compared with atomoxetine in children with attention‐deficit/hyperactivity disorder. Pharmacotherapy2004;24(10):1462‐3. [DOI: 10.1592/phco.24.14.1419.43157] StarrHL , KemnerJ . Multicenter, randomized, open‐label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African‐American children with ADHD. Journal of the National Medical Association2005;97(10 Suppl):11S‐6S. [PMC2640623; PUBMED: 16350601] ">Kemner 2005 (FOCUS)</a>; <a href="./references#CD012069-bbs2-0135" title="LakicA , KesicA , DronjakD . Tics in children with attention‐deficit/hyperactivity disorder under treatment with the sustained‐release form of methylphenidate. European Neuropsychopharmacology2012; Vol. 22, issue Suppl 2:S420. [DOI: 10.1016/S0924‐977X(12)70658‐2] ">Lakic 2012</a>; <a href="./references#CD012069-bbs2-0142" title="LeeWJ , LeeTA , PickardAS , CaskeyRN , SchumockGT . Drugs associated with adverse events in children and adolescents. Pharmacotherapy2014;34(9):918‐26. [DOI: 10.1002/phar.1455; PUBMED: 24990656] ">Lee 2014</a>; <a href="./references#CD012069-bbs2-0152" title="McCarthyS , CranswickN , PottsL , TaylorE , WongIC . Mortality associated with attention‐deficit hyperactivity disorder: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Safety2009;32(11):1089‐96. [DOI: 10.2165/11317630‐000000000‐00000; PUBMED: 19810780] ">McCarthy 2009</a>; <a href="./references#CD012069-bbs2-0158" title="MohammadiMR , KashaniL , AkhondzadehS , IzadianES , OhadiniaS . Efficacy of theophylline compared to methylphenidate for the treatment of attention‐deficit hyperactivity disorder in children and adolescents: a pilot double‐blind randomized trial. Journal of Clinical Pharmacy and Therapeutics2004;29(2):139‐44. [DOI: 10.1111/j.1365‐2710.2004.00545.x; PUBMED: 15068402] ">Mohammadi 2004</a>; <a href="./references#CD012069-bbs2-0167" title="LeeMS , LeeSI , HongSD , KimJH , ChoiJ , JoungYS . Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12‐week multicenter, open‐label study. Journal of Child and Adolescent Psychopharmacology2013;23(1):22‐7. [DOI: 10.1089/cap.2012.0018; PUBMED: 23347125] NaKS , LeeSI , HongSD , KimJH , ShimSH , ChoiJ , et al. Effect of osmotic‐release oral system methylphenidate on learning skills in adolescents with attention‐deficit/hyperactivity disorder: an open‐label study. International Clinical Psychopharmacology2013;28(4):184‐92. [DOI: 10.1097/YIC.0b013e3283612509; PUBMED: 23587983] ">Na 2013</a>; <a href="./references#CD012069-bbs2-0184" title="HoareP , RemschmidtH , MedoriR , EttrichC , RothenbergerA , SantoshP , et al. 12‐month efficacy and safety of OROS MPH in children and adolescents with attention‐deficit/hyperactivity disorder switched from MPH. European Child and Adolescent Psychiatry2005;14(6):305‐9. [DOI: 10.1007/s00787‐005‐0486‐3; PUBMED: 16220214] RemschmidtH , HoareP , EttrichC , RothenbergerA , SantoshP , SchmidtM , et al. Symptom control in children and adolescents with attention‐deficit/hyperactivity disorder on switching from immediate‐release MPH to OROS® MPH. European Child and Adolescent Psychiatry2005;14(6):297‐304. [DOI: 10.1007/s00787‐005‐0467‐6] ">Remschmidt 2005</a>; <a href="./references#CD012069-bbs2-0192" title="SchmidtJK , PlückJ , vonGontardA . Waiver of EEG diagnostics prior to and during methylphenidate therapy: dangerous or justifiable? [Verzicht auf eine EEG‐Diagnostik vor Beginn und unter einer Therapie mit Methylphenidat: gefährlich oder gerechtfertigt?]. Zeitschrift fur Kinder‐ und Jugendpsychiatrie und Psychotherapie2002;30(4):295‐302. [DOI: 10.1024/1422‐4917.30.4.295] ">Schmidt 2002</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>; <a href="./references#CD012069-bbs2-0207" title="SuY , LiH , ChenY , FangF , XuT , LuH , et al. Remission rate and functional outcomes during a 6‐month treatment with Osmotic‐Release Oral‐System methylphenidate in children with attention‐deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology2015;35(5):525‐34. [DOI: 10.1097/JCP.0000000000000389; PUBMED: 26267421] ">Su 2015</a>; <a href="./references#CD012069-bbs2-0236" title="BiedermanJ . Evaluation of once‐daily OROS methylphenidate in children with attention‐deficit/hyperactivity disorder: effects on sleep, appetite, and tics. European Neuropsychopharmacology2003;13(Suppl 4):S447‐8. BiedermanJ . Treatment of attention‐deficit/hyperactivity disorder with the once‐daily OROS formulation of methylphenidate: effect on growth in children. European Neuropsychopharmacology2003;13(Suppl 4):S448‐9. FaraoneSV , BiedermanJ , ZimmermanB . An analysis of patient adherence to treatment during a 1‐year, open‐label study of OROS methylphenidate in children with ADHD. Journal of Attention Disorders2007;11(2):157‐66. [DOI: 10.1177/1087054706295663; PUBMED: 17494833] LernerMA , SpencerT . Analysis of growth in children with ADHD during long‐term therapy with once‐daily OROS® methylphenidate. Pediatric Academic Societies' Annual Meeting; 2004 May 1‐4; San Francisco (CA). 2004; Vol. 55. PalumboDR , StarrHL . Once‐daily OROS methylphenidate: Impact on tics in children with attention deficit hyperactivity disorder. Annals of Neurology2003;54(Suppl 7):S27. [DOI: 10.1002/ana.5049/epdf] SpencerTJ , FaraoneSV , BiedermanJ , LernerM , CooperKM , ZimmermanB , Concerta Study Group. Does prolonged therapy with a long‐acting stimulant suppress growth in children with ADHD?. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(5):527‐37. [DOI: 10.1097/01.chi.0000205710.01690.d4; PUBMED: 16670649] SpencerTJ , FaraoneSV , LernerM , CooperKM , ZimmermanB . Effect of long‐term treatment with stimulant medication on growth? Drs. Spencer et al. Reply. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(3):306. [DOI: 10.1097/chi.0b013e31802ed960] WigalSB , WilensTE , WolraichM , LernerM . Hematologic and blood biochemistry monitoring during methylphenidate treatment in children with attention‐deficit/hyperactivity disorder: 2‐year, open‐label study results. Pediatrics2007;120(1):e120‐8. [DOI: 10.1542/peds.2006‐1402] WilensT , BiedermanJ , LernerM , Concerta Study Group. Effects of once‐daily osmotic‐release methylphenidate on blood pressure and heart rate in children with attention‐deficit/hyperactivity disorder: results from a one‐year follow‐up study. Journal of Clinical Psychopharmacology2004;24(1):36‐41. [DOI: 10.1097/01.jcp.0000106223.36344.df; PUBMED: 14709945] WilensT , McBurnettK , SteinM , LernerM , SpencerT , WolraichM . ADHD treatment with once‐daily OROS methylphenidate: final results from a long‐term open‐label study. Journal of the American Academy of Child and Adolescent Psychiatry2005;44(10):1015‐23. [DOI: 10.1097/01.chi.0000173291.28688.e7; PUBMED: 16175106] WilensT , McBurnettK , SteinM , LernerM , SpencerT , WolraichM . ADHD treatment with once‐daily OROS methylphenidate: final results from a long‐term open‐label study: erratum. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(5):632. [DOI: 10.1097/00004583‐200605000‐00020] WilensT , PelhamW , SteinM , ConnersCK , AbikoffH , AtkinsM , et al. ADHD treatment with once‐daily OROS methylphenidate: interim 12‐month results from a long‐term open‐label study. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(4):424‐33. [DOI: 10.1097/01.CHI.0000046814.95464.7D; PUBMED: 12649629] ">Wilens 2005</a>; <a href="./references#CD012069-bbs2-0237" title="Oral system methylphenidate for teen ADHD. Brown University Child and Adolescent Psychopharmacology Update2006;8(3):4‐5. [DOI: 10.1002/cpu.20015] BiedermanJ . Effectiveness and safety of the once‐daily OROS formulation of methylphenidate in adolescents with attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2003;13(Suppl 4):S448. GreenhillLL . Safety and efficacy of OROS MPH in adolescents with ADHD. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco (CA). 2003. McGoughJJ , McBurnettK , BuksteinO , WilensTE , GreenhillL , LernerM , et al. Once‐daily OROS methylphenidate is safe and well tolerated in adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2006;16(3):351‐6. [DOI: 10.1089/cap.2006.16.351; PUBMED: 16768642] NewcornJH , SteinMA , CooperKM . Dose‐response characteristics in adolescents with attention‐deficit/hyperactivity disorder treated with OROS methylphenidate in a 4‐week, open‐label, dose‐titration study. Journal of Child and Adolescent Psychopharmacology2010;20(3):187‐96. [DOI: 10.1089/cap.2009.0102; PUBMED: 20578931] WilensTE , McBurnettK , BuksteinO , McGoughJ , GreenhillL , LernerM , et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention‐deficit/hyperactivity disorder. Archives of Pediatrics and Adolescent Medicine2006;160(1):82‐90. [DOI: 10.1001/archpedi.160.1.82; PUBMED: 16389216] ">Wilens 2006</a>). </p> <p>We included data from 19 of these studies in 10 meta‐analyses (<a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0016" title="ArnoldLE , BozzoloDR , HodgkinsP , McKayM , Beckett‐ThurmanL , GreenbaumM , et al. Switching from oral extended‐release methylphenidate to the methylphenidate transdermal system: continued attention‐deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Current Medical Research and Opinion2010;26(1):129‐37. [DOI: 10.1185/03007990903437412; PMC3875401; PUBMED: 19916704] BuksteinOG , ArnoldLE , LandgrafJM , HodgkinsP . Does switching from oral extended‐release methylphenidate to the methylphenidate transdermal system affect health‐related quality‐of‐life and medication satisfaction for children with attention‐deficit/hyperactivity disorder?. Child and Adolescent Psychiatry and Mental Health2009;3(1):39. [DOI: 10.1186/1753‐2000‐3‐39; PMC2796990; PUBMED: 20003260] ">Arnold 2010</a>; <a href="./references#CD012069-bbs2-0034" title="CherlandE , FitzpatrickR . Psychotic side effects of psychostimulants: a 5‐year review. Canadian Journal of Psychiatry1999;44(8):811‐3. [DOI: 10.1177/070674379904400810; PUBMED: 10566114] ">Cherland 1999</a>; <a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a>; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a>; <a href="./references#CD012069-bbs2-0078" title="GerweM , StollhoffK , MossakowskiJ , KuehleHJ , GoertzU , SchaeferC , et al. Tolerability and effects of OROS® MPH (Concerta®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non‐interventional trial. Attention Deficit and Hyperactivity Disorders2009;1(2):175‐86. [DOI: 10.1007/s12402‐009‐0010‐6; PUBMED: 21432582] ">Gerwe 2009</a>; <a href="./references#CD012069-bbs2-0114" title="AbikoffH . Tailored psychosocial treatments for ADHD: the search for a good fit. Journal of Clinical Child Psychology2001; Vol. 30, issue 1:122‐5. [DOI: 10.1207/S15374424JCCP3001_14; PUBMED: 11294070] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottG , GreenhillLL , et al. National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choices. Archives of General Psychiatry1997;54(9):865‐70. [PUBMED: 9294378] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottGR , GreenhillLL , et al. NIMH collaborative multimodal treatment study of children with ADHD (MTA): design, methodology, and protocol evolution. Journal of Attention Disorders1997;2(3):141‐58. [DOI: 10.1177/108705479700200301] ArnoldLE , ChuangS , DaviesM , AbikoffHB , ConnersCK , ElliottGR , et al. Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures. Journal of Abnormal Child Psychology2004;32(1):39‐51. [PUBMED: 14998110] ArnoldLE , ElliottM , SachsL , BirdH , KraemerHC , WellsKC , et al. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14‐month outcome in ADHD. Journal of Consulting and Clinical Psychology2003;71(4):713‐27. [PUBMED: 12924677] CareyWB . What the multimodal treatment study of children with attention deficit/hyperactivity disorder did and did not say about the use of methylphenidate for attention deficits. Pediatrics2000;105(4):863‐4. [PUBMED: 10742336] ConnersCK , EpsteinJN , MarchJS , AngoldA , WellsKC , KlaricJ , et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):159‐67. [DOI: 10.1097/00004583‐200102000‐00010; PUBMED: 11211364] GalanterCA , CarlsonGA , JensenPS , GreenhillLL , DaviesM , LiW , et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. Journal of Child and Adolescent Psychopharmacology2003;13(2):123‐36. [DOI: 10.1089/104454603322163844; PUBMED: 12880507] GreeneRW , AblonJS . What does the MTA study tell us about effective psychosocial treatment for ADHD?. Journal of Clinical Child Psychology2001;30(1):114‐21. [DOI: 10.1207/S15374424JCCP3001_13; PUBMED: 11294069] GreenhillLL , AbikoffHB , ArnoldLE , CantwellDP , ConnersCK , ElliottG , et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. Journal of the American Academy of Child and Adolescent Psychiatry1996;35(10):1304‐13. [DOI: 10.1097/00004583‐199610000‐00017; PUBMED: 8885584] GreenhillLL , SwansonJM , VitielloB , DaviesM , ClevengerW , WuM , et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):180‐7. [DOI: 10.1097/00004583‐200102000‐00012; PUBMED: 11211366] HansenL , ThomsenPH . How to treat ADHD/DAMP? Is there a conclusive answer? A critical survey of the MTA trial?. Ugeskr Laeger2005;167(48):4555‐9. [PUBMED: 16324436] HinshawSP . Moderators and mediators of treatment response for children with attention‐deficit/hyperactivity disorder: the Multimodal Treatment Study of children with attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1088‐96. [PUBMED: 10591284] HinshawSP , MarchJS , AbikoffH , ArnoldLE , CantwellDP , ConnersCK , et al. Comprehensive assessment of childhood Attention‐Deficit Hyperactivity Disorder in the context of a multisite, multimodal clinical trial. Journal of Attention Disorders1997;1(4):217‐34. [DOI: 10.1177/108705479700100403] JensenPS , ArnoldLE , SwansonJM , VitielloB , AbikoffHB , GreenhillLL , et al. 3‐year follow‐up of the NIMH MTA study. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):989‐1002. [DOI: 10.1097/CHI.0b013e3180686d48; PUBMED: 17667478] JensenPS , HinshawSP , KraemerHC , LeonoraN , NewcornJH , AbikoffHB , et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. Journal of the American Academy of Child and Adolescent Psychiatry2001; Vol. 40, issue 2:147‐58. [DOI: 10.1097/00004583‐200102000‐00009; PUBMED: 11211363] JensenPS , HinshawSP , SwansonJM , GreenhillLL , ConnersCK , ArnoldLE , et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. Journal of Developmental and Behavioral Pediatrics2001;22(1):60‐73. [PUBMED: 11265923] MTA Cooperative Group. A 14‐month randomized clinical trial of treatment strategies for attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1073‐86. [DOI: 10.1001/archpsyc.56.12.1073; PUBMED: 10591283] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: 24‐month outcomes of treatment strategies for attention‐deficit/hyperactivity disorder. Pediatrics2004;113(4):754‐61. [PUBMED: 15060224] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: changes in effectiveness and growth after the end of treatment. Pediatrics2004;113(4):762‐9. [PUBMED: 15060225] MarchJS , SwansonJM , ArnoldLE , HozaB , ConnersCK , HinshawSP , et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). Journal of Abnormal Child Psychology2000;28(6):527‐41. [PUBMED: 11104315] MolinaBS , FloryK , HinshawSP , GreinerAR , ArnoldLE , SwansonJM , et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1028‐40. [DOI: 10.1097/chi.0b013e3180686d96; PUBMED: 17667481] MolinaBS , HinshawSP , EugeneAL , SwansonJM , PelhamWE , HechtmanL , et al. Adolescent substance use in the multimodal treatment study of attention‐deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. Journal of the American Academy of Child and Adolescent Psychiatry2013;52(3):250‐63. [DOI: 10.1016/j.jaac.2012.12.014; PMC3589108; PUBMED: 23452682] MolinaBS , HinshawSP , SwansonJM , ArnoldLE , VitielloB , JensenPS , et al. The MTA at 8 years: prospective follow‐up of children treated for combined‐type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(5):484‐500. [DOI: 10.1097/CHI.0b013e31819c23d0; PMC3063150] NiewegEH . Does ADHD medication stop working after 2‐3 years? On the surprising, but little known follow‐up of the MTA study [Is adhd‐medicatie na 2‐3 jaar uitgewerkt? Over de verrassende, maar weinig bekendefollow‐up van het mta‐onderzoek]. Tijdschrift voor Psychiatrie2010;52(4):245‐54. [PUBMED: 20503165] OwensEB , HinshawSP , KraemerHC , ArnoldLE , AbikoffHB , CantwellDP , et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. Journal of Consulting and Clinical Psychology2003;71(3):540‐52. [PUBMED: 12795577] PelhamWEJr . The NIMH multimodal treatment study for attention‐deficit hyperactivity disorder: just say yes to drugs alone?. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie1999;44(10):981‐90. [DOI: 10.1177/070674379904401004; PUBMED: 10637677] PelhamWE , GnagyEM , GreinerAR , HozaB , HinshawSP , SwansonJM , et al. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. Journal of Abnormal Child Psychology2000;28(6):507‐25. [PUBMED: 11104314] RichtersJE , ArnoldLE , JensenPS , AbikoffH , ConnersCK , GreenhillLL , et al. NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale. Journal of the American Academy of Child and Adolescent Psychiatry1995;34(8):987‐1000. [DOI: 10.1097/00004583‐199508000‐00008; PUBMED: 7665456] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. Journal of Attention Disorders2008;12(1):15‐43. [DOI: 10.1177/1087054708319525; PUBMED: 18573924] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. Journal of Attention Disorders2008;12(1):4‐14. [DOI: 10.1177/1087054708319345; PUBMED: 18573923] SwansonJM , ElliottGR , GreenhillLL , WigalT , ArnoldLE , VitielloB , et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow‐up. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1015‐27. [DOI: 10.1097/chi.0b013e3180686d7e; PUBMED: 17667480] SwansonJM , HinshawSP , ArnoldLE , GibbonsRD , MarcusS , HurK , et al. Secondary evaluations of MTA 36‐month outcomes: propensity score and growth mixture model analyses. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1003‐14. [DOI: 10.1097/CHI.0b013e3180686d63; PUBMED: 17667479] SwansonJM , KraemerHC , HinshawSP , ArnoldLE , ConnersCK , AbikoffHB , et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):168‐79. [DOI: 10.1097/00004583‐200102000‐00011; PUBMED: 1121136] VitielloB , ElliottGR , SwansonJM , ArnoldLE , HechtmanL , AbikoffH , et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. American Journal of Psychiatry2012; Vol. 169, issue 2:167‐77. [DOI: 10.1176/appi.ajp.2011.10111705; PMC4132884; PUBMED: 21890793] VitielloB , SevereJB , GreenhillLL , ArnoldLE , AbikoffHB , BuksteinOG , et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):188‐96. [DOI: 10.1097/00004583‐200102000‐00013; PUBMED: 11211367] ">Jensen 1999 (MTA)</a>; <a href="./references#CD012069-bbs2-0121" title="KemnerJE , StarrHL , BowenDL , CicconePL , LynchJM . Greater symptom improvement and response rates with OROS® MPH vs. atomoxetine in children with ADHD. International Journal of Neuropsychopharmacology2004;7:S273‐4. [DOI: 10.1017/S1461145704004547] KemnerJE , StarrHL , CicconePE , Hooper‐WoodCG , CrockettRS . Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Advances in Therapy2005;22(5):498‐512. [PUBMED: 16418159] KemnerJE , StarrHL , Hooper‐WoodCG , CicconePE . Greater improvement and response rates with OROS (R) methylphenidate compared with atomoxetine in children with attention‐deficit/hyperactivity disorder. Pharmacotherapy2004;24(10):1462‐3. [DOI: 10.1592/phco.24.14.1419.43157] StarrHL , KemnerJ . Multicenter, randomized, open‐label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African‐American children with ADHD. Journal of the National Medical Association2005;97(10 Suppl):11S‐6S. [PMC2640623; PUBMED: 16350601] ">Kemner 2005 (FOCUS)</a>; <a href="./references#CD012069-bbs2-0135" title="LakicA , KesicA , DronjakD . Tics in children with attention‐deficit/hyperactivity disorder under treatment with the sustained‐release form of methylphenidate. European Neuropsychopharmacology2012; Vol. 22, issue Suppl 2:S420. [DOI: 10.1016/S0924‐977X(12)70658‐2] ">Lakic 2012</a>; <a href="./references#CD012069-bbs2-0142" title="LeeWJ , LeeTA , PickardAS , CaskeyRN , SchumockGT . Drugs associated with adverse events in children and adolescents. Pharmacotherapy2014;34(9):918‐26. [DOI: 10.1002/phar.1455; PUBMED: 24990656] ">Lee 2014</a>; <a href="./references#CD012069-bbs2-0152" title="McCarthyS , CranswickN , PottsL , TaylorE , WongIC . Mortality associated with attention‐deficit hyperactivity disorder: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Safety2009;32(11):1089‐96. [DOI: 10.2165/11317630‐000000000‐00000; PUBMED: 19810780] ">McCarthy 2009</a>; <a href="./references#CD012069-bbs2-0158" title="MohammadiMR , KashaniL , AkhondzadehS , IzadianES , OhadiniaS . Efficacy of theophylline compared to methylphenidate for the treatment of attention‐deficit hyperactivity disorder in children and adolescents: a pilot double‐blind randomized trial. Journal of Clinical Pharmacy and Therapeutics2004;29(2):139‐44. [DOI: 10.1111/j.1365‐2710.2004.00545.x; PUBMED: 15068402] ">Mohammadi 2004</a>; <a href="./references#CD012069-bbs2-0167" title="LeeMS , LeeSI , HongSD , KimJH , ChoiJ , JoungYS . Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12‐week multicenter, open‐label study. Journal of Child and Adolescent Psychopharmacology2013;23(1):22‐7. [DOI: 10.1089/cap.2012.0018; PUBMED: 23347125] NaKS , LeeSI , HongSD , KimJH , ShimSH , ChoiJ , et al. Effect of osmotic‐release oral system methylphenidate on learning skills in adolescents with attention‐deficit/hyperactivity disorder: an open‐label study. International Clinical Psychopharmacology2013;28(4):184‐92. [DOI: 10.1097/YIC.0b013e3283612509; PUBMED: 23587983] ">Na 2013</a>; <a href="./references#CD012069-bbs2-0184" title="HoareP , RemschmidtH , MedoriR , EttrichC , RothenbergerA , SantoshP , et al. 12‐month efficacy and safety of OROS MPH in children and adolescents with attention‐deficit/hyperactivity disorder switched from MPH. European Child and Adolescent Psychiatry2005;14(6):305‐9. [DOI: 10.1007/s00787‐005‐0486‐3; PUBMED: 16220214] RemschmidtH , HoareP , EttrichC , RothenbergerA , SantoshP , SchmidtM , et al. Symptom control in children and adolescents with attention‐deficit/hyperactivity disorder on switching from immediate‐release MPH to OROS® MPH. European Child and Adolescent Psychiatry2005;14(6):297‐304. [DOI: 10.1007/s00787‐005‐0467‐6] ">Remschmidt 2005</a>; <a href="./references#CD012069-bbs2-0192" title="SchmidtJK , PlückJ , vonGontardA . Waiver of EEG diagnostics prior to and during methylphenidate therapy: dangerous or justifiable? [Verzicht auf eine EEG‐Diagnostik vor Beginn und unter einer Therapie mit Methylphenidat: gefährlich oder gerechtfertigt?]. Zeitschrift fur Kinder‐ und Jugendpsychiatrie und Psychotherapie2002;30(4):295‐302. [DOI: 10.1024/1422‐4917.30.4.295] ">Schmidt 2002</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>; <a href="./references#CD012069-bbs2-0207" title="SuY , LiH , ChenY , FangF , XuT , LuH , et al. Remission rate and functional outcomes during a 6‐month treatment with Osmotic‐Release Oral‐System methylphenidate in children with attention‐deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology2015;35(5):525‐34. [DOI: 10.1097/JCP.0000000000000389; PUBMED: 26267421] ">Su 2015</a>; <a href="./references#CD012069-bbs2-0237" title="Oral system methylphenidate for teen ADHD. Brown University Child and Adolescent Psychopharmacology Update2006;8(3):4‐5. [DOI: 10.1002/cpu.20015] BiedermanJ . Effectiveness and safety of the once‐daily OROS formulation of methylphenidate in adolescents with attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2003;13(Suppl 4):S448. GreenhillLL . Safety and efficacy of OROS MPH in adolescents with ADHD. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco (CA). 2003. McGoughJJ , McBurnettK , BuksteinO , WilensTE , GreenhillL , LernerM , et al. Once‐daily OROS methylphenidate is safe and well tolerated in adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2006;16(3):351‐6. [DOI: 10.1089/cap.2006.16.351; PUBMED: 16768642] NewcornJH , SteinMA , CooperKM . Dose‐response characteristics in adolescents with attention‐deficit/hyperactivity disorder treated with OROS methylphenidate in a 4‐week, open‐label, dose‐titration study. Journal of Child and Adolescent Psychopharmacology2010;20(3):187‐96. [DOI: 10.1089/cap.2009.0102; PUBMED: 20578931] WilensTE , McBurnettK , BuksteinO , McGoughJ , GreenhillL , LernerM , et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention‐deficit/hyperactivity disorder. Archives of Pediatrics and Adolescent Medicine2006;160(1):82‐90. [DOI: 10.1001/archpedi.160.1.82; PUBMED: 16389216] ">Wilens 2006</a>). The proportion of participants on methylphenidate with: </p> <p> <ol id="CD012069-list-0025"> <li> <p>sudden death was 0.20% (95% CI 0.00% to 15.9%; 3 studies, 6301 participants; <a href="./references#CD012069-bbs2-0121" title="KemnerJE , StarrHL , BowenDL , CicconePL , LynchJM . Greater symptom improvement and response rates with OROS® MPH vs. atomoxetine in children with ADHD. International Journal of Neuropsychopharmacology2004;7:S273‐4. [DOI: 10.1017/S1461145704004547] KemnerJE , StarrHL , CicconePE , Hooper‐WoodCG , CrockettRS . Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Advances in Therapy2005;22(5):498‐512. [PUBMED: 16418159] KemnerJE , StarrHL , Hooper‐WoodCG , CicconePE . Greater improvement and response rates with OROS (R) methylphenidate compared with atomoxetine in children with attention‐deficit/hyperactivity disorder. Pharmacotherapy2004;24(10):1462‐3. [DOI: 10.1592/phco.24.14.1419.43157] StarrHL , KemnerJ . Multicenter, randomized, open‐label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African‐American children with ADHD. Journal of the National Medical Association2005;97(10 Suppl):11S‐6S. [PMC2640623; PUBMED: 16350601] ">Kemner 2005 (FOCUS)</a>; <a href="./references#CD012069-bbs2-0142" title="LeeWJ , LeeTA , PickardAS , CaskeyRN , SchumockGT . Drugs associated with adverse events in children and adolescents. Pharmacotherapy2014;34(9):918‐26. [DOI: 10.1002/phar.1455; PUBMED: 24990656] ">Lee 2014</a>; <a href="./references#CD012069-bbs2-0152" title="McCarthyS , CranswickN , PottsL , TaylorE , WongIC . Mortality associated with attention‐deficit hyperactivity disorder: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Safety2009;32(11):1089‐96. [DOI: 10.2165/11317630‐000000000‐00000; PUBMED: 19810780] ">McCarthy 2009</a>; see <a href="https://zenodo.org/record/1240290#.Wur6XWcUmBE" target="_blank">supplementary file S1</a>); </p> </li> <li> <p>suicide was 0.10% (95% CI 0.0% to 0.30%; 2 studies, 5596 participants; <a href="./references#CD012069-bbs2-0114" title="AbikoffH . Tailored psychosocial treatments for ADHD: the search for a good fit. Journal of Clinical Child Psychology2001; Vol. 30, issue 1:122‐5. [DOI: 10.1207/S15374424JCCP3001_14; PUBMED: 11294070] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottG , GreenhillLL , et al. National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choices. Archives of General Psychiatry1997;54(9):865‐70. [PUBMED: 9294378] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottGR , GreenhillLL , et al. NIMH collaborative multimodal treatment study of children with ADHD (MTA): design, methodology, and protocol evolution. Journal of Attention Disorders1997;2(3):141‐58. [DOI: 10.1177/108705479700200301] ArnoldLE , ChuangS , DaviesM , AbikoffHB , ConnersCK , ElliottGR , et al. Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures. Journal of Abnormal Child Psychology2004;32(1):39‐51. [PUBMED: 14998110] ArnoldLE , ElliottM , SachsL , BirdH , KraemerHC , WellsKC , et al. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14‐month outcome in ADHD. Journal of Consulting and Clinical Psychology2003;71(4):713‐27. [PUBMED: 12924677] CareyWB . What the multimodal treatment study of children with attention deficit/hyperactivity disorder did and did not say about the use of methylphenidate for attention deficits. Pediatrics2000;105(4):863‐4. [PUBMED: 10742336] ConnersCK , EpsteinJN , MarchJS , AngoldA , WellsKC , KlaricJ , et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):159‐67. [DOI: 10.1097/00004583‐200102000‐00010; PUBMED: 11211364] GalanterCA , CarlsonGA , JensenPS , GreenhillLL , DaviesM , LiW , et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. Journal of Child and Adolescent Psychopharmacology2003;13(2):123‐36. [DOI: 10.1089/104454603322163844; PUBMED: 12880507] GreeneRW , AblonJS . What does the MTA study tell us about effective psychosocial treatment for ADHD?. Journal of Clinical Child Psychology2001;30(1):114‐21. [DOI: 10.1207/S15374424JCCP3001_13; PUBMED: 11294069] GreenhillLL , AbikoffHB , ArnoldLE , CantwellDP , ConnersCK , ElliottG , et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. Journal of the American Academy of Child and Adolescent Psychiatry1996;35(10):1304‐13. [DOI: 10.1097/00004583‐199610000‐00017; PUBMED: 8885584] GreenhillLL , SwansonJM , VitielloB , DaviesM , ClevengerW , WuM , et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):180‐7. [DOI: 10.1097/00004583‐200102000‐00012; PUBMED: 11211366] HansenL , ThomsenPH . How to treat ADHD/DAMP? Is there a conclusive answer? A critical survey of the MTA trial?. Ugeskr Laeger2005;167(48):4555‐9. [PUBMED: 16324436] HinshawSP . Moderators and mediators of treatment response for children with attention‐deficit/hyperactivity disorder: the Multimodal Treatment Study of children with attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1088‐96. [PUBMED: 10591284] HinshawSP , MarchJS , AbikoffH , ArnoldLE , CantwellDP , ConnersCK , et al. Comprehensive assessment of childhood Attention‐Deficit Hyperactivity Disorder in the context of a multisite, multimodal clinical trial. Journal of Attention Disorders1997;1(4):217‐34. [DOI: 10.1177/108705479700100403] JensenPS , ArnoldLE , SwansonJM , VitielloB , AbikoffHB , GreenhillLL , et al. 3‐year follow‐up of the NIMH MTA study. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):989‐1002. [DOI: 10.1097/CHI.0b013e3180686d48; PUBMED: 17667478] JensenPS , HinshawSP , KraemerHC , LeonoraN , NewcornJH , AbikoffHB , et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. Journal of the American Academy of Child and Adolescent Psychiatry2001; Vol. 40, issue 2:147‐58. [DOI: 10.1097/00004583‐200102000‐00009; PUBMED: 11211363] JensenPS , HinshawSP , SwansonJM , GreenhillLL , ConnersCK , ArnoldLE , et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. Journal of Developmental and Behavioral Pediatrics2001;22(1):60‐73. [PUBMED: 11265923] MTA Cooperative Group. A 14‐month randomized clinical trial of treatment strategies for attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1073‐86. [DOI: 10.1001/archpsyc.56.12.1073; PUBMED: 10591283] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: 24‐month outcomes of treatment strategies for attention‐deficit/hyperactivity disorder. Pediatrics2004;113(4):754‐61. [PUBMED: 15060224] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: changes in effectiveness and growth after the end of treatment. Pediatrics2004;113(4):762‐9. [PUBMED: 15060225] MarchJS , SwansonJM , ArnoldLE , HozaB , ConnersCK , HinshawSP , et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). Journal of Abnormal Child Psychology2000;28(6):527‐41. [PUBMED: 11104315] MolinaBS , FloryK , HinshawSP , GreinerAR , ArnoldLE , SwansonJM , et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1028‐40. [DOI: 10.1097/chi.0b013e3180686d96; PUBMED: 17667481] MolinaBS , HinshawSP , EugeneAL , SwansonJM , PelhamWE , HechtmanL , et al. Adolescent substance use in the multimodal treatment study of attention‐deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. Journal of the American Academy of Child and Adolescent Psychiatry2013;52(3):250‐63. [DOI: 10.1016/j.jaac.2012.12.014; PMC3589108; PUBMED: 23452682] MolinaBS , HinshawSP , SwansonJM , ArnoldLE , VitielloB , JensenPS , et al. The MTA at 8 years: prospective follow‐up of children treated for combined‐type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(5):484‐500. [DOI: 10.1097/CHI.0b013e31819c23d0; PMC3063150] NiewegEH . Does ADHD medication stop working after 2‐3 years? On the surprising, but little known follow‐up of the MTA study [Is adhd‐medicatie na 2‐3 jaar uitgewerkt? Over de verrassende, maar weinig bekendefollow‐up van het mta‐onderzoek]. Tijdschrift voor Psychiatrie2010;52(4):245‐54. [PUBMED: 20503165] OwensEB , HinshawSP , KraemerHC , ArnoldLE , AbikoffHB , CantwellDP , et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. Journal of Consulting and Clinical Psychology2003;71(3):540‐52. [PUBMED: 12795577] PelhamWEJr . The NIMH multimodal treatment study for attention‐deficit hyperactivity disorder: just say yes to drugs alone?. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie1999;44(10):981‐90. [DOI: 10.1177/070674379904401004; PUBMED: 10637677] PelhamWE , GnagyEM , GreinerAR , HozaB , HinshawSP , SwansonJM , et al. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. Journal of Abnormal Child Psychology2000;28(6):507‐25. [PUBMED: 11104314] RichtersJE , ArnoldLE , JensenPS , AbikoffH , ConnersCK , GreenhillLL , et al. NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale. Journal of the American Academy of Child and Adolescent Psychiatry1995;34(8):987‐1000. [DOI: 10.1097/00004583‐199508000‐00008; PUBMED: 7665456] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. Journal of Attention Disorders2008;12(1):15‐43. [DOI: 10.1177/1087054708319525; PUBMED: 18573924] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. Journal of Attention Disorders2008;12(1):4‐14. [DOI: 10.1177/1087054708319345; PUBMED: 18573923] SwansonJM , ElliottGR , GreenhillLL , WigalT , ArnoldLE , VitielloB , et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow‐up. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1015‐27. [DOI: 10.1097/chi.0b013e3180686d7e; PUBMED: 17667480] SwansonJM , HinshawSP , ArnoldLE , GibbonsRD , MarcusS , HurK , et al. Secondary evaluations of MTA 36‐month outcomes: propensity score and growth mixture model analyses. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1003‐14. [DOI: 10.1097/CHI.0b013e3180686d63; PUBMED: 17667479] SwansonJM , KraemerHC , HinshawSP , ArnoldLE , ConnersCK , AbikoffHB , et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):168‐79. [DOI: 10.1097/00004583‐200102000‐00011; PUBMED: 1121136] VitielloB , ElliottGR , SwansonJM , ArnoldLE , HechtmanL , AbikoffH , et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. American Journal of Psychiatry2012; Vol. 169, issue 2:167‐77. [DOI: 10.1176/appi.ajp.2011.10111705; PMC4132884; PUBMED: 21890793] VitielloB , SevereJB , GreenhillLL , ArnoldLE , AbikoffHB , BuksteinOG , et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):188‐96. [DOI: 10.1097/00004583‐200102000‐00013; PUBMED: 11211367] ">Jensen 1999 (MTA)</a>; <a href="./references#CD012069-bbs2-0152" title="McCarthyS , CranswickN , PottsL , TaylorE , WongIC . Mortality associated with attention‐deficit hyperactivity disorder: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Safety2009;32(11):1089‐96. [DOI: 10.2165/11317630‐000000000‐00000; PUBMED: 19810780] ">McCarthy 2009</a>; see <a href="https://zenodo.org/record/1240301#.Wur7xWcUmBE" target="_blank">supplementary file S2</a>); </p> </li> <li> <p>suicide attempt was 2.10% (95% CI 0.40% to 9.00%; 3 studies, 339 participants; <a href="./references#CD012069-bbs2-0016" title="ArnoldLE , BozzoloDR , HodgkinsP , McKayM , Beckett‐ThurmanL , GreenbaumM , et al. Switching from oral extended‐release methylphenidate to the methylphenidate transdermal system: continued attention‐deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Current Medical Research and Opinion2010;26(1):129‐37. [DOI: 10.1185/03007990903437412; PMC3875401; PUBMED: 19916704] BuksteinOG , ArnoldLE , LandgrafJM , HodgkinsP . Does switching from oral extended‐release methylphenidate to the methylphenidate transdermal system affect health‐related quality‐of‐life and medication satisfaction for children with attention‐deficit/hyperactivity disorder?. Child and Adolescent Psychiatry and Mental Health2009;3(1):39. [DOI: 10.1186/1753‐2000‐3‐39; PMC2796990; PUBMED: 20003260] ">Arnold 2010</a>; <a href="./references#CD012069-bbs2-0142" title="LeeWJ , LeeTA , PickardAS , CaskeyRN , SchumockGT . Drugs associated with adverse events in children and adolescents. Pharmacotherapy2014;34(9):918‐26. [DOI: 10.1002/phar.1455; PUBMED: 24990656] ">Lee 2014</a>; <a href="./references#CD012069-bbs2-0184" title="HoareP , RemschmidtH , MedoriR , EttrichC , RothenbergerA , SantoshP , et al. 12‐month efficacy and safety of OROS MPH in children and adolescents with attention‐deficit/hyperactivity disorder switched from MPH. European Child and Adolescent Psychiatry2005;14(6):305‐9. [DOI: 10.1007/s00787‐005‐0486‐3; PUBMED: 16220214] RemschmidtH , HoareP , EttrichC , RothenbergerA , SantoshP , SchmidtM , et al. Symptom control in children and adolescents with attention‐deficit/hyperactivity disorder on switching from immediate‐release MPH to OROS® MPH. European Child and Adolescent Psychiatry2005;14(6):297‐304. [DOI: 10.1007/s00787‐005‐0467‐6] ">Remschmidt 2005</a>; see <a href="https://zenodo.org/record/1240306#.Wur8O2cUmBE" target="_blank">supplementary file S3</a>); </p> </li> <li> <p>suicidal thoughts was 1.10% (95% CI 0.30% to 4.40%; 2 studies, 176 participants; <a href="./references#CD012069-bbs2-0184" title="HoareP , RemschmidtH , MedoriR , EttrichC , RothenbergerA , SantoshP , et al. 12‐month efficacy and safety of OROS MPH in children and adolescents with attention‐deficit/hyperactivity disorder switched from MPH. European Child and Adolescent Psychiatry2005;14(6):305‐9. [DOI: 10.1007/s00787‐005‐0486‐3; PUBMED: 16220214] RemschmidtH , HoareP , EttrichC , RothenbergerA , SantoshP , SchmidtM , et al. Symptom control in children and adolescents with attention‐deficit/hyperactivity disorder on switching from immediate‐release MPH to OROS® MPH. European Child and Adolescent Psychiatry2005;14(6):297‐304. [DOI: 10.1007/s00787‐005‐0467‐6] ">Remschmidt 2005</a>; <a href="./references#CD012069-bbs2-0237" title="Oral system methylphenidate for teen ADHD. Brown University Child and Adolescent Psychopharmacology Update2006;8(3):4‐5. [DOI: 10.1002/cpu.20015] BiedermanJ . Effectiveness and safety of the once‐daily OROS formulation of methylphenidate in adolescents with attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2003;13(Suppl 4):S448. GreenhillLL . Safety and efficacy of OROS MPH in adolescents with ADHD. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco (CA). 2003. McGoughJJ , McBurnettK , BuksteinO , WilensTE , GreenhillL , LernerM , et al. Once‐daily OROS methylphenidate is safe and well tolerated in adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2006;16(3):351‐6. [DOI: 10.1089/cap.2006.16.351; PUBMED: 16768642] NewcornJH , SteinMA , CooperKM . Dose‐response characteristics in adolescents with attention‐deficit/hyperactivity disorder treated with OROS methylphenidate in a 4‐week, open‐label, dose‐titration study. Journal of Child and Adolescent Psychopharmacology2010;20(3):187‐96. [DOI: 10.1089/cap.2009.0102; PUBMED: 20578931] WilensTE , McBurnettK , BuksteinO , McGoughJ , GreenhillL , LernerM , et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention‐deficit/hyperactivity disorder. Archives of Pediatrics and Adolescent Medicine2006;160(1):82‐90. [DOI: 10.1001/archpedi.160.1.82; PUBMED: 16389216] ">Wilens 2006</a>; see <a href="https://zenodo.org/record/1240307#.Wur8kGcUmBE" target="_blank">supplementary file S4</a>); </p> </li> <li> <p>psychotic symptoms was 1.20% (95% CI 0.50% to 2.70%; 10 studies, 55,110 participants; <a href="./references#CD012069-bbs2-0034" title="CherlandE , FitzpatrickR . Psychotic side effects of psychostimulants: a 5‐year review. Canadian Journal of Psychiatry1999;44(8):811‐3. [DOI: 10.1177/070674379904400810; PUBMED: 10566114] ">Cherland 1999</a>; <a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a>; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0091" title="GreenT , WeinbergerR , DiamondA , BerantM , HirschfeldL , FrischA , et al. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. Journal of Child and Adolescent Psychopharmacology2011;21(6):589‐95. [DOI: 10.1089/cap.2011.0042; PUBMED: 22149470] GreenT , WeinbergerR , WeizmanA , KotlerM , GothelfD . Effect of methylphenidate on neurocognitive functioning in velocardiofacial syndrome: a randomized placebo‐controlled trial. Biological Psychiatry2009;65(Suppl 8):147 S. ">Green 2011</a>; <a href="./references#CD012069-bbs2-0158" title="MohammadiMR , KashaniL , AkhondzadehS , IzadianES , OhadiniaS . Efficacy of theophylline compared to methylphenidate for the treatment of attention‐deficit hyperactivity disorder in children and adolescents: a pilot double‐blind randomized trial. Journal of Clinical Pharmacy and Therapeutics2004;29(2):139‐44. [DOI: 10.1111/j.1365‐2710.2004.00545.x; PUBMED: 15068402] ">Mohammadi 2004</a>; <a href="./references#CD012069-bbs2-0167" title="LeeMS , LeeSI , HongSD , KimJH , ChoiJ , JoungYS . Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12‐week multicenter, open‐label study. Journal of Child and Adolescent Psychopharmacology2013;23(1):22‐7. [DOI: 10.1089/cap.2012.0018; PUBMED: 23347125] NaKS , LeeSI , HongSD , KimJH , ShimSH , ChoiJ , et al. Effect of osmotic‐release oral system methylphenidate on learning skills in adolescents with attention‐deficit/hyperactivity disorder: an open‐label study. International Clinical Psychopharmacology2013;28(4):184‐92. [DOI: 10.1097/YIC.0b013e3283612509; PUBMED: 23587983] ">Na 2013</a>; <a href="./references#CD012069-bbs2-0184" title="HoareP , RemschmidtH , MedoriR , EttrichC , RothenbergerA , SantoshP , et al. 12‐month efficacy and safety of OROS MPH in children and adolescents with attention‐deficit/hyperactivity disorder switched from MPH. European Child and Adolescent Psychiatry2005;14(6):305‐9. [DOI: 10.1007/s00787‐005‐0486‐3; PUBMED: 16220214] RemschmidtH , HoareP , EttrichC , RothenbergerA , SantoshP , SchmidtM , et al. Symptom control in children and adolescents with attention‐deficit/hyperactivity disorder on switching from immediate‐release MPH to OROS® MPH. European Child and Adolescent Psychiatry2005;14(6):297‐304. [DOI: 10.1007/s00787‐005‐0467‐6] ">Remschmidt 2005</a>; <a href="./references#CD012069-bbs2-0198" title="LeeMJ , YangKC , ShyuYC , YuanSS , YangCJ , LeeSY , et al. Attention‐deficit hyperactivity disorder, its treatment with medication and the probability of developing a depressive disorder: a nationwide population‐based study in Taiwan. Journal of Affective Disorders2016;189:110‐7. [DOI: 10.1016/j.jad.2015.09.015; PUBMED: 26433758] ShyuYC , YuanSS , LeeSY , YangCJ , YangKC , LeeTL , et al. Attention‐deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: a nationwide population‐based study in Taiwan. Schizophrenia Research2015;168(1‐2):161‐7. [DOI: 10.1016/j.schres.2015.08.033; PUBMED: 26363968] ">Shyu 2015</a>; <a href="./references#CD012069-bbs2-0207" title="SuY , LiH , ChenY , FangF , XuT , LuH , et al. Remission rate and functional outcomes during a 6‐month treatment with Osmotic‐Release Oral‐System methylphenidate in children with attention‐deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology2015;35(5):525‐34. [DOI: 10.1097/JCP.0000000000000389; PUBMED: 26267421] ">Su 2015</a>; <a href="./references#CD012069-bbs2-0237" title="Oral system methylphenidate for teen ADHD. Brown University Child and Adolescent Psychopharmacology Update2006;8(3):4‐5. [DOI: 10.1002/cpu.20015] BiedermanJ . Effectiveness and safety of the once‐daily OROS formulation of methylphenidate in adolescents with attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2003;13(Suppl 4):S448. GreenhillLL . Safety and efficacy of OROS MPH in adolescents with ADHD. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22; San Francisco (CA). 2003. McGoughJJ , McBurnettK , BuksteinO , WilensTE , GreenhillL , LernerM , et al. Once‐daily OROS methylphenidate is safe and well tolerated in adolescents with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2006;16(3):351‐6. [DOI: 10.1089/cap.2006.16.351; PUBMED: 16768642] NewcornJH , SteinMA , CooperKM . Dose‐response characteristics in adolescents with attention‐deficit/hyperactivity disorder treated with OROS methylphenidate in a 4‐week, open‐label, dose‐titration study. Journal of Child and Adolescent Psychopharmacology2010;20(3):187‐96. [DOI: 10.1089/cap.2009.0102; PUBMED: 20578931] WilensTE , McBurnettK , BuksteinO , McGoughJ , GreenhillL , LernerM , et al. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention‐deficit/hyperactivity disorder. Archives of Pediatrics and Adolescent Medicine2006;160(1):82‐90. [DOI: 10.1001/archpedi.160.1.82; PUBMED: 16389216] ">Wilens 2006</a>; see <a href="https://zenodo.org/record/1240308#.Wur85GcUmBE" target="_blank">supplementary file S5</a>); </p> </li> <li> <p>seizure was 0.30% (95% CI 0.10% to 1.10%; 2 studies, 1550 participants; <a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a>; <a href="./references#CD012069-bbs2-0192" title="SchmidtJK , PlückJ , vonGontardA . Waiver of EEG diagnostics prior to and during methylphenidate therapy: dangerous or justifiable? [Verzicht auf eine EEG‐Diagnostik vor Beginn und unter einer Therapie mit Methylphenidat: gefährlich oder gerechtfertigt?]. Zeitschrift fur Kinder‐ und Jugendpsychiatrie und Psychotherapie2002;30(4):295‐302. [DOI: 10.1024/1422‐4917.30.4.295] ">Schmidt 2002</a>; see <a href="https://zenodo.org/record/1240309#.Wur9PWcUmBE" target="_blank">supplementary file S6</a>); </p> </li> <li> <p>syncope was 0.20% (95% CI 0.00% to 0.70%; 2 studies, 1425 participants; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a>; see <a href="https://zenodo.org/record/1240310#.Wur9w2cUmBE" target="_blank">supplementary file S7</a>); </p> </li> <li> <p>tremor was 0.60% (95% CI 0.20% to 2.40%; 2 studies, 395 participants; <a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0078" title="GerweM , StollhoffK , MossakowskiJ , KuehleHJ , GoertzU , SchaeferC , et al. Tolerability and effects of OROS® MPH (Concerta®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non‐interventional trial. Attention Deficit and Hyperactivity Disorders2009;1(2):175‐86. [DOI: 10.1007/s12402‐009‐0010‐6; PUBMED: 21432582] ">Gerwe 2009</a>; see <a href="https://zenodo.org/record/1240311#.Wur-J2cUmBE" target="_blank">supplementary file S8</a>); </p> </li> <li> <p>psychiatric problems was 0.40% (95% CI 0.20% to 0.80%; 3 studies, 2613 participants; <a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a>; <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a>; see <a href="https://zenodo.org/record/1240312#.Wur-gWcUmBE" target="_blank">supplementary file S9</a>); and </p> </li> <li> <p>severe depression was 1.20% (95% CI 0.30% to 4.80%; 2 studies, 166 participants; <a href="./references#CD012069-bbs2-0034" title="CherlandE , FitzpatrickR . Psychotic side effects of psychostimulants: a 5‐year review. Canadian Journal of Psychiatry1999;44(8):811‐3. [DOI: 10.1177/070674379904400810; PUBMED: 10566114] ">Cherland 1999</a>; <a href="./references#CD012069-bbs2-0135" title="LakicA , KesicA , DronjakD . Tics in children with attention‐deficit/hyperactivity disorder under treatment with the sustained‐release form of methylphenidate. European Neuropsychopharmacology2012; Vol. 22, issue Suppl 2:S420. [DOI: 10.1016/S0924‐977X(12)70658‐2] ">Lakic 2012</a>; see <a href="https://zenodo.org/record/1240314#.Wur-2GcUmBE" target="_blank">supplementary file S10</a>). </p> </li> </ol> </p> <p>Seven studies reported on other adverse events related to the central nervous system.</p> <p> <ol id="CD012069-list-0026"> <li> <p>In <a href="./references#CD012069-bbs2-0142" title="LeeWJ , LeeTA , PickardAS , CaskeyRN , SchumockGT . Drugs associated with adverse events in children and adolescents. Pharmacotherapy2014;34(9):918‐26. [DOI: 10.1002/phar.1455; PUBMED: 24990656] ">Lee 2014</a> (100 participants), the proportion of participants on methylphenidate with overdose was 6.0% (95% CI 3.0% to 12.0%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a> (1426 participants), the proportion of participants on methylphenidate with: </p> <ol id="CD012069-list-0027"> <li> <p>eating disorder was 0.07% (95% CI 0.01% to 0.40%);</p> </li> <li> <p>aphasia was 0.07% (95% CI 0.01% to 0.40%);</p> </li> <li> <p>headache was 0.02% (95% CI 0.01% to 0.06%);</p> </li> <li> <p>neurological disorder was 0.14% (CI 0.04% to 0.50%);</p> </li> <li> <p>sleep disorder was 0.07% (95% CI 0.01% to 0.40%); and</p> </li> <li> <p>mood disorder was 0.07% (95% CI 0.01% to 0.40%).</p> </li> </ol> </li> <li> <p>In <a href="./references#CD012069-bbs2-0078" title="GerweM , StollhoffK , MossakowskiJ , KuehleHJ , GoertzU , SchaeferC , et al. Tolerability and effects of OROS® MPH (Concerta®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non‐interventional trial. Attention Deficit and Hyperactivity Disorders2009;1(2):175‐86. [DOI: 10.1007/s12402‐009‐0010‐6; PUBMED: 21432582] ">Gerwe 2009</a> (306 participants), the proportion of participants on methylphenidate with: </p> <ol id="CD012069-list-0028"> <li> <p>loss of consciousness was 0.33% (95% CI 0.06% to 2.00%); and</p> </li> <li> <p>family stress was 0.33% (95% CI 0.06% to 2.00%).</p> </li> </ol> </li> <li> <p>In <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a> (1098 participants), the proportion of participants on methylphenidate with impotence was 0.09% (95% CI 0.02% to 0.50%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0184" title="HoareP , RemschmidtH , MedoriR , EttrichC , RothenbergerA , SantoshP , et al. 12‐month efficacy and safety of OROS MPH in children and adolescents with attention‐deficit/hyperactivity disorder switched from MPH. European Child and Adolescent Psychiatry2005;14(6):305‐9. [DOI: 10.1007/s00787‐005‐0486‐3; PUBMED: 16220214] RemschmidtH , HoareP , EttrichC , RothenbergerA , SantoshP , SchmidtM , et al. Symptom control in children and adolescents with attention‐deficit/hyperactivity disorder on switching from immediate‐release MPH to OROS® MPH. European Child and Adolescent Psychiatry2005;14(6):297‐304. [DOI: 10.1007/s00787‐005‐0467‐6] ">Remschmidt 2005</a> (89 participants), the proportion of participants on methylphenidate with severe aggression was 1.12% (95% CI 0.20% to 6.00%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0012" title="ArabgolF , PanaghiL , NikzadV . Risperidone versus methylphenidate in treatment of preschool children with attention‐deficit hyperactivity disorder. Iranian Journal of Pediatrics2015;25(1):1‐6. [DOI: 10.5812/ijp.265; PMC4505976] ">Arabgol 2015</a> (18 participants), the proportion of participants on methylphenidate with severe anorexia was 5.56% (95% CI 0.10% to 25.0%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0034" title="CherlandE , FitzpatrickR . Psychotic side effects of psychostimulants: a 5‐year review. Canadian Journal of Psychiatry1999;44(8):811‐3. [DOI: 10.1177/070674379904400810; PUBMED: 10566114] ">Cherland 1999</a> (98 participants), the proportion of participants on methylphenidate with amphetamine intoxication was 3.06% (95% CI 1.00% to 8.00%). </p> </li> </ol> </p> </section> <section id="CD012069-sec-0135"> <h6 class="title">2.1.3 Cardiovascular and respiratory system</h6> <p>See <a href="./references#CD012069-fig-0022" title="">Analysis 4.3</a>. Five studies reported data on serious cardiovascular and respiratory adverse events (<a href="./references#CD012069-bbs2-0014" title="ArmanAR , YilmazS , CarkaxhiuG , SoysalD , AkalinF . Risk assessment using heart rate variability due to methylphenidate treatment in children with attention deficit hyperactivity disorder. European Child and Adolescent Psychiatry. 15th International Congress of European Society for Child and Adolescent Psychiatry (ESCAP); 2013 Jul 1; Dublin (Ireland). New York: Springer, 2013; Vol. 22:S302‐S303. ">Arman 2013</a>; <a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a>; <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a>; <a href="./references#CD012069-bbs2-0100" title="Effects of high‐dose OROS methylphenidate. Brown University Child and Adolescent Psychopharmacology Update2009;11(8):7‐8. [DOI: 10.1002/cpu.20097] DanielsSR . Cardiovascular effects of methylphenidate. Journal of Pediatrics2009;155(1):A3. [DOI: 10.1016/j.jpeds.2009.05.023] HammernessP , GeorgiopoulosA , DoyleRL , UtzingerL , SchillingerM , MartelonM , et al. An open study of adjunct OROS‐methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. Journal of Child and Adolescent Psychopharmacology2009;19(5):493‐9. [DOI: 10.1089/cap.2008.0126; PMC2861956; PUBMED: 19877973] ">Hammerness 2009</a>; <a href="./references#CD012069-bbs2-0242" title="WintersteinAG , GerhardT , ShusterJ , SaidiA . Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics2009;124(1):e75‐80. [DOI: 10.1542/peds.2008‐3138; PMC3856396; PUBMED: 19564272] WintersteinAG , GerhardT , ShusterJ , ZitoJ , JohnsonM , LiuH , et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Annals of Pharmacotherapy2008;42(1):24‐31. [DOI: 10.1345/aph.1K143; PUBMED: 18042808] ">Winterstein 2009</a>). We included these five studies across three meta‐analyses and found that the proportion of participants on methylphenidate with: </p> <p> <ol id="CD012069-list-0029"> <li> <p>respiratory, thoracic and mediastinal disorders was 0.40% (95% CI 0.00% to 6.90%; 2 studies, 1155 participants; <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a>; <a href="./references#CD012069-bbs2-0100" title="Effects of high‐dose OROS methylphenidate. Brown University Child and Adolescent Psychopharmacology Update2009;11(8):7‐8. [DOI: 10.1002/cpu.20097] DanielsSR . Cardiovascular effects of methylphenidate. Journal of Pediatrics2009;155(1):A3. [DOI: 10.1016/j.jpeds.2009.05.023] HammernessP , GeorgiopoulosA , DoyleRL , UtzingerL , SchillingerM , MartelonM , et al. An open study of adjunct OROS‐methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. Journal of Child and Adolescent Psychopharmacology2009;19(5):493‐9. [DOI: 10.1089/cap.2008.0126; PMC2861956; PUBMED: 19877973] ">Hammerness 2009</a>; <a href="https://zenodo.org/record/1240317#.Wur_KmcUmBE" target="_blank">see supplementary file S11</a>); </p> </li> <li> <p>cardiac problems was 0.70% (95% CI 0.20% to 2.40%; 3 studies, 19,351 participants; <a href="./references#CD012069-bbs2-0014" title="ArmanAR , YilmazS , CarkaxhiuG , SoysalD , AkalinF . Risk assessment using heart rate variability due to methylphenidate treatment in children with attention deficit hyperactivity disorder. European Child and Adolescent Psychiatry. 15th International Congress of European Society for Child and Adolescent Psychiatry (ESCAP); 2013 Jul 1; Dublin (Ireland). New York: Springer, 2013; Vol. 22:S302‐S303. ">Arman 2013</a>; <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a>; <a href="./references#CD012069-bbs2-0242" title="WintersteinAG , GerhardT , ShusterJ , SaidiA . Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics2009;124(1):e75‐80. [DOI: 10.1542/peds.2008‐3138; PMC3856396; PUBMED: 19564272] WintersteinAG , GerhardT , ShusterJ , ZitoJ , JohnsonM , LiuH , et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Annals of Pharmacotherapy2008;42(1):24‐31. [DOI: 10.1345/aph.1K143; PUBMED: 18042808] ">Winterstein 2009</a>; <a href="https://zenodo.org/record/1240318#.Wur_pWcUmBE" target="_blank">see supplementary file S12</a>); and </p> </li> <li> <p>tachycardia was 0.20% (95% CI 0.10% to 0.40%; 2 studies, 2524 participants; <a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a>; <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a>; <a href="https://zenodo.org/record/1240319#.WusqHmcUmBE" target="_blank">see supplementary file S13</a>). </p> </li> </ol> </p> <p>Two of these studies also reported on other cardiovascular and respiratory adverse events (<a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a>; <a href="./references#CD012069-bbs2-0100" title="Effects of high‐dose OROS methylphenidate. Brown University Child and Adolescent Psychopharmacology Update2009;11(8):7‐8. [DOI: 10.1002/cpu.20097] DanielsSR . Cardiovascular effects of methylphenidate. Journal of Pediatrics2009;155(1):A3. [DOI: 10.1016/j.jpeds.2009.05.023] HammernessP , GeorgiopoulosA , DoyleRL , UtzingerL , SchillingerM , MartelonM , et al. An open study of adjunct OROS‐methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. Journal of Child and Adolescent Psychopharmacology2009;19(5):493‐9. [DOI: 10.1089/cap.2008.0126; PMC2861956; PUBMED: 19877973] ">Hammerness 2009</a>). </p> <p> <ol id="CD012069-list-0030"> <li> <p>In <a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a> (1426 participants), the proportion of participants on methylphenidate with: </p> <ol id="CD012069-list-0031"> <li> <p>severe hypertension was 0.14% (95% CI 0.00% to 0.05%); and</p> </li> <li> <p>epistaxis was 0.07% (95% CI 0.00% to 0.40%).</p> </li> </ol> </li> <li> <p>In <a href="./references#CD012069-bbs2-0100" title="Effects of high‐dose OROS methylphenidate. Brown University Child and Adolescent Psychopharmacology Update2009;11(8):7‐8. [DOI: 10.1002/cpu.20097] DanielsSR . Cardiovascular effects of methylphenidate. Journal of Pediatrics2009;155(1):A3. [DOI: 10.1016/j.jpeds.2009.05.023] HammernessP , GeorgiopoulosA , DoyleRL , UtzingerL , SchillingerM , MartelonM , et al. An open study of adjunct OROS‐methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. Journal of Child and Adolescent Psychopharmacology2009;19(5):493‐9. [DOI: 10.1089/cap.2008.0126; PMC2861956; PUBMED: 19877973] ">Hammerness 2009</a> (57 participants), the proportion of participants on methylphenidate with viral illness was 1.75% (95% CI 0.03% to 9.28%). </p> </li> </ol> </p> </section> <section id="CD012069-sec-0136"> <h6 class="title">2.1.4 Gastrointestinal system</h6> <p>See <a href="./references#CD012069-fig-0023" title="">Analysis 4.4</a>. One study with 1426 participants reported data on gastrointestinal adverse events (<a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a>). In this study, the proportion of participants on methylphenidate with: </p> <p> <ol id="CD012069-list-0032"> <li> <p>gastrointestinal disease was 0.42% (95% CI 0.19% to 0.91%); and</p> </li> <li> <p>liver disease was 0.07% (95% CI 0.00% to 0.40%).</p> </li> </ol> </p> </section> <section id="CD012069-sec-0137"> <h6 class="title">2.1.5 Musculoskeletal system</h6> <p>See <a href="./references#CD012069-fig-0024" title="">Analysis 4.5</a>. We included two studies (384 participants) providing data on musculoskeletal adverse events in a meta‐analysis (<a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0100" title="Effects of high‐dose OROS methylphenidate. Brown University Child and Adolescent Psychopharmacology Update2009;11(8):7‐8. [DOI: 10.1002/cpu.20097] DanielsSR . Cardiovascular effects of methylphenidate. Journal of Pediatrics2009;155(1):A3. [DOI: 10.1016/j.jpeds.2009.05.023] HammernessP , GeorgiopoulosA , DoyleRL , UtzingerL , SchillingerM , MartelonM , et al. An open study of adjunct OROS‐methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. Journal of Child and Adolescent Psychopharmacology2009;19(5):493‐9. [DOI: 10.1089/cap.2008.0126; PMC2861956; PUBMED: 19877973] ">Hammerness 2009</a>). The proportion of participants on methylphenidate with fractures was 1.20% (95% CI 0.10% to 11.5%; see <a href="https://zenodo.org/record/1240322#.WusBSWcUmBE" target="_blank">supplementary file S14</a>). </p> </section> <section id="CD012069-sec-0138"> <h6 class="title">2.1.6 Immune system</h6> <p>See <a href="./references#CD012069-fig-0025" title="">Analysis 4.6</a>. Only one study with 1426 participants reported data on adverse events of the immune system (<a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a>). In this study, the proportion of participants on methylphenidate with autoimmune disease was 0.07% (95% CI 0.00% to 0.40%). </p> <p>No comparative studies reported adverse events related to the urogenital or other body systems. </p> </section> <section id="CD012069-sec-0139"> <h6 class="title">2.1.9 Withdrawal of treatment</h6> <section id="CD012069-sec-0140"> <p><b>Due to serious adverse events</b></p> <p>See <a href="./references#CD012069-fig-0026" title="">Analysis 5.1</a>. Seven studies with 1173 participants reported data on the number of participants withdrawn from methylphenidate treatment due to serious adverse events (<a href="./references#CD012069-bbs2-0012" title="ArabgolF , PanaghiL , NikzadV . Risperidone versus methylphenidate in treatment of preschool children with attention‐deficit hyperactivity disorder. Iranian Journal of Pediatrics2015;25(1):1‐6. [DOI: 10.5812/ijp.265; PMC4505976] ">Arabgol 2015</a>; <a href="./references#CD012069-bbs2-0016" title="ArnoldLE , BozzoloDR , HodgkinsP , McKayM , Beckett‐ThurmanL , GreenbaumM , et al. Switching from oral extended‐release methylphenidate to the methylphenidate transdermal system: continued attention‐deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Current Medical Research and Opinion2010;26(1):129‐37. [DOI: 10.1185/03007990903437412; PMC3875401; PUBMED: 19916704] BuksteinOG , ArnoldLE , LandgrafJM , HodgkinsP . Does switching from oral extended‐release methylphenidate to the methylphenidate transdermal system affect health‐related quality‐of‐life and medication satisfaction for children with attention‐deficit/hyperactivity disorder?. Child and Adolescent Psychiatry and Mental Health2009;3(1):39. [DOI: 10.1186/1753‐2000‐3‐39; PMC2796990; PUBMED: 20003260] ">Arnold 2010</a>; <a href="./references#CD012069-bbs2-0019" title="AshkenasiA . Effect of transdermal methylphenidate wear times on sleep in children with ADHD. Journal of Neurology2012;259(Suppl 1):S33‐4. [DOI: 10.1007/s00415‐012‐6524‐4] AshkenasiA . Effect of transdermal methylphenidate wear times on sleep in children with attention deficit hyperactivity disorder. Pediatric Neurology2011;45(6):381‐6. [DOI: 10.1016/j.pediatrneurol.2011.09.003; PUBMED: 22115000] ">Ashkenasi 2011</a>; <a href="./references#CD012069-bbs2-0065" title="FaraoneSV , GieferEE . Long‐term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(9):1138‐47. [DOI: 10.1097/chi.0b013e31806ad1d7; PUBMED: 17712237] ">Faraone 2007a</a>; <a href="./references#CD012069-bbs2-0071" title="FindlingRL , KaticA , RubinR , MoonE , CivilR , LiY . A 6‐month, open‐label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2010;20(5):366‐75. [DOI: 10.1089/cap.2009.0122; PUBMED: 20973707] FindlingRL , TurnbowJ , BurnsideJ , MelmedR , CivilR , LiY . A randomized, double‐blind, multicenter, parallel‐group, placebo‐controlled, dose‐optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents. CNS Spectrums2010;15(7):419‐30. [PUBMED: 20625364] KeatingGM . Methylphenidate transdermal system in attention‐deficit hyperactivity disorder in adolescents: profile report. Drugs in R&amp;D. G.M. Keating, Adis, Private Bag 65901, 41 Centorian Drive, Mairangi Bay, North Shore 0754, Auckland, New Zealand. E‐mail: demail@springer.com, 2012; Vol. 12, issue 3:171‐3. [DOI: 10.2165/11207490‐000000000‐00000; PMC3585903; PUBMED: 22934753] ">Findling 2010</a>; <a href="./references#CD012069-bbs2-0167" title="LeeMS , LeeSI , HongSD , KimJH , ChoiJ , JoungYS . Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12‐week multicenter, open‐label study. Journal of Child and Adolescent Psychopharmacology2013;23(1):22‐7. [DOI: 10.1089/cap.2012.0018; PUBMED: 23347125] NaKS , LeeSI , HongSD , KimJH , ShimSH , ChoiJ , et al. Effect of osmotic‐release oral system methylphenidate on learning skills in adolescents with attention‐deficit/hyperactivity disorder: an open‐label study. International Clinical Psychopharmacology2013;28(4):184‐92. [DOI: 10.1097/YIC.0b013e3283612509; PUBMED: 23587983] ">Na 2013</a>; <a href="./references#CD012069-bbs2-0236" title="BiedermanJ . Evaluation of once‐daily OROS methylphenidate in children with attention‐deficit/hyperactivity disorder: effects on sleep, appetite, and tics. European Neuropsychopharmacology2003;13(Suppl 4):S447‐8. BiedermanJ . Treatment of attention‐deficit/hyperactivity disorder with the once‐daily OROS formulation of methylphenidate: effect on growth in children. European Neuropsychopharmacology2003;13(Suppl 4):S448‐9. FaraoneSV , BiedermanJ , ZimmermanB . An analysis of patient adherence to treatment during a 1‐year, open‐label study of OROS methylphenidate in children with ADHD. Journal of Attention Disorders2007;11(2):157‐66. [DOI: 10.1177/1087054706295663; PUBMED: 17494833] LernerMA , SpencerT . Analysis of growth in children with ADHD during long‐term therapy with once‐daily OROS® methylphenidate. Pediatric Academic Societies' Annual Meeting; 2004 May 1‐4; San Francisco (CA). 2004; Vol. 55. PalumboDR , StarrHL . Once‐daily OROS methylphenidate: Impact on tics in children with attention deficit hyperactivity disorder. Annals of Neurology2003;54(Suppl 7):S27. [DOI: 10.1002/ana.5049/epdf] SpencerTJ , FaraoneSV , BiedermanJ , LernerM , CooperKM , ZimmermanB , Concerta Study Group. Does prolonged therapy with a long‐acting stimulant suppress growth in children with ADHD?. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(5):527‐37. [DOI: 10.1097/01.chi.0000205710.01690.d4; PUBMED: 16670649] SpencerTJ , FaraoneSV , LernerM , CooperKM , ZimmermanB . Effect of long‐term treatment with stimulant medication on growth? Drs. Spencer et al. Reply. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(3):306. [DOI: 10.1097/chi.0b013e31802ed960] WigalSB , WilensTE , WolraichM , LernerM . Hematologic and blood biochemistry monitoring during methylphenidate treatment in children with attention‐deficit/hyperactivity disorder: 2‐year, open‐label study results. Pediatrics2007;120(1):e120‐8. [DOI: 10.1542/peds.2006‐1402] WilensT , BiedermanJ , LernerM , Concerta Study Group. Effects of once‐daily osmotic‐release methylphenidate on blood pressure and heart rate in children with attention‐deficit/hyperactivity disorder: results from a one‐year follow‐up study. Journal of Clinical Psychopharmacology2004;24(1):36‐41. [DOI: 10.1097/01.jcp.0000106223.36344.df; PUBMED: 14709945] WilensT , McBurnettK , SteinM , LernerM , SpencerT , WolraichM . ADHD treatment with once‐daily OROS methylphenidate: final results from a long‐term open‐label study. Journal of the American Academy of Child and Adolescent Psychiatry2005;44(10):1015‐23. [DOI: 10.1097/01.chi.0000173291.28688.e7; PUBMED: 16175106] WilensT , McBurnettK , SteinM , LernerM , SpencerT , WolraichM . ADHD treatment with once‐daily OROS methylphenidate: final results from a long‐term open‐label study: erratum. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(5):632. [DOI: 10.1097/00004583‐200605000‐00020] WilensT , PelhamW , SteinM , ConnersCK , AbikoffH , AtkinsM , et al. ADHD treatment with once‐daily OROS methylphenidate: interim 12‐month results from a long‐term open‐label study. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(4):424‐33. [DOI: 10.1097/01.CHI.0000046814.95464.7D; PUBMED: 12649629] ">Wilens 2005</a>). We conducted a meta‐analysis of data from these seven studies and found that the proportion of participants withdrawn from methylphenidate treatment due to serious adverse events was 1.20% (95% CI 0.60% to 2.30%; <a href="#CD012069-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD012069-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Proportion of participants withdrawn from methylphenidate due to serious adverse events" data-id="CD012069-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Proportion of participants withdrawn from methylphenidate due to serious adverse events</p> </div> </div> </div> <p>Three of the studies also reported on the proportion participants withdrawn from methylphenidate treatment due to specific serious adverse events (<a href="./references#CD012069-bbs2-0012" title="ArabgolF , PanaghiL , NikzadV . Risperidone versus methylphenidate in treatment of preschool children with attention‐deficit hyperactivity disorder. Iranian Journal of Pediatrics2015;25(1):1‐6. [DOI: 10.5812/ijp.265; PMC4505976] ">Arabgol 2015</a>; <a href="./references#CD012069-bbs2-0016" title="ArnoldLE , BozzoloDR , HodgkinsP , McKayM , Beckett‐ThurmanL , GreenbaumM , et al. Switching from oral extended‐release methylphenidate to the methylphenidate transdermal system: continued attention‐deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Current Medical Research and Opinion2010;26(1):129‐37. [DOI: 10.1185/03007990903437412; PMC3875401; PUBMED: 19916704] BuksteinOG , ArnoldLE , LandgrafJM , HodgkinsP . Does switching from oral extended‐release methylphenidate to the methylphenidate transdermal system affect health‐related quality‐of‐life and medication satisfaction for children with attention‐deficit/hyperactivity disorder?. Child and Adolescent Psychiatry and Mental Health2009;3(1):39. [DOI: 10.1186/1753‐2000‐3‐39; PMC2796990; PUBMED: 20003260] ">Arnold 2010</a>; <a href="./references#CD012069-bbs2-0019" title="AshkenasiA . Effect of transdermal methylphenidate wear times on sleep in children with ADHD. Journal of Neurology2012;259(Suppl 1):S33‐4. [DOI: 10.1007/s00415‐012‐6524‐4] AshkenasiA . Effect of transdermal methylphenidate wear times on sleep in children with attention deficit hyperactivity disorder. Pediatric Neurology2011;45(6):381‐6. [DOI: 10.1016/j.pediatrneurol.2011.09.003; PUBMED: 22115000] ">Ashkenasi 2011</a>). </p> <p>All three studies reported the proportion of participants withdrawn from methylphenidate treatment due to hallucinations (0.90%, 95% Cl 0.2% to 4.4%; 554 participants; <a href="https://zenodo.org/record/1240448#.Wuspr2mLSJA" target="_blank">See supplementary file S15</a>). </p> <p><a href="./references#CD012069-bbs2-0012" title="ArabgolF , PanaghiL , NikzadV . Risperidone versus methylphenidate in treatment of preschool children with attention‐deficit hyperactivity disorder. Iranian Journal of Pediatrics2015;25(1):1‐6. [DOI: 10.5812/ijp.265; PMC4505976] ">Arabgol 2015</a> (18 participants) also reported the proportion of participants withdrawn from methylphenidate treatment due to severe anorexia as 5.56% (95% Cl 1.00% to 25.8%). </p> <p><a href="./references#CD012069-bbs2-0016" title="ArnoldLE , BozzoloDR , HodgkinsP , McKayM , Beckett‐ThurmanL , GreenbaumM , et al. Switching from oral extended‐release methylphenidate to the methylphenidate transdermal system: continued attention‐deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Current Medical Research and Opinion2010;26(1):129‐37. [DOI: 10.1185/03007990903437412; PMC3875401; PUBMED: 19916704] BuksteinOG , ArnoldLE , LandgrafJM , HodgkinsP . Does switching from oral extended‐release methylphenidate to the methylphenidate transdermal system affect health‐related quality‐of‐life and medication satisfaction for children with attention‐deficit/hyperactivity disorder?. Child and Adolescent Psychiatry and Mental Health2009;3(1):39. [DOI: 10.1186/1753‐2000‐3‐39; PMC2796990; PUBMED: 20003260] ">Arnold 2010</a> (171 participants) also reported the proportion of participants withdrawn from methylphenidate treatment due to suicide attempt as 0.58% (95% Cl 0.10% to 3.23%). </p> </section> <section id="CD012069-sec-0141"> <p><b>Due to adverse events of unknown severity</b></p> <p>See <a href="./references#CD012069-fig-0027" title="">Analysis 5.2</a>. We conducted a meta‐analysis of data from 22 studies (3708 participants) that reported the number of patients withdrawn from methylphenidate treatment due to adverse events of unknown severity. The proportion of participants withdrawn from methylphenidate treatment due to adverse events of unknown severity was 7.3% (95% CI 5.3% to 10.0%; <a href="#CD012069-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD012069-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Proportion of participants withdrawn from methylphenidate due to adverse events of unknown severity" data-id="CD012069-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Proportion of participants withdrawn from methylphenidate due to adverse events of unknown severity </p> </div> </div> </div> </section> </section> </section> <section id="CD012069-sec-0142"> <h5 class="title">2.2 Secondary outcomes: non‐serious adverse events</h5> <p>All but 11 studies contributed data to our meta‐analyses (see details below). For the 11 studies which contributed data that we could not combine, we reported the results qualitatively (<a href="./references#CD012069-bbs2-0035" title="ChoS‐C , KimB‐N , CumminsTD , KimJ‐W , BellgroveMA . Norepinephrine transporter ‐3081(A/T) and alpha‐2A‐adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS‐methylphenidate treatment. Journal of Psychopharmacology2012; Vol. 26, issue 3:380‐9. [DOI: 10.1177/0269881111405356] ">Cho 2012</a><i>;</i><a href="./references#CD012069-bbs2-0058" title="Dubnov‐RazG , PerryA , BergerI . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2011;26(3):302‐8. [DOI: 10.1177/0883073810380051; PUBMED: 20929910] YangR , MaoS , ZhangS , LiR , ZhaoZ . Body mass index of children with attention‐deficit/hyperactivity disorder. Journal of Child Neurology2012; Vol. 27, issue 4:545‐6. [DOI: 10.1177/0883073811435326] ">Dubnov‐Raz 2011</a><i>;</i><a href="./references#CD012069-bbs2-0060" title="Durá‐TravéT , Yoldi‐PetriME , Gallinas‐VictorianoF , Zardoya‐SantosP . Effects of osmotic‐release methylphenidate on height and weight in children with attention‐deficit hyperactivity disorder (ADHD) following up to four years of treatment. Journal of Child Neurology2012; Vol. 27, issue 5:604‐9. [DOI: 10.1177/0883073811422752; PUBMED: 22190507] Durá‐TravéT , Yoldi‐PetriME , Zardoya‐SantosP . Nutrition and attention deficit hyperactivity disorder: developmental follow‐up of the anthropometric variables of a group of patients receiving treatment with osmotic controlled‐release methylphenidate [Nutrición y trastorno por déficit de atención/hiperactividad: seguimiento evolutivo de las variables antropométricas de un grupo de pacientes en tratamiento con metilfenidato de liberación osmótica]. Revista de Neurologia2011;53(5):257‐64. [PUBMED: 21796603] ">Durá‐Travé 2012</a><i>;</i><a href="./references#CD012069-bbs2-0110" title="IlgenliTF , CongologluA , OzturkC , TurkbayT , AkpinarO , KilicaslanF . Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder. Advances in Therapy2007;24(1):182‐8. [PUBMED: 17526476] ">Ilgenli 2007</a><i>;</i><a href="./references#CD012069-bbs2-0134" title="LahatE , WeissM , Ben‐ShlomoA , EvansS , BistritzerT . Bone mineral density and turnover in children with attention‐deficit hyperactivity disorder receiving methylphenidate. Journal of Child Neurology2000;15(7):436‐9. [DOI: 10.1177/088307380001500702; PUBMED: 10921512] ">Lahat 2000</a><i>;</i><a href="./references#CD012069-bbs2-0136" title="LambertiM , ItalianoD , GuerrieroL , D'AmicoG , SiracusanoR , IngrassiaM , et al. Evaluation of acute cardiovascular effects of immediate‐release methylphenidate in children and adolescents with attention‐deficit hyperactivity disorder. Neuropsychiatric Disease and Treatment2015;11:1169‐74. [DOI: 10.2147/NDT.S79866; PMC4431494; PUBMED: 26056451] ">Lamberti 2015</a><i>;</i><a href="./references#CD012069-bbs2-0171" title="ÖzcanIT , TorosF , PekdemirH , ÇiçekD , ÇamsariA , YurttaşM , et al. The effect of methylphenidate on time domain heart rate variability in the treatment of attention deficit and hyperactivity disorder [Dikkat eksikliği hiperaktivite bozukluğu tedavisinde metilfenidat kullanımının zaman bağımlı kalp hızı değişkenliği üzerine etkisi]. Turkish Journal of Child and Adolescent Mental Health2004;11(3):117‐22. ">Özcan 2004</a>; <a href="./references#CD012069-bbs2-0179" title="PoultonA , BriodyJ , McCorquodaleT , MelzerE , HerrmannM , BaurLA , et al. Weight loss on stimulant medication: how does it affect body composition and bone metabolism? ‐ A prospective longitudinal study. International Journal of Pediatric Endocrinology2012;2012(1):30. [DOI: 10.1186/1687‐9856‐2012‐30; PMC3549744; PUBMED: 23216890] PoultonA , EvansR , MelzerE , BuiQ . Stimulant medication affects growth but not bone age. Archives of Disease in Childhood2014;99(Suppl 1):A4.A5. [DOI: 10.1136/archdischild‐2014‐306237.10] PoultonA , NananR . Differential effects of dexamphetamine and methylphenidate on symptoms of inattention‐overactivity, oppositional‐defiant and weight. Archives of Disease in Childhood2014;99(Suppl 1):A70. [DOI: 10.1136/archdischild‐2014‐306237.167] ">Poulton 2012</a><i>;</i><a href="./references#CD012069-bbs2-0191" title="SchertzM , AdesmanAR , AlfieriNE , BienkowskiRS . Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication. Pediatrics1996;98(4 Pt 1):763‐9. [PUBMED: 8885958] ">Schertz 1996</a><i>;</i><a href="./references#CD012069-bbs2-0202" title="SpencerT , BiedermanJ , WrightV , DanonM . Growth deficits in children treated with desipramine: a controlled study. Journal of the American Academy of Child &amp; Adolescent Psychiatry1992;31(2):235‐43. [DOI: 10.1097/00004583‐199203000‐00009; PUBMED: 1564024] ">Spencer 1992</a><i>;</i><a href="./references#CD012069-bbs2-0224" title="VincentJ , VarleyCK , LegerP . Effects of methylphenidate on early adolescent growth. American Journal of Psychiatry1990;147(4):501‐2. [DOI: 10.1176/ajp.147.4.501; PUBMED: 2316739] ">Vincent 1990</a>). </p> <section id="CD012069-sec-0143"> <h6 class="title">Proportion of participants with adverse events of unknown severity</h6> <p>See <a href="./references#CD012069-fig-0028" title="">Analysis 6.1</a>. One study with 251 participants also reported data on the frequency of adverse events of unknown severity (<a href="./references#CD012069-bbs2-0023" title="BarbaresiWJ , ColliganRC , WeaverAL , VoigtRG , KilianJM , KatusicSK . Mortality, ADHD, and psychosocial adversity in adults with childhood ADHD: a prospective study. Pediatrics2013;132(4):637‐44. [DOI: 10.1542/peds.2012‐2354] BarbaresiWJ , KatusicSK , ColliganRC , PankratzVS , WeaverAL , WeberKJ , et al. How common is attention‐deficit/hyperactivity disorder? Incidence in a population‐based birth cohort in Rochester, Minn. Archives of Pediatrics and Adolescent Medicine2002;156(3):217‐24. [PUBMED: 11876664] BarbaresiWJ , KatusicSK , ColliganRC , WeaverAL , LeibsonCL , JacobsenSJ . Long‐term stimulant medication treatment of attention‐deficit/hyperactivity disorder: results from a population‐based study. Journal of Developmental and Behavioral Pediatrics2006;27(1):1‐10. [PUBMED: 16511362] BarbaresiWJ , KatusicSK , ColliganRC , WeaverAL , LeibsonCL , JacobsenSJ . Long‐term stimulant medication treatment of attention‐deficit/hyperactivity disorder: results from a population‐based study. Journal of Developmental and Behavioral Pediatrics2014;27(1):448‐57. [PUBMED: 16511362] HarrisMN , VoigtRG , BarbaresiWJ , VogeGA , KilianJM , WeaverAL , et al. ADHD and learning disabilities in former late preterm infants: a population‐based birth cohort. Pediatrics2013;132(3):630‐6. [DOI: 10.1542/peds.2012‐3588; PMC3876753; PUBMED: 23979091] HarstadEB , WeaverAL , KatusicSK , ColliganRC , KumarS , ChanE , et al. ADHD, stimulant treatment, and growth: a longitudinal study. Pediatrics.2014;134(4):935‐44. [DOI: 10.1542/peds.2014‐0428; PUBMED: 25180281] KatusicSK , BarbaresiW , ColliganRC , WeaverAL , LeibsonCL , JacobsenSJ . Case definition in epidemiologic studies of ADHD. Annals of Epidemiology2005;15(6):430‐7. [DOI: 10.1016/j.annepidem.2004.12.004; PUBMED: 15967390] KatusicSK , ColliganRC , BarbaresiWJ , SchaidDJ , JacobsenSJ . Potential influence of migration bias in birth cohort studies. Mayo Clinic Proceedings1998;73(11):1053‐61. [DOI: 10.4065/73.11.1053] MellonMW , NatchevBE , KatusicSK , ColliganRC , WeaverAL , VoigtRG , et al. Incidence of enuresis and encopresis among children with attention‐deficit/hyperactivity disorder in a population‐based birth cohort. Academic Pediatrics2013;13(4):322‐7. [DOI: 10.1016/j.acap.2013.02.008; PMC3886550; PUBMED: 23680296] YoshimasuK , BarbaresiWJ , ColliganRC , KilianJM , VoigtRG , WeaverAL , KatusicSK . Written‐language disorder among children with and without ADHD in a population‐based birth cohort.. Pediatrics2011;128(3):605‐12. YoshimasuK , BarbaresiWJ , ColliganRC , VoigtRG , KilianJM , WeaverAL , et al. Childhood ADHD is strongly associated with a broad range of psychiatric disorders during adolescence: a population‐based birth cohort study. Journal of Child Psychology and Psychiatry, and Allied Disciplines2012;53(10):1036‐43. [DOI: 10.1111/j.1469‐7610.2012.02567.x; PMC3608464; PUBMED: 22647074] ">Barbaresi 2006</a>). In this study, the proportion of participants on methylphenidate with adverse events of unknown severity was 25.1% (95% CI 20.0% to 31.0%). </p> </section> <section id="CD012069-sec-0144"> <h6 class="title">2.2.1 Frequency of any non‐serious adverse events</h6> <p>See <a href="./references#CD012069-fig-0029" title="">Analysis 7.1</a>. The proportion of participants on methylphenidate with non‐serious adverse events was 51.2% (41.2% to 61.1%; 49 studies; 13,978 participants; <a href="#CD012069-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD012069-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Proportion of participants on methylphenidate with any non‐serious adverse event" data-id="CD012069-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Proportion of participants on methylphenidate with any non‐serious adverse event</p> </div> </div> </div> </section> <section id="CD012069-sec-0145"> <h6 class="title">2.2.2 Central nervous system</h6> <p>See <a href="./references#CD012069-fig-0030" title="">Analysis 7.2</a>. We included 109 studies in 37 meta‐analyses. </p> <p>The proportion of participants on methylphenidate with:</p> <p> <ol id="CD012069-list-0033"> <li> <p>affect lability was 29.8% (95% CI 20.5% to 41.2%; 2 studies, 74 participants; <a href="./references#CD012069-bbs2-0187" title="SahinS , YuceM , AlacamH , KarabekirogluK , SayGN , SalisO . Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain‐derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder. International Journal of Psychiatry in Clinical Practice2014;18(4):280‐7. [DOI: 10.3109/13651501.2014.940054; PUBMED: 24994482] ">Sahin 2014</a>; <a href="./references#CD012069-bbs2-0233" title="Liquid version of methylphenidate shows efficacy in school trial. Brown University Child and Adolescent Psychopharmacology Update2013;15(3):1‐3. [DOI: 10.1002/cpu.20183/epdf] WigalS , ChildressA , BeldenH , BerryS . NWP06, an extended‐release oral suspension of methylphenidate, improved attention‐deficit/hyperactivity disorder symptoms compared with placebo in a laboratory classroom study. Journal of Child and Adolescent Psychopharmacology2013;23(1):3‐10. [DOI: 10.1089/cap.2012.0073; PMC3696913] ">Wigal 2013</a>; see <a href="https://zenodo.org/record/1240173#.WusGImcUmBE" target="_blank">supplementary file S16</a>); </p> </li> <li> <p>aggression was 2.40% (95% CI 1.60% to 3.60%; 14 studies, 4292 participants; see <a href="https://zenodo.org/record/1240343#.WusGiGcUmBE" target="_blank">supplementary file S17</a>); </p> </li> <li> <p>anorexia was 16.5% (95% CI 9.10% to 28.2%; 23 studies, 5739 participants; see <a href="https://zenodo.org/record/1240346#.WusG1mcUmBE" target="_blank">supplementary file S18</a>); </p> </li> <li> <p>anxiety was 18.4% (95% CI 11.3% to 28.7%; 22 studies, 1287 participants; see <a href="https://zenodo.org/record/1240347#.WusHJ2cUmBE" target="_blank">supplementary file S19</a>); </p> </li> <li> <p>fingernail biting was 14.3% (95% CI 6.90% to 27.5%; 9 studies, 402 participants; <a href="./references#CD012069-bbs2-0028" title="BladerJC , PliszkaSR , JensenPS , SchoolerNR , KafantarisV . Stimulant‐responsive and stimulant‐refractory aggressive behavior among children with ADHD. Pediatrics2010;126(4):e796‐806. [DOI: 10.1542/peds.2010‐0086; PMC2956067; PUBMED: 20837589] Blader JosephC . Methylphenidate dose may reduce aggressive behavior in children with ADHD. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(12):1‐7. [DOI: 10.1002/cpu.20129] ">Blader 2010</a>; <a href="./references#CD012069-bbs2-0061" title="EfronD . Methylphenidate versus dextroamphetamine in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry1999;38(5):500. [PUBMED: 10230180] EfronD , JarmanFC , BarkerMJ . Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder. Journal of Paediatrics and Child Health1998;34(3):288‐92. [DOI: 10.1046/j.1440‐1754.1998.00224.x] EfronD , JarmanFC , BarkerMJ . Medium‐term outcomes are comparable with short‐term outcomes in children with attention deficit hyperactivity disorder treated with stimulant medication. Journal of Paediatrics and Child Health2000;36(5):457‐61. [PUBMED: 11036801] EfronD , JarmanFC , BarkerMJ . Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial. Pediatrics1997;100(6):E6. [PUBMED: 9382907] EfronD , JarmanFC , BarkerMJ . Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial. Pediatrics1997;100(4):662‐6. [PUBMED: 9310521] ">Efron 1997</a>; <a href="./references#CD012069-bbs2-0062" title="El‐FikyMR , El‐NahasGM , El‐ShahawyHH , Abdel AzizMF , AliDH , KhalifaNM . Study the gender differences in ADHD children: is the response to CNS stimulants a case of one fits both?. Indian Streams Research Journal2014;4(5):1‐10. ">El‐Fiky 2014</a>; <a href="./references#CD012069-bbs2-0075" title="GauSS , ShenHY , SoongWT , GauCS . An open‐label, randomized, active‐controlled equivalent trial of osmotic release oral system methylphenidate in children with attention‐deficit/hyperactivity disorder in Taiwan. Journal of Child and Adolescent Psychopharmacology2006;16(4):441‐55. [DOI: 10.1089/cap.2006.16.441; PUBMED: 16958569] ">Gau 2006</a>; <a href="./references#CD012069-bbs2-0091" title="GreenT , WeinbergerR , DiamondA , BerantM , HirschfeldL , FrischA , et al. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. Journal of Child and Adolescent Psychopharmacology2011;21(6):589‐95. [DOI: 10.1089/cap.2011.0042; PUBMED: 22149470] GreenT , WeinbergerR , WeizmanA , KotlerM , GothelfD . Effect of methylphenidate on neurocognitive functioning in velocardiofacial syndrome: a randomized placebo‐controlled trial. Biological Psychiatry2009;65(Suppl 8):147 S. ">Green 2011</a>; <a href="./references#CD012069-bbs2-0103" title="HazellPL , StuartJE . A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(8):886‐94. [DOI: 10.1097/01.CHI.0000046908.27264.00] ">Hazell 2003</a>; <a href="./references#CD012069-bbs2-0149" title="MaiaCR . Evalution of the Exchange of Immediate Release Methylphenidate for Prolonged Release Methylphenidate in Attention Deficit/Hyperactivity Disorder [Availação da troca do metilfenidato de liberação imediata para o metilfenidato de liberação prolongada no transtorno de déficit de atenção/hiperatividade] [Masters thesis]. Rio Grande (BZ): The Federal University of Rio Grande, 2009. MaiaCR , MatteBC , LudwigHT , RohdeLA . Switching from methylphenidate immediate release to MPH‐SODAS in attention‐deficit/hyperactivity disorder. European Child and Adolescent Psychiatry2008;17(3):133‐42. [DOI: 10.1007/s00787‐007‐0647‐7; PUBMED: 17846812] ">Maia 2008</a>; <a href="./references#CD012069-bbs2-0187" title="SahinS , YuceM , AlacamH , KarabekirogluK , SayGN , SalisO . Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain‐derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder. International Journal of Psychiatry in Clinical Practice2014;18(4):280‐7. [DOI: 10.3109/13651501.2014.940054; PUBMED: 24994482] ">Sahin 2014</a>; <a href="./references#CD012069-bbs2-0195" title="ShangCY , PanYL , LinHY , HuangLW , GauSS . An open‐label, randomized trial of methylphenidate and atomoxetine treatment in children with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2015;25(7):566‐73. [DOI: 10.1089/cap.2015.0035; PUBMED: 26222447] ">Shang 2015</a>; see <a href="https://zenodo.org/record/1241601#.Wu6XYWcUmBE" target="_blank">supplementary file S20</a>); </p> </li> <li> <p>daydreams was 35.1% (95% CI 16.2% to 60.1%; 4 studies, 199 participants; <a href="./references#CD012069-bbs2-0061" title="EfronD . Methylphenidate versus dextroamphetamine in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry1999;38(5):500. [PUBMED: 10230180] EfronD , JarmanFC , BarkerMJ . Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder. Journal of Paediatrics and Child Health1998;34(3):288‐92. [DOI: 10.1046/j.1440‐1754.1998.00224.x] EfronD , JarmanFC , BarkerMJ . Medium‐term outcomes are comparable with short‐term outcomes in children with attention deficit hyperactivity disorder treated with stimulant medication. Journal of Paediatrics and Child Health2000;36(5):457‐61. [PUBMED: 11036801] EfronD , JarmanFC , BarkerMJ . Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial. Pediatrics1997;100(6):E6. [PUBMED: 9382907] EfronD , JarmanFC , BarkerMJ . Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial. Pediatrics1997;100(4):662‐6. [PUBMED: 9310521] ">Efron 1997</a>; <a href="./references#CD012069-bbs2-0075" title="GauSS , ShenHY , SoongWT , GauCS . An open‐label, randomized, active‐controlled equivalent trial of osmotic release oral system methylphenidate in children with attention‐deficit/hyperactivity disorder in Taiwan. Journal of Child and Adolescent Psychopharmacology2006;16(4):441‐55. [DOI: 10.1089/cap.2006.16.441; PUBMED: 16958569] ">Gau 2006</a>; <a href="./references#CD012069-bbs2-0091" title="GreenT , WeinbergerR , DiamondA , BerantM , HirschfeldL , FrischA , et al. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. Journal of Child and Adolescent Psychopharmacology2011;21(6):589‐95. [DOI: 10.1089/cap.2011.0042; PUBMED: 22149470] GreenT , WeinbergerR , WeizmanA , KotlerM , GothelfD . Effect of methylphenidate on neurocognitive functioning in velocardiofacial syndrome: a randomized placebo‐controlled trial. Biological Psychiatry2009;65(Suppl 8):147 S. ">Green 2011</a>; <a href="./references#CD012069-bbs2-0187" title="SahinS , YuceM , AlacamH , KarabekirogluK , SayGN , SalisO . Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain‐derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder. International Journal of Psychiatry in Clinical Practice2014;18(4):280‐7. [DOI: 10.3109/13651501.2014.940054; PUBMED: 24994482] ">Sahin 2014</a>; see <a href="https://zenodo.org/record/1240351#.WusIl2cUmBE" target="_blank">supplementary S21</a>); </p> </li> <li> <p>difficulty falling asleep was 17.9% (95% CI 14.7% to 21.6%; 82 studies, 11,507 participants; see <a href="https://zenodo.org/record/1240352#.WusI-WcUmBE" target="_blank">supplementary file S22</a>); </p> </li> <li> <p>depression was 4.00% (95% CI 2.20% to 7.10%; 13 studies, 2823 participants; see <a href="https://zenodo.org/record/1240353#.WusJQmcUmBE" target="_blank">supplementary file S23</a>); </p> </li> <li> <p>disturbed sleep was 13.2% (95% CI 7.70% to 21.8%; 24 studies, 3076 participants; see <a href="https://zenodo.org/record/1240354#.WusJkGcUmBE" target="_blank">supplementary file S24</a>); </p> </li> <li> <p>dizziness was 6.00% (95% CI 3.7% to 9.4%; 29 studies, 4521 participants; see <a href="https://zenodo.org/record/1240355#.WusJ4GcUmBE" target="_blank">supplementary file S25</a>); </p> </li> <li> <p>drowsiness was 9.50% (95% CI 5.20% to 16.6%; 17 studies, 1146 participants; see <a href="https://zenodo.org/record/1240356#.WusKJmcUmBE" target="_blank">supplementary file S26</a>); </p> </li> <li> <p>dysthymia was 0.90% (95% CI 0.10% to 5.30%; 2 studies, 255 participants; <a href="./references#CD012069-bbs2-0098" title="HaertlingF , MuellerB , Bilke‐HentschO . Effectiveness and safety of a long‐acting, once‐daily, two‐phase release formulation of methylphenidate (Ritalin® LA) in school children under daily practice conditions. Attention Deficit and Hyperactivity Disorders2015;7(2):157‐64. [DOI: 10.1007/s12402‐014‐0154‐x; PMC4449385; PUBMED: 25346231] ">Haertling 2015</a>; <a href="./references#CD012069-bbs2-0158" title="MohammadiMR , KashaniL , AkhondzadehS , IzadianES , OhadiniaS . Efficacy of theophylline compared to methylphenidate for the treatment of attention‐deficit hyperactivity disorder in children and adolescents: a pilot double‐blind randomized trial. Journal of Clinical Pharmacy and Therapeutics2004;29(2):139‐44. [DOI: 10.1111/j.1365‐2710.2004.00545.x; PUBMED: 15068402] ">Mohammadi 2004</a>; see <a href="https://zenodo.org/record/1240357#.WusKc2cUmBE" target="_blank">supplementary file S27</a>); </p> </li> <li> <p>emotional lability was 7.20% (95% CI 3.80% to 13.3%; 16 studies, 2609 participants; see <a href="https://zenodo.org/record/1241602#.Wu6Xu2cUmBE" target="_blank">supplementary file S28</a>); </p> </li> <li> <p>euphoria/hypomania was 7.90% (95% CI 3.90% to 15.4%; 9 studies, 329 participants; <a href="./references#CD012069-bbs2-0028" title="BladerJC , PliszkaSR , JensenPS , SchoolerNR , KafantarisV . Stimulant‐responsive and stimulant‐refractory aggressive behavior among children with ADHD. Pediatrics2010;126(4):e796‐806. [DOI: 10.1542/peds.2010‐0086; PMC2956067; PUBMED: 20837589] Blader JosephC . Methylphenidate dose may reduce aggressive behavior in children with ADHD. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(12):1‐7. [DOI: 10.1002/cpu.20129] ">Blader 2010</a>; <a href="./references#CD012069-bbs2-0062" title="El‐FikyMR , El‐NahasGM , El‐ShahawyHH , Abdel AzizMF , AliDH , KhalifaNM . Study the gender differences in ADHD children: is the response to CNS stimulants a case of one fits both?. Indian Streams Research Journal2014;4(5):1‐10. ">El‐Fiky 2014</a>; <a href="./references#CD012069-bbs2-0075" title="GauSS , ShenHY , SoongWT , GauCS . An open‐label, randomized, active‐controlled equivalent trial of osmotic release oral system methylphenidate in children with attention‐deficit/hyperactivity disorder in Taiwan. Journal of Child and Adolescent Psychopharmacology2006;16(4):441‐55. [DOI: 10.1089/cap.2006.16.441; PUBMED: 16958569] ">Gau 2006</a>; <a href="./references#CD012069-bbs2-0090" title="GrcevichS , RowaneWA , MarcellinoB , Sullivan‐HurstS . Retrospective comparison of Adderall and methylphenidate in the treatment of attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2001;11(1):35‐41. [DOI: 10.1089/104454601750143401; PUBMED: 11322743] ">Grcevich 2001</a>; <a href="./references#CD012069-bbs2-0091" title="GreenT , WeinbergerR , DiamondA , BerantM , HirschfeldL , FrischA , et al. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. Journal of Child and Adolescent Psychopharmacology2011;21(6):589‐95. [DOI: 10.1089/cap.2011.0042; PUBMED: 22149470] GreenT , WeinbergerR , WeizmanA , KotlerM , GothelfD . Effect of methylphenidate on neurocognitive functioning in velocardiofacial syndrome: a randomized placebo‐controlled trial. Biological Psychiatry2009;65(Suppl 8):147 S. ">Green 2011</a>; <a href="./references#CD012069-bbs2-0124" title="ChungI , HanCH , KimHW , ChoSC . The effect of prolonged‐release methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorders. European Neuropsychopharmacology2010;20(Suppl 3):S624‐5. KimHW , YoonIY , ChoSC , KimBN , ChungS , LeeH , et al. The effect of OROS methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorder. International Clinical Psychopharmacology2010;25(2):107‐15. [DOI: 10.1097/YIC.0b013e3283364411; PUBMED: 20093941] ">Kim 2010</a>; <a href="./references#CD012069-bbs2-0149" title="MaiaCR . Evalution of the Exchange of Immediate Release Methylphenidate for Prolonged Release Methylphenidate in Attention Deficit/Hyperactivity Disorder [Availação da troca do metilfenidato de liberação imediata para o metilfenidato de liberação prolongada no transtorno de déficit de atenção/hiperatividade] [Masters thesis]. Rio Grande (BZ): The Federal University of Rio Grande, 2009. MaiaCR , MatteBC , LudwigHT , RohdeLA . Switching from methylphenidate immediate release to MPH‐SODAS in attention‐deficit/hyperactivity disorder. European Child and Adolescent Psychiatry2008;17(3):133‐42. [DOI: 10.1007/s00787‐007‐0647‐7; PUBMED: 17846812] ">Maia 2008</a>; <a href="./references#CD012069-bbs2-0158" title="MohammadiMR , KashaniL , AkhondzadehS , IzadianES , OhadiniaS . Efficacy of theophylline compared to methylphenidate for the treatment of attention‐deficit hyperactivity disorder in children and adolescents: a pilot double‐blind randomized trial. Journal of Clinical Pharmacy and Therapeutics2004;29(2):139‐44. [DOI: 10.1111/j.1365‐2710.2004.00545.x; PUBMED: 15068402] ">Mohammadi 2004</a>; <a href="./references#CD012069-bbs2-0187" title="SahinS , YuceM , AlacamH , KarabekirogluK , SayGN , SalisO . Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain‐derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder. International Journal of Psychiatry in Clinical Practice2014;18(4):280‐7. [DOI: 10.3109/13651501.2014.940054; PUBMED: 24994482] ">Sahin 2014</a>; see <a href="https://zenodo.org/record/1241603#.Wu6Yl2cUmBE" target="_blank">supplementary file S29</a>); </p> </li> <li> <p>asthenia and fatigue was 5.30% (95% CI 3.00% to 9.40%; 19 studies, 2497 participants; see <a href="https://zenodo.org/record/1240444#.WusmyGcUmBE" target="_blank">supplementary file S30</a>); </p> </li> <li> <p>headache was 14.4% (95% CI 11.3% to 18.3%; 90 studies, 13,469 participants; see <a href="https://zenodo.org/record/1241606#.Wu6Y82cUmBE" target="_blank">supplementary file S31</a>); </p> </li> <li> <p>increased need to sleep was 11.7% (95% CI 4.40% to 27.5%; 8 studies, 485 participants; <a href="./references#CD012069-bbs2-0028" title="BladerJC , PliszkaSR , JensenPS , SchoolerNR , KafantarisV . Stimulant‐responsive and stimulant‐refractory aggressive behavior among children with ADHD. Pediatrics2010;126(4):e796‐806. [DOI: 10.1542/peds.2010‐0086; PMC2956067; PUBMED: 20837589] Blader JosephC . Methylphenidate dose may reduce aggressive behavior in children with ADHD. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(12):1‐7. [DOI: 10.1002/cpu.20129] ">Blader 2010</a>; <a href="./references#CD012069-bbs2-0073" title="GallandBC , TrippEG , GrayA , TaylorBJ . Apnea‐hypopnea indices and snoring in children diagnosed with ADHD: a matched case‐control study. Sleep and Breathing2011;15(3):455‐62. [DOI: 10.1007/s11325‐010‐0357‐0; PUBMED: 20440568] GallandBC , TrippEG , TaylorBJ . Methylphenidate effects on sleep in children. Brown University Child and Adolescent Psychopharmacology Update2010;12(3):5‐6. [DOI: 10.1002/cpu.20111] GallandBC , TrippEG , TaylorBJ . The sleep of children with attention deficit hyperactivity disorder on and off methylphenidate: a matched case‐control study. Journal of Sleep Research2010;19(2):366‐73. [DOI: 10.1111/j.1365‐2869.2009.00795.x; PUBMED: 20050995] ">Galland 2010</a>; <a href="./references#CD012069-bbs2-0158" title="MohammadiMR , KashaniL , AkhondzadehS , IzadianES , OhadiniaS . Efficacy of theophylline compared to methylphenidate for the treatment of attention‐deficit hyperactivity disorder in children and adolescents: a pilot double‐blind randomized trial. Journal of Clinical Pharmacy and Therapeutics2004;29(2):139‐44. [DOI: 10.1111/j.1365‐2710.2004.00545.x; PUBMED: 15068402] ">Mohammadi 2004</a>; <a href="./references#CD012069-bbs2-0161" title="MohammadiMR , MostafaviSA , KeshavarzSA , EshraghianMR , HosseinzadehP , Hosseinzadeh‐AttarMJ , et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. Iranian Journal of Psychiatry2012;7(2):87‐92. MostafaviSA , MohammadiMR , HosseinzadehP , EshraghianMR , AkhondzadehS , Hosseinzadeh‐AttarMJ , et al. Dietary intake, growth and development of children with ADHD in a randomized clinical trial of Ritalin and Melatonin co‐administration: through circadian cycle modification or appetite enhancement?. Iranian Journal of Psychiatry2012;7(3):114‐9. [PMC3488866; PUBMED: 23139692] ">Mohammadi 2012a</a>; <a href="./references#CD012069-bbs2-0167" title="LeeMS , LeeSI , HongSD , KimJH , ChoiJ , JoungYS . Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12‐week multicenter, open‐label study. Journal of Child and Adolescent Psychopharmacology2013;23(1):22‐7. [DOI: 10.1089/cap.2012.0018; PUBMED: 23347125] NaKS , LeeSI , HongSD , KimJH , ShimSH , ChoiJ , et al. Effect of osmotic‐release oral system methylphenidate on learning skills in adolescents with attention‐deficit/hyperactivity disorder: an open‐label study. International Clinical Psychopharmacology2013;28(4):184‐92. [DOI: 10.1097/YIC.0b013e3283612509; PUBMED: 23587983] ">Na 2013</a>; <a href="./references#CD012069-bbs2-0175" title="PierceD , KaticA , BuckwalterM , WebsterK . Single‐ and multiple‐dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic‐release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. Journal of Clinical Psychopharmacology2010;30(5):554‐64. [DOI: 10.1097/JCP.0b013e3181f0c2f6; PUBMED: 20814325] ">Pierce 2010</a>; <a href="./references#CD012069-bbs2-0227" title="WangY , ZhengY , DuY , SongDH , ShinYJ , ChoSC , et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double‐blind comparison trial. Australian and New Zealand Journal of Psychiatry2007;41(3):222‐30. [DOI: 10.1080/00048670601057767; PUBMED: 17464703] ">Wang 2007</a>; <a href="./references#CD012069-bbs2-0254" title="ZarinaraAR , MohammadiMR , HazratiN , TabriziM , RezazadehSA , RezaieF , et al. Venlafaxine versus methylphenidate in pediatric outpatients with attention deficit hyperactivity disorder: a randomized, double‐blind comparison trial. Human Psychopharmacology2010;25(7‐8):530‐5. [DOI: 10.1002/hup.1148; PUBMED: 20860068] ">Zarinara 2010</a>; <a href="https://zenodo.org/record/1241607#.Wu6ZVGcUmBE" target="_blank">supplementary file S32</a>); </p> </li> <li> <p>involuntary movements was 6.30% (95% CI 3.20% to 11.8%; 7 studies, 1554 participants; <a href="./references#CD012069-bbs2-0022" title="BalázsJ , DallosG , KeresztényA , CzoborP , GádorosJ . Methylphenidate treatment and dyskinesia in children with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2011;21(2):133‐8. [DOI: 10.1089/cap.2010.0030; PUBMED: 21486166] ">Balázs 2011</a>; <a href="./references#CD012069-bbs2-0025" title="AlfredA , LindermuellerA , MattejatF , DichterS , SchaeubleB . Transitioning onto OROS MPH is associated with improved functioning and quality of life in adolescents with ADHD. European Psychiatry. 18th European Congress of Psychiatry. 2010 Feb 27‐March 2; Munich (Germany)2010;25(Suppl 1):375. [DOI: 10.1016/S0924‐9338(10)70372‐2] BerekM , KordonA , HargarterL , MattejatF , SlawikL , RettigK , et al. Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?. Child &amp; Adolescent Psychiatry &amp; Mental Health2011;5(1):26. [DOI: 10.1186/1753‐2000‐5‐26] KordonA , HultzschW , MattejatF , DichterS , SchaeubleB . Transitioning onto OROS MPH is associated with improved functioning and quality of life in children and adolescents with ADHD. European Psychiatry. 18th European Congress of Psychiatry. 2010 Feb 27‐March 2; Munich (Germany). 2010; Vol. 25, issue Suppl 1:962. [DOI: 10.1016/S0924‐9338(10)70953‐6] NiederkirchnerK , SlawikL , WermelskirchenD , RettigK , SchaubleB . Transitioning to OROS® methylphenidate from atomoxetine is effective in children and adolescents with ADHD. Expert Review of Neurotherapeutics2011;11(4):499‐508. [DOI: 10.1586/ern.11.18] SchaeubleB , MattejatF , RettigK , KordonA , BerekM . Changes in function and quality of life aspects in children with ADHD after transitioning onto OROS MPH. European Child and Adolescent Psychiatry.14th International Congress of European Society for Child and Adolescent Psychiatry (ESCAP); June 11‐15 2011; Helsinki (Finland). 2011; Vol. Suppl 1:S131. WolffC , AlfredA , LindermüllerA , RettigK , MattejatF , GerweM , et al. Effect of transitioning from extended‐release methylphenidate onto osmotic, controlled‐release methylphenidate in children/adolescents with ADHD: results of a 3‐month non‐interventional study. Current Medical Research and Opinion2011;27(Suppl 2):35‐44. [DOI: 10.1185/03007995.2011.601733; PUBMED: 21787126] ">Berek 2011</a>; <a href="./references#CD012069-bbs2-0028" title="BladerJC , PliszkaSR , JensenPS , SchoolerNR , KafantarisV . Stimulant‐responsive and stimulant‐refractory aggressive behavior among children with ADHD. Pediatrics2010;126(4):e796‐806. [DOI: 10.1542/peds.2010‐0086; PMC2956067; PUBMED: 20837589] Blader JosephC . Methylphenidate dose may reduce aggressive behavior in children with ADHD. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(12):1‐7. [DOI: 10.1002/cpu.20129] ">Blader 2010</a>; <a href="./references#CD012069-bbs2-0073" title="GallandBC , TrippEG , GrayA , TaylorBJ . Apnea‐hypopnea indices and snoring in children diagnosed with ADHD: a matched case‐control study. Sleep and Breathing2011;15(3):455‐62. [DOI: 10.1007/s11325‐010‐0357‐0; PUBMED: 20440568] GallandBC , TrippEG , TaylorBJ . Methylphenidate effects on sleep in children. Brown University Child and Adolescent Psychopharmacology Update2010;12(3):5‐6. [DOI: 10.1002/cpu.20111] GallandBC , TrippEG , TaylorBJ . The sleep of children with attention deficit hyperactivity disorder on and off methylphenidate: a matched case‐control study. Journal of Sleep Research2010;19(2):366‐73. [DOI: 10.1111/j.1365‐2869.2009.00795.x; PUBMED: 20050995] ">Galland 2010</a>; <a href="./references#CD012069-bbs2-0131" title="KordonA , StollhoffK , NiederkirchnerK , MattejatF , RettigK , SchäubleB . Exploring the impact of once‐daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate‐release MPH. Postgraduate Medicine2011;123(5):27‐38. [DOI: 10.3810/pgm.2011.09.2457; PUBMED: 21904084] ">Kordon 2011</a>; <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a>; <a href="./references#CD012069-bbs2-0142" title="LeeWJ , LeeTA , PickardAS , CaskeyRN , SchumockGT . Drugs associated with adverse events in children and adolescents. Pharmacotherapy2014;34(9):918‐26. [DOI: 10.1002/phar.1455; PUBMED: 24990656] ">Lee 2014</a>; see <a href="https://zenodo.org/record/1241612#.Wu6Zp2cUmBE" target="_blank">supplementary file S33</a>); </p> </li> <li> <p>irritability was 17.2% (95% CI 11.5% to 25.0%; 35 studies, 4792 participants; see <a href="https://zenodo.org/record/1241615#.Wu6aBWcUmBE" target="_blank">supplementary file S34</a>); </p> </li> <li> <p>nervousness was 11.7% (95% CI 5.80% to 22.3%; 14 studies, 2142 participants; see <a href="https://zenodo.org/record/1240366#.WusNf2cUmBE" target="_blank">supplementary file S35</a>); </p> </li> <li> <p>nightmares was 8.10% (95% CI 5.20% to 12.5%; 11 studies, 553 participants; see <a href="https://zenodo.org/record/1241618#.Wu6aXGcUmBE" target="_blank">supplementary file S36</a>); </p> </li> <li> <p>restlessness and agitation was 7.40% (95% CI 3.60% to 14.5%; 14 studies, 1793 participants; see <a href="https://zenodo.org/record/1240442#.WusmCWcUmBE" target="_blank">supplementary file S37</a>); </p> </li> <li> <p>sadness was 16.8% (95% CI 9.40% to 28.3%; 21 studies, 1802 participants; see <a href="https://zenodo.org/record/1240370#.WusPWmcUmBE" target="_blank">supplementary file S38</a>); </p> </li> <li> <p>stares was 22.5% (95% CI 8.50% to 47.5%; 4 studies, 137 participants; <a href="./references#CD012069-bbs2-0028" title="BladerJC , PliszkaSR , JensenPS , SchoolerNR , KafantarisV . Stimulant‐responsive and stimulant‐refractory aggressive behavior among children with ADHD. Pediatrics2010;126(4):e796‐806. [DOI: 10.1542/peds.2010‐0086; PMC2956067; PUBMED: 20837589] Blader JosephC . Methylphenidate dose may reduce aggressive behavior in children with ADHD. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(12):1‐7. [DOI: 10.1002/cpu.20129] ">Blader 2010</a>; <a href="./references#CD012069-bbs2-0062" title="El‐FikyMR , El‐NahasGM , El‐ShahawyHH , Abdel AzizMF , AliDH , KhalifaNM . Study the gender differences in ADHD children: is the response to CNS stimulants a case of one fits both?. Indian Streams Research Journal2014;4(5):1‐10. ">El‐Fiky 2014</a>; <a href="./references#CD012069-bbs2-0103" title="HazellPL , StuartJE . A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(8):886‐94. [DOI: 10.1097/01.CHI.0000046908.27264.00] ">Hazell 2003</a>; <a href="./references#CD012069-bbs2-0149" title="MaiaCR . Evalution of the Exchange of Immediate Release Methylphenidate for Prolonged Release Methylphenidate in Attention Deficit/Hyperactivity Disorder [Availação da troca do metilfenidato de liberação imediata para o metilfenidato de liberação prolongada no transtorno de déficit de atenção/hiperatividade] [Masters thesis]. Rio Grande (BZ): The Federal University of Rio Grande, 2009. MaiaCR , MatteBC , LudwigHT , RohdeLA . Switching from methylphenidate immediate release to MPH‐SODAS in attention‐deficit/hyperactivity disorder. European Child and Adolescent Psychiatry2008;17(3):133‐42. [DOI: 10.1007/s00787‐007‐0647‐7; PUBMED: 17846812] ">Maia 2008</a>; see <a href="https://zenodo.org/record/1240371#.WusPn2cUmBE" target="_blank">supplementary file S39</a>); </p> </li> <li> <p>excessive talking was 17.6% (95% CI 6.10% to 41.3%; 3 studies, 146 participants; <a href="./references#CD012069-bbs2-0028" title="BladerJC , PliszkaSR , JensenPS , SchoolerNR , KafantarisV . Stimulant‐responsive and stimulant‐refractory aggressive behavior among children with ADHD. Pediatrics2010;126(4):e796‐806. [DOI: 10.1542/peds.2010‐0086; PMC2956067; PUBMED: 20837589] Blader JosephC . Methylphenidate dose may reduce aggressive behavior in children with ADHD. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(12):1‐7. [DOI: 10.1002/cpu.20129] ">Blader 2010</a>; <a href="./references#CD012069-bbs2-0103" title="HazellPL , StuartJE . A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(8):886‐94. [DOI: 10.1097/01.CHI.0000046908.27264.00] ">Hazell 2003</a>; <a href="./references#CD012069-bbs2-0122" title="KhajehpiriZ , Mahmoudi‐GharaeiJ , FaghihiT , KarimzadehI , KhaliliH , MohammadiM . Adverse reactions of Methylphenidate in children with attention deficit‐hyperactivity disorder: report from a referral center. Journal of Research in Pharmacy Practice2014;3(4):130‐6. [DOI: 10.4103/2279‐042X.145389; PMC4262859; PUBMED: 25535621] ">Khajehpiri 2014</a>; <a href="https://zenodo.org/record/1241619#.Wu6avmcUmBE" target="_blank">supplementary file S40</a>); </p> </li> <li> <p>taciturnity ('talking too little') was 16.9% (95% CI 5.90% to 39.8%; 4 studies, 141 participants; <a href="./references#CD012069-bbs2-0028" title="BladerJC , PliszkaSR , JensenPS , SchoolerNR , KafantarisV . Stimulant‐responsive and stimulant‐refractory aggressive behavior among children with ADHD. Pediatrics2010;126(4):e796‐806. [DOI: 10.1542/peds.2010‐0086; PMC2956067; PUBMED: 20837589] Blader JosephC . Methylphenidate dose may reduce aggressive behavior in children with ADHD. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(12):1‐7. [DOI: 10.1002/cpu.20129] ">Blader 2010</a>; <a href="./references#CD012069-bbs2-0062" title="El‐FikyMR , El‐NahasGM , El‐ShahawyHH , Abdel AzizMF , AliDH , KhalifaNM . Study the gender differences in ADHD children: is the response to CNS stimulants a case of one fits both?. Indian Streams Research Journal2014;4(5):1‐10. ">El‐Fiky 2014</a>; <a href="./references#CD012069-bbs2-0091" title="GreenT , WeinbergerR , DiamondA , BerantM , HirschfeldL , FrischA , et al. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. Journal of Child and Adolescent Psychopharmacology2011;21(6):589‐95. [DOI: 10.1089/cap.2011.0042; PUBMED: 22149470] GreenT , WeinbergerR , WeizmanA , KotlerM , GothelfD . Effect of methylphenidate on neurocognitive functioning in velocardiofacial syndrome: a randomized placebo‐controlled trial. Biological Psychiatry2009;65(Suppl 8):147 S. ">Green 2011</a>; <a href="./references#CD012069-bbs2-0149" title="MaiaCR . Evalution of the Exchange of Immediate Release Methylphenidate for Prolonged Release Methylphenidate in Attention Deficit/Hyperactivity Disorder [Availação da troca do metilfenidato de liberação imediata para o metilfenidato de liberação prolongada no transtorno de déficit de atenção/hiperatividade] [Masters thesis]. Rio Grande (BZ): The Federal University of Rio Grande, 2009. MaiaCR , MatteBC , LudwigHT , RohdeLA . Switching from methylphenidate immediate release to MPH‐SODAS in attention‐deficit/hyperactivity disorder. European Child and Adolescent Psychiatry2008;17(3):133‐42. [DOI: 10.1007/s00787‐007‐0647‐7; PUBMED: 17846812] ">Maia 2008</a>; see <a href="https://zenodo.org/record/1241620#.Wu6bRmcUmBE" target="_blank">supplementary file S41</a>); </p> </li> <li> <p>tics was 6.40% (95% CI 4.50% to 8.90%; 39 studies, 1980 participants; see <a href="https://zenodo.org/record/1240735#.WuwD8GcUmBE" target="_blank">supplementary file S42</a>); </p> </li> <li> <p>isolation and lack of interest in others was 15.9% (95% CI 9.40% to 25.8%; 10 studies, 524 participants; <a href="./references#CD012069-bbs2-0028" title="BladerJC , PliszkaSR , JensenPS , SchoolerNR , KafantarisV . Stimulant‐responsive and stimulant‐refractory aggressive behavior among children with ADHD. Pediatrics2010;126(4):e796‐806. [DOI: 10.1542/peds.2010‐0086; PMC2956067; PUBMED: 20837589] Blader JosephC . Methylphenidate dose may reduce aggressive behavior in children with ADHD. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(12):1‐7. [DOI: 10.1002/cpu.20129] ">Blader 2010</a>; <a href="./references#CD012069-bbs2-0061" title="EfronD . Methylphenidate versus dextroamphetamine in ADHD. Journal of the American Academy of Child and Adolescent Psychiatry1999;38(5):500. [PUBMED: 10230180] EfronD , JarmanFC , BarkerMJ . Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder. Journal of Paediatrics and Child Health1998;34(3):288‐92. [DOI: 10.1046/j.1440‐1754.1998.00224.x] EfronD , JarmanFC , BarkerMJ . Medium‐term outcomes are comparable with short‐term outcomes in children with attention deficit hyperactivity disorder treated with stimulant medication. Journal of Paediatrics and Child Health2000;36(5):457‐61. [PUBMED: 11036801] EfronD , JarmanFC , BarkerMJ . Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial. Pediatrics1997;100(6):E6. [PUBMED: 9382907] EfronD , JarmanFC , BarkerMJ . Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double‐blind, crossover trial. Pediatrics1997;100(4):662‐6. [PUBMED: 9310521] ">Efron 1997</a>; <a href="./references#CD012069-bbs2-0062" title="El‐FikyMR , El‐NahasGM , El‐ShahawyHH , Abdel AzizMF , AliDH , KhalifaNM . Study the gender differences in ADHD children: is the response to CNS stimulants a case of one fits both?. Indian Streams Research Journal2014;4(5):1‐10. ">El‐Fiky 2014</a>; <a href="./references#CD012069-bbs2-0091" title="GreenT , WeinbergerR , DiamondA , BerantM , HirschfeldL , FrischA , et al. The effect of methylphenidate on prefrontal cognitive functioning, inattention, and hyperactivity in velocardiofacial syndrome. Journal of Child and Adolescent Psychopharmacology2011;21(6):589‐95. [DOI: 10.1089/cap.2011.0042; PUBMED: 22149470] GreenT , WeinbergerR , WeizmanA , KotlerM , GothelfD . Effect of methylphenidate on neurocognitive functioning in velocardiofacial syndrome: a randomized placebo‐controlled trial. Biological Psychiatry2009;65(Suppl 8):147 S. ">Green 2011</a>; <a href="./references#CD012069-bbs2-0103" title="HazellPL , StuartJE . A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(8):886‐94. [DOI: 10.1097/01.CHI.0000046908.27264.00] ">Hazell 2003</a>; <a href="./references#CD012069-bbs2-0149" title="MaiaCR . Evalution of the Exchange of Immediate Release Methylphenidate for Prolonged Release Methylphenidate in Attention Deficit/Hyperactivity Disorder [Availação da troca do metilfenidato de liberação imediata para o metilfenidato de liberação prolongada no transtorno de déficit de atenção/hiperatividade] [Masters thesis]. Rio Grande (BZ): The Federal University of Rio Grande, 2009. MaiaCR , MatteBC , LudwigHT , RohdeLA . Switching from methylphenidate immediate release to MPH‐SODAS in attention‐deficit/hyperactivity disorder. European Child and Adolescent Psychiatry2008;17(3):133‐42. [DOI: 10.1007/s00787‐007‐0647‐7; PUBMED: 17846812] ">Maia 2008</a>; <a href="./references#CD012069-bbs2-0187" title="SahinS , YuceM , AlacamH , KarabekirogluK , SayGN , SalisO . Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain‐derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder. International Journal of Psychiatry in Clinical Practice2014;18(4):280‐7. [DOI: 10.3109/13651501.2014.940054; PUBMED: 24994482] ">Sahin 2014</a>; <a href="./references#CD012069-bbs2-0250" title="Yildiz ÖçÖ , AğaoğluB , KarakayaI , ŞişmanlarŞG , Çakin MemikN . Efficiency and tolerability of OROS‐methylphenidate in Turkish children and adolescents with attention‐deficit/hyperactivity disorder. Anadolu Psikiyatri Dergisi2010;11(1):44‐50. ">Yildiz 2010</a>; <a href="./references#CD012069-bbs2-0122" title="KhajehpiriZ , Mahmoudi‐GharaeiJ , FaghihiT , KarimzadehI , KhaliliH , MohammadiM . Adverse reactions of Methylphenidate in children with attention deficit‐hyperactivity disorder: report from a referral center. Journal of Research in Pharmacy Practice2014;3(4):130‐6. [DOI: 10.4103/2279‐042X.145389; PMC4262859; PUBMED: 25535621] ">Khajehpiri 2014</a>; <a href="./references#CD012069-bbs2-0173" title="PereraH , JeewandaraKC , SeneviratneS , GurugeC . Assessment of outcome of an ADHD treatment program using parent feedback. Sri Lanka Journal of Psychiatry2010;1(2):51‐5. [DOI: 10.4038/sljpsyc.v1i2.2575] ">Perera 2010</a> see <a href="https://zenodo.org/record/1241621#.Wu6cM2cUmBE" target="_blank">supplementary file S43</a>); </p> </li> <li> <p>'zombie‐like' demeanor was 5.20% (95% CI 1.20% to 20.6%; 3 studies, 668 participants; <a href="./references#CD012069-bbs2-0050" title="BabakiME , AshtianiRD , RazjooyanK , AminiH . Comparing the effects of buspirone and methylphenidate in children with attention deficit hyperactivity disorder. Iranian Journal of Psychiatry and Clinical Psychology2009; Vol. 15, issue 3:223‐30. Davari‐AshtianiR , ShahrbabakiME , RazjouyanK , AminiH , MazhabdarH . Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double‐blind and randomized trial. Child Psychiatry and Human Development2010;41(6):641‐8. [DOI: 10.1007/s10578‐010‐0193‐2; PUBMED: 20517641] ShahrbabakiME , SabzevariL , HaghdoostA , Davari‐AshtianiR . Buspiron versus methylphenidate in the treatment of children with ADHD. Brain, Mind and Development. 20th World IACAPAP (International Association for Child and Adolescent Psychiatry and Allied Professions) Congress; July 21‐25 2012; Paris (France). 2012; Vol. 60:Suppl 1. ">Davari‐Ashtiani 2010</a>; <a href="./references#CD012069-bbs2-0114" title="AbikoffH . Tailored psychosocial treatments for ADHD: the search for a good fit. Journal of Clinical Child Psychology2001; Vol. 30, issue 1:122‐5. [DOI: 10.1207/S15374424JCCP3001_14; PUBMED: 11294070] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottG , GreenhillLL , et al. National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choices. Archives of General Psychiatry1997;54(9):865‐70. [PUBMED: 9294378] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottGR , GreenhillLL , et al. NIMH collaborative multimodal treatment study of children with ADHD (MTA): design, methodology, and protocol evolution. Journal of Attention Disorders1997;2(3):141‐58. [DOI: 10.1177/108705479700200301] ArnoldLE , ChuangS , DaviesM , AbikoffHB , ConnersCK , ElliottGR , et al. Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures. Journal of Abnormal Child Psychology2004;32(1):39‐51. [PUBMED: 14998110] ArnoldLE , ElliottM , SachsL , BirdH , KraemerHC , WellsKC , et al. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14‐month outcome in ADHD. Journal of Consulting and Clinical Psychology2003;71(4):713‐27. [PUBMED: 12924677] CareyWB . What the multimodal treatment study of children with attention deficit/hyperactivity disorder did and did not say about the use of methylphenidate for attention deficits. Pediatrics2000;105(4):863‐4. [PUBMED: 10742336] ConnersCK , EpsteinJN , MarchJS , AngoldA , WellsKC , KlaricJ , et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):159‐67. [DOI: 10.1097/00004583‐200102000‐00010; PUBMED: 11211364] GalanterCA , CarlsonGA , JensenPS , GreenhillLL , DaviesM , LiW , et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. Journal of Child and Adolescent Psychopharmacology2003;13(2):123‐36. [DOI: 10.1089/104454603322163844; PUBMED: 12880507] GreeneRW , AblonJS . What does the MTA study tell us about effective psychosocial treatment for ADHD?. Journal of Clinical Child Psychology2001;30(1):114‐21. [DOI: 10.1207/S15374424JCCP3001_13; PUBMED: 11294069] GreenhillLL , AbikoffHB , ArnoldLE , CantwellDP , ConnersCK , ElliottG , et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. Journal of the American Academy of Child and Adolescent Psychiatry1996;35(10):1304‐13. [DOI: 10.1097/00004583‐199610000‐00017; PUBMED: 8885584] GreenhillLL , SwansonJM , VitielloB , DaviesM , ClevengerW , WuM , et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):180‐7. [DOI: 10.1097/00004583‐200102000‐00012; PUBMED: 11211366] HansenL , ThomsenPH . How to treat ADHD/DAMP? Is there a conclusive answer? A critical survey of the MTA trial?. Ugeskr Laeger2005;167(48):4555‐9. [PUBMED: 16324436] HinshawSP . Moderators and mediators of treatment response for children with attention‐deficit/hyperactivity disorder: the Multimodal Treatment Study of children with attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1088‐96. [PUBMED: 10591284] HinshawSP , MarchJS , AbikoffH , ArnoldLE , CantwellDP , ConnersCK , et al. Comprehensive assessment of childhood Attention‐Deficit Hyperactivity Disorder in the context of a multisite, multimodal clinical trial. Journal of Attention Disorders1997;1(4):217‐34. [DOI: 10.1177/108705479700100403] JensenPS , ArnoldLE , SwansonJM , VitielloB , AbikoffHB , GreenhillLL , et al. 3‐year follow‐up of the NIMH MTA study. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):989‐1002. [DOI: 10.1097/CHI.0b013e3180686d48; PUBMED: 17667478] JensenPS , HinshawSP , KraemerHC , LeonoraN , NewcornJH , AbikoffHB , et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. Journal of the American Academy of Child and Adolescent Psychiatry2001; Vol. 40, issue 2:147‐58. [DOI: 10.1097/00004583‐200102000‐00009; PUBMED: 11211363] JensenPS , HinshawSP , SwansonJM , GreenhillLL , ConnersCK , ArnoldLE , et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. Journal of Developmental and Behavioral Pediatrics2001;22(1):60‐73. [PUBMED: 11265923] MTA Cooperative Group. A 14‐month randomized clinical trial of treatment strategies for attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1073‐86. [DOI: 10.1001/archpsyc.56.12.1073; PUBMED: 10591283] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: 24‐month outcomes of treatment strategies for attention‐deficit/hyperactivity disorder. Pediatrics2004;113(4):754‐61. [PUBMED: 15060224] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: changes in effectiveness and growth after the end of treatment. Pediatrics2004;113(4):762‐9. [PUBMED: 15060225] MarchJS , SwansonJM , ArnoldLE , HozaB , ConnersCK , HinshawSP , et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). Journal of Abnormal Child Psychology2000;28(6):527‐41. [PUBMED: 11104315] MolinaBS , FloryK , HinshawSP , GreinerAR , ArnoldLE , SwansonJM , et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1028‐40. [DOI: 10.1097/chi.0b013e3180686d96; PUBMED: 17667481] MolinaBS , HinshawSP , EugeneAL , SwansonJM , PelhamWE , HechtmanL , et al. Adolescent substance use in the multimodal treatment study of attention‐deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. Journal of the American Academy of Child and Adolescent Psychiatry2013;52(3):250‐63. [DOI: 10.1016/j.jaac.2012.12.014; PMC3589108; PUBMED: 23452682] MolinaBS , HinshawSP , SwansonJM , ArnoldLE , VitielloB , JensenPS , et al. The MTA at 8 years: prospective follow‐up of children treated for combined‐type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(5):484‐500. [DOI: 10.1097/CHI.0b013e31819c23d0; PMC3063150] NiewegEH . Does ADHD medication stop working after 2‐3 years? On the surprising, but little known follow‐up of the MTA study [Is adhd‐medicatie na 2‐3 jaar uitgewerkt? Over de verrassende, maar weinig bekendefollow‐up van het mta‐onderzoek]. Tijdschrift voor Psychiatrie2010;52(4):245‐54. [PUBMED: 20503165] OwensEB , HinshawSP , KraemerHC , ArnoldLE , AbikoffHB , CantwellDP , et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. Journal of Consulting and Clinical Psychology2003;71(3):540‐52. [PUBMED: 12795577] PelhamWEJr . The NIMH multimodal treatment study for attention‐deficit hyperactivity disorder: just say yes to drugs alone?. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie1999;44(10):981‐90. [DOI: 10.1177/070674379904401004; PUBMED: 10637677] PelhamWE , GnagyEM , GreinerAR , HozaB , HinshawSP , SwansonJM , et al. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. Journal of Abnormal Child Psychology2000;28(6):507‐25. [PUBMED: 11104314] RichtersJE , ArnoldLE , JensenPS , AbikoffH , ConnersCK , GreenhillLL , et al. NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale. Journal of the American Academy of Child and Adolescent Psychiatry1995;34(8):987‐1000. [DOI: 10.1097/00004583‐199508000‐00008; PUBMED: 7665456] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. Journal of Attention Disorders2008;12(1):15‐43. [DOI: 10.1177/1087054708319525; PUBMED: 18573924] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. Journal of Attention Disorders2008;12(1):4‐14. [DOI: 10.1177/1087054708319345; PUBMED: 18573923] SwansonJM , ElliottGR , GreenhillLL , WigalT , ArnoldLE , VitielloB , et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow‐up. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1015‐27. [DOI: 10.1097/chi.0b013e3180686d7e; PUBMED: 17667480] SwansonJM , HinshawSP , ArnoldLE , GibbonsRD , MarcusS , HurK , et al. Secondary evaluations of MTA 36‐month outcomes: propensity score and growth mixture model analyses. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1003‐14. [DOI: 10.1097/CHI.0b013e3180686d63; PUBMED: 17667479] SwansonJM , KraemerHC , HinshawSP , ArnoldLE , ConnersCK , AbikoffHB , et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):168‐79. [DOI: 10.1097/00004583‐200102000‐00011; PUBMED: 1121136] VitielloB , ElliottGR , SwansonJM , ArnoldLE , HechtmanL , AbikoffH , et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. American Journal of Psychiatry2012; Vol. 169, issue 2:167‐77. [DOI: 10.1176/appi.ajp.2011.10111705; PMC4132884; PUBMED: 21890793] VitielloB , SevereJB , GreenhillLL , ArnoldLE , AbikoffHB , BuksteinOG , et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):188‐96. [DOI: 10.1097/00004583‐200102000‐00013; PUBMED: 11211367] ">Jensen 1999 (MTA)</a>; <a href="./references#CD012069-bbs2-0236" title="BiedermanJ . Evaluation of once‐daily OROS methylphenidate in children with attention‐deficit/hyperactivity disorder: effects on sleep, appetite, and tics. European Neuropsychopharmacology2003;13(Suppl 4):S447‐8. BiedermanJ . Treatment of attention‐deficit/hyperactivity disorder with the once‐daily OROS formulation of methylphenidate: effect on growth in children. European Neuropsychopharmacology2003;13(Suppl 4):S448‐9. FaraoneSV , BiedermanJ , ZimmermanB . An analysis of patient adherence to treatment during a 1‐year, open‐label study of OROS methylphenidate in children with ADHD. Journal of Attention Disorders2007;11(2):157‐66. [DOI: 10.1177/1087054706295663; PUBMED: 17494833] LernerMA , SpencerT . Analysis of growth in children with ADHD during long‐term therapy with once‐daily OROS® methylphenidate. Pediatric Academic Societies' Annual Meeting; 2004 May 1‐4; San Francisco (CA). 2004; Vol. 55. PalumboDR , StarrHL . Once‐daily OROS methylphenidate: Impact on tics in children with attention deficit hyperactivity disorder. Annals of Neurology2003;54(Suppl 7):S27. [DOI: 10.1002/ana.5049/epdf] SpencerTJ , FaraoneSV , BiedermanJ , LernerM , CooperKM , ZimmermanB , Concerta Study Group. Does prolonged therapy with a long‐acting stimulant suppress growth in children with ADHD?. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(5):527‐37. [DOI: 10.1097/01.chi.0000205710.01690.d4; PUBMED: 16670649] SpencerTJ , FaraoneSV , LernerM , CooperKM , ZimmermanB . Effect of long‐term treatment with stimulant medication on growth? Drs. Spencer et al. Reply. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(3):306. [DOI: 10.1097/chi.0b013e31802ed960] WigalSB , WilensTE , WolraichM , LernerM . Hematologic and blood biochemistry monitoring during methylphenidate treatment in children with attention‐deficit/hyperactivity disorder: 2‐year, open‐label study results. Pediatrics2007;120(1):e120‐8. [DOI: 10.1542/peds.2006‐1402] WilensT , BiedermanJ , LernerM , Concerta Study Group. Effects of once‐daily osmotic‐release methylphenidate on blood pressure and heart rate in children with attention‐deficit/hyperactivity disorder: results from a one‐year follow‐up study. Journal of Clinical Psychopharmacology2004;24(1):36‐41. [DOI: 10.1097/01.jcp.0000106223.36344.df; PUBMED: 14709945] WilensT , McBurnettK , SteinM , LernerM , SpencerT , WolraichM . ADHD treatment with once‐daily OROS methylphenidate: final results from a long‐term open‐label study. Journal of the American Academy of Child and Adolescent Psychiatry2005;44(10):1015‐23. [DOI: 10.1097/01.chi.0000173291.28688.e7; PUBMED: 16175106] WilensT , McBurnettK , SteinM , LernerM , SpencerT , WolraichM . ADHD treatment with once‐daily OROS methylphenidate: final results from a long‐term open‐label study: erratum. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(5):632. [DOI: 10.1097/00004583‐200605000‐00020] WilensT , PelhamW , SteinM , ConnersCK , AbikoffH , AtkinsM , et al. ADHD treatment with once‐daily OROS methylphenidate: interim 12‐month results from a long‐term open‐label study. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(4):424‐33. [DOI: 10.1097/01.CHI.0000046814.95464.7D; PUBMED: 12649629] ">Wilens 2005</a>; see <a href="https://zenodo.org/record/1241622#.Wu6ctWcUmBE" target="_blank">supplementary file S44</a>); </p> </li> <li> <p>somnolence was 4.10% (95% CI 2.30% to 7.30%; 9 studies, 1016 participants; <a href="./references#CD012069-bbs2-0037" title="WJChou , LJWang . The family impact in children and adolescent with ADHD after the switch of treatment from immediate‐release MPH to OROS‐MPH. Neuropsychiatrie de l'Enfance et de l'Adolescence2012;60(5S):S262. [DOI: 10.1016/j.neurenf.2012.04.683] ">Chou 2012b</a>; <a href="./references#CD012069-bbs2-0122" title="KhajehpiriZ , Mahmoudi‐GharaeiJ , FaghihiT , KarimzadehI , KhaliliH , MohammadiM . Adverse reactions of Methylphenidate in children with attention deficit‐hyperactivity disorder: report from a referral center. Journal of Research in Pharmacy Practice2014;3(4):130‐6. [DOI: 10.4103/2279‐042X.145389; PMC4262859; PUBMED: 25535621] ">Khajehpiri 2014</a>; <a href="./references#CD012069-bbs2-0153" title="LooSK , BilderR , ChoAL , SturmA , CowenJ , WelkerPW , et al. Effects of d‐Methylphenidate, Guanfacine, and their combination on electroencephalogram resting state spectral power in Attention‐Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):674‐82.e1. [DOI: 10.1016/j.jaac.2016.04.020; PMC5003618; PUBMED: 27453081] McCrackenJT , McGoughJJ , LooSK , LevittJ , Del'HommeM , CowenJ , et al. Combined stimulant and Guanfacine administration in Attention‐Deficit/Hyperactivity Disorder: a controlled, comparative study. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):657‐66.e1. [DOI: 10.1016/j.jaac.2016.05.015; PMC4976782; PUBMED: 27453079] ">McCracken 2016</a>; <a href="./references#CD012069-bbs2-0167" title="LeeMS , LeeSI , HongSD , KimJH , ChoiJ , JoungYS . Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12‐week multicenter, open‐label study. Journal of Child and Adolescent Psychopharmacology2013;23(1):22‐7. [DOI: 10.1089/cap.2012.0018; PUBMED: 23347125] NaKS , LeeSI , HongSD , KimJH , ShimSH , ChoiJ , et al. Effect of osmotic‐release oral system methylphenidate on learning skills in adolescents with attention‐deficit/hyperactivity disorder: an open‐label study. International Clinical Psychopharmacology2013;28(4):184‐92. [DOI: 10.1097/YIC.0b013e3283612509; PUBMED: 23587983] ">Na 2013</a>; <a href="./references#CD012069-bbs2-0195" title="ShangCY , PanYL , LinHY , HuangLW , GauSS . An open‐label, randomized trial of methylphenidate and atomoxetine treatment in children with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2015;25(7):566‐73. [DOI: 10.1089/cap.2015.0035; PUBMED: 26222447] ">Shang 2015</a>; <a href="./references#CD012069-bbs2-0227" title="WangY , ZhengY , DuY , SongDH , ShinYJ , ChoSC , et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double‐blind comparison trial. Australian and New Zealand Journal of Psychiatry2007;41(3):222‐30. [DOI: 10.1080/00048670601057767; PUBMED: 17464703] ">Wang 2007</a>; <a href="./references#CD012069-bbs2-0231" title="WeissM , HechtmanL , TurgayA , JainU , QuinnD , AhmedTS , et al. Once‐daily multilayer‐release methylphenidate in a double‐blind, crossover comparison to immediate‐release methylphenidate in children with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2007;17(5):675‐88. [DOI: 10.1089/cap.2006.0101; PUBMED: 17979587] ">Weiss 2007</a>; <a href="./references#CD012069-bbs2-0236" title="BiedermanJ . Evaluation of once‐daily OROS methylphenidate in children with attention‐deficit/hyperactivity disorder: effects on sleep, appetite, and tics. European Neuropsychopharmacology2003;13(Suppl 4):S447‐8. BiedermanJ . Treatment of attention‐deficit/hyperactivity disorder with the once‐daily OROS formulation of methylphenidate: effect on growth in children. European Neuropsychopharmacology2003;13(Suppl 4):S448‐9. FaraoneSV , BiedermanJ , ZimmermanB . An analysis of patient adherence to treatment during a 1‐year, open‐label study of OROS methylphenidate in children with ADHD. Journal of Attention Disorders2007;11(2):157‐66. [DOI: 10.1177/1087054706295663; PUBMED: 17494833] LernerMA , SpencerT . Analysis of growth in children with ADHD during long‐term therapy with once‐daily OROS® methylphenidate. Pediatric Academic Societies' Annual Meeting; 2004 May 1‐4; San Francisco (CA). 2004; Vol. 55. PalumboDR , StarrHL . Once‐daily OROS methylphenidate: Impact on tics in children with attention deficit hyperactivity disorder. Annals of Neurology2003;54(Suppl 7):S27. [DOI: 10.1002/ana.5049/epdf] SpencerTJ , FaraoneSV , BiedermanJ , LernerM , CooperKM , ZimmermanB , Concerta Study Group. Does prolonged therapy with a long‐acting stimulant suppress growth in children with ADHD?. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(5):527‐37. [DOI: 10.1097/01.chi.0000205710.01690.d4; PUBMED: 16670649] SpencerTJ , FaraoneSV , LernerM , CooperKM , ZimmermanB . Effect of long‐term treatment with stimulant medication on growth? Drs. Spencer et al. Reply. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(3):306. [DOI: 10.1097/chi.0b013e31802ed960] WigalSB , WilensTE , WolraichM , LernerM . Hematologic and blood biochemistry monitoring during methylphenidate treatment in children with attention‐deficit/hyperactivity disorder: 2‐year, open‐label study results. Pediatrics2007;120(1):e120‐8. [DOI: 10.1542/peds.2006‐1402] WilensT , BiedermanJ , LernerM , Concerta Study Group. Effects of once‐daily osmotic‐release methylphenidate on blood pressure and heart rate in children with attention‐deficit/hyperactivity disorder: results from a one‐year follow‐up study. Journal of Clinical Psychopharmacology2004;24(1):36‐41. [DOI: 10.1097/01.jcp.0000106223.36344.df; PUBMED: 14709945] WilensT , McBurnettK , SteinM , LernerM , SpencerT , WolraichM . ADHD treatment with once‐daily OROS methylphenidate: final results from a long‐term open‐label study. Journal of the American Academy of Child and Adolescent Psychiatry2005;44(10):1015‐23. [DOI: 10.1097/01.chi.0000173291.28688.e7; PUBMED: 16175106] WilensT , McBurnettK , SteinM , LernerM , SpencerT , WolraichM . ADHD treatment with once‐daily OROS methylphenidate: final results from a long‐term open‐label study: erratum. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(5):632. [DOI: 10.1097/00004583‐200605000‐00020] WilensT , PelhamW , SteinM , ConnersCK , AbikoffH , AtkinsM , et al. ADHD treatment with once‐daily OROS methylphenidate: interim 12‐month results from a long‐term open‐label study. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(4):424‐33. [DOI: 10.1097/01.CHI.0000046814.95464.7D; PUBMED: 12649629] ">Wilens 2005</a>; <a href="./references#CD012069-bbs2-0251" title="YildizÖ , ŞişmanlarŞG , MemikNÇ , KarakayaI , AğaoğluB . Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. Child Psychiatry and Human Development2011;42(3):257‐69. [DOI: 10.1007/s10578‐010‐0212‐3; PUBMED: 21165694] ">Yildiz 2011</a>; see <a href="https://zenodo.org/record/1240736#.WuwE6mcUmBE" target="_blank">supplementary file S45</a>); </p> </li> <li> <p>obsession was 1.50% (95% CI 0.20% to 8.60%; 3 studies, 1529 participants; <a href="./references#CD012069-bbs2-0031" title="ÇetinFH , Işik TanerY , Taş TorunY , TuncaH . Atomoxetine and methylphenidate for the treatment of attention deficit hyperactivity disorder: a six‐month follow‐up study. Improved choices of psychotropic medications: better mental health outcomes. 5th International Congress on Psychopharmacology and International Symposium on Child and Adolescent Psychopharmacology (TAP‐ICP); October 30‐November 3 2013; Antalya (Turkey). 2013; Vol. 23:S80. ÇetinFH , TaşTY , Işik TanerY . Atomoxetine versus OROS methylphenidate in attention deficit hyperactivity disorder: a six‐month follow up study for efficacy and adverse effects. Turkiye Klinikleri Journal of Medical Sciences2015;35(2):88‐96. [DOI: 10.5336/medsci.2015‐43336] ">Çetin 2015</a>; <a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a>; <a href="./references#CD012069-bbs2-0122" title="KhajehpiriZ , Mahmoudi‐GharaeiJ , FaghihiT , KarimzadehI , KhaliliH , MohammadiM . Adverse reactions of Methylphenidate in children with attention deficit‐hyperactivity disorder: report from a referral center. Journal of Research in Pharmacy Practice2014;3(4):130‐6. [DOI: 10.4103/2279‐042X.145389; PMC4262859; PUBMED: 25535621] ">Khajehpiri 2014</a>; see <a href="https://zenodo.org/record/1240380#.WusSlmcUmBE" target="_blank">supplementary file S46</a>); </p> </li> <li> <p>mood disorder was 1.50% (95% CI 0.20% to 10.6%; 2 studies, 1665 participants; <a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a>; <a href="./references#CD012069-bbs2-0098" title="HaertlingF , MuellerB , Bilke‐HentschO . Effectiveness and safety of a long‐acting, once‐daily, two‐phase release formulation of methylphenidate (Ritalin® LA) in school children under daily practice conditions. Attention Deficit and Hyperactivity Disorders2015;7(2):157‐64. [DOI: 10.1007/s12402‐014‐0154‐x; PMC4449385; PUBMED: 25346231] ">Haertling 2015</a>; see <a href="https://zenodo.org/record/1240381#.WusS52cUmBE" target="_blank">supplementary file S47</a>); </p> </li> <li> <p>confusional state was 2.30% (95% CI 0.10% to 39.4%; 2 studies, 390 participants; <a href="./references#CD012069-bbs2-0098" title="HaertlingF , MuellerB , Bilke‐HentschO . Effectiveness and safety of a long‐acting, once‐daily, two‐phase release formulation of methylphenidate (Ritalin® LA) in school children under daily practice conditions. Attention Deficit and Hyperactivity Disorders2015;7(2):157‐64. [DOI: 10.1007/s12402‐014‐0154‐x; PMC4449385; PUBMED: 25346231] ">Haertling 2015</a>; <a href="./references#CD012069-bbs2-0255" title="ZelnikN , Terkel‐DawerR . The clinical profile of children with ADHD that require OROS‐methylphenidate combined with shorter‐acting formulations. ADHD Attention Deficit and Hyperactivity Disorders2015;7(4):313‐8. [DOI: 10.1007/s12402‐015‐0168‐z; PUBMED: 25838111] ">Zelnik 2015</a>; see <a href="https://zenodo.org/record/1240382#.WusTjGcUmBE" target="_blank">supplementary file S48</a>); </p> </li> <li> <p>sleep disorder was 3.50% (95% CI 0.80% to 14.4%; 3 studies, 1211 participants; <a href="./references#CD012069-bbs2-0053" title="DittmannRW , BanaschewskiT , SchachtA , WehmeierPM . Findings from the observational COMPLY study in children and adolescents with ADHD: core symptoms, ADHD‐related difficulties, and patients' emotional expression during psychostimulant or nonstimulant ADHD treatment. Attention Deficit and Hyperactivity Disorders2014;6(2014):291‐302. [DOI: 10.1007/s12402‐014‐0136‐z; PUBMED: 24705867] ">Dittmann 2014</a>; <a href="./references#CD012069-bbs2-0055" title="BeckerA , RoessnerV , BreuerD , DöpfnerM , RothenbergerA . Relationship between quality of life and psychopathological profile: data from an observational study in children with ADHD. European Child and Adolescent Psychiatry2011;20(Suppl 2):S267‐75. [DOI: 10.1007/s00787‐011‐0204‐2; PMC3180591; PUBMED: 21901415] BreuerD , Görtz‐DortenA , RothenbergerA , DöpfnerM . Assessment of daily profiles of ADHD and ODD symptoms, and symptomatology related to ADHD medication, by parent and teacher ratings. European Child and Adolescent Psychiatry2011;20(Suppl 2):S289‐96. [DOI: 10.1007/s00787‐011‐0206‐0; PMC3180560; PUBMED: 21901413] DöpfnerM , BreuerD , WalterD , RothenbergerA . An observational study of once‐daily modified‐release methylphenidate in ADHD: the effect of previous treatment on ADHD symptoms, other externalising symptoms and quality‐of‐life outcomes. European Child and Adolescent Psychiatry2011;20(Suppl 2):S277‐88. [DOI: 10.1007/s00787‐011‐0205‐1; PMC3098980; PUBMED: 21901414] DöpfnerM , Görtz‐DortenA , BreuerD , RothenbergerA . An observational study of once‐daily modified‐release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety. European Child and Adolescent Psychiatry2011;20(Suppl 2):S243‐55. [DOI: 10.1007/s00787‐011‐0202‐4; PMC3180616; PUBMED: 21901417] DöpfnerM , RothenbergerA , OseC . Assessment of Equasym XL under routine conditions by physicians, parents, teachers, and children. International Journal of Neuropsychopharmacology2008;11(Suppl 1):290. [DOI: 10.1017/S1461145708009462] Görtz‐DortenA , BreuerD , HautmannC , RothenbergerA , DöpfnerM . What contributes to patient and parent satisfaction with medication in the treatment of children with ADHD? A report on the development of a new rating scale. European Child and Adolescent Psychiatry2011; Vol. 20, issue Suppl 2:S297‐307. [DOI: 10.1007/s00787‐011‐0207‐z; PMC3180627] RothenbergerA , BeckerA , BreuerD , DöpfnerM . An observational study of once‐daily modified‐release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence. European Child and Adolescent Psychiatry2011;20(Suppl 2):257‐65. [DOI: 10.1007/s00787‐011‐0203‐3; PMC3180635] ">Döpfner 2011a, OBSEER</a>; <a href="./references#CD012069-bbs2-0207" title="SuY , LiH , ChenY , FangF , XuT , LuH , et al. Remission rate and functional outcomes during a 6‐month treatment with Osmotic‐Release Oral‐System methylphenidate in children with attention‐deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology2015;35(5):525‐34. [DOI: 10.1097/JCP.0000000000000389; PUBMED: 26267421] ">Su 2015</a>; see <a href="https://zenodo.org/record/1240383#.WusUH2cUmBE" target="_blank">supplementary file S49</a>); </p> </li> <li> <p>propensity to cry was 24.8% (95% CI 7.00% to 59.0%; 2 studies, 61 participants; <a href="./references#CD012069-bbs2-0062" title="El‐FikyMR , El‐NahasGM , El‐ShahawyHH , Abdel AzizMF , AliDH , KhalifaNM . Study the gender differences in ADHD children: is the response to CNS stimulants a case of one fits both?. Indian Streams Research Journal2014;4(5):1‐10. ">El‐Fiky 2014</a>; <a href="./references#CD012069-bbs2-0187" title="SahinS , YuceM , AlacamH , KarabekirogluK , SayGN , SalisO . Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain‐derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder. International Journal of Psychiatry in Clinical Practice2014;18(4):280‐7. [DOI: 10.3109/13651501.2014.940054; PUBMED: 24994482] ">Sahin 2014</a>; see <a href="https://zenodo.org/record/1241623#.Wu6dbmcUmBE" target="_blank">supplementary file S50</a>); </p> </li> <li> <p>sedation was 11.8% (95% CI 3.50% to 33.2%; 2 studies, 80 participants; <a href="./references#CD012069-bbs2-0153" title="LooSK , BilderR , ChoAL , SturmA , CowenJ , WelkerPW , et al. Effects of d‐Methylphenidate, Guanfacine, and their combination on electroencephalogram resting state spectral power in Attention‐Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):674‐82.e1. [DOI: 10.1016/j.jaac.2016.04.020; PMC5003618; PUBMED: 27453081] McCrackenJT , McGoughJJ , LooSK , LevittJ , Del'HommeM , CowenJ , et al. Combined stimulant and Guanfacine administration in Attention‐Deficit/Hyperactivity Disorder: a controlled, comparative study. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):657‐66.e1. [DOI: 10.1016/j.jaac.2016.05.015; PMC4976782; PUBMED: 27453079] ">McCracken 2016</a>; <a href="./references#CD012069-bbs2-0160" title="MohammadiMR , KazemiMR , ZiaE , RezazadehSA , TabriziM , AkhondzadehS . Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double‐blind trial. Human Psychopharmacology2010;25(7‐8):560‐5. [DOI: 10.1002/hup.1154; PUBMED: 21312290] ">Mohammadi 2010</a>; see <a href="https://zenodo.org/record/1240387#.WusUumcUmBE" target="_blank">supplementary file S51</a>); </p> </li> <li> <p>daytime sleepiness was 3.60% (95% CI 0.90% to 14.0%; 2 studies, 141 participants; <a href="./references#CD012069-bbs2-0073" title="GallandBC , TrippEG , GrayA , TaylorBJ . Apnea‐hypopnea indices and snoring in children diagnosed with ADHD: a matched case‐control study. Sleep and Breathing2011;15(3):455‐62. [DOI: 10.1007/s11325‐010‐0357‐0; PUBMED: 20440568] GallandBC , TrippEG , TaylorBJ . Methylphenidate effects on sleep in children. Brown University Child and Adolescent Psychopharmacology Update2010;12(3):5‐6. [DOI: 10.1002/cpu.20111] GallandBC , TrippEG , TaylorBJ . The sleep of children with attention deficit hyperactivity disorder on and off methylphenidate: a matched case‐control study. Journal of Sleep Research2010;19(2):366‐73. [DOI: 10.1111/j.1365‐2869.2009.00795.x; PUBMED: 20050995] ">Galland 2010</a>; <a href="./references#CD012069-bbs2-0214" title="Tomás VilaM , Aleu Pérez‐GramuntM , Beseler SotoB , Benac PrefasiM , Pantoja MartínezJ , Pitarch CastellanoI . Methylphenidate and sleep: results of a multicentre study on a population of children with attention deficit hyperactivity disorder. Anales de Pediatria2010;73(2):78‐83. [DOI: 10.1016/j.anpedi.2010.05.013; PUBMED: 20605120] ">Tomás Vila 2010b</a>; see <a href="https://zenodo.org/record/1240388#.WusU92cUmBE" target="_blank">supplementary file S52</a>). </p> </li> </ol> </p> <p>Sixteen studies reported data on different adverse events related to the central nervous system (<a href="./references#CD012069-bbs2-0020" title="AtzoriP , AncillettaB , UsalaT , DanjouF , ZuddasA . Predictive parameters for methylphenidate use and compliance in children with attention deficit hyperactivity disorder. European Neuropsychopharmacology2006;16(Suppl 1):S73‐4. [DOI: 10.1016/S0924‐977X(06)80087‐8] AtzoriP , UsalaT , CarucciS , DanjouF , ZuddasA . Predictive factors for persistent use and compliance of immediate‐release methylphenidate: a 36‐month naturalistic study. Journal of Child and Adolescent Psychopharmacology2009;19(6):673‐81. [DOI: 10.1089/cap.2008.0146; PUBMED: 20035585] ">Atzori 2009</a>; <a href="./references#CD012069-bbs2-0025" title="AlfredA , LindermuellerA , MattejatF , DichterS , SchaeubleB . Transitioning onto OROS MPH is associated with improved functioning and quality of life in adolescents with ADHD. European Psychiatry. 18th European Congress of Psychiatry. 2010 Feb 27‐March 2; Munich (Germany)2010;25(Suppl 1):375. [DOI: 10.1016/S0924‐9338(10)70372‐2] BerekM , KordonA , HargarterL , MattejatF , SlawikL , RettigK , et al. Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?. Child &amp; Adolescent Psychiatry &amp; Mental Health2011;5(1):26. [DOI: 10.1186/1753‐2000‐5‐26] KordonA , HultzschW , MattejatF , DichterS , SchaeubleB . Transitioning onto OROS MPH is associated with improved functioning and quality of life in children and adolescents with ADHD. European Psychiatry. 18th European Congress of Psychiatry. 2010 Feb 27‐March 2; Munich (Germany). 2010; Vol. 25, issue Suppl 1:962. [DOI: 10.1016/S0924‐9338(10)70953‐6] NiederkirchnerK , SlawikL , WermelskirchenD , RettigK , SchaubleB . Transitioning to OROS® methylphenidate from atomoxetine is effective in children and adolescents with ADHD. Expert Review of Neurotherapeutics2011;11(4):499‐508. [DOI: 10.1586/ern.11.18] SchaeubleB , MattejatF , RettigK , KordonA , BerekM . Changes in function and quality of life aspects in children with ADHD after transitioning onto OROS MPH. European Child and Adolescent Psychiatry.14th International Congress of European Society for Child and Adolescent Psychiatry (ESCAP); June 11‐15 2011; Helsinki (Finland). 2011; Vol. Suppl 1:S131. WolffC , AlfredA , LindermüllerA , RettigK , MattejatF , GerweM , et al. Effect of transitioning from extended‐release methylphenidate onto osmotic, controlled‐release methylphenidate in children/adolescents with ADHD: results of a 3‐month non‐interventional study. Current Medical Research and Opinion2011;27(Suppl 2):35‐44. [DOI: 10.1185/03007995.2011.601733; PUBMED: 21787126] ">Berek 2011</a>; <a href="./references#CD012069-bbs2-0074" title="GargJ , ArunP , ChavanBS . Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. International Journal of Applied and Basic Medical Research2015;5(2):114‐8. [DOI: 10.4103/2229‐516X.157162; PMC4456885] GargJ , ArunP , ChavanBS . Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder. Indian Pediatrics2014;51(7):550‐4. [PUBMED: 25031133] ">Garg 2014</a>; <a href="./references#CD012069-bbs2-0073" title="GallandBC , TrippEG , GrayA , TaylorBJ . Apnea‐hypopnea indices and snoring in children diagnosed with ADHD: a matched case‐control study. Sleep and Breathing2011;15(3):455‐62. [DOI: 10.1007/s11325‐010‐0357‐0; PUBMED: 20440568] GallandBC , TrippEG , TaylorBJ . Methylphenidate effects on sleep in children. Brown University Child and Adolescent Psychopharmacology Update2010;12(3):5‐6. [DOI: 10.1002/cpu.20111] GallandBC , TrippEG , TaylorBJ . The sleep of children with attention deficit hyperactivity disorder on and off methylphenidate: a matched case‐control study. Journal of Sleep Research2010;19(2):366‐73. [DOI: 10.1111/j.1365‐2869.2009.00795.x; PUBMED: 20050995] ">Galland 2010</a>; <a href="./references#CD012069-bbs2-0098" title="HaertlingF , MuellerB , Bilke‐HentschO . Effectiveness and safety of a long‐acting, once‐daily, two‐phase release formulation of methylphenidate (Ritalin® LA) in school children under daily practice conditions. Attention Deficit and Hyperactivity Disorders2015;7(2):157‐64. [DOI: 10.1007/s12402‐014‐0154‐x; PMC4449385; PUBMED: 25346231] ">Haertling 2015</a>; <a href="./references#CD012069-bbs2-0100" title="Effects of high‐dose OROS methylphenidate. Brown University Child and Adolescent Psychopharmacology Update2009;11(8):7‐8. [DOI: 10.1002/cpu.20097] DanielsSR . Cardiovascular effects of methylphenidate. Journal of Pediatrics2009;155(1):A3. [DOI: 10.1016/j.jpeds.2009.05.023] HammernessP , GeorgiopoulosA , DoyleRL , UtzingerL , SchillingerM , MartelonM , et al. An open study of adjunct OROS‐methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. Journal of Child and Adolescent Psychopharmacology2009;19(5):493‐9. [DOI: 10.1089/cap.2008.0126; PMC2861956; PUBMED: 19877973] ">Hammerness 2009</a>; <a href="./references#CD012069-bbs2-0122" title="KhajehpiriZ , Mahmoudi‐GharaeiJ , FaghihiT , KarimzadehI , KhaliliH , MohammadiM . Adverse reactions of Methylphenidate in children with attention deficit‐hyperactivity disorder: report from a referral center. Journal of Research in Pharmacy Practice2014;3(4):130‐6. [DOI: 10.4103/2279‐042X.145389; PMC4262859; PUBMED: 25535621] ">Khajehpiri 2014</a>; <a href="./references#CD012069-bbs2-0131" title="KordonA , StollhoffK , NiederkirchnerK , MattejatF , RettigK , SchäubleB . Exploring the impact of once‐daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate‐release MPH. Postgraduate Medicine2011;123(5):27‐38. [DOI: 10.3810/pgm.2011.09.2457; PUBMED: 21904084] ">Kordon 2011</a>; <a href="./references#CD012069-bbs2-0142" title="LeeWJ , LeeTA , PickardAS , CaskeyRN , SchumockGT . Drugs associated with adverse events in children and adolescents. Pharmacotherapy2014;34(9):918‐26. [DOI: 10.1002/phar.1455; PUBMED: 24990656] ">Lee 2014</a>; <a href="./references#CD012069-bbs2-0158" title="MohammadiMR , KashaniL , AkhondzadehS , IzadianES , OhadiniaS . Efficacy of theophylline compared to methylphenidate for the treatment of attention‐deficit hyperactivity disorder in children and adolescents: a pilot double‐blind randomized trial. Journal of Clinical Pharmacy and Therapeutics2004;29(2):139‐44. [DOI: 10.1111/j.1365‐2710.2004.00545.x; PUBMED: 15068402] ">Mohammadi 2004</a>; <a href="./references#CD012069-bbs2-0187" title="SahinS , YuceM , AlacamH , KarabekirogluK , SayGN , SalisO . Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain‐derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder. International Journal of Psychiatry in Clinical Practice2014;18(4):280‐7. [DOI: 10.3109/13651501.2014.940054; PUBMED: 24994482] ">Sahin 2014</a>; <a href="./references#CD012069-bbs2-0192" title="SchmidtJK , PlückJ , vonGontardA . Waiver of EEG diagnostics prior to and during methylphenidate therapy: dangerous or justifiable? [Verzicht auf eine EEG‐Diagnostik vor Beginn und unter einer Therapie mit Methylphenidat: gefährlich oder gerechtfertigt?]. Zeitschrift fur Kinder‐ und Jugendpsychiatrie und Psychotherapie2002;30(4):295‐302. [DOI: 10.1024/1422‐4917.30.4.295] ">Schmidt 2002</a>; <a href="./references#CD012069-bbs2-0212" title="ThorellLB , DahlströmK . Children's self‐reports on perceived effects on taking stimulant medication for ADHD. Journal of Attention Disorders2009;12(5):460‐8. [DOI: 10.1177/1087054708320430; PUBMED: 18685139] ">Thorell 2009</a>; <a href="./references#CD012069-bbs2-0214" title="Tomás VilaM , Aleu Pérez‐GramuntM , Beseler SotoB , Benac PrefasiM , Pantoja MartínezJ , Pitarch CastellanoI . Methylphenidate and sleep: results of a multicentre study on a population of children with attention deficit hyperactivity disorder. Anales de Pediatria2010;73(2):78‐83. [DOI: 10.1016/j.anpedi.2010.05.013; PUBMED: 20605120] ">Tomás Vila 2010b</a>; <a href="./references#CD012069-bbs2-0219" title="Valdizán UsonJR . Methylphenidate in children and adolescents with attention‐deficit/ hyperactivity disorder: The DIHANA Study. Acta Pediatrica Espanola2013;71(3):67‐76. Valdizán UsonJR , Cánovas‐MartínezA , DeLucas‐TaracenaMT , Díaz‐AtienzaF , Eddy‐IvesLS , Fernandez‐JaenA , et al. Response to methylphenidate by adult and pediatric patients with attention‐deficit/hyperactivity disorder: the Spanish multicenter DIHANA study. Neuropsychiatric Disease and Treatment2013;9:211‐8. [DOI: 10.2147/NDT.S35836; PMC3573811] ">Valdizán Usón 2013</a>; <a href="./references#CD012069-bbs2-0251" title="YildizÖ , ŞişmanlarŞG , MemikNÇ , KarakayaI , AğaoğluB . Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. Child Psychiatry and Human Development2011;42(3):257‐69. [DOI: 10.1007/s10578‐010‐0212‐3; PUBMED: 21165694] ">Yildiz 2011</a>). </p> <p> <ol id="CD012069-list-0034"> <li> <p>In <a href="./references#CD012069-bbs2-0020" title="AtzoriP , AncillettaB , UsalaT , DanjouF , ZuddasA . Predictive parameters for methylphenidate use and compliance in children with attention deficit hyperactivity disorder. European Neuropsychopharmacology2006;16(Suppl 1):S73‐4. [DOI: 10.1016/S0924‐977X(06)80087‐8] AtzoriP , UsalaT , CarucciS , DanjouF , ZuddasA . Predictive factors for persistent use and compliance of immediate‐release methylphenidate: a 36‐month naturalistic study. Journal of Child and Adolescent Psychopharmacology2009;19(6):673‐81. [DOI: 10.1089/cap.2008.0146; PUBMED: 20035585] ">Atzori 2009</a>, the proportion of participants on methylphenidate with: </p> <ol id="CD012069-list-0035"> <li> <p>dysphoria was 1.49% (95% CI 0.40% to 5.27%, 134 participants); and</p> </li> <li> <p>logorrhoea (that is, excessive, uncontrollable or incoherent talkativeness) was 0.78% (95% CI 0.14% to 4.27%; 129 participants). </p> </li> </ol> </li> <li> <p>In <a href="./references#CD012069-bbs2-0025" title="AlfredA , LindermuellerA , MattejatF , DichterS , SchaeubleB . Transitioning onto OROS MPH is associated with improved functioning and quality of life in adolescents with ADHD. European Psychiatry. 18th European Congress of Psychiatry. 2010 Feb 27‐March 2; Munich (Germany)2010;25(Suppl 1):375. [DOI: 10.1016/S0924‐9338(10)70372‐2] BerekM , KordonA , HargarterL , MattejatF , SlawikL , RettigK , et al. Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS® MPH: is treatment response different between children and adolescents?. Child &amp; Adolescent Psychiatry &amp; Mental Health2011;5(1):26. [DOI: 10.1186/1753‐2000‐5‐26] KordonA , HultzschW , MattejatF , DichterS , SchaeubleB . Transitioning onto OROS MPH is associated with improved functioning and quality of life in children and adolescents with ADHD. European Psychiatry. 18th European Congress of Psychiatry. 2010 Feb 27‐March 2; Munich (Germany). 2010; Vol. 25, issue Suppl 1:962. [DOI: 10.1016/S0924‐9338(10)70953‐6] NiederkirchnerK , SlawikL , WermelskirchenD , RettigK , SchaubleB . Transitioning to OROS® methylphenidate from atomoxetine is effective in children and adolescents with ADHD. Expert Review of Neurotherapeutics2011;11(4):499‐508. [DOI: 10.1586/ern.11.18] SchaeubleB , MattejatF , RettigK , KordonA , BerekM . Changes in function and quality of life aspects in children with ADHD after transitioning onto OROS MPH. European Child and Adolescent Psychiatry.14th International Congress of European Society for Child and Adolescent Psychiatry (ESCAP); June 11‐15 2011; Helsinki (Finland). 2011; Vol. Suppl 1:S131. WolffC , AlfredA , LindermüllerA , RettigK , MattejatF , GerweM , et al. Effect of transitioning from extended‐release methylphenidate onto osmotic, controlled‐release methylphenidate in children/adolescents with ADHD: results of a 3‐month non‐interventional study. Current Medical Research and Opinion2011;27(Suppl 2):35‐44. [DOI: 10.1185/03007995.2011.601733; PUBMED: 21787126] ">Berek 2011</a> (822 participants), the proportion of participants on methylphenidate with impaired concentration was 1.70% (95% CI 1.01% to 2.83%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0073" title="GallandBC , TrippEG , GrayA , TaylorBJ . Apnea‐hypopnea indices and snoring in children diagnosed with ADHD: a matched case‐control study. Sleep and Breathing2011;15(3):455‐62. [DOI: 10.1007/s11325‐010‐0357‐0; PUBMED: 20440568] GallandBC , TrippEG , TaylorBJ . Methylphenidate effects on sleep in children. Brown University Child and Adolescent Psychopharmacology Update2010;12(3):5‐6. [DOI: 10.1002/cpu.20111] GallandBC , TrippEG , TaylorBJ . The sleep of children with attention deficit hyperactivity disorder on and off methylphenidate: a matched case‐control study. Journal of Sleep Research2010;19(2):366‐73. [DOI: 10.1111/j.1365‐2869.2009.00795.x; PUBMED: 20050995] ">Galland 2010</a> (28 participants), the proportion of participants on methylphenidate with difficulty waking up was 25.0% (95% CI 12.7% to 43.4%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0074" title="GargJ , ArunP , ChavanBS . Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. International Journal of Applied and Basic Medical Research2015;5(2):114‐8. [DOI: 10.4103/2229‐516X.157162; PMC4456885] GargJ , ArunP , ChavanBS . Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder. Indian Pediatrics2014;51(7):550‐4. [PUBMED: 25031133] ">Garg 2014</a> (32 participants), the proportion of participants on methylphenidate with urinary incontinence was 3.13% (95% CI 0.56% to 15.8%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0098" title="HaertlingF , MuellerB , Bilke‐HentschO . Effectiveness and safety of a long‐acting, once‐daily, two‐phase release formulation of methylphenidate (Ritalin® LA) in school children under daily practice conditions. Attention Deficit and Hyperactivity Disorders2015;7(2):157‐64. [DOI: 10.1007/s12402‐014‐0154‐x; PMC4449385; PUBMED: 25346231] ">Haertling 2015</a> (239 participants), the proportion of participants on methylphenidate with paralysis was 0.42% (95% CI 0.07% to 2.33%); and affective disorder was 0.42% (95% CI 0.07% to 2.33%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0100" title="Effects of high‐dose OROS methylphenidate. Brown University Child and Adolescent Psychopharmacology Update2009;11(8):7‐8. [DOI: 10.1002/cpu.20097] DanielsSR . Cardiovascular effects of methylphenidate. Journal of Pediatrics2009;155(1):A3. [DOI: 10.1016/j.jpeds.2009.05.023] HammernessP , GeorgiopoulosA , DoyleRL , UtzingerL , SchillingerM , MartelonM , et al. An open study of adjunct OROS‐methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. Journal of Child and Adolescent Psychopharmacology2009;19(5):493‐9. [DOI: 10.1089/cap.2008.0126; PMC2861956; PUBMED: 19877973] ">Hammerness 2009</a> (154 participants), the proportion of participants on methylphenidate with jumbled thoughts was 0.65% (95% CI 0.03% to 0.90%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0122" title="KhajehpiriZ , Mahmoudi‐GharaeiJ , FaghihiT , KarimzadehI , KhaliliH , MohammadiM . Adverse reactions of Methylphenidate in children with attention deficit‐hyperactivity disorder: report from a referral center. Journal of Research in Pharmacy Practice2014;3(4):130‐6. [DOI: 10.4103/2279‐042X.145389; PMC4262859; PUBMED: 25535621] ">Khajehpiri 2014</a> (71 participants), the proportion of participants on methylphenidate with: </p> <ol id="CD012069-list-0036"> <li> <p>bulimia was 7.04% (95% CI 3.00% to 15.5%);</p> </li> <li> <p>sleeping late was 30.9% (95% CI 21.4% to 42.5%);</p> </li> <li> <p>tooth grinding was 4.23% (95% CI 1.40% to 11.7%);</p> </li> <li> <p>tremor was 2.82% (95% CI 0.08% to 9.71%);</p> </li> <li> <p>stuttering was 5.63% (95% CI 2.21% to 13.6%); and</p> </li> <li> <p>flushing 12.7% (95% CI 6.82% to 22.4%).</p> </li> </ol> </li> <li> <p>In <a href="./references#CD012069-bbs2-0131" title="KordonA , StollhoffK , NiederkirchnerK , MattejatF , RettigK , SchäubleB . Exploring the impact of once‐daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate‐release MPH. Postgraduate Medicine2011;123(5):27‐38. [DOI: 10.3810/pgm.2011.09.2457; PUBMED: 21904084] ">Kordon 2011</a> (541 participants), the proportion of participants on methylphenidate with apathy was 1.10% (95% CI 0.50% to 2.40%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0142" title="LeeWJ , LeeTA , PickardAS , CaskeyRN , SchumockGT . Drugs associated with adverse events in children and adolescents. Pharmacotherapy2014;34(9):918‐26. [DOI: 10.1002/phar.1455; PUBMED: 24990656] ">Lee 2014</a> (100 participants), the proportion of participants on methylphenidate with abnormal behaviour was 5.00% (95% CI 2.20% to 11.2%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0158" title="MohammadiMR , KashaniL , AkhondzadehS , IzadianES , OhadiniaS . Efficacy of theophylline compared to methylphenidate for the treatment of attention‐deficit hyperactivity disorder in children and adolescents: a pilot double‐blind randomized trial. Journal of Clinical Pharmacy and Therapeutics2004;29(2):139‐44. [DOI: 10.1111/j.1365‐2710.2004.00545.x; PUBMED: 15068402] ">Mohammadi 2004</a> (16 participants), the proportion of participants on methylphenidate with stereotypies was 0.00% (95% Cl 0.00% to 19.4%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0187" title="SahinS , YuceM , AlacamH , KarabekirogluK , SayGN , SalisO . Effect of methylphenidate treatment on appetite and levels of leptin, ghrelin, adiponectin, and brain‐derived neurotrophic factor in children and adolescents with attention deficit and hyperactivity disorder. International Journal of Psychiatry in Clinical Practice2014;18(4):280‐7. [DOI: 10.3109/13651501.2014.940054; PUBMED: 24994482] ">Sahin 2014</a> (30 participants), the proportion of participants on methylphenidate with quietness was 20.0% (95% CI 9.50% to 37.3%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0192" title="SchmidtJK , PlückJ , vonGontardA . Waiver of EEG diagnostics prior to and during methylphenidate therapy: dangerous or justifiable? [Verzicht auf eine EEG‐Diagnostik vor Beginn und unter einer Therapie mit Methylphenidat: gefährlich oder gerechtfertigt?]. Zeitschrift fur Kinder‐ und Jugendpsychiatrie und Psychotherapie2002;30(4):295‐302. [DOI: 10.1024/1422‐4917.30.4.295] ">Schmidt 2002</a> (124 participants), the proportion of participants on methylphenidate with EEG changes was 20.2% (95% CI 14.0% to 28.0%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0212" title="ThorellLB , DahlströmK . Children's self‐reports on perceived effects on taking stimulant medication for ADHD. Journal of Attention Disorders2009;12(5):460‐8. [DOI: 10.1177/1087054708320430; PUBMED: 18685139] ">Thorell 2009</a> (79 participants), the proportion of participants on methylphenidate who did not like themselves was 12.7% (95% CI 6.50% to 21.8%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0214" title="Tomás VilaM , Aleu Pérez‐GramuntM , Beseler SotoB , Benac PrefasiM , Pantoja MartínezJ , Pitarch CastellanoI . Methylphenidate and sleep: results of a multicentre study on a population of children with attention deficit hyperactivity disorder. Anales de Pediatria2010;73(2):78‐83. [DOI: 10.1016/j.anpedi.2010.05.013; PUBMED: 20605120] ">Tomás Vila 2010b</a> (114 participants), the proportion of participants on methylphenidate with sleep walking was 1.75% (95% CI 0.50% to 6.20%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0219" title="Valdizán UsonJR . Methylphenidate in children and adolescents with attention‐deficit/ hyperactivity disorder: The DIHANA Study. Acta Pediatrica Espanola2013;71(3):67‐76. Valdizán UsonJR , Cánovas‐MartínezA , DeLucas‐TaracenaMT , Díaz‐AtienzaF , Eddy‐IvesLS , Fernandez‐JaenA , et al. Response to methylphenidate by adult and pediatric patients with attention‐deficit/hyperactivity disorder: the Spanish multicenter DIHANA study. Neuropsychiatric Disease and Treatment2013;9:211‐8. [DOI: 10.2147/NDT.S35836; PMC3573811] ">Valdizán Usón 2013</a> (633 participants), the proportion of participants on methylphenidate with personality and behaviour disorders was 2.20% (95% CI 1.30% to 3.70%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0251" title="YildizÖ , ŞişmanlarŞG , MemikNÇ , KarakayaI , AğaoğluB . Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. Child Psychiatry and Human Development2011;42(3):257‐69. [DOI: 10.1007/s10578‐010‐0212‐3; PUBMED: 21165694] ">Yildiz 2011</a> (11 participants), the proportion of participants on methylphenidate with vertigo was 27.3% (95% CI 9.70% to 56.6%). </p> </li> </ol> </p> </section> <section id="CD012069-sec-0146"> <h6 class="title">2.2.3 Cardiovascular and respiratory system</h6> <p>See <a href="./references#CD012069-fig-0031" title="">Analysis 7.3</a>. Thirty‐nine studies reported data on this outcome. </p> <p>We included 18 studies in seven meta‐analyses (<a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0016" title="ArnoldLE , BozzoloDR , HodgkinsP , McKayM , Beckett‐ThurmanL , GreenbaumM , et al. Switching from oral extended‐release methylphenidate to the methylphenidate transdermal system: continued attention‐deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Current Medical Research and Opinion2010;26(1):129‐37. [DOI: 10.1185/03007990903437412; PMC3875401; PUBMED: 19916704] BuksteinOG , ArnoldLE , LandgrafJM , HodgkinsP . Does switching from oral extended‐release methylphenidate to the methylphenidate transdermal system affect health‐related quality‐of‐life and medication satisfaction for children with attention‐deficit/hyperactivity disorder?. Child and Adolescent Psychiatry and Mental Health2009;3(1):39. [DOI: 10.1186/1753‐2000‐3‐39; PMC2796990; PUBMED: 20003260] ">Arnold 2010</a>; <a href="./references#CD012069-bbs2-0028" title="BladerJC , PliszkaSR , JensenPS , SchoolerNR , KafantarisV . Stimulant‐responsive and stimulant‐refractory aggressive behavior among children with ADHD. Pediatrics2010;126(4):e796‐806. [DOI: 10.1542/peds.2010‐0086; PMC2956067; PUBMED: 20837589] Blader JosephC . Methylphenidate dose may reduce aggressive behavior in children with ADHD. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(12):1‐7. [DOI: 10.1002/cpu.20129] ">Blader 2010</a>; <a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a>; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0071" title="FindlingRL , KaticA , RubinR , MoonE , CivilR , LiY . A 6‐month, open‐label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2010;20(5):366‐75. [DOI: 10.1089/cap.2009.0122; PUBMED: 20973707] FindlingRL , TurnbowJ , BurnsideJ , MelmedR , CivilR , LiY . A randomized, double‐blind, multicenter, parallel‐group, placebo‐controlled, dose‐optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents. CNS Spectrums2010;15(7):419‐30. [PUBMED: 20625364] KeatingGM . Methylphenidate transdermal system in attention‐deficit hyperactivity disorder in adolescents: profile report. Drugs in R&amp;D. G.M. Keating, Adis, Private Bag 65901, 41 Centorian Drive, Mairangi Bay, North Shore 0754, Auckland, New Zealand. E‐mail: demail@springer.com, 2012; Vol. 12, issue 3:171‐3. [DOI: 10.2165/11207490‐000000000‐00000; PMC3585903; PUBMED: 22934753] ">Findling 2010</a>; <a href="./references#CD012069-bbs2-0113" title="JafariniaM , MohammadiMR , ModabberniaA , AshrafiM , KhajaviD , TabriziM , et al. Bupropion versus methylphenidate in the treatment of children with attention‐deficit/hyperactivity disorder: randomized double‐blind study. Human Psychopharmacology2012; Vol. 27, issue 4:411‐8. [DOI: 10.1002/hup.2242; PUBMED: 22806822] ">Jafarinia 2012</a>; <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a>; <a href="./references#CD012069-bbs2-0146" title="Methylphenidate for preschool ADHD. Brown University Child and Adolescent Psychopharmacology Update2009;11(7):4‐4. [DOI: 10.1002/cpu.20095] MaayanL , PaykinaN , FriedJ , StraussT , GuggaSS , GreenhillL . The open‐label treatment of attention‐deficit/hyperactivity disorder in 4‐ and 5‐year‐old children with beaded methylphenidate. Journal of Child and Adolescent Psychopharmacology2009;19(2):147‐53. [PMC2935832; PUBMED: 19374023] ">Maayan 2009</a>; <a href="./references#CD012069-bbs2-0158" title="MohammadiMR , KashaniL , AkhondzadehS , IzadianES , OhadiniaS . Efficacy of theophylline compared to methylphenidate for the treatment of attention‐deficit hyperactivity disorder in children and adolescents: a pilot double‐blind randomized trial. Journal of Clinical Pharmacy and Therapeutics2004;29(2):139‐44. [DOI: 10.1111/j.1365‐2710.2004.00545.x; PUBMED: 15068402] ">Mohammadi 2004</a>; <a href="./references#CD012069-bbs2-0167" title="LeeMS , LeeSI , HongSD , KimJH , ChoiJ , JoungYS . Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12‐week multicenter, open‐label study. Journal of Child and Adolescent Psychopharmacology2013;23(1):22‐7. [DOI: 10.1089/cap.2012.0018; PUBMED: 23347125] NaKS , LeeSI , HongSD , KimJH , ShimSH , ChoiJ , et al. Effect of osmotic‐release oral system methylphenidate on learning skills in adolescents with attention‐deficit/hyperactivity disorder: an open‐label study. International Clinical Psychopharmacology2013;28(4):184‐92. [DOI: 10.1097/YIC.0b013e3283612509; PUBMED: 23587983] ">Na 2013</a>; <a href="./references#CD012069-bbs2-0175" title="PierceD , KaticA , BuckwalterM , WebsterK . Single‐ and multiple‐dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic‐release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. Journal of Clinical Psychopharmacology2010;30(5):554‐64. [DOI: 10.1097/JCP.0b013e3181f0c2f6; PUBMED: 20814325] ">Pierce 2010</a>; <a href="./references#CD012069-bbs2-0189" title="RostainAL . Sleep disturbances and ADHD medications. Current Psychiatry Reports2007;9(5):399‐400. [PUBMED: 17915079] SangalRB , OwensJ , AllenAJ , SuttonV , SchuhK , KelseyD . Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep2006;29(12):1573‐85. [PUBMED: 17252888] ">Sangal 2006</a>; <a href="./references#CD012069-bbs2-0195" title="ShangCY , PanYL , LinHY , HuangLW , GauSS . An open‐label, randomized trial of methylphenidate and atomoxetine treatment in children with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2015;25(7):566‐73. [DOI: 10.1089/cap.2015.0035; PUBMED: 26222447] ">Shang 2015</a>; <a href="./references#CD012069-bbs2-0207" title="SuY , LiH , ChenY , FangF , XuT , LuH , et al. Remission rate and functional outcomes during a 6‐month treatment with Osmotic‐Release Oral‐System methylphenidate in children with attention‐deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology2015;35(5):525‐34. [DOI: 10.1097/JCP.0000000000000389; PUBMED: 26267421] ">Su 2015</a>; <a href="./references#CD012069-bbs2-0227" title="WangY , ZhengY , DuY , SongDH , ShinYJ , ChoSC , et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double‐blind comparison trial. Australian and New Zealand Journal of Psychiatry2007;41(3):222‐30. [DOI: 10.1080/00048670601057767; PUBMED: 17464703] ">Wang 2007</a>; <a href="./references#CD012069-bbs2-0234" title="WigalSB , NordbrockE , AdjeiAL , ChildressA , KupperRJ , GreenhillL . Efficacy of methylphenidate hydrochloride extended‐release capsules (Aptensio XRTM) in children and adolescents with attention‐deficit/hyperactivity disorder: a phase III, randomized, double‐blind study. CNS Drugs2015;29(4):331‐40. ">Wigal 2015</a>; <a href="./references#CD012069-bbs2-0235" title="WigunaT , GuerreroAP , WibisonoS , SastroasmoroS . Effect of 12‐week administration of 20‐mg long‐acting methylphenidate on Glu/Cr, NAA/Cr, Cho/Cr, and mI/Cr ratios in the prefrontal cortices of school‐age children in Indonesia: a study using 1H Magnetic Resonance Spectroscopy (MRS). Clinical Neuropharmacology. T. Wiguna, Child and Adolescent Psychiatry Division, Department of Psychiatry, University of Indonesia, Jl. Salemba Raya 4, Jakarta 10430, Indonesia. E‐mail: twiga00@yahoo.com: Lippincott Williams and Wilkins (530 Walnut Street,P O Box 327, Philadelphia PA 19106‐3621, United States), 2012; Vol. 35, issue 2:81‐5. [DOI: 10.1097/WNF.0b013e3182452572; PUBMED: 22318191] ">Wiguna 2012</a>). The proportion of participants on methylphenidate with: </p> <p> <ol id="CD012069-list-0037"> <li> <p>cough was 7.7% (95% CI 3.80% to 15.2%; 7 studies, 724 participants; <a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0016" title="ArnoldLE , BozzoloDR , HodgkinsP , McKayM , Beckett‐ThurmanL , GreenbaumM , et al. Switching from oral extended‐release methylphenidate to the methylphenidate transdermal system: continued attention‐deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Current Medical Research and Opinion2010;26(1):129‐37. [DOI: 10.1185/03007990903437412; PMC3875401; PUBMED: 19916704] BuksteinOG , ArnoldLE , LandgrafJM , HodgkinsP . Does switching from oral extended‐release methylphenidate to the methylphenidate transdermal system affect health‐related quality‐of‐life and medication satisfaction for children with attention‐deficit/hyperactivity disorder?. Child and Adolescent Psychiatry and Mental Health2009;3(1):39. [DOI: 10.1186/1753‐2000‐3‐39; PMC2796990; PUBMED: 20003260] ">Arnold 2010</a>; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a>; <a href="./references#CD012069-bbs2-0175" title="PierceD , KaticA , BuckwalterM , WebsterK . Single‐ and multiple‐dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic‐release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. Journal of Clinical Psychopharmacology2010;30(5):554‐64. [DOI: 10.1097/JCP.0b013e3181f0c2f6; PUBMED: 20814325] ">Pierce 2010</a>; <a href="./references#CD012069-bbs2-0189" title="RostainAL . Sleep disturbances and ADHD medications. Current Psychiatry Reports2007;9(5):399‐400. [PUBMED: 17915079] SangalRB , OwensJ , AllenAJ , SuttonV , SchuhK , KelseyD . Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep2006;29(12):1573‐85. [PUBMED: 17252888] ">Sangal 2006</a>; <a href="./references#CD012069-bbs2-0227" title="WangY , ZhengY , DuY , SongDH , ShinYJ , ChoSC , et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double‐blind comparison trial. Australian and New Zealand Journal of Psychiatry2007;41(3):222‐30. [DOI: 10.1080/00048670601057767; PUBMED: 17464703] ">Wang 2007</a>; see <a href="https://zenodo.org/record/1240737#.WuwFumcUmBE" target="_blank">supplementary file S53</a>); </p> </li> <li> <p>pharyngolaryngeal pain was 5.10% (95% CI 3.50% to 7.30%; 3 studies, 547 participants; <a href="./references#CD012069-bbs2-0016" title="ArnoldLE , BozzoloDR , HodgkinsP , McKayM , Beckett‐ThurmanL , GreenbaumM , et al. Switching from oral extended‐release methylphenidate to the methylphenidate transdermal system: continued attention‐deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Current Medical Research and Opinion2010;26(1):129‐37. [DOI: 10.1185/03007990903437412; PMC3875401; PUBMED: 19916704] BuksteinOG , ArnoldLE , LandgrafJM , HodgkinsP . Does switching from oral extended‐release methylphenidate to the methylphenidate transdermal system affect health‐related quality‐of‐life and medication satisfaction for children with attention‐deficit/hyperactivity disorder?. Child and Adolescent Psychiatry and Mental Health2009;3(1):39. [DOI: 10.1186/1753‐2000‐3‐39; PMC2796990; PUBMED: 20003260] ">Arnold 2010</a>; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0175" title="PierceD , KaticA , BuckwalterM , WebsterK . Single‐ and multiple‐dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic‐release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. Journal of Clinical Psychopharmacology2010;30(5):554‐64. [DOI: 10.1097/JCP.0b013e3181f0c2f6; PUBMED: 20814325] ">Pierce 2010</a>; see <a href="https://zenodo.org/record/1240390#.WusVyGcUmBE" target="_blank">supplementary file S54</a>); </p> </li> <li> <p>upper respiratory tract infection was 10.5% (95% CI 4.40% to 22.9%; 5 studies, 614 participants; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0175" title="PierceD , KaticA , BuckwalterM , WebsterK . Single‐ and multiple‐dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic‐release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. Journal of Clinical Psychopharmacology2010;30(5):554‐64. [DOI: 10.1097/JCP.0b013e3181f0c2f6; PUBMED: 20814325] ">Pierce 2010</a>; <a href="./references#CD012069-bbs2-0227" title="WangY , ZhengY , DuY , SongDH , ShinYJ , ChoSC , et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double‐blind comparison trial. Australian and New Zealand Journal of Psychiatry2007;41(3):222‐30. [DOI: 10.1080/00048670601057767; PUBMED: 17464703] ">Wang 2007</a>; <a href="./references#CD012069-bbs2-0234" title="WigalSB , NordbrockE , AdjeiAL , ChildressA , KupperRJ , GreenhillL . Efficacy of methylphenidate hydrochloride extended‐release capsules (Aptensio XRTM) in children and adolescents with attention‐deficit/hyperactivity disorder: a phase III, randomized, double‐blind study. CNS Drugs2015;29(4):331‐40. ">Wigal 2015</a>; <a href="./references#CD012069-bbs2-0235" title="WigunaT , GuerreroAP , WibisonoS , SastroasmoroS . Effect of 12‐week administration of 20‐mg long‐acting methylphenidate on Glu/Cr, NAA/Cr, Cho/Cr, and mI/Cr ratios in the prefrontal cortices of school‐age children in Indonesia: a study using 1H Magnetic Resonance Spectroscopy (MRS). Clinical Neuropharmacology. T. Wiguna, Child and Adolescent Psychiatry Division, Department of Psychiatry, University of Indonesia, Jl. Salemba Raya 4, Jakarta 10430, Indonesia. E‐mail: twiga00@yahoo.com: Lippincott Williams and Wilkins (530 Walnut Street,P O Box 327, Philadelphia PA 19106‐3621, United States), 2012; Vol. 35, issue 2:81‐5. [DOI: 10.1097/WNF.0b013e3182452572; PUBMED: 22318191] ">Wiguna 2012</a>; see <a href="https://zenodo.org/record/1240391#.WusWNWcUmBE" target="_blank">supplementary file S55</a>); </p> </li> <li> <p>tachycardia was 2.50% (95% CI 1.40% to 4.30%; 6 studies, 2101 participants; <a href="./references#CD012069-bbs2-0028" title="BladerJC , PliszkaSR , JensenPS , SchoolerNR , KafantarisV . Stimulant‐responsive and stimulant‐refractory aggressive behavior among children with ADHD. Pediatrics2010;126(4):e796‐806. [DOI: 10.1542/peds.2010‐0086; PMC2956067; PUBMED: 20837589] Blader JosephC . Methylphenidate dose may reduce aggressive behavior in children with ADHD. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(12):1‐7. [DOI: 10.1002/cpu.20129] ">Blader 2010</a>; <a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a>; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0113" title="JafariniaM , MohammadiMR , ModabberniaA , AshrafiM , KhajaviD , TabriziM , et al. Bupropion versus methylphenidate in the treatment of children with attention‐deficit/hyperactivity disorder: randomized double‐blind study. Human Psychopharmacology2012; Vol. 27, issue 4:411‐8. [DOI: 10.1002/hup.2242; PUBMED: 22806822] ">Jafarinia 2012</a>; <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a>; <a href="./references#CD012069-bbs2-0207" title="SuY , LiH , ChenY , FangF , XuT , LuH , et al. Remission rate and functional outcomes during a 6‐month treatment with Osmotic‐Release Oral‐System methylphenidate in children with attention‐deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology2015;35(5):525‐34. [DOI: 10.1097/JCP.0000000000000389; PUBMED: 26267421] ">Su 2015</a>; see <a href="https://zenodo.org/record/1240392#.WusWpmcUmBE" target="_blank">supplementary file S56</a>); </p> </li> <li> <p>abnormal ECG was 2.90% (95% CI 0.00% to 66.6%; 2 studies, 503 participants; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0071" title="FindlingRL , KaticA , RubinR , MoonE , CivilR , LiY . A 6‐month, open‐label, extension study of the tolerability and effectiveness of the methylphenidate transdermal system in adolescents diagnosed with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2010;20(5):366‐75. [DOI: 10.1089/cap.2009.0122; PUBMED: 20973707] FindlingRL , TurnbowJ , BurnsideJ , MelmedR , CivilR , LiY . A randomized, double‐blind, multicenter, parallel‐group, placebo‐controlled, dose‐optimization study of the methylphenidate transdermal system for the treatment of ADHD in adolescents. CNS Spectrums2010;15(7):419‐30. [PUBMED: 20625364] KeatingGM . Methylphenidate transdermal system in attention‐deficit hyperactivity disorder in adolescents: profile report. Drugs in R&amp;D. G.M. Keating, Adis, Private Bag 65901, 41 Centorian Drive, Mairangi Bay, North Shore 0754, Auckland, New Zealand. E‐mail: demail@springer.com, 2012; Vol. 12, issue 3:171‐3. [DOI: 10.2165/11207490‐000000000‐00000; PMC3585903; PUBMED: 22934753] ">Findling 2010</a>; see <a href="https://zenodo.org/record/1240393#.WusW8GcUmBE" target="_blank">supplementary file S57</a>); </p> </li> <li> <p>nasal congestion was 11.8% (95% CI 8.30% to 16.4%; 3 studies, 247 participants; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0146" title="Methylphenidate for preschool ADHD. Brown University Child and Adolescent Psychopharmacology Update2009;11(7):4‐4. [DOI: 10.1002/cpu.20095] MaayanL , PaykinaN , FriedJ , StraussT , GuggaSS , GreenhillL . The open‐label treatment of attention‐deficit/hyperactivity disorder in 4‐ and 5‐year‐old children with beaded methylphenidate. Journal of Child and Adolescent Psychopharmacology2009;19(2):147‐53. [PMC2935832; PUBMED: 19374023] ">Maayan 2009</a>; <a href="./references#CD012069-bbs2-0189" title="RostainAL . Sleep disturbances and ADHD medications. Current Psychiatry Reports2007;9(5):399‐400. [PUBMED: 17915079] SangalRB , OwensJ , AllenAJ , SuttonV , SchuhK , KelseyD . Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep2006;29(12):1573‐85. [PUBMED: 17252888] ">Sangal 2006</a>; see <a href="https://zenodo.org/record/1240396#.WusXRmcUmBE" target="_blank">supplementary file S58</a>); and </p> </li> <li> <p>palpitation was 8.30% (95% CI 2.10% to 27.5%; 3 studies, 180 participants; <a href="./references#CD012069-bbs2-0158" title="MohammadiMR , KashaniL , AkhondzadehS , IzadianES , OhadiniaS . Efficacy of theophylline compared to methylphenidate for the treatment of attention‐deficit hyperactivity disorder in children and adolescents: a pilot double‐blind randomized trial. Journal of Clinical Pharmacy and Therapeutics2004;29(2):139‐44. [DOI: 10.1111/j.1365‐2710.2004.00545.x; PUBMED: 15068402] ">Mohammadi 2004</a>; <a href="./references#CD012069-bbs2-0167" title="LeeMS , LeeSI , HongSD , KimJH , ChoiJ , JoungYS . Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12‐week multicenter, open‐label study. Journal of Child and Adolescent Psychopharmacology2013;23(1):22‐7. [DOI: 10.1089/cap.2012.0018; PUBMED: 23347125] NaKS , LeeSI , HongSD , KimJH , ShimSH , ChoiJ , et al. Effect of osmotic‐release oral system methylphenidate on learning skills in adolescents with attention‐deficit/hyperactivity disorder: an open‐label study. International Clinical Psychopharmacology2013;28(4):184‐92. [DOI: 10.1097/YIC.0b013e3283612509; PUBMED: 23587983] ">Na 2013</a>; <a href="./references#CD012069-bbs2-0195" title="ShangCY , PanYL , LinHY , HuangLW , GauSS . An open‐label, randomized trial of methylphenidate and atomoxetine treatment in children with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2015;25(7):566‐73. [DOI: 10.1089/cap.2015.0035; PUBMED: 26222447] ">Shang 2015</a>; see <a href="https://zenodo.org/record/1240397#.WusXi2cUmBE" target="_blank">supplementary file S59</a>). </p> </li> </ol> </p> <section id="CD012069-sec-0147"> <p><b>Systolic blood pressure</b></p> <p>Nineteen studies provided data on this outcome (<a href="./references#CD012069-bbs2-0035" title="ChoS‐C , KimB‐N , CumminsTD , KimJ‐W , BellgroveMA . Norepinephrine transporter ‐3081(A/T) and alpha‐2A‐adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS‐methylphenidate treatment. Journal of Psychopharmacology2012; Vol. 26, issue 3:380‐9. [DOI: 10.1177/0269881111405356] ">Cho 2012:</a><a href="./references#CD012069-bbs2-0056" title="DöpfnerM , OseC , FischerR , AmmerR , ScheragA . Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention‐deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet® retard and Concerta® ‐ a randomized, controlled, double‐blind multicenter clinical crossover trial. Journal of Child &amp; Adolescent Psychopharmacology2011;21(5):445‐54. [DOI: 10.1089/cap.2010.0082; PMC3205792; PUBMED: 21790298] DöpfnerM , OseC , FischerR , AmmerR , ScheragA . The CoMeCo‐trial: comparison of the efficacy of two methylphenidate preparations for children and adolescents with ADHD in a natural setting. European Child and Adolescent Psychiatry.14th International Congress of ESCAP European Society for Child and Adolescent Psychiatry (ESCAP); June 11‐15, 2011; Helsinki (Finland)2011;20:S116. ">Döpfner 2011b</a>; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0072" title="GadowD , NolanE , SprafkinJ , SverdJ . School observations of children with attention‐deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioral Pediatrics1995;16(3):167–76. [PUBMED: 7560119] GadowD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention‐deficit hyperactivity disorder in children with tic disorder. Annual Progress in Child Psychiatry and Child Development1995;52(6):494‐522. [PUBMED: 7771914] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention‐deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention‐deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioral normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] NolanEE , GadowKD . Relation between ratings and observations of stimulant drug response in hyperactive children. Journal of Clinical Child Psychology1994;23(1):78‐90. [DOI: 10.1207/s15374424jccp2301_10] SprafkinJ , GadowKD . Double‐blind versus open evaluations of stimulant drug response in children with attention‐deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology1996;6(4):215‐28. [DOI: 10.1089/cap.1996.6.215; PUBMED: 9231315] SverdJ , GadowKD , NolanEE , SprafkinJ , EzorSN . Methylphenidate in hyperactive boys with comorbid tic disorder: I. Clinic evaluations. Advances in Neurology1992; Vol. 58:271‐81. [PUBMED: 1414633] ">Gadow 1995</a>; <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a>; <a href="./references#CD012069-bbs2-0078" title="GerweM , StollhoffK , MossakowskiJ , KuehleHJ , GoertzU , SchaeferC , et al. Tolerability and effects of OROS® MPH (Concerta®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non‐interventional trial. Attention Deficit and Hyperactivity Disorders2009;1(2):175‐86. [DOI: 10.1007/s12402‐009‐0010‐6; PUBMED: 21432582] ">Gerwe 2009</a>; <a href="./references#CD012069-bbs2-0103" title="HazellPL , StuartJE . A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(8):886‐94. [DOI: 10.1097/01.CHI.0000046908.27264.00] ">Hazell 2003</a>; <a href="./references#CD012069-bbs2-0124" title="ChungI , HanCH , KimHW , ChoSC . The effect of prolonged‐release methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorders. European Neuropsychopharmacology2010;20(Suppl 3):S624‐5. KimHW , YoonIY , ChoSC , KimBN , ChungS , LeeH , et al. The effect of OROS methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorder. International Clinical Psychopharmacology2010;25(2):107‐15. [DOI: 10.1097/YIC.0b013e3283364411; PUBMED: 20093941] ">Kim 2010</a>; <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a>; <a href="./references#CD012069-bbs2-0136" title="LambertiM , ItalianoD , GuerrieroL , D'AmicoG , SiracusanoR , IngrassiaM , et al. Evaluation of acute cardiovascular effects of immediate‐release methylphenidate in children and adolescents with attention‐deficit hyperactivity disorder. Neuropsychiatric Disease and Treatment2015;11:1169‐74. [DOI: 10.2147/NDT.S79866; PMC4431494; PUBMED: 26056451] ">Lamberti 2015</a>; <a href="./references#CD012069-bbs2-0146" title="Methylphenidate for preschool ADHD. Brown University Child and Adolescent Psychopharmacology Update2009;11(7):4‐4. [DOI: 10.1002/cpu.20095] MaayanL , PaykinaN , FriedJ , StraussT , GuggaSS , GreenhillL . The open‐label treatment of attention‐deficit/hyperactivity disorder in 4‐ and 5‐year‐old children with beaded methylphenidate. Journal of Child and Adolescent Psychopharmacology2009;19(2):147‐53. [PMC2935832; PUBMED: 19374023] ">Maayan 2009</a>; <a href="./references#CD012069-bbs2-0153" title="LooSK , BilderR , ChoAL , SturmA , CowenJ , WelkerPW , et al. Effects of d‐Methylphenidate, Guanfacine, and their combination on electroencephalogram resting state spectral power in Attention‐Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):674‐82.e1. [DOI: 10.1016/j.jaac.2016.04.020; PMC5003618; PUBMED: 27453081] McCrackenJT , McGoughJJ , LooSK , LevittJ , Del'HommeM , CowenJ , et al. Combined stimulant and Guanfacine administration in Attention‐Deficit/Hyperactivity Disorder: a controlled, comparative study. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):657‐66.e1. [DOI: 10.1016/j.jaac.2016.05.015; PMC4976782; PUBMED: 27453079] ">McCracken 2016</a>; <a href="./references#CD012069-bbs2-0167" title="LeeMS , LeeSI , HongSD , KimJH , ChoiJ , JoungYS . Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12‐week multicenter, open‐label study. Journal of Child and Adolescent Psychopharmacology2013;23(1):22‐7. [DOI: 10.1089/cap.2012.0018; PUBMED: 23347125] NaKS , LeeSI , HongSD , KimJH , ShimSH , ChoiJ , et al. Effect of osmotic‐release oral system methylphenidate on learning skills in adolescents with attention‐deficit/hyperactivity disorder: an open‐label study. International Clinical Psychopharmacology2013;28(4):184‐92. [DOI: 10.1097/YIC.0b013e3283612509; PUBMED: 23587983] ">Na 2013</a>; <a href="./references#CD012069-bbs2-0201" title="SongDH , ChoiS , JoungYS , HaEH , KimBN , ShinYJ , et al. Titrating optimal dose of osmotic‐controlled release oral delivery (OROS)‐methylphenidate and its efficacy and safety in Korean children with ADHD: a multisite open labeled study. Psychiatry Investigation2012; Vol. 9, issue 3:257‐62. [DOI: 10.4306/pi.2012.9.3.257; PMC3440475] SongDH , ChoiS , JoungYS , KimBN , HaEH , ShinYJ , et al. Titrating optimal dose of OROS‐MPH and its efficacy and safety in Korean children with ADHD: multicenter, open labeled study. International Journal of Neuropsychopharmacology2010;13(Suppl 1):193‐4. [DOI: 10.1017/S1461145710000635] ">Song 2012</a>; <a href="./references#CD012069-bbs2-0236" title="BiedermanJ . Evaluation of once‐daily OROS methylphenidate in children with attention‐deficit/hyperactivity disorder: effects on sleep, appetite, and tics. European Neuropsychopharmacology2003;13(Suppl 4):S447‐8. BiedermanJ . Treatment of attention‐deficit/hyperactivity disorder with the once‐daily OROS formulation of methylphenidate: effect on growth in children. European Neuropsychopharmacology2003;13(Suppl 4):S448‐9. FaraoneSV , BiedermanJ , ZimmermanB . An analysis of patient adherence to treatment during a 1‐year, open‐label study of OROS methylphenidate in children with ADHD. Journal of Attention Disorders2007;11(2):157‐66. [DOI: 10.1177/1087054706295663; PUBMED: 17494833] LernerMA , SpencerT . Analysis of growth in children with ADHD during long‐term therapy with once‐daily OROS® methylphenidate. Pediatric Academic Societies' Annual Meeting; 2004 May 1‐4; San Francisco (CA). 2004; Vol. 55. PalumboDR , StarrHL . Once‐daily OROS methylphenidate: Impact on tics in children with attention deficit hyperactivity disorder. Annals of Neurology2003;54(Suppl 7):S27. [DOI: 10.1002/ana.5049/epdf] SpencerTJ , FaraoneSV , BiedermanJ , LernerM , CooperKM , ZimmermanB , Concerta Study Group. Does prolonged therapy with a long‐acting stimulant suppress growth in children with ADHD?. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(5):527‐37. [DOI: 10.1097/01.chi.0000205710.01690.d4; PUBMED: 16670649] SpencerTJ , FaraoneSV , LernerM , CooperKM , ZimmermanB . Effect of long‐term treatment with stimulant medication on growth? Drs. Spencer et al. Reply. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(3):306. [DOI: 10.1097/chi.0b013e31802ed960] WigalSB , WilensTE , WolraichM , LernerM . Hematologic and blood biochemistry monitoring during methylphenidate treatment in children with attention‐deficit/hyperactivity disorder: 2‐year, open‐label study results. Pediatrics2007;120(1):e120‐8. [DOI: 10.1542/peds.2006‐1402] WilensT , BiedermanJ , LernerM , Concerta Study Group. Effects of once‐daily osmotic‐release methylphenidate on blood pressure and heart rate in children with attention‐deficit/hyperactivity disorder: results from a one‐year follow‐up study. Journal of Clinical Psychopharmacology2004;24(1):36‐41. [DOI: 10.1097/01.jcp.0000106223.36344.df; PUBMED: 14709945] WilensT , McBurnettK , SteinM , LernerM , SpencerT , WolraichM . ADHD treatment with once‐daily OROS methylphenidate: final results from a long‐term open‐label study. Journal of the American Academy of Child and Adolescent Psychiatry2005;44(10):1015‐23. [DOI: 10.1097/01.chi.0000173291.28688.e7; PUBMED: 16175106] WilensT , McBurnettK , SteinM , LernerM , SpencerT , WolraichM . ADHD treatment with once‐daily OROS methylphenidate: final results from a long‐term open‐label study: erratum. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(5):632. [DOI: 10.1097/00004583‐200605000‐00020] WilensT , PelhamW , SteinM , ConnersCK , AbikoffH , AtkinsM , et al. ADHD treatment with once‐daily OROS methylphenidate: interim 12‐month results from a long‐term open‐label study. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(4):424‐33. [DOI: 10.1097/01.CHI.0000046814.95464.7D; PUBMED: 12649629] ">Wilens 2005</a>; <a href="./references#CD012069-bbs2-0241" title="WinsbergBG , KupietzSS , SvergJ , HungundBL , YoungNL . Methylphenidate oral dose plasma concentrations and behavioral response in children. Psychopharmacology1982;76(4):329‐32. [PUBMED: 6812106] ">Winsberg 1982</a>; <a href="./references#CD012069-bbs2-0251" title="YildizÖ , ŞişmanlarŞG , MemikNÇ , KarakayaI , AğaoğluB . Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. Child Psychiatry and Human Development2011;42(3):257‐69. [DOI: 10.1007/s10578‐010‐0212‐3; PUBMED: 21165694] ">Yildiz 2011</a>; <a href="./references#CD012069-bbs2-0258" title="ZhengY , WangYF , QinJ , WangLW , ZouLP , JinXM , et al. Prospective, naturalistic study of open‐label OROS methylphenidate treatment in Chinese school‐aged children with attention‐deficit/hyperactivity disorder. Chinese Medical Journal2011;124(20):3269‐74. [PUBMED: 22088519] ">Zheng 2011</a>; <a href="./references#CD012069-bbs2-0259" title="ZhengY , LiangJM , GaoHY , YangZW , JiaFJ , LiangYZ , et al. An open‐label, self‐control, prospective study on cognitive function, academic performance, and tolerability of osmotic‐release oral system methylphenidate in children with attention‐deficit hyperactivity disorder. Chinese Medical Journal2015;128(22):2988‐97. [DOI: 10.4103/0366‐6999.168948; PMC4795269; PUBMED: 26608976] ">Zheng 2015</a>). </p> <p>Nine studies reported an increase in systolic blood pressure as follows.</p> <p> <ol id="CD012069-list-0038"> <li> <p><a href="./references#CD012069-bbs2-0035" title="ChoS‐C , KimB‐N , CumminsTD , KimJ‐W , BellgroveMA . Norepinephrine transporter ‐3081(A/T) and alpha‐2A‐adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS‐methylphenidate treatment. Journal of Psychopharmacology2012; Vol. 26, issue 3:380‐9. [DOI: 10.1177/0269881111405356] ">Cho 2012:</a> marginal increase following methylphenidate treatment, but this difference was not significant. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0072" title="GadowD , NolanE , SprafkinJ , SverdJ . School observations of children with attention‐deficit hyperactivity disorder and comorbid tic disorder: effects of methylphenidate treatment. Journal of Developmental and Behavioral Pediatrics1995;16(3):167–76. [PUBMED: 7560119] GadowD , SverdJ , SprafkinJ , NolanEE , EzorSN . Efficacy of methylphenidate for attention‐deficit hyperactivity disorder in children with tic disorder. Annual Progress in Child Psychiatry and Child Development1995;52(6):494‐522. [PUBMED: 7771914] GadowKD , NolanEE , SverdJ . Methylphenidate in hyperactive boys with comorbid tic disorder: II. Short‐term behavioral effects in school settings. Journal of the American Academy of Child and Adolescent Psychiatry1992;31(3):462‐71. [DOI: 10.1097/00004583‐199205000‐00012; PUBMED: 1592778] GadowKD , NolanEE , SverdJ , SprafkinJ , SchwartzJ . Anxiety and depression symptoms and response to methylphenidate in children with attention‐deficit hyperactivity disorder and tic disorder. Journal of Clinical Psychopharmacology2002;22(3):267‐74. [PUBMED: 12006897] GadowKD , SverdJ , SprafkinJ , NolanEE , GrossmanS . Long‐term methylphenidate therapy in children with comorbid attention‐deficit hyperactivity disorder and chronic multiple tic disorder. Archives of General Psychiatry1999;56(4):330‐6. [PUBMED: 10197827] NolanEE , GadowKD . Children with ADHD and tic disorder and their classmates: behavioral normalization with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(5):597‐604. [DOI: 10.1097/00004583‐199705000‐00009; PUBMED: 9136493] NolanEE , GadowKD . Relation between ratings and observations of stimulant drug response in hyperactive children. Journal of Clinical Child Psychology1994;23(1):78‐90. [DOI: 10.1207/s15374424jccp2301_10] SprafkinJ , GadowKD . Double‐blind versus open evaluations of stimulant drug response in children with attention‐deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology1996;6(4):215‐28. [DOI: 10.1089/cap.1996.6.215; PUBMED: 9231315] SverdJ , GadowKD , NolanEE , SprafkinJ , EzorSN . Methylphenidate in hyperactive boys with comorbid tic disorder: I. Clinic evaluations. Advances in Neurology1992; Vol. 58:271‐81. [PUBMED: 1414633] ">Gadow 1995</a> (27 participants): increase of 6 mmHg at 24 months. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a> (44 participants): significant (P = 0.03) increase from 102.2 (SD 9.89) mmHg at baseline to 105.6 (SD 10.7) mmHg at follow‐up. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0136" title="LambertiM , ItalianoD , GuerrieroL , D'AmicoG , SiracusanoR , IngrassiaM , et al. Evaluation of acute cardiovascular effects of immediate‐release methylphenidate in children and adolescents with attention‐deficit hyperactivity disorder. Neuropsychiatric Disease and Treatment2015;11:1169‐74. [DOI: 10.2147/NDT.S79866; PMC4431494; PUBMED: 26056451] ">Lamberti 2015</a> (54 participants): short‐term increase from 105.4 (SD 10.3) mmHg at baseline to 109.6 (SD 11.5) mmHg two hours postmethylphenidate. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0153" title="LooSK , BilderR , ChoAL , SturmA , CowenJ , WelkerPW , et al. Effects of d‐Methylphenidate, Guanfacine, and their combination on electroencephalogram resting state spectral power in Attention‐Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):674‐82.e1. [DOI: 10.1016/j.jaac.2016.04.020; PMC5003618; PUBMED: 27453081] McCrackenJT , McGoughJJ , LooSK , LevittJ , Del'HommeM , CowenJ , et al. Combined stimulant and Guanfacine administration in Attention‐Deficit/Hyperactivity Disorder: a controlled, comparative study. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):657‐66.e1. [DOI: 10.1016/j.jaac.2016.05.015; PMC4976782; PUBMED: 27453079] ">McCracken 2016</a> (61 participants): increase of 7.30 (SD 11.5) mmHg. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0167" title="LeeMS , LeeSI , HongSD , KimJH , ChoiJ , JoungYS . Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12‐week multicenter, open‐label study. Journal of Child and Adolescent Psychopharmacology2013;23(1):22‐7. [DOI: 10.1089/cap.2012.0018; PUBMED: 23347125] NaKS , LeeSI , HongSD , KimJH , ShimSH , ChoiJ , et al. Effect of osmotic‐release oral system methylphenidate on learning skills in adolescents with attention‐deficit/hyperactivity disorder: an open‐label study. International Clinical Psychopharmacology2013;28(4):184‐92. [DOI: 10.1097/YIC.0b013e3283612509; PUBMED: 23587983] ">Na 2013</a> (121 participants): increase from baseline of 5.26 (SD 18.5) mmHg. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0201" title="SongDH , ChoiS , JoungYS , HaEH , KimBN , ShinYJ , et al. Titrating optimal dose of osmotic‐controlled release oral delivery (OROS)‐methylphenidate and its efficacy and safety in Korean children with ADHD: a multisite open labeled study. Psychiatry Investigation2012; Vol. 9, issue 3:257‐62. [DOI: 10.4306/pi.2012.9.3.257; PMC3440475] SongDH , ChoiS , JoungYS , KimBN , HaEH , ShinYJ , et al. Titrating optimal dose of OROS‐MPH and its efficacy and safety in Korean children with ADHD: multicenter, open labeled study. International Journal of Neuropsychopharmacology2010;13(Suppl 1):193‐4. [DOI: 10.1017/S1461145710000635] ">Song 2012</a> (143 participants): increase from 105.3 (SD 12.6) mmHg to 108.4 (SD 70.9) mmHg. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0241" title="WinsbergBG , KupietzSS , SvergJ , HungundBL , YoungNL . Methylphenidate oral dose plasma concentrations and behavioral response in children. Psychopharmacology1982;76(4):329‐32. [PUBMED: 6812106] ">Winsberg 1982</a> (25 participants): increase from 103.1 mmHg to 110.5 mmHg at week five. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0236" title="BiedermanJ . Evaluation of once‐daily OROS methylphenidate in children with attention‐deficit/hyperactivity disorder: effects on sleep, appetite, and tics. European Neuropsychopharmacology2003;13(Suppl 4):S447‐8. BiedermanJ . Treatment of attention‐deficit/hyperactivity disorder with the once‐daily OROS formulation of methylphenidate: effect on growth in children. European Neuropsychopharmacology2003;13(Suppl 4):S448‐9. FaraoneSV , BiedermanJ , ZimmermanB . An analysis of patient adherence to treatment during a 1‐year, open‐label study of OROS methylphenidate in children with ADHD. Journal of Attention Disorders2007;11(2):157‐66. [DOI: 10.1177/1087054706295663; PUBMED: 17494833] LernerMA , SpencerT . Analysis of growth in children with ADHD during long‐term therapy with once‐daily OROS® methylphenidate. Pediatric Academic Societies' Annual Meeting; 2004 May 1‐4; San Francisco (CA). 2004; Vol. 55. PalumboDR , StarrHL . Once‐daily OROS methylphenidate: Impact on tics in children with attention deficit hyperactivity disorder. Annals of Neurology2003;54(Suppl 7):S27. [DOI: 10.1002/ana.5049/epdf] SpencerTJ , FaraoneSV , BiedermanJ , LernerM , CooperKM , ZimmermanB , Concerta Study Group. Does prolonged therapy with a long‐acting stimulant suppress growth in children with ADHD?. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(5):527‐37. [DOI: 10.1097/01.chi.0000205710.01690.d4; PUBMED: 16670649] SpencerTJ , FaraoneSV , LernerM , CooperKM , ZimmermanB . Effect of long‐term treatment with stimulant medication on growth? Drs. Spencer et al. Reply. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(3):306. [DOI: 10.1097/chi.0b013e31802ed960] WigalSB , WilensTE , WolraichM , LernerM . Hematologic and blood biochemistry monitoring during methylphenidate treatment in children with attention‐deficit/hyperactivity disorder: 2‐year, open‐label study results. Pediatrics2007;120(1):e120‐8. [DOI: 10.1542/peds.2006‐1402] WilensT , BiedermanJ , LernerM , Concerta Study Group. Effects of once‐daily osmotic‐release methylphenidate on blood pressure and heart rate in children with attention‐deficit/hyperactivity disorder: results from a one‐year follow‐up study. Journal of Clinical Psychopharmacology2004;24(1):36‐41. [DOI: 10.1097/01.jcp.0000106223.36344.df; PUBMED: 14709945] WilensT , McBurnettK , SteinM , LernerM , SpencerT , WolraichM . ADHD treatment with once‐daily OROS methylphenidate: final results from a long‐term open‐label study. Journal of the American Academy of Child and Adolescent Psychiatry2005;44(10):1015‐23. [DOI: 10.1097/01.chi.0000173291.28688.e7; PUBMED: 16175106] WilensT , McBurnettK , SteinM , LernerM , SpencerT , WolraichM . ADHD treatment with once‐daily OROS methylphenidate: final results from a long‐term open‐label study: erratum. Journal of the American Academy of Child and Adolescent Psychiatry2006;45(5):632. [DOI: 10.1097/00004583‐200605000‐00020] WilensT , PelhamW , SteinM , ConnersCK , AbikoffH , AtkinsM , et al. ADHD treatment with once‐daily OROS methylphenidate: interim 12‐month results from a long‐term open‐label study. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(4):424‐33. [DOI: 10.1097/01.CHI.0000046814.95464.7D; PUBMED: 12649629] ">Wilens 2005</a> (407 participants) increase from 104.7 (SD 8.10) mmHg to 108.1 (SD 8.70) mmHg at end of treatment. </p> </li> </ol> </p> <p>Six studies reported either no change or no apparent changes in systolic blood pressure: <a href="./references#CD012069-bbs2-0056" title="DöpfnerM , OseC , FischerR , AmmerR , ScheragA . Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention‐deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet® retard and Concerta® ‐ a randomized, controlled, double‐blind multicenter clinical crossover trial. Journal of Child &amp; Adolescent Psychopharmacology2011;21(5):445‐54. [DOI: 10.1089/cap.2010.0082; PMC3205792; PUBMED: 21790298] DöpfnerM , OseC , FischerR , AmmerR , ScheragA . The CoMeCo‐trial: comparison of the efficacy of two methylphenidate preparations for children and adolescents with ADHD in a natural setting. European Child and Adolescent Psychiatry.14th International Congress of ESCAP European Society for Child and Adolescent Psychiatry (ESCAP); June 11‐15, 2011; Helsinki (Finland)2011;20:S116. ">Döpfner 2011b</a> (baseline: 106.0 (SD 1.00) mmHg; follow‐up at week three: 106.0 (SD 1.00) mmHg); <a href="./references#CD012069-bbs2-0078" title="GerweM , StollhoffK , MossakowskiJ , KuehleHJ , GoertzU , SchaeferC , et al. Tolerability and effects of OROS® MPH (Concerta®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non‐interventional trial. Attention Deficit and Hyperactivity Disorders2009;1(2):175‐86. [DOI: 10.1007/s12402‐009‐0010‐6; PUBMED: 21432582] ">Gerwe 2009</a> (mean change in systolic blood pressure between visit one and four: 0.1 (SD 10.8) mmHg); <a href="./references#CD012069-bbs2-0146" title="Methylphenidate for preschool ADHD. Brown University Child and Adolescent Psychopharmacology Update2009;11(7):4‐4. [DOI: 10.1002/cpu.20095] MaayanL , PaykinaN , FriedJ , StraussT , GuggaSS , GreenhillL . The open‐label treatment of attention‐deficit/hyperactivity disorder in 4‐ and 5‐year‐old children with beaded methylphenidate. Journal of Child and Adolescent Psychopharmacology2009;19(2):147‐53. [PMC2935832; PUBMED: 19374023] ">Maayan 2009</a> (baseline: 96.2 (SD 14.0) mmHg; follow‐up at week four: 96.09 (SD 10.1) mmHg); <a href="./references#CD012069-bbs2-0258" title="ZhengY , WangYF , QinJ , WangLW , ZouLP , JinXM , et al. Prospective, naturalistic study of open‐label OROS methylphenidate treatment in Chinese school‐aged children with attention‐deficit/hyperactivity disorder. Chinese Medical Journal2011;124(20):3269‐74. [PUBMED: 22088519] ">Zheng 2011</a> (baseline: 96.6 (SD 10.6) mmHg, N = 1247; follow‐up at week six: 97.5 (SD 10.3) mmHg, N = 959); <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a> (baseline: 100.6 (SD 12.3) mmHg; follow‐up at month 24: 99.6 (SD 13.0) mmHg); and <a href="./references#CD012069-bbs2-0259" title="ZhengY , LiangJM , GaoHY , YangZW , JiaFJ , LiangYZ , et al. An open‐label, self‐control, prospective study on cognitive function, academic performance, and tolerability of osmotic‐release oral system methylphenidate in children with attention‐deficit hyperactivity disorder. Chinese Medical Journal2015;128(22):2988‐97. [DOI: 10.4103/0366‐6999.168948; PMC4795269; PUBMED: 26608976] ">Zheng 2015</a> (reporting no changes in blood pressure). </p> <p>Four studies reported a drop in systolic blood pressure. <a href="./references#CD012069-bbs2-0103" title="HazellPL , StuartJE . A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(8):886‐94. [DOI: 10.1097/01.CHI.0000046908.27264.00] ">Hazell 2003</a> reported a drop in 8/10 participants. There were also apparent decreases in systolic blood pressure in <a href="./references#CD012069-bbs2-0124" title="ChungI , HanCH , KimHW , ChoSC . The effect of prolonged‐release methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorders. European Neuropsychopharmacology2010;20(Suppl 3):S624‐5. KimHW , YoonIY , ChoSC , KimBN , ChungS , LeeH , et al. The effect of OROS methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorder. International Clinical Psychopharmacology2010;25(2):107‐15. [DOI: 10.1097/YIC.0b013e3283364411; PUBMED: 20093941] ">Kim 2010</a> (baseline: 113.8 (SD 10.2) mmHg; follow‐up: 110.0 (SD 10.6) mmHg), and <a href="./references#CD012069-bbs2-0251" title="YildizÖ , ŞişmanlarŞG , MemikNÇ , KarakayaI , AğaoğluB . Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. Child Psychiatry and Human Development2011;42(3):257‐69. [DOI: 10.1007/s10578‐010‐0212‐3; PUBMED: 21165694] ">Yildiz 2011</a> (baseline: 97.0 (SD 10.8) mmHg; week 12: 92.7 (SD 10.1) mmHg). One study, <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>, reported that across dose levels, the proportion of participants with systolic blood pressure above the upper limit of normal (&gt; 123 mmHg) ranged from 1% to 10%, whereas 1.5% had an above‐normal systolic blood pressure at baseline. </p> </section> <section id="CD012069-sec-0148"> <p><b>Diastolic blood pressure</b></p> <p>Sixteen studies reported data on this outcome (<a href="./references#CD012069-bbs2-0035" title="ChoS‐C , KimB‐N , CumminsTD , KimJ‐W , BellgroveMA . Norepinephrine transporter ‐3081(A/T) and alpha‐2A‐adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS‐methylphenidate treatment. Journal of Psychopharmacology2012; Vol. 26, issue 3:380‐9. [DOI: 10.1177/0269881111405356] ">Cho 2012</a>; <a href="./references#CD012069-bbs2-0056" title="DöpfnerM , OseC , FischerR , AmmerR , ScheragA . Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention‐deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet® retard and Concerta® ‐ a randomized, controlled, double‐blind multicenter clinical crossover trial. Journal of Child &amp; Adolescent Psychopharmacology2011;21(5):445‐54. [DOI: 10.1089/cap.2010.0082; PMC3205792; PUBMED: 21790298] DöpfnerM , OseC , FischerR , AmmerR , ScheragA . The CoMeCo‐trial: comparison of the efficacy of two methylphenidate preparations for children and adolescents with ADHD in a natural setting. European Child and Adolescent Psychiatry.14th International Congress of ESCAP European Society for Child and Adolescent Psychiatry (ESCAP); June 11‐15, 2011; Helsinki (Finland)2011;20:S116. ">Döpfner 2011b</a>; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a>; <a href="./references#CD012069-bbs2-0078" title="GerweM , StollhoffK , MossakowskiJ , KuehleHJ , GoertzU , SchaeferC , et al. Tolerability and effects of OROS® MPH (Concerta®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non‐interventional trial. Attention Deficit and Hyperactivity Disorders2009;1(2):175‐86. [DOI: 10.1007/s12402‐009‐0010‐6; PUBMED: 21432582] ">Gerwe 2009</a>; <a href="./references#CD012069-bbs2-0103" title="HazellPL , StuartJE . A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(8):886‐94. [DOI: 10.1097/01.CHI.0000046908.27264.00] ">Hazell 2003</a>; <a href="./references#CD012069-bbs2-0124" title="ChungI , HanCH , KimHW , ChoSC . The effect of prolonged‐release methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorders. European Neuropsychopharmacology2010;20(Suppl 3):S624‐5. KimHW , YoonIY , ChoSC , KimBN , ChungS , LeeH , et al. The effect of OROS methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorder. International Clinical Psychopharmacology2010;25(2):107‐15. [DOI: 10.1097/YIC.0b013e3283364411; PUBMED: 20093941] ">Kim 2010</a>; <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a>; <a href="./references#CD012069-bbs2-0136" title="LambertiM , ItalianoD , GuerrieroL , D'AmicoG , SiracusanoR , IngrassiaM , et al. Evaluation of acute cardiovascular effects of immediate‐release methylphenidate in children and adolescents with attention‐deficit hyperactivity disorder. Neuropsychiatric Disease and Treatment2015;11:1169‐74. [DOI: 10.2147/NDT.S79866; PMC4431494; PUBMED: 26056451] ">Lamberti 2015</a>; <a href="./references#CD012069-bbs2-0146" title="Methylphenidate for preschool ADHD. Brown University Child and Adolescent Psychopharmacology Update2009;11(7):4‐4. [DOI: 10.1002/cpu.20095] MaayanL , PaykinaN , FriedJ , StraussT , GuggaSS , GreenhillL . The open‐label treatment of attention‐deficit/hyperactivity disorder in 4‐ and 5‐year‐old children with beaded methylphenidate. Journal of Child and Adolescent Psychopharmacology2009;19(2):147‐53. [PMC2935832; PUBMED: 19374023] ">Maayan 2009</a>; <a href="./references#CD012069-bbs2-0153" title="LooSK , BilderR , ChoAL , SturmA , CowenJ , WelkerPW , et al. Effects of d‐Methylphenidate, Guanfacine, and their combination on electroencephalogram resting state spectral power in Attention‐Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):674‐82.e1. [DOI: 10.1016/j.jaac.2016.04.020; PMC5003618; PUBMED: 27453081] McCrackenJT , McGoughJJ , LooSK , LevittJ , Del'HommeM , CowenJ , et al. Combined stimulant and Guanfacine administration in Attention‐Deficit/Hyperactivity Disorder: a controlled, comparative study. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):657‐66.e1. [DOI: 10.1016/j.jaac.2016.05.015; PMC4976782; PUBMED: 27453079] ">McCracken 2016</a>; <a href="./references#CD012069-bbs2-0167" title="LeeMS , LeeSI , HongSD , KimJH , ChoiJ , JoungYS . Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12‐week multicenter, open‐label study. Journal of Child and Adolescent Psychopharmacology2013;23(1):22‐7. [DOI: 10.1089/cap.2012.0018; PUBMED: 23347125] NaKS , LeeSI , HongSD , KimJH , ShimSH , ChoiJ , et al. Effect of osmotic‐release oral system methylphenidate on learning skills in adolescents with attention‐deficit/hyperactivity disorder: an open‐label study. International Clinical Psychopharmacology2013;28(4):184‐92. [DOI: 10.1097/YIC.0b013e3283612509; PUBMED: 23587983] ">Na 2013</a>; <a href="./references#CD012069-bbs2-0201" title="SongDH , ChoiS , JoungYS , HaEH , KimBN , ShinYJ , et al. Titrating optimal dose of osmotic‐controlled release oral delivery (OROS)‐methylphenidate and its efficacy and safety in Korean children with ADHD: a multisite open labeled study. Psychiatry Investigation2012; Vol. 9, issue 3:257‐62. [DOI: 10.4306/pi.2012.9.3.257; PMC3440475] SongDH , ChoiS , JoungYS , KimBN , HaEH , ShinYJ , et al. Titrating optimal dose of OROS‐MPH and its efficacy and safety in Korean children with ADHD: multicenter, open labeled study. International Journal of Neuropsychopharmacology2010;13(Suppl 1):193‐4. [DOI: 10.1017/S1461145710000635] ">Song 2012</a>; <a href="./references#CD012069-bbs2-0258" title="ZhengY , WangYF , QinJ , WangLW , ZouLP , JinXM , et al. Prospective, naturalistic study of open‐label OROS methylphenidate treatment in Chinese school‐aged children with attention‐deficit/hyperactivity disorder. Chinese Medical Journal2011;124(20):3269‐74. [PUBMED: 22088519] ">Zheng 2011</a>; <a href="./references#CD012069-bbs2-0251" title="YildizÖ , ŞişmanlarŞG , MemikNÇ , KarakayaI , AğaoğluB . Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. Child Psychiatry and Human Development2011;42(3):257‐69. [DOI: 10.1007/s10578‐010‐0212‐3; PUBMED: 21165694] ">Yildiz 2011</a>; <a href="./references#CD012069-bbs2-0259" title="ZhengY , LiangJM , GaoHY , YangZW , JiaFJ , LiangYZ , et al. An open‐label, self‐control, prospective study on cognitive function, academic performance, and tolerability of osmotic‐release oral system methylphenidate in children with attention‐deficit hyperactivity disorder. Chinese Medical Journal2015;128(22):2988‐97. [DOI: 10.4103/0366‐6999.168948; PMC4795269; PUBMED: 26608976] ">Zheng 2015</a>). </p> <p>Six studies reported apparent increases in diastolic blood pressure in participants receiving methylphenidate: <a href="./references#CD012069-bbs2-0136" title="LambertiM , ItalianoD , GuerrieroL , D'AmicoG , SiracusanoR , IngrassiaM , et al. Evaluation of acute cardiovascular effects of immediate‐release methylphenidate in children and adolescents with attention‐deficit hyperactivity disorder. Neuropsychiatric Disease and Treatment2015;11:1169‐74. [DOI: 10.2147/NDT.S79866; PMC4431494; PUBMED: 26056451] ">Lamberti 2015</a> (baseline: 59.2 (SD 7.10) mmHg; follow‐up after two hours: 63.1 (SD 7.80) mmHg); <a href="./references#CD012069-bbs2-0056" title="DöpfnerM , OseC , FischerR , AmmerR , ScheragA . Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention‐deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet® retard and Concerta® ‐ a randomized, controlled, double‐blind multicenter clinical crossover trial. Journal of Child &amp; Adolescent Psychopharmacology2011;21(5):445‐54. [DOI: 10.1089/cap.2010.0082; PMC3205792; PUBMED: 21790298] DöpfnerM , OseC , FischerR , AmmerR , ScheragA . The CoMeCo‐trial: comparison of the efficacy of two methylphenidate preparations for children and adolescents with ADHD in a natural setting. European Child and Adolescent Psychiatry.14th International Congress of ESCAP European Society for Child and Adolescent Psychiatry (ESCAP); June 11‐15, 2011; Helsinki (Finland)2011;20:S116. ">Döpfner 2011b</a> (baseline: 69.0 (SD 1.00) mmHg; follow‐up after three weeks: 86.0 (SD 1.00) mmHg); <a href="./references#CD012069-bbs2-0153" title="LooSK , BilderR , ChoAL , SturmA , CowenJ , WelkerPW , et al. Effects of d‐Methylphenidate, Guanfacine, and their combination on electroencephalogram resting state spectral power in Attention‐Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):674‐82.e1. [DOI: 10.1016/j.jaac.2016.04.020; PMC5003618; PUBMED: 27453081] McCrackenJT , McGoughJJ , LooSK , LevittJ , Del'HommeM , CowenJ , et al. Combined stimulant and Guanfacine administration in Attention‐Deficit/Hyperactivity Disorder: a controlled, comparative study. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):657‐66.e1. [DOI: 10.1016/j.jaac.2016.05.015; PMC4976782; PUBMED: 27453079] ">McCracken 2016</a> (mean change: 5.80 (SD 10.4) mmHg); <a href="./references#CD012069-bbs2-0167" title="LeeMS , LeeSI , HongSD , KimJH , ChoiJ , JoungYS . Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12‐week multicenter, open‐label study. Journal of Child and Adolescent Psychopharmacology2013;23(1):22‐7. [DOI: 10.1089/cap.2012.0018; PUBMED: 23347125] NaKS , LeeSI , HongSD , KimJH , ShimSH , ChoiJ , et al. Effect of osmotic‐release oral system methylphenidate on learning skills in adolescents with attention‐deficit/hyperactivity disorder: an open‐label study. International Clinical Psychopharmacology2013;28(4):184‐92. [DOI: 10.1097/YIC.0b013e3283612509; PUBMED: 23587983] ">Na 2013</a> (mean change: 4.83 (SD 12.3) mmHg); <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a> (baseline: 63.5 (SD 7.9) mmHg; follow‐up: 66.46 (SD 7.41) mmHg, P = 0.04), and <a href="./references#CD012069-bbs2-0201" title="SongDH , ChoiS , JoungYS , HaEH , KimBN , ShinYJ , et al. Titrating optimal dose of osmotic‐controlled release oral delivery (OROS)‐methylphenidate and its efficacy and safety in Korean children with ADHD: a multisite open labeled study. Psychiatry Investigation2012; Vol. 9, issue 3:257‐62. [DOI: 10.4306/pi.2012.9.3.257; PMC3440475] SongDH , ChoiS , JoungYS , KimBN , HaEH , ShinYJ , et al. Titrating optimal dose of OROS‐MPH and its efficacy and safety in Korean children with ADHD: multicenter, open labeled study. International Journal of Neuropsychopharmacology2010;13(Suppl 1):193‐4. [DOI: 10.1017/S1461145710000635] ">Song 2012</a> (baseline: 66.9 (SD 10.1) mmHg; follow‐up: 70.9 (SD 10.5) mm Hg). One study, <a href="./references#CD012069-bbs2-0035" title="ChoS‐C , KimB‐N , CumminsTD , KimJ‐W , BellgroveMA . Norepinephrine transporter ‐3081(A/T) and alpha‐2A‐adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS‐methylphenidate treatment. Journal of Psychopharmacology2012; Vol. 26, issue 3:380‐9. [DOI: 10.1177/0269881111405356] ">Cho 2012</a>, reported a marginal increase that was not significant. </p> <p>Four studies reported minimal changes in diastolic blood pressure: <a href="./references#CD012069-bbs2-0078" title="GerweM , StollhoffK , MossakowskiJ , KuehleHJ , GoertzU , SchaeferC , et al. Tolerability and effects of OROS® MPH (Concerta®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non‐interventional trial. Attention Deficit and Hyperactivity Disorders2009;1(2):175‐86. [DOI: 10.1007/s12402‐009‐0010‐6; PUBMED: 21432582] ">Gerwe 2009</a> (mean change: 0.70 (SD 9.70) mmHg), <a href="./references#CD012069-bbs2-0146" title="Methylphenidate for preschool ADHD. Brown University Child and Adolescent Psychopharmacology Update2009;11(7):4‐4. [DOI: 10.1002/cpu.20095] MaayanL , PaykinaN , FriedJ , StraussT , GuggaSS , GreenhillL . The open‐label treatment of attention‐deficit/hyperactivity disorder in 4‐ and 5‐year‐old children with beaded methylphenidate. Journal of Child and Adolescent Psychopharmacology2009;19(2):147‐53. [PMC2935832; PUBMED: 19374023] ">Maayan 2009</a> (baseline: 61.4 (SD 13.7) mmHg; follow‐up at week 4: 60.9 (SD 14.5) mmHg), <a href="./references#CD012069-bbs2-0258" title="ZhengY , WangYF , QinJ , WangLW , ZouLP , JinXM , et al. Prospective, naturalistic study of open‐label OROS methylphenidate treatment in Chinese school‐aged children with attention‐deficit/hyperactivity disorder. Chinese Medical Journal2011;124(20):3269‐74. [PUBMED: 22088519] ">Zheng 2011</a> (baseline: 64.6 (SD 7.51) mmHg, N = 1247; follow‐up at week six: 65.6 (SD 7.32) mmHg, N = 959), and <a href="./references#CD012069-bbs2-0251" title="YildizÖ , ŞişmanlarŞG , MemikNÇ , KarakayaI , AğaoğluB . Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. Child Psychiatry and Human Development2011;42(3):257‐69. [DOI: 10.1007/s10578‐010‐0212‐3; PUBMED: 21165694] ">Yildiz 2011</a> (baseline: 63.5 (SD 12.0) mmHg; follow‐up at week 12: 62.5 (SD 9.70) mmHg). One study, <a href="./references#CD012069-bbs2-0259" title="ZhengY , LiangJM , GaoHY , YangZW , JiaFJ , LiangYZ , et al. An open‐label, self‐control, prospective study on cognitive function, academic performance, and tolerability of osmotic‐release oral system methylphenidate in children with attention‐deficit hyperactivity disorder. Chinese Medical Journal2015;128(22):2988‐97. [DOI: 10.4103/0366‐6999.168948; PMC4795269; PUBMED: 26608976] ">Zheng 2015</a>, reported no changes in blood pressure. </p> <p>Two studies reported a drop in diastolic blood pressure: <a href="./references#CD012069-bbs2-0103" title="HazellPL , StuartJE . A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry2003;42(8):886‐94. [DOI: 10.1097/01.CHI.0000046908.27264.00] ">Hazell 2003</a> (diastolic blood pressure decreased in 9/10 participants) and <a href="./references#CD012069-bbs2-0124" title="ChungI , HanCH , KimHW , ChoSC . The effect of prolonged‐release methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorders. European Neuropsychopharmacology2010;20(Suppl 3):S624‐5. KimHW , YoonIY , ChoSC , KimBN , ChungS , LeeH , et al. The effect of OROS methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorder. International Clinical Psychopharmacology2010;25(2):107‐15. [DOI: 10.1097/YIC.0b013e3283364411; PUBMED: 20093941] ">Kim 2010</a> (baseline: 75.2 (SD 12.0) mmHg; follow‐up 72.0: (SD 8.40) mmHg). One study, <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a>, reported an apparent decrease after 24 months of methylphenidate (baseline: 63.2 (SD 10.9) mmHg; follow‐up: 59.28 (SD 9.66) mmHg). </p> <p>One study, <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>, reported that no participants had an above‐normal diastolic blood pressure (&gt; 90 mmHg) at baseline; however, one participant in each methylphenidate‐dose group had an above‐normal diastolic blood pressure at some point in the study. </p> </section> <section id="CD012069-sec-0149"> <p><b>Pulse rate</b></p> <p>Fifteen studies reported data on this outcome (<a href="./references#CD012069-bbs2-0035" title="ChoS‐C , KimB‐N , CumminsTD , KimJ‐W , BellgroveMA . Norepinephrine transporter ‐3081(A/T) and alpha‐2A‐adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS‐methylphenidate treatment. Journal of Psychopharmacology2012; Vol. 26, issue 3:380‐9. [DOI: 10.1177/0269881111405356] ">Cho 2012</a>; <a href="./references#CD012069-bbs2-0056" title="DöpfnerM , OseC , FischerR , AmmerR , ScheragA . Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention‐deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet® retard and Concerta® ‐ a randomized, controlled, double‐blind multicenter clinical crossover trial. Journal of Child &amp; Adolescent Psychopharmacology2011;21(5):445‐54. [DOI: 10.1089/cap.2010.0082; PMC3205792; PUBMED: 21790298] DöpfnerM , OseC , FischerR , AmmerR , ScheragA . The CoMeCo‐trial: comparison of the efficacy of two methylphenidate preparations for children and adolescents with ADHD in a natural setting. European Child and Adolescent Psychiatry.14th International Congress of ESCAP European Society for Child and Adolescent Psychiatry (ESCAP); June 11‐15, 2011; Helsinki (Finland)2011;20:S116. ">Döpfner 2011b</a>; <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a>; <a href="./references#CD012069-bbs2-0110" title="IlgenliTF , CongologluA , OzturkC , TurkbayT , AkpinarO , KilicaslanF . Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder. Advances in Therapy2007;24(1):182‐8. [PUBMED: 17526476] ">Ilgenli 2007</a>; <a href="./references#CD012069-bbs2-0124" title="ChungI , HanCH , KimHW , ChoSC . The effect of prolonged‐release methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorders. European Neuropsychopharmacology2010;20(Suppl 3):S624‐5. KimHW , YoonIY , ChoSC , KimBN , ChungS , LeeH , et al. The effect of OROS methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorder. International Clinical Psychopharmacology2010;25(2):107‐15. [DOI: 10.1097/YIC.0b013e3283364411; PUBMED: 20093941] ">Kim 2010</a>; <a href="./references#CD012069-bbs2-0128" title="KimHJ , YangJ , LeeMS . Changes of heart rate variability during methylphenidate treatment in attention‐deficit hyperactivity disorder children: a 12‐week prospective study. Yonsei Medical Journal2015;56(5):1365‐71. [DOI: 10.3349/ymj.2015.56.5.1365; PMC4541668] ">Kim 2015a</a>; <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a>; <a href="./references#CD012069-bbs2-0136" title="LambertiM , ItalianoD , GuerrieroL , D'AmicoG , SiracusanoR , IngrassiaM , et al. Evaluation of acute cardiovascular effects of immediate‐release methylphenidate in children and adolescents with attention‐deficit hyperactivity disorder. Neuropsychiatric Disease and Treatment2015;11:1169‐74. [DOI: 10.2147/NDT.S79866; PMC4431494; PUBMED: 26056451] ">Lamberti 2015</a>; <a href="./references#CD012069-bbs2-0146" title="Methylphenidate for preschool ADHD. Brown University Child and Adolescent Psychopharmacology Update2009;11(7):4‐4. [DOI: 10.1002/cpu.20095] MaayanL , PaykinaN , FriedJ , StraussT , GuggaSS , GreenhillL . The open‐label treatment of attention‐deficit/hyperactivity disorder in 4‐ and 5‐year‐old children with beaded methylphenidate. Journal of Child and Adolescent Psychopharmacology2009;19(2):147‐53. [PMC2935832; PUBMED: 19374023] ">Maayan 2009</a>; <a href="./references#CD012069-bbs2-0153" title="LooSK , BilderR , ChoAL , SturmA , CowenJ , WelkerPW , et al. Effects of d‐Methylphenidate, Guanfacine, and their combination on electroencephalogram resting state spectral power in Attention‐Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):674‐82.e1. [DOI: 10.1016/j.jaac.2016.04.020; PMC5003618; PUBMED: 27453081] McCrackenJT , McGoughJJ , LooSK , LevittJ , Del'HommeM , CowenJ , et al. Combined stimulant and Guanfacine administration in Attention‐Deficit/Hyperactivity Disorder: a controlled, comparative study. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):657‐66.e1. [DOI: 10.1016/j.jaac.2016.05.015; PMC4976782; PUBMED: 27453079] ">McCracken 2016</a>; <a href="./references#CD012069-bbs2-0167" title="LeeMS , LeeSI , HongSD , KimJH , ChoiJ , JoungYS . Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12‐week multicenter, open‐label study. Journal of Child and Adolescent Psychopharmacology2013;23(1):22‐7. [DOI: 10.1089/cap.2012.0018; PUBMED: 23347125] NaKS , LeeSI , HongSD , KimJH , ShimSH , ChoiJ , et al. Effect of osmotic‐release oral system methylphenidate on learning skills in adolescents with attention‐deficit/hyperactivity disorder: an open‐label study. International Clinical Psychopharmacology2013;28(4):184‐92. [DOI: 10.1097/YIC.0b013e3283612509; PUBMED: 23587983] ">Na 2013</a>; <a href="./references#CD012069-bbs2-0171" title="ÖzcanIT , TorosF , PekdemirH , ÇiçekD , ÇamsariA , YurttaşM , et al. The effect of methylphenidate on time domain heart rate variability in the treatment of attention deficit and hyperactivity disorder [Dikkat eksikliği hiperaktivite bozukluğu tedavisinde metilfenidat kullanımının zaman bağımlı kalp hızı değişkenliği üzerine etkisi]. Turkish Journal of Child and Adolescent Mental Health2004;11(3):117‐22. ">Özcan 2004</a>; <a href="./references#CD012069-bbs2-0251" title="YildizÖ , ŞişmanlarŞG , MemikNÇ , KarakayaI , AğaoğluB . Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. Child Psychiatry and Human Development2011;42(3):257‐69. [DOI: 10.1007/s10578‐010‐0212‐3; PUBMED: 21165694] ">Yildiz 2011</a>; <a href="./references#CD012069-bbs2-0258" title="ZhengY , WangYF , QinJ , WangLW , ZouLP , JinXM , et al. Prospective, naturalistic study of open‐label OROS methylphenidate treatment in Chinese school‐aged children with attention‐deficit/hyperactivity disorder. Chinese Medical Journal2011;124(20):3269‐74. [PUBMED: 22088519] ">Zheng 2011</a>; <a href="./references#CD012069-bbs2-0259" title="ZhengY , LiangJM , GaoHY , YangZW , JiaFJ , LiangYZ , et al. An open‐label, self‐control, prospective study on cognitive function, academic performance, and tolerability of osmotic‐release oral system methylphenidate in children with attention‐deficit hyperactivity disorder. Chinese Medical Journal2015;128(22):2988‐97. [DOI: 10.4103/0366‐6999.168948; PMC4795269; PUBMED: 26608976] ">Zheng 2015</a>). </p> <p>Pulse rate was significantly higher in participants receiving methylphenidate in: <a href="./references#CD012069-bbs2-0035" title="ChoS‐C , KimB‐N , CumminsTD , KimJ‐W , BellgroveMA . Norepinephrine transporter ‐3081(A/T) and alpha‐2A‐adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS‐methylphenidate treatment. Journal of Psychopharmacology2012; Vol. 26, issue 3:380‐9. [DOI: 10.1177/0269881111405356] ">Cho 2012</a> (mean increase 3.83 (SD 10.5) beats per min (bpm), P = 0.001) and <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a> (baseline: 80.4 (SD 9.70) bpm; follow‐up: 86.1 (SD 12.4) bpm, P = 0.009). There was an apparent increase in <a href="./references#CD012069-bbs2-0136" title="LambertiM , ItalianoD , GuerrieroL , D'AmicoG , SiracusanoR , IngrassiaM , et al. Evaluation of acute cardiovascular effects of immediate‐release methylphenidate in children and adolescents with attention‐deficit hyperactivity disorder. Neuropsychiatric Disease and Treatment2015;11:1169‐74. [DOI: 10.2147/NDT.S79866; PMC4431494; PUBMED: 26056451] ">Lamberti 2015</a> after two hours of methylphenidate (baseline: 80.5 (SD 15.5) bpm; follow‐up: 87.7 (SD 18.4) bpm), and at week 12 in <a href="./references#CD012069-bbs2-0128" title="KimHJ , YangJ , LeeMS . Changes of heart rate variability during methylphenidate treatment in attention‐deficit hyperactivity disorder children: a 12‐week prospective study. Yonsei Medical Journal2015;56(5):1365‐71. [DOI: 10.3349/ymj.2015.56.5.1365; PMC4541668] ">Kim 2015a</a> (baseline: 86.4 (SD 11.2) bpm; follow‐up: 93.5 (SD 15.6) bpm). <a href="./references#CD012069-bbs2-0251" title="YildizÖ , ŞişmanlarŞG , MemikNÇ , KarakayaI , AğaoğluB . Atomoxetine and methylphenidate treatment in children with ADHD: the efficacy, tolerability and effects on executive functions. Child Psychiatry and Human Development2011;42(3):257‐69. [DOI: 10.1007/s10578‐010‐0212‐3; PUBMED: 21165694] ">Yildiz 2011</a> reported increased pulse rate (baseline: 80.8 (SD 9.80) bpm; follow‐up: 84.5 (SD 13.5) bpm). <a href="./references#CD012069-bbs2-0167" title="LeeMS , LeeSI , HongSD , KimJH , ChoiJ , JoungYS . Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12‐week multicenter, open‐label study. Journal of Child and Adolescent Psychopharmacology2013;23(1):22‐7. [DOI: 10.1089/cap.2012.0018; PUBMED: 23347125] NaKS , LeeSI , HongSD , KimJH , ShimSH , ChoiJ , et al. Effect of osmotic‐release oral system methylphenidate on learning skills in adolescents with attention‐deficit/hyperactivity disorder: an open‐label study. International Clinical Psychopharmacology2013;28(4):184‐92. [DOI: 10.1097/YIC.0b013e3283612509; PUBMED: 23587983] ">Na 2013</a> also reported an increase from baseline of 9.65 (SD 14.6) bpm and <a href="./references#CD012069-bbs2-0153" title="LooSK , BilderR , ChoAL , SturmA , CowenJ , WelkerPW , et al. Effects of d‐Methylphenidate, Guanfacine, and their combination on electroencephalogram resting state spectral power in Attention‐Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):674‐82.e1. [DOI: 10.1016/j.jaac.2016.04.020; PMC5003618; PUBMED: 27453081] McCrackenJT , McGoughJJ , LooSK , LevittJ , Del'HommeM , CowenJ , et al. Combined stimulant and Guanfacine administration in Attention‐Deficit/Hyperactivity Disorder: a controlled, comparative study. Journal of the American Academy of Child and Adolescent Psychiatry2016;55(8):657‐66.e1. [DOI: 10.1016/j.jaac.2016.05.015; PMC4976782; PUBMED: 27453079] ">McCracken 2016</a> an increase of 3.60 (SD 15.7) bpm. </p> <p>There was no apparent difference in pulse rate in participants after two hours of methylphenidate in <a href="./references#CD012069-bbs2-0110" title="IlgenliTF , CongologluA , OzturkC , TurkbayT , AkpinarO , KilicaslanF . Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder. Advances in Therapy2007;24(1):182‐8. [PUBMED: 17526476] ">Ilgenli 2007</a> (baseline: 88.0 (SD 13.8) bpm; two hours: 88.4 (SD 9.70) bpm), after three weeks in <a href="./references#CD012069-bbs2-0056" title="DöpfnerM , OseC , FischerR , AmmerR , ScheragA . Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention‐deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet® retard and Concerta® ‐ a randomized, controlled, double‐blind multicenter clinical crossover trial. Journal of Child &amp; Adolescent Psychopharmacology2011;21(5):445‐54. [DOI: 10.1089/cap.2010.0082; PMC3205792; PUBMED: 21790298] DöpfnerM , OseC , FischerR , AmmerR , ScheragA . The CoMeCo‐trial: comparison of the efficacy of two methylphenidate preparations for children and adolescents with ADHD in a natural setting. European Child and Adolescent Psychiatry.14th International Congress of ESCAP European Society for Child and Adolescent Psychiatry (ESCAP); June 11‐15, 2011; Helsinki (Finland)2011;20:S116. ">Döpfner 2011b</a> (baseline: 79 (SD 1) bpm; week three: 80 (SD 1) bpm), six weeks in <a href="./references#CD012069-bbs2-0124" title="ChungI , HanCH , KimHW , ChoSC . The effect of prolonged‐release methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorders. European Neuropsychopharmacology2010;20(Suppl 3):S624‐5. KimHW , YoonIY , ChoSC , KimBN , ChungS , LeeH , et al. The effect of OROS methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorder. International Clinical Psychopharmacology2010;25(2):107‐15. [DOI: 10.1097/YIC.0b013e3283364411; PUBMED: 20093941] ">Kim 2010</a> (baseline: 87.5 (SD 6.10) bpm; week six: 87.8 (SD 6.00) bpm), or 12 weeks in <a href="./references#CD012069-bbs2-0258" title="ZhengY , WangYF , QinJ , WangLW , ZouLP , JinXM , et al. Prospective, naturalistic study of open‐label OROS methylphenidate treatment in Chinese school‐aged children with attention‐deficit/hyperactivity disorder. Chinese Medical Journal2011;124(20):3269‐74. [PUBMED: 22088519] ">Zheng 2011</a> (baseline: 82.5 (SD 7.8) bpm, N = 1254; 12 weeks: 82.8 (SD 7.40) bpm, N = 942). <a href="./references#CD012069-bbs2-0259" title="ZhengY , LiangJM , GaoHY , YangZW , JiaFJ , LiangYZ , et al. An open‐label, self‐control, prospective study on cognitive function, academic performance, and tolerability of osmotic‐release oral system methylphenidate in children with attention‐deficit hyperactivity disorder. Chinese Medical Journal2015;128(22):2988‐97. [DOI: 10.4103/0366‐6999.168948; PMC4795269; PUBMED: 26608976] ">Zheng 2015</a> reported no changes in pulse rate. </p> <p>Two studies indicated a decrease in pulse rate: <a href="./references#CD012069-bbs2-0146" title="Methylphenidate for preschool ADHD. Brown University Child and Adolescent Psychopharmacology Update2009;11(7):4‐4. [DOI: 10.1002/cpu.20095] MaayanL , PaykinaN , FriedJ , StraussT , GuggaSS , GreenhillL . The open‐label treatment of attention‐deficit/hyperactivity disorder in 4‐ and 5‐year‐old children with beaded methylphenidate. Journal of Child and Adolescent Psychopharmacology2009;19(2):147‐53. [PMC2935832; PUBMED: 19374023] ">Maayan 2009</a> observed a decrease after four weeks (baseline: 95.5 (SD 16.0) bpm; follow‐up: 91.8 (12.2) bpm), and <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a> after 24 months (baseline: 79.9 (SD 12.9) bpm; follow‐up: 76.1 (SD 11.2) bpm). In one study, <a href="./references#CD012069-bbs2-0171" title="ÖzcanIT , TorosF , PekdemirH , ÇiçekD , ÇamsariA , YurttaşM , et al. The effect of methylphenidate on time domain heart rate variability in the treatment of attention deficit and hyperactivity disorder [Dikkat eksikliği hiperaktivite bozukluğu tedavisinde metilfenidat kullanımının zaman bağımlı kalp hızı değişkenliği üzerine etkisi]. Turkish Journal of Child and Adolescent Mental Health2004;11(3):117‐22. ">Özcan 2004</a>, mean heart rate also seemed to decrease (baseline: 148.2 (SD 29.7) bpm, N = 42; follow‐up: 139.9 (SD 34.0) bpm, N = 42). </p> </section> <section id="CD012069-sec-0150"> <p><b>ECG‐QT</b></p> <p>Four studies reported data on different ECG‐QT adverse events.</p> <p> <ol id="CD012069-list-0039"> <li> <p><a href="./references#CD012069-bbs2-0035" title="ChoS‐C , KimB‐N , CumminsTD , KimJ‐W , BellgroveMA . Norepinephrine transporter ‐3081(A/T) and alpha‐2A‐adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS‐methylphenidate treatment. Journal of Psychopharmacology2012; Vol. 26, issue 3:380‐9. [DOI: 10.1177/0269881111405356] ">Cho 2012</a> (101 participants) reported no significant change in QT and QRS scores after treatment. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a> (840 participants) reported that 8 out of 77 (10.4%) participants receiving methylphenidate had an altered ECG at 24 months, and that out of 38 participants, 11 (29.0%) reported sinus bradycardia, 12 (31.6%) reported sinus tachycardia, and 6 (15.8%) reported lengthened corrected QT interval (QTc). </p> </li> <li> <p><a href="./references#CD012069-bbs2-0110" title="IlgenliTF , CongologluA , OzturkC , TurkbayT , AkpinarO , KilicaslanF . Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder. Advances in Therapy2007;24(1):182‐8. [PUBMED: 17526476] ">Ilgenli 2007</a> (25 participants) reported a minimum QT of 317.00 (SD 23.3) at baseline and 322.3 (SD 21.6) after two hours, and a maximum QT of 373.7 (SD 21.8) at baseline and 361.8 (SD 29.0) after two hours. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0136" title="LambertiM , ItalianoD , GuerrieroL , D'AmicoG , SiracusanoR , IngrassiaM , et al. Evaluation of acute cardiovascular effects of immediate‐release methylphenidate in children and adolescents with attention‐deficit hyperactivity disorder. Neuropsychiatric Disease and Treatment2015;11:1169‐74. [DOI: 10.2147/NDT.S79866; PMC4431494; PUBMED: 26056451] ">Lamberti 2015</a> (54 participants) reported at baseline a corrected QT (QTc) of 407.6 (SD 12.4) ms, which was 409.8 (SD 12.0) ms at two hours postmethylphenidate. </p> </li> </ol> </p> </section> <section id="CD012069-sec-0151"> <p><b>Other specific adverse events</b></p> <p>Four studies reported on other adverse events.</p> <p> <ol id="CD012069-list-0040"> <li> <p>In <a href="./references#CD012069-bbs2-0122" title="KhajehpiriZ , Mahmoudi‐GharaeiJ , FaghihiT , KarimzadehI , KhaliliH , MohammadiM . Adverse reactions of Methylphenidate in children with attention deficit‐hyperactivity disorder: report from a referral center. Journal of Research in Pharmacy Practice2014;3(4):130‐6. [DOI: 10.4103/2279‐042X.145389; PMC4262859; PUBMED: 25535621] ">Khajehpiri 2014</a> (71 participants), the proportion of participants on methylphenidate with: </p> <ol id="CD012069-list-0041"> <li> <p>cold fingers was 18.3% (95% CI 11.0% to 28.9%); and</p> </li> <li> <p>sweating was 8.45% (95% CI 3.93% to 17.2%).</p> </li> </ol> </li> <li> <p>In <a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a> (1426 participants), the proportion of participants on methylphenidate with: </p> <ol id="CD012069-list-0042"> <li> <p>hypertension was 0.56% (95% CI 0.28% to 1.10%); and</p> </li> <li> <p>hypotension was 0.21% (95% CI 0.05% to 0.62%).</p> </li> </ol> </li> <li> <p>In <a href="./references#CD012069-bbs2-0098" title="HaertlingF , MuellerB , Bilke‐HentschO . Effectiveness and safety of a long‐acting, once‐daily, two‐phase release formulation of methylphenidate (Ritalin® LA) in school children under daily practice conditions. Attention Deficit and Hyperactivity Disorders2015;7(2):157‐64. [DOI: 10.1007/s12402‐014‐0154‐x; PMC4449385; PUBMED: 25346231] ">Haertling 2015</a> (239 participants), the proportion of participants on methylphenidate with respiratory, thoracic, and mediastinal disorders was 0.42% (95% 0.01% to 2.33%). </p> </li> <li> <p><a href="./references#CD012069-bbs2-0226" title="StopperH , KampfK , RomanosM , WarnkeA , WalitzaS , GerlachM . Does methylphenidate cause a cytogenetic effect in children with attention deficit hyperactivity disorder?. International Journal of Neuropsychopharmacology2008;11:290. WalitzaS , KampfK , ArtamonovN , RomanosM , Gnana OliR , WirthS , et al. No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy. Toxicology Letters2009;184(1):38‐43. [DOI: 10.1016/j.toxlet.2008.10.011] ">Walitza 2009</a> (26 participants) assessed the proportion of participants on methylphenidate with micro‐nucleated (Mn) peripheral lymphocytes and found no alteration in the number of Mn cells in the group of chronically treated (&gt; 12 months) children compared to the ADHD group before treatment initiation. They also reported no elevation after initiation of methylphenidate treatment at three and six months after treatment initiation. </p> </li> </ol> </p> </section> </section> <section id="CD012069-sec-0152"> <h6 class="title">2.2.4 Gastrointestinal system</h6> <p>See <a href="./references#CD012069-fig-0032" title="">Analysis 7.4</a>. We were able to use data from 102 studies in 12 meta‐analyses. The proportion of participants on methylphenidate with: </p> <p> <ol id="CD012069-list-0043"> <li> <p>abdominal pain was 10.7% (95% CI 8.60% to 13.3%; 79 studies, 11,750 participants; see <a href="https://zenodo.org/record/1240398#.WusX5mcUmBE" target="_blank">supplementary file S60</a>); </p> </li> <li> <p>constipation was 7.60% (95% CI 3.70% to 15.1%; 4 studies, 249 participants; <a href="./references#CD012069-bbs2-0013" title="ArdicUA , ErcanES , ErcanE , YuceD , BasayBK . Osmotic release oral system methylphenidate is more effective than immediate release methylphenidate: a retrospective chart review in Turkish children with attention deficit hyperactivity disorder. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(4):342‐9. [DOI: 10.5455/bcp.20141009112739] ErcanES , Akyol‐ArdicU , ErcanE , YuceD , Kabukcu‐BasayB . OROS‐MPH is more effective than IR‐MPH in Turkish children: a retrospective chart review. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(1):306‐7. [DOI: 10.5455/bcp.20141009112739] ">Ardic 2014</a>; <a href="./references#CD012069-bbs2-0122" title="KhajehpiriZ , Mahmoudi‐GharaeiJ , FaghihiT , KarimzadehI , KhaliliH , MohammadiM . Adverse reactions of Methylphenidate in children with attention deficit‐hyperactivity disorder: report from a referral center. Journal of Research in Pharmacy Practice2014;3(4):130‐6. [DOI: 10.4103/2279‐042X.145389; PMC4262859; PUBMED: 25535621] ">Khajehpiri 2014</a>; <a href="./references#CD012069-bbs2-0158" title="MohammadiMR , KashaniL , AkhondzadehS , IzadianES , OhadiniaS . Efficacy of theophylline compared to methylphenidate for the treatment of attention‐deficit hyperactivity disorder in children and adolescents: a pilot double‐blind randomized trial. Journal of Clinical Pharmacy and Therapeutics2004;29(2):139‐44. [DOI: 10.1111/j.1365‐2710.2004.00545.x; PUBMED: 15068402] ">Mohammadi 2004</a>; <a href="./references#CD012069-bbs2-0195" title="ShangCY , PanYL , LinHY , HuangLW , GauSS . An open‐label, randomized trial of methylphenidate and atomoxetine treatment in children with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2015;25(7):566‐73. [DOI: 10.1089/cap.2015.0035; PUBMED: 26222447] ">Shang 2015</a>; see <a href="https://zenodo.org/record/1240399#.WusYQ2cUmBE" target="_blank">supplementary file S61</a>); </p> </li> <li> <p>decreased appetite was 31.1% (95% CI 26.5% to 36.2%; 84 studies, 11,594 participants; see <a href="https://zenodo.org/record/1240400#.WusZLGcUmBE" target="_blank">supplementary file S62</a>); </p> </li> <li> <p>decreased weight was 8.60% (95% CI 4.90% to 14.7%; 28 studies, 5182 participants; see <a href="https://zenodo.org/record/1240404#.Wusaf2cUmBE" target="_blank">supplementary file S63</a>); </p> </li> <li> <p>diarrhoea was 4.70% (95% CI 2.00% to 10.9%; 8 studies, 809 participants; <a href="./references#CD012069-bbs2-0003" title="AbbasiSH , HeidariS , MohammadiMR , TabriziM , GhaleihaA , AkhondzadehS . Acetyl‐L‐carnitine as an adjunctive therapy in the treatment of attention‐deficit/hyperactivity disorder in children and adolescents: a placebo‐controlled trial. Child Psychiatry and Human Development2011;42(3):367‐75. [DOI: 10.1007/s10578‐011‐0220‐y; PUBMED: 21336630] ">Abbasi 2011</a>; <a href="./references#CD012069-bbs2-0028" title="BladerJC , PliszkaSR , JensenPS , SchoolerNR , KafantarisV . Stimulant‐responsive and stimulant‐refractory aggressive behavior among children with ADHD. Pediatrics2010;126(4):e796‐806. [DOI: 10.1542/peds.2010‐0086; PMC2956067; PUBMED: 20837589] Blader JosephC . Methylphenidate dose may reduce aggressive behavior in children with ADHD. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(12):1‐7. [DOI: 10.1002/cpu.20129] ">Blader 2010</a>; <a href="./references#CD012069-bbs2-0100" title="Effects of high‐dose OROS methylphenidate. Brown University Child and Adolescent Psychopharmacology Update2009;11(8):7‐8. [DOI: 10.1002/cpu.20097] DanielsSR . Cardiovascular effects of methylphenidate. Journal of Pediatrics2009;155(1):A3. [DOI: 10.1016/j.jpeds.2009.05.023] HammernessP , GeorgiopoulosA , DoyleRL , UtzingerL , SchillingerM , MartelonM , et al. An open study of adjunct OROS‐methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. Journal of Child and Adolescent Psychopharmacology2009;19(5):493‐9. [DOI: 10.1089/cap.2008.0126; PMC2861956; PUBMED: 19877973] ">Hammerness 2009</a>; <a href="./references#CD012069-bbs2-0122" title="KhajehpiriZ , Mahmoudi‐GharaeiJ , FaghihiT , KarimzadehI , KhaliliH , MohammadiM . Adverse reactions of Methylphenidate in children with attention deficit‐hyperactivity disorder: report from a referral center. Journal of Research in Pharmacy Practice2014;3(4):130‐6. [DOI: 10.4103/2279‐042X.145389; PMC4262859; PUBMED: 25535621] ">Khajehpiri 2014</a>; <a href="./references#CD012069-bbs2-0131" title="KordonA , StollhoffK , NiederkirchnerK , MattejatF , RettigK , SchäubleB . Exploring the impact of once‐daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate‐release MPH. Postgraduate Medicine2011;123(5):27‐38. [DOI: 10.3810/pgm.2011.09.2457; PUBMED: 21904084] ">Kordon 2011</a>; <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a>; <a href="./references#CD012069-bbs2-0158" title="MohammadiMR , KashaniL , AkhondzadehS , IzadianES , OhadiniaS . Efficacy of theophylline compared to methylphenidate for the treatment of attention‐deficit hyperactivity disorder in children and adolescents: a pilot double‐blind randomized trial. Journal of Clinical Pharmacy and Therapeutics2004;29(2):139‐44. [DOI: 10.1111/j.1365‐2710.2004.00545.x; PUBMED: 15068402] ">Mohammadi 2004</a>; <a href="./references#CD012069-bbs2-0160" title="MohammadiMR , KazemiMR , ZiaE , RezazadehSA , TabriziM , AkhondzadehS . Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double‐blind trial. Human Psychopharmacology2010;25(7‐8):560‐5. [DOI: 10.1002/hup.1154; PUBMED: 21312290] ">Mohammadi 2010</a>; see <a href="https://zenodo.org/record/1240405#.WusbK2cUmBE" target="_blank">supplementary file S64</a>); </p> </li> <li> <p>dry mouth was 17.8% (95% CI 9.60% to 30.6%; 9 studies, 221 participants; <a href="./references#CD012069-bbs2-0003" title="AbbasiSH , HeidariS , MohammadiMR , TabriziM , GhaleihaA , AkhondzadehS . Acetyl‐L‐carnitine as an adjunctive therapy in the treatment of attention‐deficit/hyperactivity disorder in children and adolescents: a placebo‐controlled trial. Child Psychiatry and Human Development2011;42(3):367‐75. [DOI: 10.1007/s10578‐011‐0220‐y; PUBMED: 21336630] ">Abbasi 2011</a>; <a href="./references#CD012069-bbs2-0011" title="AmiriS , MohammadiMR , MohammadiM , NouroozinejadGH , KahbaziM , AkhondzadehS . Modafinil as a treatment for Attention‐Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial. Progress in Neuro Psychopharmacology &amp; Biological Psychiatry2008;32(1):145‐9. [DOI: 10.1016/j.pnpbp.2007.07.025; PUBMED: 17765380] ">Amiri 2008</a>; <a href="./references#CD012069-bbs2-0028" title="BladerJC , PliszkaSR , JensenPS , SchoolerNR , KafantarisV . Stimulant‐responsive and stimulant‐refractory aggressive behavior among children with ADHD. Pediatrics2010;126(4):e796‐806. [DOI: 10.1542/peds.2010‐0086; PMC2956067; PUBMED: 20837589] Blader JosephC . Methylphenidate dose may reduce aggressive behavior in children with ADHD. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(12):1‐7. [DOI: 10.1002/cpu.20129] ">Blader 2010</a>; <a href="./references#CD012069-bbs2-0050" title="BabakiME , AshtianiRD , RazjooyanK , AminiH . Comparing the effects of buspirone and methylphenidate in children with attention deficit hyperactivity disorder. Iranian Journal of Psychiatry and Clinical Psychology2009; Vol. 15, issue 3:223‐30. Davari‐AshtianiR , ShahrbabakiME , RazjouyanK , AminiH , MazhabdarH . Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double‐blind and randomized trial. Child Psychiatry and Human Development2010;41(6):641‐8. [DOI: 10.1007/s10578‐010‐0193‐2; PUBMED: 20517641] ShahrbabakiME , SabzevariL , HaghdoostA , Davari‐AshtianiR . Buspiron versus methylphenidate in the treatment of children with ADHD. Brain, Mind and Development. 20th World IACAPAP (International Association for Child and Adolescent Psychiatry and Allied Professions) Congress; July 21‐25 2012; Paris (France). 2012; Vol. 60:Suppl 1. ">Davari‐Ashtiani 2010</a>; <a href="./references#CD012069-bbs2-0112" title="IşeriE , KilicBG , SenolS , KarabacakNI . Effects of methylphenidate on leptin and appetite in children with attention‐deficit hyperactivity disorder: an open label trial. Methods and Findings in Experimental and Clinical Pharmacology2007;29(1):47‐52. [DOI: 10.1358/mf.2007.29.1.1063491; PUBMED: 17344944] ">Işeri 2007</a>; <a href="./references#CD012069-bbs2-0158" title="MohammadiMR , KashaniL , AkhondzadehS , IzadianES , OhadiniaS . Efficacy of theophylline compared to methylphenidate for the treatment of attention‐deficit hyperactivity disorder in children and adolescents: a pilot double‐blind randomized trial. Journal of Clinical Pharmacy and Therapeutics2004;29(2):139‐44. [DOI: 10.1111/j.1365‐2710.2004.00545.x; PUBMED: 15068402] ">Mohammadi 2004</a>; <a href="./references#CD012069-bbs2-0160" title="MohammadiMR , KazemiMR , ZiaE , RezazadehSA , TabriziM , AkhondzadehS . Amantadine versus methylphenidate in children and adolescents with attention deficit/hyperactivity disorder: a randomized, double‐blind trial. Human Psychopharmacology2010;25(7‐8):560‐5. [DOI: 10.1002/hup.1154; PUBMED: 21312290] ">Mohammadi 2010</a>; <a href="./references#CD012069-bbs2-0161" title="MohammadiMR , MostafaviSA , KeshavarzSA , EshraghianMR , HosseinzadehP , Hosseinzadeh‐AttarMJ , et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. Iranian Journal of Psychiatry2012;7(2):87‐92. MostafaviSA , MohammadiMR , HosseinzadehP , EshraghianMR , AkhondzadehS , Hosseinzadeh‐AttarMJ , et al. Dietary intake, growth and development of children with ADHD in a randomized clinical trial of Ritalin and Melatonin co‐administration: through circadian cycle modification or appetite enhancement?. Iranian Journal of Psychiatry2012;7(3):114‐9. [PMC3488866; PUBMED: 23139692] ">Mohammadi 2012a</a>; <a href="./references#CD012069-bbs2-0162" title="MohammadiMR , HafeziP , GaleihaA , HajiaghaeeR , AkhondzadehS . Buspirone versus methylphenidate in the treatment of children with attention‐ deficit/ hyperactivity disorder: randomized double‐blind study. Acta Medica Iranica2012;50(11):723‐8. [PUBMED: 23292622] ">Mohammadi 2012b</a>; see <a href="https://zenodo.org/record/1240407#.WusbkmcUmBE" target="_blank">supplementary file S65</a>); </p> </li> <li> <p>gastrointestinal adverse events was 2.80% (95% CI 1.10% to 7.30%; 3 studies, 1487 participants; <a href="./references#CD012069-bbs2-0053" title="DittmannRW , BanaschewskiT , SchachtA , WehmeierPM . Findings from the observational COMPLY study in children and adolescents with ADHD: core symptoms, ADHD‐related difficulties, and patients' emotional expression during psychostimulant or nonstimulant ADHD treatment. Attention Deficit and Hyperactivity Disorders2014;6(2014):291‐302. [DOI: 10.1007/s12402‐014‐0136‐z; PUBMED: 24705867] ">Dittmann 2014</a>; <a href="./references#CD012069-bbs2-0076" title="GauSS , ChenSJ , ChouWJ , ChengH , TangCS , ChangHL , et al. National survey of adherence, efficacy, and side effects of methylphenidate in children with attention‐deficit/hyperactivity disorder in Taiwan. Journal of Clinical Psychiatry2008;69(1):131‐40. [PUBMED: 18312048] ">Gau 2008</a>; <a href="./references#CD012069-bbs2-0219" title="Valdizán UsonJR . Methylphenidate in children and adolescents with attention‐deficit/ hyperactivity disorder: The DIHANA Study. Acta Pediatrica Espanola2013;71(3):67‐76. Valdizán UsonJR , Cánovas‐MartínezA , DeLucas‐TaracenaMT , Díaz‐AtienzaF , Eddy‐IvesLS , Fernandez‐JaenA , et al. Response to methylphenidate by adult and pediatric patients with attention‐deficit/hyperactivity disorder: the Spanish multicenter DIHANA study. Neuropsychiatric Disease and Treatment2013;9:211‐8. [DOI: 10.2147/NDT.S35836; PMC3573811] ">Valdizán Usón 2013</a>; see <a href="https://zenodo.org/record/1240408#.Wusb-mcUmBE" target="_blank">supplementary file S66</a>); </p> </li> <li> <p>nausea was 7.60% (95% CI 5.30% to 10.6%; 41 studies, 5612 participants; see <a href="https://zenodo.org/record/1241624#.Wu6eUGcUmBE" target="_blank">supplementary file S67</a>); </p> </li> <li> <p>upset stomach was 11.0% (95% CI 7.00% to 17.0%; 3 studies, 217 participants; <a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0109" title="HulvershornL . Methylphenidate treatment of chronic irritability: symptom improvement and underlying neural mechanisms. Biological Psychiatry2015;77(1S):444S. HulvershornLA , HummerT , WangY , LothA , AnandA . The impact of methylphenidate on corticolimbic functional connectivity in children with ADHD and chronic irritability. Biological Psychiatry2012;71(8):193S. ">Hulvershorn 2012</a>; <a href="./references#CD012069-bbs2-0167" title="LeeMS , LeeSI , HongSD , KimJH , ChoiJ , JoungYS . Two different solicitation methods for obtaining information on adverse events associated with methylphenidate in adolescents: a 12‐week multicenter, open‐label study. Journal of Child and Adolescent Psychopharmacology2013;23(1):22‐7. [DOI: 10.1089/cap.2012.0018; PUBMED: 23347125] NaKS , LeeSI , HongSD , KimJH , ShimSH , ChoiJ , et al. Effect of osmotic‐release oral system methylphenidate on learning skills in adolescents with attention‐deficit/hyperactivity disorder: an open‐label study. International Clinical Psychopharmacology2013;28(4):184‐92. [DOI: 10.1097/YIC.0b013e3283612509; PUBMED: 23587983] ">Na 2013</a>; see <a href="https://zenodo.org/record/1240414#.Wusda2cUmBE" target="_blank">supplementary file S68</a>); </p> </li> <li> <p>vomiting was 7.30% (95% CI 3.70% to 13.9%; 20 studies, 2731 participants; see <a href="https://zenodo.org/record/1240417#.WusdxGcUmBE" target="_blank">supplementary file S69</a>); </p> </li> <li> <p>dyspepsia was 2.30% (95% CI 0.20% to 22.8%; 2 studies, 1502 participants; <a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a>; see <a href="https://zenodo.org/record/1240418#.WuseIWcUmBE" target="_blank">supplementary file S70</a>); and </p> </li> <li> <p>gastroenteritis was 1.80% (95% CI 0.70% to 4.40%; 2 studies, 276 participants; <a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0234" title="WigalSB , NordbrockE , AdjeiAL , ChildressA , KupperRJ , GreenhillL . Efficacy of methylphenidate hydrochloride extended‐release capsules (Aptensio XRTM) in children and adolescents with attention‐deficit/hyperactivity disorder: a phase III, randomized, double‐blind study. CNS Drugs2015;29(4):331‐40. ">Wigal 2015</a>; see <a href="https://zenodo.org/record/1241625#.Wu6etmcUmBE" target="_blank">supplementary file S71</a>). </p> </li> </ol> </p> <p>Two studies also provided data on different gastrointestinal adverse events (<a href="./references#CD012069-bbs2-0028" title="BladerJC , PliszkaSR , JensenPS , SchoolerNR , KafantarisV . Stimulant‐responsive and stimulant‐refractory aggressive behavior among children with ADHD. Pediatrics2010;126(4):e796‐806. [DOI: 10.1542/peds.2010‐0086; PMC2956067; PUBMED: 20837589] Blader JosephC . Methylphenidate dose may reduce aggressive behavior in children with ADHD. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(12):1‐7. [DOI: 10.1002/cpu.20129] ">Blader 2010</a>; <a href="./references#CD012069-bbs2-0122" title="KhajehpiriZ , Mahmoudi‐GharaeiJ , FaghihiT , KarimzadehI , KhaliliH , MohammadiM . Adverse reactions of Methylphenidate in children with attention deficit‐hyperactivity disorder: report from a referral center. Journal of Research in Pharmacy Practice2014;3(4):130‐6. [DOI: 10.4103/2279‐042X.145389; PMC4262859; PUBMED: 25535621] ">Khajehpiri 2014</a>). </p> <p> <ol id="CD012069-list-0044"> <li> <p>In <a href="./references#CD012069-bbs2-0028" title="BladerJC , PliszkaSR , JensenPS , SchoolerNR , KafantarisV . Stimulant‐responsive and stimulant‐refractory aggressive behavior among children with ADHD. Pediatrics2010;126(4):e796‐806. [DOI: 10.1542/peds.2010‐0086; PMC2956067; PUBMED: 20837589] Blader JosephC . Methylphenidate dose may reduce aggressive behavior in children with ADHD. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(12):1‐7. [DOI: 10.1002/cpu.20129] ">Blader 2010</a> (65 participants), the proportion of participants on methylphenidate with increased appetite was 1.54% (95% CI 0.27% to 8.22%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0122" title="KhajehpiriZ , Mahmoudi‐GharaeiJ , FaghihiT , KarimzadehI , KhaliliH , MohammadiM . Adverse reactions of Methylphenidate in children with attention deficit‐hyperactivity disorder: report from a referral center. Journal of Research in Pharmacy Practice2014;3(4):130‐6. [DOI: 10.4103/2279‐042X.145389; PMC4262859; PUBMED: 25535621] ">Khajehpiri 2014</a> (71 participants), the proportion of participants on methylphenidate with xerostomia was 16.9% (95% CI 9.9% to 27.2%). </p> </li> </ol> </p> </section> <section id="CD012069-sec-0153"> <h6 class="title">2.2.5 Musculoskeletal system</h6> <p>See <a href="./references#CD012069-fig-0033" title="">Analysis 7.5</a>. We were able to use data from 23 studies in 4 meta‐analyses. </p> <section id="CD012069-sec-0154"> <p><b>Chest pain</b></p> <p>We combined the data from three studies (189 participants) in a meta‐analysis (<a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0100" title="Effects of high‐dose OROS methylphenidate. Brown University Child and Adolescent Psychopharmacology Update2009;11(8):7‐8. [DOI: 10.1002/cpu.20097] DanielsSR . Cardiovascular effects of methylphenidate. Journal of Pediatrics2009;155(1):A3. [DOI: 10.1016/j.jpeds.2009.05.023] HammernessP , GeorgiopoulosA , DoyleRL , UtzingerL , SchillingerM , MartelonM , et al. An open study of adjunct OROS‐methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. Journal of Child and Adolescent Psychopharmacology2009;19(5):493‐9. [DOI: 10.1089/cap.2008.0126; PMC2861956; PUBMED: 19877973] ">Hammerness 2009</a>; <a href="./references#CD012069-bbs2-0195" title="ShangCY , PanYL , LinHY , HuangLW , GauSS . An open‐label, randomized trial of methylphenidate and atomoxetine treatment in children with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2015;25(7):566‐73. [DOI: 10.1089/cap.2015.0035; PUBMED: 26222447] ">Shang 2015</a>), and found that the proportion of participants on methylphenidate with chest pain was 2.20% (95% CI 0.80% to 6.00%; <a href="https://zenodo.org/record/1240427#.WusiK2cUmBE" target="_blank">see supplementary file S72</a>). </p> </section> <section id="CD012069-sec-0155"> <p><b>Height</b></p> <p>Six studies provided data on this outcome (<a href="./references#CD012069-bbs2-0114" title="AbikoffH . Tailored psychosocial treatments for ADHD: the search for a good fit. Journal of Clinical Child Psychology2001; Vol. 30, issue 1:122‐5. [DOI: 10.1207/S15374424JCCP3001_14; PUBMED: 11294070] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottG , GreenhillLL , et al. National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choices. Archives of General Psychiatry1997;54(9):865‐70. [PUBMED: 9294378] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottGR , GreenhillLL , et al. NIMH collaborative multimodal treatment study of children with ADHD (MTA): design, methodology, and protocol evolution. Journal of Attention Disorders1997;2(3):141‐58. [DOI: 10.1177/108705479700200301] ArnoldLE , ChuangS , DaviesM , AbikoffHB , ConnersCK , ElliottGR , et al. Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures. Journal of Abnormal Child Psychology2004;32(1):39‐51. [PUBMED: 14998110] ArnoldLE , ElliottM , SachsL , BirdH , KraemerHC , WellsKC , et al. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14‐month outcome in ADHD. Journal of Consulting and Clinical Psychology2003;71(4):713‐27. [PUBMED: 12924677] CareyWB . What the multimodal treatment study of children with attention deficit/hyperactivity disorder did and did not say about the use of methylphenidate for attention deficits. Pediatrics2000;105(4):863‐4. [PUBMED: 10742336] ConnersCK , EpsteinJN , MarchJS , AngoldA , WellsKC , KlaricJ , et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):159‐67. [DOI: 10.1097/00004583‐200102000‐00010; PUBMED: 11211364] GalanterCA , CarlsonGA , JensenPS , GreenhillLL , DaviesM , LiW , et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. Journal of Child and Adolescent Psychopharmacology2003;13(2):123‐36. [DOI: 10.1089/104454603322163844; PUBMED: 12880507] GreeneRW , AblonJS . What does the MTA study tell us about effective psychosocial treatment for ADHD?. Journal of Clinical Child Psychology2001;30(1):114‐21. [DOI: 10.1207/S15374424JCCP3001_13; PUBMED: 11294069] GreenhillLL , AbikoffHB , ArnoldLE , CantwellDP , ConnersCK , ElliottG , et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. Journal of the American Academy of Child and Adolescent Psychiatry1996;35(10):1304‐13. [DOI: 10.1097/00004583‐199610000‐00017; PUBMED: 8885584] GreenhillLL , SwansonJM , VitielloB , DaviesM , ClevengerW , WuM , et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):180‐7. [DOI: 10.1097/00004583‐200102000‐00012; PUBMED: 11211366] HansenL , ThomsenPH . How to treat ADHD/DAMP? Is there a conclusive answer? A critical survey of the MTA trial?. Ugeskr Laeger2005;167(48):4555‐9. [PUBMED: 16324436] HinshawSP . Moderators and mediators of treatment response for children with attention‐deficit/hyperactivity disorder: the Multimodal Treatment Study of children with attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1088‐96. [PUBMED: 10591284] HinshawSP , MarchJS , AbikoffH , ArnoldLE , CantwellDP , ConnersCK , et al. Comprehensive assessment of childhood Attention‐Deficit Hyperactivity Disorder in the context of a multisite, multimodal clinical trial. Journal of Attention Disorders1997;1(4):217‐34. [DOI: 10.1177/108705479700100403] JensenPS , ArnoldLE , SwansonJM , VitielloB , AbikoffHB , GreenhillLL , et al. 3‐year follow‐up of the NIMH MTA study. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):989‐1002. [DOI: 10.1097/CHI.0b013e3180686d48; PUBMED: 17667478] JensenPS , HinshawSP , KraemerHC , LeonoraN , NewcornJH , AbikoffHB , et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. Journal of the American Academy of Child and Adolescent Psychiatry2001; Vol. 40, issue 2:147‐58. [DOI: 10.1097/00004583‐200102000‐00009; PUBMED: 11211363] JensenPS , HinshawSP , SwansonJM , GreenhillLL , ConnersCK , ArnoldLE , et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. Journal of Developmental and Behavioral Pediatrics2001;22(1):60‐73. [PUBMED: 11265923] MTA Cooperative Group. A 14‐month randomized clinical trial of treatment strategies for attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1073‐86. [DOI: 10.1001/archpsyc.56.12.1073; PUBMED: 10591283] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: 24‐month outcomes of treatment strategies for attention‐deficit/hyperactivity disorder. Pediatrics2004;113(4):754‐61. [PUBMED: 15060224] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: changes in effectiveness and growth after the end of treatment. Pediatrics2004;113(4):762‐9. [PUBMED: 15060225] MarchJS , SwansonJM , ArnoldLE , HozaB , ConnersCK , HinshawSP , et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). Journal of Abnormal Child Psychology2000;28(6):527‐41. [PUBMED: 11104315] MolinaBS , FloryK , HinshawSP , GreinerAR , ArnoldLE , SwansonJM , et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1028‐40. [DOI: 10.1097/chi.0b013e3180686d96; PUBMED: 17667481] MolinaBS , HinshawSP , EugeneAL , SwansonJM , PelhamWE , HechtmanL , et al. Adolescent substance use in the multimodal treatment study of attention‐deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. Journal of the American Academy of Child and Adolescent Psychiatry2013;52(3):250‐63. [DOI: 10.1016/j.jaac.2012.12.014; PMC3589108; PUBMED: 23452682] MolinaBS , HinshawSP , SwansonJM , ArnoldLE , VitielloB , JensenPS , et al. The MTA at 8 years: prospective follow‐up of children treated for combined‐type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(5):484‐500. [DOI: 10.1097/CHI.0b013e31819c23d0; PMC3063150] NiewegEH . Does ADHD medication stop working after 2‐3 years? On the surprising, but little known follow‐up of the MTA study [Is adhd‐medicatie na 2‐3 jaar uitgewerkt? Over de verrassende, maar weinig bekendefollow‐up van het mta‐onderzoek]. Tijdschrift voor Psychiatrie2010;52(4):245‐54. [PUBMED: 20503165] OwensEB , HinshawSP , KraemerHC , ArnoldLE , AbikoffHB , CantwellDP , et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. Journal of Consulting and Clinical Psychology2003;71(3):540‐52. [PUBMED: 12795577] PelhamWEJr . The NIMH multimodal treatment study for attention‐deficit hyperactivity disorder: just say yes to drugs alone?. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie1999;44(10):981‐90. [DOI: 10.1177/070674379904401004; PUBMED: 10637677] PelhamWE , GnagyEM , GreinerAR , HozaB , HinshawSP , SwansonJM , et al. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. Journal of Abnormal Child Psychology2000;28(6):507‐25. [PUBMED: 11104314] RichtersJE , ArnoldLE , JensenPS , AbikoffH , ConnersCK , GreenhillLL , et al. NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale. Journal of the American Academy of Child and Adolescent Psychiatry1995;34(8):987‐1000. [DOI: 10.1097/00004583‐199508000‐00008; PUBMED: 7665456] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. Journal of Attention Disorders2008;12(1):15‐43. [DOI: 10.1177/1087054708319525; PUBMED: 18573924] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. Journal of Attention Disorders2008;12(1):4‐14. [DOI: 10.1177/1087054708319345; PUBMED: 18573923] SwansonJM , ElliottGR , GreenhillLL , WigalT , ArnoldLE , VitielloB , et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow‐up. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1015‐27. [DOI: 10.1097/chi.0b013e3180686d7e; PUBMED: 17667480] SwansonJM , HinshawSP , ArnoldLE , GibbonsRD , MarcusS , HurK , et al. Secondary evaluations of MTA 36‐month outcomes: propensity score and growth mixture model analyses. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1003‐14. [DOI: 10.1097/CHI.0b013e3180686d63; PUBMED: 17667479] SwansonJM , KraemerHC , HinshawSP , ArnoldLE , ConnersCK , AbikoffHB , et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):168‐79. [DOI: 10.1097/00004583‐200102000‐00011; PUBMED: 1121136] VitielloB , ElliottGR , SwansonJM , ArnoldLE , HechtmanL , AbikoffH , et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. American Journal of Psychiatry2012; Vol. 169, issue 2:167‐77. [DOI: 10.1176/appi.ajp.2011.10111705; PMC4132884; PUBMED: 21890793] VitielloB , SevereJB , GreenhillLL , ArnoldLE , AbikoffHB , BuksteinOG , et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):188‐96. [DOI: 10.1097/00004583‐200102000‐00013; PUBMED: 11211367] ">Jensen 1999 (MTA)</a>; <a href="./references#CD012069-bbs2-0124" title="ChungI , HanCH , KimHW , ChoSC . The effect of prolonged‐release methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorders. European Neuropsychopharmacology2010;20(Suppl 3):S624‐5. KimHW , YoonIY , ChoSC , KimBN , ChungS , LeeH , et al. The effect of OROS methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorder. International Clinical Psychopharmacology2010;25(2):107‐15. [DOI: 10.1097/YIC.0b013e3283364411; PUBMED: 20093941] ">Kim 2010</a>; <a href="./references#CD012069-bbs2-0161" title="MohammadiMR , MostafaviSA , KeshavarzSA , EshraghianMR , HosseinzadehP , Hosseinzadeh‐AttarMJ , et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. Iranian Journal of Psychiatry2012;7(2):87‐92. MostafaviSA , MohammadiMR , HosseinzadehP , EshraghianMR , AkhondzadehS , Hosseinzadeh‐AttarMJ , et al. Dietary intake, growth and development of children with ADHD in a randomized clinical trial of Ritalin and Melatonin co‐administration: through circadian cycle modification or appetite enhancement?. Iranian Journal of Psychiatry2012;7(3):114‐9. [PMC3488866; PUBMED: 23139692] ">Mohammadi 2012a</a>; <a href="./references#CD012069-bbs2-0224" title="VincentJ , VarleyCK , LegerP . Effects of methylphenidate on early adolescent growth. American Journal of Psychiatry1990;147(4):501‐2. [DOI: 10.1176/ajp.147.4.501; PUBMED: 2316739] ">Vincent 1990</a>; <a href="./references#CD012069-bbs2-0235" title="WigunaT , GuerreroAP , WibisonoS , SastroasmoroS . Effect of 12‐week administration of 20‐mg long‐acting methylphenidate on Glu/Cr, NAA/Cr, Cho/Cr, and mI/Cr ratios in the prefrontal cortices of school‐age children in Indonesia: a study using 1H Magnetic Resonance Spectroscopy (MRS). Clinical Neuropharmacology. T. Wiguna, Child and Adolescent Psychiatry Division, Department of Psychiatry, University of Indonesia, Jl. Salemba Raya 4, Jakarta 10430, Indonesia. E‐mail: twiga00@yahoo.com: Lippincott Williams and Wilkins (530 Walnut Street,P O Box 327, Philadelphia PA 19106‐3621, United States), 2012; Vol. 35, issue 2:81‐5. [DOI: 10.1097/WNF.0b013e3182452572; PUBMED: 22318191] ">Wiguna 2012</a>; <a href="./references#CD012069-bbs2-0246" title="YalcinO , IseriE , BukanN , ErcinU . Effects of long acting methylphenidate on ghrelin levels in male children with attention deficit hyperactivity disorder: an open label trial. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(2):146‐57. [DOI: 10.5455/bcp.20130708042604] ">Yalcin 2014</a>). </p> <p>Four studies reported increases in height in cohorts prescribed methylphenidate: <a href="./references#CD012069-bbs2-0124" title="ChungI , HanCH , KimHW , ChoSC . The effect of prolonged‐release methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorders. European Neuropsychopharmacology2010;20(Suppl 3):S624‐5. KimHW , YoonIY , ChoSC , KimBN , ChungS , LeeH , et al. The effect of OROS methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorder. International Clinical Psychopharmacology2010;25(2):107‐15. [DOI: 10.1097/YIC.0b013e3283364411; PUBMED: 20093941] ">Kim 2010</a> (baseline: 128.7 (SD 9.10) cm; follow‐up: 129.4 (SD 9.10) cm), <a href="./references#CD012069-bbs2-0161" title="MohammadiMR , MostafaviSA , KeshavarzSA , EshraghianMR , HosseinzadehP , Hosseinzadeh‐AttarMJ , et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. Iranian Journal of Psychiatry2012;7(2):87‐92. MostafaviSA , MohammadiMR , HosseinzadehP , EshraghianMR , AkhondzadehS , Hosseinzadeh‐AttarMJ , et al. Dietary intake, growth and development of children with ADHD in a randomized clinical trial of Ritalin and Melatonin co‐administration: through circadian cycle modification or appetite enhancement?. Iranian Journal of Psychiatry2012;7(3):114‐9. [PMC3488866; PUBMED: 23139692] ">Mohammadi 2012a</a> (baseline: 133.8 (SD 14.81) cm; follow‐up: 135.9 (SD 15.6) cm), <a href="./references#CD012069-bbs2-0235" title="WigunaT , GuerreroAP , WibisonoS , SastroasmoroS . Effect of 12‐week administration of 20‐mg long‐acting methylphenidate on Glu/Cr, NAA/Cr, Cho/Cr, and mI/Cr ratios in the prefrontal cortices of school‐age children in Indonesia: a study using 1H Magnetic Resonance Spectroscopy (MRS). Clinical Neuropharmacology. T. Wiguna, Child and Adolescent Psychiatry Division, Department of Psychiatry, University of Indonesia, Jl. Salemba Raya 4, Jakarta 10430, Indonesia. E‐mail: twiga00@yahoo.com: Lippincott Williams and Wilkins (530 Walnut Street,P O Box 327, Philadelphia PA 19106‐3621, United States), 2012; Vol. 35, issue 2:81‐5. [DOI: 10.1097/WNF.0b013e3182452572; PUBMED: 22318191] ">Wiguna 2012</a> (MD 0.55 cm, P = 0.06), and <a href="./references#CD012069-bbs2-0246" title="YalcinO , IseriE , BukanN , ErcinU . Effects of long acting methylphenidate on ghrelin levels in male children with attention deficit hyperactivity disorder: an open label trial. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(2):146‐57. [DOI: 10.5455/bcp.20130708042604] ">Yalcin 2014</a> (baseline: 134.6 (SD 12.32) cm; follow‐up: 136.0 (SD 12.5) cm). </p> <p><a href="./references#CD012069-bbs2-0224" title="VincentJ , VarleyCK , LegerP . Effects of methylphenidate on early adolescent growth. American Journal of Psychiatry1990;147(4):501‐2. [DOI: 10.1176/ajp.147.4.501; PUBMED: 2316739] ">Vincent 1990</a> reported no difference in expected (158.7 (SD 10.2) cm) and observed (158.7 (SD 9.80) cm) height. </p> <p><a href="./references#CD012069-bbs2-0114" title="AbikoffH . Tailored psychosocial treatments for ADHD: the search for a good fit. Journal of Clinical Child Psychology2001; Vol. 30, issue 1:122‐5. [DOI: 10.1207/S15374424JCCP3001_14; PUBMED: 11294070] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottG , GreenhillLL , et al. National Institute of Mental Health Collaborative Multimodal Treatment Study of Children with ADHD (the MTA). Design challenges and choices. Archives of General Psychiatry1997;54(9):865‐70. [PUBMED: 9294378] ArnoldLE , AbikoffHB , CantwellDP , ConnersCK , ElliottGR , GreenhillLL , et al. NIMH collaborative multimodal treatment study of children with ADHD (MTA): design, methodology, and protocol evolution. Journal of Attention Disorders1997;2(3):141‐58. [DOI: 10.1177/108705479700200301] ArnoldLE , ChuangS , DaviesM , AbikoffHB , ConnersCK , ElliottGR , et al. Nine months of multicomponent behavioral treatment for ADHD and effectiveness of MTA fading procedures. Journal of Abnormal Child Psychology2004;32(1):39‐51. [PUBMED: 14998110] ArnoldLE , ElliottM , SachsL , BirdH , KraemerHC , WellsKC , et al. Effects of ethnicity on treatment attendance, stimulant response/dose, and 14‐month outcome in ADHD. Journal of Consulting and Clinical Psychology2003;71(4):713‐27. [PUBMED: 12924677] CareyWB . What the multimodal treatment study of children with attention deficit/hyperactivity disorder did and did not say about the use of methylphenidate for attention deficits. Pediatrics2000;105(4):863‐4. [PUBMED: 10742336] ConnersCK , EpsteinJN , MarchJS , AngoldA , WellsKC , KlaricJ , et al. Multimodal treatment of ADHD in the MTA: an alternative outcome analysis. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):159‐67. [DOI: 10.1097/00004583‐200102000‐00010; PUBMED: 11211364] GalanterCA , CarlsonGA , JensenPS , GreenhillLL , DaviesM , LiW , et al. Response to methylphenidate in children with attention deficit hyperactivity disorder and manic symptoms in the multimodal treatment study of children with attention deficit hyperactivity disorder titration trial. Journal of Child and Adolescent Psychopharmacology2003;13(2):123‐36. [DOI: 10.1089/104454603322163844; PUBMED: 12880507] GreeneRW , AblonJS . What does the MTA study tell us about effective psychosocial treatment for ADHD?. Journal of Clinical Child Psychology2001;30(1):114‐21. [DOI: 10.1207/S15374424JCCP3001_13; PUBMED: 11294069] GreenhillLL , AbikoffHB , ArnoldLE , CantwellDP , ConnersCK , ElliottG , et al. Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. Journal of the American Academy of Child and Adolescent Psychiatry1996;35(10):1304‐13. [DOI: 10.1097/00004583‐199610000‐00017; PUBMED: 8885584] GreenhillLL , SwansonJM , VitielloB , DaviesM , ClevengerW , WuM , et al. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):180‐7. [DOI: 10.1097/00004583‐200102000‐00012; PUBMED: 11211366] HansenL , ThomsenPH . How to treat ADHD/DAMP? Is there a conclusive answer? A critical survey of the MTA trial?. Ugeskr Laeger2005;167(48):4555‐9. [PUBMED: 16324436] HinshawSP . Moderators and mediators of treatment response for children with attention‐deficit/hyperactivity disorder: the Multimodal Treatment Study of children with attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1088‐96. [PUBMED: 10591284] HinshawSP , MarchJS , AbikoffH , ArnoldLE , CantwellDP , ConnersCK , et al. Comprehensive assessment of childhood Attention‐Deficit Hyperactivity Disorder in the context of a multisite, multimodal clinical trial. Journal of Attention Disorders1997;1(4):217‐34. [DOI: 10.1177/108705479700100403] JensenPS , ArnoldLE , SwansonJM , VitielloB , AbikoffHB , GreenhillLL , et al. 3‐year follow‐up of the NIMH MTA study. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):989‐1002. [DOI: 10.1097/CHI.0b013e3180686d48; PUBMED: 17667478] JensenPS , HinshawSP , KraemerHC , LeonoraN , NewcornJH , AbikoffHB , et al. ADHD comorbidity findings from the MTA study: comparing comorbid subgroups. Journal of the American Academy of Child and Adolescent Psychiatry2001; Vol. 40, issue 2:147‐58. [DOI: 10.1097/00004583‐200102000‐00009; PUBMED: 11211363] JensenPS , HinshawSP , SwansonJM , GreenhillLL , ConnersCK , ArnoldLE , et al. Findings from the NIMH Multimodal Treatment Study of ADHD (MTA): implications and applications for primary care providers. Journal of Developmental and Behavioral Pediatrics2001;22(1):60‐73. [PUBMED: 11265923] MTA Cooperative Group. A 14‐month randomized clinical trial of treatment strategies for attention‐deficit/hyperactivity disorder. Archives of General Psychiatry1999;56(12):1073‐86. [DOI: 10.1001/archpsyc.56.12.1073; PUBMED: 10591283] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: 24‐month outcomes of treatment strategies for attention‐deficit/hyperactivity disorder. Pediatrics2004;113(4):754‐61. [PUBMED: 15060224] MTA Cooperative Group. National Institute of Mental Health multimodal treatment study of ADHD follow‐up: changes in effectiveness and growth after the end of treatment. Pediatrics2004;113(4):762‐9. [PUBMED: 15060225] MarchJS , SwansonJM , ArnoldLE , HozaB , ConnersCK , HinshawSP , et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). Journal of Abnormal Child Psychology2000;28(6):527‐41. [PUBMED: 11104315] MolinaBS , FloryK , HinshawSP , GreinerAR , ArnoldLE , SwansonJM , et al. Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1028‐40. [DOI: 10.1097/chi.0b013e3180686d96; PUBMED: 17667481] MolinaBS , HinshawSP , EugeneAL , SwansonJM , PelhamWE , HechtmanL , et al. Adolescent substance use in the multimodal treatment study of attention‐deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. Journal of the American Academy of Child and Adolescent Psychiatry2013;52(3):250‐63. [DOI: 10.1016/j.jaac.2012.12.014; PMC3589108; PUBMED: 23452682] MolinaBS , HinshawSP , SwansonJM , ArnoldLE , VitielloB , JensenPS , et al. The MTA at 8 years: prospective follow‐up of children treated for combined‐type ADHD in a multisite study. Journal of the American Academy of Child and Adolescent Psychiatry2009;48(5):484‐500. [DOI: 10.1097/CHI.0b013e31819c23d0; PMC3063150] NiewegEH . Does ADHD medication stop working after 2‐3 years? On the surprising, but little known follow‐up of the MTA study [Is adhd‐medicatie na 2‐3 jaar uitgewerkt? Over de verrassende, maar weinig bekendefollow‐up van het mta‐onderzoek]. Tijdschrift voor Psychiatrie2010;52(4):245‐54. [PUBMED: 20503165] OwensEB , HinshawSP , KraemerHC , ArnoldLE , AbikoffHB , CantwellDP , et al. Which treatment for whom for ADHD? Moderators of treatment response in the MTA. Journal of Consulting and Clinical Psychology2003;71(3):540‐52. [PUBMED: 12795577] PelhamWEJr . The NIMH multimodal treatment study for attention‐deficit hyperactivity disorder: just say yes to drugs alone?. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie1999;44(10):981‐90. [DOI: 10.1177/070674379904401004; PUBMED: 10637677] PelhamWE , GnagyEM , GreinerAR , HozaB , HinshawSP , SwansonJM , et al. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. Journal of Abnormal Child Psychology2000;28(6):507‐25. [PUBMED: 11104314] RichtersJE , ArnoldLE , JensenPS , AbikoffH , ConnersCK , GreenhillLL , et al. NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale. Journal of the American Academy of Child and Adolescent Psychiatry1995;34(8):987‐1000. [DOI: 10.1097/00004583‐199508000‐00008; PUBMED: 7665456] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment Study of children with ADHD (MTA): Part II: supporting details. Journal of Attention Disorders2008;12(1):15‐43. [DOI: 10.1177/1087054708319525; PUBMED: 18573924] SwansonJM , ArnoldLE , KraemerH , HechtmanL , MolinaB , HinshawSP , et al. Evidence, interpretation, and qualification from multiple reports of long‐term outcomes in the Multimodal Treatment study of Children With ADHD (MTA): part I: executive summary. Journal of Attention Disorders2008;12(1):4‐14. [DOI: 10.1177/1087054708319345; PUBMED: 18573923] SwansonJM , ElliottGR , GreenhillLL , WigalT , ArnoldLE , VitielloB , et al. Effects of stimulant medication on growth rates across 3 years in the MTA follow‐up. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1015‐27. [DOI: 10.1097/chi.0b013e3180686d7e; PUBMED: 17667480] SwansonJM , HinshawSP , ArnoldLE , GibbonsRD , MarcusS , HurK , et al. Secondary evaluations of MTA 36‐month outcomes: propensity score and growth mixture model analyses. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):1003‐14. [DOI: 10.1097/CHI.0b013e3180686d63; PUBMED: 17667479] SwansonJM , KraemerHC , HinshawSP , ArnoldLE , ConnersCK , AbikoffHB , et al. Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):168‐79. [DOI: 10.1097/00004583‐200102000‐00011; PUBMED: 1121136] VitielloB , ElliottGR , SwansonJM , ArnoldLE , HechtmanL , AbikoffH , et al. Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD. American Journal of Psychiatry2012; Vol. 169, issue 2:167‐77. [DOI: 10.1176/appi.ajp.2011.10111705; PMC4132884; PUBMED: 21890793] VitielloB , SevereJB , GreenhillLL , ArnoldLE , AbikoffHB , BuksteinOG , et al. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(2):188‐96. [DOI: 10.1097/00004583‐200102000‐00013; PUBMED: 11211367] ">Jensen 1999 (MTA)</a> reported no difference after 14 months in those who received methylphenidate (mean change: 5.88 (SD 1.80), n = 222), and those who did not (mean change: 6.93 (SD 2.21), n = 106), nor at 24 months (methylphenidate: mean 4.53 (SD 1.61), n = 106; no methylphenidate: mean 5.40 (SD 2.18)). </p> </section> <section id="CD012069-sec-0156"> <p><b>Weight</b></p> <p>Eight studies provided data on this outcome (<a href="./references#CD012069-bbs2-0050" title="BabakiME , AshtianiRD , RazjooyanK , AminiH . Comparing the effects of buspirone and methylphenidate in children with attention deficit hyperactivity disorder. Iranian Journal of Psychiatry and Clinical Psychology2009; Vol. 15, issue 3:223‐30. Davari‐AshtianiR , ShahrbabakiME , RazjouyanK , AminiH , MazhabdarH . Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double‐blind and randomized trial. Child Psychiatry and Human Development2010;41(6):641‐8. [DOI: 10.1007/s10578‐010‐0193‐2; PUBMED: 20517641] ShahrbabakiME , SabzevariL , HaghdoostA , Davari‐AshtianiR . Buspiron versus methylphenidate in the treatment of children with ADHD. Brain, Mind and Development. 20th World IACAPAP (International Association for Child and Adolescent Psychiatry and Allied Professions) Congress; July 21‐25 2012; Paris (France). 2012; Vol. 60:Suppl 1. ">Davari‐Ashtiani 2010</a>; <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a>; <a href="./references#CD012069-bbs2-0124" title="ChungI , HanCH , KimHW , ChoSC . The effect of prolonged‐release methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorders. European Neuropsychopharmacology2010;20(Suppl 3):S624‐5. KimHW , YoonIY , ChoSC , KimBN , ChungS , LeeH , et al. The effect of OROS methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorder. International Clinical Psychopharmacology2010;25(2):107‐15. [DOI: 10.1097/YIC.0b013e3283364411; PUBMED: 20093941] ">Kim 2010</a>; <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a>; <a href="./references#CD012069-bbs2-0161" title="MohammadiMR , MostafaviSA , KeshavarzSA , EshraghianMR , HosseinzadehP , Hosseinzadeh‐AttarMJ , et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. Iranian Journal of Psychiatry2012;7(2):87‐92. MostafaviSA , MohammadiMR , HosseinzadehP , EshraghianMR , AkhondzadehS , Hosseinzadeh‐AttarMJ , et al. Dietary intake, growth and development of children with ADHD in a randomized clinical trial of Ritalin and Melatonin co‐administration: through circadian cycle modification or appetite enhancement?. Iranian Journal of Psychiatry2012;7(3):114‐9. [PMC3488866; PUBMED: 23139692] ">Mohammadi 2012a</a>; <a href="./references#CD012069-bbs2-0224" title="VincentJ , VarleyCK , LegerP . Effects of methylphenidate on early adolescent growth. American Journal of Psychiatry1990;147(4):501‐2. [DOI: 10.1176/ajp.147.4.501; PUBMED: 2316739] ">Vincent 1990</a>; <a href="./references#CD012069-bbs2-0235" title="WigunaT , GuerreroAP , WibisonoS , SastroasmoroS . Effect of 12‐week administration of 20‐mg long‐acting methylphenidate on Glu/Cr, NAA/Cr, Cho/Cr, and mI/Cr ratios in the prefrontal cortices of school‐age children in Indonesia: a study using 1H Magnetic Resonance Spectroscopy (MRS). Clinical Neuropharmacology. T. Wiguna, Child and Adolescent Psychiatry Division, Department of Psychiatry, University of Indonesia, Jl. Salemba Raya 4, Jakarta 10430, Indonesia. E‐mail: twiga00@yahoo.com: Lippincott Williams and Wilkins (530 Walnut Street,P O Box 327, Philadelphia PA 19106‐3621, United States), 2012; Vol. 35, issue 2:81‐5. [DOI: 10.1097/WNF.0b013e3182452572; PUBMED: 22318191] ">Wiguna 2012</a>; <a href="./references#CD012069-bbs2-0246" title="YalcinO , IseriE , BukanN , ErcinU . Effects of long acting methylphenidate on ghrelin levels in male children with attention deficit hyperactivity disorder: an open label trial. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(2):146‐57. [DOI: 10.5455/bcp.20130708042604] ">Yalcin 2014</a>). </p> <p>Three studies reported an increase in weight in participants receiving methylphenidate. <a href="./references#CD012069-bbs2-0246" title="YalcinO , IseriE , BukanN , ErcinU . Effects of long acting methylphenidate on ghrelin levels in male children with attention deficit hyperactivity disorder: an open label trial. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(2):146‐57. [DOI: 10.5455/bcp.20130708042604] ">Yalcin 2014</a> reported weight gain in 15/33 participants while <a href="./references#CD012069-bbs2-0050" title="BabakiME , AshtianiRD , RazjooyanK , AminiH . Comparing the effects of buspirone and methylphenidate in children with attention deficit hyperactivity disorder. Iranian Journal of Psychiatry and Clinical Psychology2009; Vol. 15, issue 3:223‐30. Davari‐AshtianiR , ShahrbabakiME , RazjouyanK , AminiH , MazhabdarH . Buspirone versus methylphenidate in the treatment of attention deficit hyperactivity disorder: a double‐blind and randomized trial. Child Psychiatry and Human Development2010;41(6):641‐8. [DOI: 10.1007/s10578‐010‐0193‐2; PUBMED: 20517641] ShahrbabakiME , SabzevariL , HaghdoostA , Davari‐AshtianiR . Buspiron versus methylphenidate in the treatment of children with ADHD. Brain, Mind and Development. 20th World IACAPAP (International Association for Child and Adolescent Psychiatry and Allied Professions) Congress; July 21‐25 2012; Paris (France). 2012; Vol. 60:Suppl 1. ">Davari‐Ashtiani 2010</a> reported weight gain in 1/16. <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a> reported an increase in weight from 38.4 kg (SD 11.3) at baseline to 46.8 kg (SD 13.4) at 24 months. </p> <p>Five studies reported no apparent increase or decrease in weight: <a href="./references#CD012069-bbs2-0224" title="VincentJ , VarleyCK , LegerP . Effects of methylphenidate on early adolescent growth. American Journal of Psychiatry1990;147(4):501‐2. [DOI: 10.1176/ajp.147.4.501; PUBMED: 2316739] ">Vincent 1990</a> (observed weight = 47.90 (SD 10.30) kg; expected weight = 48.1 (SD 10.6) kg); <a href="./references#CD012069-bbs2-0124" title="ChungI , HanCH , KimHW , ChoSC . The effect of prolonged‐release methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorders. European Neuropsychopharmacology2010;20(Suppl 3):S624‐5. KimHW , YoonIY , ChoSC , KimBN , ChungS , LeeH , et al. The effect of OROS methylphenidate on the sleep of children with attention‐deficit/hyperactivity disorder. International Clinical Psychopharmacology2010;25(2):107‐15. [DOI: 10.1097/YIC.0b013e3283364411; PUBMED: 20093941] ">Kim 2010</a> (baseline: 28.5 (SD 6.40) kg; follow‐up: 27.6 (SD 5.90) kg, n = 285); <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a> (baseline: 40.7 (SD 17.2) kg; follow‐up: 40.6 (SD 18.1) kg, P = 0.20); <a href="./references#CD012069-bbs2-0161" title="MohammadiMR , MostafaviSA , KeshavarzSA , EshraghianMR , HosseinzadehP , Hosseinzadeh‐AttarMJ , et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. Iranian Journal of Psychiatry2012;7(2):87‐92. MostafaviSA , MohammadiMR , HosseinzadehP , EshraghianMR , AkhondzadehS , Hosseinzadeh‐AttarMJ , et al. Dietary intake, growth and development of children with ADHD in a randomized clinical trial of Ritalin and Melatonin co‐administration: through circadian cycle modification or appetite enhancement?. Iranian Journal of Psychiatry2012;7(3):114‐9. [PMC3488866; PUBMED: 23139692] ">Mohammadi 2012a</a> (baseline: 32.7 (SD 14.7) kg; follow‐up: 33.6 (SD 17.1) kg); and <a href="./references#CD012069-bbs2-0235" title="WigunaT , GuerreroAP , WibisonoS , SastroasmoroS . Effect of 12‐week administration of 20‐mg long‐acting methylphenidate on Glu/Cr, NAA/Cr, Cho/Cr, and mI/Cr ratios in the prefrontal cortices of school‐age children in Indonesia: a study using 1H Magnetic Resonance Spectroscopy (MRS). Clinical Neuropharmacology. T. Wiguna, Child and Adolescent Psychiatry Division, Department of Psychiatry, University of Indonesia, Jl. Salemba Raya 4, Jakarta 10430, Indonesia. E‐mail: twiga00@yahoo.com: Lippincott Williams and Wilkins (530 Walnut Street,P O Box 327, Philadelphia PA 19106‐3621, United States), 2012; Vol. 35, issue 2:81‐5. [DOI: 10.1097/WNF.0b013e3182452572; PUBMED: 22318191] ">Wiguna 2012</a> (baseline: 36.20 (SD 11.9) kg; follow‐up: 35.79 (SD 12.0) kg, P = 0.51). </p> </section> <section id="CD012069-sec-0157"> <p><b>BMI</b></p> <p>Three studies provided data on this outcome (<a href="./references#CD012069-bbs2-0078" title="GerweM , StollhoffK , MossakowskiJ , KuehleHJ , GoertzU , SchaeferC , et al. Tolerability and effects of OROS® MPH (Concerta®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non‐interventional trial. Attention Deficit and Hyperactivity Disorders2009;1(2):175‐86. [DOI: 10.1007/s12402‐009‐0010‐6; PUBMED: 21432582] ">Gerwe 2009</a>; <a href="./references#CD012069-bbs2-0161" title="MohammadiMR , MostafaviSA , KeshavarzSA , EshraghianMR , HosseinzadehP , Hosseinzadeh‐AttarMJ , et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. Iranian Journal of Psychiatry2012;7(2):87‐92. MostafaviSA , MohammadiMR , HosseinzadehP , EshraghianMR , AkhondzadehS , Hosseinzadeh‐AttarMJ , et al. Dietary intake, growth and development of children with ADHD in a randomized clinical trial of Ritalin and Melatonin co‐administration: through circadian cycle modification or appetite enhancement?. Iranian Journal of Psychiatry2012;7(3):114‐9. [PMC3488866; PUBMED: 23139692] ">Mohammadi 2012a</a>; <a href="./references#CD012069-bbs2-0246" title="YalcinO , IseriE , BukanN , ErcinU . Effects of long acting methylphenidate on ghrelin levels in male children with attention deficit hyperactivity disorder: an open label trial. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(2):146‐57. [DOI: 10.5455/bcp.20130708042604] ">Yalcin 2014</a>). </p> <p>There was no apparent change from baseline BMI in all three studies: <a href="./references#CD012069-bbs2-0078" title="GerweM , StollhoffK , MossakowskiJ , KuehleHJ , GoertzU , SchaeferC , et al. Tolerability and effects of OROS® MPH (Concerta®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non‐interventional trial. Attention Deficit and Hyperactivity Disorders2009;1(2):175‐86. [DOI: 10.1007/s12402‐009‐0010‐6; PUBMED: 21432582] ">Gerwe 2009</a> (mean change from baseline: −0.30 (SD 0.70) kg/m<sup>2</sup>); <a href="./references#CD012069-bbs2-0161" title="MohammadiMR , MostafaviSA , KeshavarzSA , EshraghianMR , HosseinzadehP , Hosseinzadeh‐AttarMJ , et al. Melatonin effects in methylphenidate treated children with attention deficit hyperactivity disorder: a randomized double blind clinical trial. Iranian Journal of Psychiatry2012;7(2):87‐92. MostafaviSA , MohammadiMR , HosseinzadehP , EshraghianMR , AkhondzadehS , Hosseinzadeh‐AttarMJ , et al. Dietary intake, growth and development of children with ADHD in a randomized clinical trial of Ritalin and Melatonin co‐administration: through circadian cycle modification or appetite enhancement?. Iranian Journal of Psychiatry2012;7(3):114‐9. [PMC3488866; PUBMED: 23139692] ">Mohammadi 2012a</a> (baseline: 18.2 (SD 4.74) kg/m<sup>2</sup>; follow‐up: 18.4 (SD 4.85) kg/m<sup>2</sup>), or <a href="./references#CD012069-bbs2-0246" title="YalcinO , IseriE , BukanN , ErcinU . Effects of long acting methylphenidate on ghrelin levels in male children with attention deficit hyperactivity disorder: an open label trial. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(2):146‐57. [DOI: 10.5455/bcp.20130708042604] ">Yalcin 2014</a> (baseline: 18.1 (SD 2.76) kg/m<sup>2</sup>; follow‐up: 17.8 (SD 2.71) kg/m<sup>2</sup>). </p> </section> <section id="CD012069-sec-0158"> <p><b>Z scores</b></p> <p> <ul id="CD012069-list-0045"> <li> <p>Height</p> </li> </ul> </p> <p>Seven studies reported that age‐ and sex‐adjusted scores were lower after follow‐up: mean 11.2 months in <a href="./references#CD012069-bbs2-0165" title="MoungnoiP , MaipangP . Long‐term effects of short‐acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health. Journal of the Medical Association of Thailand2011;94(Suppl 3):S158‐63. [PUBMED: 22043770] ">Moungnoi 2011</a> (baseline: z score = 0.09; one year: z score = 0.05, n = 83); after 14 months in <a href="./references#CD012069-bbs2-0026" title="BereketA , TuranS , KaramanMG , HaklarG , OzbayF , YazganMY . Height, weight, IGF‐I, IGFBP‐3 and thyroid functions in prepubertal children with attention deficit hyperactivity disorder: effect of methylphenidate treatment. Hormone Research2005;63(4):159‐64. [DOI: 10.1159/000084683; PUBMED: 15795512] ">Bereket 2005</a> (z score = −0.31 (SD 1.02)); after 18 months in <a href="./references#CD012069-bbs2-0178" title="PoultonA , CowellCT . Slowing of growth in height and weight on stimulants: a characteristic pattern. Journal of Paediatrics and Child Health2003;39(3):180‐5. [PUBMED: 12654140] ">Poulton 2003</a> (baseline: z score = 0.26 (SD 0.82), n = 19; 18 months: z score = −0.50 (SD 0.77), n = 13); 24 months in <a href="./references#CD012069-bbs2-0077" title="ArcieriR , GerminarioEP , BonatiM , MasiG , ZuddasA , VellaS , et al. Cardiovascular measures in children and adolescents with attention‐deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine. Journal of Child and Adolescent Psychopharmacology2012;22(6):423‐31. [PUBMED: 23362511] BaliaC , AneddaA , GranitzioF , CarucciS , ZuddasA . Long term therapy with methylphenidate induces modest effects on growth in ADHD children. European Neuropsychopharmacology2013;23(Suppl 1):S80. [DOI: 10.1016/S0924‐977X(13)70090‐7] DidoniA , SequiM , PaneiP , BonatiM , Lombardy ADHD Registry Group. One‐year prospective follow‐up of pharmacological treatment in children with attention‐deficit/hyperactivity disorder. European Journal of Clinical Pharmacology2011;67(10):1061‐7. [DOI: 10.1007/s00228‐011‐1050‐3; PUBMED: 21538145] GerminarioEP , ArcieriR , BonatiM , ZuddasA , MasiG , VellaS , et al. Attention‐deficit/hyperactivity disorder drugs and growth: an Italian prospective observational study. Journal of Child and Adolescent Psychopharmacology2013;23(7):440‐7. [DOI: 10.1089/cap.2012.0086; PMC3778954] PaneiP , ArcieriR . ADHD register: post‐marketing evaluation of the benefit‐risk profile of drugs and promotion of the appropriateness [Il registro dell'ADHD: valutazione post‐marketing del profilo beneficio‐rischio dei farmaci e promozione dell'appropriatezza]. Recenti Progressi in Medicina2013;104(6):254‐61. [DOI: 10.1701/1295.14326; PUBMED: 23801229] PaneiP , ArcieriR , BonatiM , BugariniM , DidoniA , GerminarioE . Safety of psychotropic drug prescribed for attention‐deficit/hyperactivity disorder in Italy. Adverse Drug Reaction Bulletin2010;260:999‐1002. [old.iss.it/binary/uvco/cont/Safety_of_psychotropic_drug_prescribed_for_1.pdf] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] PeddisC , EsuL , TronciMG , CarucciS , PaneiP , ZuddasA . The Italian ADHD National Registry: 3 years of active pharmacovigilance in developmental neuropsychiatry. European Child and Adolescent Psychiatry2011;20(Suppl 1):S125. [DOI: 10.1007/s00787‐011‐0181‐5] PeddisC , SannaE , UsalaT , ArcieriR , GerminarioE , BugariniM , et al. Active pharmacovigilance in developmental neuropsychiatry: the Italian ADHD National Registry. European Child and Adolescent Psychiatry2010;19(Suppl 1):S27. [DOI: 10.1007/s00787‐010‐0117‐5] RuggieroS , RafanielloC , BravaccioC , GrimaldiG , GranatoR , PascottoA , et al. Safety of attention‐deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study. Journal of Child and Adolescent Psychopharmacology2012;22(6):415‐22. [DOI: 10.1089/cap.2012.0003; PUBMED: 23234585] ">Germinario 2013</a> (baseline: z score = 0.36 (SD 1.21); 24 months: z score = 0.18 (SD 1.12)); 36 months in <a href="./references#CD012069-bbs2-0179" title="PoultonA , BriodyJ , McCorquodaleT , MelzerE , HerrmannM , BaurLA , et al. Weight loss on stimulant medication: how does it affect body composition and bone metabolism? ‐ A prospective longitudinal study. International Journal of Pediatric Endocrinology2012;2012(1):30. [DOI: 10.1186/1687‐9856‐2012‐30; PMC3549744; PUBMED: 23216890] PoultonA , EvansR , MelzerE , BuiQ . Stimulant medication affects growth but not bone age. Archives of Disease in Childhood2014;99(Suppl 1):A4.A5. [DOI: 10.1136/archdischild‐2014‐306237.10] PoultonA , NananR . Differential effects of dexamphetamine and methylphenidate on symptoms of inattention‐overactivity, oppositional‐defiant and weight. Archives of Disease in Childhood2014;99(Suppl 1):A70. [DOI: 10.1136/archdischild‐2014‐306237.167] ">Poulton 2012</a> (baseline: z score = 0.34 (SD 0.81), n = 21; 36 months: z score = −0.13 (SD 0.76), n = 17). The difference in z score between baseline and follow‐up was also lower in <a href="./references#CD012069-bbs2-0202" title="SpencerT , BiedermanJ , WrightV , DanonM . Growth deficits in children treated with desipramine: a controlled study. Journal of the American Academy of Child &amp; Adolescent Psychiatry1992;31(2):235‐43. [DOI: 10.1097/00004583‐199203000‐00009; PUBMED: 1564024] ">Spencer 1992</a> (z score difference = −0.23, SD 0.42) and marginally lower in <a href="./references#CD012069-bbs2-0191" title="SchertzM , AdesmanAR , AlfieriNE , BienkowskiRS . Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication. Pediatrics1996;98(4 Pt 1):763‐9. [PUBMED: 8885958] ">Schertz 1996</a> (z score difference = −0.1). </p> <p> <ul id="CD012069-list-0046"> <li> <p>Weight</p> </li> </ul> </p> <p>Five studies reported decreases in weight from baseline: −0.26 kg (SD 1.40) in <a href="./references#CD012069-bbs2-0078" title="GerweM , StollhoffK , MossakowskiJ , KuehleHJ , GoertzU , SchaeferC , et al. Tolerability and effects of OROS® MPH (Concerta®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non‐interventional trial. Attention Deficit and Hyperactivity Disorders2009;1(2):175‐86. [DOI: 10.1007/s12402‐009‐0010‐6; PUBMED: 21432582] ">Gerwe 2009</a>; 0.04 z score at 14 months in <a href="./references#CD012069-bbs2-0026" title="BereketA , TuranS , KaramanMG , HaklarG , OzbayF , YazganMY . Height, weight, IGF‐I, IGFBP‐3 and thyroid functions in prepubertal children with attention deficit hyperactivity disorder: effect of methylphenidate treatment. Hormone Research2005;63(4):159‐64. [DOI: 10.1159/000084683; PUBMED: 15795512] ">Bereket 2005</a>; 0.4 z score decrease at follow‐up (mean follow‐up 11.2 months) in <a href="./references#CD012069-bbs2-0191" title="SchertzM , AdesmanAR , AlfieriNE , BienkowskiRS . Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication. Pediatrics1996;98(4 Pt 1):763‐9. [PUBMED: 8885958] ">Schertz 1996</a>; a mean weight‐for‐age z score of 0.01 at baseline to −0.06 at one‐year follow‐up in <a href="./references#CD012069-bbs2-0165" title="MoungnoiP , MaipangP . Long‐term effects of short‐acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health. Journal of the Medical Association of Thailand2011;94(Suppl 3):S158‐63. [PUBMED: 22043770] ">Moungnoi 2011</a> (n = 83); from a z score of 0.44 (SD 0.97; n = 19) at baseline, to −0.15 (SD 0.98; n = 16) at 18 months, and a mean difference of −0.23 (SD 0.96; n = 17) at 36 months in <a href="./references#CD012069-bbs2-0178" title="PoultonA , CowellCT . Slowing of growth in height and weight on stimulants: a characteristic pattern. Journal of Paediatrics and Child Health2003;39(3):180‐5. [PUBMED: 12654140] ">Poulton 2003</a>. </p> <p> <ul id="CD012069-list-0047"> <li> <p>BMI</p> </li> </ul> </p> <p>In three studies, there was no difference in the BMI of participants receiving methylphenidate over 14 months (<a href="./references#CD012069-bbs2-0026" title="BereketA , TuranS , KaramanMG , HaklarG , OzbayF , YazganMY . Height, weight, IGF‐I, IGFBP‐3 and thyroid functions in prepubertal children with attention deficit hyperactivity disorder: effect of methylphenidate treatment. Hormone Research2005;63(4):159‐64. [DOI: 10.1159/000084683; PUBMED: 15795512] ">Bereket 2005</a>: z scores = 0.706 (SD = 0.65)); after 24 to 36 months (<a href="./references#CD012069-bbs2-0179" title="PoultonA , BriodyJ , McCorquodaleT , MelzerE , HerrmannM , BaurLA , et al. Weight loss on stimulant medication: how does it affect body composition and bone metabolism? ‐ A prospective longitudinal study. International Journal of Pediatric Endocrinology2012;2012(1):30. [DOI: 10.1186/1687‐9856‐2012‐30; PMC3549744; PUBMED: 23216890] PoultonA , EvansR , MelzerE , BuiQ . Stimulant medication affects growth but not bone age. Archives of Disease in Childhood2014;99(Suppl 1):A4.A5. [DOI: 10.1136/archdischild‐2014‐306237.10] PoultonA , NananR . Differential effects of dexamphetamine and methylphenidate on symptoms of inattention‐overactivity, oppositional‐defiant and weight. Archives of Disease in Childhood2014;99(Suppl 1):A70. [DOI: 10.1136/archdischild‐2014‐306237.167] ">Poulton 2012</a>: z score = 0.12 (SD = 0.43); N = 24), and over 48 months (<a href="./references#CD012069-bbs2-0060" title="Durá‐TravéT , Yoldi‐PetriME , Gallinas‐VictorianoF , Zardoya‐SantosP . Effects of osmotic‐release methylphenidate on height and weight in children with attention‐deficit hyperactivity disorder (ADHD) following up to four years of treatment. Journal of Child Neurology2012; Vol. 27, issue 5:604‐9. [DOI: 10.1177/0883073811422752; PUBMED: 22190507] Durá‐TravéT , Yoldi‐PetriME , Zardoya‐SantosP . Nutrition and attention deficit hyperactivity disorder: developmental follow‐up of the anthropometric variables of a group of patients receiving treatment with osmotic controlled‐release methylphenidate [Nutrición y trastorno por déficit de atención/hiperactividad: seguimiento evolutivo de las variables antropométricas de un grupo de pacientes en tratamiento con metilfenidato de liberación osmótica]. Revista de Neurologia2011;53(5):257‐64. [PUBMED: 21796603] ">Durá‐Travé 2012</a>: z score = −0.20 (SD = 0.99); N = 160). </p> </section> <section id="CD012069-sec-0159"> <p><b>Other specific adverse events</b></p> <p>Two studies reported on the proportion of participants on methylphenidate with different musculoskeletal adverse events (<a href="./references#CD012069-bbs2-0013" title="ArdicUA , ErcanES , ErcanE , YuceD , BasayBK . Osmotic release oral system methylphenidate is more effective than immediate release methylphenidate: a retrospective chart review in Turkish children with attention deficit hyperactivity disorder. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(4):342‐9. [DOI: 10.5455/bcp.20141009112739] ErcanES , Akyol‐ArdicU , ErcanE , YuceD , Kabukcu‐BasayB . OROS‐MPH is more effective than IR‐MPH in Turkish children: a retrospective chart review. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(1):306‐7. [DOI: 10.5455/bcp.20141009112739] ">Ardic 2014</a>; <a href="./references#CD012069-bbs2-0134" title="LahatE , WeissM , Ben‐ShlomoA , EvansS , BistritzerT . Bone mineral density and turnover in children with attention‐deficit hyperactivity disorder receiving methylphenidate. Journal of Child Neurology2000;15(7):436‐9. [DOI: 10.1177/088307380001500702; PUBMED: 10921512] ">Lahat 2000</a>). </p> <p> <ol id="CD012069-list-0048"> <li> <p>In <a href="./references#CD012069-bbs2-0013" title="ArdicUA , ErcanES , ErcanE , YuceD , BasayBK . Osmotic release oral system methylphenidate is more effective than immediate release methylphenidate: a retrospective chart review in Turkish children with attention deficit hyperactivity disorder. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(4):342‐9. [DOI: 10.5455/bcp.20141009112739] ErcanES , Akyol‐ArdicU , ErcanE , YuceD , Kabukcu‐BasayB . OROS‐MPH is more effective than IR‐MPH in Turkish children: a retrospective chart review. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(1):306‐7. [DOI: 10.5455/bcp.20141009112739] ">Ardic 2014</a> (122 participants), the proportion of participants on methylphenidate with increased mobility was 18.03% (95% CI 12% to 25%). </p> </li> <li> <p><a href="./references#CD012069-bbs2-0134" title="LahatE , WeissM , Ben‐ShlomoA , EvansS , BistritzerT . Bone mineral density and turnover in children with attention‐deficit hyperactivity disorder receiving methylphenidate. Journal of Child Neurology2000;15(7):436‐9. [DOI: 10.1177/088307380001500702; PUBMED: 10921512] ">Lahat 2000</a> (18 participants) reported on bone mineral density as follows: "...no significant difference between serum calcium, phosphorus or bone‐specific alkaline phosphatase, urinary deoxypyridinoline, or bone mineral density in the two groups of children. No child deviated from his height percentile during the treatment period." </p> </li> </ol> </p> </section> </section> <section id="CD012069-sec-0160"> <h6 class="title">2.2.6 Immune system</h6> <p>See <a href="./references#CD012069-fig-0034" title="">Analysis 7.6</a>. Fourteen studies reported data on this outcome. </p> <p>We conducted eight meta‐analyses using data from 13 studies (<a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0016" title="ArnoldLE , BozzoloDR , HodgkinsP , McKayM , Beckett‐ThurmanL , GreenbaumM , et al. Switching from oral extended‐release methylphenidate to the methylphenidate transdermal system: continued attention‐deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Current Medical Research and Opinion2010;26(1):129‐37. [DOI: 10.1185/03007990903437412; PMC3875401; PUBMED: 19916704] BuksteinOG , ArnoldLE , LandgrafJM , HodgkinsP . Does switching from oral extended‐release methylphenidate to the methylphenidate transdermal system affect health‐related quality‐of‐life and medication satisfaction for children with attention‐deficit/hyperactivity disorder?. Child and Adolescent Psychiatry and Mental Health2009;3(1):39. [DOI: 10.1186/1753‐2000‐3‐39; PMC2796990; PUBMED: 20003260] ">Arnold 2010</a>; <a href="./references#CD012069-bbs2-0056" title="DöpfnerM , OseC , FischerR , AmmerR , ScheragA . Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention‐deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet® retard and Concerta® ‐ a randomized, controlled, double‐blind multicenter clinical crossover trial. Journal of Child &amp; Adolescent Psychopharmacology2011;21(5):445‐54. [DOI: 10.1089/cap.2010.0082; PMC3205792; PUBMED: 21790298] DöpfnerM , OseC , FischerR , AmmerR , ScheragA . The CoMeCo‐trial: comparison of the efficacy of two methylphenidate preparations for children and adolescents with ADHD in a natural setting. European Child and Adolescent Psychiatry.14th International Congress of ESCAP European Society for Child and Adolescent Psychiatry (ESCAP); June 11‐15, 2011; Helsinki (Finland)2011;20:S116. ">Döpfner 2011b</a>; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0074" title="GargJ , ArunP , ChavanBS . Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. International Journal of Applied and Basic Medical Research2015;5(2):114‐8. [DOI: 10.4103/2229‐516X.157162; PMC4456885] GargJ , ArunP , ChavanBS . Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder. Indian Pediatrics2014;51(7):550‐4. [PUBMED: 25031133] ">Garg 2014</a>; <a href="./references#CD012069-bbs2-0100" title="Effects of high‐dose OROS methylphenidate. Brown University Child and Adolescent Psychopharmacology Update2009;11(8):7‐8. [DOI: 10.1002/cpu.20097] DanielsSR . Cardiovascular effects of methylphenidate. Journal of Pediatrics2009;155(1):A3. [DOI: 10.1016/j.jpeds.2009.05.023] HammernessP , GeorgiopoulosA , DoyleRL , UtzingerL , SchillingerM , MartelonM , et al. An open study of adjunct OROS‐methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. Journal of Child and Adolescent Psychopharmacology2009;19(5):493‐9. [DOI: 10.1089/cap.2008.0126; PMC2861956; PUBMED: 19877973] ">Hammerness 2009</a>; <a href="./references#CD012069-bbs2-0131" title="KordonA , StollhoffK , NiederkirchnerK , MattejatF , RettigK , SchäubleB . Exploring the impact of once‐daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate‐release MPH. Postgraduate Medicine2011;123(5):27‐38. [DOI: 10.3810/pgm.2011.09.2457; PUBMED: 21904084] ">Kordon 2011</a>; <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a>; <a href="./references#CD012069-bbs2-0139" title="LeeSI , HongSD , KimS . Efficacy and tolerability of OROS methylphenidate in Korean children with AD/HD ‐ Reply. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2007; Vol. 31, issue 5:1151‐2. [DOI: 10.1016/j.pnpbp.2007.03.019] LeeSI , HongSD , KimSY , KimEJ , KimJH , KimJH , et al. Efficacy and tolerability of OROS methylphenidate in Korean children with attention‐deficit/hyperactivity disorder. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2007;31(1):210‐6. [DOI: 10.1016/j.pnpbp.2006.09.002; PUBMED: 17046131] PaeCU . Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention‐deficit/hyperactivity disorder. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2007;31(5):1151‐2. [DOI: 10.1016/j.pnpbp.2007.03.018] ">Lee 2007</a>; <a href="./references#CD012069-bbs2-0175" title="PierceD , KaticA , BuckwalterM , WebsterK . Single‐ and multiple‐dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic‐release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. Journal of Clinical Psychopharmacology2010;30(5):554‐64. [DOI: 10.1097/JCP.0b013e3181f0c2f6; PUBMED: 20814325] ">Pierce 2010</a>; <a href="./references#CD012069-bbs2-0189" title="RostainAL . Sleep disturbances and ADHD medications. Current Psychiatry Reports2007;9(5):399‐400. [PUBMED: 17915079] SangalRB , OwensJ , AllenAJ , SuttonV , SchuhK , KelseyD . Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep2006;29(12):1573‐85. [PUBMED: 17252888] ">Sangal 2006</a>; <a href="./references#CD012069-bbs2-0203" title="HechtmanL . Effects of treatment on the overall functioning of children with ADHD. Journal of the Canadian Academy of Child and Adolescent Psychiatry2009;14(Suppl 1):10‐5. [PMC2547092] SteeleM , RiccardelliR , BinderC . The effectiveness of OROS® methylphenidate (Concerta®) vs. usual treatment with immediate‐release methylphenidate (IR MPH) in children aged 6‐12 years with attention deficit hyperactivity disorder (ADHD). International Journal of Neuropsychopharmacology2004;7(Suppl 2):S442. [DOI: 10.1017/S1461145704004547] SteeleM , WeissM , SwansonJ , WangJ , PrinzoRS , BinderCE . A randomized, controlled effectiveness trial of OROS‐methylphenidate compared to usual care with immediate‐release methylphenidate in ADHD. Canadian Journal of Clinical Pharmacology2006;13(1):e50‐62. [PUBMED: 16456216] SteeleMM , PrinzoR , BinderC . Effectiveness of Concerta versus twice or thrice daily IR‐MPH in children with ADHD. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta (GA). 2005. SteeleMM , PrinzoR , BinderC . Long‐term effectiveness and safety of Concerta in children with ADHD: a six‐month study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta (GA). 2005. ">Steele 2006</a>; <a href="./references#CD012069-bbs2-0227" title="WangY , ZhengY , DuY , SongDH , ShinYJ , ChoSC , et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double‐blind comparison trial. Australian and New Zealand Journal of Psychiatry2007;41(3):222‐30. [DOI: 10.1080/00048670601057767; PUBMED: 17464703] ">Wang 2007</a>). We found the proportion of participants on methylphenidate with: </p> <p> <ol id="CD012069-list-0049"> <li> <p>nasopharyngitis to be 8.50% (95% CI 3.50% to 19.4%; 5 studies, 521 participants; <a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0016" title="ArnoldLE , BozzoloDR , HodgkinsP , McKayM , Beckett‐ThurmanL , GreenbaumM , et al. Switching from oral extended‐release methylphenidate to the methylphenidate transdermal system: continued attention‐deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Current Medical Research and Opinion2010;26(1):129‐37. [DOI: 10.1185/03007990903437412; PMC3875401; PUBMED: 19916704] BuksteinOG , ArnoldLE , LandgrafJM , HodgkinsP . Does switching from oral extended‐release methylphenidate to the methylphenidate transdermal system affect health‐related quality‐of‐life and medication satisfaction for children with attention‐deficit/hyperactivity disorder?. Child and Adolescent Psychiatry and Mental Health2009;3(1):39. [DOI: 10.1186/1753‐2000‐3‐39; PMC2796990; PUBMED: 20003260] ">Arnold 2010</a>; <a href="./references#CD012069-bbs2-0056" title="DöpfnerM , OseC , FischerR , AmmerR , ScheragA . Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention‐deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet® retard and Concerta® ‐ a randomized, controlled, double‐blind multicenter clinical crossover trial. Journal of Child &amp; Adolescent Psychopharmacology2011;21(5):445‐54. [DOI: 10.1089/cap.2010.0082; PMC3205792; PUBMED: 21790298] DöpfnerM , OseC , FischerR , AmmerR , ScheragA . The CoMeCo‐trial: comparison of the efficacy of two methylphenidate preparations for children and adolescents with ADHD in a natural setting. European Child and Adolescent Psychiatry.14th International Congress of ESCAP European Society for Child and Adolescent Psychiatry (ESCAP); June 11‐15, 2011; Helsinki (Finland)2011;20:S116. ">Döpfner 2011b</a>; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a>; see <a href="https://zenodo.org/record/1241626#.Wu6fTGcUmBE" target="_blank">supplementary file S73</a>); </p> </li> <li> <p>pyrexia to be 12.6% (95% CI 6.60% to 22.7%; 3 studies, 412 participants; <a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0070" title="FindlingRL , WigalSB , BuksteinOG , BoellnerSW , AbikoffHB , TurnbowJM , et al. Long‐term tolerability of the methylphenidate transdermal system in pediatric attention‐deficit/hyperactivity disorder: a multicenter, prospective, 12‐month, open‐label, uncontrolled, phase III extension of four clinical trials. Clinical Therapeutics2009;31(8):1844‐55. [DOI: 10.1016/j.clinthera.2009.08.002; PUBMED: 19808143] TurnbowJM , FindlingRL , LópezFA , BurnsideJC , BuksteinOG . 12‐month safety and efficacy of methylphenidate transdermal system in attention‐deficit/hyperactivity disorder. European Neuropsychopharmacology2008;18(s4):S562‐3. [DOI: 10.1016/S0924‐977X(08)70857‐5] ">Findling 2009</a>; <a href="./references#CD012069-bbs2-0227" title="WangY , ZhengY , DuY , SongDH , ShinYJ , ChoSC , et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double‐blind comparison trial. Australian and New Zealand Journal of Psychiatry2007;41(3):222‐30. [DOI: 10.1080/00048670601057767; PUBMED: 17464703] ">Wang 2007</a>; see <a href="https://zenodo.org/record/1240429#.WusjAmcUmBE" target="_blank">supplementary file S74</a>); </p> </li> <li> <p>allergies to be 2.30% (95% CI 0.90% to 5.30%; 2 studies, 225 participants; <a href="./references#CD012069-bbs2-0100" title="Effects of high‐dose OROS methylphenidate. Brown University Child and Adolescent Psychopharmacology Update2009;11(8):7‐8. [DOI: 10.1002/cpu.20097] DanielsSR . Cardiovascular effects of methylphenidate. Journal of Pediatrics2009;155(1):A3. [DOI: 10.1016/j.jpeds.2009.05.023] HammernessP , GeorgiopoulosA , DoyleRL , UtzingerL , SchillingerM , MartelonM , et al. An open study of adjunct OROS‐methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. Journal of Child and Adolescent Psychopharmacology2009;19(5):493‐9. [DOI: 10.1089/cap.2008.0126; PMC2861956; PUBMED: 19877973] ">Hammerness 2009</a>; <a href="./references#CD012069-bbs2-0175" title="PierceD , KaticA , BuckwalterM , WebsterK . Single‐ and multiple‐dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic‐release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. Journal of Clinical Psychopharmacology2010;30(5):554‐64. [DOI: 10.1097/JCP.0b013e3181f0c2f6; PUBMED: 20814325] ">Pierce 2010</a>; see <a href="https://zenodo.org/record/1240430#.WusjTWcUmBE" target="_blank">supplementary file S75</a>); </p> </li> <li> <p>cold symptoms to be 11.8% (95% CI 3.40% to 33.9%; 3 studies, 154 participants; <a href="./references#CD012069-bbs2-0100" title="Effects of high‐dose OROS methylphenidate. Brown University Child and Adolescent Psychopharmacology Update2009;11(8):7‐8. [DOI: 10.1002/cpu.20097] DanielsSR . Cardiovascular effects of methylphenidate. Journal of Pediatrics2009;155(1):A3. [DOI: 10.1016/j.jpeds.2009.05.023] HammernessP , GeorgiopoulosA , DoyleRL , UtzingerL , SchillingerM , MartelonM , et al. An open study of adjunct OROS‐methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. Journal of Child and Adolescent Psychopharmacology2009;19(5):493‐9. [DOI: 10.1089/cap.2008.0126; PMC2861956; PUBMED: 19877973] ">Hammerness 2009</a>; <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a>; <a href="./references#CD012069-bbs2-0203" title="HechtmanL . Effects of treatment on the overall functioning of children with ADHD. Journal of the Canadian Academy of Child and Adolescent Psychiatry2009;14(Suppl 1):10‐5. [PMC2547092] SteeleM , RiccardelliR , BinderC . The effectiveness of OROS® methylphenidate (Concerta®) vs. usual treatment with immediate‐release methylphenidate (IR MPH) in children aged 6‐12 years with attention deficit hyperactivity disorder (ADHD). International Journal of Neuropsychopharmacology2004;7(Suppl 2):S442. [DOI: 10.1017/S1461145704004547] SteeleM , WeissM , SwansonJ , WangJ , PrinzoRS , BinderCE . A randomized, controlled effectiveness trial of OROS‐methylphenidate compared to usual care with immediate‐release methylphenidate in ADHD. Canadian Journal of Clinical Pharmacology2006;13(1):e50‐62. [PUBMED: 16456216] SteeleMM , PrinzoR , BinderC . Effectiveness of Concerta versus twice or thrice daily IR‐MPH in children with ADHD. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta (GA). 2005. SteeleMM , PrinzoR , BinderC . Long‐term effectiveness and safety of Concerta in children with ADHD: a six‐month study. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21‐26; Atlanta (GA). 2005. ">Steele 2006</a>; see <a href="https://zenodo.org/record/1240431#.WusjmmcUmBE" target="_blank">supplementary file S76</a>); </p> </li> <li> <p>pharyngitis to be 5.10% (95% CI 1.70% to 14.1%; 5 studies, 834 participants; <a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0056" title="DöpfnerM , OseC , FischerR , AmmerR , ScheragA . Comparison of the efficacy of two different modified release methylphenidate preparations for children and adolescents with attention‐deficit/hyperactivity disorder in a natural setting: comparison of the efficacy of Medikinet® retard and Concerta® ‐ a randomized, controlled, double‐blind multicenter clinical crossover trial. Journal of Child &amp; Adolescent Psychopharmacology2011;21(5):445‐54. [DOI: 10.1089/cap.2010.0082; PMC3205792; PUBMED: 21790298] DöpfnerM , OseC , FischerR , AmmerR , ScheragA . The CoMeCo‐trial: comparison of the efficacy of two methylphenidate preparations for children and adolescents with ADHD in a natural setting. European Child and Adolescent Psychiatry.14th International Congress of ESCAP European Society for Child and Adolescent Psychiatry (ESCAP); June 11‐15, 2011; Helsinki (Finland)2011;20:S116. ">Döpfner 2011b</a>; <a href="./references#CD012069-bbs2-0131" title="KordonA , StollhoffK , NiederkirchnerK , MattejatF , RettigK , SchäubleB . Exploring the impact of once‐daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate‐release MPH. Postgraduate Medicine2011;123(5):27‐38. [DOI: 10.3810/pgm.2011.09.2457; PUBMED: 21904084] ">Kordon 2011</a>; <a href="./references#CD012069-bbs2-0132" title="KratochvilCJ , HeiligensteinJH , DittmannR , SpencerTJ , BiedermanJ , WernickeJ , et al. Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open‐label trial. Journal of the American Academy of Child and Adolescent Psychiatry2002;41(7):776‐84. [DOI: 10.1097/00004583‐200207000‐00008; PUBMED: 12108801] ">Kratochvil 2002</a>; <a href="./references#CD012069-bbs2-0189" title="RostainAL . Sleep disturbances and ADHD medications. Current Psychiatry Reports2007;9(5):399‐400. [PUBMED: 17915079] SangalRB , OwensJ , AllenAJ , SuttonV , SchuhK , KelseyD . Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep2006;29(12):1573‐85. [PUBMED: 17252888] ">Sangal 2006</a>; see <a href="https://zenodo.org/record/1240432#.Wusj4mcUmBE" target="_blank">supplementary file S77</a>); </p> </li> <li> <p>viral infection to be 6.10% (95% CI 0.30% to 58.4%; 2 studies, 674 participants; <a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0131" title="KordonA , StollhoffK , NiederkirchnerK , MattejatF , RettigK , SchäubleB . Exploring the impact of once‐daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate‐release MPH. Postgraduate Medicine2011;123(5):27‐38. [DOI: 10.3810/pgm.2011.09.2457; PUBMED: 21904084] ">Kordon 2011</a>; see <a href="https://zenodo.org/record/1240435#.WuskNmcUmBE" target="_blank">supplementary file S78</a>); </p> </li> <li> <p>rash to be 5.50% (95% CI 3.10% to 9.70%; 3 studies, 213 participants; <a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0074" title="GargJ , ArunP , ChavanBS . Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. International Journal of Applied and Basic Medical Research2015;5(2):114‐8. [DOI: 10.4103/2229‐516X.157162; PMC4456885] GargJ , ArunP , ChavanBS . Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder. Indian Pediatrics2014;51(7):550‐4. [PUBMED: 25031133] ">Garg 2014</a>; <a href="./references#CD012069-bbs2-0139" title="LeeSI , HongSD , KimS . Efficacy and tolerability of OROS methylphenidate in Korean children with AD/HD ‐ Reply. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2007; Vol. 31, issue 5:1151‐2. [DOI: 10.1016/j.pnpbp.2007.03.019] LeeSI , HongSD , KimSY , KimEJ , KimJH , KimJH , et al. Efficacy and tolerability of OROS methylphenidate in Korean children with attention‐deficit/hyperactivity disorder. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2007;31(1):210‐6. [DOI: 10.1016/j.pnpbp.2006.09.002; PUBMED: 17046131] PaeCU . Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention‐deficit/hyperactivity disorder. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2007;31(5):1151‐2. [DOI: 10.1016/j.pnpbp.2007.03.018] ">Lee 2007</a>; see <a href="https://zenodo.org/record/1240438#.Wuskd2cUmBE" target="_blank">supplementary file S79</a>); and </p> </li> <li> <p>rhinitis to be 3.10% (95% CI 0.70% to 12.6%; 2 studies, 617 participants; <a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0131" title="KordonA , StollhoffK , NiederkirchnerK , MattejatF , RettigK , SchäubleB . Exploring the impact of once‐daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate‐release MPH. Postgraduate Medicine2011;123(5):27‐38. [DOI: 10.3810/pgm.2011.09.2457; PUBMED: 21904084] ">Kordon 2011</a>; see <a href="https://zenodo.org/record/1240439#.WuskxGcUmBE" target="_blank">supplementary file S80</a>). </p> </li> </ol> </p> <p>Three studies provided data on different adverse events related to the immune system (<a href="./references#CD012069-bbs2-0100" title="Effects of high‐dose OROS methylphenidate. Brown University Child and Adolescent Psychopharmacology Update2009;11(8):7‐8. [DOI: 10.1002/cpu.20097] DanielsSR . Cardiovascular effects of methylphenidate. Journal of Pediatrics2009;155(1):A3. [DOI: 10.1016/j.jpeds.2009.05.023] HammernessP , GeorgiopoulosA , DoyleRL , UtzingerL , SchillingerM , MartelonM , et al. An open study of adjunct OROS‐methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. Journal of Child and Adolescent Psychopharmacology2009;19(5):493‐9. [DOI: 10.1089/cap.2008.0126; PMC2861956; PUBMED: 19877973] ">Hammerness 2009</a>; <a href="./references#CD012069-bbs2-0131" title="KordonA , StollhoffK , NiederkirchnerK , MattejatF , RettigK , SchäubleB . Exploring the impact of once‐daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate‐release MPH. Postgraduate Medicine2011;123(5):27‐38. [DOI: 10.3810/pgm.2011.09.2457; PUBMED: 21904084] ">Kordon 2011</a>; <a href="./references#CD012069-bbs2-0219" title="Valdizán UsonJR . Methylphenidate in children and adolescents with attention‐deficit/ hyperactivity disorder: The DIHANA Study. Acta Pediatrica Espanola2013;71(3):67‐76. Valdizán UsonJR , Cánovas‐MartínezA , DeLucas‐TaracenaMT , Díaz‐AtienzaF , Eddy‐IvesLS , Fernandez‐JaenA , et al. Response to methylphenidate by adult and pediatric patients with attention‐deficit/hyperactivity disorder: the Spanish multicenter DIHANA study. Neuropsychiatric Disease and Treatment2013;9:211‐8. [DOI: 10.2147/NDT.S35836; PMC3573811] ">Valdizán Usón 2013</a>). </p> <p> <ol id="CD012069-list-0050"> <li> <p>In <a href="./references#CD012069-bbs2-0100" title="Effects of high‐dose OROS methylphenidate. Brown University Child and Adolescent Psychopharmacology Update2009;11(8):7‐8. [DOI: 10.1002/cpu.20097] DanielsSR . Cardiovascular effects of methylphenidate. Journal of Pediatrics2009;155(1):A3. [DOI: 10.1016/j.jpeds.2009.05.023] HammernessP , GeorgiopoulosA , DoyleRL , UtzingerL , SchillingerM , MartelonM , et al. An open study of adjunct OROS‐methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. Journal of Child and Adolescent Psychopharmacology2009;19(5):493‐9. [DOI: 10.1089/cap.2008.0126; PMC2861956; PUBMED: 19877973] ">Hammerness 2009</a> (57 participants), the proportion of participants on methylphenidate with ear disorders was 5.30% (95% Cl 1.80% to 14.4%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0131" title="KordonA , StollhoffK , NiederkirchnerK , MattejatF , RettigK , SchäubleB . Exploring the impact of once‐daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate‐release MPH. Postgraduate Medicine2011;123(5):27‐38. [DOI: 10.3810/pgm.2011.09.2457; PUBMED: 21904084] ">Kordon 2011</a> (541 participants), the proportion of participants on methylphenidate with fever was 1.70% (95% CI 0.90% to 3.30%). </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0219" title="Valdizán UsonJR . Methylphenidate in children and adolescents with attention‐deficit/ hyperactivity disorder: The DIHANA Study. Acta Pediatrica Espanola2013;71(3):67‐76. Valdizán UsonJR , Cánovas‐MartínezA , DeLucas‐TaracenaMT , Díaz‐AtienzaF , Eddy‐IvesLS , Fernandez‐JaenA , et al. Response to methylphenidate by adult and pediatric patients with attention‐deficit/hyperactivity disorder: the Spanish multicenter DIHANA study. Neuropsychiatric Disease and Treatment2013;9:211‐8. [DOI: 10.2147/NDT.S35836; PMC3573811] ">Valdizán Usón 2013</a> (689 participants), the proportion of participants on methylphenidate with infections was 1.90% (95% CI 1.10% to 3.20%) </p> </li> </ol> </p> </section> <section id="CD012069-sec-0161"> <h6 class="title">2.2.7 Urogenital system</h6> <p>See <a href="./references#CD012069-fig-0035" title="">Analysis 7.7</a>. We included three studies (141 participants) in this meta‐analysis (<a href="./references#CD012069-bbs2-0028" title="BladerJC , PliszkaSR , JensenPS , SchoolerNR , KafantarisV . Stimulant‐responsive and stimulant‐refractory aggressive behavior among children with ADHD. Pediatrics2010;126(4):e796‐806. [DOI: 10.1542/peds.2010‐0086; PMC2956067; PUBMED: 20837589] Blader JosephC . Methylphenidate dose may reduce aggressive behavior in children with ADHD. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(12):1‐7. [DOI: 10.1002/cpu.20129] ">Blader 2010</a>; <a href="./references#CD012069-bbs2-0073" title="GallandBC , TrippEG , GrayA , TaylorBJ . Apnea‐hypopnea indices and snoring in children diagnosed with ADHD: a matched case‐control study. Sleep and Breathing2011;15(3):455‐62. [DOI: 10.1007/s11325‐010‐0357‐0; PUBMED: 20440568] GallandBC , TrippEG , TaylorBJ . Methylphenidate effects on sleep in children. Brown University Child and Adolescent Psychopharmacology Update2010;12(3):5‐6. [DOI: 10.1002/cpu.20111] GallandBC , TrippEG , TaylorBJ . The sleep of children with attention deficit hyperactivity disorder on and off methylphenidate: a matched case‐control study. Journal of Sleep Research2010;19(2):366‐73. [DOI: 10.1111/j.1365‐2869.2009.00795.x; PUBMED: 20050995] ">Galland 2010</a>; <a href="./references#CD012069-bbs2-0214" title="Tomás VilaM , Aleu Pérez‐GramuntM , Beseler SotoB , Benac PrefasiM , Pantoja MartínezJ , Pitarch CastellanoI . Methylphenidate and sleep: results of a multicentre study on a population of children with attention deficit hyperactivity disorder. Anales de Pediatria2010;73(2):78‐83. [DOI: 10.1016/j.anpedi.2010.05.013; PUBMED: 20605120] ">Tomás Vila 2010b</a>). The proportion of participants on methylphenidate with enuresis was 9.30% (95% CI 4.10% to 19.9%; see <a href="https://zenodo.org/record/1240440#.WuslDWcUmBE" target="_blank">supplementary file S81</a>). </p> </section> <section id="CD012069-sec-0162"> <h6 class="title">2.2.8 Other body systems</h6> <p>See <a href="./references#CD012069-fig-0036" title="">Analysis 7.8</a>. Ten studies reported data on this outcome (<a href="./references#CD012069-bbs2-0002" title="AbbasE , DesoysaR . Use of methylphenidate for attention‐deficit‐hyperactivity disorder in childhood. Developmental Medicine and Child Neurology2006;48(Suppl 107):23. [DOI: 10.1111/j.1469‐8749.2006.tb12600.x] ">Abbas 2006</a>; <a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0042" title="CongologluMA , TurkbayT , CiyiltepeM , DurukanI , DogangunB , YuceM . Immediate effects of methylphenidate on vocal acoustic parameters in children with attention deficit hyperactivity disorder. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2009;19(4):365‐72. ">Congologlu 2009</a>; <a href="./references#CD012069-bbs2-0074" title="GargJ , ArunP , ChavanBS . Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. International Journal of Applied and Basic Medical Research2015;5(2):114‐8. [DOI: 10.4103/2229‐516X.157162; PMC4456885] GargJ , ArunP , ChavanBS . Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder. Indian Pediatrics2014;51(7):550‐4. [PUBMED: 25031133] ">Garg 2014</a>; <a href="./references#CD012069-bbs2-0084" title="GhanizadehA , SayyariZ , MohammadiMR . Effect of methylphenidate and folic acid on ADHD symptoms and quality of life and aggression: a randomized double blind placebo controlled clinical trial. Iranian Journal of Psychiatry2013;8(3):108‐12. [PMC3887226; PUBMED: 24454418] ">Ghanizadeh 2013</a>; <a href="./references#CD012069-bbs2-0098" title="HaertlingF , MuellerB , Bilke‐HentschO . Effectiveness and safety of a long‐acting, once‐daily, two‐phase release formulation of methylphenidate (Ritalin® LA) in school children under daily practice conditions. Attention Deficit and Hyperactivity Disorders2015;7(2):157‐64. [DOI: 10.1007/s12402‐014‐0154‐x; PMC4449385; PUBMED: 25346231] ">Haertling 2015</a>; <a href="./references#CD012069-bbs2-0122" title="KhajehpiriZ , Mahmoudi‐GharaeiJ , FaghihiT , KarimzadehI , KhaliliH , MohammadiM . Adverse reactions of Methylphenidate in children with attention deficit‐hyperactivity disorder: report from a referral center. Journal of Research in Pharmacy Practice2014;3(4):130‐6. [DOI: 10.4103/2279‐042X.145389; PMC4262859; PUBMED: 25535621] ">Khajehpiri 2014</a>; <a href="./references#CD012069-bbs2-0175" title="PierceD , KaticA , BuckwalterM , WebsterK . Single‐ and multiple‐dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic‐release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. Journal of Clinical Psychopharmacology2010;30(5):554‐64. [DOI: 10.1097/JCP.0b013e3181f0c2f6; PUBMED: 20814325] ">Pierce 2010</a>; <a href="./references#CD012069-bbs2-0195" title="ShangCY , PanYL , LinHY , HuangLW , GauSS . An open‐label, randomized trial of methylphenidate and atomoxetine treatment in children with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2015;25(7):566‐73. [DOI: 10.1089/cap.2015.0035; PUBMED: 26222447] ">Shang 2015</a>; <a href="./references#CD012069-bbs2-0243" title="WittKL , ShelbyMD , ItchonRN , FairclothM , KisslingGE , ChrismanAK , et al. Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry2008;47(12):1375‐83. [DOI: 10.1097/CHI.0b013e3181893620; PMC2807376; PUBMED: 18978633] ">Witt 2008</a>). </p> <p>Using data from across five studies (<a href="./references#CD012069-bbs2-0002" title="AbbasE , DesoysaR . Use of methylphenidate for attention‐deficit‐hyperactivity disorder in childhood. Developmental Medicine and Child Neurology2006;48(Suppl 107):23. [DOI: 10.1111/j.1469‐8749.2006.tb12600.x] ">Abbas 2006</a>; <a href="./references#CD012069-bbs2-0098" title="HaertlingF , MuellerB , Bilke‐HentschO . Effectiveness and safety of a long‐acting, once‐daily, two‐phase release formulation of methylphenidate (Ritalin® LA) in school children under daily practice conditions. Attention Deficit and Hyperactivity Disorders2015;7(2):157‐64. [DOI: 10.1007/s12402‐014‐0154‐x; PMC4449385; PUBMED: 25346231] ">Haertling 2015</a>; <a href="./references#CD012069-bbs2-0122" title="KhajehpiriZ , Mahmoudi‐GharaeiJ , FaghihiT , KarimzadehI , KhaliliH , MohammadiM . Adverse reactions of Methylphenidate in children with attention deficit‐hyperactivity disorder: report from a referral center. Journal of Research in Pharmacy Practice2014;3(4):130‐6. [DOI: 10.4103/2279‐042X.145389; PMC4262859; PUBMED: 25535621] ">Khajehpiri 2014</a>; <a href="./references#CD012069-bbs2-0175" title="PierceD , KaticA , BuckwalterM , WebsterK . Single‐ and multiple‐dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic‐release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. Journal of Clinical Psychopharmacology2010;30(5):554‐64. [DOI: 10.1097/JCP.0b013e3181f0c2f6; PUBMED: 20814325] ">Pierce 2010</a>; <a href="./references#CD012069-bbs2-0195" title="ShangCY , PanYL , LinHY , HuangLW , GauSS . An open‐label, randomized trial of methylphenidate and atomoxetine treatment in children with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2015;25(7):566‐73. [DOI: 10.1089/cap.2015.0035; PUBMED: 26222447] ">Shang 2015</a>), we conducted two meta‐analyses, in which we found the proportion of participants on methylphenidate with: </p> <p> <ol id="CD012069-list-0051"> <li> <p>hair loss to be 2.80% (95% CI 0.00% to 9.00%; 2 studies, 161 participants; <a href="./references#CD012069-bbs2-0002" title="AbbasE , DesoysaR . Use of methylphenidate for attention‐deficit‐hyperactivity disorder in childhood. Developmental Medicine and Child Neurology2006;48(Suppl 107):23. [DOI: 10.1111/j.1469‐8749.2006.tb12600.x] ">Abbas 2006</a>; <a href="./references#CD012069-bbs2-0122" title="KhajehpiriZ , Mahmoudi‐GharaeiJ , FaghihiT , KarimzadehI , KhaliliH , MohammadiM . Adverse reactions of Methylphenidate in children with attention deficit‐hyperactivity disorder: report from a referral center. Journal of Research in Pharmacy Practice2014;3(4):130‐6. [DOI: 10.4103/2279‐042X.145389; PMC4262859; PUBMED: 25535621] ">Khajehpiri 2014</a>; see <a href="https://zenodo.org/record/1241627#.Wu6fqGcUmBE" target="_blank">supplementary file S82</a>); and </p> </li> <li> <p>skin problems to be 1.80% (95% CI 0.80% to 4.00%; 4 studies, 447 participants; <a href="./references#CD012069-bbs2-0098" title="HaertlingF , MuellerB , Bilke‐HentschO . Effectiveness and safety of a long‐acting, once‐daily, two‐phase release formulation of methylphenidate (Ritalin® LA) in school children under daily practice conditions. Attention Deficit and Hyperactivity Disorders2015;7(2):157‐64. [DOI: 10.1007/s12402‐014‐0154‐x; PMC4449385; PUBMED: 25346231] ">Haertling 2015</a>; <a href="./references#CD012069-bbs2-0122" title="KhajehpiriZ , Mahmoudi‐GharaeiJ , FaghihiT , KarimzadehI , KhaliliH , MohammadiM . Adverse reactions of Methylphenidate in children with attention deficit‐hyperactivity disorder: report from a referral center. Journal of Research in Pharmacy Practice2014;3(4):130‐6. [DOI: 10.4103/2279‐042X.145389; PMC4262859; PUBMED: 25535621] ">Khajehpiri 2014</a>; <a href="./references#CD012069-bbs2-0175" title="PierceD , KaticA , BuckwalterM , WebsterK . Single‐ and multiple‐dose pharmacokinetics of methylphenidate administered as methylphenidate transdermal system or osmotic‐release oral system methylphenidate to children and adolescents with attention deficit hyperactivity disorder. Journal of Clinical Psychopharmacology2010;30(5):554‐64. [DOI: 10.1097/JCP.0b013e3181f0c2f6; PUBMED: 20814325] ">Pierce 2010</a>; <a href="./references#CD012069-bbs2-0195" title="ShangCY , PanYL , LinHY , HuangLW , GauSS . An open‐label, randomized trial of methylphenidate and atomoxetine treatment in children with attention‐deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2015;25(7):566‐73. [DOI: 10.1089/cap.2015.0035; PUBMED: 26222447] ">Shang 2015</a>; see <a href="https://zenodo.org/record/1240441#.WuslVGcUmBE" target="_blank">supplementary file S83</a>). </p> </li> </ol> </p> <p>Five studies reported data on patients on methylphenidate with other non‐serious adverse events (<a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a>; <a href="./references#CD012069-bbs2-0042" title="CongologluMA , TurkbayT , CiyiltepeM , DurukanI , DogangunB , YuceM . Immediate effects of methylphenidate on vocal acoustic parameters in children with attention deficit hyperactivity disorder. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2009;19(4):365‐72. ">Congologlu 2009</a>; <a href="./references#CD012069-bbs2-0074" title="GargJ , ArunP , ChavanBS . Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. International Journal of Applied and Basic Medical Research2015;5(2):114‐8. [DOI: 10.4103/2229‐516X.157162; PMC4456885] GargJ , ArunP , ChavanBS . Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder. Indian Pediatrics2014;51(7):550‐4. [PUBMED: 25031133] ">Garg 2014</a>; <a href="./references#CD012069-bbs2-0084" title="GhanizadehA , SayyariZ , MohammadiMR . Effect of methylphenidate and folic acid on ADHD symptoms and quality of life and aggression: a randomized double blind placebo controlled clinical trial. Iranian Journal of Psychiatry2013;8(3):108‐12. [PMC3887226; PUBMED: 24454418] ">Ghanizadeh 2013</a>; <a href="./references#CD012069-bbs2-0243" title="WittKL , ShelbyMD , ItchonRN , FairclothM , KisslingGE , ChrismanAK , et al. Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry2008;47(12):1375‐83. [DOI: 10.1097/CHI.0b013e3181893620; PMC2807376; PUBMED: 18978633] ">Witt 2008</a>). </p> <p> <ol id="CD012069-list-0052"> <li> <p><a href="./references#CD012069-bbs2-0015" title='ArnoldLE . Questions regarding your study "A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder" [personal communication]. Email to: EL Ramstad 17 October 2013. ArnoldLE , LindsayRL , ConnersCK , WigalSB , LevineAJ , JohnsonDE , et al. A double‐blind, placebo‐controlled withdrawal trial of dexmethylphenidate hydrochloride in children with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology2004; Vol. 14, issue 4:542‐54. [DOI: 10.1089/cap.2004.14.542; PUBMED: 15662146] '>Arnold 2004</a> (76 participants) reported the proportion of participants on methylphenidate with accidental injury as 13.2% (95% CI 7.30% to 22.6%). </p> </li> <li> <p><a href="./references#CD012069-bbs2-0042" title="CongologluMA , TurkbayT , CiyiltepeM , DurukanI , DogangunB , YuceM . Immediate effects of methylphenidate on vocal acoustic parameters in children with attention deficit hyperactivity disorder. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2009;19(4):365‐72. ">Congologlu 2009</a> suggested that "methylphenidate decreases fundamental [voice] frequency in children with ADHD, but our findings should be replicated under blind drug administration and by supporting other vocal analyses." </p> </li> <li> <p><a href="./references#CD012069-bbs2-0074" title="GargJ , ArunP , ChavanBS . Comparative efficacy of methylphenidate and atomoxetine in oppositional defiant disorder comorbid with attention deficit hyperactivity disorder. International Journal of Applied and Basic Medical Research2015;5(2):114‐8. [DOI: 10.4103/2229‐516X.157162; PMC4456885] GargJ , ArunP , ChavanBS . Comparative short term efficacy and tolerability of methylphenidate and atomoxetine in attention deficit hyperactivity disorder. Indian Pediatrics2014;51(7):550‐4. [PUBMED: 25031133] ">Garg 2014</a> (27 participants) reported the proportion of participants on methylphenidate with hypersalivation as 3.70% (95% CI 0.70% to 18.3%). </p> </li> <li> <p><a href="./references#CD012069-bbs2-0084" title="GhanizadehA , SayyariZ , MohammadiMR . Effect of methylphenidate and folic acid on ADHD symptoms and quality of life and aggression: a randomized double blind placebo controlled clinical trial. Iranian Journal of Psychiatry2013;8(3):108‐12. [PMC3887226; PUBMED: 24454418] ">Ghanizadeh 2013</a> (26 participants) reported the proportion of participants on methylphenidate with nasal bleeding as 3.90% (95% CI 0.70% to 2.20%). </p> </li> <li> <p><a href="./references#CD012069-bbs2-0243" title="WittKL , ShelbyMD , ItchonRN , FairclothM , KisslingGE , ChrismanAK , et al. Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry2008;47(12):1375‐83. [DOI: 10.1097/CHI.0b013e3181893620; PMC2807376; PUBMED: 18978633] ">Witt 2008</a> conducted a study of chromosomal aberration and "found no evidence of changes in any of the three cytogenetic endpoints examined in the lymphocytes of children treated with methylphenidate or mixed mixed amphetamine salts (MAS) based products continuously for three months". </p> </li> </ol> </p> </section> <section id="CD012069-sec-0163"> <h6 class="title">2.2.9 Withdrawal of treatment</h6> <section id="CD012069-sec-0164"> <p><b>Due to non‐serious adverse events</b></p> <p>See <a href="./references#CD012069-fig-0037" title="">Analysis 8.1</a>. We conducted a meta‐analysis of data from 37 studies (7142 participants) that reported on the number of patients withdrawn from methylphenidate due to non‐serious adverse events. The proportion of participants withdrawn from methylphenidate treatment due to non‐serious adverse events was 6.20% (95% CI 4.80% to 7.90%; <a href="#CD012069-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD012069-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Proportion of participants withdrawn from methylphenidate due to non‐serious adverse events" data-id="CD012069-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Proportion of participants withdrawn from methylphenidate due to non‐serious adverse events </p> </div> </div> </div> </section> <section id="CD012069-sec-0165"> <p><b>For unknown reasons</b></p> <p>See <a href="./references#CD012069-fig-0038" title="">Analysis 8.2</a>. We conducted a meta‐analysis of data from 57 studies (8340 participants) that reported on the number of patients withdrawn from methylphenidate for unknown reasons. The proportion of participants withdrawn from methylphenidate for unknown reasons was 16.2% (95% CI 13.0% to 19.9%; <a href="#CD012069-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD012069-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Proportion of participants withdrawn from methylphenidate for unknown reasons" data-id="CD012069-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Proportion of participants withdrawn from methylphenidate for unknown reasons</p> </div> </div> </div> </section> </section> </section> </section> <section id="CD012069-sec-0166"> <h4 class="title">3. Patient reports/series</h4> <section id="CD012069-sec-0167"> <h5 class="title">3.1. Primary outcomes: serious adverse events</h5> <section id="CD012069-sec-0168"> <h6 class="title">3.1.1 Frequency of any serious averse events</h6> <p>We found 26 patient reports/series of serious adverse events and these studies reported 149 cases of serious adverse events. </p> </section> <section id="CD012069-sec-0169"> <h6 class="title">3.1.2 Central nervous system</h6> <p>See <a href="./references#CD012069-fig-0039" title="">Analysis 9.1</a>. We found 20 patient reports/series of serious adverse events related to the central nervous system. </p> <section id="CD012069-sec-0170"> <p><b>Psychotic conditions</b></p> <p>Twelve patient reports/series described psychosis or psychotic symptoms related to methylphenidate. </p> <p> <ol id="CD012069-list-0053"> <li> <p><a href="./references#CD012069-bbs2-0001" title="AbaliO , MukaddesNM . Methylphenidate induced hallucinations: case report. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2007; Vol. 17, issue 4:195‐7. ">Abali 2007</a> reported on a 14‐year‐old girl with ADHD, major depression, and conduct disorder. She was treated with methylphenidate (20 mg/day) and fluoxetine (20 mg/day) and developed visual and auditory hallucinations a few hours after treatment initiation. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0006" title="Aguilera‐AlbesaS , Yoldi‐PetriME , Molins‐CastiellaT , Durá‐TravéT . Hallucinations caused by the introduction of methylphenidate at low doses. Revista de Neurologia2010;51(4):254‐5. [PUBMED: 20648469] ">Aguilera‐Albesa 2010</a> reported on an 8‐year‐old boy and 6‐year‐old girl, both with ADHD, who developed psychosis on modified‐release methylphenidate 18 mg/day (0.51 mg/kg/day) after two days, and modified‐release methylphenidate 10 mg for three days then 20 mg/day on the fourth day (0.45 mg/kg/day). </p> </li> <li> <p><a href="./references#CD012069-bbs2-0045" title="CoşkunM , ZorogluS . Tactile and visual hallucinations in a child with methylphenidate and fluoxetine combination. Journal of Clinical Psychopharmacology2008;28(6):723‐5. [DOI: 10.1097/JCP.0b013e31818ce752; PUBMED: 19011457] ">Coşkun 2008</a> also reported on the development of psychosis in a 10‐year‐old boy with ADHD, oppositional defiant disorder, and generalised and separation anxiety, who was also treated with a combination of methylphenidate and fluoxetine. He was taking OROS methylphenidate (18 mg/day) and fluoxetine (10 mg/day) and experienced a relatively acute‐onset episode of intense visual and tactile hallucinations three hours after taking the medication. In these cases, it was thought that the combination of methylphenidate and fluoxetine might have precipitated the psychoses. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0085" title="GoetzM , PrihodovaI , HrdlickaM . Long lasting complex nocturnal hallucinations during Osmotic Release Oral System (OROS) methylphenidate treatment in a 7‐year old girl. Neuro Endocrinology Letters2011;32(5):619‐22. [PUBMED: 22167138] ">Goetz 2011</a> described a girl with ADHD and oppositional defiant disorder who experienced a three‐hour episode of bizarre, complex, nocturnal visual hallucinations whilst taking OROS methylphenidate (18 mg/day). Authors reported a reduction of REM (rapid eye movement) sleep and two episodes of confusional arousals, hypothesising that her pre‐existing sleep impairment made her vulnerable to methylphenidate‐induced, adverse sleep effects. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0095" title="Gross‐TsurV , JosephA , ShalevRS . Hallucinations during methylphenidate therapy. Neurology2004;63(4):753‐4. [PUBMED: 15326264] PaneiP , ArcieriR , VellaS , BonatiM , MartiniN , ZuddasA . Italian attention‐deficit/hyperactivity disorder registry. Pediatrics2004;114(2):514. [PUBMED: 15286248] ">Gross‐Tsur 2004</a> described three children with ADHD treated with low‐dose methylphenidate, who developed complex visual and tactile hallucinations that appeared soon after ingestion of methylphenidate and resolved after its withdrawal. In one patient, the hallucinations reappeared after an inadvertent challenge. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0099" title="HalevyA , ShuperA . Methylphenidate induction of complex visual hallucinations. Journal of Child Neurology2009;24(8):1005‐7. [DOI: 10.1177/0883073808331357; PUBMED: 19502578] ">Halevy 2009</a> reported on a 15‐year‐old boy with ADHD who presented with complex visual hallucinations of rats running around and touching and smelling him soon after receiving a first low dose of methylphenidate. The hallucinations resolved upon discontinuation of the drug. Reintroduction of the drug seven years later at an even lower dose had the same effect. The authors suggested that the occurrence of hallucinations after a very low dose of methylphenidate on two occasions may suggest an idiosyncratic reaction. It could also be explained by a drug‐induced dysfunction of the monoamine transmitters. Given the wide use of methylphenidate, clinicians should be aware of this possible adverse event. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0111" title="IrmakA , Ince‐TasdelenB , OzmenS , OztopDB . Treatment choice in association of attention deficit‐hyperactivity disorder with Williams and Moebius Syndromes: case reports. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2014;24(Suppl 1):226. ">Irmak 2014</a> reported a nine‐year‐old boy who developed phobias and visual hallucinations during OROS methylphenidate titrated to 1 mg/kg/day. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0156" title="MinoY , AokiS . Methylphenidate‐induced psychosis in an adolescent with hyperkinetic disorder. Kawasaki Medical Journal1999;25(2):81‐5. [DOI: 10.11482/KMJ25(2)81‐85.1999.pdf] MinoY , OharaH , NagamatsuI , NagamatsuK . Methylphenidate psychosis in an adolescent with attention deficit disorder. Japanese Journal of Child and Adolescent Psychiatry1986; Vol. 27, issue 3:178‐87. ">Mino 1999</a> described a 16‐year‐old girl with hyperkinetic disorder who developed a psychosis after initially becoming depressed following three weeks of 10 mg/day of methylphenidate. Methylphenidate was stopped, but six weeks later she developed a psychosis with delusions of reference, thought block, and other psychotic features. These resolved on antipsychotic medication after two months. The authors highlighted the risk of methylphenidate precipitating psychosis. However, there had been a history of diagnostic uncertainty beginning with behavioural difficulties from the start of school and then treatment with antipsychotics for mania when she was 12 years old. This might suggest that methylphenidate treatment in a patient with possible additional vulnerability could precipitate psychosis. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0177" title="PorfirioMC , GianaG , GiovinazzoS , CuratoloP . Methylphenidate‐induced visual hallucinations. Neuropediatrics2011;42(1):30‐1. [DOI: 10.1055/s‐0031‐1275738; PUBMED: 21500140] ">Porfirio 2011</a> reported an episode of complex visual hallucinations three years after initiation of methylphenidate treatment (30 mg/day (0.5 mg/kg)). </p> </li> <li> <p><a href="./references#CD012069-bbs2-0183" title="Somatic hallucinations with methylphenidate in a 10‐year‐old boy. Brown University Child and Adolescent Psychopharmacology Update2007;9(11):8‐8. [DOI: 10.1002/cpu.20055] RashidJ , MitelmanS . Methylphenidate and somatic hallucinations. Journal of the American Academy of Child and Adolescent Psychiatry2007;46(8):945‐6. [DOI: 10.1097/CHI.0b013e318067fd7c; PUBMED: 17667474] ">Rashid 2007</a> reported a 10‐year‐old boy with ADHD and chronic somatisation who developed intensified somatic hallucinations with a change in methylphenidate dosage from 36 mg OROS methylphenidate a day to 15 mg immediate‐release methylphenidate twice daily. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0196" title="ShibibS , ChalhoubN . Stimulant induced psychosis. Child and Adolescent Mental Health2009;14(1):20‐3. [DOI: 10.1111/j.1475‐3588.2008.00490.x] ">Shibib 2009</a> describes four patients (a 14‐year‐old girl, a 14‐year‐old boy, an 8‐year‐old boy and a 10‐year‐old boy), all of whom were treated with methylphenidate in normal therapeutic doses and all of whom developed psychoses that resolved on cessation of methylphenidate treatment. Three of the four patients were taking modified‐release methylphenidate. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0213" title="Tomás VilaM , Izquierdo QuevedoFJ , Cerdán VeraMT , FernándezA , Artás FigueresM , Revert GomasM . Visual hallucinations caused by methylphenidate. Anales de Pediatria2010;72(3):229‐30. [DOI: 10.1016/j.anpedi.2009.10.013; PUBMED: 20097145] ">Tomás Vila 2010a</a> described the development of psychosis in a 10‐year‐old patient with ADHD who was treated with 30 mg of methylphenidate (50% immediate release, 50% modified release). The patient experienced visual hallucinations (insects on hands, feet, abdomen and thorax) with associated itching. It resolved on stopping methylphenidate and treatment with risperidone. </p> </li> </ol> </p> </section> <section id="CD012069-sec-0171"> <p><b>Seizures</b></p> <p>Two patient reports/series described seizures related to methylphenidate.</p> <p> <ol id="CD012069-list-0054"> <li> <p><a href="./references#CD012069-bbs2-0066" title="FeeneyDJ , KlykyloWM . Medication‐induced seizures. Journal of the American Academy of Child and Adolescent Psychiatry1997;36(8):1018‐9. [DOI: 10.1097/00004583‐199708000‐00007; PUBMED: 9256580] ">Feeney 1997</a> reported on a 13‐year‐old boy with ADHD and depressive disorder (not otherwise specified) who developed seizures a week after sertraline, 50 mg/day, was added to his 80 mg/day dose of methylphenidate (1.8 mg/kg/day). He had been established on 80 mg/day of methylphenidate for seven months; initially, this had been gradually titrated upwards to achieve symptom control, without significant adverse events. He was treated with cognitive behavioural therapy and family interventions for depression, but when this deteriorated after eight months of treatment, sertraline 25 mg/day was prescribed for a week and then increased to 50 mg/day. A week later he experienced a tonic‐clonic event witnessed by his father, which lasted a few seconds. All investigations were normal apart from a serum pH value of 7.20. The sertraline was discontinued and methylphenidate treatment continued unchanged without seizure recurrence. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0105" title="HemmerSA , PasternakJF , ZeckerSG , TrommerBL . Stimulant therapy and seizure risk in children with ADHD. Pediatric Neurology2001;24(2):99‐102. [PUBMED: 11275457] ">Hemmer 2001</a> reported seizures in a boy aged six, and two girls aged six and seven, receiving 0.30 mg/kg/day to 1 mg/kg/day of methylphenidate for six weeks, 10 months and 3 months, respectively. </p> </li> </ol> </p> </section> <section id="CD012069-sec-0172"> <p><b>Cerebral arteritis</b></p> <p>One patient report/series described cerebral arteritis related to methylphenidate (<a href="./references#CD012069-bbs2-0215" title="TrugmanJM . Cerebral arteritis and oral methylphenidate. Lancet1988;1(8585):584‐5. [PUBMED: 2894511] ">Trugman 1988</a>). This study reported on cerebral arteritis and infarction thought to have been caused by chronic oral methylphenidate use in a 12‐year‐old boy. The cerebrospinal fluid profile and angiogram at the time supported the diagnosis of inflammatory arteritis, yet laboratory evaluation revealed no identifiable cause. Magnetic resonance imaging (MRI) six years on was compatible with an old infarction. In the six years since the stroke, while not on methylphenidate, there was no evidence of active, central nervous system or systemic vasculitis. </p> </section> <section id="CD012069-sec-0173"> <p><b>Self‐harm and suicidal behaviour</b></p> <p>Three patient reports/series described self‐harm and suicidal behaviours related to methylphenidate. </p> <p> <ol id="CD012069-list-0055"> <li> <p><a href="./references#CD012069-bbs2-0018" title="ArunP , SahniS . Methylphenidate and suicidal ideation: report of two cases. Indian Journal of Psychiatry2014;56(1):79‐81. [DOI: 10.4103/0019‐5545.124721; PMC3927251] ">Arun 2014</a> reported on two children with ADHD who developed suicidal ideation, which abated after discontinuation of methylphenidate. Neither child had depressive symptoms, and the suicidal ideation could not be explained on the basis of impulsivity. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0087" title="GökceS , ÖnalA . Suicide attempt in a 12 year old boy after switching 27 mg to 36 mg of OROS methylphenidate. European Child and Adolescent Psychiatry2015;24:s 219. ">Gökce 2015</a> reported on a 12‐year‐old boy who made a suicide attempt after switching from 27 mg to 36 mg of OROS methylphenidate: the patient reported irritable mood when he took the first dose of 36 mg of long‐acting methylphenidate. This might be the cause of the suicide attempt. He had a full recovery after withdrawal from methylphenidate. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0206" title="StrandellJ , StarrK . Reports of suicide related behaviour with methylphenidate and atomoxetine in children and adolescents. Drug Safety2007;30(10):919‐90. [DOI: 10.2165/00002018‐200730100‐00105] ">Strandell 2007</a> reported concerns about suicidal behaviour, including suicide, based on information retrieved from the WHO Collaborating Centre for International Drug Monitoring (Uppsala, Sweden). A total of 116 reports of methylphenidate related to 'suicide attempts', although this term is not explicitly defined. The data included reports of methylphenidate and atomoxetine. They summarised reports on methylphenidate as: suicide (n = 7), suicide attempt (n = 25), depression, suicidal (n =1), intentional overdose (n = 0), intentional self‐injury (n = 8), non‐accidental overdose (n = 8), suicidal tendency (n = 21), thoughts of self‐harm (n = 0). </p> </li> </ol> </p> </section> <section id="CD012069-sec-0174"> <p><b>Death</b></p> <p><a href="./references#CD012069-bbs2-0217" title="TølløfsrudC , HoelT . A young man with acute dilated cardiomyopathy. Tidsskrift for Den Norske Laegeforening2006;126(10):1338‐9. [PUBMED: 16715575] ">Tølløfsrud 2006</a> reported a 17‐year‐old boy who died of heart failure (acute dilated cardiomyopathy) during methylphenidate treatment. </p> </section> <section id="CD012069-sec-0175"> <p><b>Dyskinesia</b></p> <p>We found one patient report/series on dyskinesia related to methylphenidate (<a href="./references#CD012069-bbs2-0252" title="Methylphenidate‐induced orofacial and extremity dyskinesia. Brown University Child and Adolescent Psychopharmacology Update2012;14(8):7‐7. [DOI: 10.1002/cpu.20169] YilmazAE , DonmezA , OrunE , TasT , IsikB , SonmezFM . Methylphenidate‐induced acute orofacial and extremity dyskinesia. Journal of Child Neurology2013;28(6):778‐80. [DOI: 10.1177/0883073812449905; PUBMED: 22791547] ">Yilmaz 2013</a>). This study reported a patient having involuntary movements that started about five hours after methylphenidate ingestion, including lip‐licking, lip‐smacking and tongue‐rolling movements, as well as dyskinetic tongue movements inside and outside the mouth, and involuntary bilateral arm swinging while sitting and standing. Furthermore, he opened and closed his fingers without complete extension and made occasional repetitive movements of the feet, such as beating them against each other while sitting. About 15 hours after methylphenidate ingestion, both hand‐mouth movements and excessive mobility had significantly resolved. Dyskinetic symptoms had completely disappeared on the second day of hospitalisation, and the patient was discharged. </p> </section> </section> <section id="CD012069-sec-0176"> <h6 class="title">3.1.3 Cardiovascular and respiratory system</h6> <p>See <a href="./references#CD012069-fig-0040" title="">Analysis 9.2</a>. We found three patient reports/series on adverse events related to the cardiovascular and respiratory system (<a href="./references#CD012069-bbs2-0166" title="MunkK , GormsenL , KimWY , AndersenNH . Cardiac arrest following a myocardial infarction in a child treated with methylphenidate. Case Reports in Pediatrics2015;2015:905097. [DOI: 10.1155/2015/905097] ">Munk 2015</a>; <a href="./references#CD012069-bbs2-0170" title='GhanizadehA . A commentary on "A young man with acute dilated cardiomyopathy associated with methylphenidate". Vascular Health and Risk Management2009;5(2):525‐6. [DOI: 10.2147/VHRM.S5108] NymarkTB , HovlandA , BjørnstadH , NielsenEW . A young man with acute dilated cardiomyopathy associated with methylphenidate. Vascular Health and Risk Management2008;4(2):477‐9. [PMC2496981; PUBMED: 18561524] '>Nymark 2008</a>; <a href="./references#CD012069-bbs2-0188" title="SaiehAC . Methylphenidate: arterial hypertension, a side effect to take into account [Metilfenidato: hipertensión arterial, un efecto a tener en cuenta]. Revista Chilena de Pediatria2004;75(1):80‐1. [DOI: 10.4067/S0370‐41062004000100014] ">Saieh 2004</a>). </p> <section id="CD012069-sec-0177"> <p><b>Cardiovascular events</b></p> <p>Two patient reports/series described cardiovascular events related to methylphenidate.</p> <p> <ol id="CD012069-list-0056"> <li> <p><a href="./references#CD012069-bbs2-0166" title="MunkK , GormsenL , KimWY , AndersenNH . Cardiac arrest following a myocardial infarction in a child treated with methylphenidate. Case Reports in Pediatrics2015;2015:905097. [DOI: 10.1155/2015/905097] ">Munk 2015</a> reported a case of myocardial infarction related to methylphenidate exposure in a cardiac‐healthy, 11‐year‐old boy without any cardiovascular risk factors, who was being treated with methylphenidate 54 mg/day. Treatment duration was two years. The boy experienced a cardiac arrest following exercise, without any prior complaints about chest discomfort or shortness of breath. A week before the event, he had a short episode of tachycardia. The examination showed that the myocardial infarction was of an older date (more than weeks), due to thinning of the myocardium and an adversely remodelled left ventricle. A pacemaker was inserted and methylphenidate treatment was discontinued. The boy was very thoroughly examined and the only thing that stands out is the methylphenidate treatment. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0170" title='GhanizadehA . A commentary on "A young man with acute dilated cardiomyopathy associated with methylphenidate". Vascular Health and Risk Management2009;5(2):525‐6. [DOI: 10.2147/VHRM.S5108] NymarkTB , HovlandA , BjørnstadH , NielsenEW . A young man with acute dilated cardiomyopathy associated with methylphenidate. Vascular Health and Risk Management2008;4(2):477‐9. [PMC2496981; PUBMED: 18561524] '>Nymark 2008</a> reported a case of serious cardiomyopathy during methylphenidate treatment; a serious adverse event (hospitalisation) relating to hypoxia and dyspnoea following 11 months of methylphenidate treatment. On investigation, signs of liver, renal, and heart failure were found. </p> </li> </ol> </p> </section> <section id="CD012069-sec-0178"> <p><b>Hypertension</b></p> <p>One patient report/series, <a href="./references#CD012069-bbs2-0188" title="SaiehAC . Methylphenidate: arterial hypertension, a side effect to take into account [Metilfenidato: hipertensión arterial, un efecto a tener en cuenta]. Revista Chilena de Pediatria2004;75(1):80‐1. [DOI: 10.4067/S0370‐41062004000100014] ">Saieh 2004</a>, described hypertension related to methylphenidate. <a href="./references#CD012069-bbs2-0188" title="SaiehAC . Methylphenidate: arterial hypertension, a side effect to take into account [Metilfenidato: hipertensión arterial, un efecto a tener en cuenta]. Revista Chilena de Pediatria2004;75(1):80‐1. [DOI: 10.4067/S0370‐41062004000100014] ">Saieh 2004</a> described a patient who was hospitalised due to hypertension during methylphenidate treatment. Abdominal pain with intermittent accentuation for hours was present for four days prior to hospitalisation. Secondary hypertension: persistent hypertension (158/88 mmHg to 170/105 mmHg; pulse: 78 bpm to 98 bpm). The study authors reported normal physical examination, normal eye fundus, and normal cardiological examination. After discontinuation of methylphenidate, hypertensive treatment was only necessary for 24 hours. There was also normal blood pressure after one week. </p> </section> </section> <section id="CD012069-sec-0179"> <h6 class="title">3.1.4 Gastrointestinal system</h6> <section id="CD012069-sec-0180"> <p><b>Hepatoxicity</b></p> <p>See <a href="./references#CD012069-fig-0041" title="">Analysis 9.3</a>. We found one patient report/series on hepatoxicity related to methylphenidate (<a href="./references#CD012069-bbs2-0027" title="BernhardMK , HugleB , MerkenschlagerA . Elevated liver enzymes under therapy with methylphenidate in a boy with T‐cell leukemia. Journal of Pediatric Neurology2009; Vol. 7, issue 3:297‐9. [DOI: 10.3233/JPN‐2009‐0303] ">Bernhard 2009</a>). The study authors reported a hepatotoxic reaction; liver enzymes were elevated in a four‐year‐old boy prior to therapy. Vomiting started five weeks after onset of methylphenidate therapy and increased over three days. Abdominal pain increased in intensity. Liver transaminases were elevated over 30 times the normal level, and creatine kinase (CK) level also increased (<a href="./references#CD012069-bbs2-0027" title="BernhardMK , HugleB , MerkenschlagerA . Elevated liver enzymes under therapy with methylphenidate in a boy with T‐cell leukemia. Journal of Pediatric Neurology2009; Vol. 7, issue 3:297‐9. [DOI: 10.3233/JPN‐2009‐0303] ">Bernhard 2009</a>). </p> </section> </section> <section id="CD012069-sec-0181"> <h6 class="title">3.1.5 Urogenital system</h6> <section id="CD012069-sec-0182"> <p><b>Priapism</b></p> <p>See <a href="./references#CD012069-fig-0042" title="">Analysis 9.4</a>. We found two patient reports/series on priapism related to methylphenidate. </p> <p> <ol id="CD012069-list-0057"> <li> <p>In <a href="./references#CD012069-bbs2-0030" title="Cakin‐MemikN , YildizO , SişmanlarSG , KarakayaI , AğaoğluB . Priapism associated with methylphenidate: a case report. Turkish Journal of Pediatrics2010;52(4):430‐4. [PUBMED: 21043394] ">Cakin‐Memik 2010</a>, a 14‐year‐old boy with ADHD reported three to four episodes of priapism per day, lasting 40 to 45 minutes for three days after receiving 20 mg/day of immediate‐release methylphenidate. </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0194" title="GinsbergDL . Priapism due to withdrawal from sustained‐release methylphenidate. Primary Psychiatry2004;11(10):25‐6. SchwartzRH , RushtonHG . Stuttering priapism associated with withdrawal from sustained‐release methylphenidate. Journal of Pediatrics2004;144(5):675‐6. [DOI: 10.1016/j.jpeds.2003.12.039; PUBMED: 15127013] ">Schwartz 2004</a>, a 15‐year‐old boy with ADHD also experienced intermittent painful erections two weeks after initiating OROS‐methylphenidate, which recently had been increased to 36 mg/day. The symptoms had not reoccurred two weeks or six months following cessation of methylphenidate. </p> </li> </ol> </p> <p>No [patient reports/series] reported adverse outcomes related to the musculoskeletal, immune or other body systems,or on withdrawal of treatment due to serious adverse events, or adverse events of unknown severity. </p> </section> </section> </section> <section id="CD012069-sec-0183"> <h5 class="title">3.2 Secondary outcomes: non‐serious adverse events</h5> <section id="CD012069-sec-0184"> <h6 class="title">3.2.1 Frequency of any non‐serious adverse events</h6> <p>We found 45 patient reports/series of non‐serious adverse events and these studies reported 55 cases of non‐serious adverse events. </p> </section> <section id="CD012069-sec-0185"> <h6 class="title">3.2.2. Central nervous system</h6> <p>See <a href="./references#CD012069-fig-0047" title="">Analysis 10.5</a>. We found 23 patient reports/series of non‐serious adverse events related to the central nervous system. </p> <section id="CD012069-sec-0186"> <p><b>Movement‐related outcomes</b></p> <p>See <a href="./references#CD012069-fig-0043" title="">Analysis 10.1</a> </p> <p> <ul id="CD012069-list-0058"> <li> <p>Tics</p> </li> </ul> </p> <p>Two patient reports/series described tics related to methylphenidate.</p> <p> <ol id="CD012069-list-0059"> <li> <p><a href="./references#CD012069-bbs2-0004" title="AdrianN . Explosive outbursts associated with methylphenidate. Journal of the American Academy of Child and Adolescent Psychiatry2001;40(6):618‐9. [DOI: 10.1097/00004583‐200106000‐00002; PUBMED: 11392335] ">Adrian 2001</a> showed the presence of clinically explosive outbursts of tics in a 10‐year‐old boy boy with ADHD receiving 20 mg/day of methylphenidate at seven years, which over a two‐to‐three‐year period was increased to 40 mg/day. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0032" title="ChandlerML , BarnhillJL , GualtieriCT , PattersonDR . Tryptophan antagonism of stimulant‐induced tics. Journal of Clinical Psychopharmacology1989;9(1):69‐70. [PUBMED: 2708560] ">Chandler 1989</a> described two ADHD patients: a boy aged 12 years receiving 0.2 mg/kg of methylphenidate twice a day who reported motor and vocal tics one month after treatment, and a 9‐year‐old boy treated with the same dose of methylphenidate and subsequent nortriptyline, who reported severe facial grimacing and vocal tics. </p> </li> </ol> <ul id="CD012069-list-0060"> <li> <p>Involuntary movements or dyskinesia</p> </li> </ul> </p> <p>Three patient reports/series described involuntary movements or dyskinesia related to methylphenidate. </p> <p> <ol id="CD012069-list-0061"> <li> <p><a href="./references#CD012069-bbs2-0148" title="MachadoA , CerqueiraJ , RodriguesM , Soares‐FernandesJ . Is methylphenidate‐induced chorea responsive to chlorpromazine?. Journal of Neuropsychiatry and Clinical Neurosciences2010;22(3):352.e20. [DOI: 10.1176/jnp.2010.22.3.352.e20; PUBMED: 20686158] ">Machado 2010</a> reported choreoathetoid movements of orofacial muscles, arms and legs, and dystonic postures of the right arm in a 6‐year‐old girl with ADHD after an initial dose of 18 mg of extended‐release methylphenidate. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0154" title="McLarenJL , CaubleS , BarnettRJ . Aripiprazole induced acute dystonia after discontinuation of a stimulant medication. Journal of Clinical Psychopharmacology2010;30(1):77‐8. [DOI: 10.1097/JCP.0b013e3181c92eb2; PUBMED: 20075654] ">McLaren 2010</a> showed spasmodic muscular contractions in the jaw of a boy aged 11 years old with ADHD after receiving a dose of 108 mg of OROS methylphenidate. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0106" title="HollisCP , ThompsonA . Acute dyskinesia on starting methylphenidate after risperidone withdrawal. Pediatric Neurology2007;37(4):287‐8. [DOI: 10.1016/j.pediatrneurol.2007.05.017; PUBMED: 17903675] ">Hollis 2007</a> showed acute and transient dyskinesia within hours after treatment with 36 mg of modified‐released methylphenidate in a 7‐year‐old, stimulant‐naïve boy who had recently stopped taking risperidone. </p> </li> </ol> </p> </section> <section id="CD012069-sec-0187"> <p><b>Mood disorders</b></p> <p>See <a href="./references#CD012069-fig-0044" title="">Analysis 10.2</a> </p> <p> <ul id="CD012069-list-0062"> <li> <p>Depression and disturbed mood</p> </li> </ul> </p> <p>Three patient reports/series described depression and disturbed mood related to methylphenidate.</p> <p> <ol id="CD012069-list-0063"> <li> <p><a href="./references#CD012069-bbs2-0104" title="HechtmanL . Treatment of ADHD in patients unresponsive to methylphenidate. Journal of Psychiatry and Neuroscience2011;36(3):216. [DOI: 10.1503/jpn.110020; PMC3080516] ">Hechtman 2011</a> gave an account of a 5‐year‐old boy with ADHD receiving 35 mg of OROS methylphenidate titrated to 54 mg over one to two months who was exhibiting frequent crying, marked irritability and many tantrums, which subsided after methylphenidate treatment was discontinued. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0156" title="MinoY , AokiS . Methylphenidate‐induced psychosis in an adolescent with hyperkinetic disorder. Kawasaki Medical Journal1999;25(2):81‐5. [DOI: 10.11482/KMJ25(2)81‐85.1999.pdf] MinoY , OharaH , NagamatsuI , NagamatsuK . Methylphenidate psychosis in an adolescent with attention deficit disorder. Japanese Journal of Child and Adolescent Psychiatry1986; Vol. 27, issue 3:178‐87. ">Mino 1999</a> reported depressed mood three weeks after initiating methylphenidate treatment (10 mg/day) in a 16‐year‐old girl with ADHD. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0168" title="NiederhoferH . Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?. Psychiatria Danubina2009;21(3):330. [PUBMED: 19794351] NiederhoferH . Questions regarding your study 'Combining carbamazepine, neuroleptics and acetylcholinesterase inhibitors with methylphenidate only reduces adverse side effects, but is less effective than a combination with atomoxetine' [personal communication]. Email to: HB Krogh 31 July 2013. ">Niederhofer 2009</a> found depressed mood and appetite loss in a boy aged 11 years after two months of daily dosages of 20 mg of methylphenidate. </p> </li> </ol> <ul id="CD012069-list-0064"> <li> <p>Irritability</p> </li> </ul> </p> <p>Two patient reports/series described irritability related to methylphenidate.</p> <p> <ol id="CD012069-list-0065"> <li> <p>In <a href="./references#CD012069-bbs2-0104" title="HechtmanL . Treatment of ADHD in patients unresponsive to methylphenidate. Journal of Psychiatry and Neuroscience2011;36(3):216. [DOI: 10.1503/jpn.110020; PMC3080516] ">Hechtman 2011</a>, emotional mood, frequent crying, marked irritability and multiple tantrums were observed in a patient report/series of a 5‐year‐old boy with ADHD receiving 54 mg of OROS methylphenidate once a day for one to two months. </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0186" title="SabuncuogluO . Risperidone‐to‐methylphenidate switch reaction in children: three cases. Journal of Psychopharmacology2007;21(2):216‐9. [DOI: 10.1177/0269881107069466; PUBMED: 17329303] SabuncuogluO . Severe adverse events following risperidone‐to‐methylphenidate switch. Brown University Child and Adolescent Psychopharmacology Update2007;9(5):8‐8. [DOI: 10.1002/cpu.20043] ">Sabuncuoglu 2007</a>, another three reports of irritability and agitation were reported in one boy and two girls aged 5, 6 and 15 years (all diagnosed with ADHD), upon switching from 1 mg/day of risperidone to 15 mg/day of methylphenidate. </p> </li> </ol> <ul id="CD012069-list-0066"> <li> <p>Aggression</p> </li> </ul> </p> <p>Two patient reports/series described aggression related to methylphenidate.</p> <p> <ol id="CD012069-list-0067"> <li> <p>In <a href="./references#CD012069-bbs2-0040" title="CoignouxY , EstingoyP , BastardA . From hyperactivity to schizophrenia? Clinical, neurobiological and therapeutic discussion of a case [De l'hyperactivité à la schizophrénie? Discussion clinique, neurobiologique et thérapeutique, à propos d'un cas]. Annales Médico‐psychologiques, Revue Psychatrique2009;167(1):57‐65. [DOI: 10.1016/j.amp.2008.11.006] ">Coignoux 2009</a>, a 14‐year‐old boy receiving 54 mg/day of extended‐release methylphenidate for two years developed gestural stereotypes and verbal aggression towards his parents. </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0169" title="NiederhoferH . Combining carbamazepine, neuroleptics and acetylcholinesterase inhibitors with methylphenidate only reduces adverse side effects, but is less effective than a combination with atomoxetine. Medical Hypotheses2011;76(5):764‐5. [DOI: 10.1016/j.mehy.2011.02.011; PUBMED: 21397406] ">Niederhofer 2011</a>, two boys aged 10 and 11 years, who were receiving 20 mg/day of methylphenidate for two months, exhibited aggression and emotional instability. </p> </li> </ol> <ul id="CD012069-list-0068"> <li> <p>Mania/euphoria</p> </li> </ul> </p> <p>Two patient reports/series described mania/euphoria related to methylphenidate.</p> <p> <ol id="CD012069-list-0069"> <li> <p><a href="./references#CD012069-bbs2-0043" title="CorrigallR , FordT . Methylphenidate euphoria. Journal of the American Academy of Child and Adolescent Psychiatry1996;35(11):1421. [DOI: 10.1097/00004583‐199611000‐00005; PUBMED: 8936903] ">Corrigall 1996</a> reported euphoria in a 11‐year‐old boy with ADHD and hyperkinetic disorder, who received 10 mg/day of methylphenidate for four weeks, which subsequently increased to 15 mg/day for five days. </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0082" title="GhanizadehA . Excessive talking triggered by methylphenidate in a boy with ADHD. Pharmacopsychiatry2009;42(1):35‐6. [DOI: 10.1055/s‐0028‐1083821; PUBMED: 19153945] ">Ghanizadeh 2009</a>, hypertalkativity (scaled 7 to 9 on a 10‐point visual analogue scale) was found 45 minutes after taking 10 mg/day of methylphenidate in a 5‐year old boy, continuing for three to four hours. Re‐challenge was attempted more than 20 times, with hypertalkativity reoccurring on every consecutive attempt. </p> </li> </ol> </p> </section> <section id="CD012069-sec-0188"> <p><b>Sleep problems</b></p> <p>See <a href="./references#CD012069-fig-0045" title="">Analysis 10.3</a> </p> <p> <ul id="CD012069-list-0070"> <li> <p>Disturbed sleep</p> </li> </ul> </p> <p>One patient report/series described disturbed sleep related to methylphenidate (<a href="./references#CD012069-bbs2-0137" title="LangevinR , RamdéJ . Attention deficit hyperactivity disorder (ADHD) in children, seasonal photoperiods, nocturnal movements and diurnal agitation. Journal of the Canadian Academy of Child and Adolescent Psychiatry2012;21(1):53‐8. [PMC3269251] ">Langevin 2012</a>). This controlled before‐and‐after study showed a significant baseline difference (P = 0.008) between the number of nocturnal movements in a group of five ADHD children receiving an unspecified methylphenidate dosage and five ADHD children not on stimulant treatment. </p> <p> <ul id="CD012069-list-0071"> <li> <p>Other sleep problems</p> </li> </ul> </p> <p>Two patient reports/series described sleep problems related to methylphenidate. <a href="./references#CD012069-bbs2-0018" title="ArunP , SahniS . Methylphenidate and suicidal ideation: report of two cases. Indian Journal of Psychiatry2014;56(1):79‐81. [DOI: 10.4103/0019‐5545.124721; PMC3927251] ">Arun 2014</a> observed impaired sleep onset in an eight‐year‐old boy with ADHD who was receiving 5 mg/day of immediate‐release methylphenidate for two days. In <a href="./references#CD012069-bbs2-0048" title="CoşkunM , AhmetogluE , OzturkM . Mirtazapine treatment for comorbid anxiety/depressive disorders in young subjects with attention‐deficit hyperactivity disorder: case series. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2010;20(3):246‐51. ">Coşkun 2010</a>, the following problems were reported in a patient series of seven children with ADHD who were receiving 10 mg to 54 mg or immediate‐release/OROS methylphenidate for 4 to 30 months: sleep problems (n = 4), worsening of pre‐existing sleep problems (n = 2), and no worsening of such problems (n = 1). </p> </section> <section id="CD012069-sec-0189"> <p><b>Voice and speech disorders</b></p> <p>See <a href="./references#CD012069-fig-0046" title="">Analysis 10.4</a> </p> <p> <ul id="CD012069-list-0072"> <li> <p>Voice problems</p> </li> </ul> </p> <p>One patient report/series described voice problems related to methylphenidate (<a href="./references#CD012069-bbs2-0245" title="YalcinO , AslanAA , SariBA , TurkbayT . Possible methylphenidate related hoarseness and disturbances of voice quality: two pediatric cases. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2012; Vol. 22, issue 3:278‐82. [DOI: 10.5455/bcp.20120731061626] ">Yalcin 2012</a>). In this study, a 10‐year‐old boy with ADHD who was receiving 5 mg of immediate‐release methylphenidate, exhibited disturbances of voice quality, hoarseness, bifurcation‐strain and voice over‐vibrations beginning on the first day of treatment, which was scheduled to last for two weeks. </p> <p> <ul id="CD012069-list-0073"> <li> <p>Stuttering</p> </li> </ul> </p> <p>One patient report/series described stuttering related to methylphenidate (<a href="./references#CD012069-bbs2-0009" title="AlpaslanAH , CoşkunKŞ , KocakU , GorücüY . Stuttering associated with the use of short‐acting oral methylphenidate. Klinik Psikofarmakoloji Bülteni [Journal of Clinical Psychopharmacology]2015;35(6):739‐41. [DOI: 10.1097/JCP.0000000000000403; PUBMED: 26436866] ">Alpaslan 2015</a>). This study found stuttering in a 7‐year‐old boy with ADHD 10 days after receiving 10 mg/daily of immediate‐release methylphenidate. The treatment was ended immediately, and one week later the stuttering ended. </p> </section> <section id="CD012069-sec-0190"> <p><b>Other specific adverse events</b></p> <p>See <a href="./references#CD012069-fig-0047" title="">Analysis 10.5</a> </p> <p> <ul id="CD012069-list-0074"> <li> <p>Anorexia</p> </li> </ul> </p> <p>One patient report/series described anorexia related to methylphenidate (<a href="./references#CD012069-bbs2-0069" title="FindlingRL . Open‐label treatment of comorbid depression and attentional disorders with co‐administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. Journal of Child and Adolescent Psychopharmacology1996;6(3):165‐75. [DOI: 10.1089/cap.1996.6.165; PUBMED: 9231310] ">Findling 1996</a>). In this study, an 11‐year‐old girl with ADHD received 5 mg of methylphenidate twice a day for three months and experienced mild and transient anorexia, resulting in a weight loss of 2 kg after treatment. </p> <p> <ul id="CD012069-list-0075"> <li> <p>Obsessive compulsive disorder (OCD) symptoms</p> </li> </ul> </p> <p>Two patient reports/series described OCD related to methylphenidate.</p> <p> <ol id="CD012069-list-0076"> <li> <p><a href="./references#CD012069-bbs2-0049" title="CoşkunM . Methylphenidate induced obsessive‐compulsive symptoms treated with sertraline. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2011;21(3):274. [DOI: 10.5455/bcp.20110904061403] ">Coşkun 2011</a> found symptoms of OCD, facial grimaces, nail picking and biting in a 10‐year‐old girl with ADHD who was receiving 27 mg/day of OROS methylphenidate for six weeks. The symptoms gradually disappeared upon discontinuation of methylphenidate and reoccurred when re‐administering the same dosage at a later stage. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0244" title="WoolleyJB , HeymanI . Dexamphetamine for obsessive‐compulsive disorder. American Journal of Psychiatry2003;160(1):183. ">Woolley 2003</a> found obsessions and compulsions with anxiety, such as excessive handwashing, ritual checking and emetophobia, in an 11‐year‐old boy with ADHD and comorbid OCD upon receiving 40 mg/day of immediate‐release methylphenidate for more than 15 months. These symptoms decreased rapidly upon methylphenidate withdrawal and increased when it was later reintroduced. </p> </li> </ol> <ul id="CD012069-list-0077"> <li> <p>Headache</p> </li> </ul> </p> <p>One patient report/series described headache related to methylphenidate (<a href="./references#CD012069-bbs2-0157" title="MizeW . Hemoencephalography ‐ a new therapy for attention deficit hyperactivity disorder (ADHD): case report. Journal of Neurotherapy2004;8(3):77‐97. [DOI: 10.1300/J184v0803_06] ">Mize 2004</a>). This study reported headache and mild depression in a 12‐year‐old boy after a methylphenidate dosage of 26 mg. </p> <p> <ul id="CD012069-list-0078"> <li> <p>EEG changes</p> </li> </ul> </p> <p>One patient report/series described EEG changes related to methylphenidate (<a href="./references#CD012069-bbs2-0059" title="DupuyFE , ClarkeAR , BarryRJ , McCarthyR , SelikowitzM . EEG coherence in girls with attention‐deficit/hyperactivity disorder: stimulant effects in good responders. International Journal of Psychophysiology2008;70(3):151‐7. [DOI: 10.1016/j.ijpsycho.2008.07.012; PUBMED: 18708101] ">Dupuy 2008</a>). In this study, elevated frontal coherence in all frequency bands was shown on the EEG‐measurements of nine girls with ADHD who were administered methylphenidate over six months with unreported dosages. </p> </section> </section> <section id="CD012069-sec-0191"> <h6 class="title">3.2.3 Cardiovascular and respiratory system</h6> <p>See <a href="./references#CD012069-fig-0048" title="">Analysis 10.6</a>. We found four patient reports/series of non‐serious adverse events related to the circulatory and respiratory system (<a href="./references#CD012069-bbs2-0094" title="GrossmanLK , GrossmanNJ . Methylphenidate and idiopathic thrombocytopenic purpura‐‐is there an association?. Journal of Family Practice1985;20(3):302‐4. [PUBMED: 4038730] ">Grossman 1985</a>; <a href="./references#CD012069-bbs2-0118" title="Pulmonary arterial hypertension with methylphenidate OROS initiation. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(9):8‐8. [DOI: 10.1002/cpu.20123] KaramanMG , AtalayF , TufanAE , ErdoganA . Pulmonary arterial hypertension in an adolescent treated with methylphenidate. Journal of Child &amp; Adolescent Psychopharmacology2010;20(3):229‐31. [DOI: 10.1089/cap.2009.0095; PUBMED: 20578938] ">Karaman 2010</a>; <a href="./references#CD012069-bbs2-0253" title="YuZJ , Parker‐KotlerC , TranK , WellerRA , WellerEB . Peripheral vasculopathy associated with psychostimulant treatment in children with attention‐deficit/hyperactivity disorder. Current Psychiatry Reports2010;12(2):111‐5. [DOI: 10.1007/s11920‐010‐0093‐y; PUBMED: 20425295] ">Yu 2010</a>; <a href="./references#CD012069-bbs2-0089" title="GraciousBL . Atrioventricular nodal re‐entrant tachycardia associated with stimulant treatment. Journal of Child and Adolescent Psychopharmacology1999;9(2):125‐8. [DOI: 10.1089/cap.1999.9.125; PUBMED: 10461823] ">Gracious 1999</a>). </p> <section id="CD012069-sec-0192"> <p><b>Vasculopathy</b></p> <p>One patient report/series described vasculopathy related to methylphenidate (<a href="./references#CD012069-bbs2-0253" title="YuZJ , Parker‐KotlerC , TranK , WellerRA , WellerEB . Peripheral vasculopathy associated with psychostimulant treatment in children with attention‐deficit/hyperactivity disorder. Current Psychiatry Reports2010;12(2):111‐5. [DOI: 10.1007/s11920‐010‐0093‐y; PUBMED: 20425295] ">Yu 2010</a>). This study observed signs of vasculopathy in three male patients. First, a 16‐year‐old boy was diagnosed with "decreased circulation but not Raynaud's syndrome", occurring when his methylphenidate (Concerta) dose was increased from 54 mg/day to 90 mg/day for three months while on a constant dose of dexmethylphenidate (Focalin) (10 mg/day). Second, Raynaud's syndrome with finger pain and colour changes was observed in a 10‐year‐old boy on 30 mg/day of methylphenidate hydrochloride (Ritalin LA) and 2.5 mg/day of dexmethylphenidate for five years. Third, reddish and purple colour changes in the hands and feet of an 11‐year‐old boy were observed whilst on a daily dose of 20 mg of dexmethylphenidate hydrochloride (extended‐release capsules) and 10 mg of immediate‐release dexmethylphenidate for one year. </p> </section> <section id="CD012069-sec-0193"> <p><b>Cardiovascular problems</b></p> <p>One patient report/series described cardiovascular problems related to methylphenidate (<a href="./references#CD012069-bbs2-0118" title="Pulmonary arterial hypertension with methylphenidate OROS initiation. Brown University Child &amp; Adolescent Psychopharmacology Update2010;12(9):8‐8. [DOI: 10.1002/cpu.20123] KaramanMG , AtalayF , TufanAE , ErdoganA . Pulmonary arterial hypertension in an adolescent treated with methylphenidate. Journal of Child &amp; Adolescent Psychopharmacology2010;20(3):229‐31. [DOI: 10.1089/cap.2009.0095; PUBMED: 20578938] ">Karaman 2010</a>). In this study, a 15‐year‐old with ADHD developed pulmonary arterial hypertension (PAH) after 18 months of treatment with 54 mg/day of OROS‐methylphenidate. One month following a decision to discontinue OROS methylphenidate, the symptoms disappeared. </p> </section> <section id="CD012069-sec-0194"> <p><b>Bleeding</b></p> <p>One patient report/series described bleeding related to methylphenidate (<a href="./references#CD012069-bbs2-0094" title="GrossmanLK , GrossmanNJ . Methylphenidate and idiopathic thrombocytopenic purpura‐‐is there an association?. Journal of Family Practice1985;20(3):302‐4. [PUBMED: 4038730] ">Grossman 1985</a>). This study reported on a 7‐year‐old girl with ADHD receiving 10 mg of methylphenidate three times a day for seven months, who experienced idiopathic thrombocytopenic purpura (ITP). One week following a decision to end methylphenidate treatment, the petechia began to fade, and one year later there had been no reoccurrence of petechiae or bruising. </p> </section> <section id="CD012069-sec-0195"> <p><b>Tachycardia</b></p> <p>One patient report/series described tachycardia related to methylphenidate (<a href="./references#CD012069-bbs2-0089" title="GraciousBL . Atrioventricular nodal re‐entrant tachycardia associated with stimulant treatment. Journal of Child and Adolescent Psychopharmacology1999;9(2):125‐8. [DOI: 10.1089/cap.1999.9.125; PUBMED: 10461823] ">Gracious 1999</a>). In this study, a 13‐year‐old girl with ADHD, who was administered 20 mg of methylphenidate twice daily for three months and subsequently 20 mg of sustained‐release methylphenidate for 11 months once daily, developed atrioventricular nodal re‐entrant tachycardia during treatment. </p> </section> </section> <section id="CD012069-sec-0196"> <h6 class="title">3.2.4 Gastrointestinal system</h6> <p>See <a href="./references#CD012069-fig-0049" title="">Analysis 10.7</a>. We found five patient reports/series of non‐serious, gastrointestinal adverse events (<a href="./references#CD012069-bbs2-0005" title="AgarwalV , SitholeyP . Combination of atomoxetine and methylphenidate in attention deficit/hyperactivity disorder: a case report. Journal of the Canadian Academy of Child and Adolescent Psychiatry2008;17(3):160. [PMC2527769] ">Agarwal 2008</a>; <a href="./references#CD012069-bbs2-0046" title="CoşkunM , TutkunkardasMD , ZorogluS . OROS methylphenidate‐induced skin eruptions. Journal of Child and Adolescent Psychopharmacology2009; Vol. 19, issue 5:593‐4. [DOI: 10.1089/cap.2009.0009; PUBMED: 19877987] ">Coşkun 2009a</a>; <a href="./references#CD012069-bbs2-0079" title="GhanizadehA . Insomnia, night terror, and depression related to clonidine in attention‐deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology2008;28(6):725‐6. [DOI: 10.1097/JCP.0b013e31818ce741; PUBMED: 19011458] ">Ghanizadeh 2008a</a>; <a href="./references#CD012069-bbs2-0181" title="RappaportN , CoffeyB . Psychopharmacology in the school setting: therapeutic challenges in an adolescent with attention deficit hyperactivity disorder, possible bipolar disorder, and other comorbidity. Journal of Child and Adolescent Psychopharmacology2004;14(1):3‐7. [DOI: 10.1089/104454604773840418; PUBMED: 15142385] ">Rappaport 2004</a>; <a href="./references#CD012069-bbs2-0245" title="YalcinO , AslanAA , SariBA , TurkbayT . Possible methylphenidate related hoarseness and disturbances of voice quality: two pediatric cases. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2012; Vol. 22, issue 3:278‐82. [DOI: 10.5455/bcp.20120731061626] ">Yalcin 2012</a>). </p> <section id="CD012069-sec-0197"> <p><b>Loss of appetite</b></p> <p>All five patients reports described loss of appetite related to methylphenidate.</p> <p> <ol id="CD012069-list-0079"> <li> <p><a href="./references#CD012069-bbs2-0005" title="AgarwalV , SitholeyP . Combination of atomoxetine and methylphenidate in attention deficit/hyperactivity disorder: a case report. Journal of the Canadian Academy of Child and Adolescent Psychiatry2008;17(3):160. [PMC2527769] ">Agarwal 2008</a> found decreased appetite in an 8‐year‐old boy with ADHD on 50 mg/day of immediate‐release methylphenidate and atomoxetine for six months. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0046" title="CoşkunM , TutkunkardasMD , ZorogluS . OROS methylphenidate‐induced skin eruptions. Journal of Child and Adolescent Psychopharmacology2009; Vol. 19, issue 5:593‐4. [DOI: 10.1089/cap.2009.0009; PUBMED: 19877987] ">Coşkun 2009a</a> found loss of appetite but no weight decrease in an 6‐year‐old boy receiving 10 mg/day to 20 mg/day of immediate‐release methylphenidate and 400 mg/day valproate for two months. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0079" title="GhanizadehA . Insomnia, night terror, and depression related to clonidine in attention‐deficit/hyperactivity disorder. Journal of Clinical Psychopharmacology2008;28(6):725‐6. [DOI: 10.1097/JCP.0b013e31818ce741; PUBMED: 19011458] ">Ghanizadeh 2008a</a> reported significant decreases in appetite in a 8.5‐year‐old boy with ADHD and oppositional defiant disorder on 20 mg/day of methylphenidate for one month. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0181" title="RappaportN , CoffeyB . Psychopharmacology in the school setting: therapeutic challenges in an adolescent with attention deficit hyperactivity disorder, possible bipolar disorder, and other comorbidity. Journal of Child and Adolescent Psychopharmacology2004;14(1):3‐7. [DOI: 10.1089/104454604773840418; PUBMED: 15142385] ">Rappaport 2004</a> found loss of appetite whilst on an unspecified dose of immediate‐release methylphenidate in a 14‐year‐old boy with ADHD and various comorbidities, who was comedicated with olanzapine. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0245" title="YalcinO , AslanAA , SariBA , TurkbayT . Possible methylphenidate related hoarseness and disturbances of voice quality: two pediatric cases. Klinik Psikofarmakoloji Bülteni [Bulletin of Clinical Psychopharmacology]2012; Vol. 22, issue 3:278‐82. [DOI: 10.5455/bcp.20120731061626] ">Yalcin 2012</a> observed significant appetite loss in a 11‐year‐old boy with ADHD and comorbid specific learning disorder and social anxiety, who was receiving 18 mg/day of OROS methylphenidate for two weeks. The symptoms disappeared on drug‐free days. </p> </li> </ol> </p> </section> <section id="CD012069-sec-0198"> <p><b>Nausea and vomiting</b></p> <p>One patient report/series also described nausea and vomiting related to methylphenidate (<a href="./references#CD012069-bbs2-0181" title="RappaportN , CoffeyB . Psychopharmacology in the school setting: therapeutic challenges in an adolescent with attention deficit hyperactivity disorder, possible bipolar disorder, and other comorbidity. Journal of Child and Adolescent Psychopharmacology2004;14(1):3‐7. [DOI: 10.1089/104454604773840418; PUBMED: 15142385] ">Rappaport 2004</a>). This study found nausea and vomiting in the same 14‐year‐old whilst on an unspecified dose of extended‐release methylphenidate. </p> </section> </section> <section id="CD012069-sec-0199"> <h6 class="title">3.2.5 Musculoskeletal system</h6> <section id="CD012069-sec-0200"> <p><b>Growth</b></p> <p>We found one patient report/series on reduced growth related to methylphenidate (<a href="./references#CD012069-bbs2-0107" title="HoltkampK , Peters‐WallrafB , WullerS , PfäaffleR , Herpertz‐DahlmannB . Methylphenidate‐related growth impairment. Journal of Child and Adolescent Psychopharmacology2002;12(1):55‐61. [DOI: 10.1089/10445460252943579; PUBMED: 12014596] ">Holtkamp 2002</a>). This study found growth impairment in a 7‐year‐old boy with ADHD on 20 mg/day to 25 mg/day of methylphenidate for 19 months (<a href="./references#CD012069-fig-0050" title="">Analysis 10.8</a>). </p> </section> </section> <section id="CD012069-sec-0201"> <h6 class="title">3.2.6 Immune system</h6> <section id="CD012069-sec-0202"> <p><b>Allergic reactions</b></p> <p>See <a href="./references#CD012069-fig-0051" title="">Analysis 10.9</a>. We found two patient reports/series on allergic reactions related to methylphenidate. </p> <p> <ol id="CD012069-list-0080"> <li> <p><a href="./references#CD012069-bbs2-0041" title="Confino‐CohenR , GoldbergA . Successful desensitization of methylphenidate‐induced rash. Journal of Child and Adolescent Psychopharmacology2005;15(4):703‐5. [DOI: 10.1089/cap.2005.15.703; PUBMED: 16190802] ">Confino‐Cohen 2005</a> reported pruritic maculopapular skin rash during 10 mg/day methylphenidate treatment for one week in an 8‐year‐old girl with ADHD. The rash improved with antihistamines and, while re‐challenge at a lower dose caused reappearances of rash, the symptoms were less severe the second time around. </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0222" title="VashiNA , SouzaA , CohenN , FranklinB , CohenDE . Allergic contact dermatitis caused by methylphenidate. Contact Dermatitis2011;65(3):183‐85. [DOI: 10.1111/j.1600‐0536.2011.01949.x; PUBMED: 21827513] ">Vashi 2011</a>, a 9‐year‐old girl with ADHD receiving an unknown dosage of methylphenidate patches for eight months presented with pruritic dermatitis, with itchy, burning, red lesions on her arms, legs, abdomen and back, lasting two months following methylphenidate discontinuation. Similar rashes later reoccurred upon re‐testing methylphenidate treatment. </p> </li> </ol> </p> </section> </section> <section id="CD012069-sec-0203"> <h6 class="title">3.2.7 Urogenital system</h6> <p>See <a href="./references#CD012069-fig-0052" title="">Analysis 10.10</a>. We found five patient reports/series related to the urogenital system (<a href="./references#CD012069-bbs2-0180" title="RamasamyR , DadhichP , DhingraA , LipshultzL . Case report: testicular failure possibly associated with chronic use of methylphenidate. F1000Research2014;3:207. [DOI: 10.12688/f1000research.5163.1; PMC4215747; PUBMED: 25383187] ">Ramasamy 2014</a>; <a href="./references#CD012069-bbs2-0047" title="CoşkunM , ZorogluS . A report of two cases of sexual side effects with OROS methylphenidate. Journal of Child and Adolescent Psychopharmacology2009;19(4):477‐9. [DOI: 10.1089/cap.2008.0161; PUBMED: 19702503] ">Coşkun 2009b</a>; <a href="./references#CD012069-bbs2-0209" title="TangCS , ChouWJ , ChengAT . Osmotic release oral system (OROS) methylphenidate‐induced double incontinence: a case report. Primary Care Companion to the Journal of Clinical Psychiatry2010;12(3):PCC.09l00870. [DOI: 10.4088/PCC.09l00870pur; PMC2947529] ">Tang 2010</a>; <a href="./references#CD012069-bbs2-0080" title="GhanizadehA . Methylphenidate‐associated enuresis in attention deficit hyperactivity disorder. Journal of Pediatric Urology2008;4(4):306‐7. [DOI: 10.1016/j.jpurol.2007.10.001; PUBMED: 18644535] ">Ghanizadeh 2008b</a>; <a href="./references#CD012069-bbs2-0240" title="Resolution of enuresis with stimulant treatment of ADHD. Brown University Child and Adolescent Psychopharmacology Update2011;13(6):8‐8. [DOI: 10.1002/cpu.20141] WilliamsonLB , GowerM , UlzenT . Clinical case rounds in child and adolescent psychiatry: enuresis and ADHD in older children and an adolescent treated with stimulant medication: a case series. Journal of the Canadian Academy of Child and Adolescent Psychiatry2011;20(1):53‐5. [PMC3024723] ">Williamson 2011</a>). </p> <section id="CD012069-sec-0204"> <p><b>Testicular failure</b></p> <p>We found one patient report/series on testicular failure related to methylphenidate (<a href="./references#CD012069-bbs2-0180" title="RamasamyR , DadhichP , DhingraA , LipshultzL . Case report: testicular failure possibly associated with chronic use of methylphenidate. F1000Research2014;3:207. [DOI: 10.12688/f1000research.5163.1; PMC4215747; PUBMED: 25383187] ">Ramasamy 2014</a>). In this study, a 20‐year‐old male patient with ADHD, treated with methylphenidate for approximately 17 years at various doses, reported testicular failure and poor erectile function. </p> </section> <section id="CD012069-sec-0205"> <p><b>Sexual adverse events</b></p> <p>One patient report/series described serious adverse events related to methylphenidate (<a href="./references#CD012069-bbs2-0047" title="CoşkunM , ZorogluS . A report of two cases of sexual side effects with OROS methylphenidate. Journal of Child and Adolescent Psychopharmacology2009;19(4):477‐9. [DOI: 10.1089/cap.2008.0161; PUBMED: 19702503] ">Coşkun 2009b</a>). This study reported multiple, daily, painless erections unrelated to any sexual stimuli and without ejaculation in a 15‐year‐old boy with ADHD administered 10 mg/day to 30 mg/day of immediate‐release methylphenidate for one month, 18 mg/day of OROS methylphenidate for one month and 36 mg/day of OROS methylphenidate for three weeks. They also found hypersexual behaviour and morning erections prior to ingesting methylphenidate, with no such behaviour on drug‐free days, on 18 mg/day of OROS‐methylphenidate, which were dramatically reduced on 10 mg/day to 20 mg/day of immediate‐release methylphenidate, only to return in fluctuations on 18 mg/day of OROS methylphenidate (with no hypersexual behaviour on drug‐free days). </p> </section> <section id="CD012069-sec-0206"> <p><b>Incontinence</b></p> <p>One patient report/series described incontinence related to methylphenidate (<a href="./references#CD012069-bbs2-0209" title="TangCS , ChouWJ , ChengAT . Osmotic release oral system (OROS) methylphenidate‐induced double incontinence: a case report. Primary Care Companion to the Journal of Clinical Psychiatry2010;12(3):PCC.09l00870. [DOI: 10.4088/PCC.09l00870pur; PMC2947529] ">Tang 2010</a>). In this study, almost daily urinary incontinence on 36 mg/daily of OROS methylphenidate for two weeks was observed in an 8‐year‐old boy with ADHD, which was rapidly and completely resolved after discontinuation of the treatment dose. </p> </section> <section id="CD012069-sec-0207"> <p><b>Enuresis</b></p> <p>Two patient reports/series described enuresis related to methylphenidate.</p> <p> <ol id="CD012069-list-0081"> <li> <p>In <a href="./references#CD012069-bbs2-0080" title="GhanizadehA . Methylphenidate‐associated enuresis in attention deficit hyperactivity disorder. Journal of Pediatric Urology2008;4(4):306‐7. [DOI: 10.1016/j.jpurol.2007.10.001; PUBMED: 18644535] ">Ghanizadeh 2008b</a>, 20 mg/day of methylphenidate was titrated and discontinued three times for an 11‐year‐old boy with nocturnal enuresis occurring and ceasing each consecutive time. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0240" title="Resolution of enuresis with stimulant treatment of ADHD. Brown University Child and Adolescent Psychopharmacology Update2011;13(6):8‐8. [DOI: 10.1002/cpu.20141] WilliamsonLB , GowerM , UlzenT . Clinical case rounds in child and adolescent psychiatry: enuresis and ADHD in older children and an adolescent treated with stimulant medication: a case series. Journal of the Canadian Academy of Child and Adolescent Psychiatry2011;20(1):53‐5. [PMC3024723] ">Williamson 2011</a> also found resolution of daily enuresis in a 9‐year‐old boy with ADHD on 54 mg/day of extended‐release methylphenidate and an 11‐year‐old girl with ADHD on 10 mg/daily of extended‐release dexmethylphenidate for a short‐term period. </p> </li> </ol> </p> </section> </section> <section id="CD012069-sec-0208"> <h6 class="title">3.2.8 Other body systems</h6> <p>See <a href="./references#CD012069-fig-0053" title="">Analysis 10.11</a>. We found five patient reports/series of other, non‐serious adverse events (<a href="./references#CD012069-bbs2-0039" title="CohenHA , AshkenaziA , NussinovitchM , GrossS , FrydmanM . Fixed drug eruption of the scrotum due to methylphenidate. Annals of Pharmacotherapy1992;26(11):1378‐9. [DOI: 10.1177/106002809202601107; PUBMED: 1477441] ">Cohen 1992</a>; <a href="./references#CD012069-bbs2-0046" title="CoşkunM , TutkunkardasMD , ZorogluS . OROS methylphenidate‐induced skin eruptions. Journal of Child and Adolescent Psychopharmacology2009; Vol. 19, issue 5:593‐4. [DOI: 10.1089/cap.2009.0009; PUBMED: 19877987] ">Coşkun 2009a</a>; <a href="./references#CD012069-bbs2-0081" title="GhanizadehA . Questions regarding 'Insomnia, night terror, and depression related to clonidine in attention‐deficit/hyperactivity disorder' [personal communication]. Email to: EL Ramstad 4 July 2013. GhanizadehA , AghakhaniK . Photophobia and methylphenidate. Psychopharmacology Bulletin2008;41(1):171‐3. [PUBMED: 18362880] ">Ghanizadeh 2008c</a>; <a href="./references#CD012069-bbs2-0143" title="LewisH , LewisJ . Safe and effective methylphenidate therapy in a pediatric patient with glaucoma. ADHD Attention Deficit and Hyperactivity Disorders2012; Vol. 4, issue 1:37‐9. [DOI: 10.1007/s12402‐012‐0071‐9; PUBMED: 22311620] ">Lewis 2012</a>; <a href="./references#CD012069-bbs2-0185" title="RirieDG , RirieKL , SethnaNF , FoxL . Unexpected interaction of methylphenidate (Ritalin) with anaesthetic agents. Paediatric Anaesthesia1997;7(1):69‐72. [PUBMED: 9041578] ">Ririe 1997</a>). </p> <section id="CD012069-sec-0209"> <p><b>Skin reactions</b></p> <p>Two patient reports/series described skin reactions related to methylphenidate.</p> <p> <ol id="CD012069-list-0082"> <li> <p><a href="./references#CD012069-bbs2-0039" title="CohenHA , AshkenaziA , NussinovitchM , GrossS , FrydmanM . Fixed drug eruption of the scrotum due to methylphenidate. Annals of Pharmacotherapy1992;26(11):1378‐9. [DOI: 10.1177/106002809202601107; PUBMED: 1477441] ">Cohen 1992</a> found severe swelling and redness of the scrotum in an 8‐year‐old boy with ADD, which spontaneously resolved four days after the methylphenidate dose of 10 mg/day was discontinued. Eighteen hours after methylphenidate retesting, the same skin eruption was documented, which again was resolved after another discontinuation of treatment. A 10‐year‐old boy from the same study, who was given the same methylphenidate dose, reported six hours of severe swelling and skin eruption of the scrotum within two days following treatment. The reactions were resolved upon drug withdrawal. </p> </li> <li> <p><a href="./references#CD012069-bbs2-0046" title="CoşkunM , TutkunkardasMD , ZorogluS . OROS methylphenidate‐induced skin eruptions. Journal of Child and Adolescent Psychopharmacology2009; Vol. 19, issue 5:593‐4. [DOI: 10.1089/cap.2009.0009; PUBMED: 19877987] ">Coşkun 2009a</a> found maculopapular pruritic skin eruption in an 8‐year‐old boy with ADHD following treatment with 18 mg/day of OROS methylphenidate and 400 mg/day of valproate. When the medication was discontinued, the skin lesion abated within weeks, and did not reoccur upon when restarting 10 mg/day to 20 mg/day of immediate‐release methylphenidate and 300 mg/day of gabapentine. </p> </li> </ol> </p> </section> <section id="CD012069-sec-0210"> <p><b>Problems with sedation</b></p> <p>One patient report/series described sedation problems related to methylphenidate (<a href="./references#CD012069-bbs2-0185" title="RirieDG , RirieKL , SethnaNF , FoxL . Unexpected interaction of methylphenidate (Ritalin) with anaesthetic agents. Paediatric Anaesthesia1997;7(1):69‐72. [PUBMED: 9041578] ">Ririe 1997</a>). This study reported difficulty with conscious sedation in a 6‐year‐old boy with ADHD on 10 mg/day of immediate‐release methylphenidate, who had a comorbid history of William's syndrome and supravalvar aortic stenosis. He remained alert and unable to lie still despite being given oral doses of sedatives, pointing to a potential interaction between methylphenidate and the anaesthetic agents. </p> </section> <section id="CD012069-sec-0211"> <p><b>Eye problems</b></p> <p>Two patient reports/series described eye problems related to methylphenidate.</p> <p> <ol id="CD012069-list-0083"> <li> <p>In <a href="./references#CD012069-bbs2-0081" title="GhanizadehA . Questions regarding 'Insomnia, night terror, and depression related to clonidine in attention‐deficit/hyperactivity disorder' [personal communication]. Email to: EL Ramstad 4 July 2013. GhanizadehA , AghakhaniK . Photophobia and methylphenidate. Psychopharmacology Bulletin2008;41(1):171‐3. [PUBMED: 18362880] ">Ghanizadeh 2008c</a>, photophobia occurred a few days after initiation of 35 mg/day of methylphenidate treatment in a 7‐year‐old boy. The symptoms ceased and reoccurred upon discontinuation and readministration of methylphenidate. </p> </li> <li> <p>In <a href="./references#CD012069-bbs2-0143" title="LewisH , LewisJ . Safe and effective methylphenidate therapy in a pediatric patient with glaucoma. ADHD Attention Deficit and Hyperactivity Disorders2012; Vol. 4, issue 1:37‐9. [DOI: 10.1007/s12402‐012‐0071‐9; PUBMED: 22311620] ">Lewis 2012</a>, during 18 mg/day of extended‐release methylphenidate, which was titrated to 54 mg/day over six months, a 10‐year‐old girl with ADHD showed intraocular pressure in the 16 mmHg to 19 mmHg range bilaterally in one study. </p> </li> </ol> </p> <p>No [patient reports/series] reported on withdrawal of treatment due to non‐serious adverse events or for unknown reasons. </p> </section> </section> </section> </section> <section id="CD012069-sec-0212"> <h4 class="title">Subgroup analyses</h4> <p>We conducted the subgroup analyses below using the <a href="./references#CD012069-bbs2-0453" title="BioStat . Comprehensive Meta Analysis. www.meta‐analysis.com (accessed 9 February 2018). ">Comprehensive Meta Analysis</a> software (analyses not shown). </p> <section id="CD012069-sec-0213"> <h5 class="title">Duration of methylphenidate treatment</h5> <p>We found no significant difference (P = 0.83) between the proportion of participants on methylphenidate with any serious adverse events in short‐term (less than six months: 1.20%, 95% CI 0.7% to 2.1%; 41 studies, 159,407 participants) versus long‐term (six months or more: 1.1%, 95% CI 0.3% to 3.4%; 10 studies, 3015 participants) non‐comparative studies. </p> <p>We found no significant difference (P = 0.74) between the proportion of participants on methylphenidate with any non‐serious adverse events in short‐term (less than six months: 52.3%, 95% CI 52.3% to 39.6%; 35 studies, 11,411 participants) versus long‐term (six months or more: 48.9%, 95% CI 33.7% to 64.3%; 14 studies, 2567 participants) non‐comparative studies. </p> </section> <section id="CD012069-sec-0214"> <h5 class="title">Comorbidity</h5> <p>We found no significant difference (P = 0.21) in the proportion of participants experiencing non‐serious adverse events between those with ADHD and any comorbidity (54.2%, 95% CI 42.7% to 65.5%; 40 trials, 13,039 participants) versus those with ADHD and no comorbidities (40.4%, 95% CI 24.5% to 58.7%; 9 trials, 939 participants) in non‐comparative cohort studies of methylphenidate. </p> <p>We could not carry out the subgroup analysis on serious adverse events due to insufficient data on comorbidity. </p> </section> <section id="CD012069-sec-0215"> <h5 class="title">Concurrent medication‐intervention</h5> <p>We found a significant difference (P = 0.011) in the proportion of participants with ADHD experiencing any non‐serious adverse events between those taking methylphenidate and no other medication (53.6%, 95% CI 42.9% to 64.0%; 43 trials, 12547 participants) versus those also taking other medications (27.1%, 95% CI 14.8% to 44.3%; 6 trials, 1431 participants) in non‐comparative cohort studies. </p> <p>We could not carry out the subgroup analysis on serious adverse events due to insufficient data on concurrent medication. </p> </section> <section id="CD012069-sec-0216"> <h5 class="title">Dose of methylphenidate</h5> <p>We found no significant difference (P = 0.062) in the proportion of participants experiencing any non‐serious adverse events between those on low‐dose (less than 20 mg/day: 45.3%, 95% CI 33.7% to 57.5%; 35 studies, 159,278 participants) versus high‐dose (20 mg/day and above: 64.4%, 95% CI 48.4% to 77.7%; 14 studies, 3144 participants) methylphenidate in non‐comparative studies. </p> <p>We could not carry out the subgroup analysis on serious adverse events due to insufficient data on dose of methylphenidate. </p> </section> <section id="CD012069-sec-0217"> <h5 class="title">Age of participants</h5> <p>We found no significant difference (P = 0.23) in the proportion of participants on methylphenidate with any non‐serious adverse events between non‐comparative studies where the mean participant ages are 10 years or more (53.8%, 95% CI 37.2% to 69.5%; 22 studies, 159,278 participants) versus those where the mean participant ages are less than 10 years (47.1%, 95% CI 36.0% to 57.8%; 27 studies, 3144 participants) in non‐comparative studies. </p> <p>We could not carry out the subgroup analysis on serious adverse events due to insufficient data on age of participants. </p> </section> <section id="CD012069-sec-0218"> <h5 class="title">Study design</h5> <p>We found a significant difference (P = 0.01) between the proportion of participants on methylphenidate with any serious adverse events in the non‐comparative, classic cohort studies (1.10%, 95% CI 0.60% to 2.00%; 32 studies, 159,761 participants) versus those in cohort studies from RCTs assessing methylphenidate versus other intervention for ADHD (1.60%, 95% CI 1.00% to 2.30%; 18 studies, 2661 participants) </p> <p>We found no significant difference (P = 0.17) between the proportion of participants on methylphenidate with any non‐serious adverse events in the non‐comparative, classic cohort studies (47.10%, 95% CI 35.6% to 58.9%; 36 studies, 13,035 participants), compared to those in cohort studies from RCTs assessing methylphenidate versus other intervention for ADHD (62.1%, 95% CI 44.4% to 77.1%; 13 studies, 943 participants) </p> </section> <section id="CD012069-sec-0219"> <h5 class="title">Study funding</h5> <p>We found no significant difference (P = 0.22) between the proportion of participants on methylphenidate with any serious adverse events in non‐comparative cohort studies funded by industry (1.0%, 95% CI 0.6% to 1.6%; 30 studies, 137,152 participants) versus those not funded by industry (1.80%, 95% CI 0.80% to 4.10%; 20 studies, 25,270 participants); however, when looking only at the point estimate there seems to be 0.8% more serious adverse events in the group of studies not funded by industry. </p> <p>On the other hand, in non‐comparative cohort studies we did find a significant difference (P = 0.02) in the proportion of participants on methylphenidate with any non‐serious adverse events between studies funded (41.6%, 95% CI 32.8% to 51.0%; 27 studies, 7981 participants) versus those not funded (64.2%, 95% CI 46.9% to 78.5%; 22 studies, 5997 participants) by industry. </p> </section> </section> <section id="CD012069-sec-0220"> <h4 class="title">Sensitivity analyses</h4> <p>We conducted a sensitivity analysis to test the robustness of our findings using the alternative, fixed‐effect model, for the outcome of non‐serious adverse events. In most analyses, there were no significant differences between the two statistical models. In cases where there was a statistical difference, the fixed‐effect model mostly showed a higher proportion of adverse events. Therefore, the decision to report the results of the random‐effects model was a conservative one. </p> <p>We also conducted a sensitivity analysis to test the robustness of our findings to the removal of patient‐control studies from the analysis, for the outcome of any serious adverse events; we found no statistical difference (<a href="./references#CD012069-fig-0008" title="">Analysis 1.1</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012069-sec-0221" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012069-sec-0221"></div> <section id="CD012069-sec-0222"> <h3 class="title" id="CD012069-sec-0222">Summary of main results</h3> <p>Our search found 260 relevant non‐randomized studies from 431 reports consisting of: 7 comparative cohort studies, 4 patient‐control studies, 177 non‐comparative cohort studies, 70 patient reports/series, and 2 cross‐sectional studies. We reported adverse events data from 2,283,509 participants worldwide, of both genders, aged between 3 and 20 years. The risk of bias in the comparative studies ranged from moderate to critical, whereas all non‐comparative studies were at critical risk of bias. The quality of evidence for all outcomes was very low according to GRADE standards. We found that the occurrence of serious adverse events in the comparative cohort and patient‐control studies was 1.36 times more frequent in participants that used methylphenidate when compared to controls. In cohort studies without a control group, we found a low proportion (1.20%) of any serious adverse events. Out of these, 22 studies had adverse events data for the central nervous system, 5 studies for the cardiovascular and respiratory system, 2 studies for the musculoskeletal system, and 1 study apiece for the gastrointestinal and immune systems. The largest proportion (51.2%) of non‐serious adverse events due to methylphenidate use were found in cohort studies without a control group. However, this can be interpreted as an imprecise finding due to the large CI. In non‐comparative cohort studies, the proportion of participants withdrawn from methylphenidate treatment due to: serious adverse events was 1.20%; adverse events of unknown severity, 7.30%, non‐serious adverse events, 6.20%; and unknown reasons, 16.2%. </p> <section id="CD012069-sec-0223"> <h4 class="title">Subgroup analyses</h4> <p>We conducted subgroup analyses for studies that included children who:</p> <p> <ol id="CD012069-list-0084"> <li> <p>received concurrent medication versus no concurrent medication;</p> </li> <li> <p>had comorbidities versus those who had none;</p> </li> <li> <p>were younger versus older than 10 years of age;</p> </li> <li> <p>received methylphenidate for six months or more versus less than six months; and</p> </li> <li> <p>received a higher dosage of methylphenidate (20 mg/day and above) versus a lower dosage.</p> </li> </ol> </p> <p>We also conducted a subgroup analysis in which we compared studies with higher‐quality designs (i.e. RCTs) to those of lower quality (cohorts). We concluded that adverse events reported in observational studies do not seem to depend on comorbidity or age of participants, dose or duration of methylphenidate treatment, or study design (non‐serious adverse events). However, we observed fewer adverse events in concurrent‐medication users. These subgroup analyses suggest that the most common confounding factors do not affect the proportions of adverse events. We discovered differences when comparing the proportion of participants on methylphenidate with any serious adverse events in the non‐comparative classic cohort studies to the proportion of participants on methylphenidate with any serious adverse events in the cohort studies from the RCTs, and thus reported these separately. </p> <p>Finally, we conducted subgroup analyses investigating whether there were differences in the proportions of adverse events in the studies funded versus not funded by pharmaceutical companies. We found that studies funded by pharmaceutical companies had a much lower proportion of both serious and non‐serious adverse events. This is worrying, as it shows that adverse events are underestimated in industry‐sponsored studies, confirming findings from previous systematic reviews (<a href="./references#CD012069-bbs2-0568" title="LundhA , SismondoS , LexchinJ , BusuiocOA , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2012, Issue 12. [DOI: 10.1002/14651858.MR000033.pub2] ">Lundh 2012</a>; <a href="./references#CD012069-bbs2-0569" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>). This underpins our statements in this review that the proportions of adverse events are likely underestimated and that the proportions would likely have been higher if all studies had been conducted without industry funding. </p> </section> </section> <section id="CD012069-sec-0224"> <h3 class="title" id="CD012069-sec-0224">Overall completeness and applicability of evidence</h3> <p>To our knowledge, this is the first systematic review that assesses adverse events of methylphenidate in children and adolescents from non‐randomised studies. The included studies investigated adverse event profiles of children in different countries, settings, time periods and clinical practice. Studies were conducted over approximately 10 years with a great deal of inconsistency in reporting and classifying adverse events. In addition, there are limited data on comorbidities and medicine use. </p> <p>Surprisingly, we found few comparative non‐randomised studies. Many of the comparative studies had healthy controls and therefore could not be included as comparative studies. From these studies, however, we included those receiving methylphenidate as an observational cohort study. Accordingly, most of the data in this review come from non‐comparative cohort studies (including methylphenidate groups from RCTs assessing methylphenidate versus other interventions for ADHD, and follow‐up periods from RCTs), comprising 2,207,751 participants. These data may therefore be biased due to the absence of a control group and through uncontrolled confounding factors. Thus, readers should consider the very low quality of the included studies when interpreting the findings of this review. </p> <p><a href="./references#CD012069-bbs2-0044" title="CorteseS , PaneiP , ArcieriR , GerminarioEA , CapuanoA , MargariL , et al. Safety of methylphenidate and atomoxetine in children with Attention‐Deficit/Hyperactivity Disorder (ADHD): data from the Italian National ADHD Registry. CNS Drugs2015;29(10):865‐77. [DOI: 10.1007/s40263‐015‐0266‐7; PUBMED: 26293742] ">Cortese 2015</a> reported headache and sleep disorders as serious adverse events. Whilst these may usually be considered non‐serious adverse events, it is in keeping with their definition of adverse events: "Serious adverse events (AEs) were classified as severe if their occurrence was followed by active notification by clinical centers to the Italian Medicines Agency; otherwise, they were labelled as mild. The Italian Medicines Agency requires active notification when an AE [adverse event] results in death, is life‐threatening, requires hospitalisation or prolongation of existing inpatients’ hospitalisation, results in persistent or significant disability or incapacity, or leads to a congenital anomaly or birth defect." This definition is 100% in accordance with the ICH‐GCP definition of serious adverse events (<a href="./references#CD012069-bbs2-0539" title="International Council for Harmonisation Expert Working Group. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice E6(R1) 1996. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf (accessed 6 May 2011). ">ICH 1996</a>). </p> <p>To expand our understanding of adverse events, particularly where these are rare or take time to become apparent, it is necessary to bolster the limited data from RCTs by including data from non‐randomised studies (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). There are a number of advantages to non‐randomised studies. </p> <p>Despite the fact that these non‐randomised studies may have a higher risk of bias as regards adverse events, they are the only data available and should still be considered in the evaluation of methylphenidate as a treatment. One may debate whether controlling for confounders is necessary when determining adverse events, given that they are less likely to occur when an outcome is unintended, as opposed to an intended exposure effect (<a href="./references#CD012069-bbs2-0497" title="GolderS , LokeYK , BlandM . Meta‐analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLOS Medicine2011;8(5):e1001026. [DOI: 10.1371/journal.pmed.1001026] ">Golder 2011</a>). </p> <p>The findings from this review underscore the fact that information on long‐term adverse events in the use of methylphenidate is very limited. The increased use of methylphenidate, therefore, raises concerns about possible harms, particularly regarding unknown long‐term risks. </p> <p>We found new data on unexpected adverse events, and this information is important with regard to identifying unrecognised harmful effects. Most reported adverse events were non‐serious. This information is now available to regulators so they may update the SPC with respect to frequency estimates and completeness of adverse event information. </p> <p>Few scales were used to define and/or evaluate adverse events. Assessment of causality of adverse events was also poorly reported. </p> </section> <section id="CD012069-sec-0225"> <h3 class="title" id="CD012069-sec-0225">Quality of the evidence</h3> <p>Due to the presence of a large number of cohort studies without a comparator, it was only possible to evaluate the quality of the evidence for a small number of studies. These evaluations confirmed that non‐randomised studies monitoring adverse events are at critical risk of bias. The high degree of under‐reporting in these studies, particularly within cohort studies, is of great concern. </p> <p>High risk of bias in RCTs has been shown to overestimate benefits and underestimate harms, and this is especially common in trials funded by industry (<a href="./references#CD012069-bbs2-0569" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>)<i>.</i> Thus, one can presume that the proportions we found are at the lower side of the estimate spectrum (<a href="./references#CD012069-bbs2-0496" title="GluudLL , ThorlundK , GluudC , WoodsL , HarrisR , SterneJA . Correction: reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2008;149(3):219. ">Gluud 2008</a><i>;</i><a href="./references#CD012069-bbs2-0552" title="KjaergardLL , VillumsenJ , GluudC . Reported methodologic quality and discrepancies between large and small randomized trials in meta‐analyses. Annals of Internal Medicine2001;135(11):982‐9. ">Kjaergard 2001</a><i>;</i><a href="./references#CD012069-bbs2-0569" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>; <a href="./references#CD012069-bbs2-0575" title="MoherD , PhamB , JonesA , CookDJ , JadadA , MoherM , et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta‐analysis?. Lancet1998;352(9128):609‐13. ">Moher 1998</a><i>;</i><a href="./references#CD012069-bbs2-0622" title="SavovićJ , JonesH , AltmanD , HarrisR , JüniP , PildalJ , et al. Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta‐epidemiological studies. Health Technology Assessment2012;16(35):1‐82. ">Savović 2012</a><i>;</i><a href="./references#CD012069-bbs2-0629" title="SchulzKF , ChalmersI , HayesRJ , AltmanDG . Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA1995;273(5):408‐12. ">Schulz 1995</a><i>;</i><a href="./references#CD012069-bbs2-0680" title="WoodL , EggerM , GluudLL , SchulzKF , JuniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ2008;336(7644):601–5. ">Wood 2008</a>); pharmaceutical companies funded 53 out of the 177 non‐comparative cohort studies included in our review. Furthermore, 11 other studies had authors with connections to pharmaceutical advisory boards, whilst 45 of 177 studies did not report source of funding. </p> <p>In non‐randomised studies, a number of biases can indeed affect the estimation of the efficacy outcome. However, adverse events are not usually influenced by these sources given their unpredictable nature (<a href="./references#CD012069-bbs2-0567" title="LokeYK , PriceD , HerxheimerA . Chapter 14: Adverse effects. In Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbok.cochrane.org. ">Loke 2011</a>). </p> <p>Furthermore, the use of rating scales to more reliably assess adverse events was uncommon, so we believe that the proportions reported here are an underestimation of the true value (<a href="./references#CD012069-bbs2-0595" title="PagsbergAK , JeppesenP , KlauberDG , JensenKG , RudåD , Stentebjerg‐OlesenM , et al. Quetiapine extended release versus aripiprazole in children and adolescents with first‐episode psychosis: the multicentre, double‐blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. Lancet Psychiatry2017;4(8):605‐8. ">Pagsberg 2017</a><i>).</i> </p> <p>The findings of this review should be interpreted whilst bearing in mind the very low quality of the included studies and their methodological limitations. Many of the uncontrolled confounding factors that might limit the value of this review, for example, duration of methylphenidate treatment, dosage of methylphenidate, comorbidity, age of participants, or study design (non‐serious adverse events), do not seem to affect the estimates when investigated in subgroup analyses. It is possible and even likely that the adverse event profile of methylphenidate could be worse than what we report here (<a href="./references#CD012069-bbs2-0398" title="AagaardL , HansenEH . The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsychiatric Disease and Treatment2011; Vol. 7:729‐44. ">Aagaard 2011</a>). </p> <p>Adverse events in non‐randomised studies are often the only data available on such outcomes. This is why they are still used to evaluate adverse events (<a href="./references#CD012069-bbs2-0497" title="GolderS , LokeYK , BlandM . Meta‐analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview. PLOS Medicine2011;8(5):e1001026. [DOI: 10.1371/journal.pmed.1001026] ">Golder 2011</a>). Moreover, the duration of most RCTs is seldom long enough to detect adverse events that may only appear after a lengthy duration (<a href="./references#CD012069-bbs2-0543" title="IoannidisJP . Adverse events in randomized trials: neglected, restricted, distorted, and silenced. Archives of Internal Medicine2009;169(19):1737‐9. [DOI: 10.1001/archinternmed.2009.313; PUBMED: 19858427] ">Ioannidis 2009</a>). <a href="./references#CD012069-bbs2-0627" title="SchrollJB , PenningaEI , GøtzschePC . Assessment of adverse events in protocols, clinical study reports, and published papers of trials of Orlistat: a document analysis. PLOS Medicine2016;13(8):e1002101. [DOI: 10.1371/journal.pmed.1002101; PMC4987052; PUBMED: 27529343] ">Schroll 2016</a> showed that only 3% to 33% of the total number of investigator‐reported adverse events from RCTs were reported in the clinical study reports. This further underlines the need to include non‐randomised studies when assessing harms. </p> <p>Our aggregation and assessment of patient reports/series revealed a number of serious adverse events occurring during treatment with methylphenidate. We included patient reports/series of serious adverse events that developed over several years of treatment. These reports indicate a need for more comprehensive monitoring in order to allow early detection of possible serious adverse events. </p> <p>Additionally, most study authors call for increased screening before commencing methylphenidate treatment. Examples of such procedures could be obtaining an ECG or an extensive family history of somatic and psychiatric illness. These measures cannot prevent all patients from developing serious adverse events as these can still occur in apparently healthy, screened patients. We therefore highlight the 'best practice' of both thorough pre‐treatment screening and continuous monitoring of the individual patient during treatment. </p> <p>It is important to acknowledge the limitations of patient reports/series. Again, we must stress the fact that patient reports/series are not representative and do not necessarily reflect a cause‐effect relationship. As such, we cannot generalise data based on our included patient reports/series. The quality of our included patient reports/series also varied, and they rarely followed the standards set by CARE (CAse REport) Guidelines (<a href="./references#CD012069-bbs2-0489" title="GagnierJJ , KienleG , AltmanDG , MoherD , SoxH , RileyD , CARE Group. The CARE Guidelines: Consensus‐based Clinical Case Reporting Guideline Development. Global Advances in Health and Medicine2013;2(5):38‐43. [doi: 10.7453/gahmj.2013.008. PMID: 2441669] ">Gagnier 2013</a>). This is a common issue relating to patient reporting that has repercussions in terms of their utility as a source of evidence to inform clinical practice. It is crucial to expand both the knowledge and use of reporting guidelines to enhance the quality of published patient reports/series in the future. </p> <p>One of the merits of patient reports/series is their ability to stimulate the generation of hypotheses. Based on the results of this review, one could hypothesise that the unknown severity of adverse events (which is likely to be higher than is currently recognised) and their heterogeneous characteristics, needs to be weighed up against the possible benefits of methylphenidate. </p> <p>It is also central to good practice that clinicians and researchers improve their formal reporting of adverse events in order to assess more accurately the extent of adverse events experienced. Such reporting, combined with more methodologically sound research, could ensure informed, clinical decision‐making by health professionals, patients, and the public. </p> <p>Not all clinical studies get published, leading to publication bias (<a href="./references#CD012069-bbs2-0598" title="PapanikolaouPN , ChurchillR , WahlbeckK , IoannidisJP . Safety reporting in randomized trials of mental health interventions. American Journal of Psychiatry2004;161(9):1692‐7. [DOI: 10.1176/appi.ajp.161.9.1692; PUBMED: 15337661] ">Papanikolaou 2004</a>). This is especially so in older studies with negative results for efficacy and safety (<a href="./references#CD012069-bbs2-0542" title="IoannidisJP , Contopoulos‐IoannidisDG . Reporting of safety data from randomised trials. Lancet1998;352(9142):1752‐3. [DOI: 10.1016/S0140‐6736(05)79825‐1; PUBMED: 9848355] ">Ioannidis 1998</a>). As methylphenidate was licensed in the 1960s, publication bias may well be significant, especially as many of the included studies were funded by pharmaceutical companies (<a href="./references#CD012069-bbs2-0569" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>). </p> </section> <section id="CD012069-sec-0226"> <h3 class="title" id="CD012069-sec-0226">Potential biases in the review process</h3> <p>We excluded 112 studies (121 reports) because outcomes were outside the focus of this review (e.g. visual attention test, reaction time, memory skills, and functional abnormalities, see <a href="#CD012069-sec-0092">Excluded studies</a>). This raises the issue of bias in our review process as we did not write to these authors asking whether they collected data on other outcomes. This potential bias, however, is not likely to change our conclusions<i>.</i> </p> <p>With respect to identifying unpublished studies, we contacted relevant pharmaceutical companies, but none of them responded to our requests. The letter sent to pharmaceutical companies can be seen at <a href="http://Zenodo.org" target="_blank">Zenodo.org</a> (see <a href="https://zenodo.org/record/1165119#.WnWDKmeWyxA" target="_blank">supplementary file 'Letter to pharmaceutical companies'</a>). </p> <p>We excluded methylphenidate treatment groups from placebo‐controlled trials because these are published in our systematic review comparing methylphenidate versus placebo or no intervention (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). While this was done to avoid duplicate reporting (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>), it potentially introduces bias by reducing the amount of data available for analysis. It is noteworthy that the RR for the harms outcomes from placebo‐controlled trials indicate that methylphenidate carries similar risks of serious and non‐serious adverse events as placebo (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). We found an increased likelihood of rare and serious harms in the present study, which differs from our previous work. There are two possible explanations for this. The first is that it could be due to confounders. The second is that the average exposure to methylphenidate in these studies is longer, given that they are observational studies rather than the relatively short durations of the RCTs. It is possible that longer average exposure to methylphenidate could have given rise to this increased likelihood of rare and serious harms (or both). </p> <p>We decided to combine different types of study designs in the cohort study group; classic cohort studies, treatment groups from RCTs (similar to classic cohort studies), and cross‐sectional studies. The differences between these study designs have been investigated in subgroup analyses and reported separately when necessary. </p> <p>We conducted systematic literature searches over a long period and continuously revised our search strategy in order to detect all possible relevant studies. We excluded many studies due to a lack of information about adverse events despite efforts to contact the authors for these data. We therefore assume that the current systematic review is the most up‐to‐date and comprehensive one in this area of research. </p> <p>We included a few new brand names in the January 2016 search. We only searched for the new terms in the revised adverse event strategy from 2016, so there is a small risk that we might have missed a few studies. </p> <p>One limitation of our review is that we were not able to assess the quality of all of the non‐comparative cohort studies using ROBINS‐I. We have, however, assessed all of these studies as being at critical risk of bias. Another limitation arises from the lack of some sensitivity analyses. However, we performed many subgroup analyses to investigate various possible sources of heterogeneity. </p> <p>In many countries there has been a large increase in the abuse of methylphenidate. It is therefore important to warn the scientific community about possible methylphenidate abuse, especially in individuals with drug dependence (<a href="./references#CD012069-bbs2-0487" title="FraugerE , AmaslidouD , SpadariM , Allaria‐LapierreV , BraunsteinD , SciortinoV , et al. Patterns of methylphenidate use and assessment of its abuse among the general population and individuals with drug dependence. European Addiction Research2016;22(3):119‐26. [DOI: 10.1159/000439273; PUBMED: 26491869] ">Frauger 2016</a>). In Iceland, intravenous methylphenidate abuse is very common in patients with substance use disorder. This suggests that methylphenidate has high abuse potential (<a href="./references#CD012069-bbs2-0430" title="BjarnadottirGD , HaraldssonHM , RafnarBO , et al. Prevalent intravenous abuse of methylphenidate among treatment‐seeking patients with substance abuse disorders: a descriptive population‐based study. Journal of Addiction Medicine2015;9(3):188‐94. [DOI: doi:10.1097/ADM.0000000000000115] ">Bjarnadottir 2015</a>). It is a limitation that we did not collect data on methylphenidate abuse in this review. </p> <p>We did not identify any other potential biases in the review process.</p> </section> <section id="CD012069-sec-0227"> <h3 class="title" id="CD012069-sec-0227">Agreements and disagreements with other studies or reviews</h3> <p>In this study, we reported on a small number of serious adverse events affecting a substantial proportion of participants, which is concerning. </p> <p>Methylphenidate exposure in children and adolescents with a diagnosis of ADHD is associated with arrhythmia and potentially with myocardial infarction during periods of use. It may also be associated with psychotic disorder (<a href="./references#CD012069-bbs2-0612" title="RamstadE , StorebøOJ , NilausenTD , KrogHB , Moreira‐MaiaCR , MagnussonFL , HolmskovM , SkoogM , RosendalS , GrothC , GilliesD , ZwiM , KirubakaranR , GluudC , SimonsenE . Hallicunations and other psychotic symptoms in response to methylphenidate in children and adolescents with attention deficit hyperactivity disorder (ADHD): a Cochrane Systematic Review with Meta‐analysis and Trial Sequential Analysis.. Scandinavian Journal of Child and Adolescent Psychiatry and Psychology2018 [Epub ahead of print];6(1):ns. ">Ramstad 2018</a>). </p> <p>The high proportion of withdrawals due to adverse events of unknown severity affected almost 10% of participants. This contrasts with the findings in our systematic review of 185 RCTs, in which fewer than 10% reported serious adverse events and fewer than a third reported adverse events at all (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). We observed many of the previously described adverse events, including abdominal pain, decreased appetite, tics, and headache in our present review. These findings are consistent with the results of our Cochrane Review investigating the short‐term effects of methylphenidate use in RCTs (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). </p> <p>We found evidence for previously reported serious adverse events, including psychosis, arrhythmia, myocardial infarction, seizures, and hypertension. The large cohort study by <a href="./references#CD012069-bbs2-0527" title="HennessyS , SchellemanH , DanielGW , BilkerWB , KimmelSE , GuevaraJ , et al. Cardiovascular safety of ADHD medications: rationale for and design of an investigator‐initiated observational study. Pharmacoepidemiology and Drug Safety2010;19(9):934‐41. [DOI: 10.1002/pds.1992; PUBMED: 20623519] ">Hennessy 2010</a> reported no risk of serious adverse events, including cardiac problems. We excluded this large cohort study because it included children who were not diagnosed with ADHD. As an industry‐sponsored cohort study it may well be biased (<a href="./references#CD012069-bbs2-0569" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>). Furthermore, the median follow‐up for the control group was 611 days versus only 91 days for methylphenidate users. This could increase the potential for under‐reporting of adverse events in the methylphenidate group. The <a href="./references#CD012069-bbs2-0197" title="ShinJY , RougheadEE , ParkBJ , PrattNL . Cardiovascular safety of methylphenidate among children and young people with attention‐deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. BMJ2016;353:i2550. [DOI: 10.1136/bmj.i2550] ">Shin 2016</a> study suggests that the relative risk of myocardial infarction and arrhythmias was increased in the early period after initiation of methylphenidate treatment. Their findings should be interpreted with caution, according to the authors themselves, due to the potential inaccuracies in coding and incompleteness of records. The outcome measures were limited to patients with diagnoses of cardiovascular adverse events, and they could have missed such outcomes where cardiovascular events were present but not diagnosed. A great strength of this study, however, is that it included the entire South Korean population and used the national health insurance claims database for all patients with ADHD. A large cohort study including 1.8 million pregnancies found a small increase in the risk of cardiac malformations (adjusted relative risk 1.28, 95% CI 0.94 to 1.74) associated with intrauterine exposure to methylphenidate (<a href="./references#CD012069-bbs2-0538" title="HuybrechtsKF , BrömsG , ChristensenLB , EinarsdóttirK , EngelandA , FuruK , et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the international pregnancy safety study consortium. JAMA Psychiatry2018;75(2):167‐75. [DOI: 10.1001/jamapsychiatry.2017.3644; 29238795; PUBMED: PMC5838573] ">Huybrechts 2018</a>). </p> <p>In our systematic review of RCTs, we found the proportion of participants with one or more serious adverse events to be 2.80% (95% CI 1.70% to 4.80%; 9 trials, 613 participants) in the control group, and only 1.9% (95% CI 1.10% to 3.20%; 9 trials, 919 participants) in the methylphenidate group (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). In the present review, we found that the proportion of serious adverse events was 1.20% (95% CI 0.70% to 2.00%; 50 studies, 162,422 participants) for non‐comparative studies. </p> <p>One of the excluded studies suggested an association between the use of stimulants and sudden unexplained death among children and adolescents (<a href="./references#CD012069-bbs2-0292" title="GouldMS , WalshBT , MunfakhJL , KleinmanM , DuanNH , OlfsonM , et al. Sudden death and use of stimulant medications in youths. American Journal of Psychiatry2009;166(9):992‐1001. [DOI: 10.1176/appi.ajp.2009.09040472; PUBMED: 19528194] GouldMS , WalshBT , MunfakhJL , et al. Study finds link between stimulants and sudden unexplained death in young people. Brown University Psychopharmacology Update2009;20(12):1,1‐5,6. [DOI: 10.1002/pu.20105] KuehnBM . Stimulant use linked to sudden death in children without heart problems. JAMA: Journal of the American Medical Association2009;302(6):613‐4. [DOI: 10.1001/jama.2009.1115; PUBMED: 19671894] UhlD . Stimulant therapy: sudden death cases under methylphenidate [Plötzliche Todesfälle unter Methylphenidat]. Deutsche Apotheker Zeitung2009;26:46‐8. ">Gould 2009</a>). This was a patient‐control study using a control group of healthy participants, so it did not meet our inclusion criteria (see <a href="#CD012069-sec-0030">Criteria for considering studies for this review</a>). However, it is an important study regarding sudden death among children using methylphenidate, supporting our findings regarding this risk. </p> <p>To get an idea of the clinical relevance of the proportion of non‐serious adverse events in the uncontrolled cohort studies, we compared the data with the methylphenidate and placebo groups in our Cochrane Review of RCTs (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). We also compared our results with the official SPC from Denmark (<a href="./references#CD012069-bbs2-0468" title="Danish Health and Medicines Authority. Produktresuméer–human. www.produktresume.dk/docushare/dsweb/View/Collection‐96 Accessed 2 May 2017. ">Danish Health and Medicines Authority 2017</a>), the UK (<a href="./references#CD012069-bbs2-0573" title="Medicines and Healthcare Products Regulatory Agency (MHRA). Medicines information: SPC &amp; PILs. www.mhra.gov.uk/Safetyinformation/Medicinesinformation/SPCandPILs/ (accessed 2 May 2017). ">MHRA 2017</a>), and the USA (<a href="./references#CD012069-bbs2-0665" title="USFood , Drug Administration(FDA) . FDA approved drug products. www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm (accessed 14 May 2017). ">US Food and Drug Administration (FDA) 2017</a>) (<a href="#CD012069-tbl-0003">Table 2</a>). It is striking that there is no information about total non‐serious adverse events in any of these countries. This is worrying and comparable to the findings in our published Cochrane Review, where only a small number of the included RCTs reported on non‐serious adverse events. Some would say that this is due to the fact that there are very few non‐serious adverse events, but we are concerned that we simply do not know this because the data to determine it are lacking. </p> <div class="table" id="CD012069-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Data on adverse events from published systematic review on methylphenidate versus placebo or no intervention (Storebø 2015), National Summary of Product Characteristics, and from the present review</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised clinical trials: methylphenidate group (from <a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised clinical trials: placebo or no intervention group (from <a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>National Summary of Product Characteristics (UK, USA, DK)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐comparative cohort studies and cohort studies from randomised trials (present review)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐comparative cohort studies (present review)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐comparative cohort studies from randomised trials (present review)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.90% (95% CI 1.10% to 3.20%; 9 studies, 919 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.80% (95% CI 1.70% to 4.80%; 9 studies, 613 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.20% (95% CI 0.70% to 2.00%; 51 studies, 162,434 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10% (95% CI 0.60% to 2.00%; 32 studies, 159,761 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.60% (95% CI 1.00% to 2.30%; 18 studies, 2661 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.4% (95% CI 41.9% to 60.9%; 21 studies, 1861 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.3% (95% CI 30.3% to 47.0%; 21 studies, 1271 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.2% (95% CI 41.2% to 61.1%; 49 studies, 13,978 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.1% (95% CI 35.6% to 58.9%; 36 studies, 13,035 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.1% (95% CI 44.4% to 77.1%; 13 studies, 943 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.6% (95% CI 8.80% to 13.3%; 17 studies, 1642 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.40% (95% CI 7.10% to 12.4%; 17 studies, 1082 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.4% (95% CI 11.3% to 18.3%; 90 studies, 13,469 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.90% (95% CI 7.00% to 13.9%; 57 studies, 10,929 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.3% (95% CI 18.0% to 32.1%; 33 studies, 2540 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.50% (95% CI 1.20% to 29.2%; 3 studies, 356 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.4% (95% CI 8.30% to 18.0%; 3 studies, 240 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10% (UK and DK); no information (USA)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.4% (95% CI 11.3% to 28.7%; 22 studies, 1287 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.2% (95% CI 5.30% to 18.9%; 8 studies, 938 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.9% (95% CI 17.8% to 40.8%; 14 studies, 349 participants</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleep difficulty</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.00% (95% CI 5.80% to 11.1%; 13 studies, 1417 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.30% (95% CI 6.40% to 10.7%; 13 studies, 999 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.9% (95% CI 14.7% to 21.6%; 82 studies, 11,507 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.3% (95% CI 11.2% to 18.2%; 51 studies, 9073 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.4% (95% CI 18.2% to 34.4%, 31 studies, 2434 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.40% (95% CI 3.70% to 10.8%; 11 studies, 1038 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.50% (95% CI 1.40% to 8.60%; 11 studies, 778 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.2% (95% CI 11.5% to 25%; 35 studies, 4792 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5% (95% CI 10.2% to 22.7%; 21 studies, 3298 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.6% (95% CI 7.90% to 44.1%; 14 studies, 1494 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tics</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.30% (95% CI 1.00% to 5.20%; 7 studies, 684 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.50% (95% CI 3.70% to 8.10%; 7 studies, 476 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.40% (95% CI 4.50% to 8.90%; 39 studies, 1980 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.60% (95% CI 3.80% to 8.10%; 29 studies, 1601 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.6% (95% CI 5.30% to 19.9%; 10 studies, 379 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsiness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.30% (95% CI 2.40% to 20.2%; 4 studies, 510 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.70% (95% CI 2.60% to 16.2%; 4 studies, 310 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.50% (95% CI 5.20% to 16.6%; 17 studies, 1146 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.50% (95% CI 3.10% to 17.2%; 7 studies, 644 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.3% (95% CI 5.00% to 23.3%; 10 studies, 502 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sadness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.70% (95% CI 1.30% to 21.9%; 4 studies, 382 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.20% (95% CI 0.90% to 16.9%; 4 studies, 318 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.8% (95% CI 9.40% to 28.3%; 21 studies, 1802 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.1% (95% CI 6.60% to 24.1%; 9 studies, 626 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.6% (95% CI 8.10% to 43.1%; 12 studies, 1176 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.80% (95% CI 2.30% to 9.90%; 6 studies, 471 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.50% (95% CI 4.30% to 9.60%; 6 studies, 387 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.70% (95% CI 3.00% to 10.4%; 17 studies, 2182 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.60% (95% CI 2.80% to 10.9%; 5 studies, 673 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.80% (95% CI 5.80% to 10.5%; 12 studies, 1509 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5% (95% CI 7.70% to 16.8%; 13 studies, 1406 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.60% (95% CI 5.00% to 11.5%; 13 studies, 935 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.7% (95% CI 8.60% to 13.3%; 79 studies, 11,750 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.60% (95% CI 5.70% to 10.0%; 46 studies, 9229 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3% (95% CI 11.6% to 22.4%; 33 studies, 2521 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decreased appetite</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.3 (95% CI 12.3% to 24.2%; 16 studies, 1751 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.30% (95% CI 2.40% to 7.40%; 16 studies, 1211 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.1% (95% CI 26.5% to 36.2%; 84 studies, 11,594 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.8% (95% CI 23.0% to 33.5%; 57 studies, 9662 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.7% (95% CI 27.0% to 54.0%; 27 studies, 1967 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.70% (95% CI 4.00% to 8.00%; 11 studies, 1140 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.10% (95% CI 3.5% to 7.4%; 11 studies, 776 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.30% (95% CI 3.70% to 13.4%; 20 studies, 2731 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.10% (95% CI 2.80% to 17.0%; 11 studies, 1528 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.20% (95% CI 3.30% to 15.1%; 9 studies, 1203 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.50% (95% CI 6.10% to 9.30%; 11 studies, 1174 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.20% (95% CI 3.80% to 7.10%; 11 studies, 821 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.60% (95% CI 5.30% to 10.6%; 41 studies, 5612 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.00% (95% CI 7.00% to 9.10%; 22 studies, 3921 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4% (95% CI 5.80% to 17.9%; 19 studies, 1691 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decreased weight</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.30% (95% CI 3.80% to 10.3%; 6 studies, 472 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.40% (95% CI 1.00% to 5.70%; 6 studies, 387 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.70% (95% CI 4.80% to 15.3%; 26 studies, 5182 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.60% (95% CI 3.10% to 13.3%; 17 studies, 4855 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.6% (95% CI 8.70% to 30.6%; 9 studies, 327 participants)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>CI</b> : confidence interval; <b>DK</b> : Denmark; <b>RCT</b>: randomised clinical trials.<br/> <sup>a</sup>We found substantially larger proportions of several adverse events in the present review compared to both the proportions of adverse events in the placebo group in the RCTs included in our 2015 review (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>), and the National Summary of Product Characteristics from the UK, USA, and Denmark. </p> </div> </div> <p>We included in our present review the methylphenidate‐treated groups from 49 RCTs that compared methylphenidate with other ADHD medications in randomised head‐to‐head trials. We excluded these RCTs from our first review assessing methylphenidate versus placebo or no intervention (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>). When one assesses the proportions of serious adverse events in the methylphenidate groups, originating from the two groups of RCTs and from the non‐randomised studies, the proportions appear comparable. However, when one assesses the proportions of non‐serious adverse events as well as individual non‐serious adverse events in <a href="#CD012069-tbl-0003">Table 2</a>, we see an emerging picture. Either the proportions of patients with non‐serious adverse events are the same or raised in the cohort studies (where investigators knew that the patient received methylphenidate) compared to the methylphenidate groups of the placebo‐ or no intervention‐controlled RCT (where investigators were not supposed to break the blinding, but where we previously have declared that we think the blind was broken (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>)). However, any non‐serious adverse events and individual non‐serious adverse events (headache; anxiety; sleep difficulties; irritability; tics; drowsiness; sadness; abdominal pain; decreased appetite; and decreased weight) were about two to three times higher in the methylphenidate‐exposed group from the 49 RCTs that compared this drug versus other interventions also aimed at treating ADHD. The investigators were probably less prone to breaking the blind in the latter trials. Moreover, these proportions are likely closer to the real‐life, adverse events of methylphenidate. Therefore, authors, editors, regulators, and others have not been aware of the potential harms of this drug. </p> <p>In summary, we found higher proportions of adverse events during methylphenidate treatment than have been reported previously. It would be appropriate for our findings to be incorporated into treatment guidelines so as to encourage better awareness of the risk of adverse events during methylphenidate treatment. It is sometimes not possible to distinguish between an adverse event and symptoms that are part and parcel of the underlying ADHD. For example, tics or sleep difficulties are commonly found in children with ADHD, and we do not know whether there is a causative effect or a chance association when such symptoms appear during methylphenidate treatment. We are aware that for many of the proportions of adverse events we describe, there was no comparator group or other data for comparison. Another possibility is that both ADHD and methylphenidate could act as 'shared partners'; a synergistic effect on the emergence of different symptoms. </p> <p>A qualitative review investigated the occurrence of harmful effects from methylphenidate use in 16 empirical studies using both randomised and non‐randomised study designs (<a href="./references#CD012069-bbs2-0398" title="AagaardL , HansenEH . The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsychiatric Disease and Treatment2011; Vol. 7:729‐44. ">Aagaard 2011</a>). Its findings, with respect to the type and share of serious adverse events and quality of included studies, were in agreement with the observations made in our present systematic review. </p> <p>The clinical expert opinion of Graham and colleagues, on behalf of the Guideline Group for the European Network for Hyperkinetic Disorders (EUNETHYDIS), concluded that, "some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations", whilst acknowledging that "several areas require further study to allow a more precise understanding of the risks" (<a href="./references#CD012069-bbs2-0501" title="GrahamJ , BanaschewskiT , BuitelaarJ , et al. European guidelines on managing adverse effects of medication for ADHD. European Child and Adolescent Psychiatry2011;20(1):17‐37. [DOI: doi:10.1007/s00787‐010‐0140‐6.] ">Graham 2011</a>). </p> <p>The research evidence, however, is at best uncertain, as the studies we found were of very low quality, and there were many dropouts for unexplained reasons. Some of these may well have occurred due to serious adverse events. We therefore believe that better‐quality research evidence should be presented before such reassuring conclusions are accepted. We are also aware that conscious or unconscious bias may have arisen through pharmaceutical‐industry sponsorship linked to many of these authors (<a href="./references#CD012069-bbs2-0569" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3] ">Lundh 2017</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012069-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD012069-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Proportion of participants on methylphenidate with any serious adverse events" data-id="CD012069-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Proportion of participants on methylphenidate with any serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Proportion of participants withdrawn from methylphenidate due to serious adverse events" data-id="CD012069-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Proportion of participants withdrawn from methylphenidate due to serious adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Proportion of participants withdrawn from methylphenidate due to adverse events of unknown severity" data-id="CD012069-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Proportion of participants withdrawn from methylphenidate due to adverse events of unknown severity </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Proportion of participants on methylphenidate with any non‐serious adverse event" data-id="CD012069-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Proportion of participants on methylphenidate with any non‐serious adverse event</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Proportion of participants withdrawn from methylphenidate due to non‐serious adverse events" data-id="CD012069-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Proportion of participants withdrawn from methylphenidate due to non‐serious adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Proportion of participants withdrawn from methylphenidate for unknown reasons" data-id="CD012069-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Proportion of participants withdrawn from methylphenidate for unknown reasons</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparative studies: number of serious adverse events, Outcome 1 Any serious adverse events." data-id="CD012069-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Comparative studies: number of serious adverse events, Outcome 1 Any serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparative studies: number of serious adverse events, Outcome 2 Central nervous system." data-id="CD012069-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Comparative studies: number of serious adverse events, Outcome 2 Central nervous system. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0010"> <p> <div class="table" id="CD012069-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Arrhythmias</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shin 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.61 (95% CI 1.48 to 1.74)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Hypertension</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shin 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.07 (95% CI 0.94 to 1.22)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Myocardial infarction</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shin 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.33 (95% CI 0.90 to 1.98)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Ischaemic stroke</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shin 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.70 (95% CI 0.49 to 1.01)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Heart failure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shin 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.54 (95% CI 0.30 to 0.96)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Comparative studies: number of serious adverse events, Outcome 3 Cardiovascular and respiratory system. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0010">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparative studies: number of participants with non‐serious adverse events, Outcome 1 Central nervous system: sleep‐related adverse events." data-id="CD012069-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Comparative studies: number of participants with non‐serious adverse events, Outcome 1 Central nervous system: sleep‐related adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparative studies: number of participants with non‐serious adverse events, Outcome 2 Central nervous system: other specific sleep‐related adverse events." data-id="CD012069-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Comparative studies: number of participants with non‐serious adverse events, Outcome 2 Central nervous system: other specific sleep‐related adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparative studies: number of participants with non‐serious adverse events, Outcome 3 Central nervous system: other specific adverse events." data-id="CD012069-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Comparative studies: number of participants with non‐serious adverse events, Outcome 3 Central nervous system: other specific adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparative studies: number of participants with non‐serious adverse events, Outcome 4 Cardiovascular and respiratory system." data-id="CD012069-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Comparative studies: number of participants with non‐serious adverse events, Outcome 4 Cardiovascular and respiratory system. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparative studies: number of participants with non‐serious adverse events, Outcome 5 Gastrointestinal system." data-id="CD012069-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Comparative studies: number of participants with non‐serious adverse events, Outcome 5 Gastrointestinal system. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparative studies: number of participants with non‐serious adverse events, Outcome 6 Musculoskeletal system." data-id="CD012069-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Comparative studies: number of participants with non‐serious adverse events, Outcome 6 Musculoskeletal system. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparative studies: number of participants with non‐serious adverse events, Outcome 7 Musculoskeletal system: body mass index (BMI)." data-id="CD012069-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Comparative studies: number of participants with non‐serious adverse events, Outcome 7 Musculoskeletal system: body mass index (BMI). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparative studies: number of participants with non‐serious adverse events, Outcome 8 Musculoskeletal system: z scores." data-id="CD012069-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Comparative studies: number of participants with non‐serious adverse events, Outcome 8 Musculoskeletal system: z scores. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/urn:x-wiley:14651858:media:CD012069:CD012069-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_t/tCD012069-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Comparative studies: number of participants withdrawn from methylphenidate treatment, Outcome 1 Proportion of participants withdrawn from methylphenidate for unknown reasons." data-id="CD012069-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Comparative studies: number of participants withdrawn from methylphenidate treatment, Outcome 1 Proportion of participants withdrawn from methylphenidate for unknown reasons. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/media/CDSR/CD012069/image_n/nCD012069-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012069-fig-0020"> <p> <div class="table" id="CD012069-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptoms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events/total number of participants</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Altin 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No patients experienced any serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/221</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arabgol 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ardic 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute depression and suicide attempt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/150</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ashkenasi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hallucinations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berek 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/822</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cherland 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/98</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chou 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/230</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Davari‐Ashtiani 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dittmann 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/247</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011a, OBSEER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/777</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38/822</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/1098</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gerwe 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/263</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants affected or at risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hulvershorn 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jafarinia 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jensen 1999 (MTA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/245</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kemner 2005 (FOCUS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudden death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/850</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lakic 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Strong depressive symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>542/4055</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maayan 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCarthy 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudden death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/5351</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pierce 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remschmidt 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schmidt 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Generalized tonic‐clonic seizure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/124</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schulz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/145</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shin 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1224/123,636</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sobanski 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/347</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Steele 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/689</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warshaw 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/260</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weiss 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/200</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/87</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/127</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Winterstein 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171/18,238</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/149</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Non‐comparative studies: proportion of participants with serious adverse events, Outcome 1 Any serious adverse event. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0020">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0021"> <p> <div class="table" id="CD012069-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptom</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events/total number of participants</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Sudden death</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kemner 2005 (FOCUS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudden death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/850</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudden death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCarthy 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudden death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/5351</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Suicide</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jensen 1999 (MTA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suicide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/245</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCarthy 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suicide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/5351</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Suicide attempt</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute depression and suicide attempt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/150</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suicide attempt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remschmidt 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suicide attempt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/89</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Suicide thoughts</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remschmidt 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depressive, suicidal thoughts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse events were reported in only 1 participant during the open‐label, dose‐titration phase of the study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/87</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Psychotic symptoms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cherland 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Psychotic symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hallucinations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paranoid behavior disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hallucinations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hallucinations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hallucinations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/55</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remschmidt 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Delusions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shyu 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Psychotic disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>856/52,646</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hallucinations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hallucinations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/369</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Seizure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schmidt 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Generalized tonic‐clonic seizure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/124</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Syncope</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Syncope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/327</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vasovagal syncope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1098</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Tremor</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gerwe 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/306</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Psychiatric problems</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rambling speech</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Psychiatric disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Psychiatric problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/1098</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Severe depression</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cherland 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/98</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lakic 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Strong depressive symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/68</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Overdose</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overdose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/100</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Eating disorder</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eating disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1426</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Aphasia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aphasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1426</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Headache</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/1426</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Neurological disorder</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Neurologicaol disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/1426</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Sleep disorder</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1426</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Mood disorder</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mood disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1426</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Loss of consciousness</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gerwe 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short loss of consciousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/306</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Family stress</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gerwe 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Family stress</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/306</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Impotence</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impotence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1098</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Severe aggression</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remschmidt 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/89</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Severe anorexia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arabgol 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/18</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Amphetamine intoxication</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cherland 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amphetamine intoxication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/98</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Non‐comparative studies: proportion of participants with serious adverse events, Outcome 2 Central nervous system. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0021">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0022"> <p> <div class="table" id="CD012069-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptom</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events/total number of participants</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Respiratory, thoracic and mediastinal disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aortic embolism</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1098</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spontaneous pneumothorax</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/57</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Cardiac problems</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arman 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiac rhythm abnormalities</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cardiovascular problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/1098</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Winterstein 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious cardiac problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171/18,238</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Tachycardia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/1098</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Severe hypertension</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Severe hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/1426</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Epistaxsis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Epistaxsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1426</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Viral illness</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participants affected by viral illness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/57</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Non‐comparative studies: proportion of participants with serious adverse events, Outcome 3 Cardiovascular and respiratory system. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0022">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0023"> <p> <div class="table" id="CD012069-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptom</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events/total number of participants</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Gastrointestinal disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/1426</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Liver disease</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperbilrubinemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1426</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Non‐comparative studies: proportion of participants with serious adverse events, Outcome 4 Gastrointestinal system. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0023">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0024"> <p> <div class="table" id="CD012069-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptom</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events/total number of participants</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ankle fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/327</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leg fracture</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/57</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Non‐comparative studies: proportion of participants with serious adverse events, Outcome 5 Musculoskeletal system: fractures. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0024">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0025"> <p> <div class="table" id="CD012069-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptom</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events/total number of participants</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Autoimmune disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/1426</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Non‐comparative studies: proportion of participants with serious adverse events, Outcome 6 Immune system: autoimmune disease. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0025">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0026"> <p> <div class="table" id="CD012069-tblf-0008"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Serious adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arabgol 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/171</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ashkenasi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Faraone 2007a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/268</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/162</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/121</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/407</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Hallucinations</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ashkenasi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/121</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/407</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Severe anorexia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arabgol 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/18</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Suicide attempt</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/171</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Non‐comparative studies: proportion of participants withdrawn from methylphenidate treatment due to serious adverse events, Outcome 1 Proportion of participants withdrawn from methylphenidate treatment due to serious adverse events. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0026">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0027"> <p> <div class="table" id="CD012069-tblf-0009"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Altin 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/204</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/171</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atzori 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/189</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chou 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/296</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dodangi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011a, OBSEER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/822</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51/326</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2015b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/143</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53/598</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/44</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/144</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maia 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mayes 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/69</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/69</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remschmidt 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Steele 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/130</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/50</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Non‐comparative studies: proportion of participants withdrawn from methylphenidate treatment due to serious adverse events, Outcome 2 Proportion of participants withdrawn from methylphenidate treatment due to adverse events of unknown severity. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0027">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0028"> <p> <div class="table" id="CD012069-tblf-0010"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptom</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events/total number of participants</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barbaresi 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events of unknown seriousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63/251</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Non‐comparative studies: proportion of participants with adverse events of unknown severity, Outcome 1 Proportion of participants with adverse events of unknown severity. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0028">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0029"> <p> <div class="table" id="CD012069-tblf-0011"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptom</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events/total number of participants</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Altin 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/142</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ardic 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse event (with OROS (osmotic controlled release oral delivery system) methylphenidate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52/122</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Any adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atzori 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of patients who experience adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54/134</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barrickman 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berek 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>195/762</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chou 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95/230</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>369/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dirksen 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78/287</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dittmann 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/195</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011a, OBSEER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>209/822</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40/106</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68/88</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Garg 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>180/607</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gerwe 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>160/263</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Goez 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Greenberg 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Greenhill 1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gucuyener 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/119</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haubold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jensen 1999 (MTA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>150/245</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Karabekiroglu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At least one adverse drug reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2015b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>172/541</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3513/4055</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lyon 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mayes 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35/63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58/60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total number of patients who experienced adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remschmidt 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76/89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schulz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/145</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sobanski 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/347</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>101/205</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tasdelen 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>177/689</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warshaw 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>242/260</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weiss 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42/45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>344/407</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96/135</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yatsuga 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Total adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/123</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Non‐comparative studies: proportion of participants with non‐serious adverse events, Outcome 1 Non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0029">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0030"> <p> <div class="table" id="CD012069-tblf-0012"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptom</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events/total number of participants</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Affect lability</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moodiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Affect lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/44</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Aggression</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barrickman 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anger</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berek 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aggressive reaction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/762</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Davari‐Ashtiani 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dittmann 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/195</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011a, OBSEER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/777</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kemner 2005 (FOCUS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/850</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/541</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mayes 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/69</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anger</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remschmidt 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/105</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hostility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/407</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Anorexia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arabgol 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/150</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berek 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35/762</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011a, OBSEER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/777</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gerwe 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/263</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Greenhill 1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/541</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warshaw 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/260</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weiss 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/220</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zelnik 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/128</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Çetin 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/61</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Anxiety</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Akhondzadeh 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Akhondzadeh 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amiri 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety, nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barrickman 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety or nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Davari‐Ashtiani 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Phobia &amp; anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efron 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>76/123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ghanizadeh 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazell 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jafarinia 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maia 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/407</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zelnik 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/128</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Fingernail biting</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bites fingernails</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efron 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Biting fingernails</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56/123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bites fingers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Biting fingernails</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Biting fingernails</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazell 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Biting fingernails</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maia 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bites fingernails</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nail biting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shang 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nail biting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/66</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Daydreams</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efron 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daydreams</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77/123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daydreams</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daydreams</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daydreams</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/30</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Difficulty falling asleep</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Akhondzadeh 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty falling asleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Akhondzadeh 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty falling asleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Altin 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amiri 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty falling asleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ardic 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/171</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atzori 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/129</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barrickman 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berek 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59/762</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chou 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/230</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coşkun 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Davari‐Ashtiani 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011a, OBSEER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Initial insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/777</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Initial insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efron 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trouble sleeping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79/123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Famularo 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Later sleep onset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Garg 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia or trouble sleeping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gerwe 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty falling asleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73/263</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grcevich 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trouble sleeping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Greenhill 1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gucuyener 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty falling asleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/119</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazell 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Işeri 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jafarinia 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jensen 1999 (MTA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/245</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johnson 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia (new onset)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jung 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kemner 2005 (FOCUS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53/850</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46/541</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty falling asleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maayan 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trouble sleeping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maia 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mayes 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Miller‐Horn 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty falling asleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trouble sleeping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty falling asleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Montañés‐Rada 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trouble sleeping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peyre 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/121</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remschmidt 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty falling asleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sangal 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shang 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Steele 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/205</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tasdelen 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thorell 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulties falling asleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tomás Vila 2010b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty falling asleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45/114</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Initial insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/155</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warshaw 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty falling asleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/260</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weiss 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/200</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81/229</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/220</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/127</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yatsuga 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty sleeping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zarinara 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zelnik 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/128</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zeni 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/106</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145/1154</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Çetin 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/61</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Depression</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atzori 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vegetative symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/134</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cherland 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mood symptoms or mood‐congruent psychotic symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/98</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011a, OBSEER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depressed mood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/777</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grcevich 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/262</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depressive symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/689</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weiss 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/407</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depressive symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/11</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Disturbed sleep</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbas 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleeping problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trouble sleeping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arabgol 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disturbed sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/150</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Early waking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efron 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trouble sleeping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79/123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Galland 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restless sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor sleep quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37/607</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazell 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Işeri 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Disturbed sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Montañés‐Rada 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perera 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/102</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remschmidt 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Delayed sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/105</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Steele 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor quality sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/205</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33/689</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor sleep quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/149</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Dizziness</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizzy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chou 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/230</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Davari‐Ashtiani 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efron 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazell 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jafarinia 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kemner 2005 (FOCUS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/850</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maia 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pierce 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shang 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/407</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/47</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Drowsiness</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barrickman 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efron 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Garg 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ghanizadeh 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazell 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolens</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lyon 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maia 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/407</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/220</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/11</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Dysthymia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dysphemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dysphemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/16</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Emotional lability</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ardic 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotional change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Davari‐Ashtiani 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotional lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotional lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moody</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kemner 2005 (FOCUS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotional disturbance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/850</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotional lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/598</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotional lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maayan 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotional lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Affect lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Silva 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotional lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Steele 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotional lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warshaw 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Affect lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/260</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weiss 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotional lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Affect lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotional lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/229</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotional lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/47</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Euphoria/hypomania</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unusually happy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Euphoria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Euphoric</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grcevich 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unusually happy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Euphoria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maia 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Euphoric</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Euphoria or hypomania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ecstasy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/30</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Asthenia and fatigue</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tired + low energy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Davari‐Ashtiani 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiredness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dittmann 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/195</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Galland 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daytime sleepiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Garg 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kemner 2005 (FOCUS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/850</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pierce 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sangal 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Steele 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/200</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Headache</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbas 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Akhondzadeh 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Akhondzadeh 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Altin 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amiri 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ardic 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/150</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atzori 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/129</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barrickman 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berek 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/762</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chou 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/230</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dirksen 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/287</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dittmann 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/195</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011a, OBSEER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/777</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efron 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Galland 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Morning headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Garg 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/607</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gerwe 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/263</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Goez 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Golubchik 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Greenberg 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/49</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Greenhill 1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gucuyener 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/119</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Guerreiro 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazell 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hulvershorn 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Işeri 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jafarinia 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jung 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kemner 2005 (FOCUS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33/850</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/541</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maayan 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maia 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headaches</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mayes 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Miller‐Horn 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perera 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/102</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peyre 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43/121</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pierce 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remschmidt 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/105</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sangal 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schulz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/145</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shang 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Silva 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Steele 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/205</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tasdelen 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thorell 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/155</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/689</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warshaw 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/260</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weiss 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35/200</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>123/229</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/220</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/127</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yatsuga 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zarinara 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zelnik 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107/128</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>143/1154</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Çetin 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/61</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Increased need to sleep</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trouble waking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Galland 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hard to wake + difficult to wake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased need to sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleepiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pierce 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zarinara 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/19</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Involuntary movements</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Balázs 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Involuntary movements after methylphenidate treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berek 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Muscle contractions, involuntary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34/762</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shaking + tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Galland 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restless legs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Muscle contraction, involuntary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/541</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Convulsion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/100</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Irritability</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amiri 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ardic 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atzori 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/129</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barrickman 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritabillity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efron 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100/123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Garg 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Greenhill 1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazell 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Işeri 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jensen 1999 (MTA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/245</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johnson 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kemner 2005 (FOCUS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/850</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maayan 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maia 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mayes 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritable</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/121</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sangal 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Silva 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tasdelen 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/155</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warshaw 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/260</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/200</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/47</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Nervousness</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arabgol 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berek 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/762</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jafarinia 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/541</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Steele 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weiss 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/220</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Çetin 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/61</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Nightmares</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maia 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Silva 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tomás Vila 2010b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/114</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Restlessness and agitation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restlessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Davari‐Ashtiani 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restlessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dittmann 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/195</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restlessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grcevich 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restlessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perera 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restlessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/102</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restlessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Steele 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Physical activity modifications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/689</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zarinara 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Restlessness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/19</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Sadness</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sadness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amiri 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sadness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barrickman 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low mood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Crying + sadness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Davari‐Ashtiani 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sadness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efron 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sadness or unhappiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69/123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sad</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Garg 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sadness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sadness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sadness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sad</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazell 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sad</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Işeri 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sadness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jensen 1999 (MTA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tearfulness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/245</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johnson 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sadness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kemner 2005 (FOCUS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Crying</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/850</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maia 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sad</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sadness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sadness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perera 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sadness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/102</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sadness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/30</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Stares</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stares into space</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stares a lot</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazell 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maia 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stares a lot or daydreams</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/31</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Excessive talking</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Overly talkative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazell 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Talks too much</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Speaking more</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Taciturnity ('talking too little')</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Less talkative</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Talk less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Talking little</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maia 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Talk less</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/31</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Tics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ardic 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atzori 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/129</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Davari‐Ashtiani 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011a, OBSEER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100/777</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efron 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35/123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics or involuntary movements</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Golubchik 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Motor tics exacerbation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grcevich 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Motor tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gucuyener 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Motor tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/119</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Işeri 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johnson 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics (new onset)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lakic 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Miller‐Horn 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remschmidt 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shang 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tourette disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/205</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tasdelen 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/155</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Varley 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/374</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Twitching</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40/229</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Çetin 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/16</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Isolation and lack of interest in others</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lack of interest</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efron 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uninterested in others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39/123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uninterested in others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uninterested</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazell 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uninterested</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Isolation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maia 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uninterested others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perera 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Social withdrawal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/102</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Being in own world</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Introversion (maybe isolation)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/47</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>'Zombie like' demeanour</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Davari‐Ashtiani 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zombie like</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jensen 1999 (MTA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zombie like</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/245</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/407</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Somnolence</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chou 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/230</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shang 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weiss 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/229</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/11</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Obsession</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Obsessive behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Obsession</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Çetin 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Obsession</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/32</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Mood disorder</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mood disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Emotional disorder of childhood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/239</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Confusional state</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confusional state</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/262</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zelnik 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sense of dopiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/128</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Sleep disorder</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dittmann 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/195</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011a, OBSEER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/777</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/239</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Propensity to cry</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prone to cry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sudden crying</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/30</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Sedation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/19</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Daytime sleepiness</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Galland 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Daytime sleepiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tomás Vila 2010b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Datime sleepiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/114</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Dysphoria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atzori 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dysphoria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/134</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Logorrhoea</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atzori 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loggorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/129</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Impaired concentration</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berek 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Impaired concentration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/822</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Difficulty waking up</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Galland 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficult to wake up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/28</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Urinary incontinence</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Garg 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Urinary incontinence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/32</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Paralysis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Paralysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/239</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Affective disorder</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Affective disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/239</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Jumbled thoughts</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jumbled thoughts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/154</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Bulimia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bulimia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Sleep late</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleeping late</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Tooth grinding</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tooth grinding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Tremor</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Stuttering</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stuttering</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Flushing</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Apathy</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/541</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Abnormal behaviour</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abnormal behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/100</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Stereotypies</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stereotypies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/16</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Quietness</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quietness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/30</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>EEG changes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schmidt 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pathologic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/124</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Did not like themselves</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thorell 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Does not like him‐ or herself</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/79</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Sleep walking</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tomás Vila 2010b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep walking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/114</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Personality and behaviour disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Personality and behavior disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/633</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Vertigo</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vertigo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/11</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Non‐comparative studies: proportion of participants with non‐serious adverse events, Outcome 2 Central nervous system. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0030">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0031"> <p> <div class="table" id="CD012069-tblf-0013"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptom</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events/total number of participants</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Cough</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/150</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pierce 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sangal 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/166</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Pharyngolaryngeal pain</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharyngolaryngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/150</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharyngolaryngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/326</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pierce 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharyngolaryngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Upper respiratory tract infection</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pierce 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/200</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wiguna 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/20</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Tachycardia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heart races</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/326</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jafarinia 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/239</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Abnormal ECG</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abnormal ECG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/326</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abnormal ECG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/162</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Nasal congestion</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maayan 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sangal 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/79</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Palpitation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Palpation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Palpitations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shang 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Palpation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/66</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Systolic blood pressure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cho 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐significant increase following methylphenidate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The proportion of participants with a systolic blood pressure above the upper limit of normal (&gt; 123 mmHg) ranged from 1% to 10%, whereas 1.5% had an above normal systolic blood pressure at baseline </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gadow 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100.6 mmHg (SD = 12.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gerwe 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean change from baseline: 0.1 mmHg (SD = 10.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazell 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drop in systolic blood pressure in 8/10 participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>113.8 mmHg (SD = 10.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102.2 mmHg (SD = 9.89)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lamberti 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>105.4 mmHg (SD = 10.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maayan 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.2 mmHg (SD = 14.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>105.3 mmHg (SD = 12.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>104.7 mmHg (SD = 8.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Winsberg 1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>103.1 mmHg (SD = no information)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97 mmHg (SD = 10.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.6 mmHg (SD = 10.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No changes</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Diastolic blood pressure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cho 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐significant, marginal increase after methylphenidate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69 mmHg (SD = 1.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.2 mmHg (SD = 10.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gerwe 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazell 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drop in diastolic blood pressure in 9/10 participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.2 mmHg (SD = 12.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.5 mmHg (SD = 7.90)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lamberti 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.2 mmHg (SD = 7.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maayan 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61.4 mmHg (SD = 13.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66.9 mmHg (SD = 10.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.5 mmHg (SD = 12.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64.6 mmHg (SD = 7.51)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Pulse rate</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cho 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79 beats/min (SD = 1.00)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.9 beats/min (SD = 12.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ilgenli 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88 beats/min (SD = 13.80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.5 beats/min (SD = 6.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2015a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.4 beats/min (SD = 11.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.4 beats/min (SD = 9.70)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lamberti 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.5 beats/min (SD = 15.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maayan 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.5 beats/min (SD = 16.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.57 beats/min (SD = 7.33)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.8 beats/min (SD = 9.80)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.5 beats/min (SD = 7.81)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.5 beats/min (SD = 7.81)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Özcan 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>148.2 beats/min (SD = 29.70)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>ECG‐QT</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cho 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Non‐significant change in QT and QRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>After 24 months, out of 77 patients treated with methylphenidate:</p> <p>8 (10.4%) with altered ECG (electrocardiogram) at 24 months</p> <p>11 (29.0%) with sinus bradycardia</p> <p>12 (31.6%) with sinus tachycardia</p> <p>6 (15.8%) with lengthened QTc</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ilgenli 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Minimum QT of 317.00 (23.3)</p> <p>Maximum QT of 373.7 (21.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>After 2 hours:</p> <p>Minimum QT of 322.3 (21.6)</p> <p>Maximum QT of 361.8 (29.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lamberti 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>QTc of 407.6 (12.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>After 2 hours: QTc of 409.8 (12.0)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Cold fingers</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cold fingers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Sweating</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Hypertension</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/1426</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Hypotension</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/1426</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Respiratory, thoracic and mediastinal disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Respiratory, thoracic, and mediastinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/239</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Proportion of patients with micro‐nucleated (Mn) peripheral lymphocytes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Walitza 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(MN‐Cells/1000 Cells mean)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Baseline: 4.90 (SD = 4.00)</p> <p>6 months: 4.50 (SD = 3.50)</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Non‐comparative studies: proportion of participants with non‐serious adverse events, Outcome 3 Cardiovascular and respiratory system. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0031">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0032"> <p> <div class="table" id="CD012069-tblf-0014"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptom</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events/total number of participants</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Abdominal pain</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Akhondzadeh 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Akhondzadeh 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amiri 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ardic 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach ache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/150</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atzori 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/129</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barrickman 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach ache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berek 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/762</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chou 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/230</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Davari‐Ashtiani 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dirksen 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach ache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/287</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dittmann 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Upper abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/195</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011a, OBSEER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/777</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efron 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach aches</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40/123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach aches</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Garg 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach aches</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gerwe 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/306</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Golubchik 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grcevich 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach ache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach aches</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Greenhill 1983</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach aches</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gucuyener 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach ache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/119</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach ache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazell 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Işeri 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jafarinia 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kemner 2005 (FOCUS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33/850</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/541</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lyon 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maayan 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maia 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach ache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach ache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach ache (abdominal pain)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perera 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/102</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peyre 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/121</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pierce 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remschmidt 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sangal 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schulz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/145</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shang 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Silva 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach ache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Steele 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/72</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/205</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tasdelen 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thorell 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach aches</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/155</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warshaw 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/260</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weiss 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/200</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45/229</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/220</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/127</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach ache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zarinara 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zelnik 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/128</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach ache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140/1154</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Çetin 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Stomach ache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/61</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Constipation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ardic 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shang 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/66</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Decreased appetite</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbas 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Akhondzadeh 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Akhondzadeh 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Altin 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/221</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amiri 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ardic 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47/101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/150</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Atzori 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/129</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chazan 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118/205</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chou 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95/230</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>213/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coşkun 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Davari‐Ashtiani 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dirksen 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/287</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dittmann 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lack of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/195</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011a, OBSEER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/777</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efron 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69/123</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Fiky 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Famularo 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Garg 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128/607</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gerwe 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83/263</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ghanizadeh 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Golubchik 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decrease in appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grcevich 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appetite suppression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Green 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gucuyener 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/119</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hazell 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appetite suppression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hulvershorn 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Işeri 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jafarinia 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johnson 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reduced appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jung 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appetite loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/83</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kemner 2005 (FOCUS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49/850</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lakic 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68/68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maayan 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maia 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barkley decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mayes 1994</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Miller‐Horn 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Perera 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51/102</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peyre 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reduced appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/121</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pierce 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poulton 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sangal 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shang 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Silva 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Steele 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72/205</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tasdelen 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thorell 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/155</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appetite and nutrition disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68/689</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warshaw 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77/260</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38/200</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Appetite suppression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55/229</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35/127</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yalcin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yatsuga 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27/47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zarinara 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zeni 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53/106</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>552/1154</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/123</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Decreased weight</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbas 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amiri 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ardic 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased weight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/171</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berek 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/762</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37/1426</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Davari‐Ashtiani 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dittmann 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/195</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased weight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grcevich 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Işeri 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Johnson 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/541</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lakic 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate loss of body weight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68/68</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remschmidt 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight decrease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/105</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sahin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warshaw 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased weight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/260</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/407</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Çetin 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/16</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Diarrhoea</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/541</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/19</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Dry mouth</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amiri 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Davari‐Ashtiani 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Işeri 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/20</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Gastrointestinal adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dittmann 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/247</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal upset</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/607</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastrointestinal symptomatology</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/633</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Nausea</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbasi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Akhondzadeh 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Akhondzadeh 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amiri 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ardic 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/101</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barrickman 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chou 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/230</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dittmann 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/195</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011a, OBSEER</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/777</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Garg 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ghanizadeh 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea + vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gucuyener 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/119</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Guerreiro 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Işeri 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kemner 2005 (FOCUS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/850</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/541</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting + nausea + dyspepsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pierce 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schulz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/145</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/116</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/205</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tasdelen 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warshaw 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/260</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/407</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/47</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zarinara 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/18</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Upset stomach</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dyspepsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hulvershorn 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Upset stomach</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dyspepsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/103</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Vomiting</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dittmann 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/195</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jafarinia 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kemner 2005 (FOCUS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/850</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/110</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/100</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maayan 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/20</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/103</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shang 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Silva 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/205</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/155</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/407</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zarinara 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/18</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Dyspepsia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dyspepsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cortese 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dyspepsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/1426</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Gastroenteritis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastroenteritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gastroenteritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/200</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Increased appetite</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/65</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Xerostomia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Xerostomia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/71</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Non‐comparative studies: proportion of participants with non‐serious adverse events, Outcome 4 Gastrointestinal system. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0032">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0033"> <p> <div class="table" id="CD012069-tblf-0015"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptom</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events/total number of participants</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Chest pain</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chest pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chest pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shang 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chest pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/66</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Height</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jensen 1999 (MTA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128.7 cm (SD = 9.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>133.8 cm (SD = 14.81)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vincent 1990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>158.7 cm (SD = 10.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wiguna 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.55 cm (SD = no information)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yalcin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134.6 cm (SD = 12.32)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Weight</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Davari‐Ashtiani 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight gain in 1/16 participants</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.4 kg (SD = 11.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.5 kg (SD = 6.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.7 kg (SD = 17.2)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.7 kg (SD = 14.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vincent 1990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Observed weight: 47.9 kg (SD = 10.3)</p> <p>Expected weight: 48.1 kg (SD = 10.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wiguna 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.2 kg (SD = 11.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yalcin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weight gain in 15/33 participants</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>BMI</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gerwe 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean change from baseline: −0.3 kg/m<sup>2</sup> (SD = 0.70) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18.2 kg/m<sup>2</sup> (SD = 4.74) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yalcin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Methylphenidate group: 18.1 kg/m<sup>2</sup> (SD = 2.76) </p> <p>Untreated group: 17.8k kg/m<sup>2</sup> (SD = 2.71) </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Height z score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bereket 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Z score = 0.36 (SD = 1.21)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moungnoi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Z score = 0.09 (SD = no information)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poulton 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Z score = 0.26 (SD = 0.82)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poulton 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Z score = 0.34 (SD = 0.81)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schertz 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Z score = ‐0.1(SD = no information)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Spencer 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Z score = ‐0.23 (SD = 0.42)</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Weight z score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bereket 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.2 (SD = 1.04)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gerwe 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26 kg (SD = 1.40)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moungnoi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Z score = 0.01 (SD = no information)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poulton 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Z score = 0.44 (SD = 0.97)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schertz 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>BMI z score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bereket 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>After 14 months:</p> <p>Age‐adjusted SD = 0.71</p> <p>Sex‐adjusted SD = 0.65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dubnov‐Raz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poulton 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No difference</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Increased mobility</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ardic 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased mobility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/122</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Bone mineral density</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lahat 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quote:</b> "There was no significant difference between serum calcium, phosphorus or bone‐specific alkaline phosphatase, urinary deoxypyridinoline, or bone mineral density in the two groups of children. No child deviated from his height percentile during the treatment period." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Non‐comparative studies: proportion of participants with non‐serious adverse events, Outcome 5 Musculoskeletal system. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0033">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0034"> <p> <div class="table" id="CD012069-tblf-0016"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptom</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events/total number of participants</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Nasopharyngitis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/150</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/25</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Pyrexia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33/157</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/166</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Allergies</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allergies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/154</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pierce 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pruritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Cold symptoms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cold symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever + flu syndrome</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Steele 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flu‐like symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/72</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Pharyngitis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/541</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kratochvil 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sangal 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/79</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Viral infection</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Viral infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Viral infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/598</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Rash</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Garg 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/110</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Rhinitis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/76</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/541</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Ear disorders</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ear pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/57</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Fever</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kordon 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/541</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Infections</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Valdizán Usón 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nonspecific pathogen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/689</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Non‐comparative studies: proportion of participants with non‐serious adverse events, Outcome 6 Immune system. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0034">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0035"> <p> <div class="table" id="CD012069-tblf-0017"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Symptom</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events/total number of participants</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blader 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Enuresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Galland 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Enuresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tomás Vila 2010b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Enuresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/114</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.7</div> <div class="figure-caption"> <p>Comparison 7 Non‐comparative studies: proportion of participants with non‐serious adverse events, Outcome 7 Urogenital system: enuresis. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0035">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0036"> <p> <div class="table" id="CD012069-tblf-0018"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Description</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adverse events/total number of participants</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Hair loss</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abbas 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hair loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hair loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/71</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Skin problems</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khajehpiri 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acne</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Pierce 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Application site erythema</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shang 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin eruption</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/66</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Accidental injury</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Accidental injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/76</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Voice frequency</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Congologlu 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>In conclusion, this clinical trial is the only study that has examined the effects of stimulant medication on vocal acoustic parameters in children with ADHD (attention deficit hyperactivity disorder), and evaluated a small sample on and off their clinical doses of methylphenidate. We suggest that methylphenidate decreases fundamental frequency in children with ADHD, but our findings should be replicated under blind drug administration and by supporting other vocal analyses </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Hypersalivation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Garg 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypersalivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/27</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Nasal bleeding</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ghanizadeh 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nasal bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/26</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Chromosomal aberration</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Witt 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% of cells with chromosomal abberations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Before: 0.48% (0.09). After: 0.46% (0.09)<br/> Study population: 25 </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.8</div> <div class="figure-caption"> <p>Comparison 7 Non‐comparative studies: proportion of participants with non‐serious adverse events, Outcome 8 Other body systems. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0036">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0037"> <p> <div class="table" id="CD012069-tblf-0019"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arabgol 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arnold 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/171</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Berek 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60/822</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chou 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/521</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dirksen 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/310</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Döpfner 2011b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/113</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Efron 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/125</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Faraone 2007a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45/268</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/162</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Garg 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/33</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gerwe 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43/306</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Greenberg 1987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Guerreiro 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hong 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/112</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Karabekiroglu 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Khodadust 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2014b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/119</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Maayan 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Na 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/121</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shang 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sobanski 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/381</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Song 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/143</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Su 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/239</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tasdelen 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warshaw 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/305</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weber 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weiss 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38/407</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Winsberg 1982</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/25</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yildiz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34/1447</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Çetin 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/73</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Non‐comparative studies: proportion of participants withdrawn from methylphenidate treatment due to non‐serious adverse events, Outcome 1 Proportion of participants withdrawn from methylphenidate treatment due to non‐serious adverse events. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0037">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0038"> <p> <div class="table" id="CD012069-tblf-0020"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Akhondzadeh 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Akhondzadeh 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Altin 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/204</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Amiri 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ardic 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21/122</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Balázs 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/37</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Barbaresi 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84/379</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bereket 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58/72</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chou 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34/296</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dirksen 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/310</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dittmann 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52/247</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>El‐Zein 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109/326</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54/162</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gadow 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Galland 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gau 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/137</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Germinario 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>161/351</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Guerreiro 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haertling 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16/262</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hammerness 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97/152</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hong 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/112</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jensen 1999 (MTA)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/144</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/102</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2014b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/75</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2015a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49/86</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Klein 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/129</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/144</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Li 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McCracken 2016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/69</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammadi 2012b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peyre 2012a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37/173</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poulton 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Remschmidt 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26/89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shang 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/80</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sobanski 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/381</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Steele 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/73</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tasdelen 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Walitza 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15/26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/166</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wang 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warshaw 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28/305</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weber 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weiss 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/90</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wigal 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140/407</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wilens 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36/171</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Witt 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yalcin 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/40</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yang 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/130</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zarinara 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202/1447</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zheng 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/153</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Çetin 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/73</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Non‐comparative studies: proportion of participants withdrawn from methylphenidate treatment due to non‐serious adverse events, Outcome 2 Proportion of participants withdrawn from methylphenidate for unknown reasons. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0038">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0039"> <p> <div class="table" id="CD012069-tblf-0021"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Psychotic conditions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abali 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A 14‐year‐old girl with diagnoses of ADHD (attention deficit hyperactivity disorder), major depression and conduct disorder. During her treatment with methylphenidate of 20 mg/day and fluoxetine of 20 mg/day, she developed visual and auditory hallucinations. It may be concluded that it is possible that methylphenidate may cause hallucinations in patients treated simultaneously with fluoxetine </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Aguilera‐Albesa 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 case reports of the appearance of hallucinations a few hours after methylphenidate ingestion in an 8‐year‐old boy (extended‐release methylphenidate of 18 mg/day, given once daily for 2 days) and a 6‐year‐old girl (extended‐release methylphenidate of 10 mg/day for 3 days and 20 mg/day for 1 day, given once a day). Both diagnosed with ADHD according to criteria in the DSM‐IV (<i>Diagnostic and Statistical Manual, Fourth Edition</i>) and with IQs (intelligence quotients) &gt; 85. These case reports suggest an individual susceptibility to psychotic symptoms after taking methylphenidate. This adverse event is considered idiosyncratic, extraordinary and unpredictable </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coşkun 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A paediatric patient who developed tactile and visual hallucinations with the combination of osmotic release oral system (OROS) methylphenidate and fluoxetine. </p> <p>Comments from the study authors: In conclusion, we think that the causative agent was the combination of both medications rather than either medication alone. However, in either situation, it is important to note that this distressing side effect may occur even in the absence of underlying psychotic or substance‐related disorders, and clinicians' awareness is important in this issue, particularly in cases where polypharmacy is considered </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Goetz 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of nocturnal visual hallucinations during methylphenidate treatment. A girl with ADHD and ODD (oppositional defiant disorder) experienced a 3‐hour episode of nocturnal complex bizarre visual hallucinations when treated with 18 mg of OROS methylphenidate. Nocturnal polysomnography performed 2 weeks later revealed REM (rapid eye movement) sleep reduction (17%) and fragmentation. 2 episodes of confusional arousals were recorded. This finding is typical of parasomnia associated with NREM sleep – disorder of arousal. It is hypothesized that this pre‐existing sleep impairment represents a factor of vulnerability to methylphenidate sleep side effects </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gross‐Tsur 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 children with ADHD, who were treated with low doses of methylphenidate and who developed complex visual and haptic hallucinations </p> <p>Comments from the study authors: The causal role of methylphenidate in the development of hallucinations was based on their appearance after ingestion of the drug, resolving after its withdrawal, and the absence of psychiatric comorbidity that could explain such phenomena. In 1 patient, the hallucinations reappeared after an inadvertent re‐challenge. Because methylphenidate is a widely used, well‐studied, and safe pharmacologic agent, physicians who prescribe methylphenidate should be aware of even rare adverse manifestations occurring at therapeutic doses </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Halevy 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Several days after initiation of treatment: visual hallucinations of rats, accompanied by some tactile hallucinations. Only present during the time the patient was under the influence of methylphenidate and disappeared thereafter; immediate complete resolution upon discontinuation of the drug. Reintroduction of metyhlphenidate treatment after 2 days resulted in same complex visual hallucinations, with immediate complete resolution upon discontinuation of the drug </p> <p>Key conclusions of the study authors: In our case, the occurrence of hallucinations after a very low dose of methylphenidate on 2 occasions may suggest an idiosyncratic reaction. The phenomenon might also be explained by a drug‐induced dysfunction of the monoamine transmitters. Given the wide use of methylphenidate, clinicians should be aware of this possible side effect </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Irmak 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of phobias and visual hallucinations during methylphenidate treatment in a 9‐year‐old boy. OROS methylphenidate gradually titrated up to 1 mg/kg. </p> <p>Methylphenidate prescribed at initial ADHD diagnosis and then withdrawn following the onset of phobias and visual hallucinations, as well as lack of improvement in attention problems </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mino 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report on methylphenidate‐induced psychosis in an adolescent with hyperkinetic disorder; use of methylphenidate for 1 month. Three weeks after starting methylphenidate (10 mg/day), the mother reported by telephone that the patient seemed depressed. Dose of methylphenidate was reduced to 5 mg/day. A week later the patient visited the clinic. The therapist diagnosed her condition as a depressive state and discontinued methylphenidate. Six weeks after discontinuation of methylphenidate she was diagnosed with a schizophrenic‐like psychotic state, due to symptoms of delusions of reference and persecution, delusional mood, silly smile and thought block. There was no evident hallucination. The patient took antipsychotic medication for 2 months and her psychotic symptoms disappeared </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Porfirio 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 years after start of methylphenidate treatment: An episode of complex visual hallucinations (dramatic scenes appearing before going to sleep, sometimes during the day after ingestion of methylphenidate </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rashid 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of intensified somatic hallucinations during dose increase of methylphenidate treatment in a 10‐year‐old boy with a chronic pattern of somatization, which evolved into overt somatic hallucinations with an increase in methylphenidate dosage. This pattern of somatization was retrospectively recognized as partial somatic hallucinations </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Shibib 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A report of four cases of psychosis during methylphenidate treatment</p> <p>Key conclusion of the study authors: Psychosis is an important, unpredictable side effect of stimulant medication. Symptoms resolve with discontinuation of treatment. Reemergence of ADHD symptoms are rapid and re‐challenge is often indicated. It would be advisable for all professionals involved in the care and treatment of patients with ADHD to receive mental health training to aid the early recognition and appropriate management of such side effects </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tomás Vila 2010a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>After two weeks of 50% immediate‐release and 50% extended‐release methylphenidate: visual hallucinations (insects on hands, feet, abdomen and thorax), with associated itching, initiated two hours after ingestion and ceased five hours after. Discontinuation of methylphenidate and initiation of risperidone resulted in no visual hallucinations. No re‐administration of methylphenidate due to ethical reasons </p> <p>Key conclusions of the study authors: This is the first case report of visual hallucinations caused by 50% immediate‐release and 50% extended‐release methylphenidate, which is not surprising considering the relative recent appearance of this preparation on the market </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Seizures</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Feeney 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First‐reported seizure in a patient being treated with methylphenidate and sertraline combined </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hemmer 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported seizures in a boy aged six, and two girls aged six and seven, receiving 0.3 to 1 mg/kg/day of methylphenidate for six weeks, 10 and three months, respectively </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Cerebral arteritis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trugman 1988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Key conclusions of the study authors: Cerebral arteritis and infarction were caused by chronic use of oral methylphenidate. The Cerebrospinal fluid (CSF) profile and angiogram support the diagnosis of inflammatory arteritis, yet laboratory evaluation revealed no identifiable cause. In the six years since the stroke, while not on methylphenidate, there has been no evidence of active central nervous system or systemic vasculitis </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Self‐harm and suicidal behaviour</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arun 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 case reports with 2 children having suicidal ideation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gökce 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported a 12‐year‐old boy who made a suicide attempt after switching from 27 mg to 36 mg of OROS methylphenidate: The patient reported irritable mood when he took the first dose of 36 mg of long‐acting methylphenidate. This might be the cause of the suicide attempt. He had a full recovery after withdrawal from methylphenidate </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Strandell 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported concerns about suicidal behaviour, including suicide, based on information retrieved from the WHO Collaborating Centre for International Drug Monitoring (Uppsala, Sweden). A total of 116 reports of methylphenidate related to "suicide attempts", although this term was not explicitly defined. The data included reports of methylphenidate and atomoxetine </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Death</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tølløfsrud 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of death caused by heart failure (acute dilated cardiomyopathy) during methylphenidate treatment </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Dyskinesia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yilmaz 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Involuntary movements started about 5 hours after taking MPH. Lip‐licking, lip‐smacking and tongue‐rolling movements. Dyskinetic tongue movements inside and outside the mouth and involuntary bilateral arm swinging while sitting and standing. Opening and closing his fingers without complete extension. Occasional repetitive movements of the feet, such as beating them against each other while sitting. About 15 hours after MPH intake both hand‐mouth movements and excessive mobility had significantly resolved. Dyskinetic symptoms had completely disappeared on the second day of hospitalization, and the patient was discharged </p> <p>Key conclusions of the study authors: This case is reported to emphasize the potential side effects of methylphenidate, individual differences in drug sensitivities, and drug‐receptor interactions via different mechanisms </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Patient reports/series: number of participants with serious adverse events, Outcome 1 Central nervous system. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0039">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0040"> <p> <div class="table" id="CD012069-tblf-0022"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Cardiovascular events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Munk 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The present case demonstrates that myocardial infarction can occur due to methylphenidate exposure in a healthy 11‐year‐old boy, without other known cardiovascular risk factors. 54 mg methylphenidate/day. Treatment duration was 2 years. Cardiac arrest followed exercise without prior complaints of chest pain/discomfort or shortness of breath. A week before the event, he had a short episode of tachycardia. Clinical examination showed that the myocardial infarct was not acute but had occurred weeks prior to the cardiac arrest. It was thought to be due to thinning of the myocardium and an adversely remodelled left ventricle. A pacemaker was inserted and methylphenidate treatment was discontinued. The only apparent cause, after extensive assessment, appeared to be the high‐dose methylphenidate treatment (maximum recommended) over an extended period </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nymark 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of serious cardiomyopathy during MPH treatment. Serious cardiovascular adverse effects (hypoxia and dyspnoea requiring hospitalisation) after 11 months of MPH treatment. Clinical examination showed signs of liver failure, renal failure and heart failure </p> <p>Comments of the study authors (Nymark et al): With a BMI of 40 our patient had extreme obesity. The hyperdynamic circulation, with increased cardiac output, was thought to be a compensatory adaptation to increased adipose tissue. This may have led to non‐ischaemic dilated cardiomyopathy at the expense of left ventricular hypertrophy and remodeling as may occur in severely obese subjects (McGavock et al 2006). This is, however, unlikely as the only cause in our young patient. Human obesity is also characterized by sympathetic nervous system activation (Eikelis and Esler 2005). A possible obesity‐linked susceptibility to the toxic effect of methylphenidate could therefore play a role in the development of DCM in our patient, especially with regards to the short treatment time of one year </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Hypertension</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Saieh 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of hospitalisation due to hypertension during MPH treatment</p> <p>Serious adverse events </p> <p>72‐hour hospitalisation, emergency unit</p> <p>Abdominal pain for four days prior to hospitalisation, intermittent accentuation (hours), no other symptoms </p> <p>Secondary hypertension: Persistent hypertension (158/88‐170/105, pulse: 78‐98 bpm). Normal physical examination. Normal eye fundus and normal cardiological examination </p> <p>Discontinuation of MPH: Hypertensive treatment only necessary for 24 hours</p> <p>Normal blood pressure after one week</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Patient reports/series: number of participants with serious adverse events, Outcome 2 Cardiovascular and respiratory system. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0040">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0041"> <p> <div class="table" id="CD012069-tblf-0023"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bernhard 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A hepatotoxic reaction</p> <p>Liver enzymes were elevated prior to therapy. Vomiting starting 5 weeks after onset of methylphenidate therapy and increased within the next 3 days. Abdominal pain increased in intensity. Liver transaminases elevated over 30 times of the normal level, CK level also increased </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Patient reports/series: number of participants with serious adverse events, Outcome 3 Gastrointestinal system: hepatoxicity. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0041">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0042"> <p> <div class="table" id="CD012069-tblf-0024"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cakin‐Memik 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of a 14‐year‐old male with attention deficit hyperactivity disorder (ADHD) who presented with priapism after administration of immediate‐release methylphenidate. When the usage of immediate‐release methylphenidate was terminated, priapism spontaneously disappeared </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Schwartz 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of a 15‐year‐old white male with ADHD (inattention subtype) who experienced painful erections two weeks after beginning sustained release (OROS) MPH and repeated painful erections that increased with increased doses (during withdrawal). MPH use for more than 2 months. It is likely that withdrawal from OROS methylphenidate was the cause of this adolescent boy's priapism. He was embarrassed to disclose the problem to an adult until it became quite severe. It is possible that this adverse event is under‐reported due to sensitivity and embarrassment of young people </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Patient reports/series: number of participants with serious adverse events, Outcome 4 Urogenital system: priapism. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0042">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0043"> <p> <div class="table" id="CD012069-tblf-0025"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Tics</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adrian 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of a boy aged 10 years referred to a tertiary neurodevelopmental assessment clinic for a second opinion on the management of his ADHD. He started with 20 mg/day of methylphenidate at 7 years of age and gradually increased to 40 mg/day, for 2 to 3 years. Both motor and vocal tics started at 40 mg/day of methylphenidate and subsided spontaneously after a year of treatment </p> <p>Authors' conclusion: The clinically explosive outbursts of tics were coincident with a period of treatment with methylphenidate for the treatment of ADHD (attention deficit hyperactivity disorder) and should not be mistaken for a symptom of the disorder </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chandler 1989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported non‐serious adverse events. After a month, the child's mother reported motor and phonic tics again. He was treated first with methylphenidate and then with nortriptyline. With both drugs he manifested severe facial grimacing and phonic tics; apparently, the tics had only occurred in the past when the child was treated with methylphenidate. It is, however, very difficult to attribute the tics to methylphenidate with any certainty because of the common co‐occurrence of tics in children and young people with ADHD </p> <p>Key conclusions of the study authors: Side effects, such as hypomania, hyperreflexia and diaphoresis, have been reported in patients being treated with a combination of a monoamine oxidase inhibitor and tryptophan. By itself, L‐tryptophan may be mildly sedating. In light of such a favourable side‐effect profile, combined with no evidence for adverse interaction with stimulants, and at least some rationale from preclinical research, it should be investigated further as a means of alleviating some of the harsh consequences of psychostimulant treatment in ADHD </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Involuntary movements or dyskinesia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hollis 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of acute and transient dyskinesia occurring within hours of taking modified‐release methylphenidate (Concerta XL) in a stimulant‐naïve 7‐year‐old boy who had recently stopped taking risperidone </p> <p>Key conclusions of the study authors: This report is the first of a dyskinesia occurring after a single first dose of methylphenidate in a previously stimulant‐naïve patient after neuroleptic withdrawal. It is also the first to link this effect with modified‐release methylphenidate. The dyskinesia described here consisted of both brief tic‐like movements </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Machado 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Choreoathetoid movements of orofacial muscles, arms and legs, with transient dystonic postures of the right arm induced by a single dose of extended‐release methylphenidate. Author believes that the immediate response ensuing chlorpromazine prescription argues in favour of a specific role for dopamine receptor antagonists in methylphenidate‐induced chorea </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>McLaren 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The patient experienced spasmodic muscular contractions of his jaw. The staff noticed a forceful jaw closure, contraction and tension, and the patient had difficulties opening his mouth. 50 mg of diphenhydramine was administered intramuscularly and the patient could open his mouth within 30 minutes and with no further dystonia </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Patient reports/series: number of participants with non‐serious adverse events, Outcome 1 Central nervous system: movement‐related outcomes. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0043">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0044"> <p> <div class="table" id="CD012069-tblf-0026"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Depression and disturbed mood</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hechtman 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report about a 5‐year‐old boy. MPH use for around a year. Reported non‐serious adverse events. In late afternoon and early evening, he became very emotional, with frequent crying, marked irritability and many tantrums. The emotional side effects subsided after he discontinued methylphenidate treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mino 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 weeks after starting on 10 mg/day of methylphenidate, the mother reported by telephone that the patient seemed depressed. The dose of methylphenidate was reduced to 5 mg/day. A week later the patient visited the clinic. The therapist diagnosed her condition as a depressive state and discontinued methylphenidate. 6 weeks after discontinuation of methylphenidate, she was diagnosed with a schizophrenic‐like psychotic state, due to symptoms of delusions of reference and persecution, delusional mood, silly smile and thought block. There was no evident hallucination. The patient took antipsychotic medication for 2 months and her psychotic symptoms disappeared </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Niederhofer 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>An 11‐year‐old boy received 20 mg/day of methylphenidate for 2 months, which led to depressed mood and appetite loss </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Irritability</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hechtman 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report about a boy, who became very emotional, with frequent crying episodes, marked irritability and many tantrums when treated with methylphenidate; methylphenidate was used for around a year </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sabuncuoglu 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 case reports of hyperactivity and irritability during switch from risperidone to methylphenidate </p> <p>Case 1: Methylphenidate introduced 2 days after abrupt discontinuation of 1 mg/day of risperidone (8 months), and produced agitation, irritability, vigilance, and violent behavior. No dyskinetic movements. Methylphenidate was discontinued and the adverse events disappeared. After a 6‐week long, drug‐free period, methylphenidate was reintroduced at 15 mg/day. No adverse events were observed </p> <p>Case 2: Methylphenidate introduced after discontinuation of 1 mg/day of risperidone (2 years), and produced a near manic state, irritability, agitation, racing thoughts, and distractibility. No dyskinetic movements. Methylphenidate was discontinued and the adverse events disappeared. After a couple of months, methylphenidate was reintroduced at 15 mg/day and was well‐tolerated </p> <p>Case 3: Methylphenidate introduced after a 1‐week medication‐free interval after treatment with 1 mg of risperidone, and produced irritability, agitation and discomfort. Methylphenidate was discontinued and the adverse events disappeared. The patient did not retry the medication </p> <p>Key conclusions of the study authors: This report of 3 patients draws attention to a unique condition that arises in switching from an atypical antipsychotic to stimulant medication. A drug‐free interval is recommended in switching from risperidone to methylphenidate </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Aggression</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coignoux 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of a 14‐year‐old boy receiving methylphenidate for 2 years who developed gestural stereotypies and verbal aggressiveness towards his parents whilst on methylphenidate treatment </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Niederhofer 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case series describing adverse effects (xerostomia, aggression and emotional instability) among children taking methylphenidate </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Mania/euphoria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Corrigall 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of methylphenidate euphoria in an 11‐year‐old boy diagnosed with hyperkinetic disorder </p> <p>Key conclusions of the study authors: Methylphenidate euphoria can occur in young prepubertal children and this may lead to abuse of medication </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ghanizadeh 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mother and nursery teacher complained about increased hyper‐talkativity starting about 45 minutes after taking medication. The increased hyper‐talkativity continued for about 3–4 hours. They scored the hyper‐talking as 7–9 on a 1–10 visual analogue scale. Re‐challenge was conducted many times (more than 20 times) and hyper‐talking reoccurred after every time he took the medication </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Patient reports/series: number of participants with non‐serious adverse events, Outcome 2 Central nervous system: mood disorders. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0044">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0045"> <p> <div class="table" id="CD012069-tblf-0027"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Disturbed sleep</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Langevin 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A controlled before‐and‐after study. Methylphenidate used to treat ADHD (attention deficit hyperactivity disorder), from December (time 1) to June (time 2) </p> <p>Key conclusions of the study authors: The principal results support the study's hypothesis and show a significant baseline difference (P = 0.008) between the nocturnal movements of children with ADHD and those of children in the control group </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Other sleep problems</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Arun 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of a child whose sleep was impaired for 1 night after receiving methylphenidate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coşkun 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case series of 7 children who experience side effects during methylphenidate treatment:</p> <p>Sleep problems: n = 4</p> <p>Worsening of pre‐existing sleep problems: n = 2</p> <p>No worsening of pre‐existing sleep problems: n = 1</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Patient reports/series: number of participants with non‐serious adverse events, Outcome 3 Central nervous system: sleep problems. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0045">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0046"> <p> <div class="table" id="CD012069-tblf-0028"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Voice problems</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yalcin 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Teacher and family observed disturbance of voice quality, hoarseness, bifurcation‐strain and over vibration of voice. The symptoms began on the first day of treatment with methylphenidate. Hoarseness and reduction in the voice amplitude was evident during the first visit to a psychiatric out‐hospital clinic. No symptoms were observed by parents or during the psychiatric control on drug‐free days. Experienced hoarseness when methylphenidate administered in the clinic. Voice quality returned to normal three hours after ingestion. Laryngitis or other organic conditions causing hoarseness were not observed in physical and endoscopic examination. There were no important side effects with discontinuation of methylphenidate and administration of atomoxetine </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Stuttering</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alpaslan 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of a 7‐year‐old boy who developed stuttering associated with the use of methylphenidate; received 10 mg/daily of short‐acting methylphenidate. 10 days after beginning treatment with short‐acting methylphenidate, the client began to stutter. Treatment was stopped. 1 week later, the patient's speech was back to normal. 4 weeks later atomoxetine treatment was started with no recurrence of stuttering </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Patient reports/series: number of participants with non‐serious adverse events, Outcome 4 Central nervous system: voice and speech disorders. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0046">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0047"> <p> <div class="table" id="CD012069-tblf-0029"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Anorexia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Findling 1996</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report about an 11‐year‐old girl who experienced transient side effects after receiving methylphenidate: mild and transient anorexia, transient weight loss of 2 kg observed in the initiation of methylphenidate therapy </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Obsessive compulsive disorder (OCD) symptoms</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coşkun 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of OCD symptoms during methylphenidate treatment. Decreased appetite and initial headache with 18 mg/day of osmotic‐controlled release oral delivery system (OROS) methylphenidate, and obsessive‐compulsive symptoms, decreased appetite, facial grimace, and nail picking/biting with 27 mg/day of OROS methylphenidate. Gradual disappearance of symptoms, although still subsyndromal obsessive‐compulsive symptoms, with discontinuation of medication. Mild facial grimace and similar obsessive‐compulsive symptoms with re‐administration of 27 mg/day of OROS methylphenidate. After three weeks, total score of 21 on Children's Yale‐Brown Obsessive‐Compulsive Scale (CY‐BOCS) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Woolley 2003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Obsessions and compulsions with anxiety. DSM‐IV (<i>Diagnostic and Statistical Manual of Mental Disorders, Fourth Edtion</i>) diagnosis of OCD. Washing hands excessively, which was accompanied by checking rituals, reassurance seeking, and emetophobia. When methylphenidate was withdrawn, OCD symptoms decreased rapidly but increased when methylphenidate was reintroduced </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Headache</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mize 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of headache and mild depression during methylphenidate treatment</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>EEG changes</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dupuy 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A controlled before‐and‐after study investigating the effects of stimulants on EEG (electroencephaolography) coherence in 9 girls with ADHD (attention deficit hyperactivity disorder); intrahemispheric and interhemispheric coherences in girls with ADHD who were treated with stimulant medication. Girls had elevated frontal coherence in all frequency bands </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 Patient reports/series: number of participants with non‐serious adverse events, Outcome 5 Central nervous system: other specific adverse events. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0047">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0048"> <p> <div class="table" id="CD012069-tblf-0030"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Vasculopathy</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yu 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>These case reports raise the concern that adverse effects in the peripheral vascular system of children and adolescents may be associated with psychostimulant treatment </p> <p>Patient 1: Tachycardia at age 11 while taking Concerta, 54 mg/d. Vasculopathy at age 16. His hands and feet were a continuous blue colour on his hands and fingers, which increased in frequency in cold weather. He was diagnosed with "decreased circulation but not Raynaud's syndrome". Occured when the Concerta dose was increased from 54 mg/d to 90 mg/d in 3 months with the same Focalin (dexmethylphenidate) dose (10mg/d) </p> <p>Patient 2: Vasculopathy. First diagnosed with Raynaud's syndrome with finger pain and colour changes during a neurology consultation at age 10 years. At age 12 years had diffuse erythema of both earlobes, the fingers of both hands, and the toes of his left foot. Tics at age 10 years but not clear if these were present prior to treatment for ADHD </p> <p>Patient 4: Vasculopathy. After taking Focalin for a year, he developed persistent curling of the toes of both feet. In addition, he had reddish and purple colour changes in his hands and feet with cold exposure that lasted for 20 minutes. No associated pain and only rare paraesthesia. At age 10 years, toes 2, 3 and 4 of both feet were held in a flexed position ("curled toes"), and there was skin discolouration and excoriation </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Cardiovascular problems</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Karaman 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of a 15‐year old boy with ADHD who developed pulmonary arterial hypertension (PAH) during OROS MPH treatment </p> <p>Fourth day of treatment: The patient began to experience occasional episodes of slightly shortness of breath. Continued over several months. Not associated with either exercise or anxiety </p> <p>At 18th month of treatment: Fainting. Normal weight. No sign of allergy, hypersensitivity, or sleep apnoea. Mean pulmonary arterial pressure of 40 mmHg at rest, otherwise no pathological findings from extensive testing (Examination: clear lungs, no murmurs, rubs, or gallops, and otherwise unremarkable. Laboratory tests, including C‐reactive protein, thyroid and liver function tests, electrolytes. Blood gases, antinuclear antibodies, D‐dimers, chest X‐ray, ventilation–perfusion scintigraphy, electrocardiography, respiratory function tests. Echography. Transthoracic echocardiogram: normal except for the mean pulmonary arterial pressure). No use of any other drug. No history of alcohol and substance use and no symptoms or signs of MPH misuse (intravenous injection). The personal and familial histories were also negative for pulmonary or cardiovascular diseases </p> <p>Discontinuation of OROS‐MPH, one month: free of symptoms</p> <p>After the fourth week of discontinuation: Mean pulmonary arterial pressure of 28 mmHg</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Bleeding</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grossman 1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of a 7‐year‐old girl on methylphenidate treatment who developed idiopathic trombocytopenic purpura (ITP). Physical examination at the paediatric outpatient department found countless petechiae over the entire dermal surface. Numerous areas of purpura were noted, especially over her buttocks and extremities. Multiple areas of buccal mucosal and gingival bleeding with a large hematoma presented on the left lateral surface of her tongue. Clotted blood was seen in her nostrils and ear canals bilaterally. Bone marrow aspiration showed normal to increased megakaryocytes with normal red and white cell precursors. MPH was stopped and the patient was admitted. After one week of treatment for the condition, her petechia had begun to fade. She did not start on MPH again. There has been no recurrence of petechiae or bruising one year later. MPH use for seven months prior to presentation of ITP </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Tachycardia</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gracious 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of atrioventricular (AV) nodal re‐entrant tachycardia during stimulant treatment </p> <p>Key conclusions of the study authors: Stimulant medication may evoke onset of AV nodal tachyarrhythmias in patients who have the potential to develop them, possibly in combination with a selective serotonergic reuptake inhibitor </p> <p>Comments from the study authors: The cardiologist consulted believed this patient had a structural vulnerability of genetic etiology for the arrhythmia which was then precipitated by the stimulant </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10 Patient reports/series: number of participants with non‐serious adverse events, Outcome 6 Cardiovascular and respiratory system. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0048">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0049"> <p> <div class="table" id="CD012069-tblf-0031"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Loss of appetite</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Agarwal 2008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of the combination of atomoxetine and methylphenidate treatment of ADHD. Non‐serious adverse events: decreased appetite and delayed onset in sleep </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coşkun 2009a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IR MPH, 10–20 mg/day, co‐medication: valproate 400 mg/day. Decreased appetite, no weight decrease </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ghanizadeh 2008a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of decrease in appetite during treatment with MPH</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rappaport 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of side effects during MPH treatment in a 14‐year‐old boy with ADHD and a number of other co‐morbid conditions (whilst taking immediate‐release MPH) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yalcin 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Significant appetite loss, drowsiness, disturbance of voice and hoarseness Disturbance of voice and hoarseness occurred on everyday since the first day of the medication. The symptoms started short after the single morning dose and decreased gradually to dinner time and disappeared before bedtime. Drug‐free days: no symptoms. Otolaryngology consultation: no organic pathology was detected with respect to clinical and endoscopic observation. Discontinuation of MPH and prescription of atomoxetine: no symptom of hoarseness and disturbance of voice quality </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Nausea and vomiting</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rappaport 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of side effects during MPH treatment in a 14‐year‐old boy with ADHD and a number of other co‐morbid conditions (whilst taking extended‐release MPH: Concerta) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.7</div> <div class="figure-caption"> <p>Comparison 10 Patient reports/series: number of participants with non‐serious adverse events, Outcome 7 Gastrointestinal system. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0049">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0050"> <p> <div class="table" id="CD012069-tblf-0032"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Holtkamp 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of growth impairment during MPH treatment</p> <p>Key conclusions of the study authors: One may conclude that some children are at risk of serious growth decrement when treated with MPH. The growth of children should thus be monitored carefully, even if there are no alarming gastrointestinal side effects from MPH. We found that the determination of growth velocity was a sensitive marker for the evaluation of growth impairment in our patient </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.8</div> <div class="figure-caption"> <p>Comparison 10 Patient reports/series: number of participants with non‐serious adverse events, Outcome 8 Musculoskeletal system: growth. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0050">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0051"> <p> <div class="table" id="CD012069-tblf-0033"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Confino‐Cohen 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of pruritic maculopapular skin rash developing during MPH treatment. The rash improved with antihistamines and re‐challenge at a lower dose caused the reappearance, though less severe, of the rash. Desensitisation through graded exposure of MPH in incremental doses prevented further rash development </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vashi 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>After 8 months of using an MPH patch the patient presented with pruritic dermatitis. She had itchy, burning, red lesions. Symptoms began on her hip at the area of patch placement, then progressively spread to her arms, legs, abdomen, and back. MPH discontinued: Symptoms lasted for 2 months. First and second patch test. Re‐tested with MPH patch: Nine days after the first test the patient presented with recall reaction, characterized by a return of the original pruritic dermatitis to her entire back, similar to the eruption that had occurred months previously after therapeutical use of MPH patch. Avoidance of MPH patches: symptom‐free </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.9</div> <div class="figure-caption"> <p>Comparison 10 Patient reports/series: number of participants with non‐serious adverse events, Outcome 9 Immune system: allergic reactions. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0051">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0052"> <p> <div class="table" id="CD012069-tblf-0034"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Testicular failure</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ramasamy 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of testicular failure possibly associated with chronic use of Methylphendiate. The patient was 20 years old with treatment duration of approximately 17 years with voluntary cessation a few years ago. Dosage varied with age. The patient's complaint was initially delayed puberty. He complained of high‐pitched voice, lack of libido, low energy level, chronic fatigue and poor erectile function. The patient was advised to begin testosterone supplementation. The patient described in the case study seemed to exhibit characteristics related to the effects of chronic use of methylphenidate on development of human reproductive function. The unknown effects of methylphenidate are currently being studied, but as can be seen, one should exercise caution and patients should be followed closely when prescribing methylphenidate. However, because the developmental changes that occurred in the human participant occurred over a number of years of treatment with methylphenidate, there is very little information about the patient's condition and how it developed during that period of time </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Sexual adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coşkun 2009b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Case 1: Treated with 10‐30 mg/day of immediate‐release methylphenidate and experienced initial headache and nausea. Treated with 18 mg/day osmotic‐controlled release oral delivery system (OROS) methylphenidate and experienced emotional side effects (sense of nervousness in the chest, occasional emotional numbing), multiple daily erections (unrelated to sexual stimuli, painless and without ejaculations), occurring a few hours after ingesting methylphenidate and lasting 5‐10 minutes. No erections unrelated to sexual stimuli during a 1‐week medication‐free period. With re‐administration of 35 mg/day OROS methylphenidate for 3 weeks, experienced re‐emergence of erections of a longer duration compared with 18 mg/day of OROS methylphenidate, headache, nausea, and the same emotional side effects. No erections on drug‐free days, and no erections with discontinuation of medication. </p> <p>Case 2: Treated with 18 mg/day of OROS methylphenidate and experienced loss of appetite, headache, abdominal pain, sleep problems, and conjunctival injection. Headache and abdominal pain almost disappeared after 1 week. Also experienced hypersexual behaviours, with morning erections lasting 1 hour before ingestion of methylphenidate, and a weight loss of 1.5 kg within 2 months. On drug‐free days had almost no hypersexual behaviour during the day and no erection the following morning. When treated with 10‐20 mg/day of immediate‐release methylphenidate, morning erections and hypersexual behaviours decreased dramatically, sleep and appetite problems improved mildly, and there was no conjunctival injection (after three weeks). There were, however, possible withdrawal symptoms (increased irritability and hyperactivity, getting tearful easily), several hours after each dosage. </p> <p>Had no morning erections or hypersexual behaviours with discontinuation of OROS methylphenidate</p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Incontinence</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tang 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Side effects reported by the mother: IR‐MPH, 10 mg, no side effects. OROS‐MPH, 18 mg/d, no side effects. OROS‐MPH, 36 mg/d, double incontinence; stool incontinence (every day, frequent during daytime) and urinary incontinence (almost every day). The double incontinence completely resolved rapidly after the discontinuation of OROS methylphenidate 36 mg </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Enuresis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ghanizadeh 2008b</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report of nocturnal enuresis during MPH treatment</p> <p>Non‐serious adverse events</p> <p>MPH, titrated to 20 mg/day: Nocturnal enuresis</p> <p>Discontinuation of MPH: enuresis stopped immediately</p> <p>MPH, when titrated to 20 mg/day: Immediate re‐occurence of nocturnal enuresis</p> <p>Discontinuation of MPH: enuresis stopped immediately</p> <p>MPH, when titrated to 20 mg/day: Immediate re‐occurence of nocturnal enuresis</p> <p>Discontinuation of MPH: enuresis stopped immediately</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Williamson 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Two case reports showing resolution of enuresis when treated with MPH</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.10</div> <div class="figure-caption"> <p>Comparison 10 Patient reports/series: number of participants with non‐serious adverse events, Outcome 10 Urogenitial system. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0052">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012069-fig-0053"> <p> <div class="table" id="CD012069-tblf-0035"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Skin reactions</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohen 1992</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Case 1:</p> <p>5 days of MPH treatment: hospitalisation due to two days of severe swelling and redness of the scrotum The skin eruption resolved spontaneously four days after MPH was discontinued. Two weeks later, 18 hour after MPH retrial, the same skin eruption of the scrotum was documented. Discontinued once again, and followed by a complete resolution of the rash in four days<br/> Case 2: </p> <p>7 days of MPH treatment: Six hours of severe swelling and redness of the scrotum. Discontinuation of MPH was followed by a complete resolution of rash in three days.Rechallenge with MPH two months later was followed by the same skin eruption of the scrotum within two days. Complete resolution was seen after drug withdrawal </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Coşkun 2009a</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>OROS‐MPH 18 mg/day, co‐medication: valproate 400 mg/day. Maculopapular pruritic skin eruptions on the patient's neck, arms, and legs, one week after starting OROS MPH treatment </p> <p>Re‐administering of OROS‐MPH 18 mg/day, comedication: gabapentine 300 mg/day. Same skin eruptions with same severity, nine days after starting OROS‐MPH treatment again </p> <p>Discontinuation of medication: skin lesions abated within the next several weeks</p> <p>Restart of IR‐MPH, 10–20 mg/day, co‐medication gabapentine 300 mg/day, four months: no skin eruptions </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Problems with sedation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ririe 1997</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A case report (6‐year‐old boy) on unexpected interaction of methylphenidate (Ritalin) with anaesthetic agents: There could be a potential risk of unwanted interactions between methylphenidate and anaesthetic agents. Based on the observations from the case report, a more detailed and systematic investigation of methylphenidate in patients undergoing anaesthesia or sedation is warranted </p> </td> </tr> <tr> <td align="center" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Eye problems</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ghanizadeh 2008c</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Photophobia, occurring a few days after initiation of MPH treatment</p> <p>Discontinuation of MPH at least three times: no symptoms of photophobia</p> <p>Re‐administration of MPH: immediate reoccurrence of photophobia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lewis 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>This report concluded stimulant medication (MPH) should not be withheld in patients with glaucoma as long as intraocular pressure (IOP) remains well controlled </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.11</div> <div class="figure-caption"> <p>Comparison 10 Patient reports/series: number of participants with non‐serious adverse events, Outcome 11 Other body systems. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-fig-0053">Navigate to figure in review</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012069-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methylphenidate for children and adolescents aged 18 years and under with attention deficit hyperactivity disorder (ADHD): adverse events</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Methylphenidate for children and adolescents aged 18 and under with attention deficit hyperactivity disorder (ADHD): adverse events</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population</b>: children and adolescents aged 18 years and under diagnosed with ADHD </p> <p><b>Settings</b>: outpatient clinic, inpatient hospital ward and register data </p> <p><b>Intervention</b>: methylphenidate </p> <p><b>Comparision</b>: control or no control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies) at follow‐up</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with control or no control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk difference with Methylphenidate</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b><i>Comparative studies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Measured by: proportion of serious adverse events (total)</p> <p>Average study duration (range): not stated</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>4 more per 1000</p> <p>(2 more to 7 more)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.36</b><br/> (1.17 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72,005 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="6" rowspan="1" valign=""> <p><b><i>Non‐comparative studies</i> </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p>Measured by: proportion of any serious adverse events</p> <p>Average study duration (range): 4.7 months (14 days to 21 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1.20% (0.70% to 2.00%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162,422 (51 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal of methylphenidate due to serious adverse events (non‐comparative cohort studies)</b> </p> <p>Measured by: proportion of participants withdrawn from treatment</p> <p>Average study duration (range): 7.9 months (1 month to 37 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1.20% (0.60% to 2.30%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1173 (7 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal of methylphenidate due to adverse events of unknown severity</b> </p> <p>Measured by: proportion of participants withdrawn from treatment</p> <p>Average study duration (range): 4.6 months (21 days to 36 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>7.30% (5.30% to 10.0%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3708 (22 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐serious adverse events</b> </p> <p>Measured by: proportion of any non‐serious adverse events</p> <p>Average study duration (range): 5.99 months (1 day to 41 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>51.2% (41.2% to 61.1%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13,978 (49 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal of methylphenidate due to non‐serious adverse events</b> </p> <p>Measured by: proportion of participants withdrawn from treatment</p> <p>Average study duration (range): 5.60 months (0.6 months to 41 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>6.20% (4.80% to 7.90%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7142 (37 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawal of methylphenidate for unknown reasons</b> </p> <p>Measure by: proportion of participants withdrawn from treatment</p> <p>Average study duration (range): 6.13 months (1 day to 36 months)</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>16.2% (13.0% to 19.9%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8340 (57 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>ROBINS‐I:</b> Risk Of Bias In Non‐randomised Studies ‐ of Interventions; <b>RR</b>: risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate quality</b> : we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low quality</b> : our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect.<br/> <b>Very low quality</b>: we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Outcome assessed at critical risk of bias using the ROBINS‐I. Consequently, we downgraded the quality of the evidence by 3 levels due to study limitations. <br/> <sup>b</sup>Outcome not critically assessed with ROBINS‐I due to lack of control group. However, due to the nature of the studies and the risk of confounding, we considered the studies to be at critical risk of bias. Consequently, we downgraded the quality of the evidence by 3 levels due to study limitations. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Methylphenidate for children and adolescents aged 18 years and under with attention deficit hyperactivity disorder (ADHD): adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012069-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study design</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study design</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Description</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cohort study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>An observational study in which a defined group with ≥ 1 samples of people (the cohort) is followed over time. The outcomes of people in subsets of this cohort might be compared, to examine people who were exposed or not exposed (or exposed at different levels) to a particular intervention or other factor of interest. A prospective cohort study assembles participants and follows them into the future. A retrospective (or historical) cohort study identifies participants from past records and follows them from the time of those records to the present. Because participants are not allocated by the investigator to different interventions or other exposures, adjusted analysis is usually required to minimise the influence of other factors (confounders). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient‐control study</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A study that compares people with a specific disease or outcome of interest (cases) to people from the same population without that disease or outcome (controls), and which seeks to find associations between the outcome and prior exposure to particular risk factors. This design is particularly useful when the outcome is rare and when past exposure can be reliably measured. Patient‐control studies are usually but not always retrospective. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cross‐sectional study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Studies in which the presence or absence of disease or other health‐related variables are determined for each member of the study population or in a representative sample at one particular time. This contrasts with cohort studies, which are followed over a period of time. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>Taken from the <a href="http://community.cochrane.org/glossary" target="_blank">Cochrane Glossary</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study design</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012069-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Data on adverse events from published systematic review on methylphenidate versus placebo or no intervention (Storebø 2015), National Summary of Product Characteristics, and from the present review</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse event</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised clinical trials: methylphenidate group (from <a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Randomised clinical trials: placebo or no intervention group (from <a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>National Summary of Product Characteristics (UK, USA, DK)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐comparative cohort studies and cohort studies from randomised trials (present review)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐comparative cohort studies (present review)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Non‐comparative cohort studies from randomised trials (present review)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.90% (95% CI 1.10% to 3.20%; 9 studies, 919 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.80% (95% CI 1.70% to 4.80%; 9 studies, 613 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.20% (95% CI 0.70% to 2.00%; 51 studies, 162,434 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10% (95% CI 0.60% to 2.00%; 32 studies, 159,761 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.60% (95% CI 1.00% to 2.30%; 18 studies, 2661 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐serious adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.4% (95% CI 41.9% to 60.9%; 21 studies, 1861 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.3% (95% CI 30.3% to 47.0%; 21 studies, 1271 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51.2% (95% CI 41.2% to 61.1%; 49 studies, 13,978 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47.1% (95% CI 35.6% to 58.9%; 36 studies, 13,035 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.1% (95% CI 44.4% to 77.1%; 13 studies, 943 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.6% (95% CI 8.80% to 13.3%; 17 studies, 1642 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.40% (95% CI 7.10% to 12.4%; 17 studies, 1082 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.4% (95% CI 11.3% to 18.3%; 90 studies, 13,469 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.90% (95% CI 7.00% to 13.9%; 57 studies, 10,929 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24.3% (95% CI 18.0% to 32.1%; 33 studies, 2540 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.50% (95% CI 1.20% to 29.2%; 3 studies, 356 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.4% (95% CI 8.30% to 18.0%; 3 studies, 240 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10% (UK and DK); no information (USA)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.4% (95% CI 11.3% to 28.7%; 22 studies, 1287 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.2% (95% CI 5.30% to 18.9%; 8 studies, 938 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.9% (95% CI 17.8% to 40.8%; 14 studies, 349 participants</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleep difficulty</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.00% (95% CI 5.80% to 11.1%; 13 studies, 1417 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.30% (95% CI 6.40% to 10.7%; 13 studies, 999 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.9% (95% CI 14.7% to 21.6%; 82 studies, 11,507 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.3% (95% CI 11.2% to 18.2%; 51 studies, 9073 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25.4% (95% CI 18.2% to 34.4%, 31 studies, 2434 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Irritability</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.40% (95% CI 3.70% to 10.8%; 11 studies, 1038 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.50% (95% CI 1.40% to 8.60%; 11 studies, 778 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.2% (95% CI 11.5% to 25%; 35 studies, 4792 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5% (95% CI 10.2% to 22.7%; 21 studies, 3298 participants</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.6% (95% CI 7.90% to 44.1%; 14 studies, 1494 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tics</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.30% (95% CI 1.00% to 5.20%; 7 studies, 684 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.50% (95% CI 3.70% to 8.10%; 7 studies, 476 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.40% (95% CI 4.50% to 8.90%; 39 studies, 1980 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.60% (95% CI 3.80% to 8.10%; 29 studies, 1601 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.6% (95% CI 5.30% to 19.9%; 10 studies, 379 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsiness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.30% (95% CI 2.40% to 20.2%; 4 studies, 510 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.70% (95% CI 2.60% to 16.2%; 4 studies, 310 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.50% (95% CI 5.20% to 16.6%; 17 studies, 1146 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.50% (95% CI 3.10% to 17.2%; 7 studies, 644 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.3% (95% CI 5.00% to 23.3%; 10 studies, 502 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sadness</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.70% (95% CI 1.30% to 21.9%; 4 studies, 382 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.20% (95% CI 0.90% to 16.9%; 4 studies, 318 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.8% (95% CI 9.40% to 28.3%; 21 studies, 1802 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.1% (95% CI 6.60% to 24.1%; 9 studies, 626 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.6% (95% CI 8.10% to 43.1%; 12 studies, 1176 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.80% (95% CI 2.30% to 9.90%; 6 studies, 471 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.50% (95% CI 4.30% to 9.60%; 6 studies, 387 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.70% (95% CI 3.00% to 10.4%; 17 studies, 2182 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.60% (95% CI 2.80% to 10.9%; 5 studies, 673 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.80% (95% CI 5.80% to 10.5%; 12 studies, 1509 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Abdominal pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5% (95% CI 7.70% to 16.8%; 13 studies, 1406 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.60% (95% CI 5.00% to 11.5%; 13 studies, 935 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.7% (95% CI 8.60% to 13.3%; 79 studies, 11,750 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.60% (95% CI 5.70% to 10.0%; 46 studies, 9229 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.3% (95% CI 11.6% to 22.4%; 33 studies, 2521 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decreased appetite</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17.3 (95% CI 12.3% to 24.2%; 16 studies, 1751 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.30% (95% CI 2.40% to 7.40%; 16 studies, 1211 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.1% (95% CI 26.5% to 36.2%; 84 studies, 11,594 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28.8% (95% CI 23.0% to 33.5%; 57 studies, 9662 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.7% (95% CI 27.0% to 54.0%; 27 studies, 1967 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.70% (95% CI 4.00% to 8.00%; 11 studies, 1140 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.10% (95% CI 3.5% to 7.4%; 11 studies, 776 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.30% (95% CI 3.70% to 13.4%; 20 studies, 2731 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.10% (95% CI 2.80% to 17.0%; 11 studies, 1528 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.20% (95% CI 3.30% to 15.1%; 9 studies, 1203 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.50% (95% CI 6.10% to 9.30%; 11 studies, 1174 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.20% (95% CI 3.80% to 7.10%; 11 studies, 821 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&gt; 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.60% (95% CI 5.30% to 10.6%; 41 studies, 5612 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.00% (95% CI 7.00% to 9.10%; 22 studies, 3921 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.4% (95% CI 5.80% to 17.9%; 19 studies, 1691 participants)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Decreased weight</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.30% (95% CI 3.80% to 10.3%; 6 studies, 472 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.40% (95% CI 1.00% to 5.70%; 6 studies, 387 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1% to 10%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.70% (95% CI 4.80% to 15.3%; 26 studies, 5182 participants)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.60% (95% CI 3.10% to 13.3%; 17 studies, 4855 participants)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.6% (95% CI 8.70% to 30.6%; 9 studies, 327 participants)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><b>CI</b> : confidence interval; <b>DK</b> : Denmark; <b>RCT</b>: randomised clinical trials.<br/> <sup>a</sup>We found substantially larger proportions of several adverse events in the present review compared to both the proportions of adverse events in the placebo group in the RCTs included in our 2015 review (<a href="./references#CD012069-bbs2-0652" title="StorebøOJ , RamstadE , KroghHB , NilausenTD , SkoogM , HolmskovM , et al. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD009885.pub2] ">Storebø 2015</a>), and the National Summary of Product Characteristics from the UK, USA, and Denmark. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Data on adverse events from published systematic review on methylphenidate versus placebo or no intervention (Storebø 2015), National Summary of Product Characteristics, and from the present review</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/full#CD012069-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012069-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparative studies: number of serious adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Any serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.17, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Central nervous system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>234</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.07, 23.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Psychotic disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71771</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [1.17, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular and respiratory system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Arrhythmias</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Myocardial infarction</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Ischaemic stroke</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Heart failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparative studies: number of serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012069-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Comparative studies: number of participants with non‐serious adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Central nervous system: sleep‐related adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Insomnia and sleep problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>425</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [1.24, 5.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [0.41, 3.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Snoring</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.62 [0.25, 86.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Non‐breathing or gasping while sleeping</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [0.12, 61.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Sleepwalking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.75 [0.33, 22.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Various sleep positions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.77 [0.12, 61.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 Enuresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.62 [0.25, 86.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 Talking in sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.05, 4.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Central nervous system: other specific sleep‐related adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Number of hours sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐1.32, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Number of nocturnal movements</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐27.84 [‐57.90, 2.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Sleep quality</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.74, 0.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Central nervous system: other specific adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.13 [0.48, 137.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.00 [0.23, 69.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Cardiovascular and respiratory system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Systolic blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐6.27, 6.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Diastolic blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.50 [‐1.42, 8.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Pulse rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [‐7.95, 9.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Gastrointestinal system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.64 [0.34, 20.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.16, 3.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.06 [2.12, 106.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Musculoskeletal system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Height</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.93 [‐2.61, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Weight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐1.16, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Musculoskeletal system: body mass index (BMI) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐2.96, ‐0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Musculoskeletal system: z scores <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Height z score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐0.43, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Weight z score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.30, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 BMI z score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>275</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.22, 0.24]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Comparative studies: number of participants with non‐serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012069-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Comparative studies: number of participants withdrawn from methylphenidate treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Proportion of participants withdrawn from methylphenidate for unknown reasons <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Comparative studies: number of participants withdrawn from methylphenidate treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012069-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Non‐comparative studies: proportion of participants with serious adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Any serious adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Central nervous system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Sudden death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Suicide</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Suicide attempt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Suicide thoughts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Psychotic symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Seizure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Syncope</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 Psychiatric problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 Severe depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11 Overdose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12 Eating disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13 Aphasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15 Neurological disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16 Sleep disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17 Mood disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18 Loss of consciousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19 Family stress</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20 Impotence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21 Severe aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22 Severe anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23 Amphetamine intoxication</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular and respiratory system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Respiratory, thoracic and mediastinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Cardiac problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Severe hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Epistaxsis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Viral illness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Gastrointestinal system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Gastrointestinal disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Liver disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Musculoskeletal system: fractures <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Immune system: autoimmune disease <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Non‐comparative studies: proportion of participants with serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012069-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Non‐comparative studies: proportion of participants withdrawn from methylphenidate treatment due to serious adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Proportion of participants withdrawn from methylphenidate treatment due to serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Serious adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Hallucinations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Severe anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Suicide attempt</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion of participants withdrawn from methylphenidate treatment due to adverse events of unknown severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Non‐comparative studies: proportion of participants withdrawn from methylphenidate treatment due to serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012069-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Non‐comparative studies: proportion of participants with adverse events of unknown severity</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Proportion of participants with adverse events of unknown severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Non‐comparative studies: proportion of participants with adverse events of unknown severity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012069-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Non‐comparative studies: proportion of participants with non‐serious adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Central nervous system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Affect lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Fingernail biting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 Daydreams</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 Difficulty falling asleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 Disturbed sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11 Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12 Dysthymia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.13 Emotional lability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.14 Euphoria/hypomania</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.15 Asthenia and fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.16 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.17 Increased need to sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.18 Involuntary movements</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.19 Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.20 Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.21 Nightmares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.22 Restlessness and agitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.23 Sadness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.24 Stares</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.25 Excessive talking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.26 Taciturnity ('talking too little')</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.27 Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.28 Isolation and lack of interest in others</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.29 'Zombie like' demeanour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.30 Somnolence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.31 Obsession</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.32 Mood disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.33 Confusional state</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.34 Sleep disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.35 Propensity to cry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.36 Sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.37 Daytime sleepiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.38 Dysphoria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.39 Logorrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.40 Impaired concentration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.41 Difficulty waking up</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.42 Urinary incontinence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.43 Paralysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.44 Affective disorder</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.45 Jumbled thoughts</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.46 Bulimia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.47 Sleep late</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.48 Tooth grinding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.49 Tremor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.50 Stuttering</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.51 Flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.52 Apathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.53 Abnormal behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.54 Stereotypies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.55 Quietness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.56 EEG changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.57 Did not like themselves</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.58 Sleep walking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.59 Personality and behaviour disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.60 Vertigo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Cardiovascular and respiratory system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Pharyngolaryngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Upper respiratory tract infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Abnormal ECG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Nasal congestion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 Palpitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 Systolic blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 Diastolic blood pressure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10 Pulse rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11 ECG‐QT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12 Cold fingers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13 Sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15 Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.16 Respiratory, thoracic and mediastinal disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.17 Proportion of patients with micro‐nucleated (Mn) peripheral lymphocytes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Gastrointestinal system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Decreased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4 Decreased weight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6 Dry mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7 Gastrointestinal adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8 Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9 Upset stomach</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.10 Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.11 Dyspepsia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.12 Gastroenteritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.13 Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.14 Xerostomia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Musculoskeletal system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Chest pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Height</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Weight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 BMI</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Height z score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.6 Weight z score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.7 BMI z score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.8 Increased mobility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.9 Bone mineral density</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Immune system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Nasopharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Allergies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Cold symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Pharyngitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Viral infection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 Rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.9 Ear disorders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.10 Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.11 Infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Urogenital system: enuresis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Other body systems <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Hair loss</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Skin problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Accidental injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Voice frequency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 Hypersalivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 Nasal bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.7 Chromosomal aberration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Non‐comparative studies: proportion of participants with non‐serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012069-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Non‐comparative studies: proportion of participants withdrawn from methylphenidate treatment due to non‐serious adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Proportion of participants withdrawn from methylphenidate treatment due to non‐serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Proportion of participants withdrawn from methylphenidate for unknown reasons <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Non‐comparative studies: proportion of participants withdrawn from methylphenidate treatment due to non‐serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012069-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Patient reports/series: number of participants with serious adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Central nervous system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Psychotic conditions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Seizures</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Cerebral arteritis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Self‐harm and suicidal behaviour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Cardiovascular and respiratory system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Cardiovascular events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Hypertension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Gastrointestinal system: hepatoxicity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Urogenital system: priapism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Patient reports/series: number of participants with serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012069-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Patient reports/series: number of participants with non‐serious adverse events</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Central nervous system: movement‐related outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Tics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Involuntary movements or dyskinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Central nervous system: mood disorders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Depression and disturbed mood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Irritability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Aggression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Mania/euphoria</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Central nervous system: sleep problems <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Disturbed sleep</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Other sleep problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Central nervous system: voice and speech disorders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Voice problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Stuttering</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Central nervous system: other specific adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Anorexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Obsessive compulsive disorder (OCD) symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 EEG changes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Cardiovascular and respiratory system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Vasculopathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Cardiovascular problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Bleeding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Tachycardia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Gastrointestinal system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Loss of appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Nausea and vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Musculoskeletal system: growth <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Immune system: allergic reactions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Urogenitial system <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Testicular failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Sexual adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Incontinence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.4 Enuresis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Other body systems <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Skin reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Problems with sedation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Eye problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Patient reports/series: number of participants with non‐serious adverse events</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012069.pub2/references#CD012069-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012069.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012069-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012069-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012069-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="ja#CD012069-note-0004">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD012069-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012069-note-0002">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012069\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012069\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012069\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012069\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012069\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012069\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012069\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012069\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012069\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012069\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012069\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012069\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012069\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012069\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012069\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012069\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012069\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012069\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012069.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012069.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012069.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012069.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012069.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719805086"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012069.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719805090"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012069.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df1a78eb9937f',t:'MTc0MDcxOTgwNS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 